Recently	O
,	O
it	O
was	O
shown	O
that	O
diclofenac	B
was	O
metabolized	O
in	O
rats	O
to	O
reactive	O
benzoquinone	B
imines	B
via	O
cytochrome	O
P450-catalyzed	O
oxidation	O
.	O

These	O
metabolites	O
also	O
were	O
detected	O
in	O
human	O
hepatocyte	O
cultures	O
in	O
the	O
form	O
of	O
glutathione	B
(	O
GSH	B
)	O
adducts	O
.	O

This	O
report	O
describes	O
the	O
results	O
of	O
further	O
studies	O
aimed	O
at	O
characterizing	O
the	O
human	O
hepatic	O
P450-mediated	O
bioactivation	O
of	O
diclofenac	B
.	O

The	O
reactive	O
metabolites	O
formed	O
in	O
vitro	O
were	O
trapped	O
by	O
GSH	B
and	O
analyzed	O
by	O
LC	O
/	O
MS	O
/	O
MS	O
.	O

Thus	O
,	O
three	O
GSH	B
adducts	O
,	O
namely	O
,	O
5-hydroxy-4-	B
(	I
glutathion	I
-	I
S	I
-	I
yl	I
)	I
diclofenac	I
(	O
M1	B
)	O
,	O
4'-hydroxy-3'-	B
(	I
glutathion	I
-	I
S	I
-	I
yl	I
)	I
diclofenac	I
(	O
M2	B
)	O
,	O
and	O
5-hydroxy-6-	B
(	I
glutathion	I
-	I
S	I
-	I
yl	I
)	I
diclofenac	I
(	O
M3	B
)	O
,	O
were	O
identified	O
in	O
incubations	O
of	O
diclofenac	B
with	O
human	O
liver	O
microsomes	O
in	O
the	O
presence	O
of	O
NADPH	B
and	O
GSH	B
.	O

The	O
formation	O
of	O
the	O
adducts	O
was	O
taken	O
to	O
reflect	O
the	O
intermediacy	O
of	O
the	O
corresponding	O
putative	O
benzoquinone	B
imines	I
.	O

While	O
M2	B
was	O
the	O
dominant	O
metabolite	O
over	O
a	O
substrate	O
concentration	O
range	O
of	O
10	O
-	O
50	O
microM	O
,	O
M1	B
and	O
M3	B
became	O
equally	O
important	O
products	O
at	O
>	O
/=100	O
microM	O
diclofenac	O
.	O

The	O
formation	O
of	O
M2	B
was	O
inhibited	O
by	O
sulfaphenazole	B
or	O
an	O
anti	O
-	O
P450	O
2C9	O
antibody	O
(	O
5	O
-	O
10	O
%	O
of	O
control	O
values	O
)	O
.	O

The	O
formation	O
of	O
M1	B
and	O
M3	B
was	O
inhibited	O
by	O
troleandomycin	B
,	O
ketoconazole	B
,	O
or	O
an	O
anti	O
-	O
P450	O
3A4	O
antibody	O
(	O
30	O
-	O
50	O
%	O
of	O
control	O
values	O
)	O
.	O

In	O
studies	O
in	O
which	O
recombinant	O
P450	O
isoforms	O
were	O
used	O
,	O
M2	B
was	O
generated	O
only	O
by	O
P450	O
2C9-catalyzed	O
reaction	O
,	O
while	O
M1	B
and	O
M3	B
were	O
produced	O
by	O
P450	O
3A4-catalyzed	O
reaction	O
.	O

Good	O
correlations	O
were	O
established	O
between	O
the	O
extent	O
of	O
formation	O
of	O
M2	B
and	O
P450	O
2C9	O
activities	O
(	O
r	O
=	O
0.93	O
,	O
n	O
=	O
10	O
)	O
and	O
between	O
the	O
extent	O
of	O
formation	O
of	O
M1	B
and	O
M3	B
and	O
P450	O
3A4	O
activities	O
(	O
r	O
=	O
0.98	O
,	O
n	O
=	O
10	O
)	O
in	O
human	O
liver	O
microsomal	O
incubations	O
.	O

Taken	O
together	O
,	O
the	O
data	O
suggest	O
that	O
the	O
biotransformation	O
of	O
diclofenac	B
to	O
M2	B
is	O
P450	O
2C9-dependent	O
,	O
whereas	O
metabolism	O
of	O
the	O
drug	B
to	O
M1	B
and	O
M3	B
involves	O
mainly	O
P450	O
3A4	O
.	O

Although	O
P450s	O
2C9	O
and	O
3A4	O
both	O
catalyze	O
the	O
bioactivation	O
of	O
diclofenac	B
,	O
P450	O
2C9	O
is	O
capable	O
of	O
producing	O
the	O
benzoquinone	B
imine	I
intermediate	O
at	O
lower	O
drug	O
concentrations	O
which	O
may	O
be	O
more	O
clinically	O
relevant	O
.	O

Cytochrome	O
P450	O
2C11	O
in	O
rats	O
was	O
recently	O
found	O
to	O
metabolize	O
diclofenac	B
into	O
a	O
highly	O
reactive	O
product	O
that	O
covalently	O
bound	O
to	O
this	O
enzyme	O
before	O
it	O
could	O
diffuse	O
away	O
and	O
react	O
with	O
other	O
proteins	O
.	O

To	O
determine	O
whether	O
cytochromes	O
P450	O
in	O
human	O
liver	O
could	O
catalyze	O
a	O
similar	O
reaction	O
,	O
we	O
have	O
studied	O
the	O
covalent	O
binding	O
of	O
diclofenac	B
in	O
vitro	O
to	O
liver	O
microsomes	O
of	O
16	O
individuals	O
.	O

Only	O
three	O
of	O
16	O
samples	O
were	O
found	O
by	O
immunoblot	O
analysis	O
to	O
activate	O
diclofenac	B
appreciably	O
to	O
form	O
protein	O
adducts	O
in	O
a	O
NADPH	B
-	O
dependent	O
pathway	O
.	O

Cytochrome	O
P450	O
2C9	O
,	O
which	O
catalyzes	O
the	O
major	O
route	O
of	O
oxidative	O
metabolism	O
of	O
diclofenac	B
to	O
produce	O
4'-hydroxydiclofenac	B
,	O
did	O
not	O
appear	O
to	O
be	O
responsible	O
for	O
the	O
formation	O
of	O
the	O
protein	O
adducts	O
,	O
because	O
sulfaphenazole	B
,	O
an	O
inhibitor	O
of	O
this	O
enzyme	O
,	O
did	O
not	O
affect	O
protein	O
adduct	O
formation	O
.	O

In	O
contrast	O
,	O
troleandomycin	B
,	O
an	O
inhibitor	O
of	O
P450	O
3A4	O
,	O
inhibited	O
both	O
protein	O
adduct	O
formation	O
and	O
5-hydroxylation	O
of	O
diclofenac	B
.	O

These	O
findings	O
were	O
confirmed	O
with	O
the	O
use	O
of	O
baculovirus	O
-	O
expressed	O
human	O
P450	O
2C9	O
and	O
P450	O
3A4	O
.	O

One	O
possible	O
reactive	O
intermediate	O
that	O
would	O
be	O
expected	O
to	O
bind	O
covalently	O
to	O
liver	O
proteins	O
was	O
the	O
p	B
-	I
benzoquinone	I
imine	I
derivative	I
of	I
5-hydroxydiclofenac	I
.	O

This	O
product	O
was	O
formed	O
by	O
an	O
apparent	O
metal	B
-	O
catalyzed	O
oxidation	O
of	O
5-hydroxydiclofenac	B
that	O
was	O
inhibited	O
by	O
EDTA	B
,	O
glutathione	B
,	O
and	O
NADPH	B
.	O

The	O
p	B
-	I
benzoquinone	I
imine	I
decomposition	O
product	O
bound	O
covalently	O
to	O
human	O
liver	O
microsomes	O
in	O
vitro	O
in	O
a	O
reaction	O
that	O
was	O
inhibited	O
by	O
GSH	B
.	O

In	O
contrast	O
,	O
GSH	B
did	O
not	O
prevent	O
the	O
covalent	O
binding	O
of	O
diclofenac	B
to	O
human	O
liver	O
microsomes	O
.	O

These	O
results	O
suggest	O
that	O
for	O
appreciable	O
P450-mediated	O
bioactivation	O
of	O
diclofenac	B
to	O
occur	O
in	O
vivo	O
,	O
an	O
individual	O
may	O
have	O
to	O
have	O
both	O
high	O
activities	O
of	O
P450	O
3A4	O
and	O
perhaps	O
low	O
activities	O
of	O
other	O
enzymes	O
that	O
catalyze	O
competing	O
pathways	O
of	O
metabolism	O
of	O
diclofenac	B
.	O

Moreover	O
,	O
the	O
p	B
-	I
benzoquinone	I
imine	I
derivative	I
of	I
5-hydroxydiclofenac	I
probably	O
has	O
a	O
role	O
in	O
covalent	O
binding	O
in	O
the	O
liver	O
only	O
under	O
the	O
conditions	O
where	O
levels	O
of	O
NADPH	B
,	O
GSH	B
,	O
and	O
other	O
reducing	B
agents	I
would	O
be	O
expected	O
to	O
be	O
low	O
.	O

The	O
marked	O
analgesic	O
efficacy	O
of	O
ketorolac	B
in	O
humans	O
,	O
relative	O
to	O
other	O
nonsteroidal	B
anti	I
-	I
inflammatory	I
drugs	I
(	O
NSAIDs	B
)	O
,	O
has	O
lead	O
to	O
speculation	O
as	O
to	O
whether	O
additional	O
non	O
-	O
NSAID	O
mechanism	O
(	O
s	O
)	O
contribute	O
to	O
its	O
analgesic	O
actions	O
.	O

To	O
evaluate	O
this	O
possibility	O
,	O
we	O
characterized	O
(	B
R	I
,	I
S	I
)	I
-ketorolac	I
's	O
pharmacological	O
properties	O
in	O
vivo	O
and	O
in	O
vitro	O
using	O
the	O
nonselective	O
cyclooxygenase	O
(	O
COX	O
)	O
inhibitors	O
[	O
indomethacin	B
(	O
INDO	B
)	O
and	O
diclofenac	B
sodium	I
(	O
DS	B
)	O
]	O
as	O
well	O
as	O
the	O
selective	O
COX-2	O
inhibitor	O
,	O
celecoxib	B
,	O
as	O
references	O
.	O

The	O
potency	O
of	O
racemic	O
(	B
R	I
,	I
S	I
)	I
-ketorolac	I
was	O
similar	O
in	O
tests	O
of	O
acetic	B
acid	I
-	O
induced	O
writhing	O
,	O
carrageenan	B
-	O
induced	O
paw	O
hyperalgesia	O
,	O
and	O
carrageenan	B
-	O
induced	O
edema	O
formation	O
in	O
rats	O
;	O
ID50	O
values	O
=	O
0.24	O
,	O
0	O
.	O
29	O
,	O
and	O
0.08	O
mg	O
/	O
kg	O
,	O
respectively	O
.	O

(	B
R	I
,	I
S	I
)	I
-ketorolac	I
's	O
actions	O
were	O
stereospecific	O
,	O
with	O
(	B
S	I
)	I
-ketorolac	I
possessing	O
the	O
biological	O
activity	O
of	O
the	O
racemate	O
in	O
the	O
above	O
tests	O
.	O

The	O
analgesic	O
potencies	O
for	O
(	B
R	I
,	I
S	I
)	I
-	O
,	O
(	O
S	B
)	O
-	O
,	O
and	O
(	B
R	I
)	I
-ketorolac	I
,	O
INDO	B
,	O
and	O
DS	B
were	O
highly	O
correlated	O
with	O
their	O
anti	O
-	O
inflammatory	O
potencies	O
,	O
suggesting	O
a	O
common	O
mechanism	O
.	O

(	B
R	I
,	I
S	I
)	I
-ketorolac	I
was	O
significantly	O
more	O
potent	O
than	O
INDO	B
or	O
DS	B
in	O
vivo	O
.	O

Neither	O
difference	O
in	O
relative	O
potency	O
of	O
COX	O
inhibition	O
for	O
(	B
R	I
,	I
S	I
)	I
-ketorolac	I
over	O
INDO	B
and	O
DS	B
nor	O
activity	O
of	O
(	B
S	I
)	I
-ketorolac	I
at	O
a	O
number	O
of	O
other	O
enzymes	O
,	O
channels	O
,	O
or	O
receptors	O
could	O
account	O
for	O
the	O
differences	O
in	O
observed	O
potency	O
.	O

The	O
distribution	O
coefficient	O
for	O
(	B
R	I
,	I
S	I
)	I
-ketorolac	I
was	O
approximately	O
30-fold	O
less	O
than	O
for	O
DS	B
or	O
INDO	B
,	O
indicating	O
that	O
(	B
R	I
,	I
S	I
)	I
-ketorolac	I
is	O
much	O
less	O
lipophilic	O
than	O
these	O
NSAIDs	B
.	O

Therefore	O
,	O
the	O
physicochemical	O
and	O
pharmacokinetics	O
properties	O
of	O
(	B
R	I
,	I
S	I
)	I
-ketorolac	I
may	O
optimize	O
the	O
concentrations	O
of	O
(	B
S	I
)	I
-ketorolac	I
at	O
its	O
biological	O
target	O
(	O
s	O
)	O
,	O
resulting	O
in	O
greater	O
efficacy	O
and	O
potency	O
in	O
vivo	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
distribution	O
,	O
excretion	O
and	O
metabolism	O
of	O
1,2-dimethylnaphthalene-	B
[	I
ring	I
-	I
U-3H	I
]	I
in	O
rats	O
.	O

The	O
experiments	O
were	O
performed	O
on	O
54	O
male	O
outbred	O
IMP	O
:	O

Wist	O
rats	O
with	O
body	O
weight	O
of	O
200	O
g	O
+	O
/-	O

20	O
%	O
.	O

The	O
compound	O
was	O
given	O
i.p	O
.	O

in	O
olive	B
oil	I
in	O
a	O
single	O
dose	O
of	O
28	O
mg	O
/	O
kg	O
(	O
about	O
6.2	O
MBq	O
per	O
animal	O
)	O
.	O

3H	B
radioactivity	O
was	O
traced	O
in	O
selected	O
organs	O
and	O
tissues	O
,	O
blood	O
,	O
urine	O
and	O
faeces	O
,	O
1	O
-	O
72	O
h	O
following	O
the	O
administration	O
.	O

The	O
main	O
metabolites	O
were	O
isolated	O
from	O
urine	O
and	O
identified	O
by	O
the	O
GC	O
-	O
MS	O
method	O
.	O

Faeces	O
and	O
urine	O
proved	O
to	O
be	O
the	O
main	O
route	O
of	O
tritium	B
elimination	O
.	O

Over	O
93	O
%	O
of	O
the	O
given	O
compound	O
was	O
excreted	O
during	O
the	O
first	O
72	O
h.	O
Maximum	O
level	O
of	O
tritium	B
in	O
plasma	O
was	O
observed	O
during	O
the	O
4th	O
h	O
after	O
the	O
compound	O
administration	O
.	O

The	O
accretion	O
of	O
3H	B
proceeded	O
with	O
kinetic	O
constant	O
of	O
0.7	O
h	O
,	O
followed	O
by	O
monophasic	O
decline	O
with	O
the	O
half	O
-	O
life	O
of	O
about	O
19h	O
.	O

In	O
organs	O
and	O
tissue	O
,	O
the	O
highest	O
concentration	O
during	O
the	O
first	O
hours	O
after	O
administration	O
were	O
detected	O
in	O
the	O
fat	O
,	O
adrenals	O
,	O
liver	O
,	O
spleen	O
and	O
kidneys	O
.	O

Then	O
gradual	O
decline	O
of	O
tritium	B
was	O
noticed	O
in	O
all	O
examined	O
tissues	O
.	O

The	O
following	O
urinary	O
metabolites	O
were	O
identified	O
:	O
1	O
.	O

1,2-dimethylthionaphthalene	B
,	O
2	O
.	O

1,2-dimethylnaphthol	B
,	O
3	O
.	O
1-methylnaphthalene-2-methanol	B
,	O
4	O
.	O
1-methyl-2-naphthoic	B
acid	I
and	O
5	O
.	O

1,2-dimethylmethylthionaphthalene	B
.	O

In	O
conclusion	O
,	O
1,2-dimethylnaphthalene	B
has	O
a	O
relatively	O
rapid	O
turnover	O
rate	O
in	O
the	O
rat	O
organism	O
and	O
does	O
not	O
form	O
deposits	O
in	O
the	O
tissue	O
.	O

The	O
metabolism	O
encompasses	O
ring	O
hydroxylation	O
and	O
glutathione	B
conjugation	O
leading	O
to	O
thionaphthol	B
and	O
oxygenation	O
,	O
and	O
then	O
to	O
naphthoic	B
acid	I
.	O

Trimethylbenzene	B
isomers	O
(	O
TMBs	B
)	O
:	O
1,2,4-TMB	B
(	O
pseudocumene	B
--	O
PS	B
)	O
,	O
1,2,3-TMB	B
(	O
hemimellitene	B
--	O
HM	B
)	O
and	O
1,3,5-TMB	B
(	O
mesitylene	B
--	O
MES	B
)	O
are	O
important	O
constituents	O
of	O
solvent	O
mixtures	O
.	O

In	O
the	O
US	O
,	O
the	O
adopted	O
TLV	O
-	O
TWA	O
value	O
for	O
TMBs	B
is	O
125	O
mg	O
/	O
m3	O
or	O
25	O
ppm	O
(	O
ACGIH	O
1996	O
)	O
.	O

Recent	O
experiments	O
at	O
our	O
laboratory	O
have	O
revealed	O
an	O
impaired	O
learning	O
of	O
passive	O
and	O
active	O
avoidance	O
responses	O
and	O
a	O
longer	O
persistence	O
of	O
an	O
effect	O
of	O
footshock	O
(	O
increase	O
in	O
latency	O
of	O
the	O
paw	O
-	O
lick	O
response	O
to	O
heat	O
)	O
in	O
rats	O
tested	O
several	O
weeks	O
after	O
a	O
four	O
-	O
week	O
inhalation	O
exposure	O
(	O
6h	O
/	O
day	O
,	O
five	O
days	O
/	O
week	O
)	O
to	O
PS	O
at	O
a	O
concentration	O
of	O
100	O
or	O
250	O
ppm	O
(	O
15	O
)	O
.	O

The	O
concentration	O
-	O
effect	O
relationship	O
appeared	O
to	O
be	O
nonlinear	O
;	O
the	O
effect	O
of	O
100	O
ppm	O
HM	B
was	O
more	O
pronounced	O
than	O
that	O
of	O
250	O
ppm	O
.	O

In	O
the	O
present	O
experiment	O
we	O
investigated	O
the	O
effects	O
of	O
a	O
repeated	O
four	O
-	O
week	O
(	O
6h	O
/	O
day	O
,	O
5	O
days	O
/	O
week	O
)	O
inhalation	O
exposure	O
to	O
HM	B
at	O
concentrations	O
of	O
0	O
,	O
25	O
,	O
100	O
or	O
250	O
ppm	O
on	O
radial	O
-	O
maze	O
performance	O
,	O
open	O
-	O
field	O
activity	O
,	O
passive	O
and	O
active	O
avoidance	O
learning	O
,	O
and	O
on	O
the	O
shock	O
-	O
induced	O
changes	O
in	O
latency	O
of	O
the	O
paw	O
-	O
lick	O
response	O
to	O
heat	O
(	O
hot	O
-	O
plate	O
test	O
)	O
.	O

The	O
tests	O
were	O
performed	O
between	O
days	O
14	O
and	O
61	O
after	O
the	O
last	O
exposure	O
.	O

No	O
significant	O
effects	O
on	O
radial	O
-	O
maze	O
performance	O
and	O
open	O
-	O
field	O
activity	O
were	O
noted	O
in	O
any	O
of	O
the	O
dose	O
groups	O
.	O

In	O
the	O
remaining	O
tests	O
effects	O
of	O
exposure	O
were	O
noted	O
but	O
,	O
similarly	O
as	O
in	O
the	O
case	O
of	O
PS	B
exposure	O
,	O
the	O
concentration	O
-	O
effect	O
relationship	O
was	O
not	O
linear	O
.	O

In	O
rats	O
exposed	O
to	O
HM	B
at	O
25	O
or	O
100	O
ppm	O
,	O
but	O
not	O
250	O
ppm	O
,	O
learning	O
of	O
the	O
passive	O
avoidance	O
,	O
i.e.	O
refraining	O
from	O
performance	O
of	O
a	O
punished	O
response	O
(	O
stepping	O
off	O
an	O
elevated	O
platform	O
)	O
was	O
significantly	O
impaired	O
.	O

Moreover	O
,	O
in	O
rats	O
exposed	O
to	O
100	O
,	O
but	O
not	O
250	O
ppm	O
of	O
HM	B
,	O
acquisition	O
of	O
the	O
two	O
-	O
way	O
active	O
avoidance	O
in	O
the	O
shuttle	O
-	O
box	O
was	O
slower	O
and	O
the	O
footshock	O
-	O
induced	O
increase	O
in	O
latency	O
of	O
the	O
paw	O
-	O
lick	O
response	O
to	O
heat	O
persisted	O
longer	O
than	O
in	O
the	O
unexposed	O
animals	O
.	O

The	O
results	O
suggest	O
that	O
a	O
low	O
-	O
level	O
inhalation	O
exposure	O
to	O
HM	B
,	O
just	O
like	O
low	O
-	O
level	O
exposure	O
to	O
PS	B
,	O
may	O
lead	O
to	O
long	O
-	O
lasting	O
disturbances	O
in	O
the	O
CNS	O
functions	O
.	O

The	O
nonlinear	O
concentration	O
-	O
effect	O
relationship	O
observed	O
in	O
the	O
case	O
of	O
both	O
TMB	B
-	I
s	I
requires	O
clarification	O
in	O
further	O
studies	O
.	O

All	O
the	O
benzodiazepines	B
(	O
BZDs	B
)	O
in	O
clinical	O
use	O
have	O
the	O
capacity	O
to	O
promote	O
the	O
binding	O
of	O
the	O
major	O
inhibitory	O
neurotransmitter	O
,	O
gamma	B
-	I
amino	I
-	I
butyric	I
acid	I
(	O
GABA	B
)	O
,	O
to	O
sub	O
-	O
types	O
of	O
GABA	B
receptors	O
which	O
exist	O
as	O
multi	O
-	O
subunit	O
ligand	O
-	O
gated	O
chloride	O
channels	O
.	O

Thus	O
,	O
the	O
BZDs	B
facilitate	O
the	O
actions	O
of	O
GABA	B
in	O
the	O
brain	O
.	O

The	O
BZDs	B
in	O
use	O
as	O
antiepileptic	B
drugs	I
are	O
diazepam	B
,	O
clonazepam	B
,	O
clobazam	B
,	O
nitrazepam	B
,	O
and	O
lately	O
,	O
also	O
lorazepam	B
and	O
midazolam	B
as	O
emergency	O
therapy	O
.	O

The	O
BZDs	B
have	O
a	O
wide	O
-	O
spectrum	O
of	O
proven	O
clinical	O
efficacy	O
in	O
the	O
prevention	O
of	O
different	O
kind	O
of	O
seizures	O
.	O

Clonazepam	B
and	O
clobazam	B
,	O
as	O
well	O
as	O
nitrazepam	B
in	O
some	O
cases	O
,	O
can	O
be	O
useful	O
as	O
an	O
adjunct	O
treatment	O
in	O
refractory	O
epilepsies	O
.	O

However	O
,	O
the	O
clinical	O
use	O
of	O
BZDs	B
for	O
the	O
prophylactic	O
treatment	O
of	O
epilepsy	O
is	O
associated	O
with	O
two	O
major	O
problems	O
which	O
have	O
limited	O
the	O
long	O
-	O
term	O
use	O
of	O
these	O
drugs	B
:	O
the	O
potential	O
for	O
side	O
-	O
effects	O
,	O
especially	O
sedative	O
effects	O
,	O
and	O
the	O
high	O
risk	O
of	O
development	O
of	O
tolerance	O
.	O

Despite	O
the	O
limitations	O
of	O
BZDs	B
in	O
the	O
prophylactic	O
treatment	O
of	O
epilepsies	O
,	O
these	O
drugs	B
play	O
a	O
prominent	O
role	O
in	O
clinical	O
practice	O
in	O
the	O
emergency	O
management	O
of	O
acute	O
seizures	O
and	O
status	O
epilepticus	O
.	O

Diazepam	B
,	I
clonazepam	B
and	O
lorazepam	B
are	O
all	O
considered	O
first	O
-	O
line	O
agents	O
in	O
the	O
emergency	O
management	O
of	O
acute	O
seizures	O
and	O
status	O
epilepticus	O
.	O

Furthermore	O
,	O
the	O
value	O
of	O
midazolam	B
as	O
an	O
emergency	O
therapy	O
in	O
epilepsy	O
has	O
been	O
increasingly	O
recognized	O
in	O
recent	O
years	O
.	O

Anti	O
-	O
ulcer	O
effects	O
of	O
cetraxate	B
,	O
a	O
new	O
compound	O
possessing	O
anti	O
-	O
plasmin	O
,	O
anti	O
-	O
casein	O
and	O
anti	O
-	O
trypsin	O
actions	O
were	O
investigated	O
by	O
using	O
experimental	O
gastric	O
ulcer	O
models	O
in	O
rats	O
.	O

Cetraxate	B
,	O
300	O
mg	O
/	O
kg	O
p.o	O
.	O
showed	O
significant	O
inhibitory	O
effects	O
of	O
65.3	O
%	O
,	O
70.0	O
%	O
,	O
30.2	O
%	O
,	O
and	O
67.1	O
%	O
against	O
aucte	O
types	O
of	O
ulcers	O
producing	O
by	O
aspirin	B
,	O
phenylbutazone	B
,	O
indomethacin	B
,	O
and	O
pyloric	O
ligature	O
(	O
Shay	O
's	O
ulcer	O
)	O
,	O
respectively	O
.	O

These	O
effects	O
were	O
greater	O
than	O
those	O
obtained	O
by	O
gefarnate	B
and	O
aluminum	B
sucrose	I
sulfate	I
may	O
be	O
mainly	O
attributed	O
to	O
the	O
protecting	O
action	O
of	O
this	O
drug	O
on	O
gastric	O
mucosa	O
.	O

Ctraxate	B
further	O
revealed	O
remarkable	O
inhibitory	O
effects	O
on	O
chronic	O
types	O
of	O
ulcers	O
produced	O
by	O
acetic	B
acid	I
,	I
clamping	O
,	O
and	O
clamping	O
-	O
cortisone	B
.	O

In	O
acetic	B
acid	I
ulcer	O
in	O
particular	O
,	O
cetraxate	B
was	O
found	O
to	O
have	O
a	O
dose	O
-	O
dependent	O
inhibitory	O
effect	O
at	O
doses	O
over	O
50	O
mg	O
/	O
kg	O
.	O

Of	O
test	O
drugs	B
including	O
L	B
-	I
glutamine	I
and	O
methylmethionine	B
sulfonium	I
chloride	I
,	O
cetraxate	B
showed	O
the	O
most	O
remarkable	O
inhibitory	O
effect	O
on	O
beta	O
-	O
glucuronidase	O
activity	O
in	O
ulcer	O
tissue	O
of	O
these	O
three	O
types	O
of	O
ulcers	O
.	O

These	O
findings	O
suggest	O
that	O
cetraxate	B
may	O
prevent	O
the	O
connective	O
tissue	O
in	O
the	O
ulcer	O
location	O
from	O
decomposition	O
due	O
to	O
lysosomal	O
enzymes	O
such	O
as	O
beta	O
-	O
glucuronidase	O
,	O
thereby	O
accelerating	O
the	O
recovery	O
from	O
ulcer	O
.	O

Sequence	O
analysis	O
reveals	O
that	O
the	O
Bacillus	O
subtilis	O
168	O
tuaABCDEFGH	O
operon	O
encodes	O
enzymes	O
required	O
for	O
the	O
polymerization	O
of	O
teichuronic	B
acid	I
as	O
well	O
as	O
for	O
the	O
synthesis	O
of	O
one	O
of	O
its	O
precursors	O
,	O
the	O
UDP	B
-	I
glucuronate	I
.	O

Mutants	O
deficient	O
in	O
any	O
of	O
the	O
tua	O
genes	O
,	O
grown	O
in	O
batch	O
cultures	O
under	O
conditions	O
of	O
phosphate	B
limitation	O
,	O
were	O
characterized	O
by	O
reduced	O
amounts	O
of	O
uronate	B
in	O
their	O
cell	O
walls	O
.	O

The	O
teichuronic	B
acid	I
operon	O
belongs	O
to	O
the	O
Pho	O
regulon	O
,	O
as	O
phosphate	B
limitation	O
induces	O
its	O
transcription	O
.	O

Placing	O
the	O
tuaABCDEFGH	O
operon	O
under	O
the	O
control	O
of	O
the	O
inducible	O
Pspac	O
promoter	O
allowed	O
its	O
constitutive	O
expression	O
independently	O
of	O
the	O
phosphate	B
concentration	O
in	O
the	O
medium	O
;	O
the	O
level	O
of	O
uronic	B
acid	I
in	O
cell	O
walls	O
was	O
dependent	O
on	O
the	O
concentration	O
of	O
the	O
inducer	O
.	O

Apparently	O
,	O
owing	O
to	O
an	O
interdependence	O
between	O
teichoic	B
and	O
teichuronic	B
acid	I
incorporation	O
into	O
the	O
cell	O
wall	O
,	O
in	O
examined	O
growth	O
conditions	O
,	O
the	O
balance	O
between	O
the	O
two	O
polymers	B
is	O
maintained	O
in	O
order	O
to	O
insure	O
a	O
constant	O
level	O
of	O
the	O
wall	O
negative	O
charge	O
.	O

Evidence	O
has	O
accumulated	O
supporting	O
the	O
concept	O
that	O
reactive	B
oxygen	I
metabolites	I
,	O
including	O
free	B
radical	I
spe­cies	O
(	O
such	O
as	O
superoxide	B
and	O
hydroxyl	B
)	O
,	O
and	O
other	O
oxygen	B
metabolites	B
(	O
such	O
as	O
hydrogen	B
peroxide	I
and	O
hypochlo­rous	B
acid	I
)	O
play	O
an	O
important	O
role	O
in	O
tissue	O
injury	O
(	O
BAUD	O
and	O
ARDALILLOU	O
1986	O
)	O
.	O

Recent	O
in	O
vitro	O
and	O
in	O
vivo	O
studies	O
have	O
implicated	O
reactive	B
oxygen	I
metabolites	I
in	O
various	O
forms	O
of	O
toxic	O
nephropathy	O
(	O
PALLER	O
et	O
al.	O
1984	O
;	O
WALKER	O
and	O
SHAH	O
1987	O
,	O
1988	O
;	O
PALLER	O
1988	O
;	O
SHAH	O
1989	O
)	O
.	O

The	O
putative	O
site	O
of	O
injury	O
in	O
most	O
forms	O
of	O
toxic	O
nephropathy	O
is	O
the	O
epithelial	O
cells	O
lining	O
the	O
tubules	O
(	O
BREZIS	O
et	O
al.	O
1991	O
)	O
.	O

From	O
this	O
viewpoint	O
,	O
therefore	O
,	O
protecting	O
these	O
cells	O
from	O
toxic	O
oxygen	B
metabolites	I
may	O
reduce	O
the	O
risk	O
of	O
renal	O
disorders	O
.	O

Although	O
a	O
native	O
scavenger	O
system	O
is	O
capable	O
ofdoing	O
this	O
,	O
it	O
may	O
lose	O
its	O
activity	O
under	O
pathogenic	O
conditions	O
due	O
to	O
organ	O
dysfunction	O
and	O
an	O
excess	O
of	O
free	B
radicals	I
.	O

Therefore	O
,	O
supplementation	O
with	O
chemical	B
scavengers	I
would	O
be	O
necessary	O
in	O
order	O
to	O
decompose	O
these	O
excess	O
pathogenic	O
metabolites	O
.	O

In	O
this	O
study	O
,	O
we	O
evaluated	O
the	O
membrane	O
protective	O
effects	O
of	O
some	O
flavonoids	B
on	O
the	O
LLC	O
-	O
PKj	O
cell	O
line	O
,	O
which	O
maintains	O
the	O
differentiated	O
characteristics	O
of	O
renal	O
proximal	O
tubular	O
cells	O
(	O
CANTIELLO	O
et	O
al.	O
1987	O
)	O
.	O

This	O
cell	O
line	O
has	O
been	O
used	O
extensively	O
in	O
in	O
vitro	O
studies	O
to	O
examine	O
both	O
physiologic	O
and	O
pathophysiologic	O
mecha­nisms	O
in	O
renal	O
tubules	O
(	O
CANTIELLO	O
et	O
al.	O
1987	O
;	O
MULLIN	O
and	O
McGINN	O
1988	O
;	O
ANDREOLI	O
and	O
McATEER	O
1990	O
;	O
ER­COLANI	O
et	O
al.	O
1990	O
;	O
YOKOZAWA	O
et	O
al.	O
1997a	O
,	O
1997b	O
)	O
.	O

The	O
purposes	O
of	O
this	O
study	O
were	O
to	O
screen	O
out	O
a	O
potentially	O
useful	O
agent	O
for	O
cell	O
membrane	O
protection	O
,	O
and	O
to	O
shed	O
light	O
on	O
the	O
possible	O
mechanism	O
of	O
this	O
process	O
.	O

Material	O
and	O
methods	O
Compounds	O
:	O
Flavones	B
(	O
acacetin	B
,	O
apigenin	B
,	O
apiin	B
,	O
bai­calein	B
,	O
baicalin	B
,	O
chrysoeriol	B
,	O
cirsilineol	B
,	O
cirsiliol	B
,	O
cirsimarin	B
,	O
cirsimaritin	B
,	O
cosmosiin	B
,	O
genkwanin	B
,	O
6-hydroxyluteolin	B
,	O
linarin	B
,	O
luteolin	B
,	O
luteolin	O
7	B
-glucoside	I
,	O
pectolinarigenin	B
,	O
pec­tolinarin	B
,	O
plantaginin	B
,	O
rhoifolin	B
,	O
scutellarein	B
,	O
sorbarin	B
,	O
tecto­chrysin	B
and	O
toringin	B
)	O
and	O
flavonols	B
(	O
afzelin	B
,	O
chrysosplenol	B
B	I
,	O
chrysosplenol	B
C	I
,	O
chrysosplenol	B
D	I
,	O
hyperin	B
,	O
isoquercitrin	B
,	O
isorhamnetin	B
,	O
kaempferitrin	B
,	O
kaempferol	B
,	O
kaempferol-7­glucoside	B
,	O
oxyayanin	B
A	I
,	O
quercetin	B
,	O
quercimeritrin	B
,	O
quer­citrin	B
,	O
rhamnetin	B
,	O
rutin	B
and	O
tetramethylquercitin	B
)	O
used	O
in	O
this	O
experiment	O
were	O
isolated	O
from	O
natural	O
sources	O
.	O

Medium	O
and	O
reagents	O
:	O
Dulbecco	B
's	I
modified	I
Eagle	I
medium	I
/	I
nutrient	I
mixture	I
F-12	I
(	O
D	B
-	I
MEMIF-12	I
)	O
and	O
fetal	O
calf	O
serum	O
(	O
FCS	O
)	O
were	O
purchased	O
from	O
Life	O
Technologies	O
,	O
Exp	O
Toxic	O
Patho151	O
(	O
1999	O
)	O
1	O
ries	O
(	O
Cleveland	O
,	O
OH	O
,	O
USA	O
)	O
,	O
respectively	O
.	O

A	O
commercial	O
kit	O
(	O
lactate	O
dehydrogenase	O
ClI	O
-	O
Test	O
Wako	O
)	O
for	O
assaying	O
lactate	O
dehydrogenase	O
(	O
LDH	O
)	O
was	O
obtained	O
from	O
Wako	O
Pure	O
Chemical	O
Industries	O
,	O
Ltd.	O
,	O
Osaka	O
,	O
Japan	O
.	O

Cultured	O
cell	O
experiments	O
:	O
Commercially	O
available	O
LLC	O
-	O
PK1	O
cells	O
were	O
maintained	O
at	O
37	O
°	O
C	O
in	O
a	O
humidified	O
at­mosphere	O
of	O
5	O
%	O
CO2	B
in	O
air	O
(	O
routine	O
conditions	O
)	O
on	O
culture	O
plates	O
with	O
5	O
%	O
FCS	O
-	O
supplemented	O
D	B
-	I
MEM	I
/	I
F-12	I
medium	O
.	O

After	O
confluence	O
had	O
been	O
reached	O
,	O
the	O
cells	O
were	O
seeded	O
on	O
fresh	O
96-well	O
culture	O
plates	O
at	O
104	O
per	O
well	O
.	O

Each	O
flavonoid	B
compound	O
was	O
added	O
to	O
the	O
culture	O
2	O
h	O
later	O
,	O
and	O
the	O
plates	O
were	O
incubated	O
under	O
routine	O
conditions	O
for	O
48	O
h.	O
Leakage	O
of	O
LDH	O
into	O
the	O
culture	O
medium	O
was	O
assayed	O
using	O
a	O
com­mercial	O
kit	O
.	O

The	O
level	O
of	O
lipid	B
peroxidant	I
released	O
from	O
the	O
cultured	O
cells	O
was	O
estimated	O
by	O
measuring	O
the	O
amount	O
of	O
malondialdehyde	B
(	O
MDA	B
)	O
as	O
described	O
by	O
YAGI	O
(	O
1976	O
)	O
.	O

All	O
assays	O
were	O
performed	O
5	O
times	O
.	O

Statistics	O
:	O
Data	O
are	O
presented	O
as	O
mean	O
±	O
S.E.	O
Differences	O
among	O
groups	O
were	O
analyzed	O
by	O
Dunnett	O
's	O
test	O
.	O

Signifi­cance	O
was	O
accepted	O
at	O
p	O
<	O
0.05	O
.	O

Results	O
Flavone	B
-	I
type	I
compounds	I
:	O
Eighteen	O
of	O
24	O
flavones	B
(	O
75	O
%	O
)	O
demonstrated	O
different	O
degrees	O
of	O
membrane	O
pro­tective	O
activity	O
.	O

Baicalin	B
,	O
cirsimaritin	B
,	O
6-hydroxyluteolin	B
,	O
luteolin	B
,	O
plantaginin	B
,	O
rhoifolin	B
and	O
sorbarin	B
appeared	O
to	O
be	O
the	O
most	O
effective	O
compounds	O
for	O
preventing	O
LDH	O
leakage	O
,	O
since	O
only	O
a	O
very	O
low	O
concentration	O
of	O
0.25	O
Ilg	O
/	O
ml	O
was	O
needed	O
for	O
coculture	O
with	O
the	O
cells	O
,	O
as	O
shown	O
in	O
table	O
1	O
.	O

Cirsimarin	B
,	O
luteolin	B
7	I
-glucoside	I
,	O
pectolinarigenin	B
,	O
tec­tochrysin	B
and	O
toringin	B
showed	O
significant	O
inhibition	O
at	O
a	O
concentration	O
of	O
0.5	O
Ilg	O
/	O
ml	O
.	O

Five	O
compounds	O
,	O
baicalein	B
,	O
chrysoeriol	B
,	O
cirsiliol	B
,	O
linarin	B
and	O
scutellarein	B
,	O
suppressed	O
the	O
leakage	O
significantly	O
at	O
a	O
minimum	O
concentration	O
of	O
2.5	O
Ilg	O
/	O
ml	O
.	O

However	O
,	O
the	O
other	O
flavone	B
compounds	I
acted	O
only	O
weakly	O
in	O
comparison	O
with	O
those	O
described	O
above	O
.	O

In	O
addition	O
,	O
LDH	O
efflux	O
was	O
apparently	O
associated	O
with	O
the	O
MDA	B
level	O
.	O

The	O
amount	O
ofthis	O
lipid	B
peroxidant	I
form­ed	O
declined	O
markedly	O
when	O
the	O
cells	O
were	O
cultured	O
in	O
the	O
presence	O
of	O
baicalin	B
,	O
cirsimarin	B
,	O
cirsimaritin	B
,	O
6-hydroxy­luteolin	B
,	O
luteolin	B
,	O
luteolin	B
7-glucoside	I
,	O
pectolinarigenin	B
,	O
plantaginin	B
,	O
rhoifolin	B
,	O
sorbarin	B
and	O
tectochrysin	B
.	O

The	O
in­hibition	O
ofMDA	O
formation	B
by	O
these	O
compounds	O
was	O
con­centration	O
-	O
dependent	O
.	O

Flavonol	B
-	I
type	I
compounds	I
:	O
As	O
shown	O
in	O
table	O
2	O
,	O
most	O
flavonol	B
compounds	I
tested	O
(	O
14	O
out	O
of	O
17	O
)	O
revealed	O
much	O
higher	O
activity	O
in	O
preventing	O
enzyme	O
efflux	O
.	O

Afzelin	B
,	O
hy­perin	B
,	O
isoquercitrin	B
,	O
isorhamnetin	B
,	O
kaempferitrin	B
,	O
kaemp­ferol-7	B
-glucoside	I
,	O
oxyayanin	B
A	I
,	O
quercetin	B
,	O
quercitrin	B
,	O
rhamnetin	B
and	O
rutin	B
were	O
markedly	O
effective	O
because	O
the	O
released	O
LDH	O
was	O
significantly	O
decreased	O
when	O
they	O
were	O
cocultured	O
with	O
the	O
cells	O
even	O
at	O
a	O
concentration	O
of	O
0.25	O
Ilg	O
/	O
ml	O
,	O
isoquercitrin	B
and	O
isorhamnetin	B
exerting	O
the	O
strongest	O
effect	O
.	O

Higher	O
concentrations	O
of	O
chrysosplenol	B
B	I
and	O
chrysosplenol	B
C	I
(	O
20	O
times	O
those	O
of	O
the	O
above	O
com­pounds	O
)	O
were	O
required	O
to	O
inhibit	O
LDH	O
release	O
to	O
the	O
same	O
extent	O
,	O
but	O
tetramethylquercitin	B
did	O
not	O
affect	O
LDH	O
re-	O
Exp	O
Toxic	O
Pathol	O
51	O
(	O
1999	O
)	O
1	O
MDA	B
leakage	O
from	O
LLC	O
-	O
PK1	O
Compound	O
Con­	O
centration	O
(	O
Ilg	O
/	O
ml	O
)	O
Acacetin	B
0.25	O
0.5	O
2.5	O
5	O
Apigenin	B
0.25	O
0.5	O
2.5	O
5	O
Apiin	B
0.25	O
0.5	O
2.5	O
5	O
Baicalein	B
0.25	O
0.5	O
2.5	O
5	O
Baicalin	B
0.25	O
0.5	O
2.5	O
5	O
Chrysoeriol	B
0.25	O
0.5	O
2.5	O
5	O
Cirsilineol	B
0.25	O
0.5	O
2.5	O
5	O
Cirsiliol	B
0.25	O
0.5	O
2.5	O
5	O
Cirsimarin	B
0.25	O
0.5	O
2.5	O
5	O
Cirsimaritin	B
0.25	O
0.5	O
2.5	O
5	O
Cosmosiin	B
0.25	O
0.5	O
2.5	O
5	O
cells	O
.	O

LDH	O
leakage	O
rate	O
(	O
%	O
)	O
92.8	O
±	O
6.2	O
90.2	O
±	O
6.3	O
89.8	O
±	O
5.9	O
89.2	O
±	O
9.5	O
96.7	O
±6.7	O
94.9	O
±	O
5.6	O
95.5	O
±	O
7.5	O
91.8	O
±	O
5.2	O
98.3	O
±	O
6.3	O
89.2	O
±	O
7.0	O
88.9	O
±	O
6.2	O
87.9±7.1	O
96.5	O
±	O
2.8	O
91.3	O
±	O
4.2	O
82.9	O
±	O
9.4b	O
81.4	O
±	O
6.lb	O
80.0	O
±	O
6.5	O
""""	O
80.3	O
±	O
5.ge	O
80.7	O
±	O
5.8e	O
76.2	O
±	O
3.4	O
<	O
101.1	O
±	O
5.7	O
89.3	O
±	O
4.3	O
84.6	O
±	O
8.9b	O
85.2	O
±	O
8.0	O
""""	O
99.9	O
±	O
5.9	O
96.5	O
±	O
8.9	O
93.9	O
±	O
9.5	O
88.1	O
±	O
7.6	O
94.0	O
±7.9	O
88.4	O
±	O
7.0	O
82.9	O
±	O
6.4	O
""""	O
71.6	O
±	O
6.3c	O
89.3	O
±	O
6.4	O
82.9	O
±	O
6.1b	O
77.3	O
±	O
5.7e	O
67.6	O
±	O
6.7e	O
80.5	O
±	O
5.1e	O
71.1	O
±5.9c	O
59.9	O
±	O
6.7c	O
52.8	O
±	O
7.4c	O
97.5	O
±	O
6.1	O
88.6	O
±	O
6.5	O
85.5	O
±	O
6.7	O
79.1	O
±7.5	O
""""	O
MDA	B
leakage	O
rate	O
(	O
%	O
)	O
89.5	O
±	O
8.4	O
85.7	O
±	O
8.5	O
86.4	O
±	O
8.2	O
79.9	O
±	O
6.8b	O
97.3	O
±	O
9.7	O
95.6	O
±	O
8.3	O
88.5	O
±	O
5.4	O
85.7	O
±	O
6.6	O
93.2	O
±	O
5.1	O
94.2	O
±	O
5.7	O
94.2	O
±	O
5.7	O
92.4	O
±	O
4.4	O
95.5	O
±	O
4.7	O
93.2	O
±	O
6.1	O
91.7	O
±	O
4.2	O
89.1	O
±4.4	O
""""	O
81.9	O
±	O
7.8b	O
79.0	O
±	O
5.2b	O
75.4	O
±	O
6.3e	O
72.1	O
±	O
6.1c	O
97.9	O
±	O
8.7	O
95.8	O
±	O
8.7	O
93.7	O
±	O
7.6	O
89.4	O
±	O
7.8	O
95.6	O
±	O
5.7	O
94.2	O
±	O
8.7	O
90.5	O
±	O
7.8	O
92.6	O
±	O
6.4	O
97.8±7.1	O
91.6	O
±	O
5.8	O
80.0	O
±	O
7.8b	O
76.1	O
±	O
5.9c	O
85.7	O
±	O
6.7	O
""""	O
83.2	O
±	O
7.2b	O
76.6	O
±	O
5.7e	O
69.5	O
±	O
5.8c	O
85.2	O
±	O
6.7	O
""""	O
75.7	O
±	O
5.7c	O
63.7	O
±	O
6.1e	O
57.3	O
±	O
6.0e	O
93.1	O
±	O
7.1	O
89.6	O
±	O
7.1	O
82.6	O
±	O
6.8	O
""""	O
77.2	O
±	O
6.3b	O
Compound	O
Con-	O
LDH	O
leakage	O
MDA	B
leakage	O

Compound	O
Con-	O
LDH	O
leakage	O
MDAleakage	B
centration	O
rate	O
rate	O
centration	O
rate	O
rate	O
(	O
Ilg	O
/	O
ml	O
)	O
(	O
%	O
)	O
(	O
%	O
)	O
(	O
Ilg	O
/	O
ml	O
)	O
(	O
%	O
)	O
(	O
%	O
)	O
Genkwanin	B
0.25	O
0.5	O
116.4	O
±	O
18.1	O
108.1	O
±	O
11.9	O
110.5	O
±	O
13.6	O
106.8	O
±	O
7.1	O
Tectochrysin	B
0.25	O
0.5	O
93.6	O
±	O

6.0	O
84.5	O
±	O
6.7a	O
95.0	O
±	O
7.5	O
85.2	O
±	O
7.7b	O
2.5	O
101.9	O
±	O
10.9	O
103.7	O
±	O
6.5	O
2.5	O
82.2	O
±	O
7.5b	O
85.8	O
±	O
6.9a	O
5	O
100.2	O
±	O
9.2	O
103.4	O
±	O
6.2	O
5	O
71.2	O
±	O
5.ge	O
68.4	O
±	O
7.6e	O
6-Hydro­	B
xyluteolin	I
0.25	O
n.3	O
±	O
7.2e	O
78.6	O
±	O
5.2e	O
Toringin	B
0.25	O
88.9	O
±	O
6.5	O
91.0	O
±	O
6.9	O
0.5	O
69.1	O
±5.7e	O
n.6	O
±	O
6.8c	O
0.5	O
86.9	O
±	O
7.8a	O
89.3	O
±	O
6.3	O
2.5	O
53.8	O
±	O
5.8c	O
59.4±6.1c	O
2.5	O
83.4	O
±	O
6.1b	O
78.4	O
±	O
5.7e	O
5	O
50.9	O
±	O
5.6e	O
54.7	O
±	O
7.2e	O
5	O
76.5	O
±	O
5.4e	O
73.9	O
±	O
4.ge	O
Linarin	B
0.25	O
97.4	O
±	O
5.6	O
95.3	O
±	O
7.6	O
Control	O
100.0	O
±	O
6.1	O
100.0	O
±	O
6.9	O
0.5	O
94.5	O
±	O
5.1	O
'	O
91.4	O
±	O
7.1	O
2.5	O
79.3	O
±	O
7.3e	O
82.1	O
±	O
6.2b	O
Significantly	O
different	O
from	O
the	O
control	O
value	O
:	O
ap	O
<	O
0.05	O
,	O
5	O
68.2	O
±	O
8.2e	O
69.5	O
±	O
7.6e	O
bp	O
<	O
0.01	O
,	O
ep	O
<	O
0.001	O
.	O

Luteolin	B
0.25	O
78.9±4.1e	O
83.5	O
±	O
6.2b	O
Table	O
2	O
.	O

Effect	O
of	O
flavonol	B
-	I
type	I
compounds	I
on	O
LDH	O
and	O
0.5	O
76.6	O
±	O
5.7e	O
81.7±6.1b	O
MDA	B
leakage	O
from	O
LLC	O
-	O
PK1	O
cells	O
.	O

2.5	O
74.6	O
±	O
5.8e	O
78.0	O
±	O
5.4e	O
5	O
67.8	O
±	O
5.2e	O
66.8	O
±	O
6.ge	O
Compound	O
Con-	O
LDH	O
leakage	O
MDA	B
leakage	O
Luteolin	B
centration	O
rate	O
rate	O
7	B
-glucoside	I
0.25	O
97.5	O
±	O
5.6	O
96.3	O
±	O
4.9	O
(	O
Ilg	O
/	O
ml	O
)	O
(	O
%	O
)	O
(	O
%	O
)	O
0.5	O
83.2±7.1b	O
86.3	O
±	O
6.2a	O
2.5	O
5	O
70.3	O
±	O
7.ge	O
63.2	O
±	O
7.4e	O
75.2	O
±	O
6.2e	O
65.7	O
±	O
5.8e	O
Afzelin	B
0.25	O
0.5	O
67.8	O
±	O
3.5b	O
63.2±3.1b	O
73.9	O
±	O
5.9b	O
70.8	O
±	O
6.4b	O
Pecto­	B
2.5	O
59.7	O
±	O
6.9b	O
65.3	O
±	O
6.7b	O
linarigenin	B
0.25	O
93.2	O
±	O
7.7	O
96.8	O
±4.7	O
5	O
56.1	O
±	O
4.5b	O
53.7	O
±	O
4.6b	O
0.5	O
69.2	O
±	O
5.2e	O
n.6±7.1e	O
Chryso­	B
2.5	O
57.4	O
±	O
6.1c	O
62.6	O
±	O
6.4e	O
splenol	B
B	I
0.25	O
107.7	O
±	O
7.0	O
100.2	O
±	O
9.1	O
5	O
48.0	O
±	O
6.5	O
<	O
54.1	O
±	O
5.3e	O
0.5	O
100.3	O
±	O
6.7	O
95.8	O
±	O
7.6	O
2.5	O
89.8	O
±	O
6.4	O
92.7	O
±	O
6.7	O
Pectolinarin	B
0.25	O
103.8	O
±	O
5.7	O
103.1	O
±	O
5.1	O
5	O
70.4	O
±	O
5.3b	O
76.2	O
±	O
6.8b	O
0.5	O
100.5	O
±	O
7.1	O
100.3	O
±	O
6.2	O
Chryso­	B
2.5	O
99.2	O
±	O
5.1	O
96.3	O
±	O
4.8	O
splenol	B
C	I
0.25	O
100.7	O
±	O
6.9	O
94.8	O
±	O
5.8	O
5	O
89.3	O
±	O
6.2	O
92.0	O
±	O
5.7	O
0.5	O
98.2	O
±	O
6.6	O
94.2	O
±4.5	O

2.5	O
94.6	O
±	O
6.5	O
90.5	O
±	O
7.7	O
Plantaginin	B
0.25	O
80.0	O
±	O
4.2c	O
83.2	O
±	O
4.4b	O
5	O
84.2	O
±	O
4.7a	O
81.1	O
±6.4b	O
0.5	O
71.3	O
±	O
5.2e	O
76.8	O
±	O
4.7e	O
Chryso­	B
2.5	O
67.5	O
±	O
5.7e	O
67.8	O
±	O
6.2e	O
splenol	B
D	I
0.25	O
91.6	O
±	O
6.8	O
95.2	O
±	O
4.2	O
5	O
63.0	O
±	O
6.3e	O
59.5	O
±	O
5.0e	O
0.5	O
84.7	O
±	O
5.3a	O
90.5	O
±	O
7.4	O
2.5	O
80.8	O
±	O
4.4b	O
81.1	O
±	O
5.8b	O
Rhoifolin	B
0.25	O
82.4	O
±	O
5.7e	O
85.3±6.1b	O
5	O
75.6	O
±	O
5.4b	O
73.7±5.1b	O
0.5	O
2.5	O
5	O
79.5	O
±	O
5.1e	O
71.9±6.1e	O
71.3	O
±	O
4.4e	O
81.5	O
±	O
5.ge	O
73.9	O
±	O
6.3e	O
n.l	O
±	O
6.ge	O
Hyperin	B
0.25	O
0.5	O
2.5	O
86.9	O
±	O
6.8a	O
63.7	O
±	O
5.6b	O
50.2	O
±	O
3.9b	O
94.6	O
±	O
6.1	O
71.7	O
±	O
6.9b	O
59.5	O
±	O
4.4b	O
Scutellarein	B
0.25	O
95.9	O
±	O
7.4	O
93.7	O
±	O
4.2	O
5	O
41.9	O
±	O
4.0b	O
48.2	O
±	O
4.3b	O
0.5	O
2.5	O
5	O
90.6	O
±	O
6.9	O
80.6	O
±	O
7.7b	O
63.5	O
±	O
6.4e	O
91.4	O
±	O
5.9	O
84.3	O
±	O
7.4b	O
60.0	O
±	O
5.3e	O
Isoquercitrin	B
0.25	O
0.5	O
2.5	O
47.6	O
±	O
4.9b	O
46.5	O
±	O
3.5b	O
42.2	O
±	O
4.7b	O
57.1	O
±4.9b	O
52.0	O
±	O
4.9b	O
50.5	O
±	O
5.8b	O
Sorbarin	B
0.25	O
60.0	O
±	O
4.4e	O
63.3	O
±	O
6.7e	O
5	O
39.1	O
±	O
3.5b	O
45.6	O
±	O
4.0b	O
0.5	O
2.5	O
5	O
54.9	O
±	O
5.5	O
<	O
50.1	O
±	O
7.8e	O
47.0	O
±	O
5.2e	O
59.2	O
±	O
5.5	O
<	O
53.3	O
±	O
5.8e	O
42.6	O
±	O
4.8e	O
Isorhamnetin	B
0.25	O
0.5	O
2.5	O
63.0	O
±	O
5.4b	O
51.4	O
±	O
4.8b	O
32.2	O
±	O
3.7b	O
74.2	O
±	O
6.8b	O
62.8	O
±	O
6.2b	O
40.1	O
±	O
3.6b	O
5	O
21.6	O
±	O
3.7b	O
32.3	O
±	O
3.0b	O
Exp	O
Toxic	O
Pathol51	O
(	O
1999	O
)	O

I	O
Discussion	O
Compound	O
Con	O
-	O
LDH	O
leakage	O
MDAleakage	B
centration	O
rate	O
rate	O
(	O
Ilg	O
/	O
ml	O
)	O
(	O
%	O
)	O
(	O
%	O
)	O
Kaempferitrin	B
0.25	O
78.5	O
±	O
5.4b	O
82.2	O
±	O
6.1b	O
0.5	O
75.9	O
±	O
3.2b	O
78.9	O
±	O
6.8b	O
2.5	O
74.3	O
±	O
5.6b	O
71.6	O
±	O
4.3b	O
5	O
72.3	O
±	O
6.1b	O
68.4	O
±	O
4.9b	O
Kaempferol	B
0.25	O
99.3	O
±	O
5.4	O
92.6	O
±	O
7.1	O
0.5	O
79.4	O
±	O
6.5b	O
84.1	O
±	O
4.7a	O
2.5	O
73.3	O
±	O
5.7b	O
78.9	O
±	O
4.9b	O
5	O
66.9	O
±4.4b	O
62.1	O
±4.6b	O
Kaempferol-	B
0.25	O
77.2	O
±	O
5.7b	O
81.5	O
±	O
6.9b	O
7-glucoside	B
0.5	O
72.2	O
±4.1b	O
77.9±5.1b	O
2.5	O
61.4	O
±	O
5.7b	O
66.3	O
±	O
6.2b	O
5	O
53.7	O
±	O
4.8b	O
60.2	O
±	O
4.2b	O
Oxyayanin	B
A	I
0.25	O
86.0	O
±	O
5.78	O
83.7	O
±	O
4.3a	O
0.5	O
83.3	O
±	O
4.8b	O
77.3±7.1b	O
2.5	O
73.5	O
±	O
4.7b	O
68.9	O
±	O
6.9b	O
5	O
67.6	O
±	O
4.8b	O
60.2	O
±	O
5.2b	O
Quercetin	B
0.25	O
77.2	O
±	O
5.8b	O
81.5	O
±	O
5.6b	O
0.5	O
76.5	O
±4.8b	O
79.7	O
±	O
6.2b	O
2.5	O
75.6	O
±	O
3.3b	O
72.1	O
±	O
5.0b	O
5	O
73.5	O
±	O
4.3b	O
69.5	O
±4.6b	O
Quercimeritrin	B
0.25	O
107.0	O
±	O
7.1	O
99.9	O
±4.0	O
0.5	O
98.7	O
±4.7	O
94.7	O
±	O
6.9	O
2.5	O
86.3	O
±	O
5.7a	O
89.4	O
±	O
6.1	O
5	O
74.6	O
±	O
4.4b	O
77.4	O
±4.9b	O
Quercitrin	B
0.25	O
79.1	O
±	O
3.1b	O
81.4	O
±	O
5.5b	O
0.5	O
75.5	O
±	O
4.2b	O
82.1	O
±	O
4.8b	O
2.5	O
70.5	O
±4.9b	O
74.2	O
±	O
4.2b	O
5	O
63.5	O
±	O
4.5b	O
58.1	O
±	O
5.3b	O
Rhamnetin	B
0.25	O
70.4	O
±	O
4.1	O
b	O
80.2	O
±	O
5.2b	O
0.5	O
66.3	O
±	O
4.2b	O
71.0	O
±	O
5.6b	O
2.5	O
51.3±3.1b	O
56.5	O
±	O
4.8b	O
5	O
32.3	O
±	O
3.2b	O
38.4	O
±	O
2.5b	O
Rutin	O
0.25	O
73.2	O
±	O
5.1b	O
79.5	O
±	O
5.5b	O
0.5	O
68.4	O
±	O
4.4b	O
73.4	O
±	O
6.2b	O
2.5	O
62.5	O
±	O
4.2b	O
69.7	O
±	O
5.5b	O
5	O
57.2	O
±	O
4.6b	O
62.6	O
±	O
6.8b	O
Tetramethyl-0.25	B
99.6	O
±	O
7.4	O
97.1	O
±	O
4.9	O
quercitin	B
0.5	O
94.1	O
±	O
7.7	O
96.3	O
±	O
5.3	O
2.5	O
94.3±7.1	O
91.5	O
±	O
7.7	O
5	O
93.4	O
±	O
6.8	O
90.5	O
±	O
8.0	O
Control	O
100.0±	O
5.8	O
100.0	O
±	O
7.1	O
Significantly	O
different	O
from	O
the	O
control	O
value	O
:	O
ap	O
<	O
0.01	O
,	O
bp	O
<	O
0.001	O
.	O

lease	O
.	O

The	O
generation	O
of	O
MDA	B
was	O
found	O
to	O
be	O
markedly	O
decreased	O
in	O
the	O
groups	O
with	O
decreased	O
LDH	O
efflux	O
,	O
which	O
indicated	O
a	O
possible	O
cause	O
and	O
effect	O
relationship	O
between	O
them	O
.	O

Exp	O
Toxic	O
Patho151	O
(	O
1999	O
)	O
1	O
One	O
ofremarkable	O
features	O
ofcellular	O
injury	O
is	O
leakage	O
ofLDH	O
,	O
a	O
soluble	O
cytosolic	O
enzyme	O
,	O
from	O
inside	O
the	O
cells	O
.	O

This	O
leakage	O
is	O
due	O
largely	O
to	O
increased	O
membrane	O
per­meability	O
,	O
which	O
is	O
probably	O
modified	O
by	O
certain	O
factors	O
such	O
as	O
antineoplastic	O
drugs	B
,	O
radiation	O
,	O
and	O
attack	O
by	O
oxy­gen	B
free	I
radical	I
species	I
.	O

It	O
is	O
therefore	O
a	O
useful	O
indicator	O
of	O
membrane	O
integrity	O
and	O
provides	O
a	O
convenient	O
ap­proach	O
for	O
cytotoxicity	O
evaluation	O
.	O

On	O
the	O
other	O
hand	O
,	O
ANDREOLI	O
and	O
McATEER	O
(	O
1990	O
)	O
,	O
RaVIN	O
et	O
al.	O
(	O
1990	O
)	O
and	O
WALKER	O
and	O
SHAH	O
(	O
1991	O
)	O
have	O
reported	O
that	O
renal	O
tubule	O
cells	O
have	O
the	O
potential	O
to	O
produce	O
reactive	B
oxygen	I
meta­bolites	I
in	O
response	O
to	O
various	O
stimuli	O
,	O
and	O
are	O
the	O
major	O
site	O
affected	O
in	O
renal	O
failure	O
.	O

In	O
this	O
study	O
,	O
therefore	O
,	O
we	O
used	O
LDH	O
leakage	O
from	O
LLC	O
-	O
PK1	O
cells	O
as	O
an	O
indicator	O
to	O
evaluate	O
cellular	O
membrane	O
permeability	O
upon	O
incubation	O
with	O
41	O
flavonoids	B
under	O
normal	O
culture	O
conditions	O
.	O

Flavonoids	B
are	O
phenolic	B
compounds	I
widely	O
distributed	O
in	O
plants	O
,	O
with	O
thousands	O
of	O
individual	O
substances	O
known	O
,	O
and	O
the	O
list	O
is	O
constantly	O
expanding	O
.	O

These	O
important	O
bio­active	O
compounds	B
have	O
been	O
shown	O
to	O
have	O
many	O
medi­cal	O
uses	O
,	O
such	O
as	O
diuresis	O
,	O
laxation	O
,	O
and	O
antispasmodic	O
,	O
antihypertensive	O
and	O
anti	O
-	O
inflammatory	O
actions	O
(	O
MITsv­HASHI	O
et	O
al.	O
1989	O
)	O
.	O

Most	O
of	O
the	O
compounds	O
we	O
tested	O
in	O
this	O
study	O
also	O
showed	O
significant	O
effectiveness	O
in	O
in­hibiting	O
the	O
efflux	O
of	O
LDH	O
from	O
LLC	O
-	O
PK1	O
cells	O
,	O
and	O
thus	O
appeared	O
to	O
change	O
the	O
permeability	O
of	O
the	O
cellular	O
mem­brane	O
.	O

To	O
determine	O
the	O
nature	O
of	O
their	O
effect	O
,	O
we	O
measur­ed	O
the	O
MDA	B
content	O
in	O
the	O
culture	O
medium	O
,	O
and	O
found	O
that	O
under	O
routine	O
culture	O
conditions	O
such	O
as	O
5	O
%	O
CO2	B
,	O
95	O
%	O
air	O
and	O
37	O
DC	O
for	O
48	O
h	O
,	O
a	O
certain	O
amount	O
of	O
MDA	B
was	O
generated	O
.	O

This	O
suggests	O
that	O
LDH	O
efflux	O
from	O
the	O
cells	O
may	O
be	O
due	O
largely	O
to	O
lipid	B
peroxidation	O
of	O
the	O
mem­brane	O
,	O
although	O
this	O
may	O
occur	O
slowly	O
under	O
normal	O
con­ditions	O
.	O

Interestingly	O
,	O
when	O
the	O
cells	O
were	O
cocultured	O
with	O
different	O
types	O
of	O
flavones	B
and	O
flavonols	B
,	O
the	O
levels	O
of	O
both	O
LDH	O
and	O
MDA	B
in	O
the	O
medium	O
showed	O
an	O
obvious	O
de­crease	O
,	O
indicating	O
a	O
possible	O
link	O
between	O
them	O
.	O

Itis	O
there­fore	O
reasonable	O
to	O
infer	O
that	O
an	O
antiperoxidation	O
or	O
free	B
ra­dical	I
scavenging	O
mechanism	O
is	O
involved	O
in	O
this	O
process	O
because	O
of	O
the	O
reducing	O
property	O
of	O
these	O
compounds	O
.	O

Much	O
attention	O
has	O
been	O
drawn	O
to	O
the	O
antioxidative	O
ac­tivity	O
of	O
flavonoids	B
due	O
to	O
their	O
structure	O
,	O
especially	O
since	O
a	O
superoxidation	O
injury	O
hypothesis	O
has	O
been	O
put	O
forward	O
to	O
explain	O
the	O
etiology	O
and	O
pathology	O
of	O
some	O
diseases	O
,	O
and	O
this	O
has	O
prompted	O
extensive	O
studies	O
on	O
their	O
antioxi­dative	O
and	O
lipid	B
peroxidation	O
-	O
inhibiting	O
potential	O
.	O

Our	O
data	O
revealed	O
that	O
the	O
action	O
of	O
flavonoids	B
was	O
closely	O
re­lated	O
to	O
their	O
chemical	O
structures	O
.	O

First	O
,	O
as	O
shown	O
in	O
table	O
3	O
,	O
those	O
that	O
demonstrated	O
marked	O
inhibition	O
of	O
LDH	O
efflux	O
activity	O
possess	O
more	O
phenolic	B
hydroxyl	I
groups	I
linked	O
to	O
the	O
backbone	O
.	O

For	O
example	O
,	O
having	O
an	O
extra	O
OH	B
at	O
the	O
3-position	O
made	O
10	O
of	O
the	O
17	O
flavonols	B
tested	O
here	O
exhibit	O
a	O
significant	O
effect	O
at	O
a	O
concentration	O
as	O
low	O
as	O
0.25	O
Ilg	O
in	O
the	O
medium	O
;	O
in	O
contrast	O
,	O
among	O
flavone	B
types	O
,	O
only	O
7	O
out	O
of	O
24	O
(	O
about	O
29	O
%	O
)	O
showed	O
such	O
activity	O
at	O
the	O
same	O
concentration	O
,	O
suggesting	O
that	O
hydroxyl	B
groups	I
are	O
of	O
prime	O
importance	O
for	O
their	O
effects	O
.	O

Compound	O
5	O
6	O
7	O
8	O
3	O
2	O
'	O
3	O
'	O
4	O
'	O
5	O
'	O
6	O
'	O
*	O
Aeaeetin	B
OH	O

OH	O
OMe	O
Apigenin	B
OH	O
OH	O
OH	O
Apiin	B
OH	O

OH	O
*	O
OH	O
apioglue	O
Baicalein	B
OH	O
OH	O
OH	O
Baiealin	B
OH	O
OH	O

OH	O

*	O
glueur	O
Chrysoeriol	B
OH	O
OH	O
OMe	O
OH	O
Cirsilineol	B
OH	O
OMe	O
OMe	O
OMe	O
OH	O
Cirsiliol	B
OH	O
OMe	O
OMe	O
OH	O

OH	O
Cirsimarin	B
OH	O
OMe	O
OMe	O
OH	O

*	O
glue	O
Cirsimaritin	B
OH	O
OMe	O
OMe	O
OH	O
Cosmosiin	B
OH	O

OH	O

*	O
OH	O
glue	O
Genkwanin	B
OH	O
OMe	O
OH	O
6-Hydroxyluteolin	B
OH	O
OH	O
OH	O
OH	O
OH	O
Linarin	B
OH	O

OH	O
*	O
OMe	O
rham	O
,	O
glue	O
Luteolin	B
OH	O
OH	O
OH	O
OH	O
Luteolin	B
7-glueoside	I
OH	O

OH	O

*	O
OH	O
OH	O
glue	O
Peetolinarigenin	B
OH	O
OMe	O
OMe	O
OMe	O
rham	O
,	O
glue	O
Peetolinarin	B
OH	O
OMe	O
OH	O
*	O
OMe	O
rham	O
,	O
glue	O
Plantaginin	B

OH	O
OH	O

OH	O

*	O
OH	O
glue	O
Rhoifolin	B
OH	O

OH	O
*	O
OH	O
rham	O
,	O
glue	O
Scutellarein	B
OR	O
OH	O
OH	O
OH	O
Sorbarin	B

OH	O
OH	O

OH	O
*	O
OH	O
rham	O
Tectochrysin	B
OH	O
OMe	O

Toringin	B
OH	O

*	O
OH	O
gluc	O
Afzelin	B
OH	O
OH	O

OH	O
*	O
OH	O
rham	O
Chrysosplenol	B
B	I
OH	O
OMe	O
OMe	O
OMe	O
OH	O
OH	O
Chrysosplenol	B
C	I
OH	O
OH	O
OMe	O
OMe	O
OMe	O
OH	O
Chrysosplenol	B
D	I
OH	O
OMe	O
OMe	O
OMe	O
OH	O
OH	O
Hyperin	B

OH	O
OH	O

OH	O

*	O
OH	O
OH	O
galac	O
Isoquercitrin	B
OH	O
OR	O
OH	O

*	O
OH	O
OH	O
gluc	O
Isorhamnetin	B
OR	O
OH	O
OH	O
OMe	O
OH	O
Kaempferitrin	B
OH	O

OH	O

*	O
OH	O
*	O
OH	O
rham	O
Kaempferol	B
OH	O
OH	O
OH	O
OH	O
Kaempferol-7	B
-glucoside	I
OH	O

OR	O
*	O
OH	O
OH	O
gluc	O
Oxyayanin	B
A	I
OH	O
OMe	O
OMe	O
OH	O
OMe	O
OH	O
Quercetin	B
OH	O
OH	O
OH	O
OH	O
OH	O
Quercimeritrin	B
OH	O
OR	O
*	O
OH	O
OH	O
OH	O
gluc	O
Quercitrin	B
OH	O
OH	O

OH	O
*	O
OH	O
OH	O
rham	O
Rhamnetin	B
OH	O
OMe	O
OH	O
OH	O
OH	O
Rutin	B

OH	O
OH	O

OH	O
*	O
OH	O
OH	O
rham	O
,	O
gluc	O
Tetramethylquercitin	B
OMe	O
OMe	O
OH	O
OMe	O
OMe	O
Exp	O
Toxic	O
Pathol51	O
(	O
1999	O
)	O
1	O
On	O
the	O
other	O
hand	O
,	O
different	O
capabilities	O
of	O
cell	O
mem­brane	O
protection	O
were	O
observed	O
in	O
compounds	O
ofthe	O
same	O
type	O
,	O
due	O
mainly	O
to	O
the	O
hydroxyl	O
group	O
position	O
on	O
the	O
fla­vonoid	B
backbone	O
.	O

Most	O
flavone	B
-	B
type	I
compounds	I
gener­ally	O
possessing	O
6-or	B
3'-OH	B
in	O
their	O
structure	O
demonstrat­ed	O
marked	O
LDH	O
leakage	O
inhibition	O
and	O
antioxidation	O
activity	O
.	O

For	O
example	O
,	O
baicalin	B
,	O
plantaginin	B
and	O
sorbarin	B
belonged	O
to	O
the	O
former	O
,	O
while	O
luteolin	B
and	O
luteolin	B
7-glu­coside	I
were	O
ofthe	O
latter	O
type	O
;	O
6-hydroxyluteolin	B
had	O
both	O
.	O

However	O
,	O
there	O
were	O
some	O
exceptions	O
.	O

Although	O
lacking	O
6-and	B
3'-OH	I
,	O
cirsimaritin	B
and	O
rhoifolin	B
still	O
showed	O
membrane	O
protection	O
and	O
banding	O
MDA	B
production	O
;	O
in	O
contrast	O
,	O
baicalein	B
,	O
cirsiliol	B
and	O
scutellarein	B
showed	O
a	O
weak	O
effect	O
,	O
even	O
though	O
they	O
possess	O
either	O
6	B
-	I
0H	I
or	O
3'­OH	B
.	O

The	O
reason	O
for	O
this	O
remains	O
unclear	O
.	O

In	O
addition	O
,	O
it	O
has	O
been	O
observed	O
that	O
linked	B
sugar	I
might	O
contribute	O
to	O
membrane	O
protection	O
.	O

Among	O
the	O
most	O
effective	O
com­pounds	O
in	O
this	O
study	O
-baicalin	O
,	O
cirsimaritin	B
,	O
6-hydroxy­luteolin	B
,	O
luteolin	B
,	O
plantaginin	B
,	O
rhoifolin	B
and	O
sorbarin	B
­four	O
possess	O
glucuronic	B
acid	I
,	O
glucose	B
or	O
rhamnose	B
.	O

This	O
implies	O
that	O
sugar	B
may	O
account	O
for	O
the	O
varying	O
radical	O
scavenger	O
activity	O
through	O
changing	O
the	O
electron	O
distri­bution	O
and	O
participating	O
in	O
electron	O
delocalization	O
on	O
the	O
structural	O
backbone	O
,	O
or	O
through	O
some	O
other	O
unknown	O
mechanisms	O
.	O

Similarly	O
,	O
flavonol	B
-	I
type	I
compounds	I
,	O
having	O
an	O
addi­tional	O
-OH	B
at	O
C-3	O
,	O
performed	O
more	O
effectively	O
than	O
the	O
previous	O
type	O
.	O

Chemically	O
,	O
their	O
actions	O
were	O
probably	O
dependent	O
on	O
C-7	O
,	O
3	O
'	O
or	O
4	O
'	O
,	O
as	O
well	O
as	O
3	B
-	I
0H	I
,	O
such	O
as	O
af­zelin	B
,	O
hyperin	B
,	O
isoquercitrin	B
,	O
isorhamnetin	B
,	O
kaempferitrin	B
,	O
kaempferol-7-glucoside	B
,	O
quercetin	B
,	O
quercitrin	B
,	O
rhamnetin	B
and	O
rutin	B
.	O

Sugar	B
linked	O
at	O
C-3	O
would	O
also	O
affect	O
antioxi­dation	O
capability	O
.	O

For	O
example	O
,	O
a	O
lack	O
of	O
3'-OH	O
,	O
but	O
pos­session	O
of	O
rhamnoses	B
at	O
C-3	O
and	O
7	O
,	O
made	O
kaempferitrin	B
act	O
powerfully	O
in	O
both	O
membrane	O
protection	O
and	O
anti­peroxidation	O
,	O
similarly	O
to	O
afzelin	B
,	O
hyperin	B
,	O
isoquercitrin	B
,	O
kaempferol-7	B
-glucoside	I
,	O
quercitrin	B
and	O
rutin	B
.	O

In	O
terms	O
of	O
results	O
,	O
we	O
attempted	O
to	O
draw	O
a	O
general	O
con­cept	O
about	O
the	O
structural	O
principles	O
necessary	O
for	O
optimal	O
cellular	O
membrane	O
protection	O
and	O
antioxidative	O
capacity	O
.	O

It	O
is	O
assumed	O
that	O
the	O
bioactivity	O
of	O
both	O
types	O
of	O
com­pounds	O
is	O
decided	O
mainly	O
by	O
the	O
following	O
three	O
impor­tant	O
structural	O
groups	O
:	O
(	O
a	O
)	O
the	O
o	B
-	I
dihydroxy	I
(	O
catechol	B
)	O
structure	O
in	O
the	O
B	O
ring	O
,	O
which	O
is	O
the	O
obvious	O
radical	O
target	O
site	O
for	O
all	O
flavonoids	B
with	O
a	O
saturated	O
2,3-bond	O
(	O
flavan­3-ols	B
,	O
flavanones	B
)	O
;	O
(	O
b	O
)	O
the	O
2,3-double	O
bond	O
in	O
conjugation	O
with	O
a	O
4-oxo	O
function	O
,	O
which	O
are	O
responsible	O
for	O
electron	O
delocalization	O
from	O
the	O
B	O
ring	O
;	O
and	O
(	O
c	O
)	O
the	O
additional	O
pre­sence	O
of	O
both	O
3-and	O
5-hydroxyl	O
groups	O
for	O
maximal	O
radical	B
-	O
scavenging	O
potential	O
and	O
strongest	O
radical	O
absorp­tion	O
;	O
in	O
fact	O
,	O
the	O
3-and	O
5-hydroxyl	O
groups	B
are	O
equivalent	O
owing	O
to	O
their	O
hydrogen	B
bonds	I
with	O
the	O
keto	B
group	I
,	O
from	O
a	O
kinetic	O
standpoint	O
(	O
SLABBERT	O
1977	O
)	O
.	O

These	O
sites	O
can	O
be	O
considered	O
as	O
the	O
active	O
centers	O
on	O
the	O
compounds	O
,	O
or	O
as	O
a	O
prerequisite	O
factor	O
for	O
the	O
scavenging	O
of	O
oxygen	B
free	I
radicals	I
.	O

Here	O
,	O
we	O
should	O
note	O
that	O
from	O
tables	O
1	O
and	O
2	O
,	O
the	O
po­tentials	O
of	O
the	O
two	O
types	O
of	O
compounds	O
are	O
not	O
absolutely	O
Exp	O
Toxic	O
Pathol51	O
(	O
1999	O
)	O
1	O
affected	O
by	O
whether	O
they	O
are	O
flavonoids	B
or	O
aglycones	B
.	O

It	O
is	O
thought	O
that	O
the	O
configuration	O
of	O
functional	O
groups	O
may	O
also	O
playa	O
crucial	O
role	O
in	O
determining	O
their	O
bioactivity	O
.	O

The	O
FM4	B
-	I
64	I
,	O
a	O
member	O
of	O
the	O
family	O
of	O
fluorescent	O
dyes	O
,	O
has	O
been	O
applied	O
to	O
the	O
cerebellar	O
cortex	O
to	O
evaluate	O
its	O
properties	O
as	O
an	O
intracellular	O
stain	O
and	O
intracortical	O
tracer	O
.	O

Slabs	O
of	O
hamster	O
cerebellum	O
,	O
1	O
-	O
2	O
mm	O
thick	O
,	O
were	O
incubated	O
in	O
10	O
,	O
30	O
,	O
and	O
100	O
microns	O
solutions	O
of	O
FM4	B
-	I
64	I
in	O
sodium	B
phosphate	I
buffer	O
and	O
observed	O
in	O
a	O
slow	O
scan	O
confocal	O
laser	O
scanning	O
microscope	O
.	O

Mossy	O
and	O
climbing	O
fibers	O
were	O
traced	O
in	O
the	O
cerebellar	O
white	O
and	O
gray	O
substances	O
.	O

They	O
exhibited	O
a	O
high	O
fluorescence	O
signal	O
at	O
the	O
level	O
of	O
the	O
myelin	O
sheath	O
.	O

Mossy	O
fibers	O
were	O
identified	O
in	O
the	O
granular	O
layer	O
by	O
their	O
typical	O
rosette	O
formation	O
and	O
dichotomous	O
bifurcation	O
pattern	O
.	O

Climbing	O
fiber	O
bundles	O
were	O
observed	O
crossing	O
the	O
granular	O
layer	O
and	O
giving	O
collateral	O
branches	O
around	O
Golgi	O
cell	O
bodies	O
.	O

They	O
ascend	O
to	O
the	O
Purkinje	O
cell	O
layer	O
on	O
their	O
way	O
to	O
the	O
molecular	O
layer	O
.	O

Cerebellar	O
macroneurons	O
(	O
Golgi	O
and	O
Purkinje	O
cells	O
)	O
and	O
microneurons	O
(	O
granule	O
,	O
basket	O
,	O
and	O
stellate	O
cells	O
)	O
showed	O
optimal	O
intracellular	O
staining	O
of	O
cell	O
soma	O
,	O
axonal	O
,	O
and	O
dendritic	O
processes	O
.	O

The	O
z	O
-	O
series	O
of	O
stacks	O
of	O
optodigital	O
sections	O
allowed	O
us	O
to	O
explore	O
in	O
depth	O
the	O
cytoarchitectonic	O
arrangement	O
,	O
nerve	O
and	O
glial	O
cell	O
morphology	O
,	O
and	O
the	O
topographic	O
relationship	O
with	O
the	O
afferent	O
fibers	O
.	O

AIMS	O
:	O
Cysteamine	B
,	O
the	O
only	O
drug	O
available	O
for	O
the	O
treatment	O
of	O
cystinosis	O
in	O
paediatric	O
patients	O
,	O
is	O
available	O
as	O
the	O
hydrochloride	B
,	O
the	O
bitartrate	B
and	O
as	O
sodium	B
phosphocysteamine	I
salts	O
.	O

It	O
has	O
been	O
suggested	O
that	O
cysteamine	B
bitartrate	I
and	O
phosphocysteamine	B
are	O
better	O
tolerated	O
and	O
may	O
have	O
a	O
better	O
bioavailability	O
than	O
cysteamine	B
hydrochloride	I
.	O

This	O
has	O
,	O
however	O
,	O
never	O
been	O
demonstrated	O
.	O

METHODS	O
:	O
We	O
compared	O
the	O
pharmacokinetics	O
and	O
tolerance	O
of	O
these	O
three	O
formulations	O
of	O
cysteamine	B
in	O
18	O
healthy	O
adult	O
male	O
volunteers	O
in	O
a	O
double	O
-	O
blind	O
,	O
latin	O
-	O
square	O
,	O
three	O
-	O
period	O
,	O
single	O
oral	O
dose	O
cross	O
-	O
over	O
relative	O
bioavailability	O
study	O
.	O

RESULTS	O
:	O
No	O
statistical	O
difference	O
was	O
found	O
between	O
relative	O
bioavailabilities	O
,	O
AUC	O
(	O
0	O
,	O
infinity	O
)	O
(	O
geometric	O
mean	O
and	O
s.d	O
.	O

in	O
micromol	O
l	O
(	O
-1	O
)	O
h	O
:	O
169+	O
/	O
-51	O
,	O
158+	O
/	O
-46	O
,	O
173+	O
/	O
-49	O
with	O
cysteamine	B
hydrochloride	I
,	O
phosphocysteamine	B
and	O
cysteamine	B
bitartrate	I
respectively	O
)	O
,	O
Cmax	O
(	O
geometric	O
mean	O
and	O
s.d	O
.	O

in	O
micromol	O
l	O
(	O
-1	O
)	O
;	O
66+	O
/	O
-25.5	O
,	O
59+	O
/	O
-12	O
,	O
63+	O
/	O
-20	O
)	O
and	O
tmax	O
(	O
median	O
and	O
range	O
in	O
h	O
:	O
0.88	O
(	O
0.25	O
-	O
2	O
)	O
,	O
1.25	O
(	O
0.25	O
-	O
2	O
)	O
,	O
0.88	O
(	O
0.25	O
-	O
2	O
)	O
)	O
with	O
each	O
of	O
the	O
three	O
forms	O
of	O
cysteamine	B
tested	O
.	O

Bioequivalence	O
statistics	O
(	O
90	O
%	O
confidence	O
intervals	O
)	O
showed	O
non	O
equivalence	O
of	O
Cmax	O
of	O
cysteamine	B
base	O
as	O
the	O
only	O
non	O
equivalence	O
of	O
pharmacokinetics	O
between	O
the	O
three	O
formulations	O
:	O
90	O
%	O
CI	O
for	O
Cmax	O
relative	O
ratios	O
to	O
cysteamine	B
hydrochloride	I
were	O
[	O
75.6	O
-	O
105.81	O
for	O
phosphocysteamine	B
and	O
[	O
74.2	O
-	O
124.2	O
]	O
for	O
cysteamine	B
bitartrate	I
.	O

The	O
only	O
significant	O
adverse	O
event	O
was	O
vomiting	O
whose	O
frequency	O
was	O
inversely	O
correlated	O
with	O
body	O
weight	O
(	O
Spearman	O
's	O
r=-0.76	O
,	O
P<0.001	O
)	O
.	O

The	O
nature	O
of	O
the	O
salt	B
tested	O
did	O
not	O
influence	O
vomiting	O
.	O

CONCLUSIONS	O
:	O
While	O
none	O
of	O
the	O
three	O
forms	O
of	O
cysteamine	B
tested	O
has	O
a	O
clear	O
advantage	O
over	O
the	O
others	O
in	O
terms	O
of	O
pharmacokinetics	O
and	O
tolerance	O
profile	O
,	O
this	O
should	O
now	O
however	O
be	O
addressed	O
in	O
patients	O
treated	O
for	O
cystinosis	O
during	O
repeat	O
administrations	O
.	O

Both	O
alpha-	B
and	O
beta	B
-	I
D	I
-	I
glucose	I
pentaacetate	I
(	O
1.7	O
mM	O
each	O
)	O
augmented	O
,	O
to	O
almost	O
the	O
same	O
extent	O
,	O
insulin	O
release	O
caused	O
by	O
succinic	B
acid	I
dimethyl	I
ester	I
(	O
10.0	O
mM	O
)	O
in	O
rat	O
pancreatic	O
islets	O
.	O

The	O
secretory	O
response	O
to	O
these	O
hexose	B
esters	I
largely	O
exceeded	O
that	O
evoked	O
by	O
unesterified	O
D	B
-	I
glucose	I
tested	O
at	O
the	O
same	O
concentration	O
(	O
1.7	O
mM	O
)	O
.	O

The	O
release	O
of	O
insulin	O
provoked	O
by	O
succinic	B
acid	I
dimethyl	I
ester	I
was	O
inhibited	O
,	O
however	O
,	O
by	O
alpha	B
-	I
D	I
-	I
galactose	I
pentaacetate	I
,	O
whilst	O
being	O
unaffected	O
by	O
beta	B
-	I
D	I
-	I
galactose	I
pentaacetate	I
(	O
each	O
also	O
1.7	O
mM	O
)	O
.	O

It	O
appears	O
,	O
therefore	O
,	O
that	O
the	O
insulinotropic	O
action	O
of	O
hexose	B
esters	I
is	O
not	O
attributable	O
solely	O
to	O
the	O
catabolism	O
of	O
their	O
carbohydrate	B
moiety	O
,	O
but	O
may	O
also	O
involve	O
a	O
receptor	O
system	O
that	O
displays	O
anomeric	O
specificity	O
and	O
can	O
be	O
directly	O
activated	O
or	O
inhibited	O
by	O
the	O
esters	B
themselves	O
.	O

Hence	O
,	O
it	O
is	O
proposed	O
that	O
selected	O
esters	B
of	I
non	I
-	I
nutrient	I
monosaccharides	I
may	O
represent	O
new	O
tools	O
to	O
either	O
stimulate	O
insulin	O
release	O
in	O
diabetes	O
or	O
prevent	O
excessive	O
hormonal	O
secretion	O
in	O
situations	O
of	O
hyperinsulinemia	O
.	O

Bioassay	O
-	O
directed	O
fractionation	O
of	O
the	O
methanolic	B
extract	O
of	O
seeds	O
of	O
Casimiroa	O
edulis	O
led	O
to	O
the	O
isolation	O
of	O
seven	O
constituents	O
with	O
cardiovascular	O
activity	O
,	O
namely	O
the	O
new	O
compound	O
synephrine	B
acetonide	I
and	O
the	O
known	O
compounds	O
N	B
-	I
monomethylhistamine	I
,	O
N	B
,	I
N	I
-	I
dimethylhistamine	I
,	O
proline	B
,	O
N	B
-	I
methylproline	I
,	O
gamma	B
-	I
aminobutyric	I
acid	I
and	O
casimiroedine	B
.	O

In	O
anesthetized	O
rats	O
,	O
both	O
histamine	B
derivatives	I
produced	O
transient	O
hypotension	O
mediated	O
via	O
H1-histaminergic	O
receptors	O
and	O
in	O
the	O
case	O
of	O
N	B
,	I
N	I
-	I
dimethylhistamine	I
,	I
via	O
nitric	B
oxide	I
release	O
.	O

Synephrine	B
acetonide	I
produced	O
transient	O
hypertension	O
and	O
tachycardia	O
,	O
mediated	O
via	O
alpha-	O
and	O
alpha-	O
and	O
beta	O
-	O
adrenergic	O
receptores	O
,	O
respectively	O
.	O

The	O
chromatographic	O
zone	O
containing	O
N	B
-	I
methyproline	I
,	O
proline	B
and	O
gamma	B
-	I
aminobutyric	I
acid	I
elicited	O
marked	O
and	O
prolonged	O
hypotension	O
.	O

Finally	O
,	O
casimiroedine	B
did	O
not	O
modify	O
the	O
blood	O
pressure	O
of	O
anesthetized	O
rats	O
,	O
but	O
lowered	O
it	O
persistently	O
in	O
anesthetized	O
guinea	O
pigs	O
.	O

It	O
was	O
concluded	O
that	O
hypotension	O
produced	O
by	O
C.	O
edulis	O
is	O
due	O
to	O
several	O
active	O
components	O
.	O

The	O
immediate	O
effect	O
can	O
be	O
attributed	O
to	O
the	O
histamine	B
derivatives	I
acting	O
on	O
H1-receptors	O
.	O

More	O
prolonged	O
hypotension	O
would	O
be	O
produced	O
by	O
the	O
mixture	O
of	O
amino	B
acids	I
through	O
an	O
unknown	O
mechanism	O
,	O
as	O
well	O
as	O
by	O
casimiroedine	B
,	O
possibly	O
by	O
activation	O
of	O
H3-receptors	O
.	O

Hypotension	O
is	O
partially	O
offset	O
by	O
synephrine	B
acetonide	I
through	O
adrenergic	O
mechanisms	O
.	O

Fractionation	O
of	O
cube	O
resin	O
from	O
Lonchocarpus	O
utilus	O
and	O
L.	O
urucu	O
roots	O
led	O
to	O
the	O
isolation	O
and	O
identification	O
of	O
11	O
minor	O
flavonoids	B
and	O
stilbenes	B
containing	O
the	O
gem	B
-	I
dimethylpyran	I
moiety	O
or	O
a	O
dihydrodiol	B
derivative	O
thereof	O
.	O

The	O
eight	O
new	O
compounds	O
were	O
as	O
follows	O
:	O
the	O
isoflavonoid	B
cis-4'',5''-dihydro-4'',5	B
'	I
'	I
-dihydroxylonchocarpusone	I
(	O
2	O
)	O
;	O
four	O
(	B
2S	I
)	I
-6-	I
(	I
gamma	I
,	I
gamma	I
-	I
dimethylallyl	I
)	I
-6'',6''-dimethylpyran	I
[	I
2'',3'':7	I
,	I
8	I
]	I
flavanones	I
with	B
substituents	I
of	I
5-hydroxy-3',4'-dimethoxy	I
(	O
3	O
)	O
,	O
5	B
,	I
3'-dihydroxy-4'-methoxy	I
(	O
4	O
)	O
,	O
5,4'-dihydroxy-3'-methoxy	B
(	O
5	O
)	O
,	O
and	O
3	O
'	O
,	O
4'-dimethoxy	O
(	O
6	O
)	O
;	O
and	O
three	O
6'',6''-dimethylpyran	B
[	I
2'',3'':3	I
'	I
,	I
4'	I
]	I
stilbenes	I
with	O
4-hydroxy-5'-methoxy	B
(	O
9	O
)	O
,	O
3,5'-dimethoxy-4-hydroxy	O
(	O
10	O
)	O
and	O
3,4,5-trimethoxy	B
(	O
11	O
)	O
substitution	O
patterns	O
.	O

Structure	O
-	O
activity	O
relationships	O
for	O
inhibition	O
of	O
NADH	B
:	O
ubiquinone	B
oxidoreductase	O
activity	O
(	O
bovine	O
heart	O
electron	O
transport	O
particles	O
)	O
and	O
phorbol	B
ester	I
-	O
induced	O
ornithine	B
decarboxylase	O
activity	O
(	O
cultured	O
MCF-7	O
cells	O
)	O
generally	O
parallel	O
those	O
for	O
cytotoxicity	O
(	O
MCF-7	O
and	O
Hepa	O
1clc7	O
cells	O
)	O
.	O

Reinvestigation	O
of	O
fractions	O
derived	O
from	O
large	O
-	O
scale	O
fractionation	O
of	O
Maytenus	O
buchananii	O
led	O
to	O
the	O
isolation	O
of	O
two	O
new	O
maytansinoids	B
.	O

The	O
structures	O
of	O
these	O
principles	O
were	O
determined	O
using	O
electrospray	O
MS	O
,	O
1H	O
NMR	O
,	O
13C	O
NMR	O
,	O
and	O
2D	O
NMR	O
techniques	O
.	O

One	O
principle	O
was	O
found	O
to	O
be	O
2'-N	B
-	I
demethylmaytanbutine	I
(	O
2	O
)	O
,	O
while	O
the	O
other	O
was	O
found	O
to	O
be	O
maytanbicyclinol	B
(	O
3	O
)	O
,	O
the	O
first	O
maytansinoid	B
with	O
two	O
macrocyclic	B
rings	I
to	O
be	O
isolated	O
from	O
a	O
Maytenus	O
species	O
.	O

Previous	O
studies	O
have	O
indicated	O
that	O
part	O
of	O
the	O
binding	O
of	O
[	B
3H	I
]	I
[	I
1-	I
[	I
2-	I
(	I
diphenylmethoxy	I
)	I
ethyl	I
]	I
-4-	I
(	I
3-phenylpropyl	I
)	I
piperazine	I
dihydrochloride	I
]	O
(	O
[	B
3H	I
]	I
GBR	I
12935	I
)	O
to	O
human	O
platelets	O
is	O
to	O
a	O
piperazine	O
acceptor	O
site	O
,	O
which	O
might	O
be	O
associated	O
with	O
cytochrome	O
P-450IID6	O
(	O
CYP4502D6	O
,	O
debrisoquine-4-hydroxylase	O
)	O
.	O

Due	O
to	O
mutant	O
CYP4502D6	O
alleles	O
,	O
5	O
-	O
10	O
%	O
of	O
Caucasians	O
are	O
poor	O
metabolizers	O
of	O
CYP4502D6	O
substrates	O
such	O
as	O
debrisoquine	B
and	O
dextromethorphan	B
.	O

In	O
the	O
present	O
study	O
,	O
possible	O
differences	O
in	O
binding	O
characteristics	O
of	O
[	B
3H	I
]	I
GBR	I
12935	I
in	O
platelets	O
from	O
CYP4502D6	O
poor	O
and	O
extensive	O
metabolizers	O
were	O
investigated	O
.	O

The	O
most	O
prominent	O
finding	O
was	O
a	O
gender	O
difference	O
,	O
with	O
males	O
having	O
significantly	O
higher	O
Kd	O
values	O
than	O
females	O
.	O

There	O
were	O
no	O
differences	O
in	O
Bmax	O
.	O

After	O
correction	O
for	O
gender	O
,	O
there	O
was	O
a	O
tendency	O
towards	O
higher	O
Kd	O
values	O
in	O
poor	O
metabolizers	O
than	O
in	O
extensive	O
metabolizers	O
,	O
although	O
the	O
difference	O
was	O
not	O
statistically	O
significant	O
.	O

Whether	O
this	O
finding	O
corresponds	O
to	O
reduced	O
CYP4502D6	O
activity	O
is	O
a	O
matter	O
of	O
further	O
investigation	O
.	O

Rhus	O
javanica	O
,	O
a	O
medicinal	O
herb	O
,	O
has	O
been	O
shown	O
to	O
exhibit	O
oral	O
therapeutic	O
anti	O
-	O
herpes	O
simplex	O
virus	O
(	O
HSV	O
)	O
activity	O
in	O
mice	O
.	O

We	O
purified	O
two	O
major	O
anti	O
-	O
HSV	O
compounds	O
,	O
moronic	B
acid	I
and	O
betulonic	B
acid	I
,	O
from	O
the	O
herbal	O
extract	O
by	O
extraction	O
with	O
ethyl	B
acetate	I
at	O
pH	O
10	O
followed	O
by	O
chromatographic	O
separations	O
and	O
examined	O
their	O
anti	O
-	O
HSV	O
activity	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Moronic	B
acid	I
was	O
quantitatively	O
a	O
major	O
anti	O
-	O
HSV	O
compound	O
in	O
the	O
ethyl	B
acetate	I
-	O
soluble	O
fraction	O
.	O

The	O
effective	O
concentrations	O
for	O
50	O
%	O
plaque	O
reduction	O
of	O
moronic	B
acid	I
and	O
betulonic	B
acid	I
for	O
wild	O
-	O
type	O
HSV	O
type	O
1	O
(	O
HSV-1	O
)	O
were	O
3.9	O
and	O
2.6	O
microgram	O
/	O
ml	O
,	O
respectively	O
.	O

The	O
therapeutic	O
index	O
of	O
moronic	B
acid	I
(	O
10.3	O
-	O
16.3	O
)	O
was	O
larger	O
than	O
that	O
of	O
betulonic	B
acid	I
(	O
6.2	O
)	O
.	O

Susceptibility	O
of	O
acyclovir	O
-	O
phosphonoacetic	O
acid	O
-	O
resistant	O
HSV-1	O
,	O
thymidine	O
kinase	O
-	O
deficient	O
HSV-1	O
,	O
and	O
wild	O
-	O
type	O
HSV	O
type	O
2	O
to	O
moronic	B
acid	I
was	O
similar	O
to	O
that	O
of	O
the	O
wild	O
-	O
type	O
HSV-1	O
.	O

When	O
this	O
compound	O
was	O
administered	O
orally	O
to	O
mice	O
infected	O
cutaneously	O
with	O
HSV-1	O
three	O
times	O
daily	O
,	O
it	O
significantly	O
retarded	O
the	O
development	O
of	O
skin	O
lesions	O
and/or	O
prolonged	O
the	O
mean	O
survival	O
times	O
of	O
infected	O
mice	O
without	O
toxicity	O
compared	O
with	O
the	O
control	O
.	O

Moronic	B
acid	I
suppressed	O
virus	O
yields	O
in	O
the	O
brain	O
more	O
efficiently	O
than	O
those	O
in	O
the	O
skin	O
.	O

This	O
was	O
consistent	O
with	O
the	O
prolongation	O
of	O
mean	O
survival	O
times	O
.	O

Thus	O
,	O
moronic	B
acid	I
was	O
purified	O
as	O
a	O
major	O
anti	O
-	O
HSV	O
compound	O
from	O
the	O
herbal	O
extract	O
of	O
Rhus	O
javanica	O
.	O

Mode	O
of	O
the	O
anti	O
-	O
HSV	O
activity	O
was	O
different	O
from	O
that	O
of	O
ACV	B
.	O

Moronic	B
acid	I
showed	O
oral	O
therapeutic	O
efficacy	O
in	O
HSV	O
-	O
infected	O
mice	O
and	O
possessed	O
novel	O
anti	O
-	O
HSV	O
activity	O
that	O
was	O
consistent	O
with	O
that	O
of	O
the	O
extract	O
.	O

IC202A	B
(	O
1	O
)	O
was	O
isolated	O
from	O
the	O
culture	O
filtrate	O
of	O
Streptoalloteichus	O
sp.	O
1454	O
-	O
19	O
.	O

The	O
structure	O
of	O
1	O
was	O
determined	O
by	O
spectral	O
analysis	O
including	O
a	O
variety	O
of	O
two	O
-	O
dimentional	O
NMR	O
and	O
FAB	O
-	O
MS	O
experiments	O
.	O

IC202A	B
is	O
a	O
ferrioxamine	B
-	O
related	O
compound	O
containing	O
a	O
butylidene	B
N	I
-	I
oxide	I
function	O
.	O

It	O
is	O
suspected	O
that	O
not	O
only	O
fibrinogen	O
concentration	O
but	O
also	O
the	O
quality	O
of	O
fibrin	O
networks	O
may	O
contribute	O
to	O
cardiovascular	O
risk	O
.	O

Evidence	O
is	O
accumulating	O
that	O
a	O
""""	O
prudent	O
""""	O
diet	O
may	O
protect	O
against	O
diseases	O
associated	O
with	O
raised	O
clotting	O
factors	O
.	O

The	O
effect	O
of	O
diet	O
on	O
fibrinogen	O
is	O
,	O
however	O
,	O
still	O
controversial	O
.	O

In	O
a	O
previous	O
study	O
performed	O
in	O
our	O
laboratory	O
,	O
it	O
was	O
shown	O
that	O
dietary	O
pectin	B
influences	O
fibrin	O
network	O
architecture	O
in	O
hypercholesterolaemic	O
men	O
without	O
causing	O
any	O
changes	O
in	O
fibrinogen	O
concentration	O
.	O

To	O
elucidate	O
the	O
possible	O
mechanisms	O
,	O
it	O
was	O
necessary	O
to	O
study	O
the	O
possibility	O
that	O
pectin	B
may	O
itself	O
have	O
indirect	O
effects	O
on	O
fibrin	O
network	O
architecture	O
.	O

Pectin	B
is	O
fermented	O
in	O
the	O
gastrointestinal	O
tract	O
to	O
acetate	B
,	O
propionate	B
,	O
and	O
butyrate	B
.	O

In	O
humans	O
,	O
only	O
acetate	B
reaches	O
the	O
circulation	O
beyond	O
the	O
liver	O
.	O

This	O
investigation	O
primarily	O
examined	O
the	O
possibility	O
that	O
pectin	B
may	O
,	O
through	O
acetate	B
,	O
influence	O
fibrin	O
network	O
architecture	O
in	O
vivo	O
.	O

The	O
effects	O
of	O
pectin	B
and	O
acetate	B
supplementation	O
in	O
hypercholesterolaemic	O
subjects	O
were	O
compared	O
.	O

Furthermore	O
,	O
this	O
study	O
also	O
aimed	O
at	O
describing	O
the	O
possible	O
in	O
vitro	O
effects	O
of	O
acetate	B
on	O
fibrin	O
network	O
architecture	O
.	O

Two	O
groups	O
of	O
10	O
male	O
hyperlipidaemic	O
volunteers	O
each	O
received	O
a	O
pectin	B
(	O
15	O
g	O
/	O
day	O
)	O
or	O
acetate	B
(	O
6.8	O
g	O
/	O
day	O
)	O
supplement	O
for	O
4	O
weeks	O
.	O

Acetate	B
supplementation	O
did	O
not	O
cause	O
a	O
significant	O
change	O
in	O
plasma	O
fibrinogen	O
levels	O
.	O

As	O
in	O
the	O
pectin	B
group	O
,	O
significant	O
differences	O
were	O
found	O
in	O
the	O
characteristics	O
of	O
fibrin	O
networks	O
developed	O
in	O
plasma	O
after	O
4	O
weeks	O
of	O
acetate	B
supplementation	O
.	O

Fibrin	O
networks	O
were	O
more	O
permeable	O
(	O
from	O
213+	O
/	O
-76	O
to	O
307+	O
/	O
-81	O
x	O
10	O
(	O
11	O
)	O
cm2	O
)	O
,	O
had	O
lower	O
tensile	O
strength	O
(	O
from	O
23+	O
/	O
-3	O
to	O
32+	O
/	O
-9	O
%	O
compaction	O
)	O
,	O
and	O
were	O
more	O
lyseable	O
(	O
from	O
252+	O
/	O
-11	O
to	O
130+	O
/	O
-15	O
minutes	O
)	O
.	O

These	O
results	O
strongly	O
suggest	O
that	O
the	O
effect	O
of	O
pectin	B
on	O
network	O
architecture	O
could	O
partially	O
be	O
mediated	O
by	O
acetate	B
.	O

Progressive	O
amounts	O
of	O
acetate	B
were	O
used	O
in	O
vitro	O
to	O
investigate	O
the	O
possibility	O
that	O
acetate	B
may	O
be	O
directly	O
responsible	O
for	O
changes	O
that	O
occurred	O
in	O
fibrin	O
network	O
architecture	O
in	O
the	O
plasma	O
medium	O
.	O

Results	O
indicated	O
that	O
acetate	B
influenced	O
fibrin	O
network	O
architecture	O
directly	O
.	O

From	O
the	O
results	O
,	O
it	O
seems	O
highly	O
possible	O
that	O
acetate	B
may	O
be	O
responsible	O
in	O
part	O
for	O
the	O
beneficial	O
effects	O
of	O
pectin	B
supplementation	O
in	O
vivo	O
.	O

It	O
is	O
evident	O
that	O
pectin	B
or	O
acetate	B
supplementation	O
can	O
be	O
useful	O
during	O
the	O
treatment	O
or	O
prevention	O
of	O
some	O
clinical	O
manifestations	O
,	O
especially	O
those	O
associated	O
with	O
raised	O
total	O
cholesterol	B
and	O
possibly	O
also	O
plasma	O
fibrinogen	O
.	O

INTRODUCTION	O
Chemical	O
substitution	O
of	O
ribosomal	O
proteins	O
by	O
dansyl	B
chloride	I
[	O
I	O
]	O
and	O
iodoacetamide	B
[	O
2	O
]	O
has	O
yielded	O
first	O
results	O
concerning	O
the	O
localisation	O
of	O
proteins	O
in	O
rat	O
liver	O
ribosomes	O
.	O

The	O
accessibility	O
of	O
proteins	O
can	O
be	O
further	O
Abbreviations	O
:	O
MAI	B
,	O
methyl	B
acetimidate	I
;	O
NPA	B
,	O
p	B
-	I
nitrophenyl	I
acetate	I
;	O
TEA	B
,	O
triethanol-	B
amine	I
.	O

310	O
studied	O
by	O
substitution	O
of	O
their	O
amino	B
groups	I
by	O
NPA	B
or	O
by	O
MAI	B
as	O
will	O
be	O
demonstrated	O
in	O
this	O
paper	O
.	O

These	O
new	O
results	O
agree	O
in	O
general	O
with	O
those	O
ob-	O
tained	O
earlier	O
,	O
but	O
give	O
more	O
precise	O
data	O
as	O
to	O
the	O
localisation	O
of	O
proteins	O
in	O
the	O
ribosomal	O
subunit	O
.	O

MATERIAL	O
AND	O
METHODS	O
[	B
~4C	I
]	I
MAI	I
was	O
prepared	O
immediately	O
before	O
use	O
according	O
to	O
Hunter	O
and	O
Ludwig	O
[	O
3	O
]	O
using	O
[	B
~4C	I
]	I
acetonitrile	I
(	O
1.85	O
mCi	O
/	O
mmole	O
;	O
Institute	O
for	O
Isotopes	O
,	O
Budapest	O
)	O
.	O

[	B
3H	I
]	I
NPA	I
,	O
synthesized	O
as	O
described	O
elsewhere	O
[	O
4	O
]	O
was	O
a	O
gift	O
from	O
Dr.	O
B.	O
Mehlis	O
.	O

Preparation	O
of	O
ribosomal	O
subunits	O
Polysomes	O
isolated	O
from	O
rat	O
livers	O
according	O
to	O
Noll	O
et	O
al.	O
[	O
5	O
]	O
were	O
in-	O
cubated	O
in	O
500	O
mM	O
KCI	B
,	O
50	O
mM	O
TEA	B
HC1	I
,	O
pH	O
7.8	O
,	O
1.5	O
mM	O
MgC12	B
,	O
5	O
mM	O
fi	B
-	I
mercaptoethanol	I
and	O
0.1	O
mM	O
puromycin	B
for	O
30	O
min	O
at	O
0	O
and	O
then	O
for	O
10	O
min	O
at	O
37	O
[	O
6	O
]	O
.	O

The	O
ribosomal	O
subunits	O
were	O
separated	O
according	O
to	O
Eikenberry	O
et	O
al.	O
[	O
7	O
]	O
and	O
pelleted	O
after	O
dilution	O
of	O
the	O
gradient	O
fractions	O
with	O
2	O
vol	O
.	O
of	O
50	O
mM	O
TEA	B
HC1	I
,	O
pH	O
7.8	O
,	O
30	O
mM	O
MgC12	B
.	O

Thereafter	O
the	O
sub-	O
units	O
were	O
dialysed	O
against	O
a	O
buffer	O
of	O
50	O
mM	O
TEA	B
HC1	I
,	O
pH	O
7.8	O
,	O
50	O
mM	O
KC1	B
and	O
5	O
mM	O
MgC12	B
(	O
buffer	B
A	I
)	O
and	O
clarified	O
by	O
centrifugation	O
for	O
10	O
min	O
at	O
10	O
000	O
g.	O
Isolation	O
of	O
proteins	O
of	O
ribosomal	O
subunits	O
To	O
the	O
solution	O
of	O
ribosomal	O
subunits	O
(	O
5	O
mg	O
/	O
ml	O
)	O
1	O
/	O
3	O
vol	O
.	O
of	O
1	O
N	O
HC1	B
was	O
added	O
[	O
8	O
]	O
,	O
the	O
RNA	B
was	O
pelleted	O
by	O
centrifugation	O
for	O
10	O
min	O
at	O
10	O
000	O
g	O
and	O
the	O
supernatant	O
dialysed	O
against	O
50	O
mM	O
KC1	B
,	O
50	O
mM	O
TEA	B
HC1	I
,	O
pH	O
7.8	O
,	O
1	O
mM	O
MgC12	B
,	O
4	O
M	O
urea	B
(	O
buffer	B
B	I
)	O
.	O

Substitution	O
of	O
proteins	O
or	O
ribosomal	O
subunits	O
by	O
[	B
~4C	I
]	I
methyl	I
acetimidate	I
To	O
3	O
mg	O
of	O
total	O
ribosomal	O
protein	O
mixture	O
in	O
1	O
ml	O
buffer	B
B	I
or	O
to	O
5	O
mg	O
ribosomal	O
subunits	O
in	O
1	O
ml	O
buffer	B
A	I
,	O
3	O
pmoles	O
MAI	B
were	O
added	O
and	O
incu-	O
bated	O
for	O
30	O
min	O
at	O
37	O
.	O

Thereafter	O
4	O
M	O
NH4C1	B
was	O
added	O
to	O
give	O
a	O
final	O
concentration	O
of	O
50	O
mM.	O
The	O
proteins	O
were	O
isolated	O
as	O
described	O
and	O
dial-	O
ysed	O
against	O
6	O
M	O
urea	B
,	O
5	O
mM	O
methylamine	B
acetate	I
,	O
pH	O
5.0	O
,	O
5	O
mM	O
fi	B
-	I
mercap-	I
toethanol	I
.	O

A	O
label	O
of	O
4.9	O
10s	O
dpm	O
with	O
an	O
average	O
error	O
of	O
+	O
10	O
%	O
was	O
counted	O
per	O
mg	O
protein	O
of	O
the	O
small	O
ribosomal	O
subunit	O
after	O
dialysis	O
against	O
0.1	O
M	O
sodium	B
acetate	I
(	O
pH	O
5.5	O
)	O
and	O
solubilization	O
in	O
a	O
hyamine	B
hydroxide	I
containing	O
scin-	O
tillation	O
mixture	O
as	O
described	O
below	O
.	O

Protein	O
was	O
estimated	O
by	O
the	O
Lowry	O
method	O
using	O
ribosomal	O
protein	O
as	O
a	O
standard	O
.	O

The	O
labelling	O
value	O
corre-	O
sponds	O
to	O
2.4	O
acetimidoyl	B
groups	I
per	O
20	O
000	O
daltons	O
which	O
is	O
the	O
mean	O
molecular	O
weight	O
of	O
the	O
proteins	O
of	O
the	O
small	O
ribosomal	O
subunit	O
(	O
see	O
also	O
ref	O
.	O

5	O
)	O
.	O

For	O
the	O
proteins	O
of	O
the	O
large	O
ribosomal	O
subunit	O
3.9	O
acetimidoyl	B
groups	I
per	O
20	O
000	O
daltons	O
were	O
calculated	O
.	O

Substitution	O
of	O
proteins	O
or	O
ribosomal	O
subunits	O
by	O
[	B
3	I
H	I
]	I
p	I
-	I
nitrophenyl	I
acetate	I
The	O
substitution	O
was	O
performed	O
using	O
1.5	O
pmoles	O
NPA	B
(	O
10	O
mCi	O
/	O
mmole	O
)	O
311	O
per	O
1.0	O
ml	O
by	O
incubation	O
for	O
60	O
min	O
at	O
37	O
in	O
analogy	O
to	O
the	O
reaction	O
de-	O
scribed	O
before	O
.	O

The	O
excess	O
of	O
reagent	O
was	O
destroyed	O
by	O
incubation	O
with	O
0.25	O
N	O
HC1	B
for	O
1	O
h	O
at	O
0	O
.	O

TABLE	O
I	O
SUBSTITUTION	O
OF	O
PROTEINS	O
ISOLATED	O
FROM	O
SMALL	O
RIBOSOME	O
SUBUNITS	O
OF	O
RAT	O
LIVER	O
AND	O
OF	O
SMALL	O
RIBOSOMAL	O
SUBUNITS	O
BY	O
[	B
14C	I
]	I
METHYL	I
ACETIMIDATE	I
OR	O
BY	O
[	B
3H	I
]	I
ao	I
-	I
NITROPHENYL	I
ACETATE	I
Average	O
values	O
of	O
5	O
-	O
-10	O
independent	O
experiments	O
are	O
given	O
;	O
the	O
average	O
errors	O
of	O
the	O
mean	O
values	O
not	O
specified	O
for	O
the	O
individual	O
proteins	O
did	O
not	O
exceed	O
10	O
%	O
.	O

Small	O
subunit	O
protein	O
Label	O
of	O
proteins	O
obtained	O
by	O
[	B
14C	I
]	I
methyl	I
acetimidate	I
Label	O
of	O
proteins	O
obtained	O

by	O
[	B
3H	I
]	I
p	I
-	I
nitrophenyl	I
acetate	I
1	O
2	O
3	O
4	O
1	O
2	O
3	O
Protein	O
Par-	O
Ratio	O
Classifi-	O
Protein	O
Par-	O

Ratio	O
mixture	O
ticle	O
of	O
2	O
:	O
1	O
cation	O
mixture	O
ticle	O
of	O
6	O
:	O
5	O
dpm	O
/	O
"AsT8""10"	O
-	O
3	O
%	O
dpm	O
/	O
AsTs	O
""""	O
10	O
-	O
3	O
%	O
4	O
Classifi-	O
cation	O
$	O
1	O
3.4	O
4.3	O
126	O
23.2	O
5.4	O
23	O
2	O
4.4	O

5.4	O
123	O
32.5	O
15.4	O
47	O
+	O
3	O
n.d	O
.	O

3.8	O
n.d	O
.	O

n.d	O
.	O

n.d	O
.	O

n.d	O
.	O

4	O
7.5	O
4.2	O
56	O
--	O
19.8	O
8.3	O
42	O
+	O
5	O
2.2	O
6.1	O
277	O
+	O
29.8	O
7.4	O
25	O
6	O
n.d	O
.	O

5.2	O
n.d	O
.	O

36.1	O
23.7	O
66	O
+	O
7	O
3.2	O
5.8	O
181	O
+	O
n.d	O
.	O

n.d	O
.	O

n.d	O
.	O

8	O
4.1	O
4.2	O
102	O
37.1	O
13.9	O
37	O
+	O
9	O
6.1	O
4.8	O
79	O
26.2	O
4.1	O
16	O
--	O
10	O
5.0	O
7.1	O
142	O
+	O
33.6	O
10.7	O
32	O
+	O
11	O
5.6	O
3.8	O
68	O
--	O
21.3	O
6.9	O
32	O
+	O
12	O
5.4	O
3.2	O
59	O
--	O
27.4	O
16.2	O
59	O
+	O
13	O
3.7	O
2.9	O
78	O
15.6	O
4.4	O
28	O
14	O
6.1	O
4.3	O
70	O
--	O
34.1	O
7.5	O
22	O
--	O
15	O
6.8	O
6.8	O
100	O

26.7	O
11.4	O
43	O
+	O
16	O
3.3	O
4.4	O
133	O
+	O
30.2	O
7.1	O
24	O
17	O
n.d	O
.	O

n.d	O
.	O

n.d	O
.	O

31.0	O
7.2	O
23	O
18	O
3.4	O
4.3	O
126	O
22.5	O
6.8	O
30	O
-+	O
19	O
3.8	O
3.4	O
89	O
27.3	O
5.5	O
20	O
--	O
20	O
5.2	O
4.2	O
81	O
-+	O
21.1	O
3.9	O
18	O
--	O
21	O
3.9	O
2.7	O
69	O
--	O
17.3	O
4.2	O
24	O
22	O
4.4	O
4.2	O
95	O
27.3	O
9.1	O
33	O
+	O
23	O
n.d	O
.	O

n.d	O
.	O

n.d	O
.	O

25.4	O
5.1	O
20	O
--	O
24	O
7.9	O
5.2	O
66	O
--	O
35.3	O
7.3	O
21	O
--	O
25	O
7.9	O
5.2	O
66	O
--	O
33.3	O
7.3	O
22	O
--	O
26	O
8.3	O
9.0	O
108	O
24.7	O
6.9	O
28	O
27	O
4.4	O
2.0	O
45	O
--	O
15.1	O
5.9	O
39	O
+	O
28	O
n.d	O
.	O

n.d	O
.	O

n.d	O
.	O

26.3	O
3.0	O
11	O
--	O
29	O
4.3	O
2.0	O
46	O
--	O
10.6	O
2.9	O
27	O
30	O
n.d	O
.	O

4.7	O
n.d	O
.	O

12.5	O
2.7	O
22	O
--	O
31	O
n.d	O
.	O

n.d	O
.	O

n.d	O
.	O

n.d	O
.	O

n.d	O
.	O

n.d	O
.	O

TABLE	O
II	O
SUBSTITUTION	O
OF	O
PROTEINS	O
ISOLATED	O
FROM	O
LARGE	O
RIBOSOMAL	O
SUBUNITS	O
OF	O
RAT	O
LIVER	O
AND	O
OF	O
LARGE	O
RIBO-	O
SOMAL	O
SUBUNITS	O
BY	O
[	B
14C	I
]	I
METHYL	I
ACETIMIDATE	I
Average	O
values	O
of	O
5	O
-	O
-10	O
independent	O
experiments	O
are	O
given	O
;	O
the	O
average	O
errors	O
of	O
the	O
mean	O
values	O
not	O
specified	O
for	O
the	O
individual	O
proteins	O
did	O
not	O
exceed	O
10	O
%	O
.	O

b.a	O
b~	O
Large	O
Labelling	O
coefficients	O
Large	O
subunit	O
subunit	O
protein	O
1	O
2	O
3	O
4	O
protein	O
Protein	O
Particle	O
Ratio	O
Classifi-	O
mixture	O
of	O
2	O
:	O
1	O
cation	B
dpm	O
/	O
AsT8	O
10	O
-	O
3	O
%	O
Labelling	O
coefficients	O
1	O
2	O
3	O
4	O
Protein	O
Particle	O
Ratio	O
Classifi-	O
mixture	O
of	O
2	O
:	O
1	O
cation	B
dpm	O
/	O
AsTs	O
10	O
-	O
3	O
%	O
L	O
1	O
n.d	O
.	O

5.8	O
n.d	O
.	O

L	O
21	O
2	O
9.3	O
.	O

1.1	O
12	O
--	O
22	O
3	O
n.d	O
.	O

n.d	O
.	O

n.d	O
.	O

23	O
4	O
11.0	O
3.0	O
27	O
+	O
24	O
5	O
13.0	O
4.6	O
35	O
+	O
25	O
6	O
14.2	O
5.1	O
36	O
+	O
26	O
7	O
13.9	O
3.0	O
22	O
+	O
27	O
8	O
12.4	O
2.2	O
18	O
--	O
28	O
9	O
9.6	O
1.9	O
20	O
--	O
29	O
10	O
9.0	O
1.8	O
20	O
--	O
30	O
11	O
9.0	O
1.8	O
20	O
--	O
31	O
12	O
9.7	O
n.d	O
.	O

n.d	O
.	O

32	O
13	O
6.9	O
2.5	O
36	O
+	O
33	O
14	O
n.d	O
.	O

n.d	O
.	O

n.d	O
.	O

34	O
15	O
8.1	O
2.4	O
30	O
+	O
35	O
16	O
n.d	O
.	O

3.5	O
n.d	O
.	O

36	O
17	O
6.6	O
3.0	O
45	O
+	O
37	O
18	O
n.d	O
.	O

n.d	O
.	O

n.d	O
.	O

38	O
19	O
6.1	O
1.0	O
16	O
--	O
39	O
20	O
5.9	O
1.4	O
24	O
-+	O
10.1	O
2.3	O
23	O
+	O
12.3	O
1.9	O
15	O
--	O
5.9	O
3.6	O
61	O
+	O
4.8	O
2.1	O
44	O
+	O
8.3	O
2.4	O
29	O
+	O
6.2	O
1.8	O
29	O
+	O
8.2	O
2.3	O
28	O
+	O
6.6	O
1.6	O
24	O
-+	O
7.5	O
2.3	O
31	O
+	O
6.1	O
1.9	O
31	O
+	O
9.3	O
1.3	O
14	O
--	O
7.9	O
1.3	O
16	O
--	O
4.8	O
1.5	O
31	O
+	O
6.0	O
2.4	O
40	O
+	O
7.0	O
2.0	O
28	O
+	O
-	O
7.3	O
1.7	O
23	O
+	O
n.d	O
.	O

n.d	O
.	O

n.d	O
.	O

5.5	O
3.1	O
56	O
+	O
n.d	O
.	O

n.d	O
.	O

n.d	O
.	O

313	O
For	O
the	O
proteins	O
of	O
the	O
small	O
ribosomal	O
subunit	O
1.9	O
106	O
dpm	O
per	O
mg	O
protein	O
were	O
measured	O
by	O
the	O
method	O
described	O
above	O
,	O
corresponding	O
to	O
1.7	O
acetyl	B
groups	I
per	O
20	O
000	O
daltons	O
protein	O
.	O

TABLE	O
III	O
TENTATIVE	O
LOCALIZATION	O
OF	O
PROTEINS	O
IN	O
RIBOSOMAL	O
SUBUNITS	O
OF	O
RAT	O
LIVER	O
ESTIMATED	O
BY	O
USING	O
CHEMICAL	O
SUBSTITUTIONS	O
Small	O
Substitution	O
""""	O
by	O
Preponderant	O
subunit	O
localization	O
protein	O
Methyl	B
p	B
-	I
Nitrophenyl	I
Iodo-	B
acetimidate	B
acetate	B
acetamide	B
S	O
2	O
+	O
+	O
+	O
exposed	O
5	O
+	O
-+	O
+	O
exposed	O
7	O
+	O
n.d	O
.	O

+	O
exposed	O
8	O
-+	O
+	O
+	O
exposed	O
9	O
+	O
--	O
--	O
buried	O
10	O
+	O
+	O

-+	O
exposed	O
13	O
+	O
+	O
+	O
exposed	O
14	O
--	O
--	O
--	O
buried	O
19	O
+	O
--	O
--	O
buried	O
20	O
+	O
--	O
--	O

buried	O
24	O
--	O
--	O
+	O
buried	O
25	O
--	O
--	O
--	O
buried	O
27	O
--	O
+	O
--	O

buried	O
29	O
--	O
+	O
--	O
buried	O
30	O
n.d	O
.	O

--	O
--	O
buried	O
Large	O
subunit	O
protein	O
L	O
1	O
n.d	O
.	O

--	O
buried	O
7	O
+	O
--	O
buried	O
--	O
buried	O
8	O
--	O
buried	O
10	O
+	O
11	O
15	O
+	O
+	O
exposed	O
17	O
+	O
+	O
exposed	O
--	O
buried	O
19	O
20	O
+	O
-	O
+	O
exposed	O
24	O
+	O
+	O
exposed	O
25	O
+	O
+	O
exposed	O
27	O
+	O
+	O
exposed	O
28	O
+	O
--	O
buried	O
29	O
+	O
+	O
exposed	O
--	O

buried	O
31	O
--	O
buried	O
32	O
33	O
+	O
+	O
exposed	O
34	O
+	O
+	O
exposed	O
35	O
-+	O
+	O
exposed	O
38	O
+	O
+	O
exposed	O
314	O
Two	O
-	O
dimensional	O
polyacrylamide	B
gel	I
electrophoresis	O
and	O
estimation	O
of	O
the	O
labelling	O
of	O
the	O
proteins	O
Electrophoresis	O
and	O
numbering	O
of	O
the	O
protein	O
spots	O
were	O
performed	O
as	O
de-	O
scribed	O
by	O
Welfle	O
et	O
al.	O
[	O
9	O
]	O
.	O

The	O
gel	O
slabs	O
were	O
stained	O
with	O
0.0005	O
%	O
Coo-	O
massie	O
Brillant	B
Blue	I
G	I
250	I
in	O
3	O
%	O
trichloroacetic	B
acid	I
for	O
24	O
h.	O
Thereafter	O
the	O
gel	O
pieces	O
containing	O
the	O
stained	O
proteins	O
were	O
cut	O
and	O
their	O
staining	O
intensi-	O
ties	O
measured	O
in	O
10	O
mm	O
glass	O
cuvettes	O
at	O
578	O
nm	O
.	O

For	O
the	O
estimation	O
of	O
the	O
labelling	O
the	O
gel	O
pieces	O
were	O
squashed	O
using	O
a	O
1	O
ml	O
syringe	O
with	O
a	O
I	O
mm	O
aperture	O
and	O
incubated	O
for	O
16	O
h	O
with	O
1	O
ml	O
of	O
0.5	O
N	O
hyamine	B
hydroxide	I
(	O
Packard	O
Instruments	O
,	O
Ill.	O
)	O
in	O
toluene	B
.	O

The	O
counting	O
efficiency	O
against	O
an	O
ex-	O
ternal	O
standard	O
was	O
about	O
80	O
%	O
using	O
a	O
scintillation	O
mixture	O
with	O
0.4	O
%	O
2,5-	B
diphenyloxazole	I
,	O
0.01	O
%	O
1,4-bis-	B
(	I
5-phenyloxazol-2-yl	I
)	I
benzene	I
,	O
10	O
%	O
Triton	B
X-	I
100	I
,	O
0.3	O
%	O
acetic	B
acid	I
in	O
toluene	B
.	O

After	O
measuring	O
the	O
label	O
for	O
10	O
min	O
the	O
disin-	O
tegrations	O
per	O
min	O
(	O
dpm	O
)	O
were	O
correlated	O
for	O
each	O
spot	O
to	O
1.0	O
A	O
s78	O
.	O

The	O
average	O
values	O
of	O
5	O
-	O
-10	O
independent	O
experiments	O
are	O
given	O
in	O
Tables	O
I	O
and	O
II	O
.	O

The	O
average	O
errors	O
of	O
the	O
mean	O
values	O
not	O
specified	O
for	O
the	O
individual	O
proteins	O
did	O
not	O
exceed	O
10	O
%	O
.	O

RESULTS	O
MAI	B
reacts	O
exclusively	O
with	O
the	O
amino	B
groups	I
of	O
proteins	O
[	O
3	O
]	O
,	O
whereas	O
NPA	B
also	O
substitutes	O
tyrosine	B
and	O
cysteine	B
residues	I
[	O
10	O
]	O
.	O

Because	O
of	O
the	O
relatively	O
high	O
lysine	B
content	O
,	O
the	O
low	O
portion	O
of	O
tyrosine	B
and	O
cysteine	B
in	O
ribosomal	O
proteins	O
of	O
rat	O
liver	O
[	O
11	O
]	O
and	O
the	O
lower	O
reactivity	O
of	O
tyrosine	B
OH-	I
groups	I
[	O
12	O
]	O
,	O
it	O
can	O
be	O
expected	O
that	O
both	O
reagents	O
predominantly	O
react	O
with	O
amino	B
groups	I
.	O

The	O
substitution	O
of	O
ribosomal	O
protein	O
mixtures	O
by	O
both	O
reagents	O
is	O
com-	O
pleted	O
after	O
30	O
min	O
at	O
37	O
to	O
more	O
than	O
90	O
%	O
.	O

The	O
proteins	O
isolated	O
from	O
the	O
small	O
ribosomal	O
subunit	O
incorporate	O
on	O
the	O
average	O
1,7-acetyl	O
and	O
2,4-	O
acetimidoyl	B
groups	I
,	O
respectively	O
,	O
per	O
20	O
000	O
dalton	O
,	O
and	O
the	O
proteins	O
of	O
the	O
large	O
subunit	O
bind	O
3,9-acetimidoyl	O
groups	B
per	O
20	O
000	O
dalton	O
.	O

The	O
labelling	O
values	O
for	O
the	O
proteins	O
of	O
the	O
small	O
subunit	O
are	O
presented	O
in	O
Table	O
I.	O
The	O
values	O
for	O
labelling	O
of	O
the	O
protein	O
mixture	O
with	O
NPA	B
vary	O
from	O
10	O
600	O
to	O
37	O
100	O
dpm	O
per	O
1.0	O
As78	O
.	O

When	O
using	O
the	O
subunits	O
,	O
values	O
between	O
2700	O
and	O
23	O
700	O
dpm	O
per	O
1.0	O
AsTa	O
are	O
measured	O
.	O

It	O
is	O
obvious	O
from	O
these	O
results	O
that	O
the	O
reactive	O
groups	O
of	O
the	O
proteins	O
in	O
the	O
subunit	O
structure	O
are	O
only	O
available	O
to	O
about	O
10	O
to	O
65	O
%	O
.	O

28	O
proteins	O
can	O
be	O
classified	O
into	O
3	O
groups	O
with	O
10	O
-	O
-22	O
%	O
,	O
23	O
-	O
-30	O
%	O
and	O
31	O
-	O
-66	O
%	O
remaining	O
reactivity	O
:	O
Proteins	O
$	O
9	O
,	O
14	O
,	O
19	O
,	O
20	O
,	O
23	O
,	O
24	O
,	O
25	O
,	O
28	O
and	O
30	O
{	O
marked	O
by--	O
)	O
are	O
strongly	O
protected	O
,	O
the	O
reactivity	O
of	O
9	O
other	O
proteins	O
is	O
diminished	O
moderately	O
(	O
$	O
1	O
,	O
5	O
,	O
13	O
,	O
16	O
,	O
17	O
,	O
18	O
,	O
21	O
,	O
26	O
and	O
29	O
(	O
marked	O
by	O
+	O
)	O
,	O
and	O
the	O
proteins	O
$	O
2	O
,	O
4	O
,	O
6	O
,	O
8	O
,	O
10	O
,	O
11	O
,	O
12	O
,	O
15	O
,	O
22	O
and	O
27	O
(	O
marked	O
by	O
+	O
)	O
are	O
exposed	O
to	O
a	O
relatively	O
high	O
extent	O
.	O

The	O
reaction	O
of	O
proteins	O
with	O
MAI	B
in	O
the	O
small	O
ribosomal	O
subunit	O
is	O
on	O
the	O
average	O
only	O
little	O
decreased	O
in	O
comparison	O
to	O
the	O
free	O
proteins	O
.	O

As	O
demon-	O
strated	O
in	O
Table	O
I	O
,	O
the	O
reactivity	O
of	O
proteins	O
$	O
4	O
,	O
11	O
,	O
12	O
,	O
14	O
,	O
21	O
,	O
24	O
,	O
25	O
,	O
27	O
and	O
29	O
(	O
marked	O
by	O
--	O
}	O
is	O
inhibited	O
by	O
30	O
%	O
or	O
more	O
if	O
the	O
subunit	O
is	O
com-	O
315	O
pared	O
with	O
the	O
protein	O
mixture	O
.	O

The	O
proteins	O
$	O
5	O
,	O
7	O
,	O
10	O
and	O
16	O
(	O
marked	O
by	O
+	O
}	O
are	O
labelled	O
more	O
strongly	O
in	O
the	O
subunit	O
than	O
in	O
the	O
isolated	O
protein	O
mixture	O
,	O
showing	O
values	O
of	O
more	O
than	O
130	O
%	O
.	O

For	O
11	O
proteins	O
(	O
S1	O
,	O
2	O
,	O
8	O
,	O
9	O
,	O
13	O
,	O
15	O
,	O
18	O
,	O
19	O
,	O
20	O
,	O
22	O
and	O
26	O
;	O
marked	O
by	O
-+	O
)	O
,	O
the	O
labelling	O
is	O
about	O
the	O
same	O
both	O
in	O
the	O
subunit	O
and	O
in	O
the	O
protein	O
mixture	O
{	O
70	O
-	O
-130%	O
}	O
.	O
A	O
stronger	O
inhibition	O
of	O
the	O
reaction	O
of	O
MAI	B
with	O
proteins	O
is	O
observed	O
in	O
the	O
large	O
ribosomal	O
subunit	O
(	O
Table	O
II	O
)	O
.	O

On	O
the	O
average	O
a	O
value	O
of	O
30	O
%	O
is	O
es-	O
timated	O
in	O
comparison	O
ta	O
the	O
protein	O
mixture	O
.	O

Proteins	O
L2	O
,	O
8	O
,	O
9	O
,	O
10	O
,	O
11	O
,	O
19	O
,	O
22	O
,	O
31	O
and	O
32	O
(	O
marked	O
by	O
--	O
)	O
in	O
the	O
subunit	O
structure	O
take	O
up	O
only	O
20	O
%	O
or	O
even	O
less	O
of	O
the	O
label	O
taken	O
up	O
by	O
the	O
isolated	O
protein	O
mixture	O
.	O

When	O
la-	O
belled	O
in	O
the	O
subunit	O
a	O
second	O
group	O
of	O
proteins	O
(	O
L4	O
,	O
7	O
,	O
20	O
,	O
21	O
,	O
27	O
,	O
28	O
,	O
35	O
and	O
36	O
;	O
marked	O
by	O
+	O
)	O
show	O
21	O
-	O
-28	O
%	O
and	O
a	O
third	O
group	O
{	O
L5	O
,	O
6	O
,	O
13	O
,	O
15	O
,	O
17	O
;	O
23	O
,	O
24	O
,	O
25	O
,	O
26	O
,	O
29	O
,	O
30	O
,	O
33	O
,	O
34	O
and	O
38	O
;	O
marked	O
by	O
+	O
)	O
more	O
than	O
29	O
%	O
of	O
the	O
label	O
of	O
the	O
protein	O
mixture	O
.	O

DISCUSSION	O
Chemical	O
substitutions	O
of	O
ribosomal	O
proteins	O
by	O
iodoacetate	B
and	O
2-	B
methoxy-5-nitrotropone	I
[	O
13	O
]	O
,	O
fluorescein	B
isothiocyanate	I
[	O
14	O
]	O
,	O
acetanhy-	B
dride	I
[	O
15	O
]	O
,	O
iodine	B
[	O
16,17	O
]	O
,	O
5,5-dithiobis-	B
(	I
2-nitro	I
-	I
benzoic	I
acid	I
)	I
[	O
18	O
]	O
,	O
N-	B
ethyl	I
-	I
maleimide	I
and	O
iodoacetamide	B
[	O
19	O
]	O
,	O
aldehydes	B
[	O
20	O
]	O
and	O
kethoxal	B
[	O
21	O
]	O
have	O
been	O
successfully	O
used	O
to	O
elucidate	O
the	O
topography	O
of	O
proteins	O
in	O
ribo-	O
somal	O
subunits	O
of	O
E.	O
coli	O
.	O

As	O
was	O
demonstrated	O
before	O
,	O
all	O
proteins	O
organized	O
in	O
the	O
ribosomal	O
sub-	O
units	O
of	O
rat	O
liver	O
are	O
accessible	O
to	O
the	O
reaction	O
with	O
MAI	B
and	O
with	O
NPA	B
.	O

The	O
extent	O
of	O
reaction	O
,	O
however	O
,	O
is	O
less	O
than	O
with	O
the	O
isolated	O
protein	O
mixture	O
.	O

Both	O
findings	O
are	O
in	O
good	O
agreement	O
with	O
results	O
obtained	O
with	O
iodoacet-	B
amide	I
[	O
2	O
]	O
,	O
2-methoxy-5-nitrotropone	B
[	O
22	O
]	O
and	O
also	O
with	O
conclusions	O
drawn	O
from	O
iodination	O
experiments	O
[	O
23	O
]	O
.	O

When	O
comparing	O
experiments	O
with	O
MAI	B
and	O
NPA	B
it	O
is	O
remarkable	O
that	O
the	O
reactivity	O
to	O
NPA	B
of	O
the	O
proteins	O
organized	O
in	O
the	O
small	O
ribosomal	O
subunit	O
is	O
inhibited	O
more	O
strongly	O
than	O
the	O
reactivity	O
to	O
MAI	B
in	O
comparison	O
to	O
the	O
free	O
protein	O
mixture	O
.	O

This	O
may	O
be	O
due	O
to	O
the	O
less	O
hydrophilic	O
properties	O
of	O
NPA	B
which	O
prevent	O
this	O
reagent	O
from	O
penetrating	O
the	O
ribosomal	O
subunit	O
structure	O
as	O
readily	O
as	O
the	O
more	O
hydrophilic	O
MAI	B
obviously	O
can	O
.	O

The	O
reaction	O
of	O
the	O
proteins	O
in	O
the	O
small	O
ribosomal	O
subunit	O
to	O
MAI	B
,	O
on	O
the	O
whole	O
,	O
occurs	O
more	O
readily	O
than	O
those	O
in	O
the	O
large	O
ribosomal	O
subunit	O
in	O
com-	O
parison	O
to	O
the	O
corresponding	O
free	O
protein	O
mixtures	O
.	O

This	O
finding	O
favours	O
a	O
more	O
dense	O
structure	O
of	O
the	O
large	O
ribosomal	O
subunit	O
.	O

The	O
explanation	O
that	O
more	O
reactive	O
protein	O
groups	O
are	O
localized	O
on	O
the	O
surface	O
of	O
the	O
small	O
ribo-	O
somal	O
subunit	O
in	O
comparison	O
to	O
their	O
total	O
number	O
than	O
in	O
the	O
large	O
ribo-	O
somal	O
subunit	O
is	O
unlikely	O
,	O
because	O
the	O
reaction	O
of	O
small	O
and	O
large	O
subunit	O
proteins	O
with	O
NPA	B
is	O
inhibited	O
to	O
the	O
same	O
extent	O
in	O
the	O
subunit	O
structures	O
.	O

Different	O
proportions	O
of	O
reactive	O
amino	B
groups	I
in	O
small	O
and	O
large	O
ribosomal	O
subunits	O
from	O
E.	O
coli	O
have	O
also	O
been	O
reported	O
by	O
Slobin	O
[	O
24	O
]	O
using	O
methyl	B
picolinimidate	I
.	O

316	O
If	O
the	O
proteins	O
are	O
classified	O
as	O
weakly	O
exposed	O
(	O
--	O
)	O
,	O
moderately	O
exposed	O
(	O
-+	O
)	O
and	O
strongly	O
exposed	O
(	O
+	O
)	O
proteins	O
,	O
it	O
can	O
be	O
demonstrated	O
that	O
the	O
re-	O
sults	O
obtained	O
with	O
different	O
reagents	O
agree	O
for	O
the	O
preponderantly	O
buried	O
proteins	O
$	O
14	O
,	O
25	O
,	O
L8	O
,	O
10	O
,	O
11	O
,	O
19	O
,	O
31	O
and	O
32	O
and	O
for	O
the	O
mainly	O
exposed	O
pro-	O
teins	O
L15	O
,	O
17	O
,	O
25	O
,	O
29	O
,	O
33	O
,	O
34	O
and	O
38	O
(	O
see	O
Table	O
III	O
)	O
.	O

For	O
the	O
other	O
proteins	O
also	O
listed	O
in	O
Table	O
III	O
,	O
the	O
results	O
obtained	O
with	O
different	O
reagents	O
are	O
not	O
in	O
full	O
agreement	O
.	O

However	O
,	O
the	O
accessibility	O
of	O
proteins	O
in	O
the	O
subunit	O
struc-	O
ture	O
to	O
trypsin	O
[	O
25	O
]	O
and	O
their	O
tendency	O
to	O
be	O
split	O
from	O
the	O
subunits	O
by	O
dif-	O
ferent	O
LiC1	B
concentrations	O
[	O
26	O
]	O
argue	O
in	O
favour	O
of	O
a	O
relatively	O
buried	O
locali-	O
zation	O
of	O
the	O
proteins	O
$	O
9	O
,	O
19	O
,	O
20	O
,	O
24	O
,	O
27	O
,	O
29	O
,	O
30	O
,	O
L1	O
,	O
7	O
and	O
28	O
and	O
an	O
ex-	O
posed	O
arrangement	O
of	O
the	O
proteins	O
$	O
2,5	O
,	O
7	O
,	O
8	O
,	O
10	O
,	O
13	O
,	O
L20	O
,	O
24	O
,	O
27	O
and	O
35	O
.	O

Exposed	O
positions	O
were	O
also	O
reported	O
for	O
proteins	O
moving	O
electrophoreti-	O
cally	O
like	O
L17	O
,	O
24	O
and	O
29	O
by	O
Reboud	O
,	O
studying	O
the	O
reaction	O
of	O
large	O
subunits	O
of	O
rat	O
liver	O
ribosomes	O
with	O
2-methoxy-5-nitrotropone	B
and	O
glutaraldehyde	B
[	O
22	O
]	O
,	O
respectively	O
.	O

Glutamate	B
contributes	O
to	O
secondary	O
brain	O
damage	O
,	O
resulting	O
in	O
cell	O
swelling	O
and	O
brain	O
edema	O
.	O

Under	O
in	O
vitro	O
conditions	O
,	O
increased	O
extracellular	O
levels	O
of	O
the	O
amino	B
acid	I
taurine	B
reflect	O
glutamate	O
-	O
induced	O
osmotic	O
cell	O
swelling	O
.	O

In	O
vivo	O
,	O
increases	O
in	O
cerebrospinal	O
fluid	O
(	O
CSF	O
)	O
taurine	B
could	O
,	O
therefore	O
,	O
unmask	O
glutamate	O
-	O
mediated	O
cytotoxic	O
edema	O
formation	O
and	O
possibly	O
differentiate	O
it	O
from	O
vasogenic	O
edema	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
ventricular	O
CSF	O
glutamate	B
and	O
taurine	B
levels	O
were	O
measured	O
in	O
28	O
severely	O
brain	O
-	O
injured	O
patients	O
on	O
days	O
1	O
,	O
5	O
,	O
and	O
14	O
after	O
trauma	O
.	O

Posttraumatic	O
changes	O
in	O
CSF	O
amino	B
acids	I
were	O
investigated	O
in	O
regard	O
to	O
extent	O
of	O
tissue	O
damage	O
and	O
alterations	O
in	O
brain	O
edema	O
as	O
estimated	O
by	O
computerized	O
tomography	O
.	O

On	O
day	O
1	O
,	O
CSF	O
glutamate	B
and	O
taurine	B
levels	O
were	O
significantly	O
increased	O
in	O
patients	O
with	O
subdural	O
or	O
epidural	O
hematomas	O
(	O
8+	O
/	O
-0.8	O
/	O
71+	O
/	O
-12	O
microM	O
)	O
,	O
contusions	O
(	O
21+	O
/	O
-4.1	O
/	O
122+	O
/	O
-18	O
microM	O
)	O
,	O
and	O
generalized	O
brain	O
edema	O
(	O
13+	O
/	O
-3.2	O
/	O
80+	O
/	O
-15	O
microM	O
)	O
compared	O
to	O
lumbar	O
control	O
CSF	O
(	O
1.3+	O
/	O
-0.1	O
/	O
12+	O
/	O
-1	O
microM	O
;	O
p	O
<	O
0.001	O
)	O
.	O

CSF	O
amino	B
acids	I
,	O
however	O
,	O
did	O
not	O
reflect	O
edema	O
formation	O
and	O
resolution	O
as	O
estimated	O
by	O
computerized	O
tomography	O
.	O

CSF	O
taurine	B
correlated	O
positively	O
with	O
glutamate	B
,	O
eventually	O
depicting	O
glutamate	B
-	O
induced	O
cell	O
swelling	O
.	O

However	O
,	O
parallel	O
neuronal	O
release	O
of	O
taurine	B
with	O
its	O
inhibitory	O
function	O
can	O
not	O
be	O
excluded	O
.	O

Thus	O
,	O
the	O
sensitivity	O
of	O
taurine	B
in	O
unmasking	O
cytotoxic	O
edema	O
formation	O
is	O
weakened	O
by	O
the	O
inability	O
in	O
defining	O
its	O
origin	O
and	O
function	O
under	O
the	O
conditions	O
chosen	O
in	O
the	O
present	O
study	O
.	O

Overall	O
,	O
persisting	O
pathologic	O
ventricular	O
CSF	O
glutamate	B
and	O
taurine	B
levels	O
are	O
highly	O
suggestive	O
of	O
ongoing	O
glial	O
and	O
neuronal	O
impairment	O
in	O
humans	O
following	O
severe	O
traumatic	O
brain	O
injury	O
.	O

Dopamine	B
is	O
a	O
biogenic	O
amine	B
synthesized	O
in	O
the	O
hypothalamus	O
,	O
in	O
the	O
arcuate	O
nucleus	O
,	O
the	O
caudad	O
,	O
and	O
various	O
areas	O
of	O
the	O
central	O
and	O
peripheral	O
nervous	O
system	O
.	O

It	O
has	O
been	O
widely	O
established	O
that	O
dopamine	B
and	O
its	O
agonists	B
play	O
an	O
important	O
role	O
in	O
cardiovascular	O
,	O
renal	O
,	O
hormonal	O
,	O
and	O
central	O
nervous	O
system	O
regulation	O
through	O
stimulation	O
of	O
alpha	O
and	O
beta	O
adrenergic	O
and	O
dopaminergic	O
receptors	O
.	O

There	O
are	O
several	O
agonists	O
of	O
dopamine-2	O
(	O
DA	O
2	O
)	O
dopaminergic	O
receptors	O
,	O
such	O
as	O
bromocriptine	B
,	O
pergolide	B
,	O
lisuride	B
,	O
quinpirole	B
,	O
and	O
carmoxirole	B
,	O
which	O
inhibit	O
norepinephrine	B
release	O
and	O
produce	O
a	O
decrease	O
in	O
arterial	O
blood	O
pressure	O
;	O
in	O
some	O
cases	O
,	O
bromocriptine	B
and	O
pergolide	B
also	O
reduce	O
heart	O
rate	O
.	O

From	O
a	O
therapeutic	O
point	O
of	O
view	O
,	O
the	O
above	O
-	O
mentioned	O
agonists	B
are	O
used	O
for	O
treating	O
Parkinson	O
's	O
disease	O
,	O
acting	O
over	O
DA	O
2	O
dopaminergic	O
receptors	O
of	O
the	O
nigrostriatal	O
system	O
.	O

Bromocriptine	B
and	O
the	O
other	O
dopaminergic	B
agonists	I
mentioned	O
act	O
over	O
DA	O
2	O
receptors	O
of	O
the	O
tuberoinfundibular	O
system	O
,	O
inhibiting	O
prolactin	O
release	O
and	O
decreasing	O
hyperprolactinemia	O
and	O
tumor	O
size	O
.	O

Among	O
DA	O
1	O
receptor	O
agonists	O
,	O
we	O
can	O
mention	O
fenoldopam	B
,	O
piribedil	B
,	O
ibopamine	B
,	O
SKF	B
3893	I
,	O
and	O
apomorphine	B
(	O
nonspecific	O
)	O
.	O

Activation	O
of	O
these	O
receptors	O
decreases	O
peripheral	O
resistance	O
,	O
inducing	O
lowering	O
of	O
arterial	O
blood	O
pressure	O
and	O
increases	O
in	O
heart	O
rate	O
,	O
sympathetic	O
tone	O
,	O
and	O
activity	O
of	O
the	O
renin	O
aldosterone	O
system	O
.	O

Among	O
DA	O
2	O
receptor	O
antagonists	O
,	O
we	O
can	O
mention	O
metoclopramide	B
,	O
domperidone	B
,	O
sulpiride	B
,	O
and	O
haloperidol	B
.	O

From	O
a	O
therapeutic	O
point	O
of	O
view	O
,	O
metoclopramide	B
and	O
domperidone	B
are	O
used	O
in	O
gastric	O
motility	O
disorders	O
,	O
and	O
haloperidol	B
is	O
used	O
in	O
psychotic	O
alterations	O
.	O

Antagonists	O
of	O
DA	O
1	O
receptors	O
are	O
SCH23390	B
and	O
clozapine	B
.	O

Clozapine	B
is	O
used	O
for	O
treating	O
schizophrenia	O
.	O

Administered	O
to	O
rats	O
by	O
stomach	O
tubing	O
oxythioquinox	B
(	O
Morestan	B
)	O
toxicity	O
is	O
very	O
strongly	O
increased	O
after	O
solubilisation	O
in	O
olive	B
oil	I
.	O

The	O
oxythioquinox	B
DL50	O
,	O
in	O
this	O
case	O
,	O
is	O
500	O
mg	O
/	O
kg	O
although	O
we	O
can	O
reach	O
2.8	O
g	O
/	O
kg	O
in	O
aqueous	O
suspensions	O
.	O

When	O
it	O
is	O
administered	O
(	O
1	O
g	O
/	O
kg	O
)	O
in	O
aqueous	O
suspension	O
,	O
the	O
decrease	O
in	O
body	O
weight	O
is	O
the	O
same	O
as	O
these	O
observed	O
with	O
a	O
5	O
fold	O
lower	O
dose	O
in	O
oil	B
.	O

Conversion	O
rate	O
feed	O
and	O
weight	O
of	O
differents	O
organs	O
decrease	O
when	O
animals	O
are	O
daily	O
submitted	O
to	O
oxythioquinox	B
in	O
oil	B
,	O
during	O
16	O
days	O
,	O
compared	O
with	O
animals	O
treated	O
with	O
an	O
equivalent	O
dose	O
in	O
aqueous	O
suspension	O
.	O

Potentiation	O
,	O
in	O
oil	B
solutions	O
,	O
of	O
the	O
decrease	O
of	O
oxythioquinox	B
intestinal	O
transit	O
,	O
promoting	O
its	O
absorption	O
,	O
could	O
explain	O
the	O
increase	O
of	O
oxythioquinox	B
toxicity	O
in	O
oil	O
solution	O
.	O

We	O
have	O
previously	O
shown	O
that	O
the	O
methyl	B
ester	I
of	O
hepoxilin	B
A3	I
causes	O
a	O
receptor	O
-	O
induced	O
rise	O
in	O
intracellular	O
calcium	B
through	O
the	O
release	O
from	O
intracellular	O
stores	O
in	O
suspended	O
human	O
neutrophils	O
.	O

The	O
corresponding	O
free	B
acid	I
was	O
devoid	O
of	O
activity	O
.	O

We	O
now	O
report	O
that	O
the	O
action	O
of	O
the	O
free	O
acid	O
form	O
of	O
hepoxilin	B
A3	I
is	O
dependent	O
on	O
the	O
type	O
of	O
vehicle	O
used	O
,	O
i.e.	O
it	O
is	O
active	O
in	O
releasing	O
calcium	B
when	O
used	O
in	O
an	O
ethanol	B
vehicle	O
but	O
not	O
in	O
DMSO	B
.	O

The	O
methyl	B
ester	I
is	O
equally	O
active	O
in	O
either	O
vehicle	O
.	O

The	O
pattern	O
of	O
calcium	B
release	O
between	O
the	O
free	B
acid	I
and	O
the	O
methyl	B
ester	I
is	O
qualitatively	O
different	O
.	O

Both	O
compounds	O
show	O
a	O
biphasic	O
pattern	O
,	O
i.e.	O
an	O
initial	O
rapid	O
phase	O
followed	O
by	O
a	O
slow	O
decline	O
in	O
calcium	B
levels	O
but	O
never	O
reaching	O
pre	O
-	O
hepoxilin	B
A3	I
baseline	O
levels	O
.	O

The	O
methyl	B
ester	I
appears	O
slightly	O
more	O
potent	O
in	O
the	O
initial	O
phase	O
of	O
calcium	B
release	O
than	O
the	O
free	B
acid	I
(	O
methyl	O
=	O
188+	O
/	O
-14	O
S.D.	O
,	O
free	O
acid	O
=	O
135+	O
/	O
-11	O
S.D.	O
nM	O
,	O
P	O
<	O
0.0005	O
)	O
.	O

Both	O
compounds	O
appear	O
to	O
reach	O
the	O
same	O
calcium	O
levels	O
at	O
the	O
plateau	O
of	O
the	O
second	O
prolonged	O
phase	O
(	O
methyl	O
=	O
88+	O
/	O
-8	O
S.D.	O
,	O
free	O
acid	O
=	O
107+	O
/	O
-15	O
S.D.	O
nM	O
,	O
not	O
significant	O
)	O
.	O

Lanthanum	B
chloride	I
(	O
an	O
inhibitor	O
of	O
calcium	B
influx	O
)	O
interfered	O
with	O
the	O
second	O
phase	O
of	O
the	O
curve	O
causing	O
calcium	O
levels	O
to	O
return	O
to	O
normal	O
pre	O
-	O
hepoxilin	B
levels	O
for	O
both	O
compounds	O
.	O

Addition	O
of	O
lanthanum	B
chloride	I
prior	O
to	O
the	O
hepoxilin	B
addition	O
or	O
carrying	O
out	O
the	O
experiments	O
in	O
calcium	B
-	O
free	O
medium	O
,	O
eliminated	O
the	O
second	O
phase	O
completely	O
,	O
with	O
the	O
calcium	B
peak	O
returning	O
rapidly	O
to	O
normal	O
baseline	O
levels	O
,	O
suggesting	O
that	O
the	O
second	O
phase	O
is	O
due	O
to	O
calcium	B
influx	O
.	O

Again	O
the	O
methyl	B
ester	I
is	O
more	O
active	O
than	O
the	O
free	B
acid	I
(	O
methyl	O
,	O
189+	O
/	O
-12	O
;	O
free	O
acid	O
,	O
145+	O
/	O
-6	O
S.D.	O
nM	O
,	O
P<0.005	O
)	O
.	O

Additional	O
experiments	O
with	O
tritium	O
-	O
labelled	O
methyl	B
ester	I
of	O
hepoxilin	B
A3	I
demonstrated	O
that	O
the	O
compound	O
is	O
hydrolyzed	O
into	O
the	O
free	B
acid	I
intracellularly	O
.	O

These	O
experiments	O
demonstrate	O
that	O
DMSO	B
interacts	O
with	O
hepoxilin	B
free	B
acid	I
,	O
interfering	O
with	O
its	O
entry	O
into	O
the	O
cell	O
while	O
ethanol	B
does	O
not	O
.	O

Once	O
inside	O
the	O
cell	O
,	O
hepoxilin	B
interacts	O
with	O
its	O
own	O
receptor	O
to	O
release	O
calcium	B
rapidly	O
from	O
stores	O
,	O
but	O
it	O
also	O
causes	O
a	O
more	O
prolonged	O
influx	O
of	O
calcium	B
from	O
the	O
extracellular	O
milieu	O
.	O

We	O
have	O
recently	O
shown	O
that	O
hepoxilin	B
(	O
Hx	B
)	O
A3	B
interacts	O
with	O
a	O
specific	O
binding	O
protein	O
in	O
the	O
intact	O
human	O
neutrophil	O
resulting	O
in	O
the	O
release	O
of	O
intracellular	O
calcium	B
[	O
1	O
]	O
.	O

In	O
those	O
studies	O
we	O
used	O
the	O
methyl	B
(	O
Me	B
)	O
ester	B
form	O
in	O
DMSO	B
because	O
we	O
found	O
that	O
the	O
free	B
acid	I
(	O
FA	B
)	O
was	O
without	O
effect	O
in	O
intact	O
cells	O
both	O
in	O
terms	O
of	O
binding	O
and	O
calcium	B
release	O
[	O
2	O
]	O
.	O

We	O
also	O
found	O
that	O
both	O
the	O
FA	B
and	O
Me	B
ester	I
(	O
in	O
DMSO	B
)	O
were	O
active	O
in	O
specific	O
binding	O
to	O
disrupted	O
neutrophil	O
membranes	O
[	O
3	O
]	O
.	O

This	O
suggested	O
that	O
the	O
FA	B
did	O
not	O
penetrate	O
into	O
the	O
intact	O
cell	O
and	O
that	O
the	O
binding	O
protein	O
was	O
intracellular	O
and	O
not	O
at	O
the	O
outside	O
surface	O
of	O
the	O
plasma	O
membrane	O
.	O

We	O
now	O
describe	O
new	O
findings	O
which	O
support	O
a	O
binding	O
/	O
calcium	B
release	O
coupling	O
where	O
both	O
the	O
FA	B
and	O
the	O
Me	B
ester	I
are	O
found	O
active	O
(	O
in	O
ethanol	B
vehicle	O
)	O
in	O
the	O
intact	O
neutrophil	O
and	O
demonstrate	O
a	O
biphasic	O
action	O
of	O
HxA3	B
,	O
one	O
in	O
releasing	O
calcium	B
from	O
intracellular	O
stores	O
,	O
a	O
second	O
in	O
increasing	O
calcium	B
influx	O
.	O

2	O
Materials	O
and	O
methods	O
2.1	O
Materials	O
Pure	O
8	B
(	I
R	I
)	I
-HxA3	I
Me	I
ester	I
was	O
prepared	O
in	O
our	O
laboratory	O
as	O
previously	O
reported	O
[	O
4	O
]	O
.	O

The	O
FA	B
was	O
prepared	O
by	O
hydrolysis	O
of	O
the	O
Me	B
ester	I
with	O
1	O
N	O
KOH	B
/	O
ethanol	B
followed	O
by	O
mild	O
acidification	O
,	O
extraction	O
and	O
further	O
purification	O
by	O
chromatography	O
[	O
5	O
]	O
.	O

[	B
3	I
H6	I
]	I
(	I
8R	I
)	I
-HxA3	I
Me	I
ester	I
was	O
prepared	O
as	O
previously	O
reported	O
[	O
5	O
]	O
.	O

Lanthanum	B
chloride	I
was	O
purchased	O
from	O
Sigma	O
(	O
St.	O
Louis	O
,	O
MO	O
,	O
USA	O
)	O
.	O

2.2	O
Preparation	O
of	O
human	O
neutrophils	O
Human	O
neutrophils	O
were	O
prepared	O
essentially	O
as	O
described	O
previously	O
[	O
3	O
]	O
.	O

Typically	O
,	O
neutrophils	O
were	O
obtained	O
from	O
40	O
ml	O
venous	O
blood	O
from	O
volunteers	O
that	O
had	O
not	O
taken	O
any	O
medication	O
.	O

The	O
blood	O
was	O
anti	O
-	O
coagulated	O
with	O
heparin	B
sodium	I
(	O
Organon	O
Tecknica	O
,	O
Durham	O
,	O
NC	O
,	O
USA	O
)	O
.	O

Erythrocytes	O
were	O
removed	O
by	O
4.5	O
%	O
dextran	B
sedimentation	O
.	O

Neutrophils	O
were	O
collected	O
and	O
pelleted	O
after	O
Ficoll	O
-	O
Paque	O
gradient	O
centrifugation	O
.	O

Further	O
removal	O
of	O
contaminating	O
erythrocytes	O
was	O
carried	O
out	O
by	O
ammonium	B
chloride	I
lysis	O
.	O

After	O
washing	O
twice	O
with	O
centrifugation	O
,	O
neutrophils	O
were	O
resuspended	O
in	O
RPMI	B
1640	I
medium	I
and	O
were	O
counted	O
in	O
a	O
Coulter	O
counter	O
(	O
Model	O
901	O
)	O
.	O

The	O
cells	O
were	O
adjusted	O
to	O
a	O
concentration	O
of	O
107	O
cells	O
/	O
ml	O
in	O
RPMI	B
1640	I
medium	I
.	O

2.3	O
Intracellular	O
calcium	B
release	O
Freshly	O
prepared	O
neutrophil	O
suspensions	O
(	O
1	O
ml	O
:	O
1	O
×	O
107	O
cells	O
)	O
were	O
loaded	O
with	O
3	O
mM	O
(	O
final	O
concentration	O
3	O
μM	O
)	O
of	O
the	O
acetoxymethyl	B
ester	I
precursor	O
of	O
the	O
calcium	B
indicator	O
(	O
Indo-1-AM	B
,	O
Calbiochem	O
,	O
La	O
Jolla	O
,	O
CA	O
,	O
USA	O
)	O
during	O
30	O
min	O
at	O
37	O
°	O
C	O
.	O

Excess	O
dye	O
was	O
removed	O
by	O
centrifugation	O
and	O
the	O
cells	O
were	O
suspended	O
in	O
fresh	O
RPMI	B
1640	I
medium	I
.	O

Dye	O
-	O
loaded	O
cells	O
were	O
kept	O
at	O
room	O
temperature	O
on	O
a	O
rotator	O
.	O

Each	O
measurement	O
consisted	O
of	O
the	O
following	O
:	O
2	O
×	O
106	O
cells	O
were	O
suspended	O
in	O
1	O
ml	O
of	O
assay	B
medium	I
of	O
the	O
following	O
composition	O
in	O
mM	O
:	O
NaCl	B
140	O
,	O
KCl	B
5	O
,	O
MgCl2	B
1	O
,	O
CaCl2	B
1	O
,	O
HEPES	B
sodium	I
-	I
free	I
10	O
and	O
glucose	B
10	O
,	O
pH	O
7.3	O
and	O
placed	O
in	O
a	O
plastic	O
cuvette	O
(	O
Diamed	O
Lab	O
.	O
,	O
Toronto	O
,	O
Canada	O
)	O
whose	O
temperature	O
was	O
controlled	O
at	O
37	O
°	O
C	O
.	O

Calcium	B
-	O
free	O
media	O
contained	O
no	O
calcium	B
and	O
1	O
mM	O
EGTA	B
was	O
added	O
.	O

The	O
cell	O
suspension	O
was	O
continuously	O
stirred	O
magnetically	O
.	O

Fluorescence	O
was	O
continuously	O
monitored	O
with	O
a	O
Perkin	O
-	O
Elmer	O
fluorescence	O
spectrophotometer	O
(	O
model	O
650	O
-	O
40	O
)	O
and	O
recorded	O
on	O
a	O
chart	O
recorder	O
(	O
LKB	O
model	O
2210	O
)	O
set	O
at	O
1	O
cm	O
/	O
min	O
.	O

The	O
excitation	O
wavelength	O
was	O
set	O
at	O
331	O
nm	O
,	O
the	O
emission	O
wavelength	O
at	O
410	O
nm	O
,	O
with	O
slits	O
of	O
excitation	O
and	O
emission	O
set	O
at	O
3	O
and	O
15	O
nm	O
respectively	O
.	O

At	O
the	O
end	O
of	O
each	O
test	O
,	O
a	O
calibration	O
was	O
carried	O
out	O
to	O
determine	O
the	O
maximal	O
fluorescence	O
by	O
adding	O
ionomycin	B
(	O
Sigma	O
)	O
at	O
1	O
mM	O
(	O
final	O
concentration	O
1	O
μM	O
)	O
and	O
minimal	O
fluorescence	O
by	O
adding	O
MnCl2	B
(	O
final	O
concentration	O
3	O
mM	O
)	O
as	O
previously	O
described	O
[	O
6	O
]	O
.	O

Test	O
compounds	O
were	O
prepared	O
in	O
DMSO	B
(	O
Caledon	O
,	O
Georgetown	O
,	O
OR	O
,	O
USA	O
)	O
or	O
glass	O
-	O
distilled	O
ethanol	B
(	O
100	O
%	O
)	O
at	O
a	O
stock	O
solution	O
of	O
1	O
μg	O
/	O
μl	O
or	O
5	O
μg	O
/	O
μl	O
and	O
1	O
μl	O
of	O
this	O
solution	O
was	O
added	O
to	O
2	O
×	O
106	O
cells	O
in	O
1	O
ml	O
.	O

2.4	O
Metabolism	O
of	O
[	B
3	I
H6	I
]	I
HxA3	I
Me	I
ester	I
Freshly	O
prepared	O
human	O
neutrophils	O
were	O
incubated	O
in	O
the	O
above	O
assay	B
medium	I
in	O
a	O
siliconized	O
glass	O
tube	O
to	O
which	O
had	O
been	O
added	O
[	B
3	I
H	I
]	I
(	I
8R	I
)	I
-HxA3	I
Me	I
ester	I
(	O
5	O
×	O
106	O
cpm	O
)	O
diluted	O
with	O
3	O
μg	O
of	O
the	O
unlabelled	B
compound	I
.	O

The	O
mixture	O
was	O
incubated	O
for	O
1	O
or	O
5	O
minutes	O
and	O
the	O
incubation	O
mixture	O
was	O
extracted	O
with	O
ethyl	B
acetate	I
without	O
prior	O
acidification	O
to	O
extract	O
the	O
intact	O
Hx	B
structure	O
and	O
its	O
products	B
(	O
which	O
are	O
acid	O
sensitive	O
)	O
.	O

The	O
solvent	O
was	O
evaporated	O
to	O
dryness	O
with	O
N2	B
gas	O
and	O
the	O
residue	O
was	O
dissolved	O
in	O
a	O
small	O
amount	O
of	O
ethyl	B
acetate	I
and	O
spotted	O
on	O
TLC	O
(	O
silica	B
gel	I
G	I
,	O
ethyl	B
acetate	I
/	O
acetic	B
acid	I
99.5	O
/	O
0.5	O
(	O
v	O
/	O
v	O
)	O
)	O
.	O

The	O
plate	O
was	O
developed	O
for	O
60	O
min	O
,	O
then	O
the	O
solvent	O
was	O
dried	O
with	O
cold	O
air	O
and	O
scanned	O
for	O
radioactivity	O
on	O
a	O
TLC	O
radiochromatogram	O
scanner	O
(	O
Berthold	O
)	O
.	O

Authentic	O
standards	O
of	O
HxA3	B
Me	I
ester	I
and	O
FA	B
as	O
well	O
as	O
the	O
ω	B
-	I
hydroxy	I
(	O
ωH	B
)	O
metabolite	O
FA	B
(	O
product	O
of	O
ω	O
-	O
oxidation	O
[	O
7	O
]	O
)	O
and	O
the	O
trihydroxy	B
metabolite	I
FA	I
(	O
product	O
of	O
epoxide	O
hydrolase	O
)	O
were	O
spotted	O
as	O
reference	O
compounds	O
.	O

3	O
Results	O
and	O
discussion	O
We	O
show	O
herein	O
that	O
HxA3	B
FA	I
but	O
not	O
the	O
Me	B
ester	I
is	O
vehicle	O
sensitive	O
in	O
evoking	O
a	O
rise	O
in	O
intracellular	O
calcium	B
in	O
suspensions	O
of	O
human	O
neutrophils	O
.	O

Fig.	O
1	O
A	O
shows	O
a	O
typical	O
pattern	O
of	O
intracellular	O
calcium	B
resulting	O
from	O
the	O
addition	O
of	O
HxA3	B
Me	I
ester	I
(	O
upper	O
trace	O
)	O
and	O
FA	B
(	O
lower	O
trace	O
)	O
in	O
DMSO	B
as	O
vehicle	O
.	O

This	O
is	O
compared	O
with	O
the	O
same	O
two	O
compounds	O
added	O
in	O
ethanol	B
as	O
vehicle	O
(	O
Fig.	O
1	O
B	O
)	O
.	O

The	O
following	O
three	O
points	O
are	O
apparent	O
.	O

First	O
,	O
the	O
pattern	O
for	O
the	O
Me	B
ester	I
is	O
similar	O
and	O
independent	O
of	O
the	O
vehicle	O
used	O
(	O
compare	O
upper	O
traces	O
in	O
Fig.	O
1	O
A	O
and	O
B	O
)	O
.	O

Second	O
,	O
the	O
FA	B
is	O
inactive	O
when	O
made	O
up	O
in	O
DMSO	B
but	O
is	O
active	O
when	O
added	O
in	O
ethanol	B
vehicle	O
(	O
compare	O
lower	O
traces	O
in	O
Fig.	O
1	O
A	O
and	O
B	O
)	O
.	O

Third	O
,	O
both	O
compounds	O
added	O
in	O
ethanol	B
show	O
a	O
rapid	O
action	O
(	O
rise	O
in	O
intracellular	O
calcium	B
)	O
and	O
a	O
slower	O
more	O
prolonged	O
decrease	O
in	O
calcium	B
levels	O
but	O
never	O
decreasing	O
to	O
pre	O
-	O
HxA3	B
levels	O
(	O
see	O
Fig.	O
1	O
B	O
)	O
.	O

The	O
Me	B
ester	I
appears	O
more	O
potent	O
in	O
the	O
rapid	O
initial	O
phase	O
of	O
calcium	B
release	O
than	O
the	O
FA	B
(	O
Me	B
,	O
188±14	O
S.D.	O
;	O
FA	B
,	O
135±11	O
S.D.	O
nM	O
,	O
P	O
<	O
0.0005	O
,	O
n	O
=3	O
)	O
and	O
decreases	O
to	O
a	O
similar	O
plateau	O
level	O
as	O
with	O
the	O
FA	B
(	O
Me	B
,	O
88±8	O
S.D.	O
;	O
FA	B
,	O
107±15	O
S.D.	O
nM	O
,	O
not	O
significant	O
,	O
n	O
=	O
3	O
)	O
.	O

Hence	O
,	O
the	O
decrease	O
to	O
the	O
second	O
phase	O
(	O
prolonged	O
calcium	B
rise	O
)	O
is	O
greater	O
with	O
the	O
Me	B
ester	I
(	O
from	O
188	O
to	O
88	O
nM=53	O
%	O
)	O
than	O
with	O
the	O
FA	B
(	O
from	O
135	O
to	O
107	O
nM=20	O
%	O
)	O
.	O

In	O
order	O
to	O
address	O
this	O
second	O
phase	O
of	O
calcium	B
`	O
retention	O
'	O
,	O
we	O
administered	O
lanthanum	B
chloride	I
(	O
1	O
μM	O
final	O
concentration	O
)	O
at	O
the	O
plateau	O
of	O
the	O
profile	O
(	O
about	O
5	O
min	O
after	O
the	O
addition	O
of	O
HxA3	B
)	O
.	O

Lanthanum	B
chloride	I
blocks	O
the	O
entry	O
of	O
calcium	B
by	O
inhibiting	O
calcium	B
channels	O
[	O
8	O
,	O
9	O
]	O
.	O

Lanthanum	B
caused	O
an	O
immediate	O
decrease	O
in	O
intracellular	O
calcium	B
levels	O
towards	O
the	O
baseline	O
for	O
both	O
the	O
Me	B
ester	I
as	O
well	O
as	O
the	O
FA	B
(	O
Fig.	O
1	O
B	O
,	O
upper	O
and	O
lower	O
traces	O
)	O
.	O

In	O
separate	O
experiments	O
(	O
Fig.	O
1	O
C	O
)	O
carried	O
out	O
in	O
medium	O
devoid	O
of	O
extracellular	O
calcium	B
(	O
containing	O
EGTA	B
)	O
,	O
the	O
Me	B
ester	I
(	O
tested	O
in	O
DMSO	B
or	O
ethanol	B
)	O
effected	O
the	O
same	O
rapid	O
initial	O
phase	O
of	O
intracellular	O
calcium	B
rise	O
but	O
the	O
peak	O
response	O
quickly	O
returned	O
to	O
baseline	O
(	O
Fig.	O
1	O
C	O
,	O
upper	O
trace	O
)	O
,	O
suggesting	O
that	O
the	O
second	O
(	O
longer	O
)	O
phase	O
of	O
the	O
normal	O
HxA3	B
response	O
was	O
due	O
to	O
the	O
entry	O
of	O
extracellular	O
calcium	B
.	O

Similar	O
results	O
were	O
observed	O
with	O
the	O
FA	B
of	I
HxA3	I
(	O
Fig.	O
1	O
C	O
,	O
lower	O
trace	O
)	O
.	O

Again	O
the	O
Me	B
ester	I
is	O
slightly	O
more	O
potent	O
than	O
the	O
FA	B
(	O
Me	B
,	O
189±12	O
S.D.	O
;	O
FA	B
,	O
145±6	O
S.D.	O
nM	O
,	O
P	O
<	O
0.005	O
,	O
n	O
=	O
3	O
)	O
.	O

Similar	O
results	O
to	O
the	O
extracellular	O
calcium	B
-	O
free	O
experiments	O
were	O
observed	O
when	O
lanthanum	O
chloride	O
was	O
added	O
to	O
the	O
cells	O
prior	O
to	O
HxA3	O
(	O
data	O
not	O
shown	O
)	O
.	O

In	O
order	O
to	O
investigate	O
further	O
whether	O
the	O
calcium	O
releasing	O
action	O
of	O
HxA3	B
on	O
neutrophils	O
was	O
mediated	O
via	O
its	O
conversion	O
into	O
other	O
compounds	O
,	O
we	O
incubated	O
tritiated	B
HxA3	I
Me	I
ester	I
with	O
human	O
neutrophils	O
and	O
analyzed	O
the	O
products	O
after	O
1	O
and	O
5	O
min	O
incubation	O
,	O
the	O
periods	O
of	O
maximal	O
change	O
in	O
intracellular	O
calcium	B
.	O

The	O
ethyl	B
acetate	I
extract	O
of	O
the	O
incubation	O
was	O
analyzed	O
by	O
TLC	O
.	O

Fig.	O
2	O
shows	O
that	O
within	O
a	O
1	O
min	O
incubation	O
(	O
the	O
period	O
of	O
sharp	O
initial	O
calcium	B
rise	O
)	O
the	O
Me	B
ester	I
is	O
only	O
partially	O
hydrolyzed	O
(	O
about	O
10	O
%	O
)	O
into	O
the	O
FA	B
by	O
intracellular	O
esterases	O
,	O
demonstrating	O
that	O
the	O
Me	B
ester	I
penetrates	O
into	O
the	O
cell	O
where	O
it	O
acts	O
to	O
release	O
calcium	B
from	O
calcium	B
stores	O
(	O
rapid	O
initial	O
phase	O
)	O
.	O

About	O
50	O
%	O
of	O
the	O
Me	B
ester	I
is	O
converted	O
into	O
the	O
FA	B
as	O
the	O
sole	O
metabolite	O
within	O
5	O
min	O
of	O
incubation	O
.	O

Hence	O
,	O
the	O
rapid	O
initial	O
phase	O
of	O
the	O
calcium	B
profile	O
of	O
the	O
Me	B
ester	I
of	I
HxA3	I
is	O
due	O
to	O
a	O
large	O
part	O
to	O
the	O
Me	B
ester	I
form	O
itself	O
while	O
the	O
prolonged	O
phase	O
occurs	O
during	O
and	O
subsequent	O
to	O
the	O
formation	O
of	O
the	O
FA	B
.	O

The	O
important	O
experiment	O
in	O
Fig.	O
1	O
C	O
(	O
bottom	O
trace	O
)	O
demonstrates	O
that	O
the	O
FA	B
is	O
also	O
active	O
on	O
intracellular	O
stores	O
to	O
cause	O
the	O
release	O
of	O
intracellular	O
calcium	B
,	O
i.e.	O
it	O
has	O
dual	O
actions	O
.	O

These	O
experiments	O
demonstrate	O
that	O
HxA3	B
,	O
both	O
as	O
the	O
FA	B
as	O
well	O
as	O
the	O
Me	B
ester	I
,	O
are	O
taken	O
up	O
into	O
the	O
cell	O
and	O
act	O
to	O
release	O
calcium	B
from	O
intracellular	O
stores	O
.	O

Within	O
the	O
time	O
frame	O
of	O
initial	O
action	O
(	O
rapid	O
phase	O
,	O
1	O
min	O
)	O
,	O
studies	O
with	O
tritiated	B
HxA3	I
show	O
that	O
the	O
Me	B
ester	I
is	O
not	O
substantially	O
hydrolyzed	O
into	O
the	O
FA	B
,	O
although	O
this	O
takes	O
place	O
subsequently	O
and	O
is	O
likely	O
involved	O
in	O
calcium	B
influx	O
.	O

Supporting	O
this	O
is	O
the	O
finding	O
that	O
the	O
second	O
phase	O
of	O
calcium	B
response	O
is	O
equally	O
pronounced	O
when	O
the	O
FA	B
is	O
used	O
(	O
Fig.	O
1	O
B	O
)	O
and	O
is	O
absent	O
in	O
calcium	B
-	O
free	O
medium	O
(	O
Fig.	O
1	O
C	O
)	O
.	O

Finally	O
,	O
caution	O
should	O
be	O
exerted	O
in	O
the	O
choice	O
of	O
vehicle	O
as	O
we	O
show	O
that	O
DMSO	B
interacts	O
with	O
the	O
FA	B
form	O
of	O
HxA3	B
(	O
likely	O
through	O
formation	O
of	O
a	O
polar	O
hydrogen	B
-	I
bonded	I
DMSO	B
-	I
HxA3	I
adduct	I
[	O
10	O
]	O
)	O
making	O
the	O
adduct	O
incapable	O
of	O
entering	O
the	O
cell	O
and	O
rendering	O
HxA3	B
inactive	O
.	O

In	O
ethanol	B
as	O
vehicle	O
,	O
the	O
FA	B
enters	O
the	O
cell	O
where	O
it	O
is	O
capable	O
both	O
of	O
releasing	O
calcium	B
from	O
intracellular	O
stores	O
(	O
see	O
Fig.	O
1	O
C	O
)	O
and	O
causing	O
influx	O
of	O
extracellular	O
calcium	B
(	O
compare	O
Fig.	O
1	O
B	O
and	O
C	O
)	O
.	O

Similar	O
findings	O
were	O
observed	O
with	O
Hx	B
binding	O
studies	O
.	O

The	O
FA	B
dissolved	O
in	O
DMSO	B
did	O
not	O
bind	O
to	O
intact	O
neutrophils	O
but	O
did	O
bind	O
to	O
membranes	O
from	O
disrupted	O
cells	O
,	O
while	O
the	O
Me	B
ester	I
was	O
equally	O
well	O
bound	O
to	O
the	O
intact	O
cell	O
as	O
well	O
as	O
disrupted	O
cells	O
[	O
3	O
]	O
.	O

Acknowledgements	O
This	O
study	O
was	O
supported	O
by	O
a	O
Grant	O
(	O
MT-4181	O
)	O
to	O
CRP	O
-	O
A	O
from	O
the	O
Medical	O
Research	O
Council	O
of	O
Canada	O
and	O
from	O
FO	O
/	O
FUB	O
to	O
SN	O
.	O

Manoalide	B
is	O
a	O
potent	O
analgesic	O
and	O
antiinflammatory	O
sesterterpene	B
isolated	O
in	O
1980	O
from	O
a	O
marine	O
sponge	O
.	O

The	O
antiinflammatory	O
activity	O
of	O
manoalide	B
is	O
due	O
to	O
inhibition	O
of	O
PLA2	O
,	O
through	O
irreversible	O
binding	O
to	O
several	O
lysine	B
residues	O
.	O

The	O
binding	O
is	O
realized	O
by	O
means	O
of	O
the	O
two	O
masked	O
aldehyde	B
functions	O
present	O
in	O
the	O
polar	O
part	O
of	O
manoalide	B
.	O

Of	O
the	O
two	O
aldehyde	B
groups	O
,	O
only	O
that	O
present	O
in	O
the	O
g	B
-	I
hydroxybutenolide	I
ring	O
seems	O
to	O
be	O
essential	O
,	O
since	O
cacospongionolides	B
,	O
naturally	O
occurring	O
analogues	O
lacking	O
the	O
second	O
masked	O
aldehyde	B
group	O
,	O
were	O
also	O
shown	O
to	O
be	O
irreversible	O
PLA2	O
inhibitors	O
.	O

It	O
appears	O
that	O
the	O
minimum	O
structural	O
requirement	O
for	O
exhibiting	O
manoalide	B
-	O
like	O
PLA2	O
inhibition	O
would	O
be	O
the	O
presence	O
in	O
the	O
inhibitor	O
of	O
functional	O
groups	O
able	O
to	O
seize	O
the	O
amino	B
groups	I
of	O
PLA2	O
lysine	B
residues	O
with	O
formation	O
of	O
stable	O
covalent	O
bonds	O
.	O

Many	O
manoalide	B
analogues	B
have	O
been	O
isolated	O
from	O
marine	O
sponges	O
,	O
most	O
of	O
them	O
sharing	O
PLA2	O
inhibitory	O
properties	O
.	O

Other	O
interesting	O
bioactivities	O
have	O
also	O
been	O
reported	O
for	O
some	O
of	O
these	O
compounds	O
.	O

Bis	B
(	I
monoacylglycerol	I
)	I
phosphate	I
(	O
BMP	B
)	O
was	O
first	O
described	O
in	O
1967	O
by	O
Body	O
and	O
Gray	O
[	O
1	O
]	O
,	O
and	O
was	O
shown	O
by	O
Waite	O
et	O
al.	O
[	O
2	O
]	O
to	O
be	O
synthesized	O
in	O
alveolar	O
macrophages	O
from	O
exogenous	O
phosphatidylglycerol	B
(	O
PG	B
)	O
.	O

BMP	B
is	O
a	O
unique	O
phospholipid	B
having	O
a	O
sn	B
-1	I
rather	O
than	O
sn	B
-3	I
glycerol	I
phosphate	I
ester	I
[	O
3	O
]	O
and	O
one	O
acyl	B
group	I
attached	O
to	O
each	O
of	O
the	O
glycerol	B
moieties	I
.	O

While	O
it	O
is	O
unclear	O
whether	O
the	O
acyl	B
esters	I
are	O
at	O
the	O
primary	B
or	O
secondary	B
hydroxyl	I
[	O
4,5	O
]	O
,	O
the	O
acyl	B
groups	I
of	O
BMP	B
are	O
unusually	O
rich	O
in	O
polyunsaturated	B
species	O
[	O
5–7	O
]	O
which	O
implies	O
acyl	B
linkage	O
at	O
the	O
sn	O
-2	O
and	O
sn	O
-2′	O
positions	O
.	O

We	O
proposed	O
a	O
biochemical	O
pathway	O
by	O
which	O
BMP	B
is	O
synthesized	O
but	O
this	O
remains	O
to	O
be	O
proven	O
(	O
Scheme	O
1	O
)	O
[	O
8	O
]	O
.	O

Recent	O
work	O
within	O
our	O
laboratory	O
has	O
focused	O
on	O
characterizing	O
the	O
enzymes	O
that	O
are	O
involved	O
in	O
the	O
biosynthesis	O
of	O
BMP	B
from	O
PG	B
.	O

In	O
this	O
proposed	O
pathway	O
,	O
PG	B
,	O
presumably	O
from	O
lung	O
surfactant	O
,	O
is	O
taken	O
into	O
the	O
cell	O
and	O
metabolized	O
to	O
BMP	B
.	O

There	O
is	O
reason	O
to	O
suggest	O
that	O
BMP	B
synthesis	O
occurs	O
in	O
the	O
endosomal	O
system	O
since	O
a	O
role	O
for	O
BMP	B
in	O
the	O
endosomal	O
function	O
has	O
recently	O
been	O
proposed	O
[	O
9	O
]	O
.	O

The	O
first	O
proposed	O
step	O
in	O
conversion	O
to	O
BMP	B
is	O
the	O
hydrolysis	O
of	O
PG	B
catalyzed	O
by	O
a	O
lysosomal	O
PLA2	O
to	O
form	O
1-acyl	B
-	I
sn	I
-glycero-3-phospho	I
-	I
rac	I
-glycerol	I
(	O
LPG	B
)	O
.	O

In	O
the	O
second	O
step	O
,	O
sn	B
-3	I
:	I
sn	I
-1′	I
LPG	I
is	O
acylated	O
on	O
the	O
head	O
group	O
(	O
prime	O
designation	O
)	O
glycerol	B
with	O
an	O
acyl	B
group	I
from	O
a	O
donor	O
phospholipid	B
.	O

The	O
next	O
step	O
proposed	O
is	O
the	O
reorientation	O
of	O
the	O
phosphoryl	B
ester	I
from	O
the	O
sn	B
-3	I
to	O
the	O
sn	B
-1	I
position	I
,	O
with	O
liberation	O
of	O
the	O
sn	B
-1	I
linked	I
acyl	I
chain	I
concomitant	O
to	O
the	O
phosphoryl	B
migration	O
[	O
10	O
]	O
.	O

While	O
this	O
proposal	O
provides	O
the	O
energy	O
and	O
specificity	O
for	O
the	O
transfer	O
of	O
the	O
phosphate	B
to	O
the	O
sn	B
-1	I
position	I
,	O
it	O
has	O
yet	O
to	O
be	O
demonstrated	O
in	O
a	O
cell	O
homogenate	O
.	O

The	O
final	O
proposed	O
step	O
is	O
a	O
second	O
transacylation	O
to	O
incorporate	O
an	O
acyl	B
chain	I
into	O
the	O
original	O
backbone	O
glycerol	B
(	O
non	O
-	O
prime	O
designation	O
)	O
of	O
sn	B
-1	I
:	I
sn	I
-1′	I
LPG	I
.	O

If	O
the	O
sn	B
-2	I
chain	I
of	I
a	I
phospholipid	I
were	O
the	O
substrate	O
for	O
the	O
transacylation	O
steps	O
,	O
the	O
final	O
BMP	B
structure	O
would	O
contain	O
the	O
expected	O
polyunsaturated	B
fatty	I
acid	I
.	O

Various	O
groups	O
have	O
shown	O
that	O
diacyl	B
phospholipid	I
stimulates	O
the	O
conversion	O
of	O
sn	B
-3	I
:	I
sn	I
-1′	I
LPG	I
to	O
sn	B
-3	I
:	I
sn	I
-1′	I
BMP	I
(	O
Scheme	O
1	O
step	O
2	O
)	O
.	O

Our	O
studies	O
[	O
8	O
]	O
showed	O
that	O
the	O
lipid	B
product	O
of	O
the	O
reaction	O
catalyzed	O
by	O
the	O
partially	O
purified	O
transacylase	O
was	O
BMP	B
,	O
as	O
predicted	O
in	O
Scheme	O
1	O
.	O

Matsuzawa	O
et	O
al.	O
[	O
11	O
]	O
earlier	O
reported	O
that	O
PI	B
was	O
preferentially	O
used	O
by	O
a	O
rat	O
liver	O
lysosomal	O
transacylase	O
to	O
form	O
BMP	B
,	O
whereas	O
the	O
work	O
of	O
Huterer	O
and	O
Wherett	O
[	O
12	O
]	O
indicated	O
that	O
the	O
acyl	B
moiety	O
from	O
either	O
the	O
sn	B
-1	I
or	O
sn	B
-2	I
position	I
of	I
PC	I
was	O
incorporated	O
into	O
BMP	B
.	O

Huterer	O
et	O
al.	O
[	O
13	O
]	O
proposed	O
that	O
the	O
lysosomal	O
PLA1	O
is	O
also	O
a	O
transacylase	O
and	O
could	O
be	O
responsible	O
for	O
the	O
formation	O
of	O
BMP	B
and	O
acylphosphatidylglycerol	B
(	O
APG	B
)	O
.	O

The	O
stereoconfiguration	O
of	O
the	O
BMP	B
formed	O
was	O
not	O
determined	O
in	O
the	O
later	O
reports	O
.	O

Considering	O
the	O
differences	O
in	O
these	O
reports	O
,	O
we	O
felt	O
it	O
necessary	O
to	O
more	O
clearly	O
define	O
the	O
transacylation	O
step	O
(	O
Scheme	O
1	O
step	O
2	O
)	O
.	O

In	O
particular	O
,	O
we	O
set	O
out	O
to	O
establish	O
what	O
the	O
substrate	O
(	O
s	O
)	O
for	O
the	O
reaction	O
are	O
and	O
if	O
indeed	O
the	O
presence	O
of	O
polyunsaturated	B
fatty	I
acids	I
in	O
BMP	B
was	O
accounted	O
for	O
by	O
this	O
transacylation	O
.	O

To	O
our	O
surprise	O
LPG	B
served	O
as	O
both	O
the	O
acyl	B
donor	I
and	O
acyl	B
acceptor	I
,	O
even	O
though	O
diradyl	B
phospholipid	I
enhanced	O
activity	O
several	O
-	O
fold	O
.	O

The	O
data	O
supporting	O
this	O
conclusion	O
are	O
reported	O
herein	O
.	O

2	O
Methods	O
and	O
materials	O
2.1	O

Materials	O
RAW	O
264.7	O
(	O
murine	O
monocytic	O
,	O
macrophage	O
like	O
,	O
Abelson	O
leukemia	O
virus	O
transformed	O
BALB	O
/	O
c	O
)	O
cells	O
were	O
purchased	O
from	O
American	O
Type	O
Tissue	O
Culture	O
.	O

Tissue	O
culture	O
medium	O
was	O
from	O
Gibco	O
.	O

Phospholipids	B
(	O
except	O
for	O
RAW	O
264.7	O
lipid	B
)	O
were	O
from	O
Avanti	O
Polar	O
Lipids	O
.	O

Salts	B
,	O
buffers	B
,	O
and	O
organic	B
solvents	I
were	O
from	O
Fisher	O
.	O

Protein	O
assay	O
reagents	O
were	O
from	O
Pierce	O
and	O
microconcentrators	O
were	O
from	O
Amicon	O
.	O

S-300	O
column	O
matrix	O
was	O
from	O
Pharmacia	O
.	O

Silica	B
gel	I
G	I
plates	O
were	O
from	O
Analtech	O
.	O

Preparative	O
enzymes	O
were	O
from	O
Sigma	O
.	O

The	O
1-acyl	B
[	I
1,2,3	I
-	I
3	I
H	I
]	I
-sn	I
-glycero-3-phospho	I
-	I
rac	I
-glycerol	I
(	O
[	B
3	I
H	I
]	I
LPG	I
)	O
was	O
synthesized	O
as	O
described	O
earlier	O
[	O
14	O
]	O
.	O

2.2	O
Cell	O
culture	O
RAW	O
264.7	O
cells	O
were	O
grown	O
in	O
Dulbecco	B
's	I
minimum	I
essential	I
medium	I
with	O
10	O
mM	O
HEPES	B
,	O
pH	O
7.4	O
,	O
4.5	O
g	O
/	O
l	O
of	O
d	B
-glucose	I
,	O
584	O
mg	O
/	O
l	O
of	O
l	B
-glutamine	I
,	O
110	O
mg	O
/	O
l	O
of	O
sodium	B
pyruvate	I
,	O
4	O
mg	O
/	O
l	O
of	O
pyridoxal	B
HCl	I
,	O
10	O
%	O
heat	O
inactivated	O
FBS	O
(	O
by	O
volume	O
)	O
in	O
an	O
atmosphere	O
supplemented	O
with	O
5	O
%	O
CO2	B
.	O

These	O
cells	O
were	O
grown	O
to	O
confluence	O
in	O
15	O
ml	O
of	O
medium	B
in	O
a	O
75	O
cm2	O
flask	O
,	O
then	O
passaged	O
into	O
150	O
ml	O
of	O
medium	B
in	O
225	O
cm2	O
plates	O
.	O

Once	O
the	O
population	O
reached	O
1	O
×	O
108	O
total	O
cells	O
,	O
the	O
cells	O
were	O
passed	O
into	O
200	O
ml	O
of	O
medium	B
and	O
transferred	O
to	O
a	O
500	O
ml	O
cell	O
culture	O
stir	O
bottle	O
and	O
placed	O
in	O
a	O
second	O
incubator	O
.	O

Since	O
this	O
incubator	O
did	O
not	O
have	O
a	O
CO2	B
atmosphere	O
supplementation	O
system	O
,	O
the	O
medium	B
buffering	O
capacity	O
was	O
increased	O
with	O
additional	O
HEPES	B
(	O
pH	O
7.4	O
,	O
20	O
mM	O
)	O
.	O

Suspension	O
cultures	O
were	O
initiated	O
with	O
5	O
×	O
105	O
cells	O
/	O
ml	O
and	O
allowed	O
to	O
proliferate	O
until	O
reaching	O
approx	O
.	O

2	O
×	O
106	O
/ml	O
.	O

They	O
were	O
then	O
passed	O
into	O
600	O
ml	O
of	O
medium	B
in	O
a	O
1	O
l	O
culture	O
bottle	O
and	O
allowed	O
to	O
grow	O
until	O
the	O
population	O
reached	O
6	O
×	O
108	O
cells	O
at	O
which	O
time	O
the	O
cells	O
were	O
taken	O
for	O
LPG	O
transacylase	O
(	O
TA	O
)	O
isolation	O
.	O

2.3	O
Transacylase	O
isolation	O
RAW	O
264.7	O
(	O
6	O
×	O
108	O
)	O
cells	O
were	O
pelleted	O
from	O
medium	B
by	O
centrifugation	O
at	O
1000	O
×	O
g	O
,	O
resuspended	O
,	O
then	O
washed	O
twice	O
by	O
centrifugation	O
in	O
ice	O
cold	O
0.9	O
%	O
saline	B
.	O

Cells	O
were	O
resuspended	O
in	O
5	O
ml	O
of	O
1	O
mM	O
NaHCO3	B
and	O
lipids	O
were	O
removed	O
by	O
adding	O
an	O
equal	O
volume	O
of	O
water	B
-	O
saturated	O
1-butanol	B
.	O

The	O
mixture	O
was	O
vortexed	O
for	O
15	O
s	O
,	O
placed	O
on	O
ice	O
for	O
2	O
min	O
,	O
then	O
the	O
phases	O
were	O
separated	O
by	O
centrifugation	O
at	O
20	O
000	O
×	O
g	O
for	O
15	O
min	O
at	O
4	O
°	O
C	O
.	O

The	O
aqueous	B
(	O
lower	O
)	O
layer	O
was	O
applied	O
to	O
an	O
S-300	O
column	O
(	O
1.5	O
cm	O
×	O
84	O
cm	O
)	O
which	O
had	O
been	O
previously	O
equilibrated	O
in	O
10	O
mM	O
Tris	B
,	O
pH	O
7.4	O
,	O
and	O
eluted	O
with	O
the	O
same	O
buffer	O
at	O
a	O
flow	O
rate	O
of	O
0.55	O
ml	O
/	O
min	O
.	O

Fifty	O
fractions	O
of	O
2.2	O
ml	O
were	O
collected	O
from	O
the	O
S-300	O
column	O
,	O
assayed	O
for	O
TA	O
activity	O
,	O
and	O
those	O
fractions	O
exhibiting	O
TA	O
activity	O
were	O
pooled	O
.	O

Pooled	O
TA	O
intended	O
for	O
experiments	O
utilizing	O
gas	O
chromatography	O
(	O
GC	O
)	O
or	O
mass	O
spectrometry	O
(	O
MS	O
)	O
analysis	O
were	O
concentrated	O
using	O
an	O
Amicon	O
filtration	O
system	O
.	O

Pooled	O
fractions	O
were	O
then	O
assayed	O
for	O
total	O
protein	O
concentration	O
.	O

2.4	O
Transacylase	O
assay	O
For	O
each	O
assay	O
,	O
10	O
nmol	O
of	O
diradyl	B
lipid	I
,	O
[	B
3	I
H	I
]	I
LPG	I
(	O
5	O
×	O
104	O
DPM	O
,	O
200	O
pmol	O
)	O
and	O
10	O
nmol	O
of	O
1-myristoyl	B
LPG	I
were	O
dried	O
under	O
a	O
stream	O
of	O
N2	B
and	O
0.1	O
ml	O
of	O
1	O
M	O
Na	B
acetate	I
,	O
pH	O
4.5	O
was	O
added	O
.	O

The	O
lipids	O
were	O
sonically	O
dispersed	O
and	O
0.1	O
ml	O
of	O
the	O
solution	O
was	O
aliquoted	O
to	O
the	O
various	O
tubes	O
.	O

Seventy	O
-	O
five	O
μg	O
of	O
the	O
TA	O
were	O
added	O
to	O
each	O
tube	O
,	O
the	O
reaction	O
volume	O
was	O
adjusted	O
to	O
1	O
ml	O
with	O
water	B
,	O
and	O
samples	O
were	O
incubated	O
for	O
1	O
h	O
at	O
37	O
°	O
C	O
.	O

The	O
reactions	O
were	O
stopped	O
and	O
the	O
lipids	B
extracted	O
by	O
the	O
method	O
of	O
Bligh	O
and	O
Dyer	O
[	O
15	O
]	O
.	O

The	O
organic	O
phase	O
was	O
evaporated	O
under	O
N2	B
,	O
and	O
lipids	B
were	O
spotted	O
on	O
a	O
silica	B
G	I
plate	O
in	O
methanol	B
and	O
separated	O
by	O
a	O
thin	O
layer	O
chromatography	O
(	O
TLC	O
)	O
system	O
containing	O
chloroform	B
/	O
methanol	B
/	O
ammonium	B
hydroxide	I
(	O
130:70:10	O
v	O
/	O
v	O
/	O
v	O
)	O
(	O
R	O
f	O
values	O
:	O
LPG	O
0.27	O
,	O
PG	O
0.40	O
,	O
BMP	O
0.53	O
)	O
.	O

Radioactive	O
lipids	B
were	O
visualized	O
by	O
scanning	O
the	O
TLC	O
plate	O
using	O
a	O
Bioscanner	O
detector	O
and	O
compared	O
to	O
authentic	O
standards	O
.	O

Silica	B
,	O
containing	O
the	O
radioactive	O
products	O
,	O
was	O
scraped	O
from	O
the	O
plate	O
into	O
a	O
scintillation	O
vial	O
and	O
then	O
counted	O
in	O
a	O
liquid	O
scintillation	O
counter	O
and	O
TA	O
activity	O
was	O
determined	O
as	O
the	O
percentage	O
of	O
the	O
radiolabeled	O
BMP	B
formed	O
compared	O
to	O
the	O
sum	O
of	O
radioactivity	O
from	O
the	O
silica	B
plate	O
plus	O
the	O
methanol	B
/	O
water	B
phase	O
of	O
the	O
extract	O
.	O

This	O
percentage	O
was	O
converted	O
to	O
mass	O
based	O
on	O
the	O
specific	O
radioactivity	O
of	O
the	O
substrate	O
.	O

Due	O
to	O
enzyme	O
instability	O
,	O
experiments	O
were	O
completed	O
within	O
1–2	O
days	O
of	O
preparation	O
.	O

Even	O
so	O
,	O
considerable	O
variability	O
in	O
specific	O
enzymatic	O
activity	O
existed	O
between	O
preparations	O
.	O

2.5	O
Gas	O
chromatographic	O
analysis	O
Fatty	B
acid	I
methyl	I
esters	I
were	O
prepared	O
and	O
examined	O
by	O
the	O
method	O
of	O
Wang	O
and	O
Peter	O
[	O
16	O
]	O
.	O

The	O
lipids	B
were	O
separated	O
by	O
TLC	O
and	O
5	O
μg	O
of	O
pentadecanoic	B
acid	I
(	O
C15:0	B
)	O
in	O
hexane	B
was	O
pipetted	O
onto	O
each	O
zone	O
of	O
the	O
silica	B
plate	O
to	O
be	O
scraped	O
.	O

In	O
these	O
and	O
experiments	O
employing	O
MS	O
,	O
a	O
trace	O
amount	O
of	O
[	B
3	I
H	I
]	I
LPG	I
was	O
included	O
to	O
localize	O
BMP	B
on	O
the	O
TLC	O
plate	O
.	O

One	O
ml	O
of	O
7	O
%	O
HCl	B
in	O
MeOH	B
was	O
added	O
to	O
the	O
scraped	O
silica	B
,	O
vortexed	O
,	O
and	O
heated	O
to	O
100	O
°	O
C	O
for	O
15	O
min	O
.	O

After	O
cooling	O
to	O
0	O
°	O
C	O
,	O
2	O
ml	O
of	O
hexane	B
were	O
added	O
followed	O
by	O
the	O
addition	O
of	O
1	O
ml	O
of	O
2.5	O
N	O
NaOH	B
.	O

The	O
hexane	B
was	O
collected	O
,	O
the	O
samples	O
were	O
extracted	O
again	O
with	O
2	O
ml	O
of	O
hexane	B
and	O
the	O
hexane	B
was	O
dried	O
under	O
N2	B
.	O

The	O
fatty	B
acid	I
methyl	I
esters	I
were	O
dissolved	O
in	O
100	O
μl	O
of	O
undecane	B
and	O
analyzed	O
by	O
gas	O
chromatography	O
/	O
flame	O
ionization	O
detection	O
(	O
GC	O
/	O
FID	O
)	O
.	O

2.6	O
MS	O
analysis	O
MS	O
analysis	O
was	O
conducted	O
by	O
the	O
method	O
of	O
Lehmann	O
[	O
17	O
]	O
.	O

BMP	B
was	O
isolated	O
by	O
TLC	O
,	O
dissolved	O
in	O
250	O
μl	O
of	O
MeOH	B
:	O
MeCl2	B
1:1	O
,	O
injected	O
into	O
a	O
VG	O
Quattro	O
II	O
triple	O
quadrupole	O
mass	O
spectrometer	O
,	O
and	O
resultant	O
data	O
analyzed	O
using	O
Masslynx	O
software	O
.	O

Both	O
parent	O
and	O
daughter	O
ions	O
were	O
detected	O
over	O
a	O
range	O
from	O
200	O
to	O
900	O
m	O
/	O
z	O
.	O

Ion	O
spectra	O
were	O
assigned	O
acyl	B
compositions	O
based	O
on	O
detected	O
ion	O
molecular	O
weight	O
and	O
previously	O
determined	O
standards	O
.	O

Parent	O
ions	O
were	O
detected	O
in	O
the	O
first	O
quadrupole	O
,	O
ionized	O
in	O
the	O
second	O
quadrupole	O
and	O
daughter	O
ions	O
corresponding	O
to	O
acyl	B
chains	I
esterified	I
on	I
BMP	I
detected	O
in	O
the	O
third	O
quadrupole	O
.	O

3	O
Results	O
Studies	O
reported	O
thus	O
far	O
have	O
not	O
established	O
systematically	O
the	O
optimal	O
conditions	O
for	O
the	O
TA	O
.	O

For	O
these	O
studies	O
,	O
it	O
is	O
important	O
to	O
remove	O
contaminating	O
phospholipases	B
that	O
may	O
hydrolyze	O
substrates	O
and/or	O
products	O
.	O

Previous	O
work	O
from	O
our	O
lab	O
demonstrates	O
that	O
lysosomal	O
PLA	O
activity	O
was	O
minimal	O
in	O
our	O
transacylase	O
preparation	O
and	O
that	O
no	O
ATP	B
and	O
CoA	B
dependent	O
transacylases	O
were	O
present	O
[	O
8	O
]	O
.	O

We	O
first	O
demonstrated	O
that	O
the	O
reaction	O
was	O
linear	O
for	O
30	O
min	O
using	O
our	O
standard	O
assay	O
conditions	O
,	O
and	O
although	O
at	O
a	O
somewhat	O
decreased	O
rate	O
,	O
the	O
enzyme	O
was	O
active	O
up	O
to	O
90	O
min	O
(	O
data	O
not	O
shown	O
)	O
.	O

Optimal	O
activity	O
was	O
observed	O
between	O
pH	O
4.0	O
and	O
5.5	O
,	O
as	O
previously	O
reported	O
with	O
lower	O
concentrations	O
of	O
substrate	O
[	O
8	O
]	O
.	O

We	O
also	O
showed	O
using	O
10	O
or	O
30	O
μM	O
LPG	B
that	O
lipids	B
extracted	O
from	O
the	O
RAW	O
264.7	O
cells	O
stimulated	O
the	O
TA	O
in	O
concentrations	O
up	O
to	O
50	O
μM.	O
Since	O
it	O
would	O
be	O
difficult	O
to	O
define	O
the	O
substrates	O
involved	O
in	O
transacylation	O
using	O
total	O
lipid	B
extracts	O
,	O
we	O
used	O
synthetic	O
substrates	O
with	O
defined	O
acyl	B
groups	I
,	O
with	O
the	O
exception	O
of	O
the	O
[	B
3	I
H	I
]	I
LPG	I
which	O
contained	O
mainly	O
palmitate	B
.	O

The	O
[	B
3	I
H	I
]	I
LPG	I
used	O
was	O
present	O
in	O
trace	O
amounts	O
,	O
being	O
diluted	O
approx	O
.	O

100-fold	O
with	O
synthetic	O
1-myristoyl	B
LPG	I
.	O

Using	O
LPG	B
and	O
either	O
1-palmitoyl-2-oleoyl	B
-	I
sn	I
-glycero-3-phosphocholine	I
(	O
POPC	B
)	O
or	O
1-palmitoyl-2-oleoyl	B
-	I
sn	I
-glycero-3-phosphoethanolamine	I
(	O
POPE	B
)	O
,	O
we	O
find	O
a	O
concentration	O
dependence	O
of	O
both	O
the	O
LPG	B
and	O
the	O
POPC	B
(	O
Fig.	O
1A	O
,	O
B	O
)	O
.	O

On	O
the	O
other	O
hand	O
,	O
POPE	B
did	O
not	O
stimulate	O
the	O
transacylase	O
(	O
Fig.	O
1B	O
)	O
.	O

The	O
concentration	O
dependence	O
of	O
LPG	B
and	O
POPC	B
showed	O
that	O
both	O
were	O
required	O
in	O
concentrations	O
above	O
1–3	O
μM	O
before	O
stimulation	O
was	O
seen	O
.	O

The	O
complexity	O
of	O
substrate	O
dependence	O
suggests	O
that	O
the	O
physical	O
state	O
of	O
the	O
substrate	O
may	O
regulate	O
the	O
TA	O
.	O

In	O
order	O
to	O
better	O
define	O
the	O
properties	O
of	O
the	O
reaction	O
we	O
investigated	O
the	O
effects	O
of	O
detergents	O
on	O
transacylation	O
(	O
Fig.	O
2A	O
)	O
.	O

Only	O
the	O
bile	B
acids	I
deoxycholic	B
acid	I
(	O
DOC	B
)	O
or	O
cholic	B
acid	I
(	O
CHO	B
)	O
were	O
seen	O
to	O
stimulate	O
activity	O
and	O
both	O
Tween	B
20	I
and	O
cetyltrimethylammonium	B
bromide	I
markedly	O
inhibited	O
at	O
20	O
μM.	O
The	O
stimulation	O
by	O
DOC	B
was	O
optimal	O
between	O
10	O
and	O
500	O
μM	O
while	O
it	O
became	O
inhibitory	O
above	O
that	O
concentration	O
(	O
Fig.	O
2B	O
)	O
.	O

At	O
pH	O
4.5	O
DOC	B
and	O
CHO	B
are	O
protonated	O
.	O

This	O
reduces	O
their	O
critical	O
micellar	O
concentration	O
and	O
may	O
account	O
for	O
their	O
stimulatory	O
properties	O
.	O

We	O
next	O
sought	O
to	O
determine	O
the	O
effects	O
on	O
transacylation	O
of	O
various	O
phospholipids	B
in	O
the	O
presence	O
of	O
20	O
μM	O
DOC	B
(	O
Fig.	O
3	O
)	O
.	O

The	O
purpose	O
of	O
these	O
experiments	O
was	O
to	O
determine	O
whether	O
phospholipid	B
had	O
an	O
additional	O
stimulatory	O
effect	O
beyond	O
that	O
of	O
DOC	B
and	O
to	O
determine	O
whether	O
phospholipid	B
that	O
lacked	O
an	O
acyl	B
group	I
in	O
sn	O
-1	O
and	O
sn	O
-2	O
positions	O
would	O
stimulate	O
the	O
TA	O
.	O

In	O
this	O
case	O
a	O
plasmalogen	B
rich	O
PE	B
from	O
brain	O
was	O
stimulatory	O
.	O

Perhaps	O
the	O
most	O
striking	O
feature	O
of	O
Fig.	O
3	O
is	O
the	O
stimulation	O
by	O
1,2-dihexadecyl	B
-	I
sn	I
-glycero-3-phosphocholine	I
(	O
dialkyl	B
PC	I
)	O
,	O
a	O
phospholipid	B
with	O
ether	B
rather	O
than	O
ester	B
bonds	O
that	O
can	O
not	O
undergo	O
transacylation	O
.	O

This	O
indicates	O
that	O
the	O
stimulatory	O
effect	O
of	O
diradyl	B
phospholipids	I
on	O
transacylation	O
may	O
not	O
be	O
as	O
a	O
substrate	O
but	O
provides	O
a	O
favorable	O
lipid	B
milieu	O
.	O

Since	O
the	O
lipids	B
used	O
in	O
these	O
studies	O
have	O
defined	O
acyl	B
groups	I
,	O
we	O
determined	O
whether	O
an	O
acyl	B
group	I
is	O
transferred	O
from	O
PC	B
by	O
fatty	B
acid	I
analysis	O
of	O
the	O
product	O
BMP	B
.	O

Fig.	O
4	O
shows	O
the	O
acyl	B
composition	O
of	O
the	O
BMP	B
in	O
which	O
1-myristoyl	B
LPG	I
and	O
POPC	B
were	O
used	O
as	O
substrates	O
(	O
from	O
Fig.	O
1	O
)	O
.	O

As	O
determined	O
by	O
the	O
GC	O
,	O
myristate	B
was	O
the	O
predominant	O
fatty	B
acid	I
present	O
in	O
BMP	B
with	O
only	O
a	O
trace	O
of	O
the	O
acyl	B
groups	I
,	O
palmitate	B
and	O
oleate	B
,	O
from	O
the	O
POPC	B
being	O
used	O
in	O
the	O
biosynthesis	O
of	O
BMP	B
.	O

These	O
data	O
show	O
that	O
PC	B
does	O
not	O
participate	O
significantly	O
as	O
substrate	O
in	O
transacylation	O
.	O

This	O
observation	O
is	O
consistent	O
with	O
the	O
finding	O
that	O
dialkyl	B
PC	I
can	O
stimulate	O
transacylation	O
(	O
Fig.	O
3	O
)	O
.	O

The	O
results	O
of	O
Fig.	O
4	O
were	O
verified	O
using	O
lipids	B
with	O
different	O
acyl	B
chains	I
to	O
rule	O
out	O
the	O
possibility	O
that	O
the	O
TA	O
was	O
selecting	O
only	O
myristate	B
.	O

When	O
1-palmitoyl	B
LPG	I
and	O
1-myristoyl-2-stearoyl	B
-	I
sn	I
-glycero-3-phosphocholine	I
(	O
MSPC	B
)	O
were	O
used	O
in	O
combination	O
and	O
the	O
product	O
BMP	B
analyzed	O
by	O
electrospray	O
tandem	O
MS	O
,	O
the	O
mass	O
was	O
721	O
,	O
showing	O
that	O
BMP	B
contained	O
two	O
palmitate	B
chains	I
(	O
Fig.	O
5	O
)	O
.	O

In	O
this	O
experiment	O
MSPC	B
increased	O
transacylation	O
3-fold	O
which	O
indicates	O
that	O
MSPC	B
was	O
capable	O
of	O
stimulation	O
,	O
but	O
not	O
acyl	O
donation	O
.	O

Using	O
MS	O
we	O
could	O
also	O
determine	O
whether	O
the	O
TA	O
has	O
substrate	O
specificity	O
for	O
the	O
acyl	B
chains	I
.	O

We	O
analyzed	O
BMP	B
synthesized	O
from	O
reactions	O
that	O
contained	O
dialkyl	B
PC	I
and	O
mixed	B
LPGs	I
,	O
in	O
which	O
the	O
LPG	B
contained	O
either	O
myristate	B
,	O
palmitate	B
,	O
stearate	B
,	O
or	O
oleate	B
on	O
the	O
sn	O
-1	O
position	O
.	O

Fig.	O
6A	O
shows	O
that	O
all	O
of	O
the	O
saturated	B
fatty	I
acyl	I
moieties	O
on	O
LPG	B
were	O
present	O
in	O
BMP	B
synthesized	O
whereas	O
monounsaturated	B
oleate	B
was	O
not	O
.	O

(	O
In	O
other	O
experiments	O
,	O
not	O
shown	O
,	O
where	O
a	O
single	O
species	O
of	O
LPG	B
was	O
used	O
,	O
1-oleoyl	B
LPG	I
was	O
transacylated	O
to	O
a	O
low	O
extent	O
only	O
.	O
)	O

The	O
major	O
BMP	B
ion	O
at	O
721	O
m	O
/	O
z	O
could	O
be	O
a	O
mixture	O
of	O
myristoyl	B
/	I
stearoyl	I
BMP	I
and	O
dipalmitoyl	B
BMP	I
so	O
the	O
daughter	O
ions	O
were	O
determined	O
(	O
Fig.	O
6B	O
)	O
.	O

Although	O
the	O
daughter	O
ion	O
analysis	O
is	O
not	O
strictly	O
qualitative	O
,	O
it	O
appears	O
that	O
the	O
721	O
m	O
/	O
z	O
peak	O
contains	O
approximately	O
equimolar	O
amounts	O
of	O
myristate	B
,	O
palmitate	B
,	O
and	O
stearate	B
.	O

Table	O
1	O
has	O
the	O
quantitative	O
analysis	O
of	O
the	O
data	O
in	O
Fig.	O
6A	O
and	O
indicates	O
that	O
,	O
assuming	O
equal	O
amounts	O
of	O
dipalmitoyl	B
and	O
myristoyl	B
/	I
stearoyl	I
BMP	I
are	O
present	O
in	O
the	O
721	O
m	O
/	O
z	O
peak	O
,	O
the	O
TA	O
has	O
a	O
slight	O
preference	O
for	O
the	O
longer	O
chain	O
species	O
of	O
LPG	B
.	O

We	O
then	O
examined	O
the	O
relative	O
activity	O
of	O
1-palmitoyl	B
LPG	I
vs.	O
2-oleoyl	B
LPG	I
(	O
Fig.	O
7	O
)	O
.	O

We	O
had	O
studied	O
their	O
metabolism	O
earlier	O
with	O
low	O
concentrations	O
of	O
LPGs	B
but	O
without	O
stimulatory	O
diradyl	B
phospholipid	I
.	O

In	O
that	O
case	O
we	O
found	O
that	O
the	O
TA	O
had	O
approximately	O
equal	O
activity	O
on	O
the	O
two	O
LPG	B
species	O
[	O
8	O
]	O
.	O

For	O
the	O
study	O
reported	O
here	O
,	O
1-palmitoyl-2-oleoyl	B
-	I
sn	I
-glycero-3-phospho	I
-	I
rac	I
-glycerol	I
(	O
POPG	B
)	O
was	O
hydrolyzed	O
by	O
either	O
a	O
lipase	O
from	O
Rhizopus	O
arrhizus	O
var	O
.	O

delemer	O
,	O
which	O
yields	O
2-oleoyl	B
LPG	I
[	O
18	O
]	O
or	O
porcine	O
pancreatic	O
PLA2	O
,	O
which	O
yields	O
1-palmitoyl	B
LPG	I
[	O
19	O
]	O
.	O

When	O
used	O
as	O
substrates	O
singly	O
or	O
in	O
combination	O
,	O
the	O
1-palmitoyl	B
LPG	I
was	O
the	O
better	O
substrate	O
(	O
Fig.	O
6	O
)	O
.	O

Ideally	O
,	O
the	O
experiment	O
should	O
be	O
conducted	O
with	O
the	O
same	O
acyl	B
chain	I
present	O
in	O
either	O
the	O
sn	O
-1	O
or	O
sn	O
-2	O
position	O
.	O

Technically	O
this	O
was	O
not	O
possible	O
.	O

We	O
can	O
not	O
conclude	O
,	O
therefore	O
,	O
that	O
the	O
difference	O
in	O
transacylation	O
using	O
these	O
two	O
substrates	O
is	O
the	O
sole	O
result	O
of	O
the	O
position	O
of	O
the	O
acyl	B
group	I
.	O

Since	O
some	O
1-oleoyl	B
LPG	I
was	O
transacylated	O
in	O
samples	O
containing	O
1-oleoyl	B
LPG	I
and	O
dialkyl	B
PC	I
(	O
data	O
not	O
shown	O
)	O
it	O
appears	O
that	O
the	O
TA	O
does	O
not	O
exclude	O
naturally	O
occurring	O
2-acyl	B
LPG	I
that	O
has	O
an	O
unsaturated	B
acyl	I
chain	I
as	O
substrate	O
.	O

The	O
question	O
then	O
arose	O
,	O
is	O
the	O
TA	O
specific	O
for	O
LPG	B
or	O
can	O
other	O
lysolipids	B
serve	O
as	O
substrates	O
.	O

Fig.	O
8	O
shows	O
that	O
none	O
of	O
the	O
1-acyl	B
lysolipids	I
examined	O
were	O
substrates	O
at	O
10	O
or	O
100	O
μM	O
concentrations	O
.	O

Further	O
,	O
when	O
these	O
lysolipids	B
were	O
mixed	O
at	O
a	O
concentration	O
equal	O
to	O
LPG	B
,	O
inhibition	O
was	O
seen	O
.	O

While	O
not	O
studied	O
further	O
,	O
this	O
could	O
be	O
a	O
competitive	O
type	O
inhibition	O
or	O
the	O
result	O
of	O
surface	O
dilution	O
of	O
LPG	B
in	O
the	O
lipid	B
aggregate	O
.	O

4	O
Discussion	O
The	O
results	O
presented	O
here	O
show	O
that	O
the	O
TA	O
that	O
converts	O
LPG	B
to	O
BMP	B
is	O
intramolecular	O
involving	O
the	O
transfer	O
of	O
the	O
acyl	B
group	I
from	O
one	O
LPG	B
to	O
another	O
.	O

The	O
enzyme	O
,	O
previously	O
shown	O
to	O
be	O
independent	O
of	O
ATP	B
and	O
CoA	B
[	O
8	O
]	O
,	O
most	O
likely	O
involves	O
an	O
acyl	O
enzyme	O
intermediate	O
,	O
although	O
this	O
point	O
can	O
not	O
be	O
proven	O
since	O
both	O
acceptor	O
and	O
donor	O
are	O
always	O
present	O
.	O

The	O
physical	O
state	O
of	O
the	O
substrate	O
appears	O
to	O
play	O
a	O
significant	O
role	O
in	O
the	O
reaction	O
.	O

The	O
1-myristoyl	B
LPG	I
is	O
reported	O
to	O
have	O
a	O
high	O
critical	O
micellar	O
concentration	O
(	O
CMC	O
)	O
ranging	O
from	O
160	O
to	O
3000	O
μM	O
,	O
depending	O
on	O
the	O
presence	O
of	O
salt	B
[	O
20	O
]	O
.	O

Under	O
the	O
conditions	O
used	O
in	O
our	O
standard	O
assay	O
,	O
10	O
μM	O
LPG	B
,	O
most	O
substrate	O
,	O
if	O
not	O
all	O
,	O
is	O
monomeric	O
.	O

The	O
presence	O
of	O
diradyl	B
lipid	I
or	O
bile	B
acid	I
would	O
lead	O
to	O
partitioning	O
of	O
the	O
LPG	B
into	O
a	O
lipid	B
aggregate	O
such	O
as	O
a	O
bilayer	O
vesicle	O
or	O
a	O
mixed	O
micelle	B
.	O

If	O
so	O
,	O
the	O
enzyme	O
appears	O
to	O
prefer	O
a	O
lipid	B
/	O
H2	B
O	I
interface	O
over	O
monomolecular	O
dispersions	O
of	O
LPG	B
.	O

The	O
unusual	O
dependence	O
of	O
transacylation	O
on	O
both	O
the	O
LPG	B
and	O
PC	B
concentration	O
is	O
consistent	O
with	O
this	O
interpretation	O
(	O
Fig.	O
1	O
)	O
.	O

Where	O
increasing	O
amounts	O
of	O
POPC	B
(	O
1–100	O
μM	O
)	O
are	O
added	O
to	O
a	O
fixed	O
amount	O
of	O
LPG	B
(	O
30	O
μM	O
;	O
Fig.	O
1B	O
)	O
,	O
two	O
considerations	O
must	O
be	O
made	O
,	O
first	O
the	O
intermicellar	O
concentration	O
(	O
IMC	O
)	O
of	O
LPG	B
partitioning	O
into	O
POPC	B
,	O
and	O
second	O
the	O
surface	O
dilution	O
of	O
1-myristoyl	B
LPG	I
in	O
POPC	B
.	O

The	O
fact	O
that	O
POPC	B
does	O
not	O
increase	O
transacylation	O
until	O
the	O
threshold	O
of	O
10	O
μM	O
is	O
reached	O
,	O
but	O
continues	O
to	O
stimulate	O
to	O
100	O
μM	O
,	O
suggests	O
that	O
the	O
partitioning	O
of	O
LPG	B
into	O
the	O
lipid	B
interface	O
,	O
the	O
IMC	O
,	O
has	O
more	O
influence	O
on	O
transacylation	O
than	O
does	O
substrate	O
dilution	O
.	O

Comparison	O
of	O
POPC	B
and	O
POPE	B
(	O
Fig.	O
1B	O
)	O
also	O
suggests	O
that	O
not	O
all	O
lipid	B
/	O
H2	B
O	I
interfaces	O
support	O
transacylation	O
.	O

POPE	B
,	O
a	O
lipid	B
known	O
to	O
form	O
a	O
Hex	O
II	O
phase	O
[	O
21	O
]	O
,	O
was	O
without	O
effect	O
,	O
either	O
the	O
result	O
of	O
little	O
LPG	B
partitioning	O
into	O
the	O
POPE	B
or	O
a	O
lipid	B
polymorphic	O
structure	O
,	O
presumably	O
Hex	O
II	O
,	O
that	O
the	O
TA	O
is	O
unable	O
to	O
productively	O
bind	O
.	O

When	O
a	O
different	O
matrix	O
is	O
present	O
and	O
PE	B
is	O
added	O
with	O
DOC	B
,	O
stimulation	O
is	O
observed	O
(	O
Fig.	O
3	O
)	O
.	O

We	O
recognize	O
that	O
these	O
interpretations	O
are	O
speculative	O
without	O
data	O
on	O
the	O
lipid	B
structures	O
involved	O
.	O

They	O
do	O
provide	O
,	O
however	O
,	O
a	O
reasonable	O
approach	O
to	O
the	O
understanding	O
of	O
the	O
nature	O
of	O
the	O
lipid	B
mixtures	O
used	O
.	O

Previous	O
work	O
by	O
us	O
and	O
others	O
suggested	O
that	O
the	O
conversion	O
of	O
LPG	B
to	O
BMP	B
involves	O
transferring	O
an	O
acyl	B
chain	I
from	O
a	O
diacyl	B
phospholipid	I
[	O
8,11–13	O
]	O
.	O

Those	O
results	O
were	O
obtained	O
with	O
sub	O
-	O
μM	O
concentrations	O
of	O
LPG	B
and	O
transacylation	O
was	O
dependent	O
on	O
added	O
phospholipid	B
.	O

No	O
attempt	O
was	O
made	O
in	O
those	O
experiments	O
,	O
however	O
,	O
to	O
demonstrate	O
the	O
transfer	O
of	O
a	O
radiolabeled	B
fatty	I
acid	I
to	O
BMP	B
.	O

In	O
unpublished	O
experiments	O
we	O
found	O
that	O
a	O
few	O
percent	O
of	O
radiolabeled	B
fatty	I
acid	I
are	O
transferred	O
to	O
BMP	B
from	O
diradyl	B
phospholipids	I
,	O
relative	O
to	O
the	O
total	O
amount	O
of	O
BMP	B
synthesized	O
.	O

How	O
do	O
the	O
results	O
presented	O
here	O
reconcile	O
with	O
those	O
of	O
others	O
?	O

One	O
possible	O
explanation	O
is	O
that	O
multiple	O
transacylases	O
were	O
present	O
in	O
the	O
lysosomal	O
preparation	O
used	O
by	O
others	O
,	O
but	O
not	O
in	O
our	O
partially	O
purified	O
TA	O
.	O

For	O
example	O
,	O
Huterer	O
and	O
Wherett	O
showed	O
that	O
a	O
preparation	O
of	O
rat	O
liver	O
lysosomes	O
transferred	O
[	B
3	I
H	I
]	I
oleate	I
from	O
PC	B
to	O
form	O
BMP	B
[	O
22	O
]	O
.	O

However	O
,	O
the	O
vast	O
majority	O
of	O
the	O
oleate	B
was	O
released	O
as	O
a	O
free	O
oleate	B
and	O
less	O
than	O
1	O
%	O
was	O
recovered	O
in	O
BMP	B
.	O

Further	O
,	O
the	O
amount	O
of	O
BMP	B
formed	O
from	O
LPG	B
was	O
far	O
in	O
excess	O
of	O
the	O
amount	O
of	O
oleate	B
incorporated	O
.	O

These	O
data	O
are	O
consistent	O
with	O
our	O
results	O
here	O
that	O
show	O
little	O
,	O
if	O
any	O
,	O
BMP	B
is	O
formed	O
by	O
the	O
transfer	O
of	O
an	O
acyl	B
group	I
from	O
diradyl	B
lipids	I
.	O

The	O
different	O
transacylases	O
described	O
can	O
be	O
classified	O
as	O
follows:1	O
.	O

acyl	O
-	O
CoA	O
acyltransferases	O
;	O
2	O
.	O

CoA	O
independent	O
transacylases	O
;	O
3	O
.	O
lysophospholipases	O
;	O
4	O
.	O

LPG	O
transacylases	O
(	O
TA	O
)	O
.	O

The	O
acyl	O
-	O
CoA	O
acyltransferase	O
employs	O
an	O
acyl	B
-	I
CoA	I
formed	O
by	O
acyl	O
-	O
CoA	O
synthetase	O
in	O
microsomes	O
and	O
is	O
optimal	O
at	O
pH	O
7.5	O
[	O
23	O
]	O
.	O

These	O
characteristics	O
make	O
it	O
clearly	O
different	O
from	O
the	O
activity	O
described	O
here	O
.	O

The	O
CoA	O
independent	O
transacylase	O
is	O
an	O
enzyme	O
that	O
transfers	O
an	O
acyl	B
group	I
from	O
the	O
sn	O
-2	O
position	O
of	O
a	O
diradyl	B
phospholipid	I
to	O
a	O
lysolipid	B
[	O
24	O
]	O
.	O

If	O
that	O
were	O
the	O
enzyme	O
involved	O
we	O
would	O
expect	O
that	O
PG	B
would	O
be	O
formed	O
from	O
LPG	B
yet	O
none	O
was	O
detected	O
(	O
data	O
not	O
shown	O
)	O
.	O

The	O
transfer	O
of	O
the	O
acyl	B
group	I
only	O
to	O
the	O
head	O
group	O
(	O
prime	O
)	O
glycerol	B
is	O
different	O
from	O
other	O
CoA	O
independent	O
transacylases	O
.	O

The	O
third	O
,	O
lysophospholipase	O
,	O
has	O
one	O
similarity	O
to	O
the	O
activity	O
reported	O
here	O
;	O
two	O
molecules	O
of	O
the	O
same	O
lysolipid	B
are	O
used	O
to	O
form	O
one	O
diradyl	B
phospholipid	I
[	O
25	O
]	O
.	O

This	O
enzyme	O
is	O
different	O
from	O
the	O
TA	O
in	O
two	O
important	O
respects	O
,	O
however	O
.	O

First	O
,	O
we	O
find	O
no	O
evidence	O
for	O
lysophospholipase	O
activity	O
in	O
the	O
TA	O
,	O
based	O
on	O
the	O
lack	O
of	O
fatty	B
acid	I
released	O
(	O
data	O
not	O
shown	O
)	O
.	O

Second	O
,	O
the	O
LPC	B
:	O
LPC	B
transacylase	O
has	O
a	O
broad	O
substrate	O
specificity	O
and	O
can	O
use	O
LPG	B
,	O
but	O
in	O
that	O
case	O
PG	B
,	O
not	O
BMP	B
,	O
is	O
formed	O
[	O
26	O
]	O
.	O

The	O
TA	O
described	O
here	O
,	O
therefore	O
,	O
appears	O
to	O
be	O
unique	O
.	O

How	O
do	O
the	O
findings	O
reported	O
here	O
fit	O
with	O
the	O
proposed	O
role	O
of	O
the	O
LPG	O
transacylase	O
in	O
Scheme	O
1	O
?	O

Scheme	O
2	O
provides	O
a	O
modification	O
of	O
the	O
TA	O
reaction	O
proposed	O
in	O
step	O
2	O
of	O
Scheme	O
1	O
.	O

Rather	O
than	O
utilizing	O
a	O
diacyl	B
phospholipid	I
in	O
transacylation	O
,	O
a	O
second	O
molecule	O
of	O
LPG	B
is	O
the	O
acyl	B
donor	I
with	O
the	O
production	O
of	O
glycerophosphoglycerol	B
(	O
GPG	B
)	O
in	O
addition	O
to	O
BMP	B
.	O

The	O
major	O
factor	O
that	O
can	O
not	O
be	O
accommodated	O
is	O
the	O
failure	O
of	O
the	O
TA	O
to	O
use	O
unsaturated	B
fatty	I
acids	I
significantly	O
.	O

We	O
must	O
conclude	O
that	O
polyunsaturated	B
fatty	I
acids	I
such	O
as	O
arachidonate	B
[	O
7	O
]	O
or	O
,	O
in	O
particular	O
,	O
docosahexanoate	B
[	O
27	O
]	O
are	O
incorporated	O
by	O
some	O
other	O
mechanism	O
.	O

Until	O
the	O
mechanism	O
of	O
stereochemical	O
rearrangement	O
is	O
defined	O
,	O
this	O
question	O
of	O
polyunsaturated	B
fatty	I
acid	I
incorporation	O
remains	O
open	O
.	O

Acknowledgements	O
This	O
work	O
was	O
supported	O
in	O
part	O
by	O
National	O
Institutes	O
of	O
Health	O
HL-50395	O
and	O
National	O
Cancer	O
Institute	O
Comprehensive	O
Cancer	O
Center	O
of	O
Wake	O
Forest	O
Grant	O
CA-12197	O
.	O

Use	O
of	O
the	O
Tissue	O
Culture	O
Core	O
Laboratory	O
is	O
gratefully	O
acknowledged	O
.	O

We	O
especially	O
thank	O
Dr.	O
Mike	O
Thomas	O
and	O
Mike	O
Samuel	O
from	O
Wake	O
Forest	O
University	O
for	O
their	O
technical	O
support	O
in	O
examining	O
the	O
MS	O
samples	O
,	O
and	O
Dr.	O
Nick	O
Ralston	O
and	O
Dr.	O
Koji	O
Shinozaki	O
for	O
their	O
advice	O
and	O
assistance	O
in	O
the	O
laboratory	O
.	O

The	O
authors	O
attempted	O
to	O
evaluate	O
different	O
reagents	O
in	O
order	O
to	O
quantify	O
the	O
amino	B
groups	O
of	O
the	O
platelet	O
membrane	O
.	O

The	O
study	O
was	O
carried	O
out	O
by	O
the	O
action	O
of	O
different	O
aldehydes	B
and	O
acid	B
anhydrides	I
.	O

The	O
use	O
of	O
2,4,6-trinitrobenzenesulfonic	B
acid	I
made	O
possible	O
an	O
approach	O
by	O
electrophoresis	O
and	O
chemical	O
assay	O
.	O

The	O
results	O
showed	O
an	O
increase	O
in	O
the	O
surface	O
charge	O
corresponding	O
to	O
a	O
mean	O
number	O
of	O
amino	B
groups	O
varying	O
from	O
1.86.10	O
(	O
5	O
)	O
groups	O
with	O
citraconic	B
acid	I
to	O
3.94.10	O
(	O
5	O
)	O
groups	O
with	O
acetaldehyde	B
.	O

The	O
study	O
on	O
the	O
metabolism	O
after	O
oral	O
administration	O
of	O
chenodeoxycholic	B
acid-24	I
-	B
14C	I
was	O
performed	O
by	O
analysis	O
of	O
radioactivity	O
that	O
had	O
appeared	O
in	O
bile	O
and	O
feces	O
of	O
male	O
hamsters	O
.	O

The	O
radioactive	O
bile	B
acids	I
were	O
analyzed	O
by	O
thin	O
layer	O
chromatography	O
and	O
identified	O
by	O
the	O
isotope	O
dilution	O
method	O
.	O

In	O
the	O
bile	O
of	O
the	O
hamsters	O
with	O
bile	O
fistula	O
,	O
radioactivity	O
was	O
originated	O
from	O
unchanged	O
chenodeoxycholic	B
acid	I
for	O
the	O
most	O
part	O
,	O
and	O
7-ketolithocholic	B
acid	I
,	O
lithocholic	B
acid	I
,	O
and	O
beta	B
-	I
muricholic	I
acid	I
for	O
the	O
remainder	O
.	O

In	O
the	O
feces	O
lithocholic	B
acid	I
,	O
dehydrolithocholic	B
acid	I
,	O
isolithocholic	B
acid	I
,	O
and	O
unchanged	O
form	O
were	O
identified	O
.	O

After	O
the	O
multiple	O
dosing	O
of	O
chenodeoxycholic	B
acid-24	I
-	I
14C	I
for	O
6	O
days	O
,	O
beta	B
-	I
muricholic	I
acid	I
was	O
also	O
identified	O
in	O
the	O
feces	O
.	O

1	O
.	O

Normal	O
human	O
urine	O
contains	O
small	O
amounts	O
(	O
less	O
than	O
4	O
mg	O
/	O
g	O
of	O
creatinine	B
)	O
of	O
2-ethylhydracrylic	B
acid	I
,	O
formed	O
,	O
we	O
believe	O
,	O
by	O
a	O
previously	O
undisclosed	O
endogenous	O
catabolic	O
pathway	O
for	O
the	O
oxidation	O
of	O
a	O
newly	O
described	O
series	O
of	O
R	B
metabolites	I
of	I
isoleucine	I
.	O

2	O
.	O

Urinary	O
excretion	O
of	O
2-ethylhydracrylic	B
acid	I
is	O
variably	O
increased	O
in	O
defects	O
of	O
isoleucine	B
oxidation	O
at	O
distal	O
steps	O
in	O
the	O
catabolic	O
pathway	O
(	O
3-oxoacyl	B
-	I
CoA	I
thiolase	O
deficiency	O
and	O
methylmalonyl	B
-	I
CoA	I
mutase	O
deficiency	O
)	O
and	O
is	O
diminished	O
when	O
proximal	O
steps	O
of	O
the	O
oxidative	O
pathway	O
are	O
blocked	O
as	O
in	O
branched	B
-	I
chain	I
oxo	I
acid	I
decarboxylase	O
deficiency	O
(	O
'	O
maple	O
-	O
syrup	O
-	O
urine	O
'	O
disease	O
)	O
.	O

3	O
.	O
Precursors	O
of	O
R	B
-	I
pathway	I
metabolites	I
[	O
R	B
(	I
-	I
)	I
-2-methylbutyrate	I
and	O
2-ethylacrylate	B
]	O
lead	O
to	O
increased	O
2-ethylhydracrylate	B
excretion	O
in	O
the	O
mammal	O
(	O
rat	O
,	O
rabbit	O
and	O
dog	O
)	O
;	O
the	O
corresponding	O
S	B
metabolites	I
[	O
S	B
(	I
+	I
)	I
-2-methylbutyric	I
acid	B
and	O
tiglic	B
acid	I
]	O
,	O
when	O
given	O
in	O
equimolar	O
amounts	O
,	O
have	O
little	O
effect	O
on	O
its	O
excretion	O
,	O
suggesting	O
that	O
little	O
or	O
no	O
interconversion	O
between	O
S	B
and	O
R	B
metabolites	I
occurs	O
in	O
vivo	O
.	O

4	O
.	O
Studies	O
with	O
2H	O
-	O
labelled	O
precursors	O
indicate	O
that	O
conversion	O
of	O
R	B
2-methylbutyrate	I
into	O
2-ethylhydracrylic	B
acid	I
occurs	O
by	O
a	O
direct	O
pathway	O
(	O
apparently	O
via	O
2-ethylacrylic	B
acid	I
)	O
.	O

5	O
.	O

The	O
further	O
oxidation	O
of	O
2-ethylhydracrylic	B
acid	I
to	O
ethylmalonic	B
acid	I
was	O
demonstrated	O
,	O
and	O
may	O
be	O
analogous	O
to	O
S	B
-	I
metabolite	I
oxidation	O
via	O
methyl	B
malonate	I
.	O

6	O
.	O

Valine	B
metabolites	B
do	O
not	O
interact	O
with	O
the	O
R	O
=	O
isoleucine	B
pathway	O
under	O
the	O
conditions	O
of	O
these	O
experiments	O
in	O
vivo	O
.	O

In	O
six	O
persons	O
with	O
contact	O
allergy	O
to	O
chrysanthemum	O
of	O
florists	O
,	O
patch	O
tests	O
were	O
performed	O
with	O
25	O
sequiterpene	B
lactones	I
.	O

Positive	O
responses	O
were	O
observed	O
to	O
15	O
lactones	B
.	O

The	O
most	O
frequently	O
encountered	O
positive	O
responses	O
were	O
to	O
alantolactone	B
(	O
positive	O
in	O
all	O
cases	O
)	O
and	O
to	O
arbusculin	B
A	I
,	O
8-deoxycumambrin	B
,	O
ambrosin	B
,	O
damsin	B
and	O
psilostachynin	B
.	O

The	O
findings	O
corroborate	O
the	O
assumption	O
that	O
an	O
alpha	B
-	I
methylene	I
group	I
attached	I
to	I
the	I
gamma	I
-	I
lactone	I
ring	I
is	O
an	O
essential	O
prerequisite	O
for	O
allergenic	O
activity	O
of	O
sesquiterpene	B
lactones	I
.	I

Pyrethrum	O
produced	O
a	O
positive	O
reaction	O
in	O
one	O
of	O
the	O
patients	O
,	O
pyrethrins	B
gave	O
negative	O
reactions	O
in	O
all	O
.	O

Some	O
of	O
the	O
chrysanthemum	O
patients	O
were	O
also	O
hypersensitive	O
to	O
turpentine	B
and	O
colophony	B
and	O
to	O
garlic	O
,	O
primin	B
and	O
tars	B
.	O

Depression	O
is	O
a	O
common	O
condition	O
that	O
is	O
often	O
unrecognised	O
,	O
misdiagnosed	O
and/or	O
undertreated	O
.	O

It	O
is	O
associated	O
with	O
substantial	O
direct	O
,	O
indirect	O
and	O
intangible	O
costs	O
.	O

The	O
indirect	O
costs	O
of	O
lost	O
earnings	O
/	O
productivity	O
and	O
premature	O
death	O
account	O
for	O
the	O
majority	O
of	O
these	O
costs	O
;	O
drug	O
costs	O
account	O
for	O
only	O
about	O
1	O
to	O
2	O
%	O
of	O
total	O
costs	O
and	O
about	O
10	O
to	O
12	O
%	O
of	O
direct	O
costs	O
.	O

Thus	O
,	O
better	O
recognition	O
and	O
appropriate	O
treatment	O
of	O
depression	O
would	O
increase	O
the	O
direct	O
costs	O
associated	O
with	O
this	O
illness	O
,	O
but	O
would	O
also	O
have	O
the	O
potential	O
to	O
greatly	O
reduce	O
indirect	O
costs	O
and	O
consequently	O
the	O
overall	O
cost	O
of	O
depression	O
.	O

Because	O
of	O
their	O
higher	O
acquisition	O
costs	O
relative	O
to	O
tricyclic	B
antidepressants	I
(	O
TCAs	B
)	O
,	O
there	O
has	O
been	O
much	O
debate	O
about	O
whether	O
the	O
use	O
of	O
sertraline	B
or	O
other	O
selective	B
serotonin	I
reuptake	I
inhibitors	I
(	O
SSRIs	B
)	O
for	O
first	O
-	O
line	O
treatment	O
of	O
depression	O
can	O
be	O
justified	O
.	O

While	O
these	O
agents	O
have	O
similar	O
efficacy	O
to	O
TCAs	B
,	O
they	O
are	O
better	O
tolerated	O
and	O
have	O
a	O
lower	O
risk	O
of	O
death	O
on	O
overdosage	O
.	O

Despite	O
the	O
large	O
economic	O
burden	O
of	O
depression	O
on	O
society	O
,	O
pharmacoeconomic	O
data	O
on	O
sertraline	B
and	O
antidepressant	B
drugs	I
in	O
general	O
are	O
scarce	O
.	O

Most	O
of	O
the	O
available	O
studies	O
on	O
sertraline	B
are	O
limited	O
to	O
considerations	O
of	O
direct	O
costs	O
and	O
do	O
not	O
assess	O
costs	O
from	O
a	O
societal	O
perspective	O
.	O

In	O
addition	O
,	O
a	O
number	O
of	O
studies	O
have	O
significant	O
methodological	O
problems	O
which	O
limit	O
determination	O
of	O
meaningful	O
conclusions	O
.	O

Nonetheless	O
,	O
data	O
from	O
2	O
more	O
recent	O
studies	O
with	O
fewer	O
methodological	O
problems	O
than	O
earlier	O
studies	O
indicated	O
that	O
sertraline	B
was	O
more	O
cost	O
-	O
effective	O
than	O
TCAs	B
because	O
of	O
fewer	O
psychiatrist	O
consultations	O
,	O
and	O
less	O
costly	O
than	O
fluoxetine	B
because	O
of	O
fewer	O
absences	O
from	O
work	O
and	O
fewer	O
medical	O
consultations	O
.	O

The	O
cost	O
-	O
utility	O
ratio	O
of	O
maintenance	O
therapy	O
of	O
depression	O
with	O
sertraline	B
appears	O
to	O
fall	O
within	O
the	O
range	O
of	O
accepted	O
cost	O
-	O
utility	O
ratios	O
of	O
common	O
healthcare	O
interventions	O
.	O

Thus	O
,	O
studies	O
to	O
date	O
have	O
generally	O
shown	O
that	O
overall	O
treatment	O
costs	O
with	O
sertraline	B
and	O
other	O
SSRIs	B
are	O
no	O
greater	O
than	O
those	O
for	O
TCAs	B
;	O
this	O
is	O
despite	O
the	O
lower	O
acquisition	O
costs	O
of	O
the	O
latter	O
agents	O
.	O

Therefore	O
,	O
it	O
is	O
clear	O
from	O
these	O
data	O
that	O
it	O
is	O
misleading	O
to	O
classify	O
antidepressant	B
agents	I
as	O
expensive	O
or	O
inexpensive	O
based	O
solely	O
on	O
their	O
acquisition	O
costs	O
.	O

Sertraline	B
,	O
therefore	O
,	O
can	O
be	O
considered	O
as	O
a	O
first	O
-	O
line	O
alternative	O
to	O
TCAs	B
and	O
other	O
SSRIs	B
for	O
the	O
treatment	B
of	I
depression	I
on	O
both	O
clinical	O
and	O
pharmacoeconomic	O
grounds	O
.	O

The	O
55-kDa	O
receptor	O
for	O
tumor	O
necrosis	O
factor	O
(	O
TR55	O
)	O
triggers	O
multiple	O
signaling	O
cascades	O
initiated	O
by	O
adapter	O
proteins	O
like	O
TRADD	O
and	O
FAN	O
.	O

By	O
use	O
of	O
the	O
primary	B
amine	I
monodansylcadaverine	B
(	O
MDC	B
)	O
,	O
we	O
addressed	O
the	O
functional	O
role	O
of	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
receptor	O
internalization	O
for	O
intracellular	O
signal	O
distribution	O
.	O

We	O
show	O
that	O
MDC	B
does	O
not	O
prevent	O
the	O
interaction	O
of	O
the	O
p55	O
TNF	O
receptor	O
(	O
TR55	O
)	O
with	O
FAN	O
and	O
TRADD	O
.	O

Furthermore	O
,	O
the	O
activation	O
of	O
plasmamembrane	O
-	O
associated	O
neutral	O
sphingomyelinase	O
activation	O
as	O
well	O
as	O
the	O
stimulation	O
of	O
proline	O
-	O
directed	O
protein	O
kinases	O
were	O
not	O
affected	O
in	O
MDC	B
-	O
treated	O
cells	O
.	O

In	O
contrast	O
,	O
activation	O
of	O
signaling	O
enzymes	O
that	O
are	O
linked	O
to	O
the	O
""""	O
death	O
domain	O
""""	O
of	O
TR55	O
,	O
like	O
acid	O
sphingomyelinase	O
and	O
c	O
-	O
Jun	O
-	O
N	O
-	O
terminal	O
protein	O
kinase	O
as	O
well	O
as	O
TNF	O
signaling	O
of	O
apoptosis	O
in	O
U937	O
and	O
L929	O
cells	O
,	O
are	O
blocked	O
in	O
the	O
presence	O
of	O
MDC	B
.	O

The	O
results	O
of	O
our	O
study	O
suggest	O
a	O
role	O
of	O
TR55	O
internalization	O
for	O
the	O
activation	O
of	O
select	O
TR55	O
death	O
domain	O
signaling	O
pathways	O
including	O
those	O
leading	O
to	O
apoptosis	O
.	O

Amiodarone	B
(	O
AD	B
)	O
is	O
an	O
effective	O
antidysrythmic	B
drug	I
,	O
however	O
,	O
there	O
can	O
be	O
serious	O
side	O
effects	O
,	O
such	O
as	O
hepatic	O
and	O
neurological	O
alterations	O
,	O
as	O
well	O
as	O
skin	O
photosensitization	O
,	O
as	O
seen	O
in	O
porphyrias	O
.	O

Clinical	O
signs	O
in	O
porphyrias	O
might	O
be	O
triggered	O
by	O
the	O
so	O
-	O
called	O
porphyrinogenic	B
drugs	I
.	O

Without	O
sound	O
basis	O
,	O
Amiodarone	B
has	O
been	O
classified	O
as	O
an	O
unsafe	O
drug	B
for	O
porphyric	O
patients	O
.	O

The	O
aim	O
of	O
this	O
work	O
has	O
been	O
to	O
study	O
the	O
effect	O
of	O
AD	B
,	O
both	O
in	O
vivo	O
and	O
in	O
vitro	O
,	O
on	O
heme	B
metabolism	O
.	O

In	O
the	O
in	O
vivo	O
assays	O
,	O
the	O
activities	O
of	O
5-aminolevulinate	O
synthetase	O
(	O
ALA	O
-	O
S	O
)	O
,	O
ALA	O
dehydratase	O
(	O
ALA	O
-	O
D	O
)	O
,	O
porphobilinogenase	O
(	O
PBGase	O
)	O
and	O
PBG	O
-	O
deaminase	O
(	O
PBG	O
-	O
D	O
)	O
in	O
blood	O
,	O
liver	O
,	O
and	O
kidney	O
;	O
hepatic	O
and	O
fecal	O
porphyrins	B
,	O
urinary	O
ALA	B
,	O
PBG	B
and	O
porphyrins	B
in	O
male	O
mice	O
strain	O
CF1	O
treated	O
with	O
AD	B
(	O
100	O
mg	O
i.p	O
.	O

daily	O
)	O
for	O
1	O
week	O
and	O
1	O
month	O
,	O
were	O
measured	O
.	O

No	O
significanat	O
differences	O
were	O
found	O
for	O
any	O
of	O
these	O
parameters	O
in	O
the	O
AD	B
treated	O
animals	O
as	O
compared	O
to	O
controls	O
.	O

In	O
the	O
in	O
vitro	O
experiments	O
human	O
blood	O
,	O
and	O
mice	O
blood	O
,	O
liver	O
,	O
and	O
kidney	O
,	O
were	O
used	O
to	O
measure	O
the	O
activities	O
of	O
ALA	O
-	O
S	O
,	O
ALA	O
-	O
D	O
,	O
PBGase	O
,	O
PBG	O
-	O
D	O
and	O
uroporphyrinogen	O
decarboxylase	O
,	O
in	O
the	O
presence	O
of	O
varying	O
concentrations	O
of	O
AD	B
(	O
0.0172	O
-	O
4.304	O
mM	O
)	O
.	O

AD	B
did	O
not	O
modify	O
any	O
of	O
the	O
enzyme	O
activities	O
.	O

All	O
of	O
the	O
above	O
biochemical	O
parameters	O
were	O
studied	O
in	O
17	O
cardiac	O
patients	O
under	O
AD	B
treatment	O
for	O
3	O
to	O
20	O
years	O
.	O

Neither	O
the	O
activities	O
of	O
the	O
heme	O
enzymes	O
,	O
nor	O
the	O
levels	O
of	O
precursors	O
and	O
porphyrins	B
in	O
urine	O
and	O
plasma	O
were	O
altered	O
.	O

These	O
findings	O
clearly	O
demonstrate	O
that	O
AD	B
is	O
a	O
pharmacologically	O
safe	O
drug	B
and	O
can	O
be	O
used	O
for	O
the	O
treatment	O
of	O
associated	O
pathologies	O
in	O
porphyrias	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
antimutagenicity	O
of	O
WR-1065	B
added	O
after	O
irradiation	O
of	O
cells	O
of	O
cell	O
lines	O
differing	O
in	O
their	O
ability	O
to	O
rejoin	O
radiation	O
-	O
induced	O
DNA	O
double	O
-	O
strand	O
breaks	O
(	O
DSBs	O
)	O
.	O

The	O
postirradiation	O
antimutagenicity	O
of	O
WR-1065	B
at	O
the	O
thymidine	O
kinase	O
locus	O
was	O
demonstrated	O
for	O
L5178Y	O
(	O
LY	O
)	O
-S1	O
cells	O
that	O
are	O
deficient	O
in	O
repair	O
of	O
DNA	O
DSBs	O
.	O

Less	O
postirradiation	O
antimutagenicity	O
of	O
WR-1065	B
was	O
observed	O
in	O
LY	O
-	O
R16	O
and	O
LY	O
-	O
SR1	O
cells	O
,	O
which	O
are	O
relatively	O
efficient	O
in	O
DSB	O
repair	O
.	O

Postirradiation	O
treatment	O
with	O
WR-1065	B
had	O
only	O
a	O
small	O
stimulatory	O
effect	O
on	O
DSB	O
rejoining	O
.	O

A	O
3-h	O
incubation	O
of	O
irradiated	O
LY	O
cells	O
with	O
WR-1065	B
caused	O
slight	O
changes	O
in	O
the	O
distribution	O
of	O
cells	O
in	O
the	O
phases	O
of	O
the	O
cell	O
cycle	O
that	O
differed	O
between	O
LY	O
-	O
S1	O
and	O
LY	O
-	O
SR1	O
cells	O
.	O

Both	O
LY	O
-	O
S1	O
and	O
LY	O
-	O
SR1	O
cells	O
were	O
protected	O
against	O
the	O
cytotoxic	O
and	O
mutagenic	O
effects	O
of	O
radiation	O
when	O
WR-1065	B
was	O
present	O
30	O
min	O
before	O
and	O
during	O
the	O
irradiation	O
.	O

We	O
conclude	O
that	O
the	O
differential	O
postirradiation	O
effects	O
of	O
WR-1065	B
in	O
the	O
LY	O
-	O
S1	O
and	O
LY	O
-	O
SR1	O
cells	O
are	O
not	O
caused	O
by	O
differences	O
in	O
cellular	O
uptake	O
of	O
the	O
radioprotector	O
or	O
in	O
its	O
radical	O
scavenging	O
activity	O
.	O

Possible	O
mechanisms	O
for	O
the	O
postirradiation	O
antimutagenicity	O
of	O
WR-1065	B
are	O
discussed	O
.	O

Nitric	B
oxide	I
(	O
NO	B
)	O
and	O
tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
are	O
the	O
major	O
mediators	O
produced	O
in	O
activated	O
macrophages	O
which	O
contribute	O
to	O
the	O
circulatory	O
failure	O
associated	O
with	O
septic	O
shock	O
.	O

A	O
sesquiterpene	B
lactone	I
compound	O
(	O
dehydrocostus	B
lactone	I
)	O
isolated	O
from	O
the	O
medicinal	O
plant	O
,	O
Saussurea	O
lappa	O
,	O
inhibited	O
the	O
production	O
of	O
NO	B
in	O
lipopolysaccharide	B
(	O
LPS	B
)	O
-activated	O
RAW	O
264.7	O
cells	O
by	O
suppressing	O
inducible	O
nitric	O
oxide	O
synthase	O
enzyme	O
expression	O
.	O

This	O
compound	O
also	O
decreased	O
the	O
TNF	O
-	O
alpha	O
level	O
in	O
LPS	B
-	O
activated	O
systems	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Thus	O
,	O
dehydrocostus	B
lactone	I
may	O
be	O
a	O
possible	O
candidate	O
for	O
the	O
development	O
of	O
new	O
drugs	O
to	O
treat	O
endotoxemia	O
accompanied	O
by	O
the	O
overproduction	O
of	O
NO	B
and	O
TNF	O
-	O
alpha	O
.	O

The	O
putative	O
biosynthetic	O
gene	O
cluster	O
for	O
the	O
alpha	O
-	O
glucosidase	O
inhibitor	O
acarbose	B
was	O
identified	O
in	O
the	O
producer	O
Actinoplanes	O
sp.	O
50	O
/	O
110	O
by	O
cloning	O
a	O
DNA	O
segment	O
containing	O
the	O
conserved	O
gene	O
for	O
dTDP	O
-	O
D	O
-	O
glucose	O
4,6-dehydratase	O
,	O
acbB.	O
The	O
two	O
flanking	O
genes	O
were	O
acbA	O
(	O
dTDP	O
-	O
D	O
-	O
glucose	O
synthase	O
)	O
and	O
acbC	O
,	O
encoding	O
a	O
protein	O
with	O
significant	O
similarity	O
to	O
3-dehydroquinate	O
synthases	O
(	O
AroB	O
proteins	O
)	O
.	O

The	O
acbC	O
gene	O
was	O
overexpressed	O
heterologously	O
in	O
Streptomyces	O
lividans	O
66	O
,	O
and	O
the	O
product	O
was	O
shown	O
to	O
be	O
a	O
C7-cyclitol	O
synthase	O
using	O
sedo	B
-	I
heptulose	I
7-phosphate	I
,	O
but	O
not	O
ido	B
-	I
heptulose	I
7-phosphate	I
,	O
as	O
its	O
substrate	O
.	O

The	O
cyclization	O
product	O
,	O
2-epi-5-epi	B
-	I
valiolone	I
(	O
(	B
2S,3S,4S,5R	I
)	I
-5-	I
(	I
hydroxymethyl	I
)	I
cyclohexanon-2,3,4,5-tetrol	I
)	O
,	O
is	O
a	O
precursor	O
of	O
the	O
valienamine	B
moiety	O
of	O
acarbose	B
.	O

A	O
possible	O
five	O
-	O
step	O
reaction	O
mechanism	O
is	O
proposed	O
for	O
the	O
cyclization	O
reaction	O
catalyzed	O
by	O
AcbC	O
based	O
on	O
the	O
recent	O
analysis	O
of	O
the	O
three	O
-	O
dimensional	O
structure	O
of	O
a	O
eukaryotic	O
3-dehydroquinate	O
synthase	O
domain	O
(	O
Carpenter	O
,	O
E.	O
P.	O
,	O
Hawkins	O
,	O
A.	O
R.	O
,	O
Frost	O
,	O
J.	O
W.	O
,	O
and	O
Brown	O
,	O
K.	O
A.	O
(	O
1998	O
)	O
Nature	O
394	O
,	O
299	O
-	O
302	O
)	O
.	O

The	O
mechanism	O
of	O
DNA	O
damage	O
induced	O
by	O
metabolites	B
of	I
nitrobenzene	I
was	O
investigated	O
in	O
relation	O
to	O
the	O
carcinogenicity	O
and	O
reproductive	O
toxicity	O
of	O
nitrobenzene	B
.	O

Nitrosobenzene	B
,	O
a	O
nitrobenzene	B
metabolite	B
,	O
induced	O
NADH	B
plus	O
Cu	B
(	I
II	I
)	I
-mediated	O
DNA	O
cleavage	O
frequently	O
at	O
thymine	B
and	O
cytosine	B
residues	O
.	O

Catalase	O
and	O
bathocuproine	B
inhibited	O
the	O
DNA	O
damage	O
,	O
suggesting	O
the	O
involvement	O
of	O
H2O2	B
and	O
Cu	B
(	I
I	I
)	I
.	O

Typical	O
free	B
hydroxyl	I
radical	I
scavengers	O
showed	O
no	O
inhibitory	O
effects	O
on	O
DNA	O
damage	O
.	O

Nitrosobenzene	B
caused	O
the	O
formation	O
of	O
8-oxo-7	B
,	I
8-dihydro-2'-deoxyguanosine	I
in	O
calf	O
thymus	O
DNA	O
in	O
the	O
presence	O
of	O
NADH	B
and	O
Cu	B
(	I
II	I
)	I
.	O

ESR	O
spectroscopic	O
study	O
has	O
confirmed	O
that	O
nitrosobenzene	B
is	O
reduced	O
by	O
NADH	B
to	O
the	O
phenylhydronitroxide	B
radical	I
even	O
in	O
the	O
absence	O
of	O
Cu	B
(	I
II	I
)	I
.	O

These	O
results	O
suggest	O
that	O
nitrosobenzene	B
can	O
be	O
reduced	O
non	O
-	O
enzymatically	O
by	O
NADH	B
,	O
and	O
the	O
redox	O
cycle	O
reaction	O
resulted	O
in	O
oxidative	O
DNA	O
damage	O
due	O
to	O
the	O
copper	B
-	I
oxygen	I
complex	I
,	O
derived	O
from	O
the	O
reaction	O
of	O
Cu	B
(	I
I	I
)	I
with	O
H2O2	B
.	O

1	O
.	O

The	O
urinary	O
metabolic	O
fate	O
of	O
4-fluoroaniline	B
(	O
4-FA	B
)	O
and	O
1-	B
[	I
13C	I
]	I
-4-fluoroacetanilide	I
(	O
4-FAA	B
)	O
has	O
been	O
studied	O
using	O
NMR	O
-	O
based	O
methods	O
after	O
50	O
and	O
100	O
mg	O
kg	O
(	O
-1	O
)	O
i.p	O
.	O

doses	O
respectively	O
to	O
the	O
male	O
Sprague	O
-	O
Dawley	O
rat	O
.	O

2	O
.	O
4-FA	B
was	O
both	O
ortho-	O
and	O
para	O
-	O
hydroxylated	O
.	O

The	O
major	O
metabolite	B
produced	O
by	O
ortho	O
-	O
hydroxylation	O
was	O
2-amino-5-fluorophenylsulphate	B
accounting	O
for	O
approximately	O
30	O
%	O
of	O
the	O
dose	O
.	O

Of	O
the	O
dose	O
,	O
approximately	O
10	O
%	O
was	O
excreted	O
via	O
para	O
-	O
hydroxylation	O
and	O
the	O
resulting	O
defluorinated	B
metabolites	I
were	O
N	O
-	O
acetylated	O
and	O
excreted	O
as	O
sulphate	B
(	O
major	O
)	O
,	O
glucuronide	B
(	O
minor	O
)	O
and	O
N	B
-	I
acetyl	I
-	I
cysteinyl	I
(	O
minor	O
)	O
conjugates	B
of	I
4-acetamidophenol	I
(	O
paracetamol	B
)	O
.	O

3	O
.	O

The	O
major	O
route	O
of	O
metabolism	O
of	O
1-	B
[	I
13C	I
]	I
-4-FAA	I
was	O
N	O
-	O
deacetylation	O
and	O
the	O
metabolites	B
excreted	O
in	O
the	O
urine	O
were	O
qualitatively	O
identical	O
to	O
4-FA	B
.	O

The	O
paracetamol	B
metabolites	I
produced	O
via	O
para	O
-	O
hydroxylation	O
were	O
also	O
a	O
product	O
of	O
N	O
-	O
deacetylation	O
and	O
reacetylation	O
,	O
as	O
the	O
[	O
13C	B
]	O
-label	O
was	O
not	O
retained	O
.	O

4	O
.	O

These	O
studies	O
demonstrate	O
the	O
value	O
of	O
[	O
13C	B
]	O
-labelling	O
in	O
understanding	O
the	O
contribution	O
of	O
N	O
-	O
acetylation	O
,	O
and	O
futile	O
deacetylation	O
-	O
reacetylation	O
reactions	O
,	O
in	O
aniline	B
metabolism	O
.	O

In	O
addition	O
,	O
this	O
work	O
sheds	O
new	O
light	O
on	O
the	O
metabolic	O
lability	O
of	O
certain	O
aromatic	B
fluorine	I
substituents	I
.	O

Masoprocol	B
(	O
nordihydroguaiaretic	B
acid	I
)	I
is	O
a	O
lipoxygenase	O
inhibitor	O
isolated	O
from	O
the	O
creosote	O
bush	O
and	O
used	O
by	O
native	O
healers	O
to	O
treat	O
type	O
2	O
diabetes	O
.	O

It	O
has	O
been	O
recently	O
shown	O
to	O
decrease	O
serum	O
glucose	B
,	O
free	B
fatty	I
acid	I
(	O
FFA	B
)	O
,	O
and	O
triglyceride	B
(	O
TG	B
)	O
concentrations	O
in	O
rodent	O
models	O
of	O
type	O
2	O
diabetes	O
.	O

The	O
current	O
study	O
was	O
initiated	O
to	O
quantify	O
the	O
effects	O
of	O
masoprocol	B
incubation	O
of	O
adipocytes	O
isolated	O
from	O
normal	O
rats	O
.	O

The	O
results	O
indicate	O
that	O
masoprocol	B
significantly	O
increased	O
glucose	B
uptake	O
by	O
adipocytes	O
in	O
both	O
the	O
absence	O
and	O
presence	O
of	O
insulin	O
.	O

In	O
addition	O
,	O
the	O
maximal	O
rate	O
of	O
insulin	O
-	O
stimulated	O
glucose	B
transport	O
was	O
increased	O
in	O
adipocytes	O
incubated	O
with	O
masoprocol	B
and	O
the	O
insulin	O
concentration	O
resulting	O
in	O
a	O
half	O
-	O
maximal	O
glucose	B
transport	O
rate	O
(	O
ED50	O
)	O
decreased	O
.	O

Finally	O
,	O
isoproterenol	B
-	O
stimulated	O
increases	O
in	O
FFA	B
and	O
glycerol	B
release	O
were	O
significantly	O
decreased	O
in	O
the	O
presence	O
of	O
masoprocol	B
.	O

These	O
results	O
provide	O
an	O
explanation	O
at	O
the	O
cellular	O
level	O
for	O
the	O
observation	O
that	O
masoprocol	B
decreases	O
serum	O
glucose	B
,	O
insulin	O
,	O
and	O
FFA	B
concentrations	O
in	O
rodent	O
models	O
of	O
type	O
2	O
diabetes	O
.	O

Free	O
d	B
-amino	I
acids	I
have	O
been	O
shown	O
to	O
be	O
present	O
in	O
a	O
large	O
variety	O
of	O
species	O
,	O
including	O
mammals	O
and	O
,	O
more	O
specifically	O
,	O
humans	O
[	O
1,2	O
]	O
.	O

In	O
particular	O
,	O
d	B
-aspartate	I
has	O
drawn	O
special	O
interest	O
since	O
(	O
a	O
)	O
its	O
levels	O
are	O
often	O
found	O
to	O
be	O
the	O
highest	O
amongst	O
d	B
-amino	I
acids	I
[	O
3	O
]	O
,	O
(	O
b	O
)	O
recent	O
reports	O
propose	O
some	O
yet	O
unknown	O
neuronal	O
and	O
neuroendocrine	O
roles	O
of	O
d	B
-aspartate	I
[	O
4,5	O
]	O
,	O
(	O
c	O
)	O
high	O
levels	O
of	O
d	B
-aspartate	I
in	O
the	O
brain	O
and	O
other	O
tissues	O
of	O
mammals	O
were	O
discovered	O
by	O
several	O
authors	O
[	O
6–8	O
]	O
,	O
(	O
d	O
)	O
abnormal	O
levels	O
of	O
d	B
-aspartate	I
have	O
been	O
reported	O
in	O
relation	O
to	O
Alzheimer	O
,	O
senescence	O
and	O
renal	O
diseases	O
[	O
9,10	O
]	O
,	O
(	O
e	O
)	O
various	O
levels	O
of	O
d	B
-amino	I
acids	I
are	O
produced	O
during	O
food	O
processing	O
[	O
11	O
]	O
,	O
(	O
f	O
)	O
d	B
-aspartate	I
and	O
other	O
chemically	O
related	O
molecules	O
(	O
such	O
as	O
N	B
-methyl	I
-	I
d	I
-aspartate	I
)	O
are	O
widely	O
used	O
as	O
agonists	O
or	O
antagonists	O
of	O
neurochemical	O
transmitters	O
both	O
in	O
in	O
vivo	O
and	O
in	O
vitro	O
studies	O
and	O
(	O
h	O
)	O
some	O
of	O
them	O
might	O
play	O
such	O
a	O
role	O
also	O
in	O
vivo	O
[	O
4,12,13	O
]	O
.	O

Despite	O
the	O
growing	O
interest	O
in	O
the	O
biological	O
functions	O
of	O
d	B
-aspartate	I
,	O
little	O
is	O
known	O
about	O
its	O
origin	O
and	O
metabolism	O
in	O
mammals	O
.	O

In	O
this	O
regard	O
,	O
a	O
flavoprotein	O
with	O
d	O
-aspartate	O
oxidase	O
activity	O
has	O
been	O
purified	O
,	O
characterized	O
and	O
cloned	O
from	O
beef	O
kidney	O
cortex	O
[	O
14–17	O
]	O
and	O
,	O
more	O
recently	O
,	O
from	O
human	O
brain	O
[	O
18	O
]	O
.	O

The	O
enzyme	O
from	O
beef	O
kidney	O
cortex	O
(	O
bDASPO	O
)	O
has	O
been	O
thoroughly	O
investigated	O
as	O
far	O
as	O
primary	O
structure	O
,	O
kinetic	O
mechanism	O
,	O
FAD	B
binding	O
and	O
spectroscopic	O
properties	O
of	O
the	O
free	O
and	O
ligand	O
-	O
bound	O
enzyme	O
are	O
concerned	O
[	O
14–16	O
]	O
.	O

It	O
is	O
a	O
monomer	O
with	O
a	O
molecular	O
weight	O
of	O
37	O
659	O
(	O
apo	O
-	O
protein	O
)	O
containing	O
one	O
molecule	O
of	O
flavin	B
.	O

It	O
is	O
isolated	O
as	O
a	O
mixture	O
of	O
an	O
active	O
form	O
containing	O
FAD	B
(	O
FAD	O
-	O
bDASPO	O
)	O
and	O
an	O
inactive	O
form	O
(	O
9–20	O
%	O
depending	O
on	O
the	O
purification	O
)	O
containing	O
6-OH	B
-	I
FAD	I
(	O
6-OH	O
-	O
FAD	O
-	O
bDASPO	O
)	O
.	O

The	O
enzyme	O
catalyzes	O
the	O
oxidative	O
deamination	O
of	O
dicarboxylic	B
d	I
-amino	I
acids	I
by	O
O2	B
with	O
the	O
production	O
of	O
H2	B
O2	B
,	O
NH3	B
and	O
the	O
corresponding	O
α	B
-	I
keto	I
acids	I
.	O

The	O
relatively	O
low	O
abundance	O
of	O
the	O
enzyme	O
,	O
and	O
the	O
consequently	O
long	O
purification	O
procedure	O
,	O
hampered	O
so	O
far	O
the	O
use	O
of	O
this	O
protein	O
as	O
a	O
tool	O
to	O
study	O
the	O
presence	O
and	O
biological	O
significance	O
of	O
dicarboxylic	B
d	I
-amino	I
acids	I
in	O
organisms	O
.	O

In	O
order	O
to	O
overcome	O
this	O
problem	O
,	O
a	O
procedure	O
to	O
overexpress	O
recombinant	O
d	O
-aspartate	O
oxidase	O
(	O
rDASPO	O
)	O
in	O
Escherichia	O
coli	O
has	O
been	O
set	O
up	O
[	O
17	O
]	O
.	O

Starting	O
from	O
the	O
latter	O
study	O
,	O
the	O
present	O
paper	O
reports	O
overexpression	O
and	O
purification	O
protocols	O
leading	O
to	O
large	O
amounts	O
of	O
homogeneous	O
and	O
catalytically	O
active	O
rDASPO	O
.	O

The	O
biochemical	O
characterization	O
of	O
the	O
recombinant	O
enzyme	O
shows	O
that	O
rDASPO	O
possesses	O
the	O
same	O
catalytic	O
properties	O
of	O
bDASPO	O
and	O
,	O
therefore	O
,	O
can	O
be	O
used	O
to	O
extend	O
the	O
study	O
of	O
the	O
properties	O
of	O
DASPO	O
.	O

In	O
particular	O
,	O
in	O
this	O
paper	O
we	O
focused	O
our	O
attention	O
on	O
the	O
determination	O
of	O
the	O
redox	O
potential	O
of	O
DASPO	O
and	O
to	O
possible	O
interactions	O
between	O
the	O
enzyme	O
and	O
a	O
variety	O
of	O
molecules	O
used	O
as	O
agonists	O
or	O
antagonists	O
of	O
neurotransmitters	O
[	O
12	O
]	O
.	O

2	O
Materials	O
and	O
methods	O
2.1	O
Overexpression	O
and	O
purification	O
of	O
rDASPO	O
E.	O
coli	O
GI724	O
cells	O
,	O
carrying	O
the	O
cI	O
repressor	O
gene	O
engineered	O
into	O
bacterial	O
chromosome	O
under	O
the	O
control	O
of	O
the	O
Trp	O
promoter	O
,	O
were	O
freshly	O
transformed	O
with	O
the	O
recombinant	O
plasmid	O
pED	O
carrying	O
the	O
gene	O
for	O
bovine	O
kidney	O
d	O
-aspartate	O
oxidase	O
under	O
the	O
control	O
of	O
the	O
λ	O
PL	O
promoter	O
[	O
17	O
]	O
.	O

200	O
ml	O
RM	B
medium	I
(	O
6	O
g	O
Na2	B
HPO4	I
,	O
3	O
g	O
KH2	B
PO4	I
,	O
0.5	O
g	O
NaCl	B
,	O
1	O
g	O
NH4	B
Cl	I
,	O
95.21	O
mg	O
MgCl2	B
,	O
20	O
g	O
casamino	B
acids	I
,	O
10	O
ml	O
glycerol	B
in	O
1	O
l	O
)	O
containing	O
100	O
μg	O
ampicillin	B
ml−1	O
were	O
inoculated	O
with	O
20	O
ml	O
overnight	O
precultures	O
of	O
GI724	O
(	O
pED	O
)	O
and	O
the	O
cells	O
grown	O
at	O
30	O
°	O
C	O
up	O
to	O
A	O
550	O
0.5	O
.	O

The	O
material	O
was	O
used	O
to	O
inoculate	O
6	O
l	O
of	O
induction	O
medium	O
(	O
6	O
g	O
Na2	B
HPO4	I
,	O
3	O
g	O
KH2	B
PO4	I
,	O
0.5	O
g	O
NaCl	B
,	O
1	O
g	O
NH4	B
Cl	I
,	O
95.21	O
mg	O
MgCl2	B
,	O
2	O
g	O
casamino	B
acids	I
,	O
5	O
g	O
glucose	B
for	O
1	O
l	O
)	O
containing	O
100	O
μg	O
ampicillin	B
ml−1	O
in	O
a	O
fermenter	O
(	O
BioIndustrie	O
Mantovane	O
,	O
Italy	O
)	O
and	O
the	O
cells	O
grown	O
at	O
30	O
°	O
C	O
until	O
A	O
550	O
reached	O
0.5	O
.	O

Expression	O
was	O
induced	O
by	O
adding	O
tryptophan	B
to	O
a	O
final	O
concentration	O
of	O
100	O
μg	O
ml−1	O
and	O
raising	O
the	O
temperature	O
to	O
37	O
°	O
C	O
.	O

The	O
cells	O
were	O
harvested	O
after	O
16	O
h	O
,	O
centrifuged	O
at	O
14	O
000	O
×	O
g	O
for	O
25	O
min	O
,	O
resuspended	O
in	O
cold	O
0.9	O
%	O
NaCl	B
,	O
centrifuged	O
at	O
27	O
000	O
×	O
g	O
and	O
the	O
pellet	O
stored	O
at	O
−80	O
°	O
C	O
.	O

All	O
purification	O
steps	O
were	O
performed	O
at	O
4	O
°	O
C	O
and	O
all	O
buffers	O
contained	O
0.3	O
mM	O
EDTA	B
and	O
5	O
mM	O
sodium	B
potassium	I
tartrate	I
,	O
unless	O
otherwise	O
indicated	O
.	O

Cells	O
were	O
resuspended	O
in	O
2	O
vols	O
.	O

of	O
50	O
mM	O
NaPi	B
,	O
pH	O
8.0	O
,	O
1	O
mM	O
phenylmethylsulfonyl	B
fluoride	I
,	O
20	O
μM	O
FAD	B
,	O
sonicated	O
and	O
centrifuged	O
at	O
27	O
000	O
×	O
g	O
for	O
30	O
min	O
.	O

Protamine	B
sulfate	I
was	O
slowly	O
added	O
to	O
a	O
final	O
concentration	O
of	O
0.2	O
%	O
at	O
0	O
°	O
C	O
,	O
the	O
material	O
was	O
left	O
at	O
the	O
same	O
temperature	O
for	O
an	O
additional	O
15	O
min	O
and	O
then	O
centrifuged	O
at	O
27	O
000	O
×	O
g	O
for	O
1	O
h.	O
The	O
supernatant	O
was	O
adjusted	O
to	O
0	O
.	O
15	O
M	O
NaPi	B
,	O
pH	O
6.75	O
and	O
loaded	O
on	O
a	O
Phenyl	B
-	I
Sepharose	I
CL-4B	I
column	O
(	O
13	O
×	O
2.6	O
cm	O
)	O
equilibrated	O
in	O
the	O
same	O
buffer	O
.	O

The	O
column	O
was	O
washed	O
with	O
2	O
vols	O
.	O

of	O
starting	O
buffer	O
and	O
the	O
enzyme	O
eluted	O
with	O
10	O
mM	O
NaPi	B
,	O
pH	O
8.0	O
.	O

The	O
active	O
fractions	O
(	O
total	O
volume	O
about	O
2.5	O
l	O
)	O
were	O
brought	O
to	O
20	O
μM	O
FAD	B
,	O
50	O
mM	O
MES	B
pH	O
5.5	O
using	O
a	O
concentrated	O
solution	O
of	O
this	O
buffer	O
,	O
divided	O
in	O
300	O
ml	O
aliquots	O
and	O
directly	O
loaded	O
on	O
a	O
S15	O
strong	O
cationic	O
exchanger	O
membrane	O
adsorber	O
(	O
Sartorius	O
AG	O
,	O
Germany	O
)	O
equilibrated	O
in	O
50	O
mM	O
MES	B
,	O
pH	O
5.5	O
.	O

The	O
membrane	O
was	O
washed	O
with	O
10	O
ml	O
of	O
the	O
starting	O
buffer	O
and	O
eluted	O
with	O
the	O
same	O
buffer	O
containing	O
1	O
M	O
NaCl	B
in	O
2	O
ml	O
fractions	O
.	O

The	O
active	O
fractions	O
were	O
pooled	O
and	O
equilibrated	O
in	O
50	O
mM	O
HEPES	B
,	O
pH	O
8.0	O
,	O
5	O
mM	O
sodium	O
potassium	B
tartrate	I
,	O
0.3	O
mM	O
EDTA	B
,	O
20	O
μM	O
FAD	B
using	O
an	O
Amicon	O
-	O
PM	O
10	O
membrane	O
.	O

The	O
pure	O
enzyme	O
was	O
stored	O
under	O
these	O
conditions	O
at	O
−80	O
°	O
C	O
.	O

If	O
necessary	O
,	O
excess	O
FAD	B
and	O
tartrate	B
were	O
removed	O
prior	O
to	O
experiments	O
by	O
gel	O
filtration	O
on	O
a	O
PD-10	B
column	O
(	O
Pharmacia	O
)	O
equilibrated	O
either	O
in	O
50	O
mM	O
HEPES	B
,	O
pH	O
8.0	O
or	O
in	O
0.1	O
M	O
KPi	B
,	O
pH	O
7.0	O
.	O

In	O
conclusion	O
,	O
the	O
recombinant	O
protein	O
was	O
purified	O
following	O
a	O
new	O
procedure	O
greatly	O
simplified	O
as	O
compared	O
to	O
the	O
one	O
used	O
for	O
the	O
enzyme	O
from	O
beef	O
kidney	O
cortex	O
[	O
14	O
]	O
,	O
omitting	O
the	O
heat	O
,	O
gel	O
filtration	O
and	O
Mono	B
Q	I
ion	O
-	O
exchange	O
steps	O
and	O
performing	O
the	O
final	O
ion	O
-	O
exchange	O
step	O
on	O
a	O
S15	O
strong	O
cationic	O
exchanger	O
membrane	O
adsorber	O
instead	O
of	O
the	O
original	O
Mono	B
S	I
column	O
.	O

The	O
latter	O
modification	O
has	O
the	O
main	O
advantages	O
of	O
avoiding	O
time	O
consuming	O
concentration	O
and	O
equilibration	O
steps	O
and	O
exposure	O
of	O
the	O
enzyme	O
to	O
room	O
temperature	O
during	O
FPLC	O
chromatography	O
.	O

2.2	O
Activity	O
assay	O
The	O
oxidase	O
activity	O
was	O
determined	O
by	O
the	O
spectrophotometric	O
method	O
set	O
up	O
in	O
[	O
14	O
]	O
which	O
couples	O
the	O
production	O
of	O
hydrogen	B
peroxide	I
in	O
the	O
DASPO	O
-	O
catalyzed	O
reaction	O
with	O
the	O
oxidation	O
of	O
o	B
-dianisidine	I
by	O
horseradish	O
peroxidase	O
(	O
ϵ436	O
=	O
11	O
610	O
M−1	O
cm−1	O
)	O
.	O

The	O
reaction	O
mixture	O
contained	O
90	O
μg	O
o	B
-dianisidine-2	I
HCl	I
,	O
20	O
nmol	O
FAD	B
,	O
64	O
μg	O
horseradish	O
peroxidase	O
and	O
variable	O
amounts	O
of	O
substrate	O
(	O
routinely	O
10	O
mM	O
d	B
-aspartate	I
)	O
in	O
1	O
ml	O
of	O
50	O
mM	O
KPi	B
,	O
pH	O
7.4	O
,	O
at	O
25	O
°	O
C	O
.	O

The	O
reaction	O
was	O
started	O
by	O
addition	O
of	O
variable	O
amounts	O
of	O
rDASPO	O
(	O
20	O
ng–4	O
μg	O
)	O
depending	O
on	O
the	O
substrate	O
tested	O
.	O

1	O
U	O
of	O
enzyme	O
is	O
defined	O
as	O
the	O
amount	O
which	O
oxidizes	O
1	O
μmol	O
substrate	O
min−1	O
.	O

When	O
a	O
compound	O
was	O
not	O
used	O
as	O
substrate	O
by	O
rDASPO	O
it	O
was	O
tested	O
as	O
an	O
inhibitor	O
by	O
determining	O
its	O
effect	O
on	O
the	O
rate	O
of	O
oxidation	O
of	O
d	B
-aspartate	I
(	O
using	O
10	O
mM	O
of	O
both	O
substrate	O
and	O
inhibitor	O
)	O
.	O

2.3	O
Protein	O
content	O
Protein	O
content	O
during	O
the	O
purification	O
steps	O
was	O
estimated	O
using	O
an	O
extinction	O
coefficient	O
of	O
1	O
for	O
a	O
1	O
mg	O
ml	O
−1	O
protein	O
solution	O
.	O

The	O
purified	O
enzyme	O
was	O
quantitated	O
using	O
the	O
extinction	O
coefficients	O
previously	O
determined	O
for	O
the	O
various	O
enzyme	O
forms	O
:	O
ϵ454	O
=	O
11	O
810	O
M−1	O
cm−1	O
for	O
holo	O
-	O
FAD	B
-	O
bDASPO	O
and	O
ϵ458	O
=	O
12	O
300	O
M−1	O
cm−1	O
for	O
l	B
-	I
(	I
+	I
)	I
-tartrate	I
-	O
bDASPO	O
complex	O
[	O
14	O
]	O
.	O

2.4	O
Apo	O
-	O
enzyme	O
preparation	O
Apo	O
-	O
rDASPO	O
was	O
prepared	O
according	O
to	O
the	O
procedure	O
for	O
the	O
selective	O
removal	O
of	O
FAD	O
from	O
bDASPO	O
described	O
in	O
[	O
14	O
]	O
.	O

Briefly	O
,	O
2	O
mg	O
holo	O
-	O
enzyme	O
were	O
dialyzed	O
at	O
4	O
°	O
C	O
for	O
3	O
days	O
against	O
500	O
ml	O
of	O
0.1	O
M	O
KPi	B
,	O
pH	O
7.0	O
,	O
0.3	O
mM	O
EDTA	B
containing	O
3	O
M	O
KBr	B
and	O
0.5	O
%	O
charcoal	B
,	O
followed	O
by	O
24	O
h	O
dialysis	O
against	O
2	O
l	O
of	O
the	O
same	O
buffer	O
without	O
KBr	B
and	O
charcoal	B
.	O

2.5	O
Anaerobic	O
reduction	O
of	O
d	B
-aspartate	I
oxidase	O
Anaerobic	O
reduction	O
of	O
rDASPO	O
was	O
conducted	O
at	O
25	O
°	O
C	O
in	O
0.1	O
M	O
KPi	B
,	O
pH	O
7.0	O
either	O
in	O
the	O
absence	O
or	O
presence	O
of	O
4	O
mM	O
l	O
-	O
(	B
+	I
)	I
-tartrate	I
.	O

Anaerobiosis	O
was	O
achieved	O
by	O
alternate	O
evacuation	O
and	O
flushing	O
with	O
argon	B
freed	O
from	O
any	O
residual	O
oxygen	B
using	O
High	O
Capacity	O
Gas	O
Purifier	O
and	O
OMI	O
Indicating	O
Purifier	O
devices	O
(	O
Supelco	O
,	O
USA	O
)	O
.	O

Photoreduction	O
was	O
achieved	O
by	O
irradiating	O
the	O
protein	O
with	O
a	O
slide	O
projector	O
at	O
0	O
°	O
C	O
in	O
the	O
presence	O
of	O
10	O
mM	O
EDTA	B
,	O
0.5	O
μM	O
5-deazaflavin-3-sulfonate	B
as	O
catalyst	O
and	O
5	O
μM	O
benzylviologen	B
[	O
19	O
]	O
.	O

Following	O
each	O
irradiation	O
,	O
measurements	O
were	O
started	O
when	O
spectral	O
changes	O
in	O
the	O
dark	O
were	O
complete	O
(	O
5–15	O
min	O
at	O
25	O
°	O
C	O
)	O
.	O

Alternatively	O
,	O
rDASPO	O
was	O
reduced	O
by	O
mixing	O
the	O
enzyme	O
(	O
2	O
ml	O
)	O
in	O
the	O
main	O
compartment	O
of	O
an	O
anaerobic	O
cuvette	O
with	O
10	O
mU	O
of	O
xanthine	O
oxidase	O
[	O
20	O
]	O
.	O

After	O
anaerobiosis	O
,	O
xanthine	B
and	O
benzylviologen	B
were	O
added	O
from	O
a	O
side	O
arm	O
to	O
a	O
final	O
concentration	O
of	O
250	O
μM	O
and	O
5	O
μM	O
,	O
respectively	O
,	O
to	O
start	O
the	O
reaction	O
.	O

The	O
concentrations	O
of	O
oxidized	O
,	O
semiquinone	O
and	O
reduced	O
enzyme	O
at	O
each	O
point	O
of	O
the	O
reduction	O
were	O
calculated	O
from	O
the	O
total	O
enzyme	O
present	O
and	O
from	O
the	O
absorbance	O
at	O
suitable	O
wavelengths	O
(	O
454	O
and	O
374	O
nm	O
for	O
the	O
free	O
enzyme	O
and	O
458	O
and	O
374	O
nm	O
for	O
the	O
l	B
-	I
(	I
+	I
)	I
-tartrate	I
complex	O
)	O
using	O
the	O
following	O
equation:	O
(	O
1	O
)	O
ΔA	O
(	O
ox	O
−x	O
)	O
=	O
[	O
red	O
]	O
(	O
ϵox	O
−ϵred	O
)	O
+	O
[	O
sq	O
]	O
(	O
ϵox	O
−ϵsq	O
)	O
were	O
ΔA	O
(	O
ox−x	O
)	O
is	O
the	O
decrease	O
in	O
absorbance	O
in	O
comparison	O
to	O
the	O
spectrum	O
of	O
the	O
oxidized	O
enzyme	O
,	O
ϵox	O
,	O
ϵsq	O
and	O
ϵred	O
are	O
the	O
extinction	O
coefficients	O
for	O
oxidized	O
,	O
semiquinone	O
and	O
reduced	O
form	O
of	O
the	O
enzyme	B
and	O
[	O
red	O
]	O
and	O
[	O
sq	O
]	O
are	O
the	O
molar	O
concentrations	O
of	O
reduced	O
and	O
semiquinone	O
rDASPO	O
,	O
respectively	O
.	O

In	O
order	O
to	O
determine	O
the	O
amount	O
of	O
semiquinone	O
thermodynamically	O
stabilized	O
,	O
7.7	O
μM	O
rDASPO	O
in	O
0.1	O
M	O
KPi	B
,	O
pH	O
7.0	O
,	O
0.5	O
μM	O
5-deazaflavin-3-sulfonate	B
,	O
10	O
mM	O
EDTA	B
and	O
5	O
μM	O
benzylviologen	B
was	O
completely	O
photoreduced	O
anaerobically	O
as	O
described	O
above	O
and	O
mixed	O
with	O
an	O
equimolar	O
amount	O
of	O
concentrated	O
oxidized	O
enzyme	O
previously	O
stored	O
in	O
the	O
side	O
arm	O
of	O
the	O
cell	O
.	O

The	O
reaction	O
was	O
followed	O
at	O
25	O
°	O
C	O
in	O
the	O
dark	O
until	O
no	O
further	O
absorbance	O
changes	O
could	O
be	O
detected	O
(	O
24	O
h	O
)	O
and	O
the	O
amount	O
of	O
oxidized	O
,	O
semiquinone	O
and	O
reduced	O
enzyme	O
at	O
equilibrium	O
was	O
calculated	O
as	O
described	O
above	O
.	O

2.6	O
Determination	O
of	O
redox	O
potentials	O
The	O
redox	O
potential	O
of	O
rDASPO	O
was	O
determined	O
by	O
a	O
spectrophotometric	O
method	O
employing	O
a	O
reducing	O
system	O
of	O
xanthine	B
,	O
xanthine	O
oxidase	O
and	O
a	O
suitable	O
mediator	O
such	O
as	O
benzylviologen	B
[	O
20	O
]	O
.	O

Data	O
were	O
plotted	O
according	O
to	O
[	O
21	O
]	O
.	O

The	O
amount	O
of	O
oxidized	O
and	O
reduced	O
indicator	O
dye	O
and	O
enzyme	O
was	O
calculated	O
from	O
the	O
experimentally	O
determined	O
extinction	O
coefficients	O
and	O
isosbestic	O
points	O
at	O
the	O
following	O
wavelengths	O
,	O
depending	O
on	O
the	O
experiment	O
:	O
(	O
a	O
)	O
ITS	B
(	O
600	O
nm	O
)	O
+rDASPO	O
(	O
486	O
nm	O
,	O
isosbestic	O
for	O
ITS	B
)	O
;	O
(	O
b	O
)	O
IDS	B
(	O
610	O
nm	O
)	O
+rDASPO	O
(	O
374	O
and	O
458	O
nm	O
,	O
the	O
latter	O
being	O
an	O
isosbestic	O
for	O
IDS	B
)	O
;	O
(	O
c	O
)	O
IDS	B
(	O
610	O
nm	O
)	O
+l	O
-	O
(	O
+	O
)	O
-tartrate	O
-	O
rDASPO	O
(	O
458	O
nm	O
)	O
;	O
(	O
d	O
)	O
HNQ	B
(	O
458	O
nm	O
)	O
+l	O
-	B
(	I
+	I
)	I
-tartrate	I
-	O
rDASPO	O
(	O
364	O
nm	O
)	O
.	O

2.7	O
Miscellaneous	O
methods	O
Absorption	O
spectra	O
were	O
measured	O
with	O
a	O
Hewlett	O
Packard	O
HP8452	O
diode	O
-	O
array	O
spectrophotometer	O
.	O

Fluorescence	O
spectra	O
were	O
recorded	O
on	O
a	O
Jasco	O
(	O
Japan	O
Spectroscopy	O
,	O
Japan	O
)	O
FP	O
750	O
spectrofluorimeter	O
.	O

SDS	O
-	O
PAGE	O
was	O
performed	O
according	O
to	O
[	O
22	O
]	O
.	O

N	B
-	I
Terminal	I
amino	I
acid	I
sequence	O
was	O
determined	O
using	O
an	O
Applied	O
BioSystems	O
(	O
Foster	O
City	O
,	O
USA	O
)	O
model	O
477	O
/	O
A	O
automatic	O
protein	O
sequencer	O
.	O

Commercial	O
FAD	B
was	O
purified	O
by	O
HPLC	O
as	O
reported	O
in	O
[	O
14	O
]	O
.	O

2.8	O
Materials	O
Xanthine	O
oxidase	O
was	O
purchased	O
from	O
Sigma	O
.	O

bDASPO	O
was	O
purified	O
from	O
beef	O
kidney	O
cortex	O
as	O
described	O
in	O
[	O
14	O
]	O
.	O

5-Deazaflavin-3-sulfonate	B
was	O
a	O
generous	O
gift	O
of	O
V.	O
Massey	O
(	O
University	O
of	O
Michigan	O
,	O
Ann	O
Arbor	O
,	O
MI	O
,	O
USA	O
)	O
.	O

All	O
the	O
other	O
chemicals	O
were	O
of	O
the	O
highest	O
purity	O
commercially	O
available	O
.	O

3	O
Results	O
3.1	O
Comparison	O
between	O
the	O
properties	O
of	O
rDASPO	O
and	O
bDASPO	O
Table	O
1	O
summarizes	O
the	O
purification	O
protocol	O
of	O
rDASPO	O
starting	O
from	O
38	O
g	O
of	O
wet	O
E.	O
coli	O
paste	O
.	O

Since	O
rDASPO	O
is	O
homogeneous	O
as	O
far	O
as	O
the	O
coenzyme	O
content	O
is	O
concerned	O
(	O
FAD	B
,	O
see	O
below	O
)	O
,	O
while	O
bDASPO	O
is	O
purified	O
as	O
a	O
mixture	O
of	O
an	O
active	O
FAD	B
-	O
containing	O
and	O
an	O
inactive	O
6-OH	B
-	I
FAD	I
-	O
containing	O
form	O
,	O
the	O
specific	O
activity	O
of	O
rDASPO	O
(	O
29.1	O
U	O
mg−1	O
)	O
is	O
slightly	O
higher	O
than	O
that	O
of	O
bDASPO	O
(	O
25.3	O
U	O
mg−1	O
[	O
14	O
]	O
)	O
.	O

As	O
shown	O
in	O
Fig.	O
1	O
,	O
the	O
molecular	O
mass	O
of	O
rDASPO	O
is	O
38	O
kDa	O
,	O
in	O
agreement	O
with	O
that	O
of	O
bDASPO	O
.	O

The	O
amino	O
acid	O
sequence	O
of	O
the	O
20	O
N	B
-	I
terminal	I
residues	I
of	O
purified	O
rDASPO	O
is	O
identical	O
to	O
the	O
one	O
expected	O
from	O
the	O
sequence	O
of	O
bDASPO	O
.	O

It	O
should	O
be	O
pointed	O
out	O
that	O
the	O
N	B
-	I
terminal	I
Met	I
residue	I
in	O
rDASPO	O
is	O
free	O
and	O
not	O
blocked	O
as	O
it	O
is	O
in	O
bDASPO	O
[	O
16	O
]	O
.	O

The	O
visible	O
absorption	O
spectra	O
of	O
rDASPO	O
and	O
bDASPO	O
at	O
the	O
end	O
of	O
the	O
respective	O
purification	O
procedures	O
are	O
clearly	O
different	O
,	O
since	O
the	O
former	O
lacks	O
both	O
the	O
long	O
wavelength	O
absorption	O
(	O
centered	O
around	O
610	O
nm	O
)	O
and	O
the	O
pronounced	O
shoulders	O
around	O
440	O
,	O
360	O
and	O
340	O
nm	O
typically	O
observed	O
with	O
bDASPO	O
(	O
Fig.	O
2	O
in	O
this	O
paper	O
and	O
Fig.	O
1	O
of	O
[	O
14	O
]	O
)	O
.	O

As	O
reported	O
in	O
[	O
14	O
]	O
,	O
such	O
absorption	O
features	O
are	O
due	O
to	O
the	O
presence	O
of	O
variable	O
amounts	O
of	O
6-OH	B
-	I
FAD	I
in	O
bDASPO	O
.	O

In	O
accordance	O
,	O
the	O
visible	O
absorption	O
spectrum	O
of	O
rDASPO	O
resembles	O
that	O
of	O
apo	O
-	O
bDASPO	O
reconstituted	O
with	O
FAD	B
(	O
see	O
Fig.	O
6	O
of	O
[	O
14	O
]	O
)	O
,	O
although	O
the	O
latter	O
showed	O
higher	O
absorbance	O
below	O
400	O
nm	O
,	O
probably	O
a	O
consequence	O
of	O
the	O
harsh	O
conditions	O
used	O
to	O
obtain	O
the	O
complete	O
apo	O
-	O
protein	O
[	O
14	O
]	O
.	O

In	O
order	O
to	O
confirm	O
the	O
absence	O
of	O
6-OH	B
-	I
FAD	I
from	O
preparations	O
of	O
rDASPO	O
,	O
the	O
coenzyme	O
was	O
removed	O
under	O
conditions	O
which	O
allowed	O
the	O
selective	O
removal	O
of	O
FAD	B
(	O
but	O
not	O
of	O
6-OH	B
-	I
FAD	I
)	O
from	O
bDASPO	O
[	O
14	O
]	O
.	O

As	O
expected	O
,	O
no	O
visible	O
absorption	O
was	O
present	O
after	O
removal	O
of	O
FAD	B
(	O
not	O
shown	O
)	O
.	O

The	O
absence	O
of	O
the	O
6-OH	B
-	I
FAD	I
form	O
in	O
rDASPO	O
strengthens	O
the	O
hypothesis	O
that	O
such	O
a	O
form	O
has	O
no	O
biological	O
significance	O
and	O
is	O
an	O
artifact	O
of	O
the	O
long	O
lasting	O
purification	O
procedure	O
of	O
the	O
enzyme	O
from	O
the	O
natural	O
source	O
.	O

As	O
it	O
was	O
the	O
case	O
for	O
FAD	B
-	O
bDASPO	O
,	O
rDASPO	O
shows	O
flavin	B
fluorescence	O
.	O

Binding	O
of	O
apo	O
-	O
rDASPO	O
to	O
FAD	B
quenches	O
its	O
fluorescence	O
to	O
a	O
final	O
86	O
%	O
intensity	O
,	O
a	O
value	O
only	O
slightly	O
higher	O
than	O
the	O
one	O
observed	O
for	O
FAD	B
-	O
bDASPO	O
(	O
70	O
%	O
[	O
14	O
]	O
)	O
.	O

Titration	O
of	O
rDASPO	O
with	O
l	B
-	I
(	I
+	I
)	I
-tartrate	I
(	O
Fig.	O
2	O
)	O
and	O
sulfite	B
[	O
23	O
]	O
(	O
data	O
not	O
shown	O
)	O
,	O
two	O
ligands	O
whose	O
complexes	O
with	O
FAD	B
-	O
bDASPO	O
have	O
been	O
thoroughly	O
characterized	O
,	O
further	O
confirmed	O
that	O
the	O
recombinant	O
protein	O
shares	O
the	O
same	O
properties	O
as	O
the	O
FAD	B
-	O
containing	O
form	O
of	O
the	O
enzyme	O
from	O
the	O
natural	O
source	O
.	O

In	O
fact	O
,	O
the	O
dissociation	O
constants	O
determined	O
for	O
the	O
complexes	O
between	O
rDASPO	O
and	O
l	B
-	I
(	I
+	I
)	I
-tartrate	I
or	O
sulfite	B
(	O
4.10	O
×	O
10−5	O
M	O
and	O
7.5	O
×	O
10−6	O
M	O
,	O
respectively	O
)	O
are	O
very	O
similar	O
to	O
those	O
determined	O
in	O
the	O
case	O
of	O
FAD	B
-	O
bDASPO	O
(	O
2.65	O
×	O
10−5	O
M	O
and	O
7.4	O
×	O
10	O
−6	O
M	O
,	O
respectively	O
[	O
14	O
]	O
)	O
.	O

3.2	O
Apo	O
-	O
protein	O
preparation	O
and	O
holo	O
-	O
enzyme	O
reconstitution	O
As	O
reported	O
above	O
,	O
the	O
mild	O
conditions	O
used	O
to	O
remove	O
FAD	B
from	O
rDASPO	O
produced	O
a	O
complete	O
apo	O
-	O
protein	O
with	O
no	O
residual	O
visible	O
absorption	O
and	O
activity	O
.	O

Reconstitution	O
of	O
holo	O
-	O
enzyme	O
by	O
addition	O
of	O
FAD	B
resulted	O
in	O
a	O
species	O
with	O
a	O
specific	O
activity	O
of	O
90	O
%	O
as	O
compared	O
to	O
rDASPO	O
,	O
with	O
a	O
yield	O
of	O
53	O
%	O
.	O

Such	O
a	O
value	O
is	O
significantly	O
higher	O
than	O
the	O
one	O
obtained	O
in	O
the	O
case	O
of	O
bDASPO	O
(	O
24	O
%	O
)	O
,	O
due	O
to	O
the	O
harsher	O
conditions	O
necessary	O
to	O
remove	O
6-OH	B
-	I
FAD	I
from	O
bDASPO	O
[	O
14	O
]	O
.	O

3.3	O
Redox	O
potential	O
of	O
rDASPO	O
In	O
order	O
to	O
determine	O
the	O
redox	O
potential	O
of	O
the	O
enzyme	O
by	O
the	O
spectrophotometric	O
method	O
described	O
by	O
Massey	O
[	O
20	O
]	O
it	O
was	O
first	O
necessary	O
to	O
determine	O
the	O
extinction	O
coefficients	O
of	O
the	O
oxidized	O
(	O
EFAD	B
)	O
,	O
one	O
-	O
electron	O
reduced	O
(	O
semiquinone	B
,	O
EFAD−⋅	B
)	O
and	O
two	O
-	O
electron	O
reduced	O
rDASPO	O
(	O
EFADH−	B
)	O
both	O
free	O
and	O
in	O
complex	O
with	O
l	B
-	I
(	I
+	I
)	I
-tartrate	I
.	O

Fig.	O
3	O
shows	O
the	O
reduction	O
of	O
free	O
rDASPO	O
using	O
the	O
xanthine	B
/	O
xanthine	O
oxidase	O
reducing	O
system	O
.	O

Almost	O
quantitative	O
formation	O
of	O
red	O
anionic	B
semiquinone	I
(	O
91	O
%	O
)	O
was	O
observed	O
in	O
the	O
first	O
part	O
of	O
the	O
experiment	O
,	O
followed	O
by	O
complete	O
reduction	O
of	O
the	O
enzyme	O
.	O

Extinction	O
coefficients	O
at	O
any	O
wavelength	O
could	O
be	O
obtained	O
for	O
the	O
oxidized	O
and	O
fully	O
reduced	O
form	O
from	O
the	O
initial	O
and	O
the	O
final	O
spectrum	O
,	O
respectively	O
,	O
and	O
for	O
the	O
semiquinone	B
by	O
means	O
of	O
plots	O
such	O
as	O
that	O
shown	O
in	O
the	O
inset	O
of	O
Fig.	O
3	O
.	O

It	O
should	O
be	O
pointed	O
out	O
that	O
when	O
the	O
enzyme	O
was	O
photoreduced	O
,	O
under	O
the	O
same	O
experimental	O
conditions	O
,	O
a	O
much	O
lower	O
amount	O
of	O
semiquinone	B
was	O
detected	O
(	O
about	O
26	O
%	O
at	O
maximum	O
formation	O
,	O
data	O
not	O
shown	O
)	O
.	O

The	O
significant	O
difference	O
in	O
the	O
percentage	O
of	O
semiquinone	B
observed	O
during	O
the	O
experiments	O
using	O
different	O
reduction	O
systems	O
suggests	O
that	O
the	O
stabilization	O
of	O
the	O
radical	B
was	O
at	O
least	O
in	O
part	O
kinetic	O
rather	O
than	O
thermodynamic	O
.	O

This	O
was	O
experimentally	O
proved	O
(	O
for	O
the	O
free	O
enzyme	O
)	O
by	O
mixing	O
equimolar	O
amounts	O
of	O
EFADH−	B
and	O
EFAD	B
in	O
the	O
presence	O
of	O
benzylviologen	B
as	O
mediator	O
and	O
allowing	O
the	O
system	O
to	O
reach	O
complete	O
equilibrium	O
;	O
32	O
%	O
of	O
red	O
semiquinone	B
was	O
observed	O
after	O
24	O
h.	O
This	O
value	O
corresponds	O
to	O
a	O
semiquinone	B
formation	O
constant	O
K	O
of	O
0.89	O
,	O
where	O
[	O
24,25	O
]	O
(	O
2	O
)	O
K=	O
{	O
2	O
[	O
semiquinonemax	O
]	O
/	O
(	O
1−	O
[	O
semiquinonemax	O
]	O
)	O

}	O
2	O
From	O
the	O
relation	O
[	O
24	O
]	O
(	O
3	O
)	O
(	O
E2	O
°	O
′−E1	O
°	O
′	O
)	O
=−	O
(	O
RT	O
/	O
F	O
)	O
ln	O
K	O

it	O
can	O
be	O
predicted	O
that	O
for	O
the	O
free	O
enzyme	O
E	O
2	O
°	O
′	O
(	O
EFAD−⋅	B
/EFADH−	O
)	O
is	O
3	O
mV	O
more	O
positive	O
than	O
E	O
1	O
°	O
′	O
(	O
EFAD	B
/	O
EFAD−⋅	B
)	O
.	O

When	O
the	O
reduction	O
was	O
performed	O
in	O
the	O
presence	O
of	O
4	O
mM	O
l	B
-	I
(	I
+	I
)	I
-tartrate	I
a	O
maximum	O
amount	O
of	O
83	O
%	O
and	O
46	O
%	O
was	O
observed	O
using	O
the	O
xanthine	B
/	O
xanthine	O
oxidase	O
or	O
the	O
EDTA	B
/	O
light	O
reduction	O
method	O
,	O
respectively	O
.	O

Again	O
,	O
extinction	O
coefficients	O
for	O
oxidized	O
,	O
one	O
-	O
electron	O
and	O
two	O
-	O
electron	O
reduced	O
l	B
-	I
(	I
+	I
)	I
-tartrate	I
-	O
rDASPO	O
were	O
calculated	O
from	O
the	O
experiment	O
using	O
xanthine	B
/	O
xanthine	O
oxidase	O
(	O
data	O
not	O
shown	O
)	O
.	O

Table	O
2	O
shows	O
the	O
experimentally	O
determined	O
redox	O
potential	O
of	O
rDASPO	O
and	O
l	B
-	I
(	I
+	I
)	I
-tartrate	I
-	O
rDASPO	O
complex	O
in	O
0.1	O
M	O
KPi	B
,	O
pH	O
7.0	O
,	O
25	O
°	O
C	O
.	O

The	O
redox	O
potential	O
of	O
the	O
free	O
enzyme	O
was	O
determined	O
using	O
ITS	B
and	O
IDS	B
as	O
indicator	O
dyes	O
.	O

In	O
the	O
case	O
of	O
ITS	B
(	O
Fig.	O
4	O
)	O
no	O
semiquinone	B
formation	O
was	O
detected	O
and	O
a	O
midpoint	O
potential	O
of	O
−97	O
mV	O
(	O
slope=1.1	O
)	O
was	O
calculated	O
from	O
the	O
Minnaert	O
plot	O
shown	O
in	O
inset	O
of	O
Fig.	O
4	O
.	O

On	O
the	O
contrary	O
,	O
using	O
IDS	B
a	O
significant	O
amount	O
of	O
semiquinone	B
(	O
up	O
to	O
58	O
%	O
)	O
was	O
detected	O
.	O

This	O
allowed	O
to	O
calculate	O
the	O
redox	O
potentials	O
for	O
each	O
electron	O
using	O
data	O
from	O
the	O
first	O
part	O
of	O
the	O
experiment	O
for	O
E	O
1	O
°	O
′	O
(	O
−96	O
mV	O
,	O
slope=1.9	O
)	O
and	O
from	O
the	O
second	O
part	O
of	O
the	O
reaction	O
for	O
E	O
2	O
°	O
′	O
(	O
−95	O
mV	O
,	O
slope=2.0	O
)	O
(	O
Fig.	O
5	O
and	O
Table	O
2	O
)	O
.	O

The	O
calculated	O
E	O
m	O
°	O
′	O
(	O
−95.5	O
mV	O
)	O
agrees	O
well	O
with	O
the	O
midpoint	O
potential	O
determined	O
with	O
ITS	B
,	O
as	O
does	O
the	O
difference	O
between	O
E	O
2	O
°	O
′	O
and	O
E	O
1	O
°	O
′	O
(	O
determined	O
+	O
1	O
mV	O
,	O
predicted	O
from	O
the	O
semiquinone	B
formation	O
constant	O
+	O
3	O
mV	O
)	O
.	O

From	O
the	O
shift	O
in	O
the	O
midpoint	O
potential	O
of	O
FAD	B
(	O
−207	O
mV	O
,	O
Massey	O
)	O
upon	O
binding	O
to	O
rDASPO	O
(	O
−97	O
mV	O
)	O
and	O
the	O
known	O
dissociation	O
constant	O
of	O
FAD	B
for	O
the	O
oxidized	O
protein	O
(	O
5	O
×	O
10−8	O
M	O
[	O
14	O
]	O
)	O
a	O
value	O
of	O
1.0	O
×	O
10−11	O
M	O
for	O
K	O
red	O
(	O
the	O
dissociation	O
constant	O
of	O
the	O
reduced	O
coenzyme	O
)	O
can	O
be	O
calculated	O
using	O
the	O
following	O
equation	O
[	O
24	O
]	O
:	O
(	O
4	O
)	O
ΔE	O
°	O
′=RT	O
/	O
nF	O
×	O
ln	O
(	O
Kox	O
/Kred	O
)	O
In	O
the	O
presence	O
of	O
4	O
mM	O
l	B
-	I
(	I
+	I
)	I
-tartrate	I
,	O
a	O
concentration	O
100-fold	O
higher	O
than	O
the	O
dissociation	O
constant	O
of	O
the	O
ligand	O
for	O
the	O
oxidized	O
enzyme	O
,	O
a	O
midpoint	O
potential	O
of	O
−157	O
(	O
slope=1.1	O
)	O
and	O
−156	O
mV	O
(	O
slope=1.1	O
)	O
was	O
determined	O
for	O
the	O
l	B
-	I
(	I
+	I
)	I
-tartrate	I
-	O
rDASPO	O
complex	O
using	O
IDS	B
and	O
HNQ	B
(	O
Table	O
2	O
and	O
Fig.	O
6	O
)	O
as	O
indicator	O
dyes	O
,	O
respectively	O
.	O

No	O
detectable	O
formation	O
of	O
semiquinone	O
was	O
observed	O
.	O

Eq.	O
5	O
[	O
26	O
]	O
allows	O
to	O
calculate	O
the	O
dissociation	O
constant	O
of	O
l	B
-	I
(	I
+	I
)	I
-tartrate	I
for	O
reduced	O
rDASPO	O
(	O
K	O
red	O
′=3.6	O
×	O
10−2	O
M	O
)	O
:	O
(	O
5	O
)	O
ΔE	O
°	O
′=RT	O
/	O
nF	O
×	O
ln	O
{	O
(	O
1+	O
[	O
L	O
]	O
/Kred	O
′	O
)	O
/	O
(	O
1+	O
[	O
L	O
]	O
/Kox	O
′	O
)	O
}	O
where	O
ΔE	O
°	O
′	O
is	O
the	O
difference	O
between	O
the	O
redox	O
potential	O
in	O
the	O
presence	O
and	O
in	O
the	O
absence	O
of	O
the	O
ligand	O
,	O
K	O
red	O
′	O
is	O
the	O
dissociation	O
constant	O
of	O
l	B
-	I
(	I
+	I
)	I
-tartrate	I
from	O
reduced	O
rDASPO	O
and	O
K	O
ox	O
′	O
is	O
the	O
known	O
dissociation	O
constant	O
for	O
the	O
same	O
ligand	O
from	O
the	O
oxidized	O
enzyme	O
(	O
K	O
ox	O
′	O
,	O
4.1	O
×	O
10−5	O
M	O
,	O
see	O
above	O
)	O
,	O
and	O
[	O
L	O
]	O
the	O
concentration	O
of	O
l	B
-	I
(	I
+	I
)	I
-tartrate	I
used	O
.	O

It	O
can	O
be	O
concluded	O
that	O
l	B
-	I
(	I
+	I
)	I
-tartrate	I
binds	O
also	O
to	O
EFADH−	B
,	O
although	O
with	O
a	O
much	O
lower	O
affinity	O
as	O
compared	O
to	O
EFAD	B
.	O

This	O
result	O
confirms	O
those	O
obtained	O
for	O
another	O
ligand	O
(	O
oxaloacetate	B
)	O
and	O
for	O
the	O
substrate	O
(	O
d	B
-aspartate	I
)	O
,	O
based	O
on	O
kinetic	O
data	O
[	O
15	O
]	O
.	O

3.4	O
Oxidase	O
activity	O
towards	O
neurotransmitter	O
agonists	O
DASPO	O
is	O
strictly	O
specific	O
for	O
d	B
-amino	I
acids	I
since	O
l	B
-amino	I
acids	I
do	O
not	O
act	O
as	O
substrates	O
or	O
inhibitors	O
.	O

However	O
,	O
it	O
is	O
not	O
strictly	O
specific	O
for	O
d	B
-aspartate	I
,	O
being	O
active	O
also	O
against	O
a	O
variety	O
of	O
other	O
d	B
-amino	I
acids	I
,	O
with	O
a	O
strong	O
preference	O
for	O
dicarboxylic	O
ones	O
[	O
27,28	O
]	O
.	O

The	O
availability	O
of	O
large	O
amounts	O
of	O
pure	O
active	O
enzyme	O
allows	O
to	O
extend	O
the	O
characterization	O
of	O
the	O
substrate	O
specificity	O
of	O
DASPO	O
to	O
a	O
series	O
of	O
other	O
d	B
-amino	I
acids	I
which	O
are	O
known	O
to	O
possess	O
pharmacological	O
activity	O
as	O
neurotransmitter	O
agonists	O
[	O
12	O
]	O
.	O

The	O
apparent	O
kinetic	O
parameters	O
have	O
been	O
obtained	O
under	O
conditions	O
in	O
which	O
DASPO	O
was	O
shown	O
to	O
follow	O
Michaelis	O
-	O
Menten	O
kinetics	O
with	O
d	B
-aspartate	I
(	O
from	O
2	O
mM	O
to	O
30	O
mM	O
[	O
15	O
]	O
)	O
.	O

Linear	O
double	O
reciprocal	O
plots	O
were	O
obtained	O
for	O
all	O
substrates	O
in	O
this	O
range	O
.	O

The	O
results	O
obtained	O
are	O
listed	O
in	O
Table	O
3	O
.	O

It	O
should	O
be	O
pointed	O
out	O
that	O
many	O
of	O
the	O
compounds	O
listed	O
are	O
indeed	O
oxidized	O
at	O
a	O
significant	O
rate	O
by	O
DASPO	O
.	O

Analysis	O
of	O
the	O
data	O
of	O
Table	O
3	O
suggests	O
that	O
the	O
compounds	O
can	O
be	O
divided	O
into	O
three	O
groups	O
:	O
the	O
first	O
comprises	O
those	O
which	O
do	O
not	O
seem	O
to	O
interact	O
with	O
DASPO	O
,	O
since	O
they	O
are	O
neither	O
substrates	O
nor	O
inhibitors	O
;	O
the	O
second	O
contains	O
d	B
-aspartate	I
and	O
N	B
-methyl	I
-	I
d	I
-aspartate	I
,	O
which	O
are	O
by	O
far	O
the	O
best	O
substrates	O
;	O
the	O
third	O
comprises	O
the	O
remaining	O
substrates	O
,	O
which	O
are	O
oxidized	O
at	O
similar	O
rates	O
(	O
apparent	O
turnover	O
number	O
ranging	O
between	O
0.22	O
and	O
2.2	O
s−1	O
)	O
.	O

As	O
regards	O
the	O
latter	O
group	O
,	O
the	O
results	O
suggest	O
that	O
substitution	O
of	O
a	O
sulfonic	B
(	O
d	B
,	I
l	I
-cysteic	I
acid	I
)	O
or	O
phosphonic	B
(	O
d	O
,	B
l	I
-2-amino-3-phosphonopropanoic	I
acid	I
)	O
group	B
for	O
the	O
β	B
-	I
carboxylic	I
group	I
of	I
d	I
-aspartate	I
causes	O
a	O
dramatic	O
decrease	O
in	O
the	O
turnover	O
number	O
.	O

The	O
presence	O
of	O
a	O
second	O
acidic	O
group	O
,	O
however	O
,	O
is	O
not	O
an	O
absolute	O
requirement	O
,	O
since	O
d	B
-aspartate	I
-	I
β	I
-	I
hydroxamate	I
is	O
a	O
substrate	O
.	O

In	O
accordance	O
,	O
d	B
-proline	I
was	O
shown	O
to	O
be	O
a	O
substrate	O
for	O
bDASPO	O
(	O
apparent	O
turnover	O
number	O
0.4	O
s−1	O
,	O
K	O
m	O
9	O
×	O
10−4	O
M	O
[	O
28	O
]	O
)	O
and	O
d	B
-asparagine	I
and	O
d	B
-glutamine	I
for	O
DASPO	O
from	O
Octopus	O
but	O
not	O
for	O
bDASPO	O
[	O
28	O
]	O
.	O

An	O
increase	O
in	O
the	O
length	O
of	O
the	O
carbon	B
chain	I
also	O
causes	O
a	O
drop	O
in	O
the	O
oxidation	O
rate	O
,	O
as	O
observed	O
with	O
d	B
-glutamate	I
,	O
d	B
-homocysteic	I
acid	I
and	O
,	O
more	O
dramatically	O
,	O
with	O
d	B
,	I
l	I
-2-amino-4-phosphonobutanoic	I
acid	I
,	O
which	O
is	O
neither	O
a	O
substrate	O
nor	O
an	O
inhibitor	O
.	O

A	O
further	O
decrease	O
in	O
the	O
rate	O
of	O
oxidation	O
is	O
observed	O
with	O
the	O
C6-dicarboxylic	B
compound	I
d	B
-α	I
-	I
aminoadipic	I
acid	I
.	O

As	O
expected	O
from	O
previous	O
studies	O
on	O
a	O
related	O
compound	O
(	O
2,3-diaminosuccinic	B
acid	I
[	O
29	O
]	O
)	O
,	O
threo	B
-β	I
-	I
hydroxy	I
-	I
d	I
-aspartate	I
does	O
not	O
interact	O
with	O
DASPO	O
either	O
as	O
a	O
substrate	O
or	O
an	O
inhibitor	O
.	O

The	O
oxidative	O
activity	O
of	O
DASPO	O
towards	O
glycyl	B
-	I
d	I
-aspartate	I
is	O
of	O
particular	O
relevance	O
since	O
this	O
compound	O
has	O
been	O
proposed	O
to	O
be	O
involved	O
in	O
synaptic	O
transmission	O
in	O
prefrontal	O
cortex	O
in	O
vivo	O
[	O
13	O
]	O
.	O

4	O
Discussion	O
4.1	O
Purification	O
and	O
properties	O
of	O
rDASPO	O
This	O
paper	O
reports	O
overexpression	O
and	O
purification	O
conditions	O
leading	O
to	O
about	O
2	O
mg	O
pure	O
rDASPO	O
each	O
g	O
of	O
wet	O
E.	O
coli	O
paste	O
.	O

rDASPO	O
has	O
been	O
shown	O
to	O
possess	O
the	O
same	O
general	O
biochemical	O
properties	O
of	O
bDASPO	O
,	O
except	O
that	O
the	O
former	O
contains	O
only	O
FAD	B
,	O
while	O
the	O
latter	O
is	O
a	O
mixture	O
of	O
two	O
forms	O
,	O
an	O
active	O
one	O
containing	O
FAD	B
and	O
an	O
inactive	O
one	O
containing	O
6-OH	B
-	I
FAD	I
(	O
9–20	O
%	O
depending	O
on	O
the	O
preparation	O
)	O
[	O
14	O
]	O
.	O

For	O
such	O
reason	O
,	O
apart	O
from	O
the	O
amount	O
of	O
enzyme	O
obtained	O
and	O
the	O
ease	O
and	O
quickness	O
of	O
the	O
purification	O
protocol	O
,	O
the	O
procedure	O
reported	O
has	O
the	O
following	O
advantages	O
over	O
the	O
one	O
previously	O
used	O
to	O
obtain	O
bDASPO	O
from	O
the	O
natural	O
source	O
(	O
beef	O
kidney	O
cortex	O
)	O
:	O
rDASPO	O
possesses	O
a	O
specific	O
activity	O
higher	O
than	O
bDASPO	O
,	O
apo	O
-	O
protein	O
preparation	O
requires	O
milder	O
conditions	O
,	O
resulting	O
in	O
a	O
higher	O
yield	O
of	O
reconstitutable	O
holo	O
-	O
enzyme	O
,	O
and	O
spectroscopic	O
studies	O
are	O
facilitated	O
by	O
the	O
absence	O
of	O
a	O
second	O
compound	O
with	O
visible	O
absorption	O
properties	O
which	O
partially	O
overlap	O
those	O
of	O
FAD	B
.	O

The	O
latter	O
feature	O
has	O
been	O
used	O
to	O
determine	O
the	O
redox	O
potential	O
of	O
the	O
enzyme	O
by	O
the	O
spectrophotometric	O
method	O
set	O
up	O
by	O
Massey	O
[	O
20	O
]	O
.	O

4.2	O
Redox	O
potentials	O
of	O
DASPO	O
The	O
midpoint	O
potential	O
of	O
DASPO	O
in	O
0.1	O
M	O
KPi	B
,	O
pH	O
7.0	O
,	O
25	O
°	O
C	O
is	O
−97	O
mV.	O
Thus	O
,	O
the	O
binding	O
to	O
the	O
apo	O
-	O
enzyme	O
increases	O
the	O
redox	O
potential	O
of	O
the	O
flavin	B
by	O
110	O
mV	O
as	O
compared	O
to	O
free	O
FAD	B
,	O
a	O
shift	O
which	O
is	O
consistent	O
with	O
the	O
role	O
of	O
the	O
enzyme	O
as	O
a	O
dehydrogenase	O
/	O
oxidase	O
.	O

Useful	O
comparisons	O
can	O
be	O
made	O
with	O
the	O
redox	O
properties	O
of	O
the	O
closely	O
related	O
well	O
known	O
enzyme	O
d	O
-amino	O
acid	O
oxidase	O
,	O
which	O
catalyzes	O
the	O
same	O
reaction	O
catalyzed	O
by	O
DASPO	O
but	O
with	O
different	O
substrate	O
specificity	O
,	O
being	O
active	O
only	O
towards	O
neutral	O
and	O
basic	O
d	B
-amino	I
acids	I
[	O
30	O
]	O
.	O

The	O
general	O
properties	O
of	O
the	O
two	O
enzymes	O
have	O
been	O
shown	O
to	O
be	O
similar	O
,	O
although	O
their	O
kinetic	O
mechanism	O
is	O
slightly	O
different	O
[	O
15,30	O
]	O
.	O

Van	O
den	O
Berghe	O
and	O
Stankovich	O
determined	O
E	O
1	O
°	O
′	O
of	O
–98	O
mV	O
and	O
E	O
2	O
°	O
′	O
of	O
117	O
mV	O
in	O
50	O
mM	O
KPi	O
,	O
pH	O
7.0	O
,	O
18	O
°	O
C	O
for	O
d	O
-amino	O
acid	O
oxidase	O
[	O
31	O
]	O
.	O

Thus	O
,	O
the	O
calculated	O
midpoint	O
potential	O
and	O
the	O
amount	O
of	O
semiquinone	B
stabilized	O
(	O
–108	O
mV	O
and	O
40	O
%	O
,	O
respectively	O
)	O
are	O
only	O
slightly	O
different	O
from	O
the	O
ones	O
determined	O
for	O
DASPO	O
(	O
–97	O
mV	O
and	O
32	O
%	O
)	O
.	O

In	O
accordance	O
,	O
the	O
presence	O
of	O
a	O
specific	O
inhibitor	O
causes	O
similar	O
negative	O
shifts	O
in	O
the	O
redox	O
potential	O
of	O
the	O
two	O
enzymes	O
(	O
39	O
mV	O
in	O
the	O
case	O
of	O
d	O
-amino	O
acid	O
oxidase	O
with	O
benzoate	B
,	O
58	O
mV	O
for	O
DASPO	O
in	O
the	O
presence	O
of	O
l	B
-	I
(	I
+	I
)	I
-tartrate	I
)	O
.	O

In	O
conclusion	O
,	O
the	O
redox	O
properties	O
of	O
DASPO	O
conform	O
to	O
those	O
expected	O
for	O
a	O
typical	O
flavoprotein	O
oxidase	O
[	O
32	O
]	O
.	O

This	O
is	O
in	O
marked	O
contrast	O
with	O
what	O
has	O
been	O
observed	O
for	O
E.	O
coli	O
l	O
-aspartate	O
oxidase	O
,	O
a	O
flavoenzyme	O
which	O
catalyzes	O
the	O
oxidation	O
of	O
l	B
-aspartate	I
by	O
O2	B
and	O
can	O
not	O
use	O
d	B
-aspartate	I
as	O
a	O
substrate	O
,	O
whose	O
redox	O
potential	O
(	O
–216	O
mV	O
)	O
is	O
actually	O
lower	O
than	O
that	O
of	O
free	O
FAD	B
[	O
33	O
]	O
.	O

Thus	O
,	O
the	O
redox	O
potential	O
data	O
confirm	O
other	O
experimental	O
evidence	O
which	O
suggests	O
that	O
,	O
although	O
DASPO	O
and	O
l	O
-aspartate	O
oxidase	O
catalyze	O
the	O
same	O
reaction	O
but	O
with	O
different	O
enantio	O
-	O
specificity	O
,	O
their	O
properties	O
are	O
largely	O
different	O
[	O
33–35	O
]	O
.	O

This	O
fact	O
can	O
be	O
ascribed	O
both	O
to	O
the	O
need	O
to	O
assure	O
absolute	O
stereospecificity	O
and	O
to	O
respond	O
to	O
totally	O
different	O
metabolic	O
demands	O
and	O
controls	O
.	O

In	O
fact	O
,	O
the	O
biological	O
role	O
of	O
DASPO	O
is	O
likely	O
to	O
be	O
mainly	O
catabolic	O
[	O
36	O
]	O
,	O
while	O
that	O
of	O
l	O
-aspartate	O
oxidase	O
is	O
exclusively	O
anabolic	O
,	O
since	O
it	O
catalyzes	O
the	O
first	O
step	O
in	O
the	O
de	O
novo	O
biosynthesis	O
of	O
pyridinic	B
nucleotides	I
in	O
several	O
microorganisms	O
and	O
plants	O
[	O
37	O
]	O
.	O

4.3	O
Substrate	O
specificity	O
of	O
DASPO	O
The	O
investigation	O
of	O
the	O
interaction	O
between	O
DASPO	O
and	O
dicarboxylic	B
compounds	I
which	O
are	O
known	O
to	O
possess	O
pharmacological	O
activities	O
as	O
agonists	O
/	O
antagonists	O
for	O
excitatory	O
amino	O
acid	O
receptors	O
has	O
allowed	O
to	O
identify	O
two	O
new	O
substrates	O
for	O
the	O
enzyme	O
,	O
i.e.	O
d	B
-aspartate	I
-	I
β	I
-	I
hydroxamate	I
and	O
glycyl	B
-	I
d	I
-aspartate	I
,	O
and	O
to	O
determine	O
the	O
kinetic	O
parameters	O
for	O
these	O
and	O
a	O
number	O
of	O
other	O
substrates	O
.	O

The	O
results	O
are	O
of	O
particular	O
interest	O
for	O
two	O
reasons	O
:	O
first	O
of	O
all	O
,	O
the	O
presence	O
of	O
d	B
-aspartate	I
,	O
d	B
-glutamate	I
,	O
N	B
-methyl	I
-	I
d	I
-aspartate	I
and	O
glycyl	B
-	I
d	I
-aspartate	I
have	O
been	O
reported	O
in	O
several	O
organisms	O
[	O
4–10,13,38	O
]	O
;	O
secondly	O
,	O
all	O
of	O
the	O
compounds	O
listed	O
in	O
Table	O
3	O
are	O
used	O
for	O
both	O
in	O
vivo	O
and	O
in	O
vitro	O
studies	O
as	O
agonists	O
/	O
antagonists	O
for	O
excitatory	O
amino	O
acid	O
receptors	O
but	O
the	O
metabolic	O
fate	O
of	O
most	O
,	O
if	O
not	O
all	O
,	O
of	O
them	O
is	O
still	O
unknown	O
.	O

Since	O
DASPO	O
has	O
been	O
shown	O
to	O
be	O
present	O
in	O
a	O
number	O
of	O
tissues	O
,	O
the	O
possibility	O
exists	O
that	O
the	O
effect	O
of	O
such	O
compounds	O
can	O
be	O
influenced	O
both	O
in	O
vivo	O
and	O
in	O
vitro	O
by	O
the	O
amount	O
of	O
DASPO	O
present	O
.	O

Acknowledgements	O
We	O
wish	O
to	O
thank	O
Prof.	O
Tatjana	O
Simonic	O
for	O
providing	O
E.	O
coli	O
GI724	O
(	O
pED	O
)	O
cells	O
.	O

This	O
paper	O
was	O
supported	O
by	O
grants	O
from	O
the	O
Ministero	O
della	O
Università	O
e	O
della	O
Ricerca	O
Scientifica	O
and	O
from	O
the	O
Consiglio	O
Nazionale	O
delle	O
Ricerche	O
(	O
Italy	O
)	O
.	O

The	O
cardiotoxic	O
effect	O
of	O
karminomycin	B
and	O
adriamycin	B
administered	O
intravenously	O
for	O
5	O
times	O
in	O
equitoxic	O
doses	O
constituting	O
equal	O
portions	O
of	O
LD50	O
of	O
the	O
respective	O
antibiotic	B
on	O
its	O
single	O
intravenous	O
administration	O
was	O
studied	O
on	O
albino	O
mice	O
.	O

Histological	O
examination	O
of	O
the	O
heart	O
showed	O
that	O
almost	O
identical	O
damages	O
of	O
the	O
myocardium	O
occured	O
after	O
administration	O
of	O
karminomycin	B
and	O
adriamycin	B
in	O
doses	O
of	O
0.45	O
of	O
LD50	O
(	O
1.5	O
mg	O
/	O
kg	O
)	O
and	O
0.3	O
of	O
LD50	O
(	O
6.3	O
mg	O
/	O
kg	O
)	O
respectively	O
.	O

The	O
character	O
of	O
the	O
damages	O
due	O
to	O
the	O
antibiotics	B
was	O
close	O
,	O
the	O
most	O
significant	O
changes	O
were	O
observed	O
when	O
the	O
animals	O
were	O
sacrificed	O
1	O
month	O
after	O
the	O
last	O
administration	O
of	O
the	O
drug	B
.	O

The	O
histological	O
method	O
is	O
of	O
value	O
in	O
estimation	O
of	O
the	O
cardiotoxic	O
effect	O
of	O
the	O
drugs	B
,	O
using	O
mice	O
as	O
the	O
model	O
suitable	O
for	O
the	O
investigation	O
.	O

Adriamycin	B
had	O
more	O
pronounced	O
cumulative	O
properties	O
as	O
compared	O
to	O
karminomycin	B
:	O
suppression	O
of	O
the	O
weight	O
gain	O
in	O
the	O
mice	O
and	O
their	O
death	O
rate	O
were	O
higher	O
with	O
the	O
use	O
of	O
adriamycin	B
.	O

Three	O
sialosylated	B
and	O
three	O
neutral	B
glycosphingolipids	I
sharing	O
a	O
common	O
iso	B
-	I
neolacto	I
core	O
were	O
isolated	O
from	O
porcine	O
kidney	O
cortex	O
.	O

They	O
were	O
purified	O
by	O
preparative	O
HPTLC	O
,	O
and	O
were	O
characterized	O
by	O
partial	O
exoglycosidase	O
hydrolysis	O
followed	O
by	O
thin	O
layer	O
chromatography	O
and	O
immunostaining	O
with	O
anti	O
-	O
Galalpha1	O
-	O
->3Gal	O
,	O
anti	O
-	O
type	O
2	O
lactosamine	O
and	O
anti	O
-	O
Lewis	O
(	O
x	O
)	O
antibodies	O
,	O
methylation	O
analysis	O
,	O
MALDI	O
-	O
TOF	O
mass	O
spectrometry	O
and	O
1H	O
-	O
NMR	O
spectroscopy	O
.	O

Among	O
neutral	B
glycolipids	I
,	O
one	O
was	O
a	O
known	O
structure	O
,	O
VI3VI'3	B
(	I
alphaGal	I
)	I
2-iso	I
-	I
nLc8Cer	I
,	O
and	O
two	O
were	O
novel	O
structures	O
differing	O
by	O
the	O
number	O
of	O
Galalpha3Lewis	B
(	I
x	I
)	I
determinants	O
:	O
VI3VI'3	B
(	I
alphaGal	I
)	I
2V'3alphaFuc	I
-	I
iso	I
-	I
nLc8	I
,	O
and	O
VI3VI'3	B
(	I
alphaGal	I
)	I
2	I
V3V'3	I
(	I
alphaFuc	I
)	I
2-iso	I
-	I
nLc8	I
.	O

The	O
single	O
Galalpha3Lewis	B
(	I
x	I
)	I
determinant	O
was	O
found	O
on	O
the	O
6-linked	O
antenna	O
.	O

Among	O
sialosylated	B
glycolipids	I
,	O
two	O
had	O
been	O
previously	O
found	O
in	O
other	O
species	O
and	O
tissues	O
,	O
VI3VI'3	B
(	I
NeuAc	I
)	I
2-iso	I
-	I
nLc8	I
,	O
and	O
VI3NeuAcVI'3alphaGal	B
-	I
iso	I
-	I
nLc8	I
.	I

A	O
novel	O
structure	O
was	O
discovered	O
presenting	O
a	O
Galalpha3Lewis	B
(	I
x	I
)	I
determinant	O
on	O
the	O
6-linked	O
antenna	O
and	O
a	O
N	B
-	I
acetylneuraminic	I
acid	I
on	O
the	O
3-linked	O
antenna	O
,	O
VI3NeuAcVI'3alphaGalV'3alphaFuc	B
-	I
iso	I
-	I
nLc8	I
.	I

These	O
results	O
indicate	O
that	O
,	O
in	O
vivo	O
,	O
the	O
porcine	O
kidney	O
alpha3fucosyltransferase	O
synthesizes	O
the	O
Gala3Lewis	B
(	I
x	I
)	I
determinant	O
,	O
acting	O
on	O
the	O
6-linked	O
before	O
the	O
3-linked	O
Galalpha3neolactosamine	B
,	O
and	O
appears	O
unable	O
to	O
synthesize	O
the	O
sialosylated	B
Lewis	I
(	I
x	I
)	I
determinant	O
on	O
neolactoseries	O
glycolipids	B
.	O

A	O
monoclonal	O
antibody	O
(	O
MAb	O
)	O
was	O
produced	O
against	O
the	O
p	B
-	I
nitrophenylphosphate	I
derivative	I
of	I
3	I
alpha	I
,	I
5	I
beta	I
-	I
lithocholic	I
acid	I
,	O
a	O
transition	O
-	O
state	O
analog	O
for	O
hydrolysis	O
of	O
a	O
steroidal	B
p	I
-	I
nitrophenylcarbonate	I
.	O

The	O
indicated	O
reaction	O
was	O
catalyzed	O
by	O
this	O
Ab	O
with	O
kinetic	O
constants	O
kcat	O
=	O
4.0	O
x	O
10	O
(	O
-2	O
)	O
/	O
min	O
and	O
K	O
(	O
m	O
)	O
=	O
3.3	O
microM	O
at	O
pH	O
9.0	O
and	O
35	O
degrees	O
C.	O
The	O
Ab	O
also	O
hydrolyzed	O
the	O
isomeric	O
p	B
-	I
nitrophenylcarbonate	I
of	I
3	I
beta	I
,	I
5	I
beta	I
-	I
lithocholic	I
acid	I
with	O
kcat	O
=	O
8.4	O
x	O
10	O
(	O
-2	O
)	O
/	O
min	O
and	O
K	O
(	O
m	O
)	O
=	O
1.0	O
microM.	O
Bovine	O
serum	O
albumin	O
(	O
BSA	O
)	O
was	O
found	O
to	O
catalyze	O
the	O
same	O
reactions	O
with	O
similar	O
turnover	O
rates	O
and	O
Michaelis	O
constants	O
of	O
15	O
and	O
14	O
microM	O
,	O
respectively	O
.	O

Although	O
the	O
BSA	O
-	O
catalyzed	O
reaction	O
was	O
only	O
weakly	O
inhibited	O
by	O
the	O
phosphate	B
ester	I
TSA	B
(	O
IC50	O
ca	O
.	O

40	O
microM	O
)	O
,	O
the	O
Ab	O
-	O
catalyzed	O
reaction	O
was	O
completely	O
inhibited	O
at	O
less	O
than	O
1	O
microM	O
of	O
the	O
TSA	B
.	O

The	O
relative	O
rates	O
and	O
efficiencies	O
of	O
the	O
MAb	O
-	O
catalyzed	O
and	O
BSA	O
-	O
catalyzed	O
reactions	O
are	O
discussed	O
in	O
the	O
context	O
of	O
the	O
hydrophobic	O
sites	O
and	O
intrinsic	O
reactivity	O
of	O
the	O
protein	O
surfaces	O
,	O
and	O
the	O
induction	O
of	O
groups	O
on	O
the	O
Ab	O
to	O
enhance	O
the	O
enzymatic	O
function	O
.	O

To	O
clarify	O
the	O
relationship	O
between	O
the	O
occurrence	O
of	O
unusual	O
trihydroxy	B
bile	I
acids	I
,	O
namely	O
hyocholic	B
acid	I
,	O
ursocholic	B
acid	I
(	O
UCA	B
)	O
,	O
and	O
omega	B
-	I
muricholic	I
acid	I
(	O
omega	B
-	I
MCA	I
)	O
in	O
urine	O
and	O
liver	O
disease	O
severity	O
,	O
urinary	O
bile	B
acids	I
were	O
analyzed	O
by	O
gas	O
-	O
liquid	O
chromatography	O
in	O
acute	O
and	O
late	O
phases	O
of	O
acute	O
hepatitis	O
and	O
before	O
and	O
after	O
ursodeoxycholic	B
acid	I
(	O
UDCA	B
)	O
loading	O
in	O
healthy	O
adults	O
and	O
liver	O
cirrhosis	O
patients	O
.	O

In	O
11	O
patients	O
with	O
acute	O
hepatitis	O
,	O
the	O
occurrence	O
rates	O
and	O
amounts	O
of	O
unusual	O
trihydroxy	B
bile	I
acids	I
were	O
increased	O
in	O
the	O
late	O
(	O
recovery	O
)	O
phase	O
,	O
as	O
compared	O
with	O
those	O
in	O
the	O
early	O
phase	O
.	O

In	O
10	O
patients	O
with	O
severe	O
acute	O
hepatitis	O
who	O
had	O
prothrombin	O
times	O
exceeding	O
16	O
seconds	O
,	O
these	O
bile	B
acids	I
had	O
completely	O
disappeared	O
from	O
the	O
urine	O
in	O
the	O
early	O
phase	O
but	O
reappeared	O
in	O
the	O
late	O
phase	O
in	O
those	O
who	O
had	O
a	O
good	O
outcome	O
,	O
though	O
never	O
in	O
a	O
patient	O
who	O
died	O
.	O

After	O
UDCA	B
administration	O
for	O
a	O
week	O
,	O
the	O
amounts	O
of	O
unusual	O
bile	B
acids	I
,	O
especially	O
UCA	B
and	O
omega	B
-	I
MCA	I
,	O
which	O
are	O
thought	O
to	O
be	O
synthesized	O
through	O
12	O
alpha-	O
and	O
6	O
alpha	O
-	O
hydroxylations	O
,	O
respectively	O
,	O
from	O
UDCA	B
,	O
were	O
clearly	O
increased	O
in	O
10	O
healthy	O
adults	O
but	O
only	O
slightly	O
changed	O
in	O
10	O
patients	O
with	O
liver	O
cirrhosis	O
.	O

In	O
conclusion	O
,	O
hepatic	O
hydroxylations	O
of	O
dihydroxy	B
bile	I
acids	I
as	O
a	O
detoxification	O
reaction	O
were	O
impaired	O
in	O
severe	O
liver	O
diseases	O
,	O
which	O
may	O
play	O
a	O
role	O
in	O
the	O
intensification	O
and	O
perpetuation	O
of	O
hepatocellular	O
injuries	O
.	O

1	O
.	O

Bioactivation	O
of	O
sulphamethoxazole	B
(	O
SMX	B
)	O
to	O
chemically	O
-	O
reactive	O
metabolites	B
and	O
subsequent	O
protein	O
conjugation	O
is	O
thought	O
to	O
be	O
involved	O
in	O
SMX	B
hypersensitivity	O
.	O

We	O
have	O
therefore	O
examined	O
the	O
cellular	O
metabolism	O
,	O
disposition	O
and	O
conjugation	O
of	O
SMX	B
and	O
its	O
metabolites	B
in	O
vitro	O
.	O

2	O
.	O

Flow	O
cytometry	O
revealed	O
binding	O
of	O
N	B
-	I
hydroxy	I
(	O
SMX	B
-	I
NHOH	I
)	O
and	O
nitroso	B
(	O
SMX	B
-	I
NO	I
)	O
metabolites	B
of	I
SMX	I
,	O
but	O
not	O
of	O
SMX	B
itself	O
,	O
to	O
the	O
surface	O
of	O
viable	O
white	O
blood	O
cells	O
.	O

Cellular	O
haptenation	O
by	O
SMX	B
-	I
NO	I
was	O
reduced	O
by	O
exogenous	O
glutathione	B
(	O
GSH	B
)	O
.	O

3	O
.	O
SMX	B
-	I
NHOH	I
and	O
SMX	B
-	I
NO	I
were	O
rapidly	O
reduced	O
back	O
to	O
the	O
parent	O
compound	O
by	O
cysteine	B
(	O
CYS	B
)	O
,	O
GSH	B
,	O
human	O
peripheral	O
blood	O
cells	O
and	O
plasma	O
,	O
suggesting	O
that	O
this	O
is	O
an	O
important	O
and	O
ubiquitous	O
bioinactivation	O
mechanism	O
.	O

4	O
.	O
Fluorescence	O
HPLC	O
showed	O
that	O
SMX	B
-	I
NHOH	I
and	O
SMX	B
-	I
NO	I
depleted	O
CYS	B
and	O
GSH	B
in	O
buffer	B
,	O
and	O
to	O
a	O
lesser	O
extent	O
,	O
in	O
cells	O
and	O
plasma	O
.	O

5	O
.	O

Neutrophil	O
apoptosis	O
and	O
inhibition	O
of	O
neutrophil	O
function	O
were	O
induced	O
at	O
lower	O
concentrations	O
of	O
SMX	B
-	I
NHOH	I
and	O
SMX	B
-	I
NO	I
than	O
those	O
inducing	O
loss	O
of	O
membrane	O
viability	O
,	O
with	O
SMX	B
having	O
no	O
effect	O
.	O

Lymphocytes	O
were	O
significantly	O
(	O
P<0.05	O
)	O
more	O
sensitive	O
to	O
the	O
direct	O
cytotoxic	O
effects	O
of	O
SMX	B
-	I
NO	I
than	O
neutrophils	O
.	O

6	O
.	O

Partitioning	O
of	O
SMX	B
-	I
NHOH	I
into	O
red	O
blood	O
cells	O
was	O
significantly	O
(	O
P<0.05	O
)	O
lower	O
than	O
with	O
the	O
hydroxylamine	B
of	I
dapsone	I
.	O

7	O
.	O

Our	O
results	O
suggest	O
that	O
the	O
balance	O
between	O
oxidation	O
of	O
SMX	B
to	O
its	O
toxic	O
metabolites	B
and	O
their	O
reduction	O
is	O
an	O
important	O
protective	O
cellular	O
mechanism	O
.	O

If	O
an	O
imbalance	O
exists	O
,	O
haptenation	O
of	O
the	O
toxic	O
metabolites	B
to	O
bodily	O
proteins	O
including	O
the	O
surface	O
of	O
viable	O
cells	O
can	O
occur	O
,	O
and	O
may	O
result	O
in	O
drug	B
hypersensitivity	O
.	O

Proline	B
(	O
Pro	B
)	O
and	O
hydroxyproline	B
(	O
Hyp	B
)	O
formed	O
by	O
hydroxylation	O
of	O
Pro	B
during	O
collagen	O
biosynthesis	O
are	O
commonly	O
found	O
in	O
connective	O
tissue	O
proteins	O
such	O
as	O
collagen	O
at	O
high	O
concentrations	O
.	O

These	O
amino	B
acids	I
are	O
released	O
after	O
degradation	O
of	O
collagen	O
and	O
excreted	O
into	O
urine	O
as	O
amino	B
acids	I
,	O
small	B
peptides	I
and	O
large	B
peptides	I
.	O

According	O
to	O
previous	O
reports	O
[	O
1–4	O
]	O
,	O
total	O
Hyp	B
excreted	O
in	O
urine	O
is	O
comprised	O
of	O
∼85	O
%	O
small	B
peptides	I
and	O
1–5	O
%	O
free	O
Hyp	B
.	O

The	O
main	O
peptide	B
containing	O
Hyp	B
was	O
prolylhydroxyproline	B
(	O
Pro	B
–	I
Hyp	I
)	O
which	O
accounted	O
for	O
about	O
60	O
%	O
of	O
peptide	O
Hyp	B
or	O
44	O
%	O
of	O
total	O
urinary	O
Hyp	B
[	O
2,4	O
]	O
.	O

The	O
concentration	O
of	O
total	O
urinary	O
Pro	B
and	O
Hyp	B
varied	O
in	O
association	O
with	O
various	O
diseases	O
including	O
bone	O
diseases	O
[	O
1,5–7	O
]	O
and	O
tumor	O
[	O
8–10	O
]	O
and	O
excretion	O
of	O
dipeptides	B
containing	B
Pro	B
or	O
Hyp	B
increases	O
in	O
patients	O
with	O
disorders	O
involving	O
collagen	O
metabolism	O
[	O
11–13	O
]	O
.	O

Therefore	O
,	O
sensitive	O
and	O
reliable	O
determinations	O
of	O
these	O
metabolites	O
in	O
human	O
urine	O
are	O
useful	O
for	O
understanding	O
of	O
various	O
disorders	O
.	O

Currently	O
,	O
a	O
few	O
methods	O
for	O
the	O
determination	O
of	O
dipeptides	B
that	O
contain	O
Pro	B
or	O
Hyp	B
in	O
urine	O
by	O
gas	O
chromatograpgy	O
–	O
mass	O
spectrometry	O
(	O
GC	O
–	O
MS	O
)	O
[	O
11–14	O
]	O
,	O
liquid	O
chromatography	O
(	O
LC	O
)	O
–MS	O
[	O
15–17	O
]	O
and	O
high	O
-	O
performance	O
liquid	O
chromatography	O
(	O
HPLC	O
)	O
[	O
18	O
]	O
have	O
been	O
reported	O
.	O

However	O
,	O
the	O
GC	O
–	O
MS	O
and	O
LC	O
–	O
MS	O
methods	O
require	O
tedious	O
procedures	O
including	O
a	O
two	O
-	O
step	O
column	O
separation	O
for	O
pre	O
-	O
treatment	O
of	O
urine	O
and	O
further	O
,	O
the	O
GC	O
–	O
MS	O
methods	O
require	O
a	O
two	O
-	O
step	O
derivatization	O
procedure	O
to	O
convert	O
dipeptides	B
into	O
volatile	O
derivatives	O
after	O
pre	O
-	O
treatment	O
.	O

In	O
the	O
HPLC	O
method	O
employing	O
a	O
pre	O
-	O
column	O
derivatization	O
technique	O
with	O
4-chloro-7-nitrobenzofurazan	B
as	O
a	O
fluorescent	O
labelling	O
reagent	O
,	O
a	O
relatively	O
large	O
sample	O
volume	O
(	O
5	O
ml	O
)	O
is	O
required	O
because	O
of	O
low	O
sensitivity	O
to	O
prolyl	B
dipeptides	I
.	O

Recently	O
,	O
we	O
developed	O
an	O
extremely	O
sensitive	O
fluorescent	O
labelling	O
reagent	O
,	O
4-	B
(	I
5,6-dimethoxy-2-phthalimidinyl	I
)	I
-2-methoxyphenylsulfonyl	I
chloride	I
(	O
DMS	B
-	I
Cl	I
)	O
,	O
which	O
reacts	O
quantitatively	O
with	O
amino	B
acids	I
to	O
form	O
fluorescent	O
sulfonamides	B
(	O
maximum	O
wavelength	O
:	O
318	O
nm	O
for	O
excitation	O
and	O
392	O
nm	O
for	O
emission	O
)	O
,	O
and	O
applied	O
the	O
reagent	O
for	O
determination	O
of	O
urinary	O
free	O
Hyp	B
by	O
a	O
pre	O
-	O
column	O
HPLC	O
method	O
[	O
19	O
]	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
found	O
DMS	B
-	I
Cl	I
reacted	O
with	O
prolyl	B
dipeptides	I
to	O
give	O
fluorescent	O
derivatives	O
.	O

In	O
addition	O
,	O
a	O
highly	O
sensitive	O
HPLC	O
method	O
for	O
simultaneous	O
determination	O
of	O
prolyl	B
dipeptides	I
,	O
Pro	B
and	O
Hyp	B
in	O
urine	O
by	O
fluorescence	O
detection	O
after	O
pre	O
-	O
column	O
derivatization	O
with	O
DMS	B
-	I
Cl	I
was	O
established	O
.	O

2	O
Experimental	O
2.1	O
Chemicals	O
and	O
solvents	O
All	O
chemicals	O
were	O
of	O
analytical	O
reagent	O
grade	O
,	O
unless	O
stated	O
otherwise	O
.	O

DMS	B
-	I
Cl	I
was	O
prepared	O
as	O
described	O
previously	O
[	O
19	O
]	O
.	O

o	B
-Phthalaldehyde	I
(	O
OPA	B
)	O
,	O
acetonitrile	B
(	O
HPLC	O
-	O
grade	O
)	O
and	O
Creatinine	O
Test	O
Wako	O
were	O
obtained	O
from	O
Wako	O
Pure	O
Chemicals	O
(	O
Osaka	O
,	O
Japan	O
)	O
.	O

Pro	B
–	I
Asp	I
,	O
Pro	B
–	I
Gln	I
,	O
Pro	B
–	I
Glu	I
,	O
Pro	B
–	I
Leu	I
,	O
Pro	B
–	I
Pro	I
and	O
Pro	B
–	I
Ser	I
were	O
purchased	O
from	O
Kokusan	O
Chemical	O
Works	O
(	O
Tokyo	O
,	O
Japan	O
)	O
and	O
Pro	B
–	I
Ala	I
,	O
Pro	B
–	I
Asn	I
,	O
Pro	B
–	I
Gly	I
,	O
Pro	B
–	I
Hyp	I
,	O

Pro	B
–	I
Ile	I
,	O
Pro	B
–	I
Met	I
,	O
Pro	B
–	I
Phe	I
,	O
Pro	B
–	I
Trp	I
,	O
Pro	B
–	I
Tyr	I
,	O
Pro	B
–	I
Val	I
and	O
3,4-dehydro	B
-	I
dl	I
-proline	I
(	B
internal	I
standard	I
,	O
I.S.	B
)	O
were	O
from	O
Sigma	O
(	O
St.	O
Louis	O
,	O
MO	O
,	O
USA	O
)	O
.	O

l	B
-Amino	I
acids	I
except	O
Asn	B
,	O
Hyp	B
and	O
Ser	B
(	O
Nacalai	O
Tesque	O
,	O
Kyoto	O
,	O
Japan	O
)	O
were	O
purchased	O
from	O
Kyowa	O
Hakko	O
(	O
Tokyo	O
,	O
Japan	O
)	O
.	O

Organic	O
solvents	O
except	O
acetonitrile	B
were	O
of	O
highest	O
purity	O
available	O
and	O
used	O
as	O
received	O
.	O

Bond	B
Elut	I
C18	I
(	O
100	O
mg	O
/	O
1	O
ml	O
,	O
Varian	O
,	O
CA	O
,	O
USA	O
)	O
was	O
conditioned	O
with	O
2	O
ml	O
of	O
methanol	B
followed	O
by	O
2	O
ml	O
of	O
water	B
and	O
1	O
ml	O
of	O
Na2	B
HPO4	I
(	O
50	O
mM	O
)	O
prior	O
to	O
use	O
.	O

2.2	O
Instrumental	O
conditions	O
The	O
HPLC	O
system	O
consisted	O
of	O
two	O
LC-10AD	O
HPLC	O
pumps	O
(	O
Shimadzu	O
,	O
Kyoto	O
,	O
Japan	O
)	O
,	O
a	O
CTO-10AC	O
column	O
oven	O
(	O
Shimadzu	O
)	O
,	O
a	O
DGU-14A	O
on	O
-	O
line	O
degasser	O
(	O
Shimadzu	O
)	O
,	O
an	O
SIL-10Axl	O
auto	O
injector	O
(	O
Shimadzu	O
)	O
,	O
an	O
L-7480	O
fluorescence	O
detector	O
(	O
Hitachi	O
,	O
Tokyo	O
,	O
Japan	O
)	O
and	O
a	O
CLASS	O
-	O
LC10	O
LC	O
work	O
-	O
station	O
(	O
Shimadzu	O
)	O
with	O
a	O
CBM-10A	O
communications	O
bus	O
module	O
(	O
Shimadzu	O
)	O
.	O

A	O
TSK	O
-	O
guard	O
gel	O
ODS-80Ts	O
(	O
15	O
×	O
3.2	O
mm	O
I.D.	O
,	O
Tosoh	O
,	O
Tokyo	O
,	O
Japan	O
)	O
and	O
tandem	O
Nova	O
Pak	O
C18	O
columns	O
(	O
150	O
×	O
3.9	O
mm	O
I.D.	O
,	O
4	O
μm	O
,	O
Waters	O
,	O
Milford	O
,	O
MA	O
,	O
USA	O
)	O
were	O
used	O
at	O
55	O
°	O
C	O
with	O
a	O
gradient	O
system	O
of	O
(	O
A	O
)	O
aqueous	B
acetic	I
acid	I
(	O
10	O
mM	O
)	O
–	O
(	O
B	O
)	O
acetonitrile	B
–	O
aqueous	B
acetic	I
acid	I
(	O
50	O
mM	O
)	O
(	O
8:2	O
,	O
v	O
/	O
v	O
)	O
.	O

The	O
elution	O
program	O
consisted	O
of	O
an	O
isocratic	O
elution	O
of	O
25	O
%	O
B	O
for	O
20	O
min	O
,	O
followed	O
by	O
a	O
linear	O
gradient	O
elution	O
from	O
25	O
to	O
55	O
%	O
of	O
B	O
for	O
30	O
min	O
,	O
and	O
finally	O
a	O
stepwise	O
decrease	O
to	O
25	O
%	O
of	O
B	O
to	O
re	O
-	O
equilibrate	O
the	O
column	O
for	O
10	O
min	O
.	O

The	O
flow	O
-	O
rate	O
was	O
1	O
ml	O
/	O
min	O
.	O

The	O
fluorescence	O
intensities	O
were	O
monitored	O
at	O
excitation	O
and	O
emission	O
wavelengths	O
of	O
318	O
nm	O
and	O
392	O
nm	O
,	O
respectively	O
.	O

2.3	O
Derivatization	O
procedure	O
To	O
a	O
test	O
solution	O
(	O
20	O
μl	O
)	O
of	O
prolyl	B
dipeptides	I
,	O
Pro	B
,	O
Hyp	B
and	O
the	O
I.S.	B
were	O
placed	O
in	O
a	O
screw	O
-	O
capped	O
glass	O
vial	O
,	O
Na2	B
HPO4	I
(	O
50	O
mM	O
,	O
280	O
μl	O
)	O
and	O
DMS	B
-	I
Cl	I
(	O
2	O
mM	O
in	O
acetone	B
,	O
500	O
μl	O
)	O
were	O
successively	O
added	O
and	O
mixed	O
.	O

The	O
mixture	O
was	O
allowed	O
to	O
stand	O
for	O
20	O
min	O
at	O
70	O
°	O
C	O
.	O

After	O
cooling	O
,	O
the	O
reaction	O
mixture	O
was	O
mixed	O
with	O
dichloromethane	B
(	O
0.8	O
ml	O
)	O
and	O
Na2	B
CO3	I
(	O
0.1	O
M	O
,	O
30	O
μl	O
)	O
and	O
then	O
centrifuged	O
(	O
500	O
g	O
)	O
for	O
10	O
min	O
.	O

An	O
aliquot	O
(	O
10	O
μl	O
)	O
of	O
the	O
aqueous	O
layer	O
was	O
subjected	O
to	O
HPLC	O
.	O

2.4	O
Procedure	O
for	O
determination	O
of	O
urinary	O
prolyl	B
dipeptides	I
,	O
Pro	B
and	O
Hyp	B
2.4.1	O
Method	O
A	O
(	O
recommended	O
method	O
)	O
:	O
solid	O
-	O
phase	O
extraction	O
method	O
To	O
human	O
urine	O
(	O
25	O
μl	O
)	O
were	O
added	O
I.S.	B
(	O
10	O
μM	O
,	O
25	O
μl	O
)	O
,	O
Na2	B
HPO4	I
(	O
50	O
mM	O
,	O
150	O
μl	O
)	O
and	O
OPA	B
[	O
4	O
%	O
,	O
w	O
/	O
v	O
,	O
in	O
acetonitrile	B
–	O
Na2	B
HPO4	I
(	O
50	O
mM	O
)	O
(	O
1:1	O
,	O
v	O
/	O
v	O
)	O
,	O
50	O
μl	O
]	O
.	O

After	O
standing	O
for	O
3	O
min	O
,	O
the	O
OPA	B
-	O
treated	O
mixture	O
(	O
200	O
μl	O
)	O
was	O
passed	O
through	O
a	O
Bond	B
Elut	I
C18	I
column	O
and	O
then	O
the	O
column	O
was	O
washed	O
with	O
acetonitrile	B
–	O
Na2	B
HPO4	I
(	O
50	O
mM	O
)	O
(	O
1:9	O
,	O
v	O
/	O
v	O
,	O
800	O
μl	O
)	O
.	O

The	O
effluent	O
with	O
the	O
OPA	B
-	O
treated	O
mixture	O
and	O
the	O
washings	O
were	O
mixed	O
.	O

The	O
mixture	O
(	O
300	O
μl	O
)	O
was	O
reacted	O
with	O
DMS	B
-	I
Cl	I
(	O
2	O
mM	O
in	O
acetone	B
,	O
500	O
μl	O
)	O
at	O
70	O
°	O
C	O
for	O
20	O
min	O
.	O

The	O
reaction	O
mixture	O
was	O
mixed	O
with	O
dichloromethane	B
(	O
0.8	O
ml	O
)	O
and	O
Na2	B
CO3	I
(	O
0.1	O
M	O
,	O
30	O
μl	O
)	O
and	O
then	O
centrifuged	O
(	O
500	O
g	O
)	O
for	O
10	O
min	O
.	O

The	O
aqueous	B
layer	O
(	O
10	O
μl	O
)	O
was	O
subjected	O
to	O
HPLC	O
.	O

The	O
Bond	B
Elut	I
C18	I
column	O
was	O
used	O
at	O
least	O
20	O
times	O
by	O
washing	O
twice	O
sequentially	O
with	O
methanol	B
and	O
water	B
(	O
2	O
ml	O
each	O
)	O
after	O
each	O
use	O
.	O

2.4.2	O
Method	O
B	O
:	O
solvent	O
extraction	O
-	O
stripping	O
method	O
To	O
human	O
urine	O
(	O
20	O
μl	O
)	O
were	O
added	O
I.S.	B
(	O
10	O
μM	O
,	O
20	O
μl	O
)	O
,	O
Na2	B
HPO4	I
(	O
50	O
mM	O
,	O
260	O
μl	O
)	O
and	O
OPA	B
(	O
4	O
%	O
,	O
w	O
/	O
v	O
,	O
in	O
acetone	B
,	O
50	O
μl	O
)	O
.	O

After	O
standing	O
for	O
3	O
min	O
,	O
DMS	B
-	I
Cl	I
(	O
2	O
mM	O
in	O
acetone	B
,	O
450	O
μl	O
)	O
was	O
successively	O
added	O
and	O
mixed	O
.	O

The	O
mixture	O
was	O
allowed	O
to	O
stand	O
for	O
20	O
min	O
at	O
70	O
°	O
C	O
.	O

After	O
cooling	O
,	O
the	O
reaction	O
mixture	O
was	O
acidified	O
with	O
HCl	B
(	O
5	O
M	O
,	O
50	O
μl	O
)	O
,	O
saturated	O
with	O
NaCl	B
(	O
ca	O
.	O
150	O
mg	O
)	O
and	O
then	O
extracted	O
with	O
dichloromethane	B
(	O
1	O
ml	O
)	O
.	O

The	O
organic	O
layer	O
(	O
1	O
ml	O
)	O
was	O
mixed	O
with	O
Na2	B
CO3	I
(	O
10	O
mM	O
,	O
300	O
μl	O
)	O
and	O
then	O
centrifuged	O
(	O
500	O
g	O
)	O
for	O
10	O
min	O
.	O

The	O
aqueous	B
layer	O
(	O
10	O
μl	O
)	O
was	O
subjected	O
to	O
HPLC	O
.	O

3	O
Results	O
and	O
discussion	O
3.1	O
Chromatographic	O
separation	O
DMS	B
-	I
Cl	I
reacted	O
with	O
prolyl	B
dipeptides	I
in	O
a	O
basic	O
medium	O
to	O
give	O
the	O
corresponding	O
fluorescent	O
derivatives	O
(	O
Fig.	O
1	O
)	O
.	O

The	O
separation	O
of	O
the	O
derivatives	O
of	O
prolyl	B
dipeptides	I
(	O
16	O
species	O
)	O
,	O
Pro	B
,	O
Hyp	B
and	O
I.S.	O
labelled	O
with	O
DMS	B
-	I
Cl	I
were	O
examined	O
by	O
use	O
of	O
tandem	O
reversed	O
-	O
phase	O
columns	O
and	O
gradient	O
elution	O
.	O

A	O
typical	O
chromatogram	O
of	O
the	O
reaction	O
mixture	O
of	O
a	O
standard	O
solution	O
is	O
shown	O
in	O
Fig.	O
2	O
.	O

The	O
peaks	O
due	O
to	O
12	O
species	O
of	O
prolyl	B
dipeptides	I
(	O
retention	O
time	O
:	O
Pro	B
–	B
Asn	B
,	O
14.8	O
;	O
–Gln	B
,	O
16.2	O
;	O
–Hyp	O
,	O
17.1	O
;	O
–Glu	B
,	O
23.9	O
;	O
–Gly	B
,	O
27.0	O
;	O
–Ala	B
,	O
33.8	O
;	O
–Pro	B
,	O
35.0	O
;	O
–Tyr	B
,	O
37.7	O
;	O
–Met	B
,	O
42.1	O
;	O
–Val	B
,	O
43.7	O
;	O
–Trp	B
,	O
47.3	O
;	O
–Phe	B
,	O
49.1	O
min	O
)	O
,	O
Pro	B
(	O
34.4	O
min	O
)	O
,	O
Hyp	B
(	O
12.2	O
min	O
)	O
and	O
I.S.	B
(	O
31.0	O
min	O
)	O
were	O
separate	O
from	O
each	O
other	O
and	O
the	O
reagent	O
blank	O
components	O
,	O
although	O
the	O
peaks	O
due	O
to	O
Pro	B
–	I
Asp	I
(	O
18.6	O
min	O
)	O
and	O
Pro	B
–	I
Ser	I
(	O
18.7	O
min	O
)	O
and	O
those	O
due	O
to	O
Pro	B
–	I
Ile	I
(	O
47.9	O
min	O
)	O
and	O
Pro	B
–	I
Leu	I
(	O
48.0	O
min	O
)	O
overlapped	O
.	O

As	O
the	O
chromatographic	O
separation	O
of	O
DMS	B
derivatives	B
of	I
prolyl	I
dipeptides	I
,	O
Pro	B
,	O
Hyp	B
and	O
I.S.	B
was	O
affected	O
by	O
the	O
pH	O
in	O
the	O
mobile	O
phase	O
,	O
the	O
effect	O
of	O
the	O
pH	O
was	O
examined	O
using	O
acetate	B
buffer	I
[	O
10	O
mM	O
for	O
mobile	O
phase	O
(	O
A	O
)	O
and	O
50	O
mM	O
for	O
mobile	O
phase	O
(	O
B	O
)	O
,	O
pH	O
4.0–6.0	O
]	O
instead	O
of	O
acetic	B
acid	I
.	O

As	O
shown	O
in	O
Fig.	O
3	O
,	O
the	O
retention	O
times	O
of	O
all	O
peaks	O
became	O
shorter	O
with	O
increased	O
pH	O
and	O
the	O
prolyl	B
dipeptide	I
peaks	O
overlapped	O
at	O
pH	O
greater	O
than	O
pH	O
4.5	O
.	O

The	O
pH	O
of	O
acetic	B
acid	I
(	O
10	O
mM	O
)	O
in	O
mobile	O
phase	O
was	O
about	O
3.4	O
.	O

3.2	O
Labelling	O
reaction	O
conditions	O
A	O
standard	O
solution	O
of	O
prolyl	B
dipeptides	I
,	O
Pro	B
and	O
Hyp	B
(	O
10	O
μM	O
each	O
)	O
was	O
used	O
to	O
determine	O
the	O
optimum	O
labelling	O
conditions	O
.	O

The	O
reaction	O
of	O
Hyp	B
with	O
DMS	B
-	I
Cl	I
was	O
complete	O
within	O
5	O
min	O
regardless	O
of	O
the	O
temperature	O
(	O
labelling	O
yield	O
:	O
99.7	O
%	O
)	O
[	O
19	O
]	O
.	O

However	O
,	O
the	O
labelling	O
reactions	O
of	O
prolyl	B
dipeptides	I
with	O
DMS	B
-	I
Cl	I
were	O
incomplete	O
under	O
the	O
above	O
conditions	O
,	O
while	O
the	O
reactions	O
of	O
Pro	B
and	O
I.S.	B
with	O
DMS	B
-	I
Cl	I
were	O
similar	O
to	O
that	O
of	O
Hyp	B
.	O

Therefore	O
,	O
the	O
effect	O
of	O
the	O
reaction	O
time	O
on	O
the	O
labelling	O
reaction	O
was	O
examined	O
at	O
various	O
temperatures	O
.	O

The	O
results	O
obtained	O
for	O
Pro	B
–	I
Hyp	I
are	O
shown	O
in	O
Fig.	O
4	O
.	O

The	O
maximum	O
peak	O
area	O
was	O
obtained	O
from	O
the	O
reactions	O
performed	O
at	O
above	O
70	O
°	O
C	O
,	O
for	O
10	O
min	O
.	O

Similar	O
results	O
were	O
obtained	O
from	O
other	O
prolyl	B
dipeptides	I
.	O

Consequently	O
,	O
subsequent	O
labelling	O
reactions	O
for	O
prolyl	B
dipeptides	I
,	O
Pro	B
,	O
Hyp	B
and	O
I.S.	B
with	O
DMS	B
-	I
Cl	I
were	O
carried	O
out	O
at	O
70	O
°	O
C	O
for	O
20	O
min	O
.	O

The	O
reaction	O
mixture	O
was	O
stable	O
for	O
at	O
least	O
48	O
h	O
at	O
room	O
temperature	O
.	O

As	O
the	O
labelling	O
reaction	O
of	O
prolyl	B
dipeptides	I
,	O
Pro	B
,	O
Hyp	B
and	O
I.S.	B
with	O
DMS	B
-	I
Cl	I
proceeded	O
in	O
a	O
basic	O
medium	O
,	O
the	O
effect	O
of	O
the	O
pH	O
of	O
phosphate	B
buffer	I
(	O
50	O
mM	O
)	O
on	O
the	O
labelling	O
reaction	O
was	O
examined	O
.	O

The	O
results	O
for	O
Pro	B
–	I
Hyp	I
,	O
Pro	B
–	I
Gly	I
,	O
Pro	B
–	I
Pro	I
and	O
I.S.	B
are	O
shown	O
in	O
Fig.	O
5	O
.	O

Each	O
peak	O
exhibited	O
a	O
maximum	O
and	O
constant	O
area	O
in	O
the	O
range	O
of	O
pH	O
8–10	O
.	O

Similar	O
results	O
were	O
obtained	O
from	O
other	O
prolyl	B
dipeptides	I
,	O
Pro	B
and	O
Hyp	B
.	O

The	O
effect	O
of	O
the	O
anionic	O
component	O
of	O
the	O
buffer	O
solution	O
was	O
also	O
examined	O
using	O
acetate	B
,	O
borate	B
and	O
phosphate	B
buffer	I
(	O
50	O
mM	O
,	O
pH	O
8)	O
.	O

The	O
maximum	O
peak	O
areas	O
of	O
prolyl	B
dipeptides	I
were	O
obtained	O
in	O
phosphate	B
buffer	I
(	O
peak	O
area	O
relative	O
to	O
phosphate	B
buffer	I
:	O
acetate	B
buffer	I
,	I
75–98	O
%	O
;	O
borate	B
buffer	I
,	O
91–100	O
%	O
except	O
61	O
%	O
for	O
Pro	B
–	I
Tyr	I
)	O
.	O

Therefore	O
,	O
Na2	B
HPO4	I
(	O
50	O
mM	O
,	O
pH	O
ca	O
.	O

9.3	O
)	O
was	O
adopted	O
.	O

When	O
the	O
effect	O
of	O
the	O
concentration	O
of	O
Na2	B
HPO4	I
(	O
10–100	O
mM	O
)	O
was	O
examined	O
,	O
the	O
maximum	O
and	O
constant	O
peak	O
areas	O
were	O
obtained	O
at	O
a	O
concentration	O
of	O
more	O
than	O
25	O
mM	O
.	O

The	O
concentration	O
of	O
DMS	B
-	I
Cl	I
was	O
determined	O
by	O
the	O
peak	O
areas	O
due	O
to	O
prolyl	O
dipeptides	B
,	O
Pro	B
and	O
Hyp	B
(	O
100	O
μM	O
each	O
)	O
.	O

The	O
maximum	O
peak	O
areas	O
were	O
obtained	O
at	O
more	O
than	O
1.5	O
mM	O
DMS	B
-	I
Cl	I
.	O

Dichloromethane	B
extraction	O
was	O
carried	O
out	O
to	O
remove	O
excess	O
DMS	B
-	I
Cl	I
,	O
which	O
was	O
suspected	O
of	O
causing	O
the	O
guard	O
column	O
to	O
degrade	O
.	O

The	O
extraction	O
was	O
achieved	O
after	O
addition	O
of	O
Na2	B
CO3	I
(	O
0.1	O
M	O
,	O
30	O
μl	O
)	O
because	O
parts	O
of	O
the	O
derivatives	B
of	I
prolyl	I
dipeptides	I
that	O
eluted	O
after	O
the	O
derivatives	B
of	I
Pro	I
–	I
Ala	I
on	O
the	O
HPLC	O
column	O
were	O
lost	O
with	O
dichloromethane	B
extraction	O
without	O
Na2	B
CO3	I
.	O

3.3	O
Linearity	O
and	O
detection	O
limit	O
Linearity	O
was	O
studied	O
over	O
wide	O
ranges	O
of	O
concentration	O
of	O
prolyl	B
dipeptides	I
,	O
Pro	B
and	O
Hyp	B
(	O
between	O
0.1	O
and	O
100	O
μM	O
each	O
)	O
.	O

The	O
peak	O
-	O
area	O
ratios	O
of	O
analytes	O
to	O
I.S.	B
were	O
linear	O
in	O
the	O
concentration	O
ranges	O
investigated	O
(	O
r	O
>	O
0.999	O
each	O
)	O
.	O

When	O
the	O
precision	O
was	O
tested	O
using	O
standard	O
solutions	O
(	O
1	O
,	O
10	O
and	O
100	O
μM	O
each	O
)	O
,	O
the	O
relative	O
standard	O
deviations	O
(	O
RSDs	O
,	O
n	O
=	O
10	O
)	O
were	O
less	O
than	O
4.1	O
%	O
.	O

The	O
detection	O
limits	O
(	O
S	O
/	O
N=3	O
)	O
for	O
prolyl	B
dipeptides	I
were	O
1–5	O
fmol	O
/	O
injection	O
.	O

3.4	O
Pretreatment	O
of	O
urine	O
and	O
HPLC	O
chromatograms	O
For	O
determination	O
of	O
urinary	O
prolyl	B
dipeptides	I
,	O
Pro	B
and	O
Hyp	B
by	O
pre	O
-	O
column	O
HPLC	O
,	O
OPA	B
treatment	O
[	O
20	O
]	O
was	O
employed	O
to	O
eliminate	O
primary	B
amino	I
compounds	I
coexisting	O
with	O
analytes	O
in	O
urine	O
.	O

However	O
,	O
the	O
reaction	O
mixture	O
of	O
urine	O
with	O
OPA	B
was	O
colored	O
darkly	O
.	O

Therefore	O
,	O
two	O
methods	O
,	O
method	O
A	O
(	O
solid	O
-	O
phase	O
extraction	O
)	O
and	O
method	O
B	O
(	O
solvent	O
extraction	O
-	O
stripping	O
)	O
described	O
in	O
Section	O
2.4	O
were	O
tested	O
to	O
remove	O
the	O
colored	O
products	O
.	O

The	O
colored	O
products	O
were	O
retained	O
on	O
the	O
Bond	B
Elut	I
C18	I
column	O
in	O
method	O
A	O
and	O
were	O
not	O
extracted	O
with	O
dichloromethane	B
at	O
acidic	O
pH	O
in	O
method	O
B.	O
The	O
typical	O
chromatograms	O
of	O
a	O
standard	O
solution	O
and	O
urine	O
obtained	O
according	O
to	O
the	O
procedures	O
of	O
methods	O
A	O
and	O
B	O
are	O
shown	O
in	O
Fig.	O
6A	O
and	O
B	O
and	O
Fig.	O
7A	O
and	O
B	O
,	O
respectively	O
.	O

As	O
shown	O
in	O
Fig.	O
6A	O
,	O
some	O
prolyldipeptides	B
(	O
Pro	B
–	B
Tyr	I
,	O
–Val	B
,	O
–Met	B
,	O
–Trp	B
,	O
–Ile	B
,	O
–Leu	B
and	O
–Phe	B
)	O
were	O
unable	O
to	O
be	O
measured	O
by	O
method	O
A	O
,	O
because	O
these	O
peptides	B
were	O
retained	O
on	O
the	O
Bond	B
Elut	I
C18	I
column	O
under	O
the	O
conditions	O
used	O
.	O

When	O
urine	O
was	O
analyzed	O
by	O
method	O
A	O
,	O
peaks	O
due	O
to	O
Pro	B
–	I
Hyp	I
,	O
Pro	B
–	I
Gly	I
,	O
Pro	B
–	I
Pro	I
,	O
Pro	B
and	O
Hyp	B
at	O
retention	O
times	O
of	O
17.1	O
,	O
27.0	O
,	O
35.0	O
,	O
34.3	O
and	O
12.2	O
min	O
,	O
respectively	O
,	O
were	O
observed	O
(	O
Fig.	O
6B	O
)	O
.	O

In	O
contrast	O
,	O
for	O
method	O
B	O
,	O
all	O
prolyl	B
dipeptides	I
in	O
a	O
standard	O
solution	O
were	O
detected	O
(	O
Fig.	O
7A	O
)	O
.	O

However	O
,	O
the	O
seven	O
prolyl	B
dipeptides	I
that	O
could	O
not	O
be	O
measured	O
by	O
method	O
A	O
were	O
not	O
recognized	O
in	O
urine	O
(	O
Fig.	O
7B	O
)	O
,	O
although	O
the	O
three	O
prolyl	B
dipeptides	I
mentioned	O
above	O
were	O
recognized	O
in	O
urine	O
.	O

Despite	O
these	O
issues	O
,	O
urinary	O
Pro	B
–	I
Hyp	I
,	O
Pro	B
–	I
Gly	I
,	O
Pro	B
–	I
Pro	I
,	O
Pro	B
,	O
Hyp	B
and	O
I.S.	B
were	O
separated	O
from	O
the	O
reagent	O
blank	O
and	O
other	O
urinary	O
components	O
(	O
Figs.	O
6B	O
and	O
7B	O
)	O
.	O

These	O
urinary	O
analytes	O
were	O
identified	O
by	O
comparing	O
the	O
retention	O
times	O
with	O
those	O
of	O
standard	O
solutions	O
and	O
also	O
by	O
co	O
-	O
chromatography	O
of	O
a	O
standard	O
solution	O
and	O
urine	O
.	O

3.5	O
Recovery	O
and	O
precision	O
Recovery	O
tests	O
were	O
examined	O
by	O
means	O
of	O
both	O
methods	O
using	O
three	O
urine	O
samples	O
spiked	O
with	O
various	O
amounts	O
of	O
standard	O
Pro	B
–	I
Hyp	I
(	O
urinary	O
concentration	O
:	O
25	O
,	O
50	O
,	O
100	O
,	O
250	O
and	O
500	O
μM	O
)	O
,	O
Pro	B
–	I
Gly	I
,	O
Pro	B
–	I
Pro	I
,	O
Hyp	B
(	O
0.5	O
,	O
1	O
,	O
2	O
,	O
5	O
and	O
10	O
μM	O
each	O
)	O
and	O
Pro	B
(	O
1	O
,	O
2	O
,	O
4	O
,	O
10	O
and	O
20	O
μM	O
)	O
.	O

The	O
relationships	O
between	O
the	O
peak	O
-	O
area	O
ratios	O
of	O
analytes	O
to	O
I.S.	B
and	O
the	O
concentrations	O
of	O
analytes	O
were	O
linear	O
.	O

According	O
to	O
method	O
A	O
,	O
the	O
regression	O
equations	O
for	O
standard	O
solutions	O
without	O
urine	O
were	O
y	O
=	O
0.1300x	O
+	O
0.1183	O
(	O
r	O
=	O
0.9999	O
)	O
for	O
Pro	B
–	I
Hyp	I
,	O
y	O
=	O
0.1384x	O
−0.0001	O
(	O
r	O
=	O
0.9999	O
)	O
for	O
Pro	B
–	I
Gly	I
,	O
y	O
=	O
0.1069x	O
+	O
0.0020	O
(	O
r	O
=	O
0.9998	O
)	O
for	O
Pro	B
–	I
Pro	I
,	O
y	O
=	O
0.1135x	O
+	O
0.0735	O
(	O
r	O
=	O
0.9994	O
)	O
for	O
Pro	B
and	O
y	O
=	O
0.1140x	O
+	O
0.0066	O
(	O
r	O
=	O
0.9996	O
)	O
for	O
Hyp	B
,	O
where	O
y	O
is	O
the	O
peak	O
-	O
area	O
ratio	O
of	O
analyte	O
to	O
I.S.	B
and	O
x	O
is	O
the	O
concentration	O
of	O
analyte	O
(	O
μM	O
)	O
.	O

The	O
recoveries	O
were	O
obtained	O
from	O
the	O
slope	O
ratios	O
of	O
regression	O
equations	O
of	O
analytes	O
with	O
/	O
without	O
urine	O
.	O

The	O
slopes	O
of	O
regression	O
equations	O
and	O
the	O
recoveries	O
by	O
methods	O
A	O
and	O
B	O
are	O
shown	O
in	O
Table	O
1	O
.	O

The	O
recoveries	O
of	O
the	O
analytes	O
except	O
Pro	B
–	I
Gly	I
by	O
method	O
A	O
were	O
almost	O
100	O
%	O
,	O
while	O
those	O
by	O
method	O
B	O
were	O
very	O
low	O
.	O

In	O
method	O
B	O
,	O
some	O
organic	O
solvents	O
such	O
as	O
chloroform	B
,	O
benzene	B
,	O
ethyl	B
acetate	I
and	O
diethyl	B
ether	I
instead	O
of	O
dichloromethane	B
were	O
also	O
used	O
.	O

However	O
,	O
the	O
maximum	O
peak	O
areas	O
of	O
DMS	B
-	B
derivatives	I
were	O
obtained	O
with	O
use	O
of	O
dichloromethane	B
.	O

In	O
addition	O
,	O
when	O
the	O
concentration	O
of	O
Na2	B
CO3	I
(	O
1	O
,	O
5	O
,	O
10	O
and	O
20	O
mM	O
)	O
for	O
stripping	O
of	O
the	O
derivatives	B
of	I
prolyl	I
dipeptides	I
was	O
examined	O
,	O
maximum	O
peak	O
areas	O
were	O
obtained	O
by	O
use	O
of	O
more	O
than	O
5	O
mM	O
Na2	B
CO3	I
.	O

These	O
results	O
suggest	O
that	O
method	O
A	O
is	O
appropriate	O
for	O
the	O
determination	O
of	O
urinary	O
prolyl	B
dipeptides	I
.	O

Incidentally	O
,	O
when	O
the	O
recoveries	O
of	O
standard	O
prolyl	B
dipeptides	I
,	O
Pro	B
,	O
Hyp	B
(	O
0.02	O
,	O
0.2	O
,	O
2	O
and	O
10	O
nmol	O
each	O
)	O
and	O
I.S.	B
from	O
Bond	B
Elut	I
C18	I
were	O
examined	O
,	O
the	O
recoveries	O
were	O
96.1–101.1	O
%	O
(	O
except	O
the	O
seven	O
species	O
prolyl	B
dipeptides	I
mentioned	O
above	O
)	O
.	O

Therefore	O
,	O
for	O
determination	O
of	O
urinary	O
prolyl	B
dipeptides	I
,	O
Pro	B
and	O
Hyp	B
,	O
method	O
A	O
was	O
employed	O
and	O
the	O
regression	O
equations	O
in	O
water	B
described	O
above	O
were	O
used	O
.	O

However	O
,	O
the	O
estimated	O
values	O
of	O
urinary	O
Pro	B
–	I
Gly	I
were	O
corrected	O
using	O
the	O
mean	O
value	O
(	O
0.866	O
,	O
n	O
=	O
6	O
)	O
of	O
recovery	O
derived	O
from	O
additional	O
experiments	O
using	O
another	O
three	O
urine	O
samples	O
(	O
the	O
recoveries	O
:	O
85.8	O
,	O
85.9	O
and	O
86.8	O
%	O
)	O
.	O

The	O
within	O
-	O
day	O
and	O
between	O
-	O
day	O
precisions	O
of	O
method	O
A	O
were	O
evaluated	O
using	O
three	O
urine	O
samples	O
.	O

The	O
within	O
-	O
day	O
precision	O
was	O
examined	O
with	O
ten	O
replicate	O
assays	O
in	O
each	O
one	O
day	O
and	O
the	O
between	O
-	O
day	O
precision	O
by	O
assays	O
on	O
five	O
different	O
days	O
.	O

As	O
shown	O
in	O
Table	O
2	O
,	O
RSDs	O
of	O
the	O
within	O
-	O
day	O
and	O
between	O
-	O
day	O
precisions	O
were	O
1.5–4.8	O
and	O
1.7–5.8	O
%	O
,	O
respectively	O
.	O

3.6	O
Selection	O
of	O
I.S.	O
Some	O
secondary	B
amino	I
acids	I
(	O
10	O
μM	O
each	O
)	O
were	O
examined	O
to	O
select	O
I.S.	B
Although	O
the	O
peaks	O
due	O
to	O
l	B
-azetidine-2-calboxylic	I
acid	I
,	O
l	B
-thioproline	I
,	O
isonipecotic	B
acid	I
,	O
nipecotic	B
acid	I
and	O
dl	B
-pipecolic	I
acid	I
were	O
eluted	O
at	O
23.0	O
,	O
34.7	O
,	O
36.9	O
,	O
39.9	O
and	O
42.0	O
min	O
,	O
respectively	O
,	O
those	O
peaks	O
overlapped	O
with	O
peaks	O
due	O
to	O
urinary	O
components	O
.	O

The	O
peak	O
due	O
to	O
3,4-dehydro	B
-	I
dl	I
-proline	I
(	O
31.0	O
min	O
)	O
was	O
successfully	O
separated	O
from	O
those	O
of	O
urinary	O
components	O
.	O

3.7	O
Influence	O
of	O
amino	B
acids	I
The	O
influence	O
of	O
amino	B
acids	I
on	O
determination	O
of	O
prolyl	B
dipeptides	I
,	O
Pro	B
and	O
Hyp	B
by	O
method	O
A	O
was	O
examined	O
with	O
urine	O
spiked	O
with	O
25	O
species	O
of	O
primary	B
amino	I
acids	I
(	O
Ala	B
,	O
Arg	B
,	O
Asp	B
,	O
Asn	B
,	O
Cit	B
,	O
Cys	B
,	O
Cys	B
–	I
Cys	I
,	O
Glu	B
,	O
Gln	B
,	O
Gly	B
,	O
His	B
,	O
Hse	B
,	O
Ile	B
,	O
Leu	B
,	O
Lys	B
,	O
Met	B
,	O
Orn	B
,	O
Phe	B
,	O
Ser	B
,	O
Thr	B
,	O
Trp	B
,	O
Tyr	B
,	O
Val	B
,	O
γ	B
-	I
aminobutyric	I
acid	I
and	O
ϵ-aminocaproic	B
acid	I
,	O
5	O
nmol	O
each	O
)	O
.	O

These	O
amino	B
acids	I
did	O
not	O
interfere	O
with	O
the	O
determination	O
of	O
Pro	B
–	I
Hyp	I
,	O
Pro	B
–	I
Gly	I
,	O
Pro	B
–	I
Pro	I
,	O
Pro	B
and	O
Hyp	B
.	O

3.8	O
Determination	O
of	O
urinary	O
prolyl	B
dipeptides	I
,	O
Pro	B
and	O
Hyp	B
The	O
concentrations	O
of	O
prolyl	B
dipeptides	I
,	O
Pro	B
and	O
Hyp	B
in	O
urine	O
from	O
ten	O
healthy	O
volunteers	O
(	O
Japanese	O
staff	O
and	O
students	O
in	O
our	O
laboratory	O
)	O
who	O
were	O
eating	O
self	O
-	O
selected	O
diets	O
were	O
measured	O
by	O
method	O
A.	O
Overnight	O
urine	O
was	O
collected	O
in	O
the	O
early	O
morning	O
and	O
stored	O
at	O
−20	O
°	O
C	O
until	O
use	O
.	O

The	O
concentrations	O
of	O
urinary	O
prolyl	B
dipeptides	I
,	O
Pro	B
and	O
Hyp	B
are	O
given	O
in	O
Table	O
3	O
.	O

The	O
mean	O
values	O
(	O
mean±SD	O
)	O
of	O
urinary	O
Pro	B
–	I
Hyp	I
,	O
Pro	B
–	I
Gly	I
,	O
Pro	B
–	I
Pro	I
,	O
Pro	B
and	O
Hyp	B
were	O
97.6±28.2	O
,	O
2.74±1.48	O
,	O
2.08±1.13	O
,	O
6.71±3.34	O
and	O
2.30±1.59	O
nmol	O
/	O
mg	O
creatinine	B
,	O
respectively	O
.	O

When	O
the	O
concentration	O
of	O
Hyp	B
in	O
hydrolysed	O
urine	O
(	O
total	O
Hyp	B
)	O
was	O
measured	O
according	O
to	O
the	O
method	O
reported	O
previously	O
[	O
20	O
]	O
,	O
the	O
concentration	O
ratios	O
(	O
%	O
,	O
mean±SD	O
)	O
of	O
Pro	B
–	I
Hyp	I
and	O
free	O
Hyp	B
to	O
total	O
Hyp	B
were	O
45.7–64.5	O
%	O
(	O
53.1±6.7	O
%	O
)	O
and	O
0.4–2.2	O
%	O
(	O
1.3±0.7	O
%	O
)	O
,	O
respectively	O
.	O

These	O
values	O
were	O
similar	O
to	O
the	O
values	O
reported	O
previously	O
[	O
2,3,19	O
]	O
.	O

The	O
proposed	O
method	O
for	O
the	O
determination	O
of	O
prolyl	B
dipeptides	I
,	O
Pro	B
and	O
Hyp	B
in	O
urine	O
is	O
highly	O
sensitive	O
and	O
reliable	O
.	O

As	O
the	O
sensitive	O
and	O
reliable	O
determination	O
of	O
these	O
components	O
can	O
provide	O
useful	O
information	O
for	O
diagnosis	O
and	O
prognosis	O
of	O
diseases	O
,	O
the	O
proposed	O
method	O
may	O
be	O
useful	O
for	O
biochemical	O
and	O
clinical	O
research	O
.	O

Further	O
clinical	O
research	O
including	O
a	O
determination	O
of	O
bone	O
metastasis	O
stages	O
in	O
cancer	O
patients	O
is	O
now	O
progressing	O
in	O
our	O
laboratories	O
.	O

The	O
eight	O
enzymes	O
of	O
the	O
tricarboxylic	B
acid	I
(	O
TCA	B
)	O
cycle	O
are	O
encoded	O
by	O
at	O
least	O
15	O
different	O
nuclear	O
genes	O
in	O
Saccharomyces	O
cerevisiae	O
.	O

We	O
have	O
constructed	O
a	O
set	O
of	O
yeast	O
strains	O
defective	O
in	O
these	O
genes	O
as	O
part	O
of	O
a	O
comprehensive	O
analysis	O
of	O
the	O
interactions	O
among	O
the	O
TCA	B
cycle	O
proteins	O
.	O

The	O
15	O
major	O
TCA	B
cycle	O
genes	O
can	O
be	O
sorted	O
into	O
five	O
phenotypic	O
categories	O
on	O
the	O
basis	O
of	O
their	O
growth	O
on	O
nonfermentable	O
carbon	B
sources	O
.	O

We	O
have	O
previously	O
reported	O
a	O
novel	O
phenotype	O
associated	O
with	O
mutants	O
defective	O
in	O
the	O
IDH2	O
gene	O
encoding	O
the	O
Idh2p	O
subunit	O
of	O
the	O
NAD+-dependent	O
isocitrate	O
dehydrogenase	O
(	O
NAD	O
-	O
IDH	O
)	O
.	O

Null	O
and	O
nonsense	O
idh2	O
mutants	O
grow	O
poorly	O
on	O
glycerol	B
,	O
but	O
growth	O
can	O
be	O
enhanced	O
by	O
extragenic	O
mutations	O
,	O
termed	O
glycerol	B
suppressors	O
,	O
in	O
the	O
CIT1	O
gene	O
encoding	O
the	O
TCA	O
cycle	O
citrate	O
synthase	O
and	O
in	O
other	O
genes	O
of	O
oxidative	O
metabolism	O
.	O

The	O
TCA	B
cycle	O
mutant	O
collection	O
was	O
utilized	O
to	O
search	O
for	O
other	O
genes	O
that	O
can	O
suppress	O
idh2	O
mutants	O
and	O
to	O
identify	O
TCA	B
cycle	O
genes	O
that	O
display	O
a	O
similar	O
suppressible	O
growth	O
phenotype	O
on	O
glycerol	B
.	O

Mutations	O
in	O
7	O
TCA	B
cycle	O
genes	O
were	O
capable	O
of	O
functioning	O
as	O
suppressors	O
for	O
growth	O
of	O
idh2	O
mutants	O
on	O
glycerol	B
.	O

The	O
only	O
other	O
TCA	B
cycle	O
gene	O
to	O
display	O
the	O
glycerol	B
-	O
suppressor	O
-	O
accumulation	O
phenotype	O
was	O
IDH1	O
,	O
which	O
encodes	O
the	O
companion	O
Idh1p	O
subunit	O
of	O
NAD	O
-	O
IDH	O
.	O

These	O
results	O
provide	O
genetic	O
evidence	O
that	O
NAD	O
-	O
IDH	O
plays	O
a	O
unique	O
role	O
in	O
TCA	B
cycle	O
function	O
.	O

A	O
mixture	O
of	O
oligosaccharides	B
produced	O
by	O
beta	O
-	O
galactosidase	O
using	O
lactose	B
as	O
a	O
substrate	O
was	O
fractionated	O
according	O
to	O
degree	O
of	O
polymerization	O
using	O
gel	O
filtration	O
,	O
followed	O
by	O
high	O
-	O
pH	O
anion	O
-	O
exchange	O
chromatography	O
.	O

The	O
fractions	O
obtained	O
were	O
analyzed	O
using	O
monosaccharide	B
analysis	O
,	O
methylation	O
analysis	O
,	O
mass	O
spectrometry	O
,	O
and	O
NMR	O
spectroscopy	O
.	O

Twelve	O
novel	O
non	O
-	O
reducing	O
oligosaccharides	O
were	O
characterized	O
,	O
namely	O
,	O
[	B
beta	I
-	I
D	I
-	I
Galp-	I
(	I
1	I
-	I
->4	I
)	I
]	I
n	I
-	I
alpha	I
-	I
D	I
-	I
Glcp-	I
(	I
1<-->1	I
)	I
-beta	I
-	I
D	I
-	I
Galp	I
[	I
-	I
(	I
4<--1	I
)	I
-beta	I
-	I
D	I
-	I
Galp	I
]	I
m	I
,	O
with	O
n	O
,	O
m	O
=	O
(	O
1	O
,	O
2	O
,	O
3	O
,	O
or	O
4	O
)	O
and	O
beta	B
-	I
D	I
-	I
Galp-	I
(	I
1	I
-	I
->2	I
)	I
-alpha	I
-	I
D	I
-	I
Glcp-	I
(	I
1<-->1	I
)	I
-beta	I
-	I
D	I
-	I
Galp	I
.	I

Concentration	O
of	O
L	B
-	I
cystathionine	I
was	O
distinctly	O
increased	O
in	O
rabbit	O
brain	O
within	O
the	O
period	O
of	O
maximal	O
action	O
of	O
drugs	B
,	O
stimulating	O
the	O
central	O
nervous	O
system	O
(	O
phenamine	B
,	O
strychnine	B
corasole	B
)	O
.	O

A	O
distinct	O
decrease	O
in	O
content	O
of	O
L	B
-	I
cystathionine	I
was	O
observed	O
within	O
one	O
hour	O
after	O
the	O
administration	O
of	O
strychnine	B
and	O
corasole	B
.	O

Lactosylceramide	O
synthase	O
is	O
an	O
enzyme	O
that	O
catalyzes	O
the	O
transfer	O
of	O
galactose	B
from	O
UDP	B
-	I
Gal	I
to	O
glucosylceramide	B
,	O
and	O
thus	O
participates	O
in	O
the	O
biosynthesis	O
of	O
most	O
glycolipids	B
in	O
mammals	O
.	O

We	O
have	O
isolated	O
and	O
sequenced	O
the	O
cDNA	O
clone	O
encoding	O
human	O
lactosylceramide	O
synthase	O
.	O

The	O
deduced	O
amino	B
acid	I
sequence	O
of	O
the	O
human	O
lactosylceramide	O
synthase	O
showed	O
94.2	O
%	O
identity	O
with	O
rat	O
lactosylceramide	O
synthase	O
.	O

Northern	O
blotting	O
analysis	O
revealed	O
that	O
lactosylceramide	O
synthase	O
mRNA	O
was	O
expressed	O
in	O
various	O
tissues	O
,	O
with	O
the	O
highest	O
level	O
in	O
brain	O
and	O
adrenal	O
gland	O
.	O

Microsomal	O
cytochrome	O
P450-dependent	O
lauric	O
acid	O
hydroxylase	O
activities	O
were	O
characterized	O
in	O
liver	O
,	O
kidney	O
,	O
and	O
intestinal	O
mucosa	O
of	O
the	O
sea	O
bass	O
(	O
Dicentrarchus	O
labrax	O
)	O
.	O

Microsomes	O
from	O
these	O
organs	O
generated	O
(	B
omega-1	I
)	I
-hydroxylauric	I
acid	I
and	O
a	O
mixture	O
of	O
positional	O
isomers	O
including	O
(	B
omega	I
)	I
-	I
,	O
(	B
omega-2	I
)	I
-	I
,	O
(	B
omega-3	I
)	I
-	I
and	O
(	B
omega-4	I
)	I
-hydroxylauric	I
acids	I
,	O
which	O
were	O
identified	O
by	O
RP	O
-	O
HPLC	O
and	O
GC	O
-	O
MS	O
analysis	O
.	O

Peroxisome	O
proliferators	O
,	O
such	O
as	O
clofibrate	B
and	O
especially	O
di	B
(	I
2-ethylhexyl	I
)	I
phthalate	I
,	O
increased	O
kidney	O
microsomal	O
lauric	O
acid	O
hydroxylase	O
activities	O
.	O

The	O
synthesis	O
of	O
11-hydroxylauric	B
acid	I
was	O
enhanced	O
5.3-fold	O
in	O
kidney	O
microsomes	O
.	O

Liver	O
microsomal	O
lauric	O
acid	O
hydroxylase	O
activities	O
were	O
weakly	O
affected	O
and	O
no	O
significant	O
induction	O
was	O
found	O
in	O
small	O
intestine	O
microsomes	O
from	O
clofibrate	B
or	O
di	B
(	I
2-ethylhexyl	I
)	I
phthalate	I
-	O
treated	O
fish	O
.	O

The	O
differences	O
in	O
lauric	B
acid	I
metabolisation	O
and	O
the	O
tissue	O
-	O
specific	O
induction	O
by	O
peroxisome	O
proliferators	O
suggest	O
the	O
involvement	O
of	O
several	O
P450s	O
in	O
this	O
reaction	O
.	O

Incubations	O
of	O
liver	O
and	O
kidney	O
microsomes	O
with	O
lauric	B
acid	I
analogues	B
(	O
11-	B
or	O
10-dodecynoic	B
acids	I
)	O
resulted	O
in	O
a	O
time-	O
and	O
concentration	O
-	O
dependent	O
loss	O
of	O
lauric	O
acid	O
hydroxylase	O
activities	O
.	O

The	O
induction	O
of	O
these	O
activities	O
in	O
fish	O
by	O
phthalates	B
,	O
which	O
are	O
widely	O
-	O
distributed	O
environmental	O
pollutants	O
,	O
may	O
be	O
taken	O
into	O
consideration	O
for	O
the	O
development	O
of	O
new	O
biomarkers	O
.	O

6-Chloro-7-arylamino-5,8-isoquinolinediones	B
were	O
newly	O
synthesized	O
and	O
evaluated	O
for	O
in	O
vitro	O
cytotoxic	O
activities	O
against	O
five	O
human	O
solid	O
tumor	O
cell	O
lines	O
.	O

Among	O
them	O
,	O
5b	B
,	O
5c	B
and	O
5d	B
exhibited	O
potent	O
activities	O
against	O
the	O
cell	O
lines	O
HCT-15	O
and	O
SK	O
-	O
MEL-2	O
.	O

We	O
developed	O
a	O
novel	O
fluorometric	O
assay	O
method	O
for	O
the	O
measurement	O
of	O
glycosyltransferase	O
activities	O
using	O
mono-	B
and	O
di	B
-	I
saccharides	I
aminated	O
and	O
tagged	O
with	O
7-hydroxycoumarin-3-carboxylic	B
acid	I
(	O
coumarin	B
)	O
as	O
substrates	O
,	O
N	B
-	I
acetylglucosamine	I
(	O
GlcNAc	B
)	O
-coumarin	B
for	O
beta1,4-galactosyltransferase	O
from	O
bovine	O
milk	O
and	O
Gal	B
beta1	I
-	I
4GlcNAc	I
-	I
coumarin	I
for	O
alpha2,3-	O
and	O
alpha2,6-sialyltransferases	O
from	O
rat	O
liver	O
.	O

Using	O
Gal	B
beta1	I
-	I
3GlcNAc	I
and	O
Gal	B
beta1	I
-	I
4Glc	I
-	I
NAc	I
-	I
coumarin	I
,	O
alpha1,3	O
/	O
4-	O
and	O
alpha1,3-fucosyltransferase	O
activities	O
were	O
also	O
determined	O
,	O
respectively	O
.	O

These	O
enzymatic	O
products	O
liberated	O
by	O
the	O
reactions	O
of	O
glycosyltransferases	O
in	O
the	O
presence	O
of	O
sugar	B
nucleotides	I
,	O
were	O
separated	O
by	O
a	O
normal	O
phase	O
or	O
an	O
ion	O
-	O
pair	O
reversed	O
phase	O
HPLC	O
with	O
an	O
isocratic	O
elution	O
and	O
fluorescence	O
detection	O
.	O

We	O
applied	O
this	O
assay	O
method	O
to	O
determine	O
the	O
glycosyltransferase	O
activities	O
in	O
8	O
kinds	O
of	O
human	O
tumor	O
cell	O
lines	O
,	O
including	O
the	O
cell	O
lines	O
derived	O
from	O
hepatocytes	O
(	O
HuH-7	O
,	O
HepG2	O
)	O
,	O
colonic	O
cells	O
(	O
Colo205	O
,	O
HT-29	O
)	O
,	O
myelocytes	O
(	O
HL-60	O
,	O
U-937	O
)	O
,	O
B	O
-	O
lymphocytes	O
(	O
Daudi	O
)	O
and	O
T	O
-	O
lymphocytes	O
(	O
Jurkat	O
)	O
.	O

This	O
assay	O
method	O
is	O
accurate	O
and	O
easy	O
compared	O
with	O
other	O
isotopic	O
and	O
non	O
-	O
isotopic	O
assay	O
methods	O
,	O
and	O
is	O
sensitive	O
enough	O
to	O
measure	O
glycosyltransferase	O
activities	O
in	O
cell	O
homogenates	O
.	O

Anandamide	B
(	O
N	B
-	I
arachidonoylethanolamine	I
)	O
and	O
six	O
fatty	B
acid	I
ethanolamides	I
were	O
synthesized	O
and	O
their	O
pharmacological	O
effects	O
in	O
mice	O
were	O
assessed	O
using	O
catalepsy	O
,	O
hypothermia	O
and	O
pentobarbital	B
-	O
induced	O
sleep	O
prolongation	O
as	O
indices	O
.	O

The	O
effects	O
of	O
phenylmethylsulfonyl	B
fluoride	I
(	O
PMSF	B
)	O
pretreatment	O
on	O
anandamide	B
effects	O
were	O
also	O
evaluated	O
and	O
discussed	O
in	O
relation	O
to	O
inhibition	O
of	O
anandamide	O
amidohydrolase	O
in	O
mouse	O
brain	O
and	O
liver	O
.	O

The	O
cataleptogenic	O
effect	O
of	O
anandamide	B
(	O
ED50=6.0	O
mg	O
/	O
kg	O
,	O
i.v	O
.	O
)	O
was	O
4	O
to	O
6	O
times	O
more	O
active	O
than	O
those	O
of	O
N	B
-	I
oleoyl-	I
(	O
ED50=26.5	O
mg	O
/	O
kg	O
,	O
i.v	O
.	O
)	O
and	O
N	B
-	I
linoleoylethanolamine	I
(	O
ED50=37.5	O
mg	O
/	O
kg	O
,	O
i.v	O
.	O
)	O
,	O
although	O
the	O
peak	O
time	O
in	O
the	O
effect	O
was	O
observed	O
within	O
1	O
min	O
after	O
i.v	O
.	O

administration	O
.	O

None	O
of	O
the	O
saturated	B
fatty	I
acid	I
ethanolamides	I
(	O
N	B
-	I
myristoyl-	I
,	O
N	B
-	I
palmitoyl-	I
,	O
N	B
-	I
stearoyl-	I
and	O
N	B
-	I
arachidoylethanolamine	I
)	O
showed	O
a	O
positive	O
response	O
in	O
the	O
cataleptogenic	O
effect	O
even	O
at	O
a	O
dose	O
up	O
to	O
40	O
mg	O
/	O
kg	O
i.v	O
.	O

Anandamide	B
,	O
N	B
-	I
linoleoyl-	I
,	O
N	B
-	I
oleoyl-	I
and	O
N	B
-	I
myristoylethanolamine	I
(	O
10	O
mg	O
/	O
kg	O
,	O
i.v	O
.	O
)	O
produced	O
a	O
significant	O
hypothermia	O
(	O
0.19	O
to	O
0.59	O
degrees	O
C	O
)	O
at	O
5	O
to	O
15	O
min	O
after	O
administration	O
.	O

The	O
duration	O
of	O
the	O
effects	O
of	O
these	O
ethanolamides	B
was	O
also	O
relatively	O
short	O
.	O

Anandamide	B
,	O
N	B
-	I
linoleoyl-	I
,	O
N	B
-	I
oleoyl-	I
and	O
N	B
-	I
palmitoylethanolamine	I
(	O
5	O
or	O
10	O
mg	O
/	O
kg	O
,	O
i.v	O
.	O
)	O
significantly	O
prolonged	O
pentobarbital	B
-	O
induced	O
sleeping	O
time	O
by	O
148	O
-	O
207	O
%	O
of	O
control	O
sleeping	O
time	O
.	O

The	O
cataleptogenic	O
effect	O
of	O
anandamide	B
was	O
markedly	O
potentiated	O
by	O
pretreatment	O
of	O
mice	O
with	O
PMSF	B
(	O
100	O
mg	O
/	O
kg	O
,	O
i.p	O
.	O
)	O
.	O

The	O
ED50	O
(	O
mg	O
/	O
kg	O
,	O
i.v	O
.	O
)	O
of	O
anandamide	B
was	O
0.48	O
(	O
0.24	O
-	O
0.96	O
)	O
in	O
PMSF	B
-	O
pretreated	O
mice	O
.	O

The	O
pretreatment	O
of	O
mice	O
with	O
PMSF	B
significantly	O
decreased	O
the	O
metabolic	O
clearance	O
rate	O
of	O
anandamide	B
in	O
microsomal	O
fractions	O
of	O
liver	O
and	O
brain	O
.	O

Thus	O
,	O
the	O
Vmax	O
/	O
Km	O
values	O
of	O
brain	O
and	O
hepatic	O
microsomes	O
were	O
26	O
and	O
10	O
%	O
,	O
respectively	O
,	O
as	O
compared	O
with	O
those	O
of	O
control	O
mice	O
.	O

The	O
present	O
study	O
demonstrated	O
that	O
anandamide	B
and	O
N	B
-	I
acylethanolamines	I
of	I
unsaturated	I
fatty	I
acids	I
exhibited	O
cannabinoid	B
-	O
like	O
effects	O
in	O
mice	O
,	O
and	O
that	O
anandamide	O
amidohydrolase	O
has	O
an	O
important	O
role	O
in	O
the	O
pharmacological	O
effects	O
of	O
anandamide	B
in	O
vivo	O
.	O

Localized	O
1H	O
NMR	O
homonuclear	O
J	O
editing	O
spectroscopy	O
was	O
used	O
to	O
measure	O
the	O
concentration	O
of	O
2-pyrrolidinone	B
(	O
PRDN	B
)	O
in	O
the	O
human	O
occipital	O
lobe	O
of	O
five	O
normal	O
and	O
six	O
epileptic	O
subjects	O
taking	O
vigabatrin	B
.	O

PRDN	B
is	O
a	O
lactam	B
cyclization	O
product	O
of	O
gamma	B
-	I
aminobutyric	I
acid	I
(	O
GABA	B
)	O
.	O

From	O
a	O
localized	O
volume	O
of	O
13.5	O
cm3	O
in	O
the	O
occipital	O
cortex	O
,	O
the	O
concentration	O
of	O
PRDN	B
ranged	O
from	O
0.2	O
to	O
0.3	O
micromol	O
/	O
g	O
in	O
normal	O
subjects	O
,	O
whereas	O
in	O
epileptic	O
subjects	O
on	O
vigabatrin	B
PRDN	B
was	O
elevated	O
to	O
0.6	O
+	O
/-	O

0.1	O
micromol	O
/	O
g	O
.	O

The	O
elevated	O
PRDN	B
in	O
patients	O
on	O
vigabatrin	B
was	O
in	O
accord	O
with	O
raised	O
GABA	B
levels	O
compared	O
with	O
normals	O
.	O

1H	O
NMR	O
measurements	O
of	O
PRDN	B
will	O
be	O
important	O
in	O
assessment	O
of	O
the	O
role	O
of	O
this	O
metabolite	O
for	O
improved	O
seizure	O
control	O
.	O

Phosphatoquinones	B
A	B
and	O
B	B
were	O
isolated	O
from	O
the	O
cultured	O
broth	O
of	O
Streptomyces	O
sp.	O
TA-0363	O
and	O
their	O
structures	O
were	O
elucidated	O
by	O
spectroscopic	O
analyses	O
.	O

Phosphatoquinones	B
A	B
and	O
B	B
inhibited	O
the	O
protein	O
tyrosine	O
phosphatase	O
activity	O
prepared	O
from	O
human	O
Ball-1	O
cells	O
with	O
IC50	O
of	O
28	O
microM	O
and	O
2.9	O
microM	O
,	O
respectively	O
.	O

The	O
biosynthesis	O
of	O
polyketomycin	B
was	O
investigated	O
by	O
feeding	O
13C	B
-	I
labeled	I
acetate	B
and	O
propionate	B
to	O
the	O
growing	O
cultures	O
of	O
Streptomyces	O
diastatochromogenes	O
Tu	O
6028	O
.	O

13C	O
NMR	O
spectral	O
analysis	O
demonstrated	O
the	O
polyketide	B
origin	O
of	O
the	O
aglycone	B
and	O
the	O
dimethylsalicyloyl	B
moieties	I
.	O

The	O
O	B
-	I
methyl	I
group	I
and	O
6-CH3	B
of	O
the	O
aglycone	B
as	O
well	O
as	O
3B	B
-	I
CH3	I
of	O
L	B
-	I
axenose	I
and	O
3C	B
-	I
CH3	I
of	O
the	O
salicyloyl	B
residue	O
were	O
labeled	O
by	O
feeding	O
L-	B
[	I
methyl-13C	I
]	I
methionine	I
.	O

Both	O
deoxysugars	B
emerged	O
from	O
D	B
-	I
glucose	I
.	O

The	O
biosynthesis	O
of	O
the	O
aglycone	B
and	O
the	O
assembly	O
of	O
the	O
glycoside	B
are	O
discussed	O
.	O

The	O
polyketomycin	B
producing	O
strain	O
may	O
be	O
a	O
candidate	O
for	O
further	O
exploration	O
in	O
combinatorial	O
biosynthesis	O
.	O

The	O
effect	O
of	O
thirteen	O
different	O
fungal	O
azaphilones	B
,	O
which	O
have	O
a	O
common	O
6-iso	B
-	I
chromane	I
-	O
like	O
ring	O
,	O
was	O
tested	O
on	O
cholesteryl	O
ester	O
transfer	O
protein	O
(	O
CETP	O
)	O
activity	O
in	O
vitro	O
.	O

Chaetoviridin	B
B	I
showed	O
the	O
most	O
potent	O
inhibitory	O
activity	O
with	O
an	O
IC50	O
value	O
of	O
<	O
6.2	O
microM	O
,	O
followed	O
by	O
sclerotiorin	B
with	O
an	O
IC50	O
value	O
of	O
19.4	O
microM.	O
Rotiorin	B
,	O
chaetoviridin	B
A	I
and	O
rubrorotiorin	B
had	O
moderate	O
inhibitory	O
activity	O
(	O
IC50	O
;	O
30	O
approximately	O
40	O
microM	O
)	O
,	O
but	O
others	O
showed	O
very	O
weak	O
or	O
no	O
inhibitory	O
activity	O
.	O

The	O
relationship	O
between	O
the	O
structures	O
and	O
their	O
inhibitory	O
activity	O
indicated	O
that	O
the	O
presence	O
of	O
an	O
electrophilic	O
ketone	B
(	O
s	O
)	O
and/or	O
enone	B
(	O
s	O
)	O
at	O
both	O
C-6	O
and	O
C-8	O
positions	O
in	O
the	O
isochromane	B
-	O
like	O
ring	O
is	O
essential	O
for	O
eliciting	O
CETP	O
inhibitory	O
activity	O
.	O

The	O
transfer	O
activity	O
of	O
both	O
CE	O
and	O
TG	O
was	O
inhibited	O
by	O
sclerotiorin	B
to	O
approximately	O
the	O
same	O
extent	O
(	O
IC50	O
:	O
14.4	O
and	O
10.3	O
microM	O
,	O
respectively	O
)	O
.	O

A	O
model	O
of	O
the	O
reaction	O
suggested	O
that	O
sclerotiorin	B
reacts	O
with	O
a	O
primary	O
amine	O
of	O
amino	O
acids	O
such	O
as	O
lysine	O
in	O
the	O
protein	O
to	O
form	O
a	O
covalent	O
bond	O
.	O

Six	O
new	O
(	O
1	O
-	O
6	O
)	O
and	O
three	O
known	O
(	O
7	O
-	O
9	O
)	O
sesquiterpene	B
esters	I
were	O
isolated	O
from	O
the	O
roots	O
of	O
Celastrus	O
orbiculatus	O
.	O

The	O
structures	O
of	O
the	O
new	O
compounds	O
were	O
elucidated	O
as	O
1beta	B
-	I
acetoxy-6alpha	I
-	I
furoyloxy-9alpha	I
-	I
benzoyl	I
oxydihydro	I
-	I
beta	I
-	I
agarofur	I
an	I
(	O
1	O
)	O
,	O
1beta	B
-	I
acetoxy-6alpha	I
-	I
benzoyloxy-9alpha	I
-	I
furoyloxydih	I
ydro	I
-	I
beta	I
-	I
agarofur	I
an	I
(	O
2	O
)	O
,	O
1beta	B
-	I
acetoxy-6alpha	I
,	I
9alpha	I
-	I
difuroyloxydihydro	I
-	I
beta	I
-	I
agarofuran	I
(	O
3	O
)	O
,	O
1beta	B
,	I
2beta	I
-	I
diacetoxy-6alpha	I
-	I
furoyloxy-9alpha	I
-	I
benzo	I
yloxydihydro	I
-	I
beta	I
-	I
agarof	I
uran	I
(	O
4	O
)	O
,	O
1beta	B
-	I
acetoxy-2beta	I
,	I
6alpha	I
-	I
difuroyloxy-9alpha	I
-	I
benzoyloxydihydro	I
-	I
beta	I
-agarofuran	I
(	O
5	O
)	O
,	O
and	O
1beta	B
-	I
acetoxy-2beta,6alpha	I
,	I
9alpha	I
-	I
tribenzoyloxydihydro	I
-	I
beta	I
-	I
agarofuran	I
(	O
6	O
)	O
.	O

Compounds	O
4	O
,	O
5	O
,	O
and	O
7	B
-	I
9	I
were	O
shown	O
to	O
be	O
more	O
active	O
than	O
verapamil	B
in	O
reversing	O
vinblastine	B
resistance	O
in	O
multidrug	O
-	O
resistant	O
KB	O
-	O
V1	O
cells	O
.	O

Late	O
-	O
onset	O
drinking	O
is	O
a	O
common	O
problem	O
in	O
elderly	O
people	O
related	O
to	O
stress	O
induced	O
by	O
social	O
isolation	O
.	O

Experiments	O
were	O
performed	O
in	O
order	O
to	O
evaluate	O
the	O
effects	O
of	O
alprazolam	B
,	O
a	O
benzodiazepine	B
agonist	O
anxiolytic	O
,	O
on	O
the	O
free	O
-	O
choice	O
ethanol	B
consumption	O
in	O
aged	O
rats	O
subjected	O
to	O
isolation	O
stress	O
.	O

The	O
animals	O
we	O
offered	O
a	O
two	O
-	O
bottle	O
choice	O
consumption	O
(	O
one	O
of	O
0.2	O
%	O
saccharin	B
and	O
the	O
other	O
with	O
10	O
%	O
ethanol	B
/	O
0.2	O
%	O
saccharin	B
)	O
and	O
then	O
exposed	O
to	O
4	O
days	O
of	O
isolation	O
stress	O
on	O
an	O
irregular	O
,	O
unpredictable	O
schedule	O
.	O

Stress	O
resulted	O
in	O
significant	O
increase	O
in	O
ethanol	B
consumption	O
.	O

Treatment	O
with	O
alprazolam	B
(	O
1	O
mg	O
/	O
Kg	O
)	O
partially	O
reversed	O
this	O
adverse	O
effect	O
of	O
stress	O
.	O

The	O
elucidation	O
of	O
N	B
-glycans	I
in	O
plants	O
has	O
raised	O
increasing	O
interest	O
in	O
the	O
past	O
years	O
due	O
to	O
several	O
physiological	O
roles	O
which	O
could	O
be	O
attributed	O
to	O
these	O
structures	O
:	O
correct	O
folding	O
,	O
biological	O
activity	O
and	O
stability	O
of	O
proteins	O
can	O
be	O
affected	O
by	O
the	O
presence	O
of	O
N	B
-glycans	I
(	O
Driouich	O
,	O
Gonnet	O
,	O
Makkie	O
,	O
Laine	O
,	O
&	O
Faye	O
,	O
1989	O
;	O
Sheldon	O
,	O
&	O
Bowles	O
,	O
1992	O
;	O
Nagai	O
,	O
&	O
Yamaguchi	O
,	O
1993	O
)	O
.	O

Moreover	O
,	O
the	O
involvement	O
of	O
N	B
-linked	I
oligosaccharides	I
in	O
plant	O
development	O
was	O
demonstrated	O
(	O
Ettlinger	O
,	O
Schindler	O
,	O
&	O
Lehle	O
,	O
1986	O
)	O
.	O

Besides	O
these	O
physiological	O
roles	O
,	O
N	B
-glycans	I
can	O
influence	O
the	O
immunogenicity	O
of	O
glycoproteins	O
,	O
representing	O
antigenic	O
epitopes	B
by	O
themselves:	O
(	O
i	O
)	O
The	O
injection	O
of	O
horseradish	O
peroxidase	O
(	O
HRP	O
)	O
into	O
rabbits	O
resulted	O
in	O
polyclonal	O
anti	O
-	O
HRP	O
antiserum	O
which	O
also	O
reacted	O
with	O
many	O
other	O
plant	O
glycoproteins	O
carrying	O
glycans	B
similar	O
to	O
those	O
from	O
horseradish	O
peroxidase	O
.	O

β1,2-xylose	B
,	O
present	O
in	O
all	O
the	O
glycoprotein	O
–	O
glycans	O
of	O
the	O
study	O
,	O
but	O
absent	O
in	O
mammalian	O
organisms	O
,	O
was	O
supposed	O
to	O
be	O
responsible	O
for	O
the	O
observed	O
cross	O
-	O
reactivity	O
(	O
Faye	O
,	O
Johnson	O
,	O
Sturm	O
,	O
&	O
Chrispeels	O
,	O
1993	O
)	O
.	O

(	O
ii	O
)	O
The	O
crossreactivity	O
of	O
a	O
polyclonal	O
antiserum	O
against	O
HRP	O
with	O
other	O
plant	O
glycoproteins	O
and	O
with	O
bee	O
-	O
venom	O
phospholipase	O
A2	O
,	O
due	O
to	O
a	O
common	O
carbohydrate	B
epitope	B
could	O
be	O
demonstrated	O
.	O

(	O
Prenner	O
,	O
Mach	O
,	O
Glössl	O
,	O
&	O
März	O
,	O
1992	O
;	O
Wilson	O
,	O
Harthill	O
,	O
Mullin	O
,	O
Ashford	O
,	O
&	O
Altmann	O
,	O
1998	O
)	O
.	O

Chemical	O
defucosylation	O
as	O
well	O
as	O
ELISA	O
inhibition	O
experiments	O
indicated	O
that	O
α1,3-fucose	B
is	O
sufficient	O
to	O
create	O
an	O
immunogenic	O
epitope	B
.	O

The	O
assumption	O
that	O
N	B
-glycans	I
or	O
parts	O
of	O
these	O
structures	O
can	O
not	O
only	O
represent	O
antigenic	O
,	O
but	O
also	O
allergenic	O
epitopes	B
was	O
confirmed	O
by	O
Tretter	O
,	O
Altmann	O
,	O
Kubelka	O
,	O
März	O
,	O
and	O
Becker	O
(	O
1993	O
)	O
;	O
in	O
the	O
case	O
of	O
bee	O
-	O
venom	O
allergic	O
patients	O
,	O
the	O
reactivity	O
of	O
IgE	O
antibodies	O
to	O
glycopeptides	O
of	O
phospholipase	O
A2	O
was	O
demonstrated	O
;	O
the	O
proximal	O
α1,3-fucose	B
residue	O
was	O
identified	O
as	O
the	O
IgE	O
-	O
reactive	O
determinant	O
.	O

The	O
involvement	O
of	O
carbohydrate	B
structures	O
in	O
food	O
allergies	O
is	O
presently	O
discussed	O
quite	O
controversial	O
.	O

However	O
,	O
there	O
is	O
increasing	O
evidence	O
that	O
certain	O
carbohydrates	B
,	O
especially	O
N	B
-glycans	I
,	O
might	O
play	O
a	O
role	O
in	O
these	O
adverse	O
food	O
reactions	O
(	O
Aalberse	O
,	O
Koshte	O
,	O
&	O
Clemens	O
,	O
1981	O
)	O
,	O
deduced	O
from	O
the	O
following	O
observations	O
:	O
many	O
proteins	O
which	O
are	O
of	O
allergological	O
importance	O
are	O
glycosylated	O
;	O
many	O
allergic	O
individuals	O
show	O
hypersensitivity	O
to	O
various	O
types	O
of	O
allergens	O
which	O
are	O
not	O
taxonomically	O
related	O
,	O
thus	O
suggesting	O
common	O
,	O
ubiquitous	O
structures	O
as	O
glycans	B
;	O
and	O
finally	O
,	O
many	O
pollen	O
allergic	O
patients	O
are	O
also	O
sensitive	O
to	O
certain	O
food	O
stuffs	O
,	O
which	O
also	O
implies	O
common	O
structural	O
epitopes	B
(	O
Möller	O
et	O
al.	O
,	O
1997	O
)	O
.	O

In	O
immunological	O
investigations	O
,	O
mostly	O
indirect	O
methods	O
are	O
applied	O
which	O
shall	O
prove	O
the	O
involvement	O
of	O
glycans	B
in	O
allergic	O
reactions	O
,	O
such	O
as	O
deglycosylation	O
,	O
lectin	O
binding	O
and	O
compositional	O
analysis	O
(	O
Petersen	O
,	O
Becker	O
,	O
Moll	O
,	O
Blümke	O
,	O
&	O
Schlaak	O
,	O
1995	O
;	O
Batanero	O
,	O
Villalba	O
,	O
Monsalve	O
,	O
&	O
Rodriguez	O
,	O
1996	O
;	O
Tsuji	O
et	O
al.	O
,	O
1997	O
)	O
;	O
however	O
,	O
structural	O
information	O
is	O
a	O
prerequisite	O
for	O
making	O
correct	O
conclusions	O
about	O
the	O
allergenicity	O
of	O
N	B
-glycans	I
or	O
epitopes	B
,	O
respectively	O
.	O

We	O
report	O
here	O
on	O
the	O
structural	O
elucidation	O
of	O
the	O
N	B
-linked	I
oligosaccharides	I
in	O
tomato	O
fruit	O
,	O
which	O
shall	O
help	O
to	O
understand	O
some	O
observed	O
cross	O
-	O
reactivities	O
reported	O
recently	O
by	O
Petersen	O
,	O
Vieths	O
,	O
Aulepp	O
,	O
Schlaak	O
,	O
and	O
Becker	O
(	O
1996	O
)	O
.	O

2	O
Results	O
2.1	O
Preparation	O
of	O
N	B
-glycans	I
from	O
tomato	O
fruit	O
To	O
isolate	O
the	O
protein	O
fraction	O
from	O
tomato	O
fruit	O
,	O
two	O
procedures	O
were	O
carried	O
out	O
alternatively	O
:	O
on	O
the	O
one	O
hand	O
,	O
the	O
tomatoes	O
were	O
homogenized	O
in	O
an	O
appropriate	O
extraction	O
buffer	O
and	O
the	O
proteins	O
were	O
precipitated	O
by	O
addition	O
of	O
ammonium	B
sulfate	I
.	O

On	O
the	O
other	O
hand	O
,	O
a	O
low	O
-	O
temperature	O
acetone	B
powder	O
method	O
,	O
first	O
described	O
by	O
Clements	O
(	O
1965	O
)	O
,	O
was	O
employed	O
;	O
the	O
proteins	O
precipitated	O
in	O
acetone	B
,	O
whereas	O
small	O
hydrophobic	O
compounds	O
(	O
flavonoids	B
,	O
carotinoids	B
)	O
as	O
well	O
as	O
most	O
of	O
the	O
salts	B
were	O
effectively	O
removed	O
;	O
the	O
proteins	O
were	O
extracted	O
from	O
the	O
resulting	O
powder	O
,	O
yielding	O
concentrations	O
of	O
180–310	O
μg	O
/	O
ml	O
as	O
determined	O
according	O
to	O
Bradford	O
(	O
1976	O
)	O
;	O
these	O
values	O
are	O
in	O
the	O
same	O
order	O
of	O
magnitude	O
with	O
those	O
reported	O
by	O
Vieths	O
,	O
Schöning	O
,	O
Brockmann	O
,	O
and	O
Aulepp	O
(	O
1992	O
)	O
,	O
who	O
used	O
this	O
procedure	O
for	O
the	O
preparation	O
of	O
several	O
fruit	O
and	O
vegetable	O
extracts	O
.	O

A	O
cation	O
-	O
exchange	O
chromatography	O
eliminated	O
most	O
of	O
the	O
by	O
-	O
products	O
in	O
the	O
sample	O
.	O

The	O
binding	O
fraction	O
was	O
assayed	O
for	O
the	O
amount	O
of	O
N	B
-acetylglucosamine	I
by	O
OPA	O
-	O
aminosugar	B
analysis	O
,	O
yielding	O
170–260	O
nmol	O
GlcNAc	B
,	O
dependent	O
on	O
the	O
sample	O
.	O

From	O
these	O
values	O
it	O
could	O
be	O
deduced	O
that	O
about	O
85–130	O
nmol	O
of	O
N	B
-glycans	I
are	O
present	O
in	O
the	O
glycopeptide	O
fractions	O
(	O
assuming	O
2	O
moles	O
of	O
GlcNAc	B
/	O
mol	O
of	O
oligosaccharide	B
)	O
.	O

The	O
oligosaccharides	B
were	O
released	O
from	O
the	O
glycopeptides	O
using	O
N	O
-glycosidase	O
A	O
,	O
separated	O
from	O
peptides	O
and	O
residual	O
glycopeptides	O
by	O
reverse	O
-	O
phase	O
chromatography	O
and	O
derivatized	O
with	O
the	O
fluorescent	O
tag	O
2-aminopyridine	B
.	O

2.2	O
Separation	O
and	O
structural	O
elucidation	O
of	O
the	O
N	B
-linked	I
oligosaccharides	I
The	O
pyridylaminated	O
oligosaccharides	B
were	O
first	O
size	O
-	O
fractionated	O
on	O
MicroPak	O
AX-5	O
(	O
Fig.	O
1	O
Fig.	O
1	O
A	O
)	O
;	O
11	O
fractions	O
were	O
manually	O
collected	O
and	O
rechromatographed	O
if	O
necessary	O
.	O

Individual	O
fractions	O
were	O
subjected	O
to	O
reverse	O
-	O
phase	O
HPLC	O
,	O
yielding	O
a	O
total	O
of	O
sixteen	O
subfractions	O
(	O
additionally	O
,	O
an	O
aliquot	O
of	O
the	O
total	O
glycan	B
pool	O
was	O
applied	O
to	O
the	O
reverse	O
-	O
phase	O
system	O
,	O
see	O
Fig.	O
1	O
B	O
)	O
.	O

The	O
elution	O
position	O
of	O
each	O
isolated	O
oligosaccharides	B
was	O
determined	O
on	O
both	O
columns	O
and	O
compared	O
to	O
those	O
from	O
reference	O
oligosaccharides	B
.	O

The	O
individual	O
peaks	O
were	O
then	O
subjected	O
to	O
exoglycosidase	O
treatment	O
using	O
α	O
-	O
mannosidase	O
,	O
β	O
-	O
N	O
-acetylhexosaminidase	O
and	O
endoglycosidase	O
H.	O
The	O
digests	O
were	O
again	O
chromatographed	O
on	O
reverse	O
-	O
phase	O
and	O
MicroPak	O
to	O
monitor	O
the	O
change	O
in	O
the	O
elution	O
behavior	O
(	O
Tables	O
1	O
and	O
2	O
)	O
.	O

Whenever	O
possible	O
,	O
a	O
tentatively	O
identified	O
peak	O
was	O
coinjected	O
with	O
the	O
corresponding	O
reference	O
oligosaccharide	B
to	O
verify	O
the	O
identical	O
elution	O
behavior	O
.	O

In	O
the	O
following	O
,	O
the	O
structural	O
assignment	O
of	O
each	O
peak	O
is	O
described	O
;	O
the	O
proposed	O
structures	O
are	O
depicted	O
in	O
Table	O
3	O
.	O

2.3	O
Complex	O
and	O
truncated	O
complex	O
glycans	B
The	O
retention	O
data	O
of	O
oligosaccharide	B
1-A	I
,	O
a	O
minor	O
component	O
present	O
in	O
all	O
the	O
tomato	O
samples	O
,	O
did	O
not	O
fit	O
with	O
any	O
of	O
the	O
available	O
reference	O
compounds	O
.	O

However	O
,	O
the	O
glycan	B
exhibited	O
resistance	O
to	O
α	O
-	O
mannosidase	O
treatment	O
.	O

The	O
identity	O
could	O
be	O
presumed	O
from	O
complete	O
digestion	O
of	O
MMF3	O
from	O
phospholipase	O
A2	O
with	O
α	O
-	O
mannosidase	O
,	O
resulting	O
in	O
a	O
peak	O
with	O
the	O
same	O
retention	O
behavior	O
as	O
oligosaccharide	B
1-A	I
on	O
both	O
columns	O
.	O

1-A	B
is	O
therefore	O
presumed	O
to	O
be	O
00F3	B
.	O

Oligosaccharide	B
1-B	I
also	O
was	O
resistant	O
to	O
α	O
-	O
mannosidase	O
.	O

Together	O
with	O
its	O
size	O
and	O
having	O
the	O
same	O
retention	O
time	O
on	O
reverse	O
-	O
phase	O
HPLC	O
as	O
the	O
product	O
of	O
α	O
-	O
mannosidase	O
digestion	O
of	O
the	O
major	O
structure	O
of	O
horseradish	O
peroxidase	O
(	O
MMXF3	B
)	O
,	O
1-B	B
was	O
deduced	O
to	O
be	O
00XF3	B
.	O

The	O
third	O
peak	O
present	O
in	O
the	O
first	O
MicroPak	O
fraction	O
,	O
1-C	O
,	O
showed	O
a	O
remarkably	O
high	O
retention	O
time	O
on	O
reverse	O
-	O
phase	O
(	O
11.0	O
glucose	B
units	O
)	O
and	O
sensitivity	O
to	O
α	O
-	O
mannosidase	O
,	O
resulting	O
in	O
a	O
reduction	O
of	O
the	O
retention	O
time	O
to	O
8.5	O
glucose	B
units	O
.	O

This	O
corresponds	O
to	O
the	O
retention	O
time	O
of	O
completely	O
digested	O
MMX	O
from	O
zucchini	O
ascorbate	O
–	O
oxidase	O
(	O
Altmann	O
,	O
1998	O
)	O
.	O

Coelution	O
of	O
the	O
limited	O
digestion	O
product	O
from	O
the	O
reference	O
oligosaccharide	B
with	O
1-C	B
yields	O
a	O
single	O
,	O
homogenous	O
peak	O
as	O
calculated	O
from	O
addition	O
of	O
the	O
peak	O
areas	O
;	O
1-C	B
was	O
therefore	O
found	O
to	O
be	O
M0X	B
.	O

Peak	O
2	O
from	O
MicroPak	O
gave	O
a	O
single	O
peak	O
on	O
reverse	O
-	O
phase	O
,	O
which	O
was	O
sensitive	O
to	O
α	O
-	O
mannosidase	O
;	O
two	O
peaks	O
,	O
lacking	O
one	O
and	O
two	O
mannose	B
residues	O
as	O
deduced	O
from	O
the	O
retention	O
behavior	O
on	O
MicroPak	O
HPLC	O
,	O
were	O
obtained	O
.	O

The	O
second	O
peak	O
on	O
the	O
size	O
fractionation	O
column	O
exhibited	O
the	O
same	O
retention	O
time	O
as	O
fraction	O
1	O
of	O
phospholipase	O
A2	O
.	O

Therefore	O
,	O
the	O
structure	O
of	O
peak	O
2	O
was	O
assumed	O
to	O
be	O
MM	O
.	O

This	O
was	O
confirmed	O
by	O
coinjection	O
of	O
MM	O
(	O
prepared	O
from	O
bovine	O
fibrin	O
)	O
,	O
resulting	O
in	O
a	O
single	O
peak	O
.	O

Furthermore	O
,	O
the	O
α	O
-	O
mannosidase	O
digest	O
of	O
fibrin	O
MM	O
behaved	O
exactly	O
the	O
same	O
way	O
as	O
the	O
digest	O
of	O
peak	O
2	O
on	O
both	O
HPLC	O
columns	O
.	O

Oligosaccharide	B
3-A	B
exhibited	O
the	O
same	O
elution	O
behavior	O
in	O
both	O
HPLC	O
systems	O
as	O
the	O
reference	O
oligosaccharide	B
from	O
pineapple	O
stem	O
bromelain	O
,	O
M0XF3	B
.	O

α	O
-	O
mannosidase	O
digestion	O
of	O
3-A	B
resulted	O
in	O
a	O
single	O
peak	O
,	O
which	O
coeluted	O
with	O
compound	O
1-B	B
(	O
5.2	O
glucose	B
units	O
on	O
reverse	O
-	O
phase	O
HPLC	O
)	O
.	O

Peak	O
3-B	B
was	O
identified	O
based	O
on	O
its	O
size	O
and	O
retention	O
times	O
before	O
and	O
after	O
α	O
-	O
mannosidase	O
digestions	O
in	O
comparison	O
with	O
the	O
standard	O
MMX	B
from	O
fraction	O
1	O
of	O
ascorbate	O
oxidase	O
.	O

Partial	O
digestion	O
with	O
α	O
-	O
mannosidase	O
resulted	O
in	O
a	O
peak	O
which	O
coeluted	O
with	O
compound	O
1-C.	B
The	O
final	O
proof	O
of	O
peak	O
identity	O
was	O
again	O
provided	O
by	O
coinjection	O
of	O
the	O
MMX	B
reference	O
compound	O
.	O

Peak	O
4	O
,	O
which	O
appeared	O
to	O
be	O
non	O
-	O
homogenous	O
on	O
MicroPak	O
eluted	O
as	O
one	O
major	O
peak	O
(	O
>	O
85	O
%	O
)	O
on	O
the	O
reverse	O
-	O
phase	O
column	O
.	O

The	O
minor	O
components	O
(	O
at	O
least	O
five	O
peaks	O
)	O
were	O
present	O
in	O
minute	O
quantities	O
and	O
could	O
not	O
be	O
analyzed	O
further	O
.	O

The	O
major	O
peak	O
was	O
subjected	O
to	O
α	O
-	O
mannosidase	O
digestion	O
,	O
yielding	O
two	O
signals	O
on	O
reverse	O
-	O
phase	O
HPLC	O
with	O
retention	O
times	O
of	O
5.1	O
and	O
4.4	O
glucose	B
units	O
,	O
thus	O
indicating	O
the	O
presence	O
of	O
two	O
mannose	B
residues	O
in	O
the	O
structure	O
.	O

The	O
first	O
peak	O
on	O
reverse	O
-	O
phase	O
coeluted	O
with	O
compound	O
1-A	B
,	O
thus	O
indicating	O
peak	O
4	O
to	O
represent	O
MMF3	B
.	O

This	O
assumption	O
could	O
be	O
proved	O
by	O
(	O
i	O
)	O
coinjection	O
of	O
phospholipase	O
A2	O
-compound	O
5A	B
(	O
MMF3	B
)	O
,	O
resulting	O
in	O
a	O
single	O
peak	O
and	O
(	O
ii	O
)	O
by	O
digesting	O
the	O
reference	O
compound	O
with	O
α	O
-	O
mannosidase	O
,	O
yielding	O
the	O
same	O
two	O
degradation	O
products	O
as	O
for	O
peak	O
4	O
.	O

The	O
major	O
oligosaccharide	B
(	O
5	B
)	O
in	O
all	O
the	O
samples	O
,	O
representing	O
47–59	O
%	O
of	O
the	O
total	O
N	B
-glycan	I
amount	O
,	O
was	O
shown	O
to	O
be	O
susceptible	O
to	O
α	O
-	O
mannosidase	O
digestion	O
,	O
resulting	O
in	O
two	O
peaks	O
:	O
the	O
first	O
eluted	O
at	O
retention	O
times	O
identical	O
to	O
those	O
from	O
oligosaccharide	B
3-A	B
and	O
the	O
M0XF3	B
reference	O
compound	O
,	O
the	O
second	O
coeluted	O
with	O
oligosaccharide	B
1-B	B
,	O
already	O
being	O
elucidated	O
as	O
00XF3	B
.	O

Furthermore	O
,	O
additional	O
evidence	O
for	O
the	O
peak	O
being	O
MMXF3	B
was	O
obtained	O
from	O
coinjection	O
of	O
the	O
reference	O
oligosaccharide	B
from	O
horseradish	O
peroxidase	O
,	O
yielding	O
a	O
single	O
peak	O
.	O

Fraction	O
6	O
from	O
MicroPak	O
gave	O
two	O
peaks	O
on	O
the	O
reverse	O
-	O
phase	O
column	O
with	O
relative	O
retention	O
times	O
of	O
4.7	O
and	O
5.8	O
glucose	B
units	O
,	O
respectively	O
.	O

These	O
peaks	O
were	O
digestible	O
by	O
β	O
-	O
N	O
-acetyl	O
-	O
hexosaminidase	O
to	O
a	O
common	O
new	O
compound	O
,	O
exhibiting	O
the	O
same	O
elution	O
behavior	O
as	O
compound	O
5	O
.	O

Furthermore	O
,	O
hornbeam	O
GnGnXF3	B
digestion	O
with	O
the	O
same	O
enzyme	O
resulted	O
in	O
formation	O
of	O
the	O
two	O
peaks	O
mentioned	O
above	O
.	O

Again	O
,	O
the	O
final	O
proof	O
,	O
that	O
the	O
two	O
peaks	O
represent	O
MGnXF3	B
and	O
GnMXF3	B
was	O
accomplished	O
by	O
coinjection	O
of	O
the	O
corresponding	O
oligosaccharides	B
obtained	O
from	O
limited	O
β	O
-	O
N	O
-acetylglucosaminidase	O
digestion	O
of	O
hornbeam	O
pollen	O
GnGnXF3	B
.	O

Oligosaccharide	B
8	B
also	O
gave	O
one	O
major	O
peak	O
on	O
reverse	O
-	O
phase	O
HPLC	O
.	O

An	O
initial	O
hexosaminidase	O
digestion	O
resulted	O
in	O
the	O
presence	O
of	O
the	O
peaks	O
with	O
4.8	O
and	O
5.8	O
glucose	B
units	O
on	O
reverse	O
-	O
phase	O
,	O
thus	O
presumably	O
representing	O
the	O
above	O
mentioned	O
components	O
MGnXF3	B
and	O
GnMXF3	B
.	O

Complete	O
digestion	O
with	O
β	O
-	O
N	O
-acetyl	O
-	O
hexosaminidase	O
yielded	O
a	O
single	O
peak	O
,	O
coeluting	O
with	O
compound	O
5	O
and	O
the	O
reference	O
compound	O
MMXF3	B
.	O

Hence	O
,	O
oligosaccharide	B
8	B
can	O
be	O
designated	O
to	O
be	O
GnGnXF3	B
.	O

2.4	O
Oligomannosidic	B
glycans	I
From	O
the	O
relative	O
retention	O
times	O
on	O
MicroPak	O
of	O
7.7	O
,	O
8.7	O
,	O
9.7	O
and	O
10.6	O
glucose	B
units	O
,	O
oligomannosidic	B
glycans	I
were	O
predicted	O
.	O

This	O
surmise	O
was	O
verified	O
by	O
performing	O
α	O
-	O
mannosidase	O
digestions	O
of	O
these	O
compounds	O
:	O
each	O
fraction	O
was	O
accessible	O
to	O
α	O
-	O
mannosidase	O
,	O
resulting	O
in	O
the	O
same	O
two	O
peaks	O
(	O
exhibiting	O
relative	O
retention	O
times	O
of	O
3.7	O
/	O
8.7	O
and	O
2.9	O
/	O
7.2	O
glucose	O
units	O
on	O
MicroPak	O
and	O
Hypersil	O
ODS	O
,	O
respectively	O
;	O
Table	O
1	O
)	O
for	O
all	O
four	O
fractions	O
.	O

The	O
assumption	O
of	O
these	O
peaks	O
being	O
Manα1–6Manβ1–4GlcNAcβ1–4GlcNAc	B
–	I
pyridylamine	I
and	O
Manβ1–4GlcNAcβ1–4GlcNAc	B
–	I
pyridylamine	I
was	O
confirmed	O
by	O
a	O
limited	O
α	O
-	O
mannosidase	O
digest	O
of	O
MM	B
,	O
which	O
yielded	O
the	O
same	O
two	O
peaks	O
.	O

Furthermore	O
,	O
endoglycosidase	O
H	O
-	O
digests	O
of	O
the	O
peaks	O
7	O
and	O
9–11	O
resulted	O
in	O
the	O
formation	O
of	O
pyridylamino	B
–	I
GlcNAc	I
(	O
3.5	O
glucose	B
units	O
on	O
reverse	O
-	O
phase	O
column	O
)	O
,	O
also	O
proving	O
the	O
presence	O
of	O
oligomannosidic	B
structures	O
.	O

Additionally	O
,	O
the	O
authentic	O
oligosaccharides	B
from	O
soybean	O
7S	O
-glycoprotein	O
were	O
used	O
to	O
confirm	O
the	O
identities	O
of	O
the	O
four	O
above	O
-	O
mentioned	O
peaks	O
.	O

Coelution	O
of	O
peaks	O
7	O
,	O
9	O
and	O
10	O
was	O
observed	O
with	O
the	O
corresponding	O
reference	O
compounds	O
Man6	B
GlcNAc2	I
–Man8	O
GlcNAc2	B
.	O

Peak	O
9	O
consisted	O
of	O
two	O
structural	O
isomers	O
(	O
M7.1	B
and	O
M7.2	B
)	O
,	O
occurring	O
in	O
relative	O
amounts	O
of	O
45	O
and	O
55	O
%	O
(	O
for	O
sample	O
NotAP2	O
(	O
Table	O
4	O
)	O
)	O
,	O
respectively	O
.	O

Man8	B
GlcNAc2	I
is	O
a	O
homogenous	O
peak	O
on	O
reverse	O
-	O
phase	O
(	O
4.7	O
GcU	O
)	O
,	O
which	O
can	O
be	O
therefore	O
assigned	O
to	O
be	O
the	O
M8.1	B
-isomer	O
.	O

The	O
elution	O
behavior	O
of	O
peak	O
11	O
corresponds	O
to	O
published	O
data	O
(	O
Tomiya	O
et	O
al.	O
,	O
1991	O
;	O
Kubelka	O
,	O
Altmann	O
,	O
Kornfeld	O
,	O
&	O
März	O
,	O
1994	O
)	O
and	O
can	O
therefore	O
assigned	O
to	O
be	O
the	O
Man9	B
-isomer	O
M9.1	B
.	O

Additional	O
confirmation	O
of	O
the	O
results	O
was	O
obtained	O
by	O
MALDI	O
–	O
TOF	O
analysis	O
of	O
individual	O
HPLC	O
fractions	O
.	O

Fig.	O
2	O
Fig.	O
2	O
shows	O
the	O
mass	O
spectrum	O
of	O
fraction	O
5	O
,	O
identified	O
as	O
MMXF3	B
;	O
Table	O
5	O
summarizes	O
the	O
results	O
,	O
which	O
corroborate	O
the	O
assignments	O
based	O
upon	O
two	O
-	O
dimensional	O
mapping	O
.	O

2.5	O
Analysis	O
of	O
tomatoes	O
from	O
two	O
varieties	O
.	O

Analysis	O
of	O
red	O
and	O
green	O
tomatoes	O
Red	O
Notoro	O
-	O
type	O
tomatoes	O
were	O
subjected	O
to	O
the	O
two	O
different	O
isolation	O
procedures	O
in	O
order	O
to	O
monitor	O
the	O
impact	O
of	O
sample	O
preparation	O
on	O
the	O
glycan	B
pattern	O
in	O
terms	O
of	O
quality	O
and	O
quantity	O
.	O

Furthermore	O
,	O
red	O
and	O
green	O
San	O
Marzano	O
-	O
type	O
fruits	O
were	O
analyzed	O
to	O
distinguish	O
differences	O
in	O
the	O
glycan	B
pattern	O
due	O
to	O
the	O
variety	O
and	O
the	O
stage	O
of	O
ripening	O
,	O
respectively	O
.	O

Table	O
4	O
shows	O
the	O
condensed	O
results	O
in	O
terms	O
of	O
relative	O
abundances	O
of	O
individual	O
fractions	O
on	O
the	O
total	O
N	B
-glycan	I
amounts	O
.	O

It	O
could	O
be	O
demonstrated	O
that	O
irrespective	O
of	O
the	O
preparation	O
method	O
very	O
similar	O
results	O
were	O
obtained	O
;	O
San	O
Marzano	O
-	O
type	O
tomatoes	O
contain	O
the	O
same	O
sixteen	O
structures	O
and	O
also	O
the	O
relative	O
quantities	O
were	O
rather	O
similar	O
in	O
the	O
examined	O
varieties	O
.	O

Interestingly	O
,	O
also	O
the	O
state	O
of	O
ripening	O
does	O
not	O
seem	O
to	O
have	O
a	O
significant	O
impact	O
on	O
the	O
appearance	O
of	O
the	O
glycan	B
pattern	O
in	O
terms	O
of	O
quality	O
and	O
quantity	O
although	O
it	O
has	O
to	O
be	O
stated	O
that	O
more	O
samples	O
have	O
to	O
be	O
analyzed	O
for	O
a	O
statistical	O
interpretation	O
.	O

3	O
Discussion	O
The	O
N	B
-glycans	I
of	O
tomato	O
fruit	O
were	O
structurally	O
elucidated	O
,	O
thereby	O
comparing	O
two	O
varieties	O
as	O
well	O
as	O
two	O
stages	O
of	O
ripening	O
.	O

The	O
low	O
protein	O
content	O
of	O
tomatoes	O
and	O
the	O
high	O
amount	O
of	O
free	O
sugars	B
and	O
polysaccharides	B
(	O
Seymour	O
,	O
Colquhoun	O
,	O
DuPont	O
,	O
Parsely	O
,	O
&	O
Selvendran	O
,	O
1990	O
;	O
York	O
,	O
Kumar	O
Kolli	O
,	O
Orlando	O
,	O
Albersheim	O
,	O
&	O
Darvill	O
,	O
1997	O
)	O
complicated	O
the	O
effective	O
isolation	O
of	O
the	O
protein	O
fraction	O
.	O

However	O
,	O
the	O
employed	O
low	O
-	O
temperature	O
acetone	B
powder	O
method	O
proved	O
to	O
be	O
very	O
efficient	O
for	O
this	O
application	O
:	O
several	O
by	O
-	O
products	O
are	O
effectively	O
removed	O
,	O
the	O
resulting	O
powder	O
can	O
be	O
stored	O
for	O
several	O
months	O
at	O
−20	O
°	O
C	O
and	O
,	O
although	O
not	O
of	O
relevance	O
in	O
the	O
present	O
study	O
,	O
protein	O
denaturation	O
is	O
minimized	O
due	O
to	O
the	O
extremely	O
low	O
temperature	O
during	O
isolation	O
,	O
yielding	O
extracts	O
of	O
high	O
immunochemical	O
activity	O
(	O
Vieths	O
,	O
Schöning	O
,	O
&	O
Baltes	O
,	O
1992	O
)	O
.	O

In	O
the	O
further	O
sample	O
preparation	O
,	O
two	O
steps	O
shall	O
be	O
briefly	O
addressed	O
:	O
borohydride	B
reduction	O
,	O
which	O
was	O
employed	O
in	O
order	O
to	O
prevent	O
residual	O
free	O
sugars	B
from	O
subsequent	O
derivatization	O
which	O
proved	O
its	O
necessity	O
in	O
the	O
case	O
of	O
grass	O
pollen	O
extracts	O
where	O
several	O
artefactic	O
peaks	O
appeared	O
on	O
the	O
chromatogramms	O
without	O
this	O
step	O
(	O
F.	O
Altmann	O
,	O
personal	O
communication	O
)	O
.	O

Second	O
,	O
N	O
-glycosidase	O
A	O
from	O
almonds	O
was	O
used	O
for	O
the	O
deglycosylation	O
of	O
the	O
glycopeptides	O
,	O
which	O
is	O
important	O
,	O
since	O
the	O
(	O
more	O
)	O
frequently	O
used	O
N	O
-glycosidase	O
F	O
from	O
Flavobacterium	O
meningosepticum	O
can	O
not	O
cleave	O
glycans	B
containing	O
fucose	B
linked	O
α1–3	O
to	O
Asn	B
–	I
GlcNAc	I
(	O
Tretter	O
,	O
Altmann	O
,	O
&	O
März	O
,	O
1991	O
;	O
Altmann	O
,	O
Schweiszer	O
,	O
&	O
Weber	O
,	O
1995	O
)	O
.	O

The	O
methodology	O
for	O
the	O
structural	O
characterization	O
,	O
using	O
two	O
-	O
dimensional	O
HPLC	O
in	O
combination	O
with	O
exoglycosidase	O
digestions	O
,	O
was	O
first	O
introduced	O
by	O
Tomiya	O
et	O
al.	O
(	O
1988	O
)	O
and	O
has	O
been	O
employed	O
for	O
glycoprotein	O
–	O
glycans	B
from	O
various	O
sources	O
(	O
Takahashi	O
et	O
al.	O
,	O
1986	O
;	O
Kubelka	O
et	O
al.	O
,	O
1994	O
;	O
Ohsuga	O
et	O
al.	O
,	O
1996	O
)	O
.	O

Complex	O
-	O
type	O
structures	O
,	O
most	O
of	O
them	O
truncated	O
and	O
exhibiting	O
α1–3	O
linked	O
fucose	B
and/or	O
β1–2	O
linked	O
xylose	B
,	O
as	O
well	O
as	O
oligomannosidic	B
glycans	I
were	O
detected	O
.	O

Most	O
of	O
these	O
structures	O
have	O
been	O
reported	O
to	O
occur	O
in	O
other	O
plant	O
glycoproteins	O
;	O
MMXF3	B
,	O
addressed	O
to	O
be	O
the	O
typical	O
vacuole	O
-	O
type	O
plant	O
N	B
-glycan	I
(	O
Sturm	O
,	O
1995	O
)	O
and	O
the	O
most	O
abundant	O
oligosaccharide	B
in	O
tomato	O
fruit	O
,	O
has	O
also	O
been	O
found	O
in	O
horseradish	O
peroxidase	O
(	O
Kurosaka	O
et	O
al.	O
,	O
1991	O
)	O
,	O
a	O
protease	O
inhibitor	O
from	O
barbados	O
pride	O
(	O
Caesalpinia	O
Pulcherrima	O
Sw	O
.	O
)	O
seeds	O
(	O
Hase	O
et	O
al.	O
,	O
1986	O
)	O
,	O
Sophora	O
japonica	O
lectin	O
(	O
Fournet	O
et	O
al.	O
,	O
1987	O
)	O
and	O
ricin	O
D	O
from	O
the	O
seeds	O
of	O
castor	O
plants	O
(	O
Ricinus	O
communis	O
)	O
(	O
Kimura	O
et	O
al.	O
,	O
1988	O
)	O
.	O

M0XF3	B
,	O
another	O
structure	O
which	O
occurs	O
in	O
relatively	O
high	O
amounts	O
in	O
tomato	O
(	O
17–22	O
%	O
)	O
,	O
has	O
been	O
reported	O
for	O
both	O
pineapple	O
stem	O
bromelain	O
(	O
Van	O
Kuik	O
et	O
al.	O
,	O
1986	O
)	O
and	O
barley	O
peroxidase	O
(	O
Johannson	O
,	O
Rasmussen	O
,	O
Harthill	O
,	O
&	O
Welinder	O
,	O
1992	O
)	O
.	O

Small	O
α1,3-fucosylated	B
and/or	O
β1,2-xylosylated	B
glycans	I
that	O
are	O
minor	O
fractions	O
in	O
tomato	O
,	O
have	O
recently	O
also	O
been	O
found	O
in	O
other	O
plants	O
;	O
MMX	B
was	O
found	O
to	O
be	O
the	O
most	O
abundant	O
N	B
-glycan	I
in	O
rice	O
α	O
-	O
amylase	O
from	O
germinated	O
seedlings	O
(	O
Hayashi	O
et	O
al.	O
,	O
1990	O
)	O
and	O
also	O
represents	O
the	O
complex	O
oligosaccharide	B
side	O
chain	O
of	O
the	O
bean	O
storage	O
protein	O
phaseolin	O
(	O
Sturm	O
,	O
van	O
Kuik	O
,	O
Vliegenthart	O
,	O
&	O
Chrispeels	O
,	O
1987	O
)	O
.	O

M0X	B
accounts	O
for	O
15	O
%	O
of	O
the	O
N	B
-glycans	I
of	O
barley	O
(	O
1–3,1–4	O
)	O
-β	O
-	O
d	O
-glucan	O
4-glucanohydrolase	O
isoenzyme	O
EII	O
(	O
Harthill	O
,	O
&	O
Thomsen	O
,	O
1995	O
)	O
,	O
whereas	O
MMF3	B
was	O
found	O
to	O
be	O
a	O
minor	O
fraction	O
of	O
soybean	O
peroxidase	O
(	O
Gray	O
,	O
Yun	O
Yang	O
,	O
Hull	O
,	O
Venzke	O
,	O
&	O
Montgomery	O
,	O
1996	O
)	O
.	O

Three	O
structures	O
that	O
exhibit	O
outer	O
-	O
arm	O
GlcNAc	B
residues	O
and	O
represent	O
6–14	O
%	O
of	O
the	O
N	B
-glycans	I
in	O
tomato	O
fruit	O
,	O
have	O
been	O
previously	O
reported	O
for	O
lactase	O
from	O
sycamore	O
cells	O
(	O
Harthill	O
,	O
&	O
Thomsen	O
,	O
1995	O
)	O
.	O

GnMXF3	B
and	O
MGnXF3	B
were	O
also	O
found	O
to	O
be	O
present	O
in	O
red	O
kidney	O
bean	O
Fe	O
(	O
III	O
)	O
–Zn	O
(	O
II	O
)	O
purple	O
acid	O
phosphatase	O
(	O
Stahl	O
et	O
al.	O
,	O
1994	O
)	O
.	O

Oligomannosidic	B
structures	O
,	O
accounting	O
for	O
only	O
3–9	O
%	O
of	O
the	O
N	B
-glycans	I
in	O
tomato	O
fruit	O
,	O
are	O
wide	O
-	O
spread	O
among	O
plants	O
(	O
e.g.	O
soybean	O
agglutinin	O
(	O
Dorland	O
,	O
van	O
Halbeek	O
,	O
Vliegenthart	O
,	O
Lis	O
,	O
&	O
Sharon	O
,	O
1981	O
)	O
,	O
phaseolin	O
of	O
the	O
common	O
bean	O
(	O
Sturm	O
et	O
al.	O
,	O
1987	O
)	O
,	O
rice	O
α	O
-	O
amylase	O
(	O
Hayashi	O
et	O
al.	O
,	O
1990	O
)	O
,	O
α	O
-	O
amylase	O
inhibitor	O
from	O
white	O
kidney	O
bean	O
(	O
Phasolus	O
vulgaris	O
)	O
(	O
Yamaguchi	O
,	O
Funaoka	O
,	O
&	O
Iwamoto	O
,	O
1992	O
)	O
,	O
but	O
are	O
also	O
found	O
in	O
insect	O
,	O
yeast	O
and	O
mammalian	O
glycoproteins	O
.	O

α-1,3-Fucosylation	B
of	O
the	O
innermost	O
N	B
-acetylglucosamine	I
residue	O
,	O
a	O
typical	O
feature	O
of	O
N	B
-glycans	I
from	O
plants	O
but	O
also	O
from	O
insects	O
,	O
was	O
found	O
in	O
8	O
of	O
the	O
16	O
tomato	O
N	B
-linked	I
oligosaccharides	I
,	O
accounting	O
for	O
86–90	O
%	O
of	O
the	O
N	B
-glycan	I
pool	O
in	O
tomato	O
fruits	O
.	O

Such	O
fucosyl	B
residues	I
as	O
well	O
as	O
β1,2-linked	B
xylosyl	I
residues	I
are	O
not	O
present	O
in	O
mammalian	O
glycoproteins	O
and	O
therefore	O
render	O
plant	O
glycoproteins	O
immunogenic	O
(	O
Wilson	O
et	O
al.	O
,	O
1998	O
)	O
.	O

In	O
fact	O
,	O
even	O
IgE	O
antibodies	O
may	O
be	O
directed	O
against	O
this	O
epitope	B
.	O

Owing	O
to	O
their	O
widespread	O
occurrence	O
,	O
α1,3-fucosylated	B
N	I
-glycans	I
(	O
with	O
or	O
without	O
xylose	B
)	O
constitute	O
a	O
highly	O
cross	O
-	O
reactive	O
carbohydrate	B
determinant	O
detected	O
in	O
a	O
wide	O
variety	O
of	O
plant	O
as	O
well	O
as	O
insect	O
allergens	O
(	O
Tretter	O
et	O
al.	O
,	O
1993	O
;	O
Garcia	O
-	O
Casado	O
et	O
al.	O
,	O
1996	O
;	O
Jankiewicz	O
,	O
Aulepp	O
,	O
Altmann	O
,	O
Foetisch	O
,	O
&	O
Vieths	O
,	O
1998	O
)	O
.	O

As	O
far	O
as	O
tomatoes	O
are	O
concerned	O
,	O
Petersen	O
et	O
al.	O
(	O
1996	O
)	O
reported	O
the	O
reactivity	O
of	O
IgE	O
antibodies	O
of	O
grass	O
pollen	O
allergic	O
individuals	O
to	O
tomato	O
extracts	O
.	O

Lectin	O
blotting	O
of	O
proteins	O
and	O
ELISA	O
inhibition	O
experiments	O
using	O
glycopeptides	O
of	O
known	O
glycan	B
structures	O
suggested	O
the	O
presence	O
of	O
carbohydrate	B
IgE	O
epitopes	B
with	O
an	O
α1,3-fucose	B
residue	O
.	O

The	O
characterization	O
of	O
the	O
tomato	O
N	B
-glycans	I
presented	O
in	O
this	O
work	O
,	O
revealing	O
a	O
high	O
degree	O
of	O
α1,3-fucosylated	B
structures	O
in	O
the	O
fruit	O
,	O
offers	O
the	O
structural	O
explanation	O
for	O
these	O
findings	O
.	O

4	O
Experimental	O
4.1	O
Materials	O
Red	O
tomatoes	O
(	O
variety	O
Notoro	O
)	O
were	O
bought	O
in	O
a	O
retail	O
shop	O
;	O
red	O
and	O
green	O
tomatoes	O
(	O
variety	O
San	O
Marzano	O
)	O
were	O
obtained	O
from	O
RIKILT	O
-	O
DLO	O
,	O
Netherlands	O
.	O

N	O
-glycosidase	O
A	O
from	O
almonds	O
and	O
endoglycosidase	O
H	O
from	O
Streptomyces	O
plicatus	O
were	O
purchased	O
from	O
Boehringer	O
Mannheim	O
.	O

β	O
-	O
N	O
-acetylglucosaminidase	O
(	O
jack	O
bean	O
)	O
,	O
α	O
-	O
mannosidase	O
(	O
jack	O
bean	O
)	O
and	O
pepsin	O
(	O
from	O
porcine	O
stomach	O
mucosa	O
)	O
were	O
obtained	O
from	O
Sigma	O
.	O

2-aminopyridine	B
,	O
sodium	B
cyanoborohydride	I
,	O
dithioerythritol	B
,	O
benzamidine	B
and	O
PMSF	B
were	O
obtained	O
from	O
Sigma	O
.	O

4.2	O
Precipitation	O
of	O
proteins	O
using	O
a	O
low	O
-	O
temperature	O
acetone	B
powder	O
method	O
The	O
extracts	O
were	O
prepared	O
in	O
a	O
similar	O
manner	O
to	O
that	O
described	O
by	O
Vieths	O
,	O
Schöning	O
,	O
and	O
Petersen	O
(	O
1994	O
)	O
:	O
200	O
g	O
of	O
tomato	O
fruit	O
were	O
homogenized	O
in	O
400	O
ml	O
of	O
ice	B
-	O
cold	O
acetone	B
on	O
dry	B
ice	I
.	O

Another	O
400	O
ml	O
of	O
ice	B
-	O
cold	O
acetone	B
were	O
added	O
and	O
the	O
sample	O
was	O
kept	O
on	O
dry	B
ice	I
overnight	O
with	O
occasional	O
stirring	O
during	O
the	O
first	O
few	O
hours	O
.	O

The	O
resulting	O
precipitate	O
was	O
filtered	O
through	O
sintered	O
glass	O
and	O
washed	O
twice	O
with	O
acetone	B
and	O
once	O
with	O
acetone	B
/	O
diethylether	B
(	O
1:1	O
,	O
v	O
/	O
v	O
)	O
at	O
−20	O
°	O
C	O
.	O

The	O
sediment	O
was	O
lyophilized	O
.	O

4	O
g	O
of	O
acetone	B
powder	O
were	O
taken	O
up	O
in	O
150	O
ml	O
phosphate	B
buffered	O
saline	B
(	O
10	O
mM	O
phosphate	B
pH	O
7.4	O
;	O
0.15	O
M	O
NaCl	B
)	O
and	O
stirred	O
at	O
4	O
°	O
C	O
for	O
60	O
min	O
.	O

After	O
centrifugation	O
(	O
20000	O
rpm	O
,	O
20	O
min	O
,	O
0	O
°	O
C	O
)	O
,	O
the	O
supernatant	O
was	O
filtered	O
(	O
0.45	O
μm	O
)	O
,	O
extensively	O
dialyzed	O
against	O
double	O
-	O
distilled	O
water	B
(	O
membrane	O
3.5	O
kD	O
cut	O
-	O
off	O
)	O
overnight	O
and	O
lyophilized	O
.	O

4.3	O
Ammonium	B
sulfate	I
precipitation	O
As	O
an	O
alternative	O
to	O
the	O
above	O
-	O
mentioned	O
procedure	O
,	O
ammonium	B
sulfate	I
precipitation	O
was	O
per	O
-	O
formed	O
:	O
to	O
200	O
g	O
of	O
tomato	O
fruit	O
400	O
ml	O
of	O
extraction	O
buffer	O
(	O
10	O
mM	O
phosphate	B
pH	O
7.4	O
,	O
150	O
mM	O
NaCl	B
,	O
1	O
mM	O
EDTA	B
,	O
1	O
mM	O
benzamidine	B
,	O
1	O
mM	O
DTE	B
,	O
0.1	O
mM	O
PMSF	B
)	O
was	O
added	O
and	O
the	O
sample	O
was	O
homogenized	O
.	O

Centrifugation	O
was	O
carried	O
out	O
at	O
20000	O
rpm	O
(	O
20	O
min	O
,	O
4	O
°	O
C	O
)	O
.	O

Solid	O
ammonium	B
sulfate	I
was	O
added	O
to	O
the	O
supernatant	O
to	O
a	O
final	O
concentration	O
of	O
80	O
%	O
saturation	O
.	O

The	O
mixture	O
was	O
stirred	O
at	O
4	O
°	O
C	O
for	O
3	O
h	O
,	O
centrifuged	O
(	O
20000	O
rpm	O
,	O
20	O
min	O
,	O
4	O
°	O
C	O
)	O
and	O
the	O
pellet	O
was	O
dialyzed	O
against	O
double	O
-	O
distilled	O
water	B
and	O
lyophilized	O
.	O

4.4	O
Purification	O
of	O
N	B
-glycans	I
The	O
lyophilisate	O
was	O
dissolved	O
in	O
5	O
%	O
v	O
/	O
v	O
formic	B
acid	I
and	O
digested	O
with	O
pepsin	O
(	O
2	O
%	O
,	O
w	O
/	O
w	O
)	O
for	O
48	O
h	O
at	O
37	O
°	O
C	O
.	O

(	O
Another	O
1	O
%	O
w	O
/	O
w	O
pepsin	O
was	O
added	O
after	O
24	O
h	O
)	O
.	O

After	O
centrifugation	O
(	O
10000	O
rpm	O
,	O
10	O
min	O
)	O
,	O
the	O
supernatant	O
was	O
adjusted	O
to	O
pH	O
2.5	O
and	O
chromatographed	O
on	O
an	O
ion	O
-	O
exchange	O
SP650-M	O
column	O
,	O
1	O
×	O
5	O
cm	O
(	O
Toso	O
Haas	O
)	O
,	O
equilibrated	O
with	O
5	O
%	O
acetic	B
acid	I
.	O

After	O
application	O
of	O
the	O
sample	O
,	O
the	O
column	O
was	O
rinsed	O
with	O
40	O
ml	O
5	O
%	O
acetic	B
acid	I
.	O

The	O
glycopeptide	O
fraction	O
was	O
eluted	O
with	O
1	O
M	O
ammonia	B
(	O
collection	O
of	O
2	O
ml	O
fractions	O
)	O
.	O

Carbohydrate	B
-	O
positive	O
fractions	O
,	O
detected	O
using	O
the	O
orcinol	B
–	O
sulfuric	B
acid	I
reagent	O
according	O
to	O
Winzler	O
(	O
1955	O
)	O
,	O
were	O
pooled	O
and	O
lyophilized	O
.	O

The	O
sample	O
was	O
taken	O
up	O
in	O
1	O
ml	O
water	B
;	O
the	O
pH	O
was	O
adjusted	O
to	O
9	O
with	O
ammonia	B
.	O

100	O
μl	O
of	O
a	O
2	O
%	O
w	O
/	O
v	O
sodium	B
borohydride	I
solution	O
was	O
added	O
and	O
the	O
sample	O
was	O
incubated	O
at	O
room	O
temperature	O
overnight	O
.	O

After	O
addition	O
of	O
acetic	B
acid	I
and	O
evaporation	O
,	O
this	O
step	O
was	O
repeated	O
twice	O
with	O
1	O
%	O
v	O
/	O
v	O
acetic	B
acid	I
in	O
methanol	B
and	O
twice	O
with	O
MeOH	B
.	O

The	O
sample	O
was	O
dissolved	O
in	O
100	O
μl	O
citrate	B
/	O
phosphate	B
pH	O
5.0	O
and	O
digested	O
with	O
0.5	O
mU	O
of	O
N	O
-glycosidase	O
A	O
for	O
37	O
°	O
C	O
for	O
48	O
h.	O
Oligosaccharides	B
were	O
separated	O
from	O
residual	O
glycopeptides	O
and	O
peptides	O
using	O
a	O
reverse	O
-	O
phase	O
cartridge	O
as	O
described	O
by	O
Dell	O
et	O
al.	O
(	O
Dell	O
et	O
al.	O
,	O
1993	O
)	O
.	O

The	O
glycans	B
were	O
labelled	O
with	O
2-aminopyridine	B
according	O
to	O
Hase	O
,	O
Ibuki	O
,	O
and	O
Ikenaka	O
(	O
1984	O
)	O
.	O

To	O
remove	O
the	O
excess	O
of	O
reagent	O
,	O
a	O
gelfiltration	O
step	O
was	O
performed	O
using	O
a	O
1	O
×	O
40	O
cm	O
Sephadex	O
G15	O
column	O
,	O
equilibrated	O
with	O
1	O
%	O
w	O
/	O
v	O
acetic	B
acid	I
.	O

4.5	O
Fractionation	O
of	O
pyridylaminated	B
oligosaccharides	I
by	O
two	O
-	O
dimensional	O
HPLC	O
A	O
Shimadzu	O
module	O
system	O
,	O
consisting	O
of	O
a	O
system	O
controller	O
,	O
a	O
pump	O
and	O
a	O
fluorescence	O
detector	O
was	O
used	O
.	O

Separations	O
of	O
the	O
pyridylamino	B
-	I
oligosaccharides	I
using	O
two	O
different	O
HPLC	O
columns	O
were	O
performed	O
at	O
room	O
temperature	O
.	O

Glucose	B
oligomers	B
were	O
used	O
in	O
both	O
systems	O
for	O
calibration	O
and	O
as	O
internal	O
standards	O
.	O

Elution	O
volumes	O
of	O
the	O
samples	O
were	O
expressed	O
in	O
glucose	B
units	O
according	O
to	O
Lee	O
,	O
Lee	O
,	O
Tomiya	O
,	O
and	O
Takahashi	O
(	O
1990	O
)	O
.	O

Fractionation	O
according	O
to	O
size	O
was	O
accomplished	O
on	O
a	O
MicroPak	O
AX-5	O
column	O
(	O
4	O
×	O
300	O
mm	O
,	O
VARIAN	O
)	O
;	O
the	O
eluents	O
were	O
as	O
follows	O
:	O
(	O
A	O
)	O
3	O
%	O
w	O
/	O
v	O
acetic	B
acid	I
,	O
triethylamine	B
pH	O
7.3	O
:	O
acetonitrile	B
35:65	O
,	O
v	O
/	O
v	O
and	O
(	O
B	O
)	O
3	O
%	O
w	O
/	O
v	O
acetic	B
acid	I
,	O
triethylamine	O
pH	O
7.3	O
:	O
acetonitrile	B
50:50	O
,	O
v	O
/	O
v	O
.	O

A	O
linear	O
gradient	O
of	O
0–60%B	O
in	O
30	O
min	O
at	O
a	O
flow	O
rate	O
of	O
1	O
ml	O
/	O
min	O
was	O
applied	O
.	O

Further	O
separation	O
was	O
achieved	O
by	O
reverse	O
-	O
phase	O
HPLC	O
on	O
a	O
5	O
μm	O
hypersil	O
ODS	O
column	O
(	O
Shandon	O
)	O
.	O

The	O
column	O
was	O
equilibrated	O
with	O
0.1	O
M	O
ammonium	B
acetate	I
pH	O
4.0	O
and	O
eluted	O
with	O
a	O
linear	O
gradient	O
of	O
0–7.5	O
%	O
(	O
by	O
vol	O
.	O
)	O
methanol	B
in	O
25	O
min	O
at	O
a	O
flow	O
rate	O
of	O
1.5	O
ml	O
/	O
min	O
.	O

In	O
both	O
systems	O
,	O
pyridylaminated	B
oligosaccharides	I
were	O
detected	O
by	O
fluorescence	O
using	O
excitation	O
and	O
emission	O
wavelengths	O
of	O
320	O
and	O
400	O
nm	O
,	O
respectively	O
.	O

4.6	O
Exoglycosidase	O
digestions	O
Generally	O
,	O
about	O
50–100	O
pmol	O
of	O
oligosaccharide	B
were	O
incubated	O
for	O
20	O
h	O
at	O
37	O
°	O
C	O
.	O

The	O
following	O
buffers	O
and	O
enzyme	O
quantities	O
were	O
used	O
:	O
50	O
mU	O
α	O
-	O
mannosidase	O
in	O
50	O
mM	O
sodium	B
acetate	I
,	O
pH	O
4.2	O
containing	O
0.1	O
mM	O
ZnCl2	B
to	O
achieve	O
complete	O
removal	O
of	O
α	O
-	O
linked	O
mannose	B
residues	O
;	O
5	O
mU	O
of	O
α	O
-	O
mannosidase	O
to	O
selectively	O
remove	O
α1,3-linked	O
mannose	B
residues	O
;	O
2	O
mU	O
β	O
-	O
N	O
-acetylhexosaminidase	O
(	O
for	O
partial	O
hydrolysis	O
)	O
or	O
10	O
mU	O
of	O
the	O
enzyme	O
for	O
complete	O
hydrolysis	O
,	O
using	O
0.1	O
M	O
sodium	B
citrate	I
,	O
pH	O
5.0	O
;	O
1	O
mU	O
endoglycosidase	O
H	O
in	O
0.1	O
M	O
sodium	B
citrate	I
/	O
phosphate	B
,	O
pH	O
5.0	O
.	O

4.7	O
Preparation	O
of	O
reference	O
oligosaccharides	B
Pyridylaminated	B
oligosaccharides	I
used	O
as	O
reference	O
substances	O
were	O
prepared	O
from	O
the	O
following	O
sources	O
:	O
Manα1–6	B
(	I
Manα1–3	I
)	I
Manβ1–4GlcNAcβ1–4GlcNAc	I
(	O
MM	B
)	O
from	O
bovine	O
fibrin	O
(	O
Staudacher	O
,	O
Kubelka	O
,	O
&	O
März	O
,	O
1992	O
)	O
;	O
Manα1–6	B
(	I
Manα1–3	I
)	I
(	I
Xylβ1–2	I
)	I
Manβ1–4GlcNAcβ1–4GlcNAc	I
(	O
MMX	B
)	O
from	O
zucchini	O
ascorbate	O
oxidase	O
(	O
Altmann	O
,	O
1998	O
)	O
;	O
Manα1–6	B
(	I
Manα1–3	I
)	I
Manβ1–4GlcNAcβ1–4	I
(	I
Fucα1–3	I
)	I
GlcNAc	I
(	O
MMF3	B
)	O
from	O
honeybee	O
venom	O
phospholipase	O
A2	O
(	O
Kubelka	O
et	O
al.	O
,	O
1993	O
)	O
;	O
Manα1–6	B
(	I
Xylβ1–2	I
)	I
Manβ1–4GlcNAcβ1–4	I
(	I
Fucα1–3	I
)	I
GlcNAc	I
(	O
M0XF3	B
)	O
from	O
pineapple	O
stem	O
bromelain	O
(	O
Van	O
Kuik	O
et	O
al.	O
,	O
1986	O
)	O
;	O
Manα1–6	B
(	I
Manα1–3	I
)	I
(	I
Xylβ1–2	I
)	I
Manβ1–4GlcNAcβ1–4	I
(	I
Fucα1–3	I
)	I
GlcNAc	I
(	O
MMXF3	B
)	O
from	O
horseradish	O
peroxidase	O
(	O
Kurosaka	O
et	O
al.	O
,	O
1991	O
)	O
;	O
GlcNAcβ1–2Manα1–6	B
(	I
GlcNAcβ1–2Manα1–3	I
)	I
(	I
Xylβ1–2	I
)	I
Manβ1–4GlcNAcβ1–4	I
(	I
Fucα1–3	I
)	I
GlcNAc	I
(	O
GnGnXF3	B
)	O
from	O
hornbeam	O
pollen	O
(	O
Wilson	O
,	O
&	O
Altmann	O
,	O
1998	O
)	O
;	O
Man6	B
GlcNAc2	I
[	B
M6.1	I
]	I
1	I
Codes	O
for	O
oligomannose	B
structures	O
according	O
to	O
Tomiya	O
et	O
al.	O
(	O
1991	O
)	O
.	O

1	O
,	O
Man7	B
GlcNAc2	I
[	B
M7.1	I
]	I
1	I
,	O
[	B
M7.2	I
]	I
1	I
,	O
and	O
Man8	B
GlcNAc2	I
[	B
M8.1	I
]	I
1	I
from	O
soybean	O
7S	O
-glycoprotein	O
(	O
Neeser	O
,	O
Vedovo	O
,	O
Mutsaers	O
,	O
&	O
Vliegenthart	O
,	O
1985	O
)	O
.	O

The	O
structures	O
of	O
the	O
reference	O
oligosaccharides	B
were	O
confirmed	O
by	O
methylation	B
analysis	O
(	O
data	O
not	O
shown	O
)	O
.	O

For	O
column	O
calibration	O
,	O
pyridylaminated	B
isomaltooligosaccharides	I
were	O
prepared	O
from	O
partially	O
hydrolyzed	O
dextran	B
.	O

4.8	O
Matrix	O
-	O
assisted	O
laser	O
desorption	O
/	O
ionization	O
–	O
time	O
of	O
flight	O
–	O
mass	O
spectrometry	O
MALDI	O
–	O
TOF	O
–	O
MS	O
data	O
was	O
obtained	O
using	O
a	O
Dynamo	O
instrument	O
(	O
Thermo	O
Bioanalysis	O
,	O
UK	O
)	O
,	O
operating	O
in	O
the	O
positiv	O
-	O
ion	O
linear	O
mode	O
.	O

About	O
5–10	O
pmol	O
of	O
pyridylaminated	B
tomato	O
N	B
-glycans	I
(	O
individual	O
reverse	O
-	O
phase	O
HPLC	O
fractions	O
)	O
were	O
repeatedly	O
dried	O
under	O
nitrogen	B
to	O
remove	O
buffer	O
components	O
;	O
the	O
samples	O
were	O
finally	O
dissolved	O
in	O
6	O
μl	O
water	B
and	O
3	O
μl	O
matrix	O
solution	O
(	O
2	O
%	O
2,5-dihydroxybenzoic	B
acid	I
in	O
water	B
containing	O
30	O
%	O
acetonitrile	B
and	O
0,5	O
mM	O
NaCl	B
)	O
.	O

Aliquots	O
of	O
1	O
μl	O
were	O
applied	O
on	O
the	O
target	O
and	O
allowed	O
to	O
dry	O
.	O

Mass	O
spectra	O
were	O
obtained	O
by	O
averaging	O
20	O
single	O
spectra	O
.	O

External	O
mass	O
calibration	O
was	O
performed	O
with	O
pyridylaminated	B
GlcNAc2	I
Man3	I
GlcNAc2	I
(	O
MNa+	O
=	O
1418,2	O
Da	O
)	O
which	O
was	O
prepared	O
from	O
bovine	O
fibrin	O
as	O
described	O
(	O
Altmann	O
,	O
Schwihla	O
,	O
Staudacher	O
,	O
Glössl	O
,	O
&	O
März	O
,	O
1995	O
)	O
.	O

4.9	O
HPLC	O
-	O
analysis	O
of	O
OPA	B
-	I
aminosugars	I
An	O
aliquot	O
of	O
the	O
glycopeptide	O
fraction	O
was	O
hydrolyzed	O
with	O
4	O
M	O
TFA	B
and	O
aminosugar	B
analysis	O
by	O
reverse	O
-	O
phase	O
chromatography	O
was	O
performed	O
as	O
described	O
by	O
Altmann	O
(	O
1992	O
)	O
.	O

Acknowledgements	O

We	O
thank	O
Hubert	O
Noteborn	O
,	O
RILILT	O
-	O
DLO	O
for	O
supplying	O
us	O
with	O
the	O
tomato	O
samples	O
and	O
Thomas	O
Dalik	O
for	O
performing	O
the	O
aminosugar	B
analyses	O
.	O

This	O
work	O
was	O
financed	O
by	O
the	O
EU	O
-	O
project	O
AIR3-CT94	O
-	O
2311	O
.	O

2-Nitrofluorene	B
(	O
NF	B
)	O
is	O
an	O
air	B
pollutant	O
which	O
has	O
been	O
used	O
as	O
a	O
model	O
substance	O
of	O
nitrated	B
polycyclic	I
aromatic	I
hydrocarbons	I
(	O
nitro	B
-	I
PAHs	I
)	O
[	O
1	O
,	O
2	O
]	O
.	O

NF	B
enters	O
in	O
vivo	O
into	O
an	O
oxidative	O
or	O
a	O
reductive	O
metabolic	O
pathway	O
,	O
depending	O
on	O
the	O
route	O
of	O
administration	O
[	O
3–5	O
]	O
.	O

Oral	O
administration	O
results	O
mainly	O
in	O
reduced	B
metabolites	I
[	O
5	O
]	O
,	O
e.g.	O
,	O
2-aminofluorene	B
(	O
AF	B
)	O
and	O
2-acetylaminofluorene	B
(	O
AAF	B
)	O
,	O
both	O
are	O
carcinogens	B
.	O

It	O
is	O
reported	O
that	O
NF	B
induces	O
DNA	B
adduct	I
formation	O
in	O
vivo	O
with	O
dG	B
-	I
C8-AF	I
as	O
one	O
of	O
the	O
characterized	O
DNA	B
adducts	I
[	O
6	O
,	O
7	O
]	O
.	O

dG	B
-	I
C8-AF	I
,	O
together	O
with	O
other	O
known	O
AF-	B
and	O
AAF	B
-	O
related	O
DNA	O
adducts	O
(	O
i.e.	O
,	O
dG	B
-	I
C8-AAF	I
,	O
dG	B
-	I
N	I
2	I
-AAF	I
,	O
etc	O
.	O
)	O
have	O
been	O
suspected	O
to	O
be	O
pre	O
-	O
mutagenic	O
or	O
toxic	O
[	O
8	O
]	O
.	O

Carcinogens	B
have	O
been	O
shown	O
to	O
induce	O
DNA	B
adducts	I
[	O
6	O
,	O
7	O
,	O
9	O
,	O
10	O
]	O
.	O

Exposures	O
of	O
human	O
populations	O
to	O
complex	O
mixtures	O
with	O
known	O
or	O
suspected	O
risk	O
of	O
inducing	O
cancer	O
is	O
also	O
associated	O
with	O
formation	O
of	O
DNA	B
adducts	I
[	O
11–13	O
]	O
.	O

High	O
levels	O
of	O
DNA	B
adducts	I
in	O
normal	O
human	O
colonic	O
mucosa	O
is	O
significantly	O
associated	O
with	O
colorectal	O
cancer	O
[	O
14	O
]	O
.	O

In	O
polluted	O
areas	O
,	O
the	O
seasonal	O
change	O
of	O
DNA	B
adducts	I
in	O
human	O
lymphocytes	O
varies	O
with	O
the	O
seasonal	O
changes	O
of	O
air	B
pollutants	O
[	O
15	O
]	O
.	O

Thus	O
,	O
DNA	B
adducts	I
may	O
be	O
used	O
as	O
biomarkers	O
for	O
genotoxic	O
risk	O
.	O

DNA	B
adducts	I
have	O
different	O
stabilities	O
owing	O
to	O
factors	O
such	O
as	O
DNA	O
repair	O
and	O
chemical	O
instability	O
.	O

No	O
uniform	O
correlation	O
is	O
found	O
between	O
adduct	O
persistence	O
and	O
tumor	O
induction	O
.	O

However	O
,	O
it	O
is	O
postulated	O
that	O
the	O
persistent	O
DNA	B
adducts	I
represent	O
dormant	O
lesions	O
that	O
may	O
become	O
fixed	O
as	O
mutations	O
long	O
after	O
exposure	O
to	O
the	O
carcinogen	O
and	O
contribute	O
to	O
the	O
malignant	O
transformation	O
as	O
a	O
result	O
of	O
cell	O
division	O
[	O
16	O
]	O
.	O

Measurement	O
of	O
DNA	B
adducts	I
from	O
carcinogenic	O
alkenylbenzenes	B
in	O
preweanling	O
male	O
B6C3F1	O
mice	O
suggests	O
the	O
virtual	O
absence	O
of	O
DNA	O
repair	O
for	O
these	O
adducts	B
[	O
17	O
]	O
.	O

This	O
has	O
been	O
postulated	O
to	O
play	O
a	O
role	O
in	O
the	O
carcinogenicity	O
of	O
safrole	B
and	O
related	O
alkenylbenzenes	B
in	O
newborn	O
mice	O
[	O
17–20	O
]	O
.	O

Further	O
experiments	O
show	O
that	O
rapid	O
repair	O
of	O
O	B
6	I
-methylguanine	I
-	I
DNA	I
adducts	I
protects	O
transgenic	O
mice	O
from	O
N	B
-methylnitrosourea	I
-	O
induced	O
thymic	O
lymphomas	O
[	O
21	O
]	O
.	O

It	O
has	O
also	O
been	O
reported	O
that	O
increased	O
platinum	B
removal	O
from	O
total	O
genomic	O
DNA	O
was	O
associated	O
with	O
increased	O
cisplatin	B
resistance	O
in	O
human	O
ovarian	O
cancer	O
cell	O
lines	O
[	O
22	O
]	O
.	O

A	O
recently	O
published	O
long	O
-	O
term	O
tumor	O
study	O
on	O
Wistar	O
rats	O
showed	O
that	O
NF	B
induces	O
tumors	O
in	O
the	O
liver	O
,	O
kidney	O
and	O
forestomach	O
.	O

DNA	B
adducts	I
are	O
formed	O
at	O
higher	O
levels	O
during	O
the	O
early	O
stage	O
of	O
NF	B
administration	O
in	O
these	O
tumor	O
-	O
target	O
organs	O
compared	O
with	O
some	O
non	O
-	O
tumor	O
target	O
organs	O
(	O
heart	O
,	O
spleen	O
and	O
glandular	O
stomach	O
)	O
[	O
23	O
]	O
.	O

However	O
,	O
NF	B
and	O
also	O
a	O
lot	O
of	O
other	O
carcinogens	B
induce	O
DNA	B
adducts	I
in	O
both	O
tumor	O
-	O
target	O
and	O
non	O
-	O
tumor	O
target	O
tissues	O
.	O

It	O
is	O
thus	O
of	O
significance	O
to	O
know	O
the	O
biochemical	O
characteristics	O
and	O
mutagenic	O
effects	O
of	O
the	O
individual	O
DNA	B
adduct	I
induced	O
by	O
carcinogens	B
.	O

Better	O
correlation	O
may	O
be	O
achieved	O
when	O
an	O
individual	O
DNA	B
adduct	I
is	O
compared	O
with	O
tumor	O
formation	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
formation	O
and	O
persistence	O
and	O
the	O
characterization	O
of	O
DNA	B
adducts	I
during	O
and	O
after	O
a	O
long	O
-	O
term	O
administration	O
of	O
NF	B
.	O

2	O
Materials	O
and	O
methods	O
2.1	O
Animal	O
experiment	O
Male	O
Wistar	O
rats	O
from	O
Möllegaard	O
Breeding	O
Center	O
(	O
Skensved	O
,	O
Denmark	O
)	O
with	O
a	O
body	O
weight	O
of	O
approximately	O
90	O
g	O
,	O
were	O
used	O
for	O
the	O
experiment	O
.	O

The	O
rats	O
were	O
housed	O
in	O
wire	O
-	O
bottomed	O
cages	O
under	O
standardized	O
conditions	O
of	O
light	O
(	O
12	O
h	O
light	O
and	O
dark	O
cycle	O
)	O
,	O
humidity	O
(	O
55–60	O
%	O
)	O
and	O
temperature	O
(	O
21±1	O
°	O
C	O
)	O
.	O

The	O
rats	O
were	O
acclimatized	O
for	O
1	O
week	O
before	O
the	O
start	O
of	O
the	O
experiment	O
.	O

During	O
the	O
entire	O
experiment	O
,	O
the	O
rats	O
had	O
access	O
to	O
food	O
and	O
water	B
ad	O
libitum	O
.	O

The	O
rats	O
were	O
randomly	O
divided	O
into	O
four	O
groups	O
.	O

Three	O
groups	O
were	O
fed	O
diets	O
supplemented	O
with	O
different	O
concentrations	O
of	O
NF	B
which	O
were	O
0.24	O
mmol	O
(	O
LD	O
=	O
low	O
dose	O
)	O
,	O
0.95	O
mmol	O
(	O
MD	O
=	O
medium	O
dose	O
)	O
and	O
2.37	O
mmol	O
(	O
HD	O
=	O
high	O
dose	O
)	O
per	O
kg	O
diet	O
,	O
respectively	O
.	O

One	O
group	O
was	O
fed	O
basal	O
diet	O
(	O
R3	O
,	O
Ewos	O
,	O
Södertälje	O
,	O
Sweden	O
)	O
as	O
a	O
control	O
group	O
.	O

The	O
rats	O
were	O
fed	O
NF	B
-	O
supplemented	O
diets	O
continuously	O
for	O
11	O
months	O
,	O
thereafter	O
,	O
all	O
groups	O
were	O
fed	O
basal	O
diet	O
for	O
a	O
further	O
13	O
months	O
.	O

The	O
tumor	O
results	O
of	O
this	O
study	O
were	O
previously	O
reported	O
[	O
23	O
]	O
.	O

In	O
the	O
present	O
study	O
,	O
DNA	B
adducts	I
were	O
not	O
detected	O
in	O
the	O
LD	O
group	O
.	O

Different	O
tissues	O
,	O
i.e.	O
,	O
liver	O
,	O
kidney	O
,	O
forestomach	O
,	O
glandular	O
stomach	O
and	O
spleen	O
,	O
were	O
collected	O
for	O
DNA	B
adduct	I
analysis	O
.	O

The	O
early	O
stage	O
DNA	B
adduct	I
levels	O
were	O
obtained	O
from	O
three	O
rats	O
after	O
10	O
days	O
of	O
HD	O
NF	B
administration	O
.	O

The	O
later	O
stage	O
DNA	B
adduct	I
analysis	O
was	O
focused	O
on	O
the	O
samples	O
which	O
were	O
obtained	O
from	O
three	O
rats	O
that	O
were	O
killed	O
shortly	O
before	O
the	O
cessation	O
of	O
the	O
HD	O
NF	B
diet	O
(	O
11	O
months	O
)	O
.	O

The	O
persistence	O
of	O
DNA	B
adduct	I
levels	O
in	O
the	O
liver	O
after	O
the	O
termination	O
of	O
NF	B
administration	O
was	O
monitored	O
in	O
the	O
MD	O
group	O
.	O

2.2	O
DNA	B
adduct	I
analyses	O
Tissues	O
from	O
the	O
rat	O
were	O
homogenized	O
in	O
a	O
buffer	O
of	O
1	O
%	O
SDS	B
,	O
1	O
mM	O
EDTA	B
and	O
10	O
mM	O
Tris	B
–	I
HCl	I
(	O
pH	O
7.4	O
)	O
while	O
kept	O
cold	O
on	O
an	O
ice	B
bed	O
.	O

After	O
RNAse	O
and	O
proteinase	O
K	O
digestion	O
,	O
DNA	O
was	O
extracted	O
by	O
the	O
phenol	B
and	O
chloroform	B
and	O
then	O
hydrolyzed	O
by	O
micrococcal	O
nuclease	O
and	O
spleen	O
phosphodiesterase	O
.	O

DNA	B
adducts	I
were	O
enriched	O
by	O
butanol	B
extraction	O
in	O
the	O
presence	O
of	O
tetrabutylammonium	B
chloride	I
.	O

DNA	B
adducts	I
were	O
then	O
labeled	O
with	O
[	B
γ-32	I
P	I
]	I
ATP	I
by	O
polynucleotide	O
kinase	O
.	O

The	O
method	O
used	O
was	O
originally	O
from	O
Beach	O
and	O
Gupta	O
[	O
24	O
]	O
with	O
small	O
modifications	O
in	O
different	O
steps	O
[	O
25	O
,	O
26	O
]	O
.	O

32	B
P	I
-HPLC	O
-	O
analyses	O
of	O
postlabeled	O
DNA	B
adducts	I
were	O
performed	O
by	O
injecting	O
the	O
total	O
unrefined	O
32	B
P	I
-labeling	O
mixture	O
into	O
the	O
32	B
P	I
-HPLC	O
.	O

In	O
each	O
analysis	O
,	O
2.8	O
μg	O
of	O
DNA	O
(	O
5	O
μCi	O
)	O
was	O
injected	O
.	O

A	O
DeltaPak	O
™	O
5	O
μm	O
C18–100	O
Å	O
column	O
,	O
with	O
a	O
0.5	O
ml	O
/	O
min	O
flow	O
rate	O
of	O
2	O
M	O
ammonium	B
formate	I
,	O
0.4	O
M	O
formic	B
acid	I
(	O
pH	O
4.5	O
)	O
with	O
a	O
linear	O
gradient	O
of	O
0–35	O
%	O
acetonitrile	B
(	O
0–70	O
min	O
)	O
was	O
used	O
for	O
the	O
separation	O
of	O
phosphorylated	B
nucleotides	I
and	O
adducts	B
.	O

The	O
32	B
P	I
-HPLC	O
method	O
for	O
analyses	O
of	O
postlabeled	O
DNA	B
adducts	I
is	O
described	O
in	O
detail	O
elsewhere	O
[	O
25	O
,	O
26	O
]	O
.	O

2.3	O
Detection	O
of	O
NF	B
-	I
DNA	I
adducts	I
after	O
different	O
enrichment	O
procedures	O
Butanol	B
extraction	O
and	O
nuclease	O
P1	O
(	O
Sigma	O
,	O
St.	O
Louis	O
,	O
MO	O
)	O
treatment	O
were	O
run	O
in	O
parallel	O
for	O
the	O
comparison	O
of	O
enrichment	O
efficiency	O
of	O
the	O
NF	B
-	I
DNA	I
adducts	I
.	O

Liver	O
samples	O
were	O
collected	O
from	O
rats	O
receiving	O
11	O
months	O
of	O
HD	O
NF	B
feeding	O
.	O

In	O
the	O
nuclease	O
P1	O
enrichment	O
procedure	O
,	O
normal	O
nucleotides	B
were	O
dephosphorylated	O
by	O
40	O
min	O
37	O
°	O
C	O
incubation	O
with	O
nuclease	O
P1	O
(	O
in	O
1	O
mM	O
ZnCI2	B
)	O
in	O
1	O
μg	O
/	O
μg	O
DNA	B
level	O
.	O

The	O
hydrolysates	O
were	O
thereafter	O
evaporated	O
to	O
dryness	O
and	O
redissolved	O
in	O
water	B
for	O
32	B
P	I
-labeling	O
as	O
described	O
above	O
.	O

2.4	O
Identification	O
of	O
NF	B
-	I
DNA	I
adducts	I
DNA	B
adducts	I
formed	O
in	O
the	O
liver	O
after	O
11-month	O
HD	O
NF	B
administration	O
were	O
co	O
-	O
chromatographed	O
with	O
DNA	B
adduct	I
standards	O
:	O
dGp	B
-	I
C8-AF	I
,	O
dGp	B
-	I
C8-AAF	I
and	O
dGp	B
-	I
N	I
2	I
-AAF	I
(	O
Fig.	O
1	O
)	O
.	O

The	O
DNA	B
adduct	I
standards	O
were	O
kindly	O
supplied	O
by	O
Dr.	O
F.A.	O
Beland	O
,	O
National	O
Center	O
for	O
Toxicological	O
Research	O
,	O
Jefferson	O
,	O
AR	O
,	O
USA	O
.	O

3	O
Results	O
Four	O
DNA	B
adducts	I
(	O
DNA	B
adduct	I
A	B
,	O
B	B
,	O
C	B
and	O
D	B
)	O
were	O
found	O
in	O
rat	O
tissues	O
after	O
10	O
days	O
as	O
well	O
as	O
11	O
months	O
of	O
HD	O
NF	B
feeding	O
.	O

Fig.	O
2	O
shows	O
representative	O
32	B
P	I
-HPLC	O
chromatograms	O
of	O
DNA	B
adducts	I
formed	O
in	O
the	O
liver	O
,	O
kidney	O
and	O
spleen	O
after	O
10	O
days	O
(	O
Fig.	O
2	O
a	O
–	O
c	O
)	O
and	O
11	O
months	O
(	O
Fig.	O
2	O
d	O
–	O
f	O
)	O
of	O
HD	O
NF	B
feeding	O
.	O

DNA	B
adducts	I
A	B
and	O
B	B
increased	O
dramatically	O
in	O
the	O
liver	O
and	O
kidney	O
during	O
the	O
period	O
of	O
NF	B
administration	O
.	O

Adducts	B
C	B
and	O
D	B
showed	O
less	O
marked	O
changes	O
over	O
time	O
.	O

Fig.	O
3	O
shows	O
representative	O
chromatograms	O
of	O
DNA	B
adducts	I
formed	O
in	O
forestomach	O
and	O
glandular	O
stomach	O
after	O
10	O
days	O
of	O
HD	O
NF	B
administration	O
.	O

A	O
dramatic	O
difference	O
was	O
seen	O
between	O
these	O
two	O
tissues	O
regarding	O
DNA	B
adduct	I
levels	O
which	O
was	O
mainly	O
caused	O
by	O
high	O
DNA	B
adduct	I
D	I
level	O
in	O
the	O
forestomach	O
.	O

DNA	B
adducts	I
A	B
and	O
C	B
were	O
not	O
detectable	O
either	O
in	O
the	O
forestomach	O
or	O
the	O
glandular	O
stomach	O
.	O

Fig.	O
4	O
displays	O
the	O
DNA	B
adduct	I
levels	O
in	O
different	O
tissues	O
after	O
10	O
days	O
(	O
upper	O
)	O
and	O
11	O
months	O
(	O
lower	O
)	O
of	O
HD	O
NF	B
feeding	O
,	O
respectively	O
.	O

After	O
10	O
days	O
of	O
NF	B
feeding	O
,	O
the	O
levels	O
of	O
DNA	B
adducts	I
A	B
,	I
B	B
and	O
C	B
were	O
much	O
lower	O
compared	O
to	O
11	O
months	O
of	O
NF	B
feeding	O
.	O

Adduct	B
D	I
,	O
which	O
was	O
a	O
major	O
DNA	B
adduct	I
especially	O
in	O
the	O
liver	O
at	O
early	O
stage	O
(	O
10	O
days	O
)	O
of	O
NF	B
feeding	O
,	O
did	O
not	O
increase	O
significantly	O
over	O
time	O
(	O
10	O
days	O
to	O
11	O
months	O
)	O
.	O

Adducts	B
A	B
and	O
B	B
,	O
on	O
the	O
other	O
hand	O
,	O
increased	O
dramatically	O
during	O
the	O
NF	B
feeding	O
and	O
consequently	O
,	O
became	O
dominant	O
adducts	O
in	O
the	O
liver	O
and	O
kidney	O
after	O
11	O
months	O
of	O
NF	B
feeding	O
.	O

Compared	O
to	O
the	O
liver	O
and	O
kidney	O
,	O
spleen	O
showed	O
a	O
different	O
adduct	O
pattern	O
in	O
which	O
adduct	B
A	I
was	O
not	O
detectable	O
.	O

Fig.	O
5	O
shows	O
the	O
DNA	B
adduct	I
levels	O
formed	O
in	O
the	O
forestomach	O
and	O
glandular	O
stomach	O
after	O
10	O
days	O
of	O
HD	O
NF	B
feeding	O
.	O

A	O
significant	O
difference	O
was	O
seen	O
with	O
respect	O
to	O
the	O
level	O
of	O
adduct	B
D	I
in	O
these	O
two	O
tissues	O
.	O

DNA	B
adducts	I
A	B
and	O
C	B
were	O
not	O
found	O
in	O
these	O
tissues	O
.	O

To	O
characterize	O
the	O
four	O
major	O
DNA	B
adducts	I
induced	O
by	O
NF	B
,	O
32	B
P	I
-HPLC	O
co	O
-	O
chromatography	O
was	O
performed	O
.	O

DNA	B
adduct	I
D	I
co	O
-	O
migrated	O
with	O
dG	B
-	I
C8-AF	I
and	O
DNA	B
adduct	I
C	I
co	O
-	O
migrated	O
with	O
dG	B
-	I
N	I
2	I
-AAF	I
.	O

Neither	O
DNA	B
adduct	I
A	B
nor	O
B	B
co	O
-	O
migrated	O
with	O
any	O
of	O
the	O
three	O
adduct	O
standards	O
(	O
Fig.	O
6	O
)	O
.	O

Higher	O
levels	O
of	O
DNA	B
adduct	I
A	B
and	O
C	B
were	O
detected	O
after	O
nuclease	O
P1	O
treatment	O
compared	O
to	O
the	O
butanol	B
extraction	O
.	O

On	O
the	O
other	O
hand	O
,	O
DNA	B
adducts	I
B	B
and	O
D	B
were	O
not	O
detectable	O
after	O
nuclease	B
P1	I
treatment	O
(	O
Fig.	O
7	O
)	O
.	O

The	O
decline	O
of	O
total	O
NF	B
-	I
DNA	I
adducts	I
in	O
the	O
rat	O
liver	O
after	O
the	O
withdrawal	O
of	O
MD	O
NF	B
administration	O
showed	O
a	O
biphasic	O
manner	O
(	O
Fig.	O
8	O
)	O
.	O

The	O
pattern	O
of	O
DNA	B
adduct	I
removal	O
for	O
different	O
DNA	B
adducts	I
varied	O
.	O

Adducts	B
B	B
and	O
D	B
showed	O
a	O
sharp	O
drop	O
1	O
month	O
after	O
the	O
withdrawal	O
of	O
NF	B
feeding	O
.	O

DNA	B
adduct	I
D	I
,	O
in	O
the	O
later	O
stage	O
of	O
the	O
period	O
,	O
reached	O
an	O
undetectable	O
level	O
.	O

On	O
the	O
other	O
hand	O
,	O
DNA	B
adducts	I
A	B
and	O
C	B
showed	O
a	O
slow	O
decline	O
.	O

DNA	B
adduct	I
A	I
maintained	O
a	O
high	O
level	O
after	O
11	O
months	O
on	O
the	O
basal	O
diet	O
(	O
Fig.	O
8	O
)	O
.	O

4	O
Discussion	O
A	O
long	O
-	O
term	O
NF	B
feeding	O
to	O
rats	O
induces	O
tumors	O
in	O
the	O
liver	O
,	O
kidney	O
and	O
forestomach	O
[	O
23	O
]	O
.	O

Both	O
DNA	B
adduct	I
levels	O
and	O
tumor	O
formation	O
showed	O
a	O
dose	O
-	O
dependent	O
manner	O
[	O
23	O
]	O
.	O

DNA	B
adduct	I
levels	O
after	O
short	O
-	O
term	O
(	O
days	O
)	O
NF	B
administration	O
were	O
associated	O
with	O
the	O
locations	O
of	O
tumors	O
up	O
to	O
2	O
years	O
later	O
[	O
23	O
]	O
.	O

In	O
the	O
present	O
experiment	O
,	O
four	O
major	O
DNA	B
adducts	I
,	I
named	O
as	O
DNA	B
adduct	I
A	B
,	O
B	B
,	O
C	B
and	O
D	B
,	O
were	O
found	O
in	O
the	O
liver	O
and	O
kidney	O
after	O
10	O
days	O
and	O
11	O
months	O
of	O
NF	B
feeding	O
.	O

The	O
levels	O
of	O
different	O
NF	B
-	I
DNA	I
adducts	I
increased	O
with	O
varied	O
rates	O
during	O
the	O
period	O
of	O
NF	B
feeding	O
.	O

In	O
one	O
of	O
the	O
non	O
-	O
tumor	O
target	O
tissues	O
,	O
spleen	O
,	O
adducts	B
B	B
,	O
C	B
,	O
and	O
D	B
were	O
detected	O
at	O
low	O
levels	O
after	O
short-	O
or	O
long	O
-	O
term	O
of	O
NF	B
feeding	O
.	O

Glandular	O
stomach	O
,	O
as	O
another	O
non	O
-	O
tumor	O
target	O
tissue	O
,	O
showed	O
only	O
low	O
levels	O
of	O
DNA	B
adducts	I
B	B
and	O
D	B
after	O
10	O
days	O
of	O
NF	B
feeding	O
.	O

DNA	B
adduct	I
formation	O
in	O
forestomach	O
after	O
11-month	O
NF	B
administration	O
could	O
not	O
be	O
analysed	O
since	O
multiple	O
tumors	O
which	O
generally	O
covered	O
the	O
forestomach	O
membrane	O
were	O
formed	O
in	O
this	O
tissue	O
in	O
almost	O
all	O
the	O
NF	B
-	O
dosed	O
rats	O
(	O
HD	O
,	O
MD	O
and	O
LD	O
group	O
)	O
.	O

At	O
the	O
early	O
stage	O
,	O
DNA	B
adduct	I
D	I
,	O
which	O
co	O
-	O
migrated	O
with	O
dG	B
-	I
C8-AF	I
,	O
constituted	O
a	O
large	O
part	O
of	O
total	O
NF	B
-	I
DNA	I
adducts	I
,	O
especially	O
in	O
the	O
liver	O
.	O

At	O
the	O
later	O
stage	O
of	O
NF	B
feeding	O
,	O
DNA	B
adducts	I
A	B
and	O
B	B
increased	O
,	O
becoming	O
the	O
major	O
part	O
of	O
total	O
DNA	B
adducts	I
,	O
while	O
DNA	B
adduct	I
D	I
(	O
dG	B
-	I
C8-AF	I
)	O
did	O
not	O
increase	O
significantly	O
compared	O
to	O
the	O
level	O
at	O
the	O
early	O
stage	O
.	O

Expressed	O
as	O
a	O
percentage	O
of	O
total	O
DNA	B
adducts	I
,	O
DNA	B
adduct	I
D	I
(	O
dG	B
-	I
C8-AF	I
)	O
decreased	O
from	O
42	O
(	O
10-day	O
NF	B
administration	O
)	O
to	O
10	O
%	O
of	O
total	O
DNA	B
adducts	I
(	O
11-month	O
NF	B
administration	O
)	O
in	O
the	O
liver	O
during	O
the	O
feeding	O
period	O
.	O

The	O
rat	O
stomach	O
consists	O
of	O
two	O
parts	O
,	O
i.e.	O
,	O
the	O
forestomach	O
and	O
the	O
glandular	O
stomach	O
.	O

A	O
dramatically	O
higher	O
DNA	B
adduct	I
level	O
was	O
detected	O
in	O
the	O
forestomach	O
,	O
corresponding	O
to	O
the	O
high	O
tumor	O
incidence	O
in	O
this	O
tissue	O
,	O
compared	O
to	O
the	O
level	O
of	O
DNA	B
adducts	I
in	O
the	O
glandular	O
stomach	O
,	O
a	O
non	O
-	O
tumor	O
target	O
tissue	O
of	O
NF	B
[	O
23	O
]	O
.	O

In	O
the	O
high	O
dose	O
group	O
,	O
most	O
of	O
the	O
rats	O
grew	O
liver	O
tumors	O
while	O
they	O
were	O
still	O
on	O
NF	B
diet	O
or	O
not	O
long	O
after	O
the	O
termination	O
of	O
NF	B
diet	O
.	O

Samples	O
were	O
unable	O
to	O
be	O
collected	O
for	O
certain	O
period	O
after	O
the	O
termination	O
of	O
NF	B
diet	O
.	O

MD	O
group	O
of	O
rats	O
grew	O
tumors	O
in	O
a	O
scattered	O
time	O
points	O
generally	O
after	O
the	O
termination	O
of	O
NF	B
diet	O
.	O

Liver	O
samples	O
from	O
the	O
MD	O
group	O
were	O
therefore	O
chosen	O
for	O
the	O
study	O
of	O
DNA	B
adduct	I
persistence	O
.	O

The	O
use	O
of	O
mature	O
rats	O
minimizes	O
the	O
significance	O
of	O
DNA	B
adduct	I
dilution	O
through	O
cell	O
proliferation	O
in	O
the	O
liver	O
.	O

The	O
early	O
rapid	O
diminution	O
of	O
DNA	B
adducts	I
followed	O
by	O
a	O
slower	O
rate	O
of	O
elimination	O
was	O
seen	O
for	O
adducts	B
B	B
and	O
D	B
(	O
but	O
not	O
for	O
adducts	B
A	B
and	O
C	B
)	O
.	O

The	O
biphasic	O
removal	O
is	O
consistent	O
with	O
what	O
observed	O
in	O
rat	O
tissues	O
after	O
in	O
vivo	O
administration	O
of	O
substances	O
that	O
form	O
bulky	O
adducts	O
[	O
16	O
,	O
27–30	O
]	O
.	O

The	O
two	O
-	O
step	O
removal	O
process	O
may	O
be	O
attributed	O
to	O
the	O
heterogeneity	O
in	O
efficiency	O
of	O
DNA	O
repair	O
,	O
with	O
adducts	O
in	O
some	O
genomic	O
regions	O
being	O
more	O
accessible	O
to	O
DNA	O
repair	O
than	O
these	O
in	O
others	O
[	O
31	O
,	O
32	O
]	O
.	O

Among	O
the	O
four	O
major	O
DNA	B
adducts	I
induced	O
by	O
NF	B
,	O
adduct	B
D	I
and	O
C	O
co	O
-	O
migrated	O
with	O
dG	B
-	I
C8-AF	I
and	O
dG	B
-	I
N	I
2	I
-AAF	I
,	O
respectively	O
.	O

DNA	B
adducts	I
A	B
and	O
B	B
did	O
not	O
co	O
-	O
migrate	O
with	O
any	O
of	O
the	O
adduct	O
standards	O
used	O
.	O

Some	O
characteristics	O
of	O
the	O
four	O
NF	B
-	I
DNA	I
adducts	I
are	O
summarized	O
in	O
Table	O
1	O
.	O

For	O
DNA	B
adduct	I
enrichment	O
,	O
generally	O
,	O
butanol	B
extraction	O
is	O
used	O
for	O
aromatic	B
amines	I
-	O
DNA	B
adducts	I
and	O
nuclease	O
P1	O
is	O
used	O
for	O
PAHs	B
-	I
DNA	I
adducts	I
.	O

The	O
values	O
of	O
DNA	B
adduct	I
A	B
and	O
C	B
were	O
much	O
higher	O
after	O
nuclease	O
P1	O
treatment	O
compared	O
to	O
that	O
of	O
butanol	B
extraction	O
.	O

On	O
the	O
other	O
hand	O
,	O
DNA	B
adducts	I
B	B
and	O
D	B
were	O
undetectable	O
when	O
the	O
nuclease	O
P1	O
enrichment	O
procedure	O
was	O
used	O
.	O

DNA	B
adduct	I
A	I
as	O
an	O
unknown	O
major	O
NF	B
adduct	B
may	O
be	O
the	O
same	O
DNA	B
adduct	I
as	O
that	O
described	O
by	O
Wierckx	O
et	O
al.	O
[	O
7	O
]	O
.	O

This	O
DNA	B
adduct	I
could	O
possibly	O
represent	O
an	O
oxidative	B
NF	I
metabolite	I
reacted	O
with	O
DNA	B
,	O
either	O
via	O
a	O
ring	O
epoxide	B
or	O
via	O
a	O
reaction	O
with	O
the	O
hydroxyl	B
group	I
.	O

It	O
was	O
reported	O
that	O
OH	B
-	I
NFs	I
are	O
potent	O
genotoxins	O
with	O
a	O
hydroxy	B
function	O
at	O
position	O
7	O
or	O
9	O
of	O
NF	B
,	O
while	O
hydroxylization	O
at	O
position	O
5	O
makes	O
a	O
detoxification	O
product	O
[	O
33	O
]	O
.	O

DNA	B
adduct	I
B	I
,	O
which	O
was	O
sensitive	O
to	O
nuclease	O
P1	O
hydrolyzation	O
,	O
could	O
possibly	O
be	O
an	O
arylamine	B
DNA	B
adduct	I
[	O
34	O
,	O
35	O
]	O
.	O

Another	O
possibility	O
is	O
that	O
DNA	B
adduct	I
B	I
is	O
the	O
bis	O
-	O
phosphate	B
of	O
DNA	B
adduct	I
A.	I
Upon	O
nuclease	O
P1	O
treatment	O
,	O
DNA	B
adduct	I
B	I
is	O
converted	O
to	O
DNA	B
adduct	I
A.	I
Since	O
DNA	B
adduct	I
levels	O
varied	O
after	O
different	O
enrichment	O
procedures	O
(	O
Fig.	O
7	O
)	O
,	O
it	O
is	O
therefore	O
of	O
importance	O
to	O
relate	O
DNA	B
adduct	I
levels	O
to	O
specific	O
enrichment	O
procedures	O
.	O

Culp	O
et	O
al.	O
[	O
36	O
]	O
demonstrates	O
a	O
biphasic	O
removal	O
of	O
DNA	B
adducts	I
in	O
the	O
rat	O
liver	O
after	O
administration	O
of	O
AAF	B
.	O

The	O
present	O
study	O
dealt	O
with	O
NF	B
,	O
which	O
is	O
mainly	O
but	O
not	O
completely	O
metabolized	O
to	O
AF	B
and	O
AAF	B
in	O
rats	O
[	O
2	O
,	O
3	O
,	O
5	O
]	O
.	O

Two	O
DNA	B
adducts	I
,	O
i.e.	O
,	O
dG	B
-	I
C8-AF	I
and	O
dG	B
-	I
N	I
2	I
-AAF	I
,	O
were	O
induced	O
in	O
the	O
rat	O
liver	O
both	O
by	O
NF	B
(	O
present	O
study	O
)	O
and	O
AAF	B
[	O
36	O
]	O
.	O

Although	O
the	O
strain	O
of	O
the	O
rats	O
and	O
length	O
of	O
administration	O
are	O
different	O
between	O
the	O
present	O
study	O
and	O
the	O
AAF	B
study	O
[	O
36	O
]	O
,	O
the	O
persistence	O
of	O
the	O
two	O
common	O
DNA	B
adducts	I
is	O
rather	O
consistent	O
.	O

Three	O
out	O
of	O
the	O
four	O
NF	B
-	I
DNA	I
adducts	I
were	O
still	O
detectable	O
in	O
rat	O
liver	O
after	O
the	O
rats	O
were	O
on	O
basal	O
diet	O
for	O
11	O
months	O
.	O

The	O
long	O
persistence	O
of	O
NF	B
-	I
DNA	I
adducts	I
may	O
increase	O
their	O
chances	O
to	O
be	O
fixed	O
as	O
mutations	O
.	O

In	O
conclusion	O
,	O
the	O
air	O
pollutant	O
NF	B
induces	O
mainly	O
four	O
DNA	B
adducts	I
.	O

Two	O
DNA	B
adducts	I
,	O
i.e.	O
,	O
adducts	B
C	B
and	O
D	B
,	O
are	O
characterized	O
as	O
dG	B
-	I
N	I
2	I
-AAF	I
and	O
dG	B
-	I
C8-AF	I
,	O
respectively	O
.	O

DNA	B
adducts	I
A	B
and	O
B	B
,	O
with	O
structures	O
unknown	O
,	O
are	O
the	O
major	O
NF	B
-	I
DNA	I
adducts	I
after	O
11	O
months	O
of	O
NF	B
feeding	O
.	O

NF	B
-	I
DNA	I
adducts	I
persist	O
long	O
after	O
the	O
withdrawal	O
of	O
NF	B
,	O
especially	O
DNA	B
adducts	I
A	B
and	O
C	B
which	O
are	O
repaired	O
only	O
to	O
a	O
minor	O
extent	O
over	O
a	O
period	O
that	O
corresponds	O
to	O
approximately	O
half	O
the	O
life	O
time	O
of	O
the	O
rats	O
.	O

Three	O
out	O
of	O
the	O
four	O
NF	B
-	I
DNA	I
adducts	I
are	O
still	O
detectable	O
in	O
the	O
rat	O
liver	O
11	O
months	O
after	O
the	O
withdrawal	O
of	O
NF	B
feeding	O
.	O

Further	O
characterization	O
of	O
individual	O
NF	B
-	I
DNA	I
adducts	I
may	O
help	O
to	O
elucidate	O
the	O
mechanism	O
of	O
NF	B
-	O
induced	O
carcinogenesis	O
.	O

Acknowledgements	O
The	O
authors	O
wish	O
to	O
express	O
their	O
gratitude	O
to	O
Mary	O
-	O
Ann	O
Zetterqvist	O
for	O
skillful	O
technical	O
assistance	O
.	O

This	O
study	O
was	O
supported	O
by	O
grants	O
from	O
Swedish	O
Environmental	O
Protection	O
Agency	O
and	O
Swedish	O
Cancer	O
Society	O
.	O

Nausea	O
and	O
vomiting	O
are	O
frequent	O
side	O
effects	O
caused	O
by	O
cancer	O
chemotherapeutic	B
agents	I
.	O

Traditional	O
Chinese	O
herbal	O
drugs	B
with	O
anti	O
-	O
emetic	O
potential	O
can	O
be	O
used	O
to	O
prevent	O
them	O
.	O

However	O
,	O
the	O
effects	O
of	O
anti	O
-	O
emetic	O
active	O
principles	O
of	O
these	O
crude	O
drugs	B
need	O
to	O
be	O
studied	O
using	O
modern	O
pharmacological	O
methods	O
.	O

One	O
of	O
the	O
difficul­ties	O
in	O
testing	O
for	O
anti	O
-	O
emetic	O
activity	O
of	O
natural	B
prod­ucts	I
is	O
the	O
selection	O
of	O
adequate	O
animal	O
models	O
.	O

We	O
previously	O
reported	O
anti	O
-	O
emetic	O
principles	O
from	O
Magnolia	O
obovata	O
bark	O
,	O
Zingiber	O
officinale	O
rhizome	O
(	O
Kawai	O
et	O
al.	O
,	O
1994	O
)	O
,	O
Inula	O
linariaefolia	O
flowers	O
and	O
Forsythia	O
suspensa	O
fruits	O
(	O
Kinoshita	O
et	O
al.	O
,	O
1996	O
)	O
,	O
and	O
Poria	O
cocos	O
(	O
Tai	O
et	O
al.	O
,	O
1995	O
)	O
using	O
frogs	O
as	O
test	O
sub­jects	O
.	O

The	O
long	O
emetic	O
latency	O
of	O
frogs	O
induced	O
by	O
the	O
emetic	B
agent	I
was	O
not	O
suitable	O
for	O
testing	O
many	O
samples	O
within	O
a	O
short	O
period	O
of	O
time	O
.	O

Therefore	O
,	O
we	O
studied	O
a	O
new	O
screening	O
method	O
using	O
chicks	O
for	O
anti	O
-	O
emetic	O
ac­tivity	O
(	O
Akita	O
et	O
al.	O
,	O
1998	O
)	O
to	O
overcome	O
these	O
difficulties	O
.	O

The	O
present	O
paper	O
describes	O
the	O
screening	O
of	O
31	O
ex­tracts	O
from	O
8	O
traditional	O
Chinese	O
herbal	O
drugs	B
for	O
anti­emetic	O
activities	O
,	O
using	O
young	O
chicks	O
,	O
and	O
the	O
identifica­tion	O
of	O
some	O
of	O
the	O
active	O
principles	O
contained	O
in	O
Po­gostemon	O
cablin	O
(	O
Blanco	O
)	O
Benth	O
.	O

Materials	O
and	O
Methods	O
Materials	O

The	O
dry	O
plant	O
materials	O
used	O
here	O
were	O
commercial	O
products	O
.	O

Alpinia	O
katsumadai	O
seeds	O
,	O
Alpinia	O
officina­rum	O
rhizome	O
,	O
Amomum	O
kravanh	O
fruits	O
,	O
Amomum	O
tsao	O
-	O
ko	O
fruits	O
,	O
Amomum	O
xanthioides	O
fruits	O
,	O
Eupato­rium	O
fortunei	O
leaves	O
and	O
stem	O
,	O
and	O
Nelumbo	O
nucifera	O
seeds	O
were	O
purchased	O
from	O
Kotaro	O
Pharmaceutical	O
Co.	O
,	O
Ltd.	O
(	O
Osaka	O
,	O
Japan	O
)	O
.	O

Pogostemon	O
cab	O
/	O
in	O
leaves	O
were	O
purchased	O
from	O
Kinokuniya	O
Kanyakkyoku	O
(	O
To­kyo	O
,	O
Japan	O
)	O
.	O

Spectrometry	O
and	O
chromatography	O
lH_and13C	O
-	O
NMRspectrawererecorded	O
usingaJEOL	O
GSX-400	O
spectrometer	O
in	O
CDCl3	B
or	O
DMSO	B
-	I
d6	I
with	O
tet­ramethylsilane	B
as	O
an	O
internal	O
standard	O
.	O

Kieselgel	B
60	I
F254-precoated	I
plates	O
were	O
employed	O
for	O
thin	O
-	O
layer	O
chromatography	O
(	O
TLC	O
)	O
.	O

Column	O
chromatography	O
was	O
carried	O
out	O
on	O
70	O
-	O
230	O
mesh	O
silica	B
gel	I
.	O

HPLC	O
was	O
per­formed	O
using	O
an	O
SSC-3100-J	O
pump	O
with	O
an	O
Oyo	O
-	O
Bunko	O
Uvilog	O
7	O
UV	O
detector	O
.	O

HR	O
-	O
MS	O
and	O
EI	O
-	O
MS	O
were	O
ob­tained	O
using	O
a	O
JEOL	O
JMX	O
-	O
DX	O
302	O
.	O

0944	O
-	O
7113	O
/	O
99106	O
/	O
02	O
-	O
089	O
$	O
12.0010	O
Y.	O
Yang	O
et	O
al.	O

Animals	O
nally	O
at	O
a	O
volume	O
of	O
10	O
rnl	O
/	O
kg	O
.	O

After	O
10	O
min	O
,	O
copper	B
sul­	O
Young	O
male	O
chicks	O
(	O
4	O
days	O
of	O
age	O
)	O
weighing	O
25	O
-	O
35	O
g	O
fate	O
anhydride	O
was	O
administered	O
orally	O
at	O
50	O
mg	O
/	O
kg	O
,	O
each	O
were	O
purchased	O
from	O
Goto	O
Furanjo	O
Co.	O
,	O
Ltd.	O
(	O
Sai­then	O
the	O
number	O
of	O
retching	O
(	O
an	O
emetic	O
action	O
without	O
tama	O
,	O
Japan	O
)	O
.	O

vomiting	O
gastric	O
materials	O
)	O
was	O
recorded	O
during	O
the	O
next	O
10	O
min	O
.	O

The	O
results	O
were	O
judged	O
by	O
the	O
decrease	O
in	O
Bioassay	O
of	O
anti	O
-	O
emetic	O
activity	O
number	O
of	O
retching	O
in	O
contrast	O
with	O
those	O
of	O
control	O
.	O

The	O
young	O
chicks	O
were	O
divided	O
into	O
1	O
-	O
3	O
groups	O
con	O
­The	O
inhibition	O
(	O
%	O
)	O
was	O
calculated	O
as	O
follows	O
:	O
sisting	O
of	O
six	O
each	O
,	O
and	O
each	O
young	O
chick	O
was	O
set	O
asi­de	O
for	O
10	O
min	O
to	O
stabilize	O
in	O
large	O
beakers	O
at	O
25	O
°	O
C	O
.	O

The	O
Inhibition	O
(	O
%	O
)	O
=	O
[	O
(	O
A	O
-	O
B	O
)	O
A	O
]	O
X	O
100	O
sample	O
was	O
dissolved	O
in	O
0.9	O
%	O
saline	B
containing	O
5	O
%	O
A	O
:	O
control	O
frequency	O
of	O
retching	O
DMSO	B
and	O
1	O
%	O
Tween	B
80	I
and	O
administered	O
abdomi	O
-	O
B	O
:	O
frequency	O
retching	O
after	O
sample	O
treatment	O
Table1	O
.	O

Screeningtestofmedicinalplantsforanti	O
-	O
emeticeffectagainstcoppersulfate	O
-	O
inducedemesisinyoungchicks	O
.	O

Crude	O
drugs	B
Extracts	O
No.	O
of	O
young	O
chicks	O
No.	O
of	O
retches	O
Inhibition	O
(	O
mean	O
±	O
S.E.M.	O
)	O
(	O
%	O
)	O
control	O

6	O
69.8	O
±	O
3.19	O
Pogostemon	O
cab	O
/	O
in	O
n	B
-	I
hexane	I
6	O
28.9	O
±	O
4.31	O

*	O
*	O
*	O
58.6	O
CHCl3	B
6	O
45.8	O
±	O
6.75	O
""""	O
'	O
34.4	O
MeOH	B
6	O
47.8	O
±	O
6.39	O
""""	O
31.5	O
control	O
6	O
70.6	O
±	O
1.25	O
Alpinia	O
katsumadai	O
n	B
-	I
hexane	I
6	O
52.4	O
±3.39	O
*	O
*	O
25.8	O
CHCl3	B
6	O
28.0	O
±	O
5.09	O

*	O

*	O

*	O
60.3	O
MeOH	B
6	O
18.4	O
±	O
0.93	O

*	O
*	O
*	O
73.9	O
H2O	B
6	O
46.2	O
±	O
8.12	O
34.6	O
control	O
6	O
48.8	O
±	O
4.34	O
Amomum	O
tsao	O
-	O
ko	O
n	B
-	I
hexane	I
6	O
46.6	O
±	O
3.29	O
4.5	O
CHCl3	B
6	O
36.6	O
±	O
5.39	O
25.6	O
MeOH	B
6	O
22.2	O
±	O
3.28	O

*	O

*	O
*	O
54.5	O
H2O	B
6	O
39.3	O
±	O
7.23	O
19.5	O
control	O
6	O
75.9	O
±	O
1.38	O
Amomum	O
kravanh	O
n	B
-	I
hexane	I
6	O
78.6	O
±	O
3.14	O
-3.6	O
CHCl3	B
6	O
36.0	O
±	O
5.96	O
*	O
*	O
52.6	O
MeOH	B
6	O
70.0	O
±	O
11.0	O
7.8	O
H2O	B
6	O
52.0	O
±2.98	O
""""	O
31.5	O
control	O
6	O
64.5	O
±	O
4.46	O
Amomum	O
xanthioides	O
n	B
-	I
hexane	I
6	O
41.8	O
±	O
9.05	O
*	O
35.2	O
CHCI3	B
6	O
29.8	O
±	O
3.94	O

*	O

*	O
*	O

53.8	O
MeOH	B
6	O
34.8	O
±	O
8.47	O
*	O
46.0	O
H2O	B
6	O
43.5	O
±	O
7.70	O
'	O
:	O
'	O
32.6	O
control	O
6	O
68.2±2.31	O
Eupatorium	O
[	O
ortunei	O
n	B
-	I
hexane	I
6	O
61.3	O
±	O
6.68	O
10.1	O
CHCI3	B
6	O
46.3	O
±	O
7.32	O
32.1	O
MeOH	B
6	O
50.8	O
±	O
2.42	O

*	O
*	O
*	O
25.5	O
H2O	B
6	O
54.2	O
±	O
3.16	O
*	O
20.5	O
control	O
6	O
86.8	O
±	O
3.69	O
Nelumbo	O
nucifera	O
n	B
-	I
hexane	I
6	O
75.3	O
±	O
9.81	O
13.2	O
CHCl3	B
6	O
63.2	O
±3.06	O
*	O
""""	O
27.2	O
MeOH	B
6	O
77.6	O
±	O
2.98	O
10.6	O
H2O	B
6	O
71.6	O
±	O
5.83	O
17.6	O
control	O
6	O
44.5	O
±	O
2.33	O
Alpinia	O
officinarum	O
n	B
-	I
hexane	I
6	O
37.5	O
±	O
4.19	O
15.7	O
CHel3	O
6	O
24.2	O
±	O
3.23	O

*	O

*	O
*	O
45.6	O
MeOH	B
6	O
32.7	O
±	O
3.74	O
*	O
26.5	O
H2O	B
6	O
31.2	O
±	O
4.26	O
*	O
29.9	O
Significantly	O
different	O
from	O
the	O
control	O
value	O
,	O
""""	O
p	O
<	O
0.05	O
,	O
""""	O
""""	O
p	O
<	O
0.01	O
,	O
*	O
,	O
'	O
""""	O
p	O
<	O
0.001	O
.	O

fate	O
-	O
induced	O
emesis	O
in	O
young	O
chicks	O
.	O

Drugs	B
Dose	O
No.	O
of	O
young	O
chicks	O
No	O
.	O

of	O
retches	O
Inhibition	O
(	O
mg	O
/	O
kg	O
)	O
(	O
rnean	O
e	O
SEM	O
)	O
(	O
%	O
)	O
control	O
6	O
47	O
.8	O
:	O
!	O
:	O
6.14	O
Fr	O
.	O

1	O
150	O
6	O
37.4:!:5.17	O
21.8	O
Fr	O
.	O

2	O
150	O
6	O
11.6	O
:	O
!	O

:	O

7.08	O
·	O
·	O
·	O
·	O
75	O
.	O
7	O
Fr	O
.	O

3	O
150	O
6	O
7.6	O
:	O
!	O

:	O
1.25	O

*	O
*	O
""""	O
84.1	O
control	O
6	O
45	O
.0	O
:	O
!	O
:	O
8.45	O
Fr	O
.	O

4	O
150	O
6	O
31.2:!:3.36	O
30.7	O
Fr	O
.	O

5	O
150	O
6	O
25	O
.	O
7	O
:	O
!	O

:	O
6.92	O
42.9	O
Fr	O
.	O

6	O
150	O
6	O
28.4	O
:	O
!	O

:	O
6.95	O
36.9	O
control	O
6	O
47.8	O
:	O
!	O
:	O
6.14	O
Fr	O
.	O

7	O
150	O
6	O
21	O
.	O
6	O
:	O
!	O

:	O
4.25	O
""""	O
*	O
54.8	O
Fr	O
.	O

8	O
150	O
6	O
38.2	O
:	O
!	O

:	O

7.87	O
20.1	O
Significantly	O
different	O
from	O
the	O
control	O
value	O
,	O
*	O
p	O
<	O
0.05	O
,	O

*	O
*	O
p	O
<	O
0.01	O
,	O
""""	O

*	O
*	O
p	O
<	O
0.001	O
.	O

Table	O
3	O
.	O

Anti	O
-	O
emetic	O
effects	O
of	O
compounds	O
1	O
-	O
5	O
against	O
sulfate	B
-	O
induced	O
emesis	O
in	O
young	O
chicks	O
.	O

Drugs	O
Dose	O
No.	O
of	O
young	O
chicks	O
No.	O
of	O
retches	O
Inhibition	O
(	O
mg	O
/	O
kg	O
)	O
(	O
mean	O
a	O
SEM	O
)	O
(	O
%	O
)	O
control	O
6	O
60.0	O
:	O
!	O

:	O
4.73	O
patchouli	B
alcohol	I
(	O
1	B
)	O
10	O
6	O
54.5	O
:	O
!	O
:	O
7.58	O
9.2	O
20	O
6	O
50.3	O
:	O
!	O

:	O
6.90	O
16.2	O
50	O
6	O
36.0	O
:	O
!	O

:	O
3.69	O

*	O
""""	O
40.0	O
70	O
6	O
25.4	O
:	O
!	O

:	O

2.80	O

*	O

*	O
""""	O
57.7	O
control	O
5	O
67.2	O
:	O
!	O
:	O
2.81	O
pogostol	B
(	O
2	B
)	O
10	O
5	O
40.8	O
:	O
!	O

:	O
4.79	O

*	O

*	O
39.3	O
20	O
5	O
38.8	O
:	O
!	O

:	O
8.73	O
*	O
42.3	O
50	O
5	O
38.2	O
:	O
!	O

:	O
6.13	O
""""	O
*	O
43.2	O
control	O
6	O
55.7	O
:	O
!	O
:	O
4.6	O
stigmast-4-en-10	B
6	O
54.9	O
:	O
!	O
:	O
8.80	O
1.4	O
3-one	B
(	O
3	O
)	O
20	O
6	O
39.6	O
:	O
!	O
:	O

7.48	O
28.9	O
50	O
6	O
24.7	O
:	O
!	O

:	O
1.21	O
""""	O
>	O
'	O
*	O
55.7	O
control	O
6	O
67.5	O
:	O
!	O
:	O
6.63	O
retusin	B
(	O
4	B
)	O
10	O
6	O
49.0	O
:	O
!	O
:	O
6.97	O
27.4	O
20	O
6	O
48.0	O
:	O
!	O
:	O

4.97	O
*	O
28.9	O
50	O
6	O
36.7:!:3.21	O
*	O
*	O
45.6	O
control	O
5	O
56.6	O
:	O
!	O
:	O
3.93	O
pachypodol	B
(	O
5	B
)	O
10	O
5	O
53.4	O
:	O
!	O
:	O
3.93	O
5.7	O
20	O
5	O
44.6	O
:	O
!	O

:	O
7.27	O
21.2	O
50	O
5	O
28.0	O
:	O
!	O

:	O
3.09	O
'	O
'	O
'	O
'	O
*	O
50.5	O
Significantly	O
different	O
from	O
the	O
control	O
value	O
,	O
""""	O
p	O
<	O
0.05	O
,	O
*	O
""""	O
p	O
<	O
0.01	O
,	O
*	O

*	O
""""	O
p	O
<	O
0.001	O
.	O

Statistical	O
analysis	O
was	O
concentrated	O
to	O
yield	O
n	B
-	I
hexane	I
,	O
CHCI3	B
,	O
MeOH	B
,	O
All	O
numerical	O
data	O
were	O
expressed	O
as	O
the	O
mean	O
:	O
t	O
and	O
water	B
extracts	O
,	O
respectively	O
.	O

S.E.M.	O
The	O
statistical	O
significance	O
of	O
the	O
difference	O
was	O
determined	O
by	O
an	O
unpaired	O
student	O
's	O
z	O
-	O
test	O
,	O
Isolation	O
and	O
purification	O
of	O
the	O
anti	O
-	O
emetic	O
principles	O
from	O
Pogostemon	O
cablin	O
Preparation	O
of	O
extract	O
The	O
crushed	O
dry	O
leaves	O
of	O
Pogostemon	O
cablin	O
(	O
1	O
kg	O
)	O
Crusheddryplantmaterials	O
(	O
1kg	O
)	O
wereextractedthree	O
wereextractedsuccessivelywithn	O
-	B
hexane	I
,	O
CHCI3,and	B
timessuccessively	O
with4In	O
-	B
hexane	I
,	O
CHCI3,MeOH	B
MeOH	B
,	O
andeach	O
extractwasexaminedforanti	O
-	O
emetic	O
and	O
water	B
at	O
room	O
temperature	O
for	O
24	O
h.	O

Each	O
extract	O
activity	O
using	O
young	O
chicks	O
.	O

The	O
n	B
-	I
hexane	I
extract	O
Y.	O
Yang	O
et	O
al.	O
patchouli	B
alcohol	I
(	O
1	B
)	O
pogostol	B
(	O
2	B
)	O
sigmast-4-en-3-one	B
(	O
3	B
)	O
OCHa	O
OH	O
HaCO	O
HaCO	O
OCHa	O
OCH3	O
OH0	O
OH0	O
pachypodol	B
(	O
5	B
)	O
retusin	O
(	O
4	B
)	O
Fig.	O
1	O
.	O

The	O
structures	O
of	O
active	O
compounds	O
isolated	O
from	O
Pogostemon	O
cab	O
/	O
in	O
Benth	O
which	O
showed	O
the	O
highest	O
anti	O
-	O
emetic	O
activity	O
(	O
58.6	O
%	O
)	O
was	O
chromatographed	O
on	O
a	O
silica	B
gel	I
column	O
(	O
n	B
-	I
hex­ane	I
:	O
EtOAc	B
)	O
,	O
and	O
8	O
fractions	O
(	O
fr	O
,	O
1	O
-	O
8	O
)	O
obtained	O
.	O

Each	O
fraction	O
was	O
tested	O
for	O
anti	O
-	O
emetic	O
activity	O
,	O
and	O
fro	O
2	O
,	O
fro	O
3	O
,	O
fro	O
7	O
showed	O
positive	O
activity	O
(	O
Table	O
2	O
)	O
.	O

Fraction	O
2	O
was	O
subjected	O
to	O
HPLC	O
using	O
a	O
silica	B
gel	I
co­lumn	O
[	O
Silica-4251-N	B
10	O
0	O
X	O
250	O
mm	O
,	O
n	B
-	I
Hexane­EtOAc	I
(	O
11:1	O
)	O
]	O
,	O
and	O
compound	B
1	I
(	O
l.72	O
g	O
)	O
was	O
obtained	O
and	O
identified	O
as	O
patchouli	B
alcohol	I
by	O
comparison	O
with	O
published	O
spectral	O
data	O
(	O
Barton	O
et	O
al.	O
,	O
1987	O
)	O
.	O

An	O
active	O
fraction	O
,	O
fro	O
3	O
,	O
was	O
chromatographed	O
on	O
a	O
silica	B
gel	I
column	O
(	O
n	B
-	I
hexane	I
:	O
acetone	B
)	O
and	O
HPLC	O
using	O
a	O
silica	B
gel	I
column	O
[	O
Silica-4251-N	B
100	O
X	O
250	O
mm	O
,	O
n­Hexane	B
-	O
EtOAc	O
(	O
5:1	O
)	O
]	O
.	O

Compounds	B
2	B
(	O
79.7	O
mg	O
)	O
and	O
3	B
(	O
41.3	O
mg	O
)	O
were	O
identified	O
as	O
pogostol	B
and	O
stigmast-4­en	B
-	I
S	I
-	I
one	I
by	O
comparison	O
with	O
published	O
spectral	O
data	O
(	O
Hikino	O
et	O
al.	O
,	O
1968	O
;	O
Greca	O
et	O
al.	O
,	O
1990	O
)	O
.	O

Fraction	O
7	O
was	O
subjected	O
to	O
on	O
HPLC	O
using	O
a	O
silica	B
gel	I
column	O
[	O
Silica-4251-N	B
100	O
X	O
250	O
mm	O
,	O
n	B
-	I
Hexane­acetone	I
(	O
75:25	O
)	O
]	O
,	O
and	O
compounds	B
4	B
(	O
62.6	O
mg	O
)	O
and	O
5	B
(	O
48.0	O
mg	O
)	O
were	O
obtained	O
and	O
examined	O
by	O
MS	O
,	O
lH	O
_	O
and	O
13C	O
-	O
NMR	O
,	O
DEPT	O
experiment	O
,	O
IH_13C	O
COSY	O
,	O
IH_13C	O
long	O
range	O
COSY	O
(	O
COLOq	O
and	O
the	O
difference	O
of	O
Overhauser	O
enhancement	O
(	O
nOe	O
)	O
spectra	O
.	O

These	O
obser­	O
vations	O
suggested	O
that	O
compounds	B
4	B
and	O
5	B
were	O
retusin	B
and	O
pachypodol	B
,	O
respectively	O
.	O

Results	O
and	O
Discussion	O
As	O
shown	O
in	O
Table	O
1,20	O
extracts	O
significantly	O
inhibited	O
emetic	O
action	O
induced	O
by	O
CUS04	B
in	O
young	O
chicks	O
.	O

The	O
n	B
-	I
hexane	I
,	O
CHCl3	B
and	O
MeOH	B
extracts	O
of	O
Pogostemon	O
cablin	O
showed	O
significant	O
inhibition	O
at	O
a	O
dose	O
of	O
300	O
mg	O
/	O
kg	O
.	O

Patchouli	B
alcohol	I
(	O
1	B
)	O
,	O
pogostol	B
(	O
2	B
)	O
,	O
stigmast-4­en-3-one	B
(	O
3	B
)	O
,	O
retusin	B
(	O
4	B
)	O
and	O
pachypodol	B
(	O
5	B
)	O
previously	O
isolated	O
from	O
the	O
n	B
-	I
hexane	I
extract	O
(	O
Barton	O
et	O
al.	O
,	O
1987	O
;	O
Hinoki	O
et	O
al.	O
,	O
1968	O
;	O
Greca	O
et	O
al.	O
,	O
1990	O
;	O
Dominquez	O
et	O
al.	O
,	O
1968	O
;	O
Valesi	O
et	O
al.	O
,	O
1972	O
)	O
also	O
showed	O
anti	O
-	O
emetic	O
activity	O
Patchouli	B
alcohol	I
(	O
1	B
)	O
was	O
active	O
at	O
two	O
doses	O
of	O
50	O
mg	O
/	O
kg	O
and	O
70	O
mg	O
/	O
kg	O
.	O

Pogostol	B
(	O
2	B
)	O
significantly	O
inhibit­ed	O
emetic	O
action	O
at	O
three	O
doses	O
of	O
10	O
mg	O
/	O
kg-50	O
mg	O
/	O
kg	O
.	O

Stigmast-4-en-3-one	B
(	O
3	B
)	O
and	O
pachypodol	B
(	O
5	B
)	O
showed	O
anti	O
-	O
emetic	O
activity	O
at	O
doses	O
of	O
50	O
mg	O
/	O
kg	O
.	O

Retusin	B
(	O
4	B
)	O
inhibited	O
emetic	O
action	O
at	O
two	O
doses	O
of	O
20	O
mg	O
/	O
kg	O
and	O
50	O
mg	O
/	O
kg	O
.	O

Pogostemon	O
cablin	O
is	O
one	O
of	O
the	O
traditional	O
Chinese	O
medicines	O
used	O
mainly	O
for	O
the	O
treatment	O
of	O
dyspepsia	O
,	O
vomiting	O
,	O
diarrhea	O
and	O
poor	O
appetite	O
.	O

It	O
is	O
also	O
known	O
that	O
inward	O
Ca2	B
+	I
influx	O
through	O
the	O
cell	O
membranes	O
may	O
induce	O
excessive	O
excitation	O
of	O
smooth	O
muscles	O
,	O
and	O
excessive	O
contraction	O
of	O
digestive	O
organ	O
muscles	O
may	O
cause	O
vomiting	O
and	O
diarrhea	O
.	O

Therefore	O
,	O
the	O
Ca2	B
+	I
antagonist	O
is	O
expected	O
to	O
alleviate	O
those	O
symptoms	O
by	O
depressing	O
excessive	O
contraction	O
of	O
digestive	O
organ	O
muscles	O
.	O

It	O
has	O
been	O
reported	O
that	O
patchouli	B
alcohol	I
showed	O
Ca2	O
+	O
antagonist	O
activity	O
in	O
vitro	O
(	O
Ichikawa	O
et	O
al.	O
,	O
1989	O
)	O
.	O

These	O
results	O
indicate	O
that	O
the	O
anti	O
-	O
emetic	O
activity	O
of	O
patchouli	B
alcohol	I
may	O
be	O
due	O
to	O
depressing	O
excessive	O
contraction	O
of	O
digestive	O
organ	O
muscles	O
by	O
in­hibition	O
of	O
inward	O
Ca2	B
+	I
influx	O
through	O
the	O
cell	O
embra­nes	O
.	O

Patchouli	B
alcohol	I
contained	O
abundantly	O
in	O
Po­gostemon	O
cablin	O
(	O
>	O
0.1	O
%	O
)	O
may	O
playa	O
main	O
role	O
in	O
anti	O
-	O
emetic	O
effect	O
clinically	O
in	O
view	O
of	O
its	O
traditional	O
use	O
in	O
Chinese	O
medicine	O
.	O

Acknowledgements	O
The	O
authors	O
would	O
like	O
to	O
thank	O
Professor	O
emeritus	O
Shoji	O
Shibata	O
,	O
University	O
of	O
Tokyo	O
,	O
for	O
his	O
encouragement	O
.	O

This	O
study	O
was	O
partly	O
supported	O
by	O
a	O
Sasakawa	O
Scientific	O
Research	O
Grant	O
from	O
the	O
Japan	O
Science	O
Society	O
(	O
1996	O
-	O
7	O
)	O
.	O

Anti	O
-	O
emetic	O
principles	O
of	O
Pogostemon	O
cablin	O

SCH66336	B
,	O
(	B
+	I
)	I
4-	I
{	I
2-	I
[	I
4-	I
(	I
8-chloro-3	I
,	I
10-dibromo-6	I
,	I
11-dihydro-5H	I
-	I
benzo	I
[	I
5,6	I
]	I
cyclohepta	I
[	I
1,2-b	I
]	I
pyridin-11-yl	I
)	I
-1-piperidinyl	I
]	I
-2-oxoethyl	I
}	I
-1-piperidinecarboxamide	I
(	O
Fig.	O
1	O
)	O
,	O
is	O
a	O
potent	O
inhibitor	O
of	O
farnesyl	O
protein	O
transferase	O
(	O
FPT	O
)	O
.	O

FPT	O
catalyzes	O
the	O
initial	O
step	O
in	O
the	O
post	O
-	O
translational	O
processing	O
of	O
the	O
ras	O
gene	O
,	O
that	O
is	O
,	O
the	O
transfer	O
of	O
the	O
15-carbon	O
farnesyl	B
group	I
onto	O
a	O
cysteine	B
residue	O
in	O
the	O
carboxy	B
terminal	O
of	O
all	O
Ras	O
proteins	O
[	O
1–6	O
]	O
.	O

The	O
farnesylation	B
step	O
appears	O
to	O
be	O
essential	O
for	O
Ras	O
proteins	O
to	O
become	O
membrane	O
-	O
associated	O
and	O
induces	O
cell	O
transformation	O
[	O
4	O
]	O
.	O

In	O
normal	O
cells	O
,	O
Ras	O
protein	O
in	O
its	O
active	O
GTP	B
-	O
bound	O
state	O
initiates	O
several	O
intracellular	O
signaling	O
pathways	O
that	O
lead	O
to	O
cell	O
proliferation	O
and	O
differentiation	O
.	O

The	O
signal	O
is	O
terminated	O
by	O
the	O
hydrolysis	O
of	O
GTP	B
to	O
the	O
inactive	O
GDP	B
-	O
bound	O
form	O
of	O
the	O
Ras	O
protein	O
[	O
7	O
]	O
.	O

The	O
capacity	O
of	O
certain	O
oncogenic	O
forms	O
of	O
Ras	O
to	O
hydrolyze	O
GTP	B
to	O
GDP	B
is	O
greatly	O
reduced	O
,	O
leading	O
to	O
continuous	O
intracellular	O
signaling	O
which	O
results	O
in	O
alteration	O
of	O
cellular	O
proliferation	O
and	O
differentiation	O
[	O
4,8	O
]	O
.	O

Oncogenic	O
forms	O
of	O
Ras	O
proteins	O
have	O
been	O
reported	O
to	O
be	O
associated	O
with	O
nearly	O
one	O
-	O
third	O
of	O
all	O
human	O
cancers	O
,	O
including	O
50	O
%	O
of	O
colon	O
cancers	O
and	O
90	O
%	O
of	O
pancreatic	O
cancers	O
[	O
4	O
]	O
.	O

Blocking	O
the	O
farnesylation	O
step	O
by	O
inhibiting	O
FPT	O
is	O
an	O
attractive	O
target	O
for	O
the	O
discovery	O
of	O
compounds	B
with	O
anti	O
-	O
tumor	O
activity	O
[	O
9	O
]	O
.	O

This	O
form	O
of	O
therapy	O
has	O
enormous	O
potential	O
because	O
of	O
the	O
prevalance	O
of	O
mutated	O
ras	O
gene	O
in	O
human	O
cancers	O
[	O
4,10	O
]	O
.	O

In	O
vivo	O
studies	O
in	O
nude	O
mice	O
demonstrated	O
that	O
SCH	B
66336	I
has	O
a	O
potent	O
oral	O
activity	O
profile	O
in	O
a	O
wide	O
array	O
of	O
human	O
tumor	O
xenograft	O
models	O
including	O
tumors	O
of	O
colon	O
,	O
lung	O
,	O
pancreas	O
,	O
prostate	O
,	O
and	O
urinary	O
bladder	O
origin	O
[	O
11	O
]	O
.	O

When	O
used	O
to	O
treat	O
Ha	O
-	O
Ras	O
transgenic	O
mice	O
with	O
spontaneously	O
occurring	O
tumors	O
prior	O
to	O
tumor	O
onset	O
,	O
SCH	B
66336	I
delayed	O
tumor	O
onset	O
,	O
reduced	O
the	O
average	O
number	O
of	O
tumors	O
per	O
mouse	O
and	O
reduced	O
the	O
average	O
tumor	O
weight	O
per	O
animal	O
[	O
11	O
]	O
.	O

In	O
a	O
therapeutic	O
mode	O
,	O
where	O
gavage	O
treatment	O
was	O
initiated	O
after	O
the	O
transgenic	O
mice	O
had	O
developed	O
palpable	O
tumors	O
,	O
significant	O
tumor	O
regression	O
was	O
induced	O
by	O
SCH	B
66336	I
in	O
a	O
dose	O
-	O
dependent	O
fashion	O
[	O
11	O
]	O
.	O

The	O
issue	O
of	O
chirality	O
has	O
emerged	O
as	O
a	O
major	O
theme	O
in	O
drug	B
design	O
and	O
discovery	O
[	O
12,13	O
]	O
.	O

Since	O
enantiomers	B
often	O
differ	O
in	O
pharmacological	O
activity	O
,	O
toxicity	O
and	O
pharmacokinetics	O
characteristics	O
,	O
it	O
is	O
important	O
that	O
enantiomeric	O
drug	B
candidates	O
be	O
evaluated	O
in	O
an	O
optically	O
pure	O
form	O
.	O

SCH	B
66336	I
is	O
a	O
single	O
enantiomer	B
which	O
contains	O
one	O
chiral	O
center	O
.	O

During	O
the	O
discovery	O
stage	O
of	O
this	O
compound	O
,	O
it	O
was	O
of	O
interest	O
to	O
determine	O
its	O
pharmacokinetics	O
and	O
possible	O
chiral	O
inversion	O
in	O
animals	O
prior	O
to	O
administration	O
in	O
humans	O
.	O

Therefore	O
,	O
these	O
studies	O
were	O
initiated	O
to	O
develop	O
HPLC	O
methods	O
for	O
its	O
determination	O
in	O
cynomolgus	O
monkey	O
plasma	O
and	O
for	O
the	O
evaluation	O
of	O
its	O
chiral	O
inversion	O
in	O
rat	O
and	O
cynomolgus	O
monkey	O
plasma	O
that	O
had	O
been	O
dosed	O
with	O
SCH	B
66336	I
.	O

2	O
Experimental	O
2.1	O
Reagents	O
Hexane	B
,	O
methanol	B
,	O
acetonitrile	B
,	O
methylene	B
chloride	I
,	O
ethanol	B
,	O
diethyl	B
amine	I
and	O
sodium	B
bicarbonate	I
were	O
purchased	O
from	O
Fisher	O
Scientific	O
(	O
Fair	O
Lawn	O
,	O
NJ	O
,	O
USA	O
)	O
.	O

SCH	B
66336	I
,	O
SCH	B
66337	I
(	O
enantiomer	B
of	I
SCH	I
66336	I
)	O
and	O
SCH	B
66347	I
(	O
internal	O
standard	O
for	O
the	O
chiral	O
assay	O
)	O
were	O
provided	O
by	O
Schering	O
-	O
Plough	O
Research	O
Institute	O
(	O
Kenilworth	O
,	O
NJ	O
,	O
USA	O
)	O
.	O

Azatadine	B
maleate	I
(	O
internal	O
standard	O
for	O
the	O
achiral	O
assay	O
)	O
was	O
obtained	O
from	O
U.S.	O
Pharmacopeial	O
Convention	O
,	O
Inc.	O
(	O
Rockville	O
,	O
MD	O
,	O
USA	O
)	O
.	O

2.2	O
Calibration	O
standards	O
For	O
the	O
achiral	O
HPLC	O
analysis	O
,	O
stock	O
solution	O
of	O
SCH	B
66336	I
was	O
prepared	O
in	O
methanol	B
at	O
200	O
μg	O
/	O
ml	O
;	O
the	O
internal	O
standard	O
was	O
prepared	O
in	O
water	B
at	O
100	O
μg	O
/	O
ml	O
.	O

The	O
stock	O
solutions	O
were	O
stored	O
at	O
−20	O
°	O
C	O
.	O

Eight	O
calibration	O
standards	O
(	O
at	O
0.1	O
,	O
0.2	O
,	O
0.5	O
,	O
1	O
,	O
2	O
,	O
5	O
,	O
10	O
,	O
and	O
20	O
μg	O
/	O
ml	O
)	O
were	O
prepared	O
in	O
triplicate	O
on	O
each	O
of	O
three	O
validation	O
days	O
.	O

Three	O
sets	O
of	O
quality	O
control	O
samples	O
(	O
QC	O
samples	O
)	O
at	O
concentration	O
of	O
0.2	O
(	O
low	O
)	O
,	O
1.5	O
(	O
medium	O
)	O
and	O
15	O
μg	O
/	O
ml	O
(	O
high	O
)	O
were	O
prepared	O
in	O
bulk	O
from	O
separate	O
weighing	O
,	O
aliquotted	O
and	O
stored	O
at	O
−20	O
°	O
C	O
for	O
use	O
during	O
the	O
entire	O
validation	O
and	O
sample	O
analysis	O
.	O

For	O
the	O
chiral	O
HPLC	O
assay	O
,	O
stock	O
solutions	O
of	O
SCH	B
66336	I
,	O
SCH	B
66337	I
and	O
SCH	B
66347	I
were	O
prepared	O
in	O
methanol	B
at	O
100	O
μg	O
/	O
ml	O
and	O
stored	O
at	O
−20	O
°	O
C	O
.	O

Three	O
sets	O
of	O
quality	O
control	O
samples	O
at	O
concentration	O
of	O
0.4	O
(	O
low	O
)	O
,	O
2.5	O
(	O
medium	O
)	O
and	O
8.0	O
μg	O
/	O
ml	O
(	O
high	O
)	O
were	O
prepared	O
in	O
bulk	O
from	O
separate	O
weighings	O
,	O
aliquotted	O
and	O
stored	O
at	O
−20	O
°	O
C	O
for	O
use	O
during	O
the	O
entire	O
validation	O
and	O
sample	O
analysis	O
.	O

2.3	O
Sample	O
preparation	O
For	O
the	O
achiral	O
assay	O
,	O
a	O
0.2-ml	O
volume	O
of	O
monkey	O
plasma	O
standard	O
,	O
QC	O
sample	O
or	O
unknown	O
was	O
placed	O
into	O
a	O
15-ml	O
screw	O
-	O
capped	O
test	O
tube	O
containing	O
0.2	O
ml	O
of	O
internal	O
standard	O
solution	O
(	O
2	O
μg	O
/	O
ml	O
)	O
.	O

Saturated	O
sodium	B
bicarbonate	I
solution	O
(	O
0.3	O
ml	O
)	O
was	O
added	O
followed	O
by	O
4.0	O
ml	O
of	O
30	O
%	O
(	O
v	O
/	O
v	O
)	O
methylene	B
chloride	I
in	O
hexane	B
,	O
mixed	O
on	O
a	O
mechanical	O
vortexer	O
for	O
10	O
min	O
and	O
centrifuged	O
.	O

The	O
organic	O
layer	O
was	O
transferred	O
into	O
15-ml	O
conical	O
test	O
tubes	O
and	O
20	O
μl	O
of	O
0.8	O
M	O
HCl	B
in	O
methanol	B
was	O
added	O
.	O

The	O
samples	O
were	O
evaporated	O
to	O
dryness	O
at	O
40	O
°	O
C	O
under	O
a	O
gentle	O
stream	O
of	O
nitrogen	B
,	O
the	O
residue	O
was	O
reconstituted	O
in	O
0.2	O
ml	O
of	O
mobile	O
phase	O
and	O
50	O
μl	O
was	O
injected	O
onto	O
the	O
HPLC	O
column	O
for	O
analysis	O
.	O

For	O
the	O
chiral	O
analysis	O
,	O
a	O
0.2-ml	O
volume	O
of	O
rat	O
or	O
monkey	O
plasma	O
standard	O
,	O
QC	O
sample	O
,	O
or	O
unknown	O
was	O
applied	O
onto100	O
mg	O
of	O
the	O
solid	O
-	O
phase	O
extraction	O
(	O
SPE	O
)	O
cartridge	O
ethyl	B
Bond	O
Elute	O
cartridge	O
which	O
has	O
been	O
pre	O
-	O
washed	O
with	O
3	O
ml	O
of	O
methanol	B
and	O
3	O
ml	O
of	O
water	B
.	O

The	O
SPE	O
cartridge	O
was	O
washed	O
with	O
2	O
ml	O
of	O
water	B
and	O
2	O
ml	O
of	O
10	O
%	O
(	O
v	O
/	O
v	O
)	O
acetonitrile	B
in	O
water	O
.	O

The	O
compounds	B
were	O
eluted	O
with	O
3	O
ml	O
of	O
acetonitrile	B
.	O

The	O
eluate	O
was	O
evaporated	O
to	O
dryness	O
under	O
nitrogen	B
and	O
the	O
residue	O
was	O
reconstituted	O
with	O
0.5	O
ml	O
of	O
mobile	O
phase	O
;	O
a	O
0.1	O
ml	O
aliquot	O
was	O
injected	O
onto	O
the	O
HPLC	O
column	O
for	O
analysis	O
.	O

2.4	O
Chromatographic	O
conditions	O
The	O
HPLC	O
system	O
consisted	O
of	O
a	O
Shimadzu	O
LC-10	O
AD	O
pump	O
and	O
a	O
Waters	B
486	O
absorbance	O
detector	O
set	O
at	O
280	O
nm	O
.	O

The	O
achiral	O
separation	O
was	O
accomplished	O
on	O
a	O
Spherisorb	O
CN	B
,	O
5	O
μm	O
,	O
150	O
×	O
4.6	O
mm	O
column	O
which	O
was	O
preceded	O
by	O
an	O
on	O
-	O
line	O
filter	O
.	O

The	O
Millennium	O
2020	O
Chromatography	O
Manager	O
Soft	O
System	O
was	O
used	O
for	O
data	O
handling	O
.	O

The	O
mobile	O
phase	O
consisted	O
of	O
0.02	O
M	O
potassium	B
phosphate	I
(	O
pH	O
4	O
)	O
–acetonitrile	O
(	O
65:35	O
,	O
v	O
/	O
v	O
)	O
,	O
and	O
was	O
delivered	O
at	O
0.9	O
ml	O
/	O
min	O
.	O

The	O
chiral	O
HPLC	O
method	O
involved	O
the	O
use	O
of	O
a	O
Chiral	O
Pak	O
AD	O
column	O
(	O
Chiral	O
Technologies	O
,	O
Eaton	O
,	O
PA	O
)	O
set	O
at	O
39	O
°	O
C	O
and	O
a	O
mobile	O
phase	O
of	O
hexane	B
–	O
ethanol	B
–	O
diethylamine	B
(	O
30:70:0.2	O
,	O
v	O
/	O
v	O
/	O
v	O
)	O
at	O
a	O
flow	O
of	O
0.8	O
ml	O
/	O
min	O
.	O

2.5	O
Administration	O
of	O
SCH	B
66336	I
Six	O
male	O
cynomolgus	O
monkeys	O
were	O
dosed	O
orally	O
with	O
a	O
100-mg	O
experimental	O
tablet	O
of	O
SCH	B
66336	I
(	O
approximately	O
15	O
mg	O
/	O
kg	O
)	O
for	O
pharmacokinetic	O
evaluation	O
.	O

Also	O
,	O
rats	O
and	O
cynomolgus	O
monkeys	O
were	O
given	O
SCH	B
66336	I
at	O
a	O
single	O
oral	O
dose	O
of	O
300	O
and	O
120	O
mg	O
/	O
kg	O
,	O
respectively	O
,	O
as	O
a	O
suspension	O
in	O
0.4	O
%	O
methylcellulose	B
for	O
the	O
evaluation	O
of	O
chiral	O
inversion	O
of	O
SCH	B
66336	I
.	O

Blood	O
samples	O
were	O
collected	O
at	O
intervals	O
after	O
dosing	O
,	O
centrifuged	O
and	O
plasma	O
stored	O
at	O
−20	O
°	O
C	O
pending	O
analysis	O
.	O

Plasma	O
concentrations	O
equal	O
to	O
or	O
above	O
the	O
limit	O
of	O
quantitation	O
(	O
LOQ	O
,	O
0.1	O
μg	O
/	O
ml	O
)	O
were	O
used	O
for	O
pharmacokinetic	O
analysis	O
using	O
model	O
-	O
independent	O
methods	O
[	O
14	O
]	O
.	O

The	O
maximum	O
plasma	O
concentration	O
(	O
C	O
max	O
)	O
and	O
time	O
of	O
maximum	O
plasma	O
concentration	O
(	O
T	O
max	O
)	O
were	O
the	O
observed	O
values	O
.	O

The	O
area	O
under	O
the	O
plasma	O
concentration	O
–	O
time	O
curve	O
from	O
time	O
zero	O
to	O
the	O
time	O
of	O
the	O
final	O
measurable	O
sample	O
[	O
AUC	O
(	O
tf	O
)	O
]	O
was	O
calculated	O
using	O
the	O
linear	O
trapezoidal	O
method	O
,	O
and	O
was	O
extrapolated	O
to	O
infinity	O
(	O
I	O
)	O
according	O
to	O
the	O
following	O
equation	O
:	O
AUC	O
(	O
I	O
)	O
=	O
AUC	O
(	O
tf	O
)	O
+C	O
(	O
tf	O
)	O
/	O
k	O
where	O
C	O
(	O
tf	O
)	O
is	O
the	O
estimated	O
concentration	O
at	O
tf	O
using	O
the	O
above	O
regression	O
.	O

3	O
Results	O
3.1	O
Achiral	O
HPLC	O
Typical	O
chromatograms	O
of	O
drug	B
-	O
free	O
monkey	O
plasma	O
and	O
plasma	O
spiked	O
with	O
SCH	B
66336	I
and	O
the	O
internal	O
standard	O
azatadine	B
maleate	I
are	O
illustrated	O
in	O
Fig.	O
2	O
.	O

The	O
retention	O
times	O
of	O
SCH	B
66336	I
and	O
the	O
internal	O
standard	O
were	O
approximately	O
7.2	O
and	O
10.5	O
min	O
,	O
respectively	O
.	O

There	O
were	O
no	O
endogenous	O
peaks	O
in	O
plasma	O
of	O
six	O
undosed	O
monkeys	O
that	O
coeluted	O
with	O
SCH	B
66336	I
or	O
the	O
internal	O
standard	O
,	O
indicating	O
that	O
the	O
method	O
was	O
selective	O
.	O

The	O
linearity	O
of	O
the	O
assay	O
was	O
evaluated	O
over	O
a	O
concentration	O
range	O
of	O
0.1–20	O
μg	O
/	O
ml	O
.	O

Linear	O
regression	O
parameters	O
of	O
the	O
peak	O
height	O
ratios	O
versus	O
concentrations	O
along	O
with	O
back	O
-	O
calculated	O
concentrations	O
of	O
nine	O
calibration	O
curves	O
are	O
presented	O
in	O
Table	O
1	O
.	O

The	O
results	O
showed	O
highly	O
reproducible	O
calibration	O
curves	O
with	O
correlation	O
coefficients	O
of	O
>	O
0.99	O
,	O
indicating	O
that	O
the	O
response	O
was	O
linear	O
over	O
the	O
concentration	O
range	O
studied	O
.	O

Intra	O
-	O
day	O
precision	O
and	O
accuracy	O
were	O
evaluated	O
at	O
SCH	B
66336	I
concentrations	O
of	O
0.2	O
,	O
1.5	O
and	O
15	O
μg	O
/	O
ml	O
.	O

Six	O
samples	O
were	O
analyzed	O
at	O
each	O
concentration	O
on	O
the	O
same	O
day	O
.	O

The	O
results	O
showed	O
satisfactory	O
intra	O
-	O
day	O
precision	O
and	O
accuracy	O
as	O
indicated	O
by	O
a	O
coefficient	O
of	O
variation	O
(	O
CV	O
)	O
of	O
<	O
2.5	O
%	O
and	O
a	O
bias	O
of	O
<	O
5.1	O
%	O
(	O
Table	O
2	O
)	O
.	O

Inter	O
-	O
day	O
precision	O
and	O
accuracy	O
were	O
evaluated	O
at	O
the	O
same	O
concentrations	O
as	O
above	O
and	O
the	O
samples	O
were	O
analyzed	O
on	O
three	O
separate	O
days	O
.	O

The	O
results	O
demonstrated	O
satisfactory	O
inter	O
-	O
day	O
precision	O
and	O
accuracy	O
as	O
shown	O
by	O
CV	O
and	O
bias	O
values	O
of	O
<	O
3.4	O
%	O
and	O
<	O
6.1	O
%	O
,	O
respectively	O
(	O
Table	O
3	O
)	O
.	O

The	O
LOQ	O
,	O
defined	O
as	O
the	O
lowest	O
concentration	O
in	O
the	O
calibration	O
curve	O
that	O
could	O
be	O
determined	O
with	O
acceptable	O
precision	O
and	O
accuracy	O
,	O
was	O
0.1	O
μg	O
/	O
ml	O
.	O

At	O
this	O
concentration	O
,	O
the	O
precision	O
and	O
accuracy	O
from	O
the	O
back	O
-	O
calculated	O
concentrations	O
were	O
satisfactory	O
(	O
CV=5	O
%	O
,	O
bias	O
0	O
%	O
;	O
Table	O
1	O
)	O
.	O

The	O
recovery	O
was	O
consistent	O
over	O
a	O
concentration	O
range	O
of	O
0.2–15	O
μg	O
/	O
ml	O
(	O
>	O
83	O
%	O
)	O
.	O

The	O
recovery	O
of	O
the	O
internal	O
standard	O
at	O
the	O
concentration	O
used	O
(	O
2.0	O
μg	O
/	O
ml	O
)	O
was	O
88.7	O
%	O
.	O

The	O
stability	O
of	O
SCH	B
66336	I
in	O
plasma	O
was	O
evaluated	O
through	O
three	O
freeze	O
–	O
thaw	O
cycles	O
at	O
concentrations	O
of	O
0.2	O
,	O
1.5	O
and	O
15	O
μg	O
/	O
ml	O
.	O

The	O
samples	O
were	O
thawed	O
in	O
a	O
water	B
bath	O
at	O
room	O
temperature	O
and	O
frozen	O
within	O
5	O
min	O
of	O
thawing	O
in	O
each	O
cycle	O
.	O

After	O
three	O
cycles	O
,	O
the	O
changes	O
from	O
nominal	O
concentrations	O
were	O
−5.0	O
,	O
+	O
13.3	O
and	O
+	O
12.7	O
%	O
for	O
the	O
0.2	O
,	O
1.5	O
and	O
15	O
μg	O
/	O
ml	O
,	O
respectively	O
,	O
demonstrating	O
that	O
SCH	B
66336	I
was	O
stable	O
in	O
plasma	O
through	O
three	O
freeze	O
–	O
thaw	O
cycles	O
.	O

Long	O
-	O
term	O
stability	O
was	O
determined	O
following	O
316	O
days	O
of	O
storage	O
at	O
−20	O
°	O
C	O
at	O
the	O
concentrations	O
above	O
.	O

The	O
changes	O
from	O
the	O
nominal	O
concentrations	O
ranged	O
from	O
0.7–5.0	O
%	O
indicating	O
that	O
SCH	B
66336	I
was	O
stable	O
in	O
plasma	O
for	O
at	O
least	O
316	O
days	O
.	O

In	O
-	O
process	O
stability	O
was	O
performed	O
for	O
up	O
to	O
72	O
h	O
after	O
sample	O
processing	O
.	O

Three	O
sets	O
of	O
processed	O
plasma	O
samples	O
at	O
the	O
above	O
SCH	B
66336	I
concentrations	O
were	O
analyzed	O
after	O
storage	O
at	O
room	O
temperature	O
for	O
72	O
h.	O
The	O
changes	O
from	O
nominal	O
concentrations	O
were	O
−5.0	O
,	O
2.0	O
and	O
3.3	O
%	O
for	O
the	O
0.2	O
,	O
1.5	O
and	O
15	O
μg	O
/	O
ml	O
,	O
respectively	O
,	O
demonstrating	O
that	O
SCH	B
66336	I
was	O
stable	O
under	O
the	O
conditions	O
evaluated	O
.	O

3.2	O
Chiral	O
HPLC	O
Typical	O
chromatograms	O
of	O
drug	B
-	O
free	O
rat	O
and	O
cynomolgus	O
monkey	O
plasma	O
and	O
plasma	O
spiked	O
with	O
the	O
internal	O
standard	O
,	O
SCH	B
66336	I
and	O
its	O
enantiomer	B
SCH	B
66337	I
are	O
illustrated	O
in	O
Figs.	O
3	O
and	O
4	O
,	O
respectively	O
.	O

The	O
retention	O
times	O
of	O
SCH	B
66337	I
,	O
SCH	B
66336	I
and	O
the	O
internal	O
standard	O
were	O
approximately	O
5.7	O
,	O
8.3	O
and	O
13.4	O
min	O
,	O
respectively	O
.	O

There	O
were	O
no	O
endogenous	O
peaks	O
in	O
plasma	O
of	O
undosed	O
rats	O
or	O
monkeys	O
that	O
coeluted	O
with	O
SCH	B
66337	I
,	O
SCH	B
66336	I
or	O
the	O
internal	O
standard	O
,	O
indicating	O
that	O
the	O
method	O
was	O
selective	O
.	O

The	O
linearity	O
was	O
evaluated	O
over	O
a	O
concentration	O
range	O
of	O
0.25–10	O
μg	O
/	O
ml	O
,	O
the	O
correlation	O
coefficients	O
were	O
>	O
0.99	O
indicating	O
that	O
the	O
response	O
was	O
linear	O
over	O
the	O
concentration	O
range	O
studied	O
(	O
Tables	O
4	O
and	O
5	O
)	O
.	O

Intra	O
-	O
day	O
precision	O
and	O
accuracy	O
were	O
evaluated	O
at	O
plasma	O
SCH	B
66337	I
and	O
SCH	B
66336	I
concentrations	O
of	O
0.4	O
,	O
2.5	O
and	O
8.0	O
μg	O
/	O
ml	O
.	O

Three	O
samples	O
were	O
analyzed	O
at	O
each	O
concentration	O
on	O
the	O
same	O
day	O
;	O
the	O
results	O
are	O
shown	O
in	O
Table	O
6	O
.	O

Intra	O
-	O
day	O
precision	O
and	O
accuracy	O
were	O
satisfactory	O
as	O
indicated	O
by	O
a	O
CV	O
of	O
<	O
13	O
%	O
and	O
a	O
bias	O
of	O
<	O
12	O
%	O
for	O
both	O
enantiomers	B
.	O

The	O
LOQ	O
was	O
0.25	O
μg	O
/	O
ml	O
;	O
at	O
this	O
concentration	O
,	O
the	O
precision	O
and	O
accuracy	O
from	O
the	O
back	O
-	O
calculated	O
concentrations	O
were	O
satisfactory	O
(	O
CV	O
<	O
14	O
%	O
,	O
bias=6	O
%	O
)	O
.	O

The	O
recovery	O
values	O
at	O
10	O
μg	O
/	O
ml	O
for	O
SCH	B
66337	I
,	O
SCH	B
66336	I
and	O
the	O
internal	O
standard	O
were	O
83	O
,	O
80	O
and	O
79	O
%	O
,	O
respectively	O
.	O

4	O
Discussion	O
SCH	O
66336	O
belongs	O
to	O
the	O
tricyclic	O
class	O
of	O
FPT	O
inhibitors	O
which	O
are	O
structurally	O
distinct	O
from	O
other	O
reported	O
FPT	O
inhibitors	O
,	O
many	O
of	O
which	O
were	O
derived	O
from	O
peptidomimetic	B
approaches	O
[	O
15,16	O
]	O
.	O

These	O
differences	O
,	O
including	O
the	O
absence	O
of	O
a	O
sulfhydryl	B
function	O
,	O
are	O
likely	O
to	O
contribute	O
to	O
the	O
favorable	O
oral	O
pharmacokinetic	O
properties	O
of	O
the	O
tricyclic	O
class	O
.	O

Initial	O
compounds	O
in	O
this	O
series	O
,	O
such	O
as	O
SCH	B
44342	I
(	O
IC50	O
=	O
250	O
nM	O
)	O
,	O
displayed	O
less	O
than	O
optimal	O
pharmacokinetic	O
properties	O
in	O
the	O
mouse	O
,	O
including	O
a	O
very	O
rapid	O
oxidative	O
metabolism	O
[	O
15	O
]	O
.	O

Blocking	O
the	O
susceptible	O
metabolic	O
sites	O
on	O
SCH	B
44342	I
greatly	O
improved	O
the	O
pharmacokinetic	O
properties	O
of	O
compounds	O
in	O
this	O
series	O
.	O

SCH	B
66336	I
was	O
the	O
lead	B
compound	I
that	O
emerged	O
from	O
these	O
efforts	O
.	O

In	O
addition	O
to	O
improved	O
metabolic	O
stability	O
,	O
its	O
intrinsic	O
potency	O
was	O
also	O
improved	O
as	O
indicated	O
by	O
an	O
FPT	O
IC50	O
of	O
1.9	O
nM	O
.	O

Due	O
to	O
these	O
improvements	O
,	O
SCH	B
66336	I
persisted	O
in	O
mouse	O
serum	O
at	O
concentrations	O
greater	O
than	O
its	O
IC50	O
for	O
Ha	O
-	O
Ras	O
processing	O
in	O
Cos	O
cells	O
for	O
over	O
16	O
h	O
following	O
a	O
single	O
oral	O
dose	O
of	O
25	O
mg	O
/	O
kg	O
[	O
11	O
]	O
.	O

We	O
have	O
attempted	O
to	O
improve	O
the	O
sensitivity	O
of	O
the	O
achiral	O
HPLC	O
method	O
by	O
solid	O
-	O
phase	O
extraction	O
on	O
ethyl	B
column	O
.	O

However	O
,	O
because	O
of	O
the	O
high	O
plasma	O
background	O
,	O
the	O
sensitivity	O
was	O
reduced	O
(	O
LOQ	O
was	O
0.25	O
μg	O
/	O
ml	O
)	O
.	O

Gas	O
chromatography	O
(	O
GC	O
)	O
with	O
electron	O
capture	O
detection	O
(	O
ECD	O
)	O
appeared	O
to	O
be	O
a	O
suitable	O
mean	O
for	O
developing	O
a	O
sensitive	O
assay	O
,	O
since	O
the	O
compound	B
contains	O
three	O
halogens	B
(	O
Fig.	O
1	O
)	O
.	O

Because	O
SCH	B
66336	I
was	O
non	O
-	O
volatile	O
,	O
the	O
GC	O
column	O
temperature	O
needed	O
to	O
be	O
kept	O
above	O
320	O
°	O
C	O
to	O
observe	O
a	O
signal	O
.	O

However	O
,	O
the	O
compound	B
was	O
thermally	O
unstable	O
at	O
this	O
high	O
temperature	O
.	O

The	O
achiral	O
analytical	O
method	O
was	O
used	O
to	O
characterize	O
the	O
pharmacokinetic	O
profile	O
of	O
SCH	B
66336	I
in	O
the	O
cynomolgus	O
monkey	O
treated	O
orally	O
with	O
a	O
100-mg	O
experimental	O
capsule	O
of	O
SCH	B
66336	I
.	O

SCH	B
66336	I
was	O
quantifiable	O
in	O
plasma	O
between	O
2	O
and	O
24	O
h	O
after	O
oral	O
administration	O
(	O
Fig.	O
5	O
)	O
.	O

The	O
mean	O
C	O
max	O
of	O
SCH	B
66336	I
was	O
6.82	O
μg	O
/	O
ml	O
which	O
was	O
attained	O
at	O
a	O
mean	O
T	O
max	O
of	O
7.67	O
h.	O

The	O
area	O
under	O
the	O
plasma	O
concentration	O
–	O
time	O
curve	O
(	O
AUC0–24	O
h	O
)	O
was	O
84.5	O
μg	O
h	O
/	O
ml	O
(	O
Table	O
7	O
)	O
.	O

Enantiomers	B
of	O
biologically	B
active	I
molecules	I
may	O
differ	O
in	O
potency	O
,	O
pharmacological	O
action	O
,	O
metabolism	O
,	O
toxicity	B
and	O
pharmacokinetics	O
[	O
12	O
]	O
.	O

Therefore	O
,	O
it	O
is	O
highly	O
desirable	O
that	O
only	O
the	O
active	O
enantiomer	B
be	O
the	O
drug	B
candidate	O
.	O

The	O
tools	O
for	O
chiral	O
resolution	O
have	O
been	O
progressively	O
improving	O
by	O
the	O
development	O
of	O
a	O
great	O
variety	O
of	O
chiral	O
HPLC	O
-	O
stationary	O
phases	O
.	O

Chiral	O
phases	O
containing	O
cavities	O
such	O
as	O
cyclodextrins	B
or	O
cellulose	B
derivatives	B
have	O
played	O
a	O
significant	O
role	O
in	O
the	O
area	O
of	O
chiral	O
resolution	O
[	O
13	O
]	O
.	O

The	O
chiral	O
recognition	O
of	O
cavity	O
-	O
containing	O
stationary	O
phases	O
is	O
believed	O
to	O
be	O
a	O
result	O
of	O
the	O
insertion	O
of	O
the	O
aromatic	O
portion	O
of	O
the	O
solute	O
into	O
the	O
chiral	O
cavity	O
,	O
in	O
addition	O
to	O
hydrogen	B
bonding	O
interactions	O
.	O

A	O
great	O
number	O
of	O
chiral	O
drugs	B
have	O
been	O
resolved	O
on	O
cyclodextrin	B
(	O
cyclobond	O
)	O
,	O
cellulose	B
(	O
chiralcel	O
)	O
or	O
amylose	B
(	O
chiralpak	O
)	O
based	O
columns	O
.	O

Several	O
chiral	O
HPLC	O
columns	O
were	O
evaluated	O
for	O
the	O
separation	O
of	O
SCH	B
66336	I
and	O
SCH	B
66336	I
including	O
Cyclobond	O
1	O
,	O
Chiralcel	O
OD	O
(	O
cellulose	B
carbamate	I
derivative	B
)	O
and	O
Chiralpak	O
AD	O
(	O
amylose	B
carbamate	I
derivative	B
)	O
.	O

The	O
Cyclobond	O
1	O
and	O
Chiralcel	O
OD	O
columns	O
gave	O
broad	O
peaks	O
with	O
asymmetric	O
peak	O
shape	O
(	O
tailing	O
)	O
without	O
baseline	O
separations	O
.	O

The	O
Chiralpak	O
AD	O
column	O
was	O
selected	O
because	O
of	O
symmetrical	O
peaks	O
and	O
baseline	O
separation	O
resulting	O
in	O
a	O
better	O
sensitivity	O
.	O

The	O
chiral	O
HPLC	O
method	O
was	O
used	O
to	O
evaluate	O
the	O
possible	O
chiral	O
inversion	O
of	O
SCH	B
66336	I
in	O
animals	O
.	O

It	O
should	O
be	O
pointed	O
out	O
that	O
SCH	B
66336	I
administered	O
to	O
animals	O
contained	O
approximately	O
1.5–2.0	O
%	O
SCH	B
66337	I
as	O
an	O
impurity	O
.	O

In	O
rat	O
plasma	O
,	O
SCH	B
66337	I
concentrations	O
were	O
below	O
the	O
LOQ	O
,	O
while	O
the	O
concentrations	O
of	O
SCH	B
66336	I
ranged	O
from	O
5.5–25.0	O
μg	O
/	O
ml	O
.	O

In	O
cynomolgus	O
monkey	O
plasma	O
,	O
the	O
concentrations	O
of	O
SCH	B
66336	I
were	O
within	O
the	O
range	O
of	O
0.32–	O
28.9	O
μg	O
/	O
ml	O
,	O
while	O
those	O
for	O
SCH	B
66337	I
were	O
within	O
the	O
range	O
of	O
below	O
the	O
LOQ	O
to	O
0.9	O
μg	O
/	O
ml	O
.	O

The	O
ratios	O
of	O
the	O
concentrations	O
of	O
SCH	B
66337	I
to	O
SCH	B
66337	I
in	O
the	O
samples	O
that	O
contained	O
quantifiable	O
levels	O
of	O
both	O
analytes	O
were	O
within	O
the	O
range	O
of	O
2.5–3	O
%	O
,	O
which	O
is	O
similar	O
to	O
the	O
ratio	O
seen	O
as	O
an	O
impurity	O
in	O
SCH	B
66336	I
.	O

Therefore	O
,	O
it	O
is	O
concluded	O
that	O
SCH	B
66336	I
is	O
not	O
subjected	O
to	O
chiral	O
inversion	O
in	O
rats	O
and	O
cynomolgus	O
monkeys	O
.	O

In	O
conclusion	O
,	O
the	O
HPLC	O
assay	O
for	O
the	O
determination	O
of	O
SCH	B
66336	I
in	O
cynomolgus	O
monkey	O
plasma	O
was	O
shown	O
to	O
be	O
accurate	O
and	O
reliable	O
over	O
a	O
concentration	O
range	O
of	O
0.1	O
to	O
20	O
μg	O
/	O
ml	O
with	O
an	O
average	O
CV	O
of	O
6	O
%	O
and	O
an	O
average	O
bias	O
of	O
7	O
%	O
.	O

The	O
assay	O
was	O
used	O
successfully	O
to	O
monitor	O
plasma	O
concentrations	O
of	O
SCH	B
66336	I
in	O
cynomolgus	O
monkey	O
.	O

A	O
reliable	O
chiral	O
HPLC	O
method	O
was	O
also	O
developed	O
to	O
separate	O
SCH	B
66336	I
from	O
its	O
enantiomer	B
SCH	B
66337	I
in	O
monkey	O
and	O
rat	O
plasma	O
.	O

Chiral	O
HPLC	O
analysis	O
indicated	O
that	O
SCH	B
66336	I
was	O
not	O
subjected	O
to	O
chiral	O
inversion	O
in	O
rats	O
and	O
cynomolgus	O
monkeys	O
.	O

The	O
growing	O
demand	O
for	O
peptides	B
with	O
biological	O
,	O
pharmaceutical	O
and	O
food	O
ingredients	O
applications	O
requires	O
the	O
development	O
of	O
efficient	O
synthetic	O
methods	O
[	O
1	O
]	O
.	O

Recently	O
,	O
the	O
successful	O
performance	O
of	O
enzymatic	O
peptide	B
synthesis	O
in	O
heterogenous	O
substrate	O
mixtures	O
[	O
2–5	O
]	O
has	O
provided	O
a	O
new	O
and	O
efficient	O
route	O
to	O
peptide	B
syntheses	O
.	O

It	O
was	O
found	O
that	O
some	O
amino	B
acid	I
amides	B
can	O
form	O
supercooled	O
liquid	O
mixtures	O
with	O
N	B
-carbobenzyloxy	I
-	I
l	I
-tyrosine	I
ethyl	I
ester	I
(	O
CBZ	B
-	I
Tyroet	I
)	O
and	O
acetyl	B
-	I
l	I
-tyrosine	I
ethyl	I
ester	I
(	O
Ac	B
-	I
Tyroet	I
)	O
,	O
in	O
which	O
enzymic	O
catalysis	O
of	O
transesterfication	O
reactions	O
can	O
take	O
place	O
.	O

For	O
example	O
,	O
the	O
dipeptide	B
(	O
N	B
-CBZ	I
-	I
Tyr	I
-	I
leuNH	I
)	O
was	O
obtained	O
in	O
the	O
supercooled	O
liquid	O
mixtures	O
of	O
l	B
-leucinamide	I
with	O
CBZ	B
-	I
Tyroet	I
when	O
subtilisin	O
or	O
α	O
-	O
chymotrypsin	O
were	O
used	O
.	O

However	O
,	O
the	O
enzymatic	O
peptide	B
synthesis	O
in	O
the	O
absence	O
of	O
solvent	B
depends	O
on	O
the	O
ability	O
of	O
the	O
mixtures	O
to	O
form	O
supercooled	O
liquid	O
mixtures	O
[	O
2–5	O
]	O
.	O

For	O
instance	O
,	O
supercooled	O
-	O
liquid	O
mixtures	O
can	O
not	O
be	O
formed	O
on	O
mixing	O
l	B
-leucinamide	I
and	O
N	B
-trifluoroacetyl	I
-	I
l	I
-tyrosine	I
ethyl	I
ester	I
(	O
TFAc	B
-	I
Tyroet	I
)	O
and	O
no	O
dipeptide	B
can	O
be	O
obtained	O
.	O

It	O
is	O
therefore	O
important	O
to	O
understand	O
the	O
mechanism	O
of	O
the	O
formation	O
of	O
supercooled	O
liquid	O
in	O
the	O
mixtures	O
of	O
amino	B
acid	I
amides	B
and	O
tyrosine	B
derivatives	B
.	O

As	O
part	O
of	O
the	O
systematic	O
study	O
of	O
amino	B
acid	I
derivatives	B
,	O
the	O
proton	O
relaxation	O
behaviour	O
and	O
crystal	O
structure	O
of	O
l	B
-leucinamide	I
[	O
6	O
,	O
7	O
]	O
and	O
the	O
proton	O
relaxation	O
of	O
l	B
-alaninamide	I
[	O
8	O
]	O
has	O
been	O
studied	O
.	O

It	O
was	O
found	O
that	O
methyl	B
group	I
and	O
amino	B
group	I
rotations	O
are	O
the	O
main	O
spin	O
-	O
lattice	O
relaxation	O
mechanisms	O
.	O

In	O
this	O
paper	O
,	O
we	O
examine	O
the	O
NMR	O
proton	O
relaxation	O
behaviours	O
of	O
three	O
tyrosine	B
derivatives	B
,	O
namely	O
,	O
Ac	B
-	I
Tyroet	I
,	O
CBZ	B
-	I
Tyroet	I
,	O
TFAc	B
-	I
Tyroet	I
(	O
Fig.	O
1	O
)	O
,	O
and	O
their	O
mixtures	O
with	O
l	B
-leucinamide	I
in	O
order	O
to	O
understand	O
the	O
molecular	O
dynamics	O
of	O
these	O
compounds	O
and	O
the	O
contributions	O
of	O
molecular	O
motions	O
in	O
the	O
formation	O
of	O
supercooled	O
liquids	O
.	O

2	O
Experimental	O
2.1	O
Sample	O
preparation	O
2.1.1	O
N	B
-	I
carbobenzyloxy	I
-	I
l	I
-tyrosine	I
ethyl	I
ester	I
(	O
CBZ	B
-	I
Tyroet	I
)	O
CBZ	B
-	I
Tyroet	I
was	O
prepared	O
from	O
the	O
corresponding	O
free	O
acid	B
using	O
the	O
thionyl	B
chloride	I
method	O
[	O
9	O
]	O
.	O

A	O
10	O
g	O
N	B
-carbobenzyloxy	I
-	I
l	I
-tyrosine	I
(	O
Sigma	O
)	O
was	O
dissolved	O
in	O
absolute	O
ethanol	B
(	O
BDH	O
)	O
and	O
2.8	O
ml	O
of	O
thionyl	B
chloride	I
(	O
Sigma	O
)	O
was	O
slowly	O
added	O
in	O
.	O

The	O
reaction	O
was	O
carried	O
out	O
at	O
40	O
°	O
C	O
for	O
2	O
h	O
in	O
a	O
water	B
bath	O
located	O
in	O
a	O
fume	O
cupboard	O
,	O
followed	O
by	O
rotary	O
evaporation	O
.	O

The	O
products	O
were	O
then	O
dissolved	O
in	O
ethyl	B
acetate	I
(	O
BDH	O
)	O
and	O
washed	O
by	O
0.1	O
M	O
aqueous	O
sodium	B
hydrogen	I
carbonate	I
(	O
Sigma	O
)	O
solution	O
3	O
or	O
4	O
times	O
to	O
remove	O
non	O
-	O
reacted	O
N	B
-carbobenzyloxy	I
-	I
l	I
-tyrosine	I
.	O

To	O
dry	O
the	O
ethyl	B
acetate	I
solution	O
,	O
an	O
excess	O
of	O
magnesium	B
sulphate	I
(	O
BDH	O
)	O
was	O
added	O
,	O
followed	O
by	O
filtration	O
and	O
rotary	O
evaporation	O
.	O

The	O
CBZ	B
-	I
Tyroet	I
was	O
then	O
crystallised	O
from	O
hot	O
ethyl	B
acetate	I
and	O
petroleum	B
ether	I
(	O
BDH	O
)	O
.	O

A	O
deuterated	O
sample	O
(	O
D2-CBZ	B
-	I
Tyroet	I
)	O
was	O
prepared	O
by	O
stirring	O
the	O
CBZ	B
-	I
Tyroet	I
in	O
D2	B
O	I
(	O
Fluorochem	O
)	O
for	O
ca	O
.	O

2	O
h	O
,	O
followed	O
by	O
freeze	O
-	O
drying	O
.	O

This	O
process	O
was	O
repeated	O
3	O
times	O
to	O
ensure	O
that	O
all	O
the	O
exchangeable	O
protons	O
are	O
replaced	O
by	O
deuterium	B
.	O

The	O
samples	O
were	O
stored	O
in	O
a	O
desiccator	O
over	O
di	B
-	I
phosphorus	I
pentoxide	I
at	O
room	O
temperature	O
.	O

The	O
moisture	O
content	O
was	O
0.1	O
wt.%	O
as	O
measured	O
by	O
Karl	O
–	O
Fischer	O
titration	O
.	O

2.1.2	O
N	B
-	I
trifluoroacetyl	I
-	I
l	I
-tyrosine	I
ethyl	I
ester	I
(	O
TFAc	B
-	I
Tyroet	I
)	O
TFAc	B
-	I
Tyroet	I
was	O
prepared	O
by	O
trifluoroacetylation	B
of	O
l	B
-tyrosine	I
ethyl	I
ester	I
(	O
Sigma	O
)	O
with	O
ethyl	B
trifluoroacetate	I
(	O
Sigma	O
)	O
,	O
in	O
the	O
presence	O
of	O
tetramethyl	B
guanidine	I
(	O
Sigma	O
)	O
[	O
10	O
]	O
.	O

A	O
20	O
g	O
l	B
-tyrosine	I
ethyl	I
ester	I
was	O
dissolved	O
in	O
120	O
ml	O
of	O
absolute	O
ethanol	B
,	O
1.2	O
ml	O
of	O
tetramethyl	B
guanidine	I
followed	O
by	O
12.5	O
ml	O
of	O
ethyl	B
trifluoroacetate	I
was	O
added	O
.	O

The	O
mixture	O
was	O
stirred	O
at	O
room	O
temperature	O
for	O
5	O
h	O
in	O
a	O
fume	O
cupboard	O
.	O

When	O
the	O
synthesis	O
had	O
been	O
completed	O
,	O
15	O
g	O
Dowex	B
50X2	I
-	I
400	I
(	O
Sigma	O
)	O
followed	O
by	O
2	O
g	O
Norit	O
-	O
A	O
activated	O
carbon	B
(	O
Sigma	O
)	O
was	O
added	O
.	O

The	O
mixture	O
was	O
stirred	O
for	O
a	O
further	O
15	O
min	O
.	O

The	O
mixture	O
was	O
filtered	O
through	O
diatomaceous	B
earth	I
(	O
Sigma	O
)	O
and	O
followed	O
by	O
rotary	O
evaporation	O
.	O

The	O
TFAc	B
-	I
Tyroet	I
was	O
recrystallised	O
from	O
hot	O
dichloromethane	B
(	O
BDH	O
)	O
and	O
ethanol	B
.	O

The	O
moisture	O
content	O
was	O
0.18	O
wt.%	O
as	O
measured	O
by	O
Karl	O
–	O
Fischer	O
titration	O
.	O

The	O
deuterated	O
TFAc	B
-	I
Tyroet	I
(	O
D2-TFAc	B
-	I
Tyroet	I
)	O
was	O
prepared	O
in	O
the	O
same	O
way	O
as	O
the	O
D2-CBZ	B
-	I
Tyroet	I
.	O

2.1.3	O
Acetyl	B
-	I
l	I
-tyrosine	I
ethyl	I
ester	I
(	O
Ac	B
-	I
Tyroet	I
)	O
Ac	B
-	I
Tyroet	I
was	O
purchased	O
from	O
Sigma	O
and	O
used	O
without	O
any	O
further	O
treatment	O
.	O

The	O
moisture	O
content	O
was	O
6.5	O
wt.%	O
as	O
measured	O
by	O
Karl	O
–	O
Fischer	O
titration	O
.	O

The	O
deuterated	B
Ac	I
-	I
Tyroet	I
(	O
D2-Ac	B
-	I
Tyroet	I
)	O
was	O
prepared	O
in	O
the	O
same	O
way	O
as	O
the	O
D2-CBZ	B
-	I
Tyroet	I
.	O

2.2	O
Solid	O
state	O
NMR	O
measurements	O
All	O
the	O
proton	O
NMR	O
relaxation	O
measurements	O
were	O
carried	O
out	O
on	O
a	O
Bruker	O
MSL-100	O
spectrometer	O
operating	O
at	O
a	O
proton	O
frequency	O
of	O
100.13	O
MHz	O
over	O
the	O
temperature	O
range	O
between	O
110	O
and	O
350	O
K.	O
Experiments	O
were	O
always	O
started	O
from	O
the	O
lowest	O
temperature	O
.	O

T	O
2	O
was	O
measured	O
directly	O
from	O
the	O
free	O
induction	O
decay	O
(	O
FID	O
)	O
following	O
a	O
90	O
°	O
pulse	O
.	O

A	O
90	O
°	O
pulse	O
length	O
of	O
1	O
μs	O
was	O
used	O
and	O
the	O
receiver	O
deadtime	O
following	O
the	O
pulse	O
was	O
5	O
μs	O
.	O

The	O
proton	O
second	O
moment	O
was	O
calculated	O
from	O
the	O
FID	O
assuming	O
Gaussian	O
line	O
shapes	O
[	O
11	O
]	O
.	O

The	O
spin	O
-	O
lattice	O
relaxation	O
time	O
(	O
T	O
1	O
)	O
was	O
measured	O
via	O
the	O
inversion	O
recovery	O
(	O
180x	O
°	O
-τ	O
-90x	O
°	O
-detect	O
)	O
method	O
[	O
12	O
]	O
.	O

The	O
signal	O
intensity	O
at	O
the	O
beginning	O
of	O
each	O
FID	O
was	O
recorded	O
,	O
a	O
total	O
of	O
48	O
data	O
points	O
were	O
collected	O
.	O

In	O
order	O
to	O
ensure	O
that	O
the	O
spread	O
of	O
τ	O
values	O
was	O
sufficient	O
to	O
test	O
for	O
the	O
existence	O
of	O
multi	O
-	O
exponential	O
relaxation	O
,	O
the	O
values	O
of	O
τ	O
were	O
chosen	O
according	O
to	O
τ	O
=	O
A	O
×10	O
(	O
n	O
−1	O
)	O
/	O
12	O
,	O
where	O
A	O
is	O
a	O
constant	O
varying	O
between	O
1–4	O
ms	O
,	O
depending	O
on	O
the	O
estimate	O
of	O
T	O
1	O
,	O
and	O
n	O
is	O
the	O
number	O
of	O
data	O
points	O
.	O

The	O
spin	O
-	O
lattice	O
relaxation	O
times	O
in	O
the	O
rotating	O
frame	O
,	O
T	O
1ρ	O
,	O
were	O
determined	O
by	O
spin	O
-	O
locking	O
the	O
magnetization	O
in	O
the	O
rotating	O
frame	O
for	O
a	O
suitable	O
period	O
and	O
monitoring	O
the	O
intensity	O
of	O
the	O
resulting	O
FID	O
(	O
90	O
°	O
-spin	O
-	O
lock	O
-	O
acquire	O
)	O
[	O
13	O
]	O
.	O

The	O
spin	O
-	O
locking	O
field	O
strength	O
were	O
40	O
kHz	O
equivalent	O
to	O
a	O
90	O
°	O
pulse	O
length	O
of	O
6.25	O
μs	O
.	O

The	O
spin	O
-	O
locking	O
time	O
varied	O
from	O
400	O
μs	O
to	O
51.2	O
ms	O
.	O

Single	O
point	O
sampling	O
was	O
used	O
,	O
10	O
μs	O
after	O
spin	O
-	O
locking	O
pulse	O
.	O

Dependent	O
on	O
the	O
length	O
of	O
the	O
T	O
1ρ	O
,	O
48–128	O
data	O
points	O
were	O
collected	O
for	O
each	O
experiment	O
.	O

Co	O
-	O
added	O
were	O
2–4	O
scans	O
to	O
improve	O
the	O
signal	O
to	O
noise	O
ratio	O
in	O
both	O
T	O
1	O
and	O
T	O
1ρ	O
measurements	O
.	O

All	O
data	O
were	O
analyzed	O
using	O
TableCurve	O
(	O
Jandel	O
Scientific	O
)	O
which	O
is	O
a	O
simultaneous	O
multiple	O
non	O
-	O
linear	O
curve	O
-	O
fitting	O
program	O
and	O
uses	O
the	O
Levenburg	O
–	O
Marquardt	O
algorithm	O
to	O
minimize	O
the	O
sum	O
of	O
squares	O
of	O
the	O
deviations	O
between	O
a	O
calculated	O
summation	O
curve	O
and	O
the	O
observed	O
data	O
points	O
[	O
14	O
]	O
.	O

3	O
Results	O
and	O
discussion	O
3.1	O
Pure	O
tyrosine	B
derivatives	B
3.1.1	O
Second	O
moment	O
The	O
transverse	O
relaxation	O
processes	O
of	O
the	O
three	O
tyrosine	B
derivatives	B
can	O
be	O
fitted	O
by	O
a	O
single	O
Gaussian	O
process	O
.	O

Fig.	O
2	O
shows	O
the	O
temperature	O
dependence	O
of	O
the	O
second	O
moments	O
for	O
the	O
three	O
tyrosine	B
derivatives	B
.	O

Generally	O
,	O
the	O
second	O
moments	O
(	O
M	O
2	O
)	O
reflect	O
the	O
strength	O
of	O
static	O
dipolar	O
interactions	O
in	O
the	O
system	O
.	O

The	O
general	O
decrease	O
in	O
second	O
moment	O
with	O
increasing	O
temperature	O
is	O
probably	O
due	O
to	O
lattice	O
expansion	O
rather	O
than	O
motional	O
averaging	O
since	O
no	O
clear	O
transition	O
is	O
observed	O
.	O

The	O
lower	O
average	O
value	O
of	O
second	O
moment	O
observed	O
for	O
TFAc	B
-	I
Tyroet	I
compared	O
to	O
Ac	B
-	I
Tyroet	I
is	O
due	O
to	O
the	O
lower	O
density	O
of	O
protons	O
in	O
the	O
sample	O
.	O

The	O
lowest	O
second	O
moments	O
are	O
shown	O
by	O
CBZ	B
-	I
Tyroet	I
,	O
these	O
may	O
be	O
due	O
to	O
the	O
bulky	O
benzene	B
ring	O
substituent	O
causing	O
poor	O
crystal	O
packing	O
and	O
reducing	O
the	O
intermolecular	O
contribution	O
to	O
the	O
second	O
moment	O
.	O

3.1.2	O
Spin	O
-	O
lattice	O
relaxation	O
in	O
the	O
laboratory	O
frame	O
The	O
T	O
1	O
s	O
of	O
tyrosine	B
derivatives	B
were	O
measured	O
over	O
the	O
temperature	O
range	O
130–360	O
K.	O
The	O
relaxation	O
time	O
can	O
be	O
fitted	O
to	O
a	O
single	O
exponential	O
in	O
all	O
cases	O
.	O

The	O
variation	O
of	O
R	O
1	O
with	O
temperature	O
is	O
shown	O
in	O
Fig.	O
3	O
.	O

R	O
1	O
of	O
Ac	B
-	I
Tyroet	I
shows	O
two	O
well	O
-	O
resolved	O
R	O
1	O
maxima	O
at	O
170	O
and	O
320	O
K.	O
This	O
indicates	O
that	O
the	O
spin	O
-	O
lattice	O
relaxation	O
is	O
mainly	O
driven	O
by	O
two	O
independent	O
motions	O
,	O
one	O
of	O
which	O
is	O
effective	O
below	O
250	O
K	O
and	O
the	O
other	O
one	O
is	O
effective	O
above	O
that	O
temperature	O
.	O

Previous	O
studies	O
on	O
the	O
proton	O
relaxation	O
of	O
amino	B
acid	I
amides	B
suggest	O
that	O
methyl	B
groups	I
and	O
their	O
reorientations	O
are	O
expected	O
to	O
be	O
important	O
in	O
relaxing	O
the	O
system	O
[	O
6	O
,	O
8	O
]	O
.	O

The	O
low	O
-	O
temperature	O
relaxation	O
rate	O
maximum	O
of	O
Ac	B
-	I
Tyroet	I
occurs	O
at	O
within	O
about	O
30	O
°	O
C	O
of	O
temperature	O
as	O
in	O
l	B
-leucinamide	I
(	O
200	O
K	O
)	O
[	O
6	O
]	O
.	O

Therefore	O
,	O
the	O
effective	O
motion	O
that	O
occurs	O
below	O
250	O
K	O
is	O
likely	O
to	O
be	O
the	O
methyl	B
group	I
rotation	O
.	O

To	O
identify	O
the	O
relaxation	O
process	O
at	O
high	O
temperature	O
,	O
the	O
spin	O
-	O
lattice	O
relaxation	O
times	O
of	O
deuterated	B
Ac	I
-	I
Tyroet	I
were	O
measured	O
.	O

The	O
temperature	O
dependence	O
of	O
relaxation	O
is	O
similar	O
for	O
both	O
protonated	B
and	O
deuterated	B
Ac	I
-	I
Tyroet	I
and	O
shown	O
in	O
Fig.	O
4	O
.	O

This	O
phenomenon	O
is	O
also	O
observed	O
in	O
the	O
T	O
1	O
of	O
deuterated	B
CBZ	I
-	I
Tyroet	I
and	O
TFAc	B
-	I
Tyroet	I
.	O

This	O
implies	O
that	O
motions	O
closely	O
related	O
to	O
NH	B
or	O
OH	B
or	O
residual	O
H2	B
O	I
can	O
be	O
eliminated	O
(	O
see	O
Section	O
2.1	O
)	O
.	O

The	O
most	O
likely	O
motion	O
left	O
for	O
relaxing	O
the	O
system	O
is	O
a	O
benzene	B
ring	O
flip	O
motion	O
.	O

Therefore	O
the	O
methyl	B
group	I
reorientation	O
and	O
benzene	B
ring	O
flip	O
are	O
assumed	O
to	O
be	O
the	O
major	O
relaxation	O
mechanisms	O
for	O
Ac	B
-	I
Tyroet	I
.	O

The	O
data	O
were	O
fitted	O
to	O
an	O
expression	O
which	O
was	O
found	O
to	O
be	O
very	O
useful	O
in	O
the	O
previous	O
studies	O
[	O
6	O
,	O
8	O
]	O
:	O
(	O
1	O
)	O
R1obs	O
=	O
1	O
T1	O
=	O
2	O
3	O
Pa	O
M2a	O
τa	O
1+ω2	O
τ2	O
a	O
+	O
4τa	O
1	O
+	O
4ω2	O
τ2	O
a	O
+	O
2	O
3	O
Pb	O
M2b	O
τb	O
1+ω2	O
τ2	O
b	O
+	O
4τb	O
1	O
+	O
4ω2	O
τ2	O
b	O
.	O

This	O
is	O
an	O
extension	O
of	O
the	O
well	O
-	O
known	O
relaxation	O
expression	O
of	O
Kubo	O
and	O
Tomita	O
[	O
15	O
]	O
to	O
two	O
independent	O
relaxation	O
processes	O
.	O

ω	O
/2π	O
is	O
the	O
frequency	O
of	O
measurement	O
in	O
Hertz	O
;	O
τ	O
is	O
the	O
correlation	O
time	O
of	O
the	O
molecular	O
motion	O
responsible	O
for	O
spin	O
-	O
lattice	O
relaxation	O
and	O
M	O
2	O
is	O
the	O
second	O
moment	O
modulated	O
by	O
the	O
corresponding	O
motion	O
.	O

P	O
a	O
and	O
P	O
b	O
are	O
the	O
relative	O
populations	O
of	O
methyl	B
protons	O
and	O
protons	O
on	O
the	O
aromatic	B
ring	I
.	O

They	O
are	O
6	O
/	O
17	O
and	O
4	O
/	O
17	O
for	O
Ac	B
-	I
Tyroet	I
.	O

It	O
is	O
also	O
assumed	O
that	O
the	O
temperature	O
dependence	O
of	O
the	O
correlation	O
time	O
is	O
exponential	O
,	O
hence:	O
(	O
2	O
)	O
τ	O
=	O
τ0	O
exp	O
Ea	O
RT	O
.	O

Fig.	O
3	O
shows	O
the	O
good	O
agreement	O
between	O
the	O
calculated	O
curve	O
and	O
experimental	O
data	O
for	O
Ac	B
-	I
Tyroet	I
.	O

The	O
optimized	O
motional	O
parameters	O
of	O
M	O
2	O
,	O
τ	O
0	O
and	O
E	O
a	O
are	O
summarised	O
in	O
Table	O
1	O
.	O

The	O
activation	O
energy	O
E	O
a	O
,	O
corresponding	O
to	O
the	O
low	O
temperature	O
motion	O
,	O
is	O
11.8	O
kJ	O
/	O
mol	O
which	O
is	O
in	O
good	O
agreement	O
with	O
that	O
found	O
for	O
methyl	B
groups	I
in	O
l	B
-leucinamide	I
(	O
10.9	O
kJ	O
/	O
mol	O
)	O
[	O
6	O
]	O
.	O

However	O
,	O
the	O
second	O
moment	O
obtained	O
is	O
about	O
1.0	O
×	O
108	O
s−2	O
which	O
is	O
smaller	O
than	O
that	O
from	O
l	B
-leucinamide	I
(	O
2.7	O
×	O
108	O
s−2	O
)	O
.	O

Examination	O
of	O
the	O
chemical	O
formula	O
of	O
Ac	B
-	I
Tyroet	I
shows	O
two	O
methyl	B
groups	I
;	O
one	O
of	O
which	O
is	O
bonded	O
to	O
a	O
carbonyl	B
carbon	B
and	O
the	O
other	O
one	O
is	O
next	O
to	O
a	O
CH2	B
group	I
.	O

The	O
rotations	O
of	O
the	O
two	O
methyl	B
groups	I
are	O
expected	O
to	O
behave	O
differently	O
;	O
the	O
one	O
bonded	O
to	O
a	O
carbonyl	B
carbon	B
has	O
a	O
larger	O
distance	O
between	O
methyl	B
group	I
and	O
other	O
protons	O
.	O

The	O
behaviour	O
of	O
this	O
methyl	B
group	I
is	O
expected	O
to	O
be	O
similar	O
to	O
those	O
in	O
methionine	B
methyl	B
d	I
-α	I
-	I
galacturonic	I
acid	I
methyl	I
ester	I
[	O
16	O
]	O
or	O
methylpyranisides	B
[	O
17	O
,	O
18	O
]	O
.	O

This	O
type	O
of	O
methyl	B
group	I
is	O
less	O
hindered	O
,	O
with	O
a	O
estimated	O
activation	O
energy	O
of	O
6	O
kJ	O
/	O
mol	O
and	O
pre	O
-	O
exponential	O
term	O
of	O
2	O
×	O
10−13	O
s	O
[	O
16	O
]	O
.	O

At	O
100	O
MHz	O
,	O
this	O
type	O
of	O
methyl	B
group	I
has	O
a	O
relaxation	O
maximum	O
at	O
about	O
80	O
K.	O
The	O
maximum	O
observed	O
at	O
170	O
K	O
is	O
therefore	O
likely	O
to	O
be	O
due	O
to	O
the	O
motion	O
of	O
the	O
more	O
hindered	O
group	O
,	O
CH2	B
–CH3	I
.	O

In	O
this	O
case	O
,	O
the	O
value	O
of	O
P	O
a	O
in	O
Eq.	O
(	O
1	O
)	O
should	O
be	O
3	O
/	O
17	O
instead	O
of	O
6	O
/	O
17	O
,	O
and	O
M	O
2a	O
should	O
be	O
2.0	O
×	O
108	O
s−2	O
which	O
is	O
much	O
more	O
consistent	O
with	O
other	O
data	O
.	O

The	O
second	O
motion	O
controlling	O
the	O
relaxation	O
at	O
high	O
temperature	O
(	O
maximum	O
at	O
320	O
K	O
)	O
was	O
assumed	O
to	O
be	O
a	O
benzene	B
ring	O
flip	O
.	O

The	O
second	O
moment	O
obtained	O
from	O
the	O
curve	O
fitting	O
(	O
2.7	O
×	O
107	O
s−2	O
)	O
is	O
an	O
order	O
of	O
magnitude	O
smaller	O
than	O
that	O
from	O
the	O
methyl	B
group	I
rotation	O
,	O
but	O
is	O
in	O
broad	O
agreement	O
with	O
that	O
found	O
in	O
phenylalanine	B
(	O
M	O
2	O
:	O
1.3	O
×	O
107	O
s−2	O
)	O
[	O
19	O
]	O
.	O

The	O
maximum	O
of	O
relaxation	O
rate	O
occurs	O
at	O
255	O
K	O
for	O
benzene	B
ring	O
flipping	O
motion	O
in	O
phenylalanine	B
[	O
19	O
]	O
.	O

In	O
Ac	B
-	I
Tyroet	I
,	O
there	O
is	O
a	O
hydroxyl	B
group	I
on	O
the	O
end	O
of	O
benzene	B
ring	O
,	O
which	O
is	O
hydrogen	B
-	O
bonded	O
to	O
a	O
amide	B
group	O
in	O
a	O
neighbouring	O
molecule	O
[	O
20	O
]	O
and	O
thus	O
,	O
restricting	O
the	O
motion	O
of	O
the	O
ring	O
.	O

Since	O
the	O
rotation	O
is	O
more	O
restricted	O
,	O
the	O
rate	O
maximum	O
is	O
likely	O
to	O
occur	O
at	O
a	O
higher	O
temperature	O
.	O

Fig.	O
3	O
also	O
shows	O
the	O
temperature	O
dependence	O
of	O
spin	O
-	O
lattice	O
relaxation	O
rate	O
of	O
CBZ	B
-	I
Tyroet	I
.	O

Following	O
the	O
results	O
obtained	O
in	O
Ac	B
-	I
Tyroet	I
,	O
the	O
rotational	O
motion	O
of	O
the	O
methyl	B
group	I
as	O
the	O
origin	O
of	O
spin	O
-	O
lattice	O
relaxation	O
in	O
the	O
laboratory	O
frame	O
at	O
low	O
temperature	O
is	O
also	O
assumed	O
.	O

The	O
data	O
suggest	O
that	O
the	O
relaxation	O
at	O
high	O
temperature	O
is	O
relatively	O
efficient	O
(	O
Fig.	O
3	O
insert	O
)	O
,	O
indicating	O
a	O
second	O
effective	O
motion	O
occurring	O
above	O
220	O
K	O
,	O
although	O
no	O
obvious	O
relaxation	O
rate	O
maximum	O
was	O
seen	O
.	O

The	O
second	O
motion	O
is	O
also	O
assumed	O
to	O
be	O
the	O
benzene	B
ring	O
flipping	O
.	O

The	O
observed	O
temperature	O
dependence	O
of	O
R	O
1	O
was	O
therefore	O
fitted	O
to	O
Eqs.	O
(	O
1	O
)	O
and	O
(	O
2	O
)	O
with	O
a	O
P	O
a	O
value	O
of	O
3	O
/	O
21	O
and	O
a	O
P	O
b	O
value	O
of	O
9	O
/	O
21	O
.	O

Good	O
agreement	O
between	O
the	O
fitted	O
curve	O
and	O
experimental	O
data	O
was	O
obtained	O
.	O

Examination	O
of	O
the	O
activation	O
energy	O
and	O
pre	O
-	O
exponential	O
term	O
of	O
methyl	B
group	I
rotation	O
shows	O
good	O
agreement	O
between	O
CBZ	B
-	I
Tyroet	I
and	O
Ac	B
-	I
Tyroet	I
(	O
Table	O
1	O
)	O
.	O

However	O
,	O
the	O
second	O
moment	O
obtained	O
from	O
assuming	O
both	O
methyl	B
groups	I
were	O
active	O
in	O
Ac	B
-	I
Tyroet	I
is	O
about	O
half	O
of	O
that	O
from	O
CBZ	B
-	I
Tyroet	I
.	O

This	O
further	O
suggests	O
that	O
the	O
methyl	B
group	I
bonded	O
to	O
the	O
carbonyl	B
carbon	B
in	O
Ac	B
-	I
Tyroet	I
is	O
less	O
hindered	O
and	O
does	O
not	O
have	O
contribution	O
to	O
the	O
relaxation	O
at	O
170	O
K.	O
Effectively	O
,	O
the	O
system	O
is	O
relaxed	O
by	O
only	O
one	O
methyl	B
group	I
.	O

In	O
contrast	O
to	O
Ac	B
-	I
Tyroet	I
where	O
there	O
is	O
an	O
R	O
1	O
maximum	O
at	O
320	O
K	O
,	O
there	O
are	O
no	O
obvious	O
high	O
temperature	O
R	O
1	O
maxima	O
in	O
CBZ	B
-	I
Tyroet	I
.	O

Inspection	O
of	O
the	O
chemical	O
structure	O
of	O
the	O
two	O
molecules	O
shows	O
the	O
presence	O
of	O
two	O
benzene	B
rings	O
in	O
CBZ	B
-	I
Tyroet	I
,	O
one	O
of	O
which	O
is	O
restricted	O
by	O
a	O
hydroxyl	B
group	I
and	O
the	O
other	O
one	O
is	O
not	O
.	O

The	O
relatively	O
free	O
benzene	B
ring	O
motion	O
is	O
expected	O
to	O
relax	O
the	O
system	O
efficiently	O
at	O
the	O
temperature	O
below	O
320	O
K.	O
It	O
is	O
very	O
likely	O
that	O
the	O
relaxation	O
mechanism	O
occurring	O
at	O
higher	O
temperature	O
comprises	O
two	O
ring	O
flip	O
motions	O
having	O
different	O
activation	O
energies	O
,	O
the	O
non	O
-	O
hydrogen	B
-	O
bonded	O
benzene	B
ring	O
flipping	O
at	O
lower	O
temperature	O
.	O

The	O
presence	O
of	O
unrestricted	O
benzene	B
ring	O
motion	O
is	O
manifest	O
in	O
the	O
differences	O
in	O
proton	O
T	O
1	O
value	O
of	O
CBZ	B
-	I
Tyroet	I
(	O
1.75	O
s	O
)	O
and	O
Ac	B
-	I
Tyroet	I
(	O
3.56	O
s	O
)	O
at	O
250	O
K.	O
However	O
,	O
the	O
fitting	O
procedure	O
was	O
unable	O
to	O
discriminate	O
two	O
motions	O
and	O
only	O
one	O
motion	O
was	O
assumed	O
in	O
the	O
fit	O
.	O

T	O
1	O
s	O
of	O
TFAc	B
-	I
Tyroet	I
were	O
measured	O
over	O
the	O
temperature	O
range	O
of	O
150–360	O
K.	O
The	O
variation	O
of	O
the	O
spin	O
-	O
lattice	O
relaxation	O
rate	O
with	O
temperature	O
is	O
shown	O
in	O
Fig.	O
3	O
.	O

In	O
contrast	O
to	O
the	O
Ac	B
-	I
Tyroet	I
and	O
CBZ	B
-	I
Tyroet	I
,	O
it	O
shows	O
only	O
one	O
maximum	O
at	O
around	O
170	O
K.	O
This	O
indicates	O
the	O
presence	O
of	O
a	O
motion	O
whose	O
correlation	O
time	O
is	O
about	O
10−9	O
s	O
at	O
170	O
K.	O
Following	O
the	O
previous	O
study	O
,	O
the	O
motion	O
occurring	O
at	O
170	O
K	O
is	O
likely	O
to	O
be	O
the	O
methyl	B
group	I
rotation	O
.	O

The	O
observed	O
R	O
1	O
is	O
therefore	O
fitted	O
to	O
the	O
Eqs.	O
(	O
1	O
)	O
and	O
(	O
2	O
)	O
assuming	O
that	O
only	O
methyl	B
rotation	O
is	O
present	O
.	O

In	O
this	O
case	O
,	O
P	O
a	O
in	O
the	O
Eq.	O
(	O
1	O
)	O
is	O
3	O
/	O
14	O
for	O
the	O
TFAc	B
-	I
Tyroet	I
.	O

Good	O
agreement	O
was	O
found	O
between	O
the	O
experimental	O
data	O
and	O
the	O
fitted	O
curve	O
.	O

The	O
calculated	O
relaxation	O
parameters	O
for	O
methyl	B
group	I
reorientation	O
are	O
summarised	O
in	O
Table	O
1	O
.	O

The	O
calculated	O
relaxation	O
parameters	O
for	O
methyl	B
group	I
rotation	O
in	O
TFAc	B
-	I
Tyroet	I
are	O
in	O
good	O
agreement	O
with	O
those	O
of	O
CBZ	B
-	I
Tyroet	I
and	O
Ac	O
-	O
Tyroet	O
,	O
confirming	O
the	O
assumption	O
made	O
as	O
to	O
the	O
origin	O
of	O
the	O
relaxation	O
.	O

However	O
,	O
the	O
flipping	O
motion	O
of	O
benzene	B
ring	O
in	O
the	O
TFAc	B
-	I
Tyroet	I
is	O
not	O
observed	O
in	O
the	O
temperature	O
range	O
studied	O
,	O
indicating	O
that	O
the	O
motion	O
is	O
significantly	O
hindered	O
.	O

The	O
hindered	O
motion	O
is	O
presumably	O
due	O
to	O
the	O
presence	O
of	O
the	O
perfluorinated	B
group	I
.	O

This	O
lack	O
of	O
motion	O
may	O
have	O
a	O
role	O
in	O
the	O
failure	O
of	O
this	O
compound	O
to	O
form	O
mixtures	O
with	O
amino	B
acid	I
amides	B
.	B

3.1.3	O
Spin	O
-	O
lattice	O
relaxation	O
in	O
the	O
rotating	O
frame	O
T	O
1ρ	O
of	O
protonated	O
and	O
deuterated	O
Ac	B
-	I
Tyroet	I
were	O
measured	O
at	O
spin	O
-	O
locking	O
field	O
of	O
40	O
kHz	O
in	O
the	O
temperature	O
range	O
130–290	O
K	O
,	O
single	O
-	O
exponential	O
T	O
1ρ	O
relaxation	O
was	O
observed	O
.	O

The	O
dependence	O
of	O
R	O
1ρ	O
on	O
temperature	O
shown	O
in	O
Fig.	O
5	O
clearly	O
illustrates	O
that	O
the	O
system	O
is	O
mainly	O
relaxed	O
by	O
two	O
motions	O
,	O
one	O
motion	O
is	O
effective	O
below	O
240	O
K	O
and	O
the	O
other	O
one	O
is	O
effective	O
above	O
it	O
.	O

Furthermore	O
,	O
the	O
curves	O
for	O
Ac	B
-	I
Tyroet	I
and	O
D2-Ac	B
-	I
Tyroet	I
are	O
similar	O
at	O
temperatures	O
below	O
240	O
K	O
,	O
however	O
,	O
the	O
higher	O
temperature	O
motion	O
is	O
affected	O
by	O
replacing	O
exchangeable	O
protons	O
with	O
deuterium	B
.	O

The	O
data	O
can	O
be	O
fitted	O
to	O
equations	O
similar	O
to	O
those	O
used	O
in	O
the	O
T	O
1	O
analysis	O
[	O
21	O
]	O
:	O
(	O
3	O
)	O
R1ρ	O
=	O
1	O
T1ρ	O
=	O
Pa	O
M2a	O
τa	O
1	O
+	O
4ω2	O
τ2	O
a	O
+	O
Pb	O
M2b	O
τb	O
1	O
+	O
4ω2	O
τ2	O
b	O
.	O

This	O
equation	O
is	O
generally	O
valid	O
when	O
τ	O
a	O
,	O
b	O
<	O
T	O
2	O
and	O
B	O
1	O
≫B	O
L	O
[	O
22	O
]	O
;	O
B	O
1	O
is	O
the	O
spin	O
-	O
locking	O
field	O
and	O
B	O
L	O
,	O
the	O
local	O
dipolar	O
field	O
.	O

In	O
the	O
experiments	O
,	O
B	O
1	O
of	O
40	O
kHz	O
was	O
used	O
and	O
the	O
averaged	O
local	O
dipolar	O
field	O
for	O
Ac	B
-	I
Tyroet	I
was	O
52	O
kHz	O
,	O
thus	O
,	O
B	O
1	O
<	O
B	O
L	O
which	O
does	O
not	O
meet	O
the	O
requirement	O
.	O

Therefore	O
,	O
account	O
must	O
be	O
taken	O
for	O
the	O
effects	O
of	O
the	O
local	O
dipolar	O
field	O
.	O

McCall	O
and	O
Douglass	O
[	O
23	O
]	O
have	O
suggested	O
using	O
an	O
equation	O
of	O
the	O
form	O
ω	O
2	O
=	O
ω	O
1	O
2	O
+	O
ω	O
L	O
2	O
,	O
where	O
ω	O
L	O
/2π	O
is	O
the	O
local	O
dipolar	O
field	O
which	O
equals	O
to	O
square	O
root	O
of	O
one	O
third	O
of	O
second	O
moment	O
.	O

From	O
the	O
T	O
1	O
of	O
Ac	B
-	I
Tyroet	I
,	O
the	O
effect	O
of	O
benzene	O
ring	O
motion	O
was	O
detected	O
at	O
320	O
K	O
,	O
it	O
is	O
reasonable	O
to	O
assume	O
that	O
the	O
motion	O
below	O
240	O
K	O
is	O
benzene	O
ring	O
motion	O
since	O
the	O
measurement	O
of	O
spin	O
-	O
lattice	O
relaxation	O
in	O
the	O
rotating	O
frame	O
has	O
the	O
effect	O
of	O
shifting	O
the	O
relaxation	O
maxima	O
into	O
a	O
lower	O
temperature	O
range	O
.	O

Therefore	O
,	O
P	O
a	O
in	O
Eq.	O
(	O
3	O
)	O
is	O
4	O
/	O
17	O
for	O
Ac	B
-	I
Tyroet	I
and	O
4	O
/	O
15	O
for	O
D2-Ac	B
-	I
Tyroet	I
.	O

Since	O
the	O
second	O
motion	O
is	O
difficult	O
to	O
identify	O
positively	O
,	O
a	O
P	O
b	O
value	O
of	O
13	O
/	O
17	O
for	O
Ac	B
-	I
Tyroet	I
and	O
11	O
/	O
15	O
for	O
D2-Ac	B
-	I
Tyroet	I
is	O
assumed	O
for	O
the	O
curve	O
fitting	O
.	O

Fig.	O
5	O
shows	O
the	O
quality	O
of	O
the	O
fitting	O
.	O

The	O
results	O
of	O
the	O
fitting	O
are	O
summarised	O
in	O
Table	O
1	O
.	O

The	O
values	O
of	O
M	O
2	O
,	O
E	O
a	O
and	O
τ	O
0	O
are	O
the	O
same	O
within	O
experimental	O
error	O
for	O
both	O
protonated	O
and	O
deuterated	O
samples	O
in	O
the	O
temperature	O
range	O
below	O
240	O
K	O
,	O
indicating	O
that	O
deuteration	O
has	O
little	O
effect	O
on	O
this	O
motion	O
.	O

Supposing	O
that	O
the	O
benzene	B
ring	O
flip	O
is	O
responsible	O
for	O
the	O
T	O
1ρ	O
relaxation	O
in	O
this	O
temperature	O
range	O
,	O
therefore	O
,	O
the	O
temperature	O
dependence	O
of	O
R	O
1ρ	O
curve	O
can	O
be	O
predicted	O
from	O
the	O
relaxation	O
parameters	O
(	O
within	O
the	O
error	O
range	O
)	O
of	O
benzene	B
flipping	O
motion	O
obtained	O
from	O
T	O
1	O
.	O

Fig.	O
5	O
shows	O
the	O
predicted	O
curve	O
.	O

Clearly	O
,	O
the	O
fitted	O
curve	O
does	O
not	O
agree	O
very	O
well	O
with	O
the	O
predicted	O
one	O
;	O
the	O
fitted	O
curve	O
is	O
wider	O
than	O
the	O
predicted	O
one	O
.	O

This	O
may	O
arise	O
because	O
the	O
fitting	O
of	O
the	O
T	O
1	O
data	O
is	O
rather	O
poor	O
,	O
the	O
peak	O
is	O
rather	O
weak	O
and	O
is	O
at	O
the	O
end	O
of	O
the	O
temperature	O
range	O
.	O

The	O
pre	O
-	O
exponential	O
factor	O
found	O
for	O
the	O
T	O
1	O
data	O
is	O
also	O
very	O
small	O
.	O

This	O
suggests	O
that	O
the	O
T	O
1ρ	O
data	O
are	O
more	O
reliable	O
.	O

In	O
contrast	O
to	O
the	O
motion	O
at	O
lower	O
temperature	O
,	O
the	O
higher	O
temperature	O
motion	O
is	O
affected	O
by	O
replacing	O
exchangeable	O
protons	O
with	O
deuterium	B
.	O

Fig.	O
5	O
shows	O
that	O
deuterated	O
sample	O
is	O
relaxed	O
more	O
efficiently	O
in	O
this	O
temperature	O
region	O
.	O

This	O
must	O
be	O
due	O
to	O
the	O
decrease	O
in	O
the	O
number	O
of	O
protons	O
to	O
be	O
relaxed	O
by	O
the	O
motion	O
[	O
6	O
,	O
15	O
]	O
.	O

The	O
motion	O
that	O
becomes	O
apparent	O
may	O
be	O
a	O
motion	O
involving	O
a	O
large	O
part	O
of	O
the	O
molecule	O
.	O

However	O
,	O
its	O
origin	O
is	O
not	O
certain	O
so	O
the	O
motion	O
will	O
be	O
referred	O
to	O
simply	O
as	O
the	O
third	O
motion	O
.	O

T	O
1ρ	O
of	O
solid	O
CBZ	B
-	I
Tyroet	I
was	O
measured	O
over	O
the	O
temperature	O
range	O
150–340	O
K	O
and	O
the	O
dependence	O
of	O
R	O
1ρ	O
on	O
temperature	O
is	O
shown	O
in	O
Fig.	O
6	O
.	O

Relaxation	O
of	O
CBZ	B
-	I
Tyroet	I
(	O
Fig.	O
6	O
)	O
is	O
similar	O
to	O
that	O
of	O
Ac	B
-	I
Tyroet	I
(	O
Fig.	O
5	O
)	O
.	O

One	O
motion	O
occurs	O
below	O
270	O
K	O
and	O
the	O
other	O
one	O
is	O
effective	O
at	O
higher	O
temperature	O
.	O

As	O
with	O
Ac	B
-	I
Tyroet	I
,	O
benzene	B
ring	O
flipping	O
and	O
the	O
third	O
mode	O
of	O
motion	O
are	O
assumed	O
to	O
account	O
for	O
the	O
R	O
1ρ	O
of	O
CBZ	B
-	I
Tyroet	I
.	O

The	O
data	O
are	O
therefore	O
fitted	O
to	O
Eq.	O
(	O
3	O
)	O
with	O
a	O
P	O
a	O
value	O
of	O
9	O
/	O
21	O
and	O
a	O
P	O
b	O
of	O
12	O
/	O
21	O
for	O
CBZ	B
-	I
Tyroet	I
.	O

The	O
local	O
dipolar	O
field	O
,	O
ω	O
L	O
,	O
(	O
44	O
kHz	O
)	O
has	O
also	O
been	O
taken	O
into	O
account	O
.	O

A	O
fit	O
of	O
Eq.	O
(	O
3	O
)	O
to	O
the	O
temperature	O
dependence	O
of	O
R	O
1ρ	O
of	O
CBZ	B
-	I
Tyroet	I
gives	O
a	O
pre	O
-	O
exponential	O
factor	O
of	O
7.0	O
×	O
10−10	O
for	O
the	O
motion	O
effective	O
below	O
270	O
K.	O
This	O
value	O
is	O
too	O
high	O
for	O
the	O
motion	O
at	O
low	O
temperature	O
.	O

Usually	O
,	O
this	O
is	O
indicative	O
of	O
a	O
distribution	O
of	O
correlation	O
time	O
[	O
24	O
,	O
25	O
]	O
.	O

From	O
the	O
discussion	O
of	O
T	O
1	O
of	O
CBZ	B
-	I
Tyroet	I
,	O
two	O
benzene	B
rings	O
are	O
present	O
in	O
the	O
CBZ	B
-	I
Tyroet	I
.	O

Therefore	O
,	O
the	O
relaxation	O
below	O
270	O
K	O
can	O
be	O
treated	O
simply	O
as	O
the	O
sum	O
of	O
two	O
individual	O
motions	O
corresponding	O
to	O
restricted	O
and	O
unrestricted	O
benzene	B
ring	O
flipping	O
motions	O
and	O
thus	O
,	O
the	O
R	O
1ρ	O
below	O
290	O
K	O
may	O
be	O
written	O
as:	O
(	O
4	O
)	O
R1ρ	O
=	O
1	O
T1ρ	O
=	O
Pa	O
M2a	O
τa	O
1	O
+	O
4ω2	O
τ2	O
a	O
+	O
τb	O
1	O
+	O
4ω2	O
τ2	O
b	O
where	O
τ	O
a	O
and	O
τ	O
b	O
correspond	O
to	O
correlation	O
times	O
of	O
the	O
unrestricted	O
and	O
restricted	O
benzene	B
ring	O
flipping	O
motions	O
.	O

The	O
fitted	O
results	O
are	O
listed	O
in	O
Table	O
1	O
.	O

Fig.	O
6	O
shows	O
the	O
good	O
agreement	O
between	O
the	O
fitted	O
curve	O
and	O
the	O
experimental	O
data	O
.	O

The	O
calculated	O
activation	O
energy	O
and	O
the	O
pre	O
-	O
exponential	O
term	O
for	O
the	O
restricted	O
benzene	O
ring	O
motion	O
in	O
CBZ	B
-	I
Tyroet	I
is	O
in	O
good	O
agreement	O
with	O
those	O
in	O
Ac	B
-	I
Tyroet	I
although	O
large	O
uncertainties	O
occurred	O
in	O
the	O
curve	O
fitting	O
(	O
Table	O
1	O
)	O
.	O

The	O
activation	O
energy	O
obtained	O
for	O
the	O
unrestricted	O
motion	O
is	O
lower	O
than	O
that	O
of	O
restricted	O
one	O
,	O
which	O
is	O
expected	O
.	O

The	O
third	O
motion	O
appearing	O
at	O
higher	O
temperatures	O
is	O
affected	O
by	O
deuterium	B
replacement	O
of	O
exchangeable	O
proton	O
,	O
which	O
is	O
similar	O
to	O
the	O
observation	O
made	O
for	O
Ac	B
-	I
Tyroet	I
.	O

However	O
,	O
since	O
such	O
a	O
small	O
part	O
of	O
the	O
curve	O
was	O
observable	O
no	O
reliable	O
fitted	O
data	O
could	O
be	O
obtained	O
.	O

The	O
variation	O
of	O
R	O
1ρ	O
of	O
TFAc	B
-	I
Tyroet	I
and	O
D2-TFAc	B
-	I
Tyroet	I
with	O
temperature	O
is	O
shown	O
in	O
Fig.	O
7	O
.	O

The	O
proton	O
spin	O
-	O
lattice	O
relaxation	O
in	O
the	O
rotating	O
frame	O
of	O
both	O
protonated	O
and	O
deuterated	O
samples	O
is	O
increasingly	O
efficient	O
below	O
240	O
K	O
and	O
no	O
relaxation	O
rate	O
maximum	O
was	O
seen	O
.	O

This	O
is	O
in	O
contrast	O
to	O
the	O
results	O
from	O
Ac	B
-	I
Tyroet	I
and	O
CBZ	B
-	I
Tyroet	I
where	O
benzene	B
ring	O
motion	O
was	O
observed	O
at	O
200	O
K.	O
In	O
the	O
T	O
1	O
of	O
TFAc	B
-	I
Tyroet	I
analysis	O
,	O
methyl	B
group	I
reorientation	O
was	O
found	O
to	O
be	O
the	O
only	O
relaxation	O
mechanism	O
.	O

It	O
is	O
expected	O
that	O
it	O
is	O
also	O
responsible	O
for	O
T	O
1ρ	O
relaxation	O
at	O
very	O
low	O
temperature	O
.	O

The	O
temperature	O
at	O
which	O
the	O
maximum	O
occurs	O
is	O
predicted	O
to	O
be	O
around	O
92	O
K	O
using	O
the	O
relaxation	O
parameters	O
for	O
methyl	B
group	I
rotation	O
found	O
in	O
the	O
T	O
1	O
analysis	O
.	O

To	O
confirm	O
this	O
,	O
T	O
1ρ	O
of	O
TFAc	B
-	I
Tyroet	I
was	O
measured	O
between	O
110	O
to	O
140	O
K	O
and	O
it	O
was	O
found	O
that	O
the	O
relaxation	O
becomes	O
more	O
efficient	O
as	O
the	O
temperature	O
is	O
decreased	O
(	O
see	O
the	O
insert	O
Fig.	O
7	O
)	O
.	O

Therefore	O
,	O
the	O
only	O
relaxation	O
mechanism	O
for	O
the	O
T	O
1ρ	O
of	O
TFAc	B
-	I
Tyroet	I
can	O
be	O
reasonably	O
assigned	O
to	O
methyl	B
group	I
rotation	O
.	O

This	O
is	O
consistent	O
with	O
the	O
observation	O
made	O
in	O
the	O
T	O
1	O
analysis	O
and	O
suggests	O
that	O
the	O
crystal	O
structure	O
results	O
in	O
a	O
more	O
rigid	O
molecule	O
than	O
in	O
the	O
other	O
compounds	O
.	O

This	O
may	O
be	O
the	O
cause	O
of	O
the	O
failure	O
to	O
form	O
a	O
supercooled	O
liquid	O
mixture	O
with	O
l	B
-leucinamide	I
.	O

3.2	O
Mixtures	O
of	O
l	B
-leucinamide	I
/	O
tyrosine	B
derivatives	B
l	B
-leucinamide	I
can	O
spontaneously	O
form	O
supercooled	O
liquid	O
mixtures	O
with	O
CBZ	B
-	I
Tyroet	I
and	O
Ac	B
-	I
Tyroet	I
.	O

However	O
,	O
the	O
melts	O
of	O
l	B
-leuNH	I
/	O
TFAc	B
-	I
Tyroet	I
do	O
not	O
supercool	O
but	O
rather	O
crystallise	O
into	O
separated	O
phases	O
.	O

The	O
mixtures	O
containing	O
1:1	O
l	B
-leucinamide	I
/	O
tyrosine	B
derivatives	B
were	O
studied	O
by	O
the	O
temperature	O
dependence	O
of	O
proton	O
spin	O
-	O
lattice	O
relaxation	O
time	O
in	O
the	O
laboratory	O
frame	O
.	O

For	O
the	O
supercooled	O
liquid	O
mixture	O
of	O
l	B
-leuNH	I
/	O
CBZ	B
-	I
Tyroet	I
,	O
a	O
single	O
exponential	O
T	O
1	O
relaxation	O
was	O
found	O
in	O
the	O
temperature	O
range	O
below	O
330	O
K	O
,	O
above	O
that	O
temperature	O
,	O
a	O
slightly	O
double	O
exponential	O
recovery	O
of	O
magnetization	O
was	O
detected	O
.	O

For	O
the	O
supercooled	O
liquid	O
mixture	O
of	O
l	B
-leuNH	I
/	O
Ac	B
-	I
Tyroet	I
,	O
a	O
slightly	O
double	O
exponential	O
recovery	O
of	O
magnetization	O
was	O
detected	O
above	O
345	O
K.	O
The	O
behaviour	O
of	O
spin	O
-	O
lattice	O
relaxation	O
of	O
a	O
two	O
-	O
component	O
system	O
depends	O
on	O
the	O
spin	O
diffusion	O
rate	O
between	O
the	O
components	O
.	O

When	O
the	O
spin	O
diffusion	O
rate	O
is	O
faster	O
than	O
the	O
rate	O
at	O
which	O
spin	O
energy	O
flows	O
from	O
the	O
spin	O
to	O
lattice	O
,	O
averaging	O
of	O
the	O
spatial	O
inhomogeneities	O
of	O
the	O
spin	O
-	O
lattice	O
relaxation	O
occurs	O
and	O
results	O
in	O
an	O
observed	O
single	O
relaxation	O
time	O
.	O

The	O
spin	O
diffusion	O
rate	O
is	O
dependent	O
on	O
the	O
strength	O
of	O
homonuclear	O
dipolar	O
interactions	O
which	O
,	O
in	O
turn	O
,	O
depends	O
on	O
both	O
the	O
distance	O
between	O
nuclei	O
and	O
molecular	O
mobilities	O
.	O

At	O
below	O
300	O
K	O
,	O
the	O
transverse	O
relaxation	O
of	O
the	O
mixture	O
comprises	O
a	O
Gaussian	O
and	O
an	O
exponential	O
process	O
,	O
above	O
300	O
K	O
it	O
is	O
exponential	O
.	O

A	O
single	O
exponential	O
spin	O
-	O
lattice	O
relaxation	O
is	O
observed	O
below	O
300	O
K.	O
This	O
is	O
due	O
to	O
the	O
strong	O
static	O
dipolar	O
interactions	O
,	O
which	O
exist	O
in	O
this	O
temperature	O
regime	O
.	O

When	O
the	O
temperature	O
is	O
above	O
330	O
K	O
,	O
the	O
dipolar	O
interactions	O
are	O
weakened	O
as	O
the	O
result	O
of	O
molecular	O
motion	O
,	O
consequently	O
,	O
the	O
spin	O
diffusion	O
rate	O
is	O
slow	O
,	O
resulting	O
in	O
non	O
-	O
exponential	O
recovery	O
of	O
T	O
1	O
.	O

However	O
,	O
in	O
the	O
temperature	O
range	O
between	O
300	O
to	O
330	O
K	O
,	O
the	O
single	O
exponential	O
T	O
1	O
relaxation	O
observed	O
in	O
the	O
mixture	O
of	O
LeuNH	B
/	O
CBZ	B
-	I
Tyroet	I
is	O
not	O
the	O
result	O
of	O
strong	O
static	O
interactions	O
since	O
the	O
transverse	O
relaxation	O
of	O
the	O
mixture	O
LeuNH	B
/	O
CBZ	B
-	I
Tyroet	I
is	O
an	O
exponential	O
process	O
.	O

The	O
single	O
exponential	O
T	O
1	O
observed	O
in	O
this	O
case	O
may	O
be	O
due	O
to	O
the	O
strong	O
intra-	O
and	O
intermolecular	O
interactions	O
resulting	O
from	O
the	O
fact	O
that	O
molecules	O
in	O
the	O
mixtures	O
are	O
in	O
close	O
contact	O
to	O
each	O
other	O
.	O

The	O
spin	O
-	O
lattice	O
relaxation	O
behaviour	O
of	O
both	O
the	O
mixtures	O
was	O
treated	O
as	O
a	O
single	O
exponential	O
process	O
in	O
the	O
temperature	O
range	O
150–360	O
K	O
since	O
only	O
a	O
few	O
data	O
show	O
the	O
double	O
-	O
exponential	O
behaviour	O
,	O
and	O
fitting	O
our	O
data	O
to	O
a	O
single	O
exponential	O
function	O
does	O
not	O
affect	O
the	O
analysis	O
drastically	O
.	O

Fig.	O
8	O
Fig.	O
9	O
show	O
the	O
spin	O
-	O
lattice	O
relaxation	O
rates	O
of	O
the	O
mixtures	O
LeuNH	B
/	O
Ac	B
-	I
Tyroet	I
and	O
LeuNH	B
/	O
CBZ	B
-	I
Tyroet	I
plotted	O
against	O
temperature	O
.	O

Clearly	O
,	O
two	O
independent	O
dominant	O
relaxation	O
mechanisms	O
were	O
detected	O
,	O
one	O
of	O
which	O
is	O
effective	O
below	O
250	O
K	O
and	O
the	O
other	O
one	O
is	O
effective	O
above	O
that	O
temperature	O
.	O

The	O
methyl	B
group	I
rotation	O
is	O
expected	O
to	O
be	O
responsible	O
for	O
the	O
relaxation	O
at	O
low	O
temperature	O
[	O
6	O
]	O
.	O

To	O
clarify	O
the	O
high	O
temperature	O
relaxation	O
mechanism	O
,	O
the	O
spin	O
-	O
lattice	O
relaxation	O
times	O
of	O
a	O
deuterated	O
supercooled	O
liquid	O
mixture	O
of	O
l	B
-leuND	I
/	O
D2-CBZ	B
-	I
Tyroet	I
(	O
Fig.	O
9	O
)	O
were	O
measured	O
in	O
the	O
temperature	O
range	O
140–360	O
K	O
and	O
plotted	O
against	O
temperature	O
.	O

Relatively	O
efficient	O
relaxation	O
was	O
still	O
found	O
at	O
high	O
temperature	O
.	O

This	O
suggests	O
that	O
the	O
spin	O
-	O
lattice	O
relaxation	O
at	O
high	O
temperature	O
is	O
not	O
only	O
due	O
to	O
the	O
motions	O
of	O
NH2	B
or	O
OH	B
,	O
but	O
also	O
some	O
other	O
contributions	O
.	O

Inspection	O
of	O
the	O
spin	O
-	O
lattice	O
relaxation	O
times	O
of	O
the	O
pure	O
CBZ	B
-	I
Tyroet	I
and	O
Ac	B
-	I
Tyroet	I
shows	O
that	O
the	O
benzene	B
ring	O
flipping	O
motion	O
is	O
expected	O
in	O
this	O
temperature	O
range	O
.	O

However	O
,	O
the	O
strength	O
of	O
the	O
relaxation	O
in	O
the	O
mixtures	O
is	O
much	O
larger	O
than	O
that	O
could	O
be	O
generated	O
by	O
the	O
benzene	B
ring	O
flipping	O
,	O
since	O
this	O
is	O
a	O
weaker	O
relaxation	O
source	O
than	O
the	O
methyl	B
group	I
rotation	O
(	O
Fig.	O
4	O
)	O
.	O

The	O
system	O
is	O
likely	O
,	O
in	O
this	O
case	O
,	O
to	O
be	O
relaxed	O
by	O
the	O
molecular	O
tumbling	O
motion	O
since	O
considerable	O
line	O
narrowing	O
was	O
observed	O
in	O
the	O
FID	O
in	O
this	O
temperature	O
range	O
.	O

Therefore	O
,	O
it	O
is	O
reasonable	O
to	O
assume	O
that	O
rapid	O
molecule	O
tumbling	O
is	O
the	O
major	O
relaxation	O
mechanism	O
for	O
the	O
spin	O
-	O
lattice	O
relaxation	O
of	O
the	O
system	O
at	O
high	O
temperature	O
.	O

The	O
experimental	O
data	O
were	O
then	O
fitted	O
in	O
Eq.	O
(	O
1	O
)	O
.	O

P	O
a	O
is	O
the	O
methyl	B
group	I
proton	O
population	O
,	O
the	O
value	O
is	O
9	O
/	O
35	O
for	O
the	O
mixture	O
of	O
l	B
-leuNH	I
/	O
CBZ	B
-	I
Tyroet	I
and	O
9	O
/	O
31	O
for	O
l	B
-leuNH	I
/	O
Ac	B
-	I
Tyroet	I
.	O

P	O
b	O
is	O
set	O
to	O
unity	O
since	O
all	O
the	O
protons	O
in	O
the	O
mixture	O
contribute	O
to	O
the	O
relaxation	O
.	O

Figs.	O
8	O
and	O
9	O
show	O
the	O
good	O
agreement	O
between	O
the	O
fitted	O
curves	O
and	O
experimental	O
data	O
.	O

The	O
results	O
are	O
given	O
in	O
Table	O
2	O
.	O

The	O
second	O
moment	O
calculated	O
for	O
methyl	B
group	I
rotation	O
is	O
in	O
the	O
same	O
order	O
of	O
magnitude	O
as	O
those	O
in	O
pure	O
solids	O
.	O

However	O
,	O
the	O
activation	O
energy	O
of	O
the	O
methyl	B
group	I
rotation	O
in	O
the	O
mixture	O
is	O
smaller	O
than	O
those	O
found	O
for	O
the	O
pure	O
solids	O
.	O

The	O
molecules	O
in	O
supercooled	O
liquid	O
mixtures	O
are	O
loosely	O
packed	O
.	O

As	O
a	O
consequence	O
,	O
rotation	O
of	O
methyl	B
group	I
might	O
be	O
less	O
hindered	O
compared	O
to	O
the	O
corresponding	O
crystal	O
state	O
.	O

This	O
might	O
be	O
the	O
reason	O
for	O
the	O
low	O
activation	O
energy	O
observed	O
.	O

The	O
relaxation	O
rates	O
of	O
these	O
mixtures	O
at	O
low	O
temperature	O
can	O
be	O
predicted	O
from	O
the	O
corresponding	O
crystals	O
assuming	O
that	O
methyl	B
group	I
rotation	O
is	O
the	O
relaxation	O
mechanism	O
.	O

The	O
predictions	O
shown	O
in	O
Figs.	O
8	O
and	O
9	O
differ	O
from	O
the	O
experimental	O
values	O
.	O

This	O
indicates	O
the	O
effects	O
of	O
molecular	O
arrangement	O
on	O
the	O
methyl	B
group	I
rotation	O
.	O

In	O
contrast	O
to	O
the	O
mixtures	O
of	O
l	B
-leuNH	I
/	O
CBZ	B
-	I
Tyroet	I
and	O
l	B
-leuNH	I
/	O
Ac	B
-	I
Tyroet	I
,	O
the	O
mixture	O
of	O
l	B
-leuNH	I
/	O
TFAc	B
-	I
Tyroet	I
does	O
not	O
form	O
a	O
supercooled	O
liquid	O
.	O

The	O
T	O
1	O
of	O
a	O
mixture	O
of	O
l	B
-leuNH	I
/	O
TFAc	B
-	I
Tyroet	I
(	O
1:1	O
)	O
were	O
measured	O
over	O
the	O
temperature	O
range	O
150–360	O
K.	O
Unlike	O
the	O
liquid	O
mixtures	O
,	O
double	O
exponential	O
relaxation	O
times	O
were	O
found	O
for	O
the	O
temperature	O
range	O
studied	O
.	O

The	O
short	O
T	O
1	O
component	O
varied	O
between	O
0.08	O
to	O
0.69	O
s	O
and	O
the	O
long	O
T	O
1	O
component	O
varied	O
between	O
0.3	O
to	O
10	O
s.	O
The	O
double	O
exponential	O
behaviour	O
of	O
spin	O
-	O
lattice	O
relaxation	O
indicates	O
that	O
the	O
mixture	O
of	O
l	B
-leuNH	I
/	O
TFAc	B
-	I
Tyroet	I
is	O
a	O
two	O
phase	O
system	O
and	O
that	O
the	O
spin	O
diffusion	O
between	O
the	O
two	O
components	O
is	O
slow	O
on	O
the	O
time	O
scale	O
of	O
T	O
1	O
.	O

The	O
temperature	O
dependence	O
of	O
relaxation	O
rate	O
of	O
both	O
components	O
is	O
shown	O
in	O
Fig.	O
10	O
.	O

A	O
comparison	O
of	O
both	O
the	O
relaxation	O
times	O
with	O
the	O
pure	O
components	O
of	O
l	B
-leuNH	I
and	O
TFAc	B
-	I
Tyroet	I
shows	O
that	O
the	O
long	O
relaxation	O
component	O
coincides	O
well	O
with	O
the	O
R	O
1	O
of	O
TFAc	B
-	I
Tyroet	I
and	O
that	O
the	O
short	O
component	O
is	O
close	O
to	O
the	O
R	O
1	O
of	O
l	B
-leuNH	I
.	O

From	O
this	O
observation	O
,	O
it	O
can	O
be	O
inferred	O
that	O
the	O
mixture	O
of	O
l	B
-leuNH	I
/	O
TFAc	B
-	I
Tyroet	I
behaves	O
as	O
if	O
both	O
components	O
were	O
in	O
their	O
pure	O
states	O
.	O

This	O
suggestion	O
is	O
confirmed	O
by	O
the	O
proportion	O
of	O
the	O
two	O
components	O
.	O

At	O
temperatures	O
above	O
260	O
K	O
,	O
the	O
proportion	O
of	O
short	O
T	O
1	O
component	O
comprises	O
about	O
50	O
%	O
.	O

This	O
agrees	O
very	O
well	O
with	O
the	O
proton	O
population	O
of	O
l	B
-leuNH	I
.	O

The	O
short	O
T	O
1	O
represents	O
the	O
population	O
of	O
l	B
-leuNH	I
protons	O
,	O
and	O
the	O
long	O
T	O
1	O
represents	O
that	O
of	O
the	O
TFAc	B
-	I
Tyroet	I
protons	O
.	O

This	O
is	O
in	O
contrast	O
to	O
the	O
liquid	O
mixtures	O
where	O
the	O
mixtures	O
act	O
differently	O
from	O
their	O
pure	O
states	O
.	O

At	O
low	O
temperature	O
(	O
below	O
210	O
K	O
)	O
there	O
is	O
significant	O
deviation	O
of	O
the	O
LeuNH	B
data	O
in	O
the	O
mixture	O
from	O
the	O
pure	O
state	O
,	O
both	O
apparent	O
population	O
and	O
relaxation	O
rate	O
deviate	O
.	O

This	O
may	O
be	O
due	O
to	O
long	O
range	O
spin	O
diffusion	O
effects	O
at	O
this	O
temperature	O
.	O

The	O
ability	O
to	O
form	O
supercooled	O
liquid	O
mixture	O
can	O
be	O
related	O
to	O
the	O
molecular	O
dynamics	O
of	O
the	O
pure	O
substrates	O
.	O

A	O
comparison	O
of	O
the	O
dynamics	O
of	O
these	O
tyrosine	B
derivatives	B
shows	O
that	O
the	O
benzene	B
ring	O
flipping	O
motion	O
and	O
the	O
third	O
motion	O
are	O
absent	O
in	O
the	O
fluorine	B
substituted	B
compound	I
.	O

The	O
reason	O
remains	O
unclear	O
.	O

The	O
preliminary	O
X	O
-	O
ray	O
data	O
did	O
not	O
show	O
strong	O
interactions	O
between	O
the	O
fluorine	B
atoms	O
and	O
the	O
benzene	B
ring	O
,	O
which	O
agrees	O
with	O
the	O
conclusions	O
from	O
UV	O
and	O
Raman	O
spectra	O
.	O

The	O
absence	O
of	O
benzene	B
ring	O
flipping	O
and	O
the	O
third	O
motion	O
in	O
the	O
fluorinated	B
compound	I
implies	O
that	O
the	O
level	O
of	O
order	O
in	O
this	O
crystal	O
is	O
higher	O
than	O
those	O
in	O
the	O
other	O
compounds	O
studied	O
.	O

On	O
crystallisation	O
there	O
will	O
be	O
only	O
one	O
molecular	O
conformation	O
(	O
with	O
respect	O
to	O
the	O
benzene	B
ring	O
)	O
that	O
is	O
possible	O
.	O

Formation	O
of	O
a	O
crystal	O
is	O
therefore	O
only	O
a	O
matter	O
of	O
the	O
whole	O
molecule	O
assuming	O
the	O
correct	O
orientation	O
with	O
respect	O
to	O
its	O
neighbours	O
and	O
packing	O
closely	O
.	O

In	O
the	O
case	O
of	O
Ac	B
-	I
Tyroet	I
there	O
is	O
variability	O
in	O
the	O
conformation	O
with	O
respect	O
to	O
the	O
benzene	B
ring	O
in	O
molecules	O
in	O
the	O
crystal	O
.	O

This	O
will	O
mean	O
that	O
,	O
in	O
effect	O
,	O
the	O
benzene	B
rings	O
will	O
occupy	O
a	O
greater	O
volume	O
than	O
if	O
they	O
were	O
static	O
(	O
in	O
the	O
case	O
of	O
TFAc	B
-	I
Tyroet	I
)	O
and	O
therefore	O
,	O
the	O
intermolecular	O
distances	O
will	O
be	O
greater	O
than	O
in	O
the	O
fluorinated	B
analogue	I
.	O

This	O
in	O
turn	O
implies	O
a	O
weaker	O
intermolecular	O
interactions	O
.	O

This	O
suggestion	O
is	O
supported	O
by	O
the	O
fact	O
that	O
fluorine	B
substitution	O
increases	O
the	O
melting	O
point	O
of	O
the	O
crystal	O
from	O
about	O
78	O
°	O
C	O
to	O
175	O
°	O
C	O
.	O

The	O
presence	O
of	O
highly	O
mobile	O
,	O
non	O
-	O
rigid	O
molecules	O
are	O
also	O
likely	O
to	O
inhibit	O
crystal	O
formation	O
.	O

In	O
the	O
presence	O
of	O
another	O
solute	O
,	O
this	O
is	O
likely	O
to	O
lead	O
to	O
the	O
formation	O
of	O
supercooling	O
systems	O
since	O
only	O
weak	O
interactions	O
in	O
solute	O
will	O
be	O
enough	O
to	O
prevent	O
crystallisation	O
.	O

Similar	O
observations	O
of	O
the	O
effects	O
of	O
fluorination	O
have	O
been	O
made	O
by	O
Dow	O
et	O
al.	O
[	O
26	O
]	O
.	O

It	O
was	O
found	O
that	O
fluorine	B
-	B
substituted	I
lipids	I
form	O
solids	O
on	O
cooling	O
in	O
30–60	O
min	O
,	O
whereas	O
unsubstituted	O
lipids	O
require	O
a	O
cooling	O
period	O
of	O
hours	O
or	O
days	O
.	O

It	O
was	O
also	O
shown	O
that	O
less	O
mobility	O
was	O
associated	O
with	O
fluorine	B
-	B
substituted	I
lipids	I
[	O
26	O
]	O
.	O

4	O
Conclusions	O
The	O
proton	O
relaxation	O
behaviour	O
of	O
three	O
tyrosine	B
derivatives	B
:	O
Ac	B
-	I
Tyroet	I
,	O
CBZ	B
-	I
Tyroet	I
,	O
TFAc	B
-	I
Tyroet	I
and	O
their	O
mixtures	O
with	O
l	B
-leucinamide	I
was	O
studied	O
.	O

The	O
extension	O
of	O
the	O
well	O
-	O
known	O
relaxation	O
expression	O
of	O
Kubo	O
and	O
Tomita	O
to	O
several	O
independent	O
relaxation	O
processes	O
was	O
used	O
to	O
identify	O
the	O
relaxation	O
mechanisms	O
and	O
estimate	O
the	O
relaxation	O
parameters	O
.	O

It	O
was	O
found	O
that	O
methyl	B
group	I
rotation	O
is	O
important	O
for	O
relaxing	O
the	O
system	O
at	O
low	O
temperature	O
in	O
both	O
the	O
pure	O
state	O
and	O
mixtures	O
.	O

In	O
addition	O
,	O
both	O
benzene	B
ring	O
flipping	O
and	O
a	O
third	O
motion	O
were	O
found	O
to	O
be	O
the	O
relaxation	O
mechanisms	O
for	O
Ac	B
-	I
Tyroet	I
and	O
CBZ	B
-	I
Tyroet	I
,	O
however	O
,	O
these	O
motions	O
are	O
absent	O
in	O
TFAc	B
-	I
Tyroet	I
.	O

In	O
the	O
mixtures	O
,	O
molecular	O
tumbling	O
motion	O
is	O
responsible	O
for	O
relaxing	O
the	O
supercooled	O
liquids	O
l	B
-leuNH	I
/	O
CBZ	B
-	I
Tyroet	I
and	O
l	B
-leuNH	I
/	O
Ac	B
-	I
Tyroet	I
.	O

However	O
,	O
this	O
motion	O
is	O
absent	O
in	O
the	O
mixture	O
l	B
-leuNH	I
/	O
TFAc	B
-	I
Tyroet	I
.	I

The	O
absence	O
of	O
benzene	B
ring	O
flipping	O
motion	O
and	O
the	O
third	O
motion	O
in	O
the	O
pure	O
tyrosine	B
derivatives	B
may	O
affect	O
its	O
ability	O
to	O
form	O
a	O
supercooled	O
liquid	O
with	O
l	B
-leucinamide	I
.	O

Acknowledgements	O
The	O
authors	O
wish	O
to	O
acknowledge	O
funding	O
from	O
the	O
BBSRC	O
competitive	O
strategic	O
grant	O
.	O

Y.L.	O
Wang	O
wishes	O
to	O
thank	O
the	O
BBSRC	O
for	O
provision	O
of	O
a	O
studentship	O
.	O

d	B
-Penicillamine	I
(	O
d	B
-pen	I
)	O
is	O
a	O
drug	B
used	O
in	O
the	O
treatment	O
of	O
patients	O
with	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
,	O
cystinuria	O
and	O
Wilson	O
's	O
disease	O
.	O

A	O
small	O
molecule	O
,	O
similar	O
in	O
structure	O
to	O
cysteine	B
(	O
see	O
Fig.	O
2	O
)	O
,	O
it	O
has	O
a	O
sulfhydryl	B
group	I
that	O
allows	O
it	O
to	O
couple	O
covalently	O
to	O
proteins	O
(	O
Coleman	O
et	O
al.	O
,	O
1988	O
)	O
,	O
resulting	O
in	O
slow	O
elimination	O
from	O
the	O
body	O
.	O

Its	O
mechanism	O
of	O
action	O
in	O
RA	O
remains	O
unclear	O
,	O
but	O
its	O
variable	O
and	O
unpredictable	O
efficacy	O
,	O
coupled	O
with	O
a	O
relatively	O
high	O
incidence	O
of	O
side	O
-	O
effects	O
,	O
has	O
led	O
to	O
a	O
decline	O
in	O
its	O
use	O
in	O
recent	O
years	O
.	O

Such	O
side	O
-	O
effects	O
include	O
the	O
development	O
of	O
a	O
number	O
of	O
autoimmune	O
disorders	O
including	O
lupus	O
erythematosus	O
,	O
pemphigus	O
,	O
Goodpasture	O
's	O
syndrome	O
,	O
neuromyotonia	O
and	O
myasthenia	O
gravis	O
(	O
MG	O
;	O
Fernandes	O
et	O
al.	O
,	O
1980	O
)	O
.	O

d	B
-Pen	I
is	O
not	O
the	O
only	O
drug	B
capable	O
of	O
inducing	O
autoimmune	O
disease	O
,	O
but	O
it	O
is	O
almost	O
alone	O
in	O
its	O
ability	O
to	O
cause	O
autoimmune	O
MG	O
.	O

As	O
with	O
other	O
drug	B
-	O
induced	O
disorders	O
,	O
d	B
-pen	I
-	O
induced	O
MG	O
is	O
associated	O
with	O
the	O
development	O
of	O
autoantibodies	O
,	O
in	O
this	O
case	O
to	O
the	O
acetylcholine	B
receptor	O
(	O
AChR	O
)	O
(	O
Russell	O
and	O
Lindstrom	O
,	O
1978	O
)	O
.	O

The	O
avidity	O
and	O
specificities	O
of	O
these	O
autoantibodies	O
in	O
d	B
-pen	I
-	O
induced	O
MG	O
are	O
similar	O
to	O
those	O
found	O
in	O
early	O
-	O
onset	O
patients	O
(	O
EOMG	O
)	O
,	O
particularly	O
early	O
in	O
the	O
course	O
of	O
the	O
disease	O
(	O
Vincent	O
and	O
Newsom	O
-	O
Davis	O
,	O
1982	O
;	O
Heidenreich	O
et	O
al.	O
,	O
1988	O
)	O
;	O
however	O
,	O
the	O
MG	O
normally	O
remits	O
within	O
6	O
months	O
of	O
stopping	O
the	O
drug	B
,	O
with	O
a	O
concomitant	O
fall	O
in	O
the	O
anti	O
-	O
AChR	O
antibody	O
titer	O
(	O
Vincent	O
et	O
al.	O
,	O
1978	O
;	O
Kuncl	O
et	O
al.	O
,	O
1986	O
)	O
,	O
whereas	O
idiopathic	O
MG	O
is	O
usually	O
long	O
-	O
lasting	O
.	O

Delamere	O
et	O
al.	O
(	O
1983	O
)	O
and	O
Garlepp	O
et	O
al.	O
(	O
1983	O
)	O
reported	O
that	O
,	O
in	O
contrast	O
with	O
other	O
MG	O
subgroups	O
,	O
the	O
condition	O
is	O
associated	O
with	O
HLA	O
-	O
DR1	O
,	O
though	O
its	O
rarity	O
means	O
that	O
the	O
numbers	O
of	O
patients	O
studied	O
are	O
small	O
.	O

How	O
d	B
-pen	I
induces	O
MG	O
is	O
unclear	O
.	O

Administration	O
of	O
the	O
drug	B
to	O
experimental	O
animals	O
did	O
not	O
result	O
in	O
the	O
production	O
of	O
anti	O
-	O
AChR	O
antibodies	O
,	O
although	O
they	O
showed	O
an	O
augmented	O
antibody	O
response	O
to	O
immunization	O
with	O
AChR	O
and	O
the	O
resulting	O
MG	O
signs	O
were	O
sometimes	O
more	O
severe	O
(	O
Bever	O
et	O
al.	O
,	O
1984	O
)	O
.	O

The	O
size	O
of	O
the	O
molecule	O
and	O
its	O
reactive	O
sulfhydryl	B
group	I
suggest	O
that	O
the	O
drug	B
is	O
acting	O
as	O
a	O
hapten	B
and/or	O
modifying	O
self	O
protein	O
(	O
s	O
)	O
/	O
peptide	B
(	O
s	O
)	O
,	O
thereby	O
creating	O
neo	O
-	O
epitope	O
(	O
s	O
)	O
.	O

Indeed	O
,	O
coupling	O
of	O
d	B
-pen	I
to	O
an	O
unidentified	O
serum	O
protein	O
has	O
been	O
demonstrated	O
in	O
patients	O
on	O
d	B
-pen	I
therapy	O
(	O
Laycock	O
et	O
al.	O
,	O
1994	O
)	O
,	O
though	O
its	O
significance	O
for	O
autoimmunity	O
is	O
not	O
clear	O
.	O

To	O
examine	O
the	O
role	O
of	O
d	B
-pen	I
in	O
MG	O
,	O
we	O
have	O
isolated	O
a	O
number	O
of	O
CD3	O
+	O
,	O
CD4	O
+	O
T	O
cell	O
clones	O
from	O
the	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
of	O
a	O
patient	O
with	O
d	B
-pen	I
-	O
induced	O
MG	O
that	O
respond	O
to	O
the	O
drug	B
in	O
vitro	O
together	O
with	O
HLA	O
-	O
DR1	O
+	O
PBMC	O
.	O

We	O
provide	O
evidence	O
that	O
the	O
drug	B
is	O
acting	O
by	O
coupling	O
directly	O
to	O
the	O
MHC	O
class	O
II	O
/	O
peptide	B
complex	O
,	O
and	O
discuss	O
how	O
this	O
might	O
result	O
in	O
the	O
development	O
of	O
MG	O
.	O

2	O
Materials	O
and	O
methods	O
2.1	O
Patient	O
details	O
We	O
studied	O
a	O
68-year	O
old	O
woman	O
(	O
D	O
-	O
P1	O
)	O
with	O
erosive	O
seropositive	O
RA	O
(	O
HLA	O
A1,32	O
;	O
B8,35	O
;	O
C4,701	O
;	O
DR1,3,DR52a	O
;	O
DQ2,5	O
)	O
who	O
had	O
been	O
on	O
d	B
-pen	I
treatment	O
for	O
9	O
months	O
before	O
she	O
developed	O
right	O
-	O
sided	O
ptosis	O
.	O

Six	O
months	O
later	O
,	O
single	O
fiber	O
electromyography	O
in	O
the	O
affected	O
orbicularis	O
oculi	O
muscle	O
showed	O
markedly	O
increased	O
jitter	O
,	O
consistent	O
with	O
a	O
defect	O
in	O
neuromuscular	O
transmission	O
.	O

Her	O
anti	O
-	O
AChR	O
antibody	O
titer	O
was	O
3.2	O
nM	O
,	O
confirming	O
the	O
diagnosis	O
of	O
MG	O
:	O
the	O
d	B
-pen	I
treatment	O
was	O
therefore	O
stopped	O
.	O

At	O
this	O
time	O
,	O
we	O
took	O
a	O
blood	O
sample	O
from	O
which	O
d	B
-pen	I
-	O
specific	O
lines	O
and	O
clones	O
were	O
obtained	O
.	O

The	O
recovery	O
of	O
her	O
mainly	O
ocular	O
symptoms	O
was	O
slow	O
;	O
about	O
two	O
years	O
after	O
d	B
-pen	I
treatment	O
started	O
,	O
she	O
was	O
given	O
a	O
short	O
course	O
of	O
oral	O
corticosteroids	B
before	O
they	O
resolved	O
completely	O
within	O
9	O
further	O
months	O
.	O

2.2	O
Generation	O
of	O
primary	O
T	O
cell	O
lines	O
d	B
-Pen	I
HCl	I
(	O
Sigma	O
,	O
Poole	O
,	O
UK	O
)	O
was	O
dissolved	O
in	O
sterile	O
water	B
and	O
aliquots	O
stored	O
at	O
−70	O
°	O
C	O
.	O

The	O
cellular	O
toxicity	O
of	O
the	O
drug	B
was	O
determined	O
by	O
inhibition	O
of	O
PHA	O
(	O
Difco	O
Laboratories	O
,	O
Detroit	O
,	O
USA	O
)	O
-induced	O
proliferation	O
of	O
PBMCs	O
from	O
healthy	O
controls	O
by	O
increasing	O
concentrations	O
of	O
d	B
-pen	I
;	O
doses	O
of	O
100–500	O
μg	O
/	O
ml	O
were	O
found	O
to	O
be	O
optimal	O
,	O
and	O
toxicity	O
was	O
seen	O
at	O
doses	O
of	O
1	O
mg	O
/	O
ml	O
and	O
above	O
.	O

PBMCs	O
were	O
separated	O
from	O
heparinized	O
blood	O
on	O
Lymphoprep	O
(	O
Nycomed	O
,	O
Oslo	O
,	O
Norway	O
)	O
,	O
washed	O
and	O
cultured	O
at	O
2	O
×	O
106	O
/1	O
ml	O
well	O
(	O
Nunc	O
,	O
Roskilde	O
,	O
Denmark	O
)	O
with	O
100–500	O
μg	O
/	O
ml	O
d	B
-pen	I
in	O
RPMI	O
(	O
Hyclone	O
,	O
Cramlington	O
,	O
UK	O
)	O
supplemented	O
with	O
5	O
%	O
heat	O
-	O
inactivated	O
human	O
serum	O
(	O
Blood	O
Transfusion	O
Service	O
,	O
Oxford	O
,	O
UK	O
)	O
,	O
l	B
-glutamine	I
(	O
Gibco	O
Life	O
Technologies	O
,	O
Paisley	O
,	O
Scotland	O
)	O
and	O
50	O
μg	O
/	O
ml	O
gentamycin	B
(	O
Gibco	O
)	O
,	O
i.e.	O
,	O
without	O
penicillin	B
.	O

After	O
7	O
days	O
,	O
stimulation	O
was	O
assessed	O
by	O
culturing	O
triplicate	O
samples	O
(	O
5	O
%	O
)	O
from	O
each	O
well	O
with	O
1	O
μCi	O
of	O
3	O
H	O
thymidine	B
(	O
Amersham	O
International	O
,	O
Amersham	O
,	O
UK	O
)	O
for	O
18	O
h	O
,	O
followed	O
by	O
harvesting	O
onto	O
filter	O
mats	O
(	O
Wallac	O
,	O
Turku	O
,	O
Finland	O
)	O
and	O
counting	O
on	O
a	O
Betaplate	O
flatbed	O
liquid	O
scintillation	O
counter	O
(	O
Wallac	O
)	O
.	O

A	O
response	O
was	O
considered	O
positive	O
when	O
the	O
activity	O
was	O
greater	O
than	O
twice	O
the	O
control	O
value	O
,	O
i.e.	O
,	O
the	O
stimulation	O
index	O
(	O
SI	O
)	O
was	O
>	O
2	O
.	O

We	O
expanded	O
positive	O
wells	O
into	O
lines	O
using	O
a	O
cycle	O
of	O
fortnightly	O
restimulation	O
with	O
autologous	O
30	O
Gy	O
-	O
irradiated	O
PBMC	O
(	O
PBMCx	O
)	O
and	O
d	B
-pen	I
,	O
and	O
supplementing	O
with	O
20U	O
IL-2	O
(	O
Biotest	O
(	O
UK	O
)	O
,	O
Solihull	O
,	O
UK	O
)	O
approximately	O
every	O
72	O
h	O
thereafter	O
.	O

Specificity	O
of	O
the	O
lines	O
for	O
the	O
drug	B
was	O
confirmed	O
by	O
culturing	O
3	O
×	O
104	O
T	O
cells	O
with	O
1	O
×	O
105	O
PBMCx	O
pretreated	O
with	O
500	O
μg	O
/	O
ml	O
d	O
-pen	O
for	O
4	O
h	O
at	O
37	O
°	O
C	O
in	O
RPMI	O
/	O
5	O
%	O
human	O
serum	O
and	O
then	O
washed	O
twice	O
before	O
being	O
used	O
in	O
the	O
assay	O
.	O

2.3	O
Isolation	O
of	O
d	B
-pen	I
-	O
specific	O
T	O
cell	O
clones	O
One	O
of	O
the	O
d	B
-pen	I
-	O
specific	O
lines	O
derived	O
from	O
patient	O
D	O
-	O
P1	O
was	O
cloned	O
by	O
limiting	O
dilution	O
in	O
Terasaki	O
wells	O
(	O
Nunc	O
)	O
using	O
PBMCx	O
prepulsed	O
with	O
500	O
μg	O
/	O
ml	O
d	B
-pen	I
as	O
the	O
stimulus	O
.	O

Proliferating	O
clones	O
were	O
expanded	O
with	O
IL-2	O
and	O
fortnightly	O
restimulation	O
with	O
PHA	O
and	O
allogeneic	O
PBMCx	O
,	O
and	O
then	O
assayed	O
for	O
a	O
response	O
to	O
d	B
-pen	I
,	O
as	O
described	O
above	O
.	O

Specificity	O
was	O
confirmed	O
by	O
comparing	O
the	O
response	O
to	O
d	B
-pen	I
with	O
that	O
to	O
the	O
isomer	O
,	O
l	B
-penicillamine	I
,	O
and	O
the	O
analogue	B
,	O
d	B
-cysteine	I
(	O
both	O
at	O
500	O
μg	O
/	O
ml	O
;	O
Sigma	O
)	O
.	O

Surface	O
phenotype	O
was	O
determined	O
by	O
FACS	O
analysis	O
(	O
Becton	O
Dickinson	O
,	O
Oxford	O
,	O
UK	O
)	O
using	O
conventional	O
two	O
color	O
staining	O
with	O
anti	O
-	O
CD3	O
(	O
OKT3	O
)	O
directly	O
conjugated	O
to	O
fluorescein	B
isothiocyanate	I
(	O
FITC	B
;	O
gift	O
of	O
S.J.	O
Curnow	O
)	O
and	O
anti	O
-	O
CD4	O
and	O
-CD8	O
conjugated	O
to	O
phycoerythrin	O
(	O
Dako	O
,	O
High	O
Wycombe	O
,	O
UK	O
)	O
.	O

2.4	O
Class	O
II	O
restriction	O
The	O
restricting	O
class	O
II	O
isotype	O
was	O
determined	O
by	O
adding	O
the	O
following	O
class	O
II	O
-	O
blocking	O
mAbs	O
to	O
the	O
presenting	O
cells	O
in	O
the	O
standard	O
assay	O
:	O
mouse	O
anti	O
-	O
human	O
DR	O
(	O
L243	O
;	O
gift	O
of	O
H.	O
McDevitt	O
)	O
,	O
anti	O
-	O
human	O
DP	O
(	O
gift	O
of	O
F.	O
Brodsky	O
)	O
or	O
anti	O
-	O
human	O
DQ	O
(	O
L2	O
;	O
gift	O
of	O
D.	O
Altmann	O
)	O
.	O

Comparing	O
the	O
ability	O
of	O
HLA	O
-	O
sharing	O
PBMCx	O
to	O
present	O
d	B
-pen	I
to	O
the	O
clones	O
then	O
identified	O
the	O
allele	O
.	O

2.5	O
Cytokine	O
profile	O
The	O
supernatant	O
from	O
T	O
cell	O
clones	O
cultured	O
with	O
PBMCx's±d	O
-pen	O
was	O
analyzed	O
for	O
interferon	O
-	O
γ	O
(	O
IFN	O
-	O
γ	O
)	O
and	O
interleukin-4	O
(	O
IL-4	O
)	O
by	O
ELISA	O
(	O
Pharmingen	O
,	O
San	O
Diego	O
,	O
CA	O
)	O
according	O
to	O
the	O
manufacturer	O
's	O
instructions	O
.	O

2.6	O
TCR	O
gene	O
usage	O
T	O
cell	O
receptors	O
were	O
cloned	O
using	O
the	O
anchored	O
polymerase	O
chain	O
reaction	O
(	O
Moss	O
et	O
al.	O
,	O
1993	O
)	O
.	O

Briefly	O
,	O
cDNA	O
was	O
synthesized	O
from	O
5	O
μg	O
of	O
RNA	O
using	O
AMV	O
-	O
RT	O
and	O
an	O
oligo	O
dT	O
primer	O
.	O

cDNA	O
was	O
precipitated	O
three	O
times	O
using	O
4	O
M	O
ammonium	B
acetate	I
and	O
an	O
oligo	O
dG	O
homopolymer	O
tail	O
added	O
using	O
TdT.	B
cDNA	O
was	O
then	O
amplified	O
using	O
an	O
anchor	O
primer	O
and	O
primers	O
complementary	O
to	O
TCRA	O
and	O
TCRB	O
constant	O
regions	O
.	O

PCR	O
products	O
were	O
then	O
cloned	O
into	O
M13mp18	O
and	O
sequenced	O
.	O

2.7	O
Requirement	O
for	O
human	O
serum	O
and	O
antigen	O
processing	O
for	O
antigenicity	O
Fresh	O
PBMCs	O
were	O
washed	O
and	O
kept	O
in	O
serum	O
-	O
free	O
medium	O
before	O
irradiation	O
and	O
pulsing	O
in	O
plain	O
RPMI	O
,	O
in	O
5	O
%	O
human	O
or	O
fetal	O
calf	O
serum	O
(	O
Tissue	O
Culture	O
Services	O
,	O
Buckingham	O
,	O
UK	O
)	O
or	O
in	O
serum	O
-	O
free	O
AIM	O
V	O
®	O
medium	O
(	O
Gibco	O
)	O
which	O
contains	O
human	O
albumin	O
,	O
transferrin	O
and	O
insulin	O
.	O

The	O
PBMCx	O
were	O
then	O
counted	O
so	O
that	O
any	O
cell	O
losses	O
could	O
be	O
corrected	O
.	O

We	O
also	O
tested	O
B	O
cell	O
lines	O
,	O
including	O
the	O
homozygous	O
DR1	O
line	O
EHM	O
and	O
one	O
raised	O
from	O
the	O
patient	O
herself	O
;	O
they	O
were	O
pretreated	O
with	O
50	O
μg	O
/	O
ml	O
of	O
mitomycin	B
C	I
(	O
Sigma	O
)	O
and	O
washed	O
before	O
co	O
-	O
culture	O
with	O
the	O
T	O
cells	O
.	O

The	O
requirement	O
for	O
antigen	O
processing	O
was	O
determined	O
by	O
preincubating	O
the	O
presenting	O
cells	O
with	O
chloroquine	B
(	O
Sigma	O
)	O
for	O
30	O
min	O
before	O
pulsing	O
with	O
500	O
μg	O
/	O
ml	O
d	O
-pen	O
for	O
4	O
h	O
,	O
after	O
which	O
the	O
cells	O
were	O
washed	O
and	O
plated	O
routinely	O
.	O

To	O
confirm	O
their	O
subsequent	O
viability	O
,	O
we	O
checked	O
their	O
capacity	O
to	O
present	O
peptide	B
antigen	O
to	O
a	O
well	O
characterized	O
T	O
cell	O
clone	O
,	O
TB-2	O
,	O
that	O
recognizes	O
a	O
fragment	O
of	O
the	O
α	O
subunit	O
of	O
the	O
AChR	O
,	O
α:144–163	O
,	O
presented	O
by	O
DR52a	O
(	O
Nagvekar	O
et	O
al.	O
,	O
1998	O
)	O
.	O

3	O
Results	O
3.1	O
Initial	O
T	O
cell	O
responses	O
to	O
d	B
-pen	I
In	O
a	O
preliminary	O
screen	O
using	O
d	B
-pen	I
at	O
500	O
μg	O
/	O
ml	O
,	O
we	O
found	O
positive	O
responses	O
by	O
PBL	O
T	O
cells	O
(	O
SI>2	O
)	O
in	O
four	O
of	O
five	O
RA	O
patients	O
with	O
recent	O
onset	O
d	B
-pen	I
MG	O
(	O
SIs	O
3–12	O
)	O
;	O
in	O
one	O
of	O
four	O
RA	O
patients	O
without	O
MG	O
or	O
anti	O
-	O
AChR	O
antibodies	O
despite	O
d	B
-pen	I
treatment	O
(	O
SI	O
4.1	O
)	O
;	O
in	O
zero	O
of	O
three	O
patients	O
with	O
idiopathic	O
EOMG	O
and	O
in	O
4	O
of	O
11	O
healthy	O
controls	O
(	O
SI	O
2.3	O
,	O
4.5	O
,	O
4.8	O
and	O
15.0	O
)	O
.	O

All	O
of	O
the	O
d	B
-pen	I
MG	O
patients	O
had	O
HLA	O
-	O
DR1	O
,	O
as	O
did	O
the	O
one	O
other	O
responder	O
with	O
RA	O
.	O

However	O
,	O
none	O
of	O
the	O
healthy	O
responders	O
was	O
DR1	O
+	O
;	O
some	O
of	O
their	O
responses	O
might	O
conceivably	O
be	O
related	O
to	O
prior	O
exposure	O
to	O
penicillin	B
.	O

Only	O
one	O
of	O
the	O
responder	O
d	B
-pen	I
MG	O
patients	O
(	O
D	O
-	O
P1	O
;	O
SI	O
4.3	O
)	O
was	O
tested	O
before	O
taking	O
corticosteroids	B
;	O
as	O
she	O
was	O
readily	O
available	O
for	O
further	O
sampling	O
,	O
T	O
cell	O
lines	O
were	O
initiated	O
from	O
her	O
for	O
detailed	O
characterization	O
of	O
this	O
response	O
.	O

3.2	O
Selecting	O
d	B
-pen	I
-	O
responsive	O
T	O
cell	O
lines	O
and	O
clones	O
from	O
patient	O
D	O
-	O
P1	O
Several	O
T	O
cell	O
lines	O
were	O
successfully	O
raised	O
and	O
maintained	O
by	O
culturing	O
with	O
d	B
-pen	I
at	O
500	O
μg	O
/	O
ml	O
.	O

Three	O
findings	O
established	O
that	O
this	O
drug	B
was	O
not	O
merely	O
acting	O
as	O
a	O
non	O
-	O
specific	O
mitogen	O
.	O

Firstly	O
,	O
two	O
well	O
-	O
characterized	O
AChR	O
-	O
specific	O
T	O
cell	O
clones	O
,	O
TB-2	O
and	O
PM	O
-	O
A1	O
,	O
failed	O
to	O
show	O
any	O
proliferative	O
response	O
to	O
d	B
-pen	I
at	O
50–500	O
μg	O
/	O
ml	O
(	O
not	O
shown	O
)	O
.	O

Secondly	O
,	O
the	O
drug	B
-	O
specific	O
lines	O
also	O
responded	O
optimally	O
to	O
autologous	O
APC	O
preincubated	O
with	O
the	O
drug	O
for	O
4	O
h	O
and	O
then	O
washed	O
thoroughly	O
,	O
while	O
unpulsed	O
autologous	O
APC	O
failed	O
to	O
stimulate	O
.	O

Thirdly	O
,	O
there	O
was	O
no	O
response	O
when	O
the	O
APC	O
were	O
HLA	O
-	O
mismatched	O
(	O
see	O
below	O
)	O
.	O

3.3	O
Characteristics	O
of	O
d	B
-pen	I
-	O
specific	O
T	O
cell	O
clones	O
The	O
d	B
-pen	I
-	O
specific	O
line	O
that	O
showed	O
the	O
greatest	O
response	O
to	O
the	O
drug	B
was	O
cloned	O
by	O
limiting	O
dilution	O
in	O
the	O
presence	O
of	O
d	B
-pen	I
-	O
prepulsed	O
autologous	O
PBMCx	O
.	O

Among	O
the	O
175	O
clones	O
grown	O
,	O
40	O
%	O
(	O
70	O
)	O
responded	O
to	O
d	B
-pen	I
(	O
SI>5	O
)	O
,	O
showing	O
that	O
there	O
was	O
a	O
high	O
precursor	O
frequency	O
of	O
d	B
-pen	I
-	O
specific	O
T	O
cells	O
in	O
the	O
line	O
.	O

Some	O
10	O
clones	O
were	O
chosen	O
for	O
further	O
study	O
;	O
they	O
were	O
all	O
CD3	O
+	O
CD4	O
+	O
and	O
behaved	O
identically	O
in	O
all	O
experiments	O
,	O
responding	O
to	O
autologous	O
PBMCx	O
preincubated	O
with	O
d	B
-pen	I
in	O
a	O
dose	O
-	O
dependent	O
manner	O
(	O
Fig.	O
1	O
)	O
.	O

Moreover	O
,	O
the	O
clones	O
were	O
highly	O
specific	O
for	O
l	B
-pen	I
,	O
as	O
shown	O
by	O
their	O
failure	O
to	O
respond	O
to	O
the	O
analogues	O
d	B
-pen	I
and	O
d	B
-cysteine	I
(	O
Fig.	O
2	O
)	O
.	O

The	O
10	O
clones	O
tested	O
all	O
proved	O
to	O
be	O
restricted	O
to	O
HLA	O
-	O
DR1	O
.	O

An	O
isotype	O
-	O
specific	O
anti	O
-	O
HLA	O
-	O
DR	O
mAb	O
almost	O
completely	O
blocked	O
the	O
responses	O
of	O
these	O
clones	O
(	O
Fig.	O
3	O
a	O
)	O
;	O
furthermore	O
,	O
they	O
all	O
recognized	O
d	B
-pen	I
-	O
pulsed	O
PBMCx	O
from	O
a	O
number	O
of	O
healthy	O
DR1	O
+	O
individuals	O
(	O
Fig.	O
3	O
b	O
)	O
.	O

The	O
two	O
clones	O
tested	O
were	O
both	O
phenotypically	O
Th1	O
,	O
producing	O
large	O
amounts	O
of	O
IFN	O
-	O
γ	O
(	O
2	O
×	O
104	O
pg	O
/	O
ml	O
)	O
,	O
but	O
no	O
detectable	O
IL-4	O
(	O
not	O
shown	O
)	O
.	O

They	O
proved	O
to	O
have	O
identical	O
TCR	O
gene	O
usage	O
,	O
namely	O
Vα4.1	O
,	O
Jα1.3	O
,	O
Vβ6.1	O
,	O
Jβ2.3	O
,	O
suggesting	O
that	O
they	O
are	O
sister	O
clones	O
.	O

Intriguingly	O
,	O
this	O
β	O
chain	O
sequence	O
shares	O
a	O
PG	O
motif	O
in	O
the	O
CDR3	O
region	O
(	O
Fig.	O
4	O
)	O
with	O
a	O
previously	O
characterized	O
AChR	O
ε	O
-	O
specific	O
T	O
cell	O
clone	O
isolated	O
from	O
a	O
patient	O
with	O
EOMG	O
(	O
Hill	O
et	O
al.	O
,	O
1999	O
)	O
.	O

3.4	O
Potential	O
`	O
carrier	O
'	O
molecules	O
for	O
d	B
-pen	I
To	O
determine	O
whether	O
the	O
d	B
-pen	I
was	O
coupling	O
to	O
a	O
serum	O
protein	O
,	O
PBMCx	O
were	O
pulsed	O
with	O
d	B
-pen	I
in	O
the	O
presence	O
or	O
absence	O
of	O
serum	O
.	O

Regardless	O
of	O
whether	O
we	O
used	O
5	O
%	O
human	O
or	O
fetal	O
calf	O
serum	O
,	O
serum	O
-	O
free	O
AIM	O
V	O
®	O
medium	O
(	O
containing	O
human	O
albumin	O
,	O
transferrin	O
and	O
insulin	O
)	O
or	O
even	O
plain	O
RPMI	O
,	O
the	O
PBMCx	O
all	O
stimulated	O
the	O
two	O
T	O
cell	O
clones	O
tested	O
very	O
efficiently	O
(	O
Fig.	O
5	O
)	O
.	O

This	O
result	O
suggested	O
that	O
the	O
drug	B
was	O
coupling	O
to	O
pre	O
-	O
existing	O
cellular	O
proteins	O
,	O
whether	O
internal	O
or	O
on	O
the	O
surface	O
.	O

To	O
determine	O
whether	O
these	O
require	O
further	O
processing	O
,	O
we	O
tested	O
the	O
effects	O
of	O
chloroquine	B
,	O
a	O
potent	O
lysosomotropic	O
inhibitor	O
of	O
antigen	O
processing	O
(	O
Ziegler	O
and	O
Unanue	O
,	O
1982	O
)	O
.	O

As	O
a	O
standard	O
,	O
we	O
used	O
the	O
response	O
of	O
clone	O
TB-2	O
to	O
both	O
the	O
full	O
-	O
length	O
AChR	O
α	O
subunit	O
(	O
α:1–437	O
)	O
,	O
which	O
requires	O
processing	O
,	O
and	O
its	O
peptide	B
,	O
α:144–163	B
,	O
which	O
does	O
not	O
(	O
Fig.	O
6	O
)	O
.	O

Pretreatment	O
of	O
PBMCx	O
with	O
chloroquine	B
had	O
no	O
detectable	O
effect	O
on	O
the	O
responses	O
to	O
d	B
-pen	I
or	O
α:144–163	B
at	O
doses	O
that	O
almost	O
completely	O
abolished	O
those	O
to	O
the	O
full	O
-	O
length	O
α:1–437	O
(	O
Fig.	O
6	O
b	O
)	O
,	O
clearly	O
showing	O
that	O
the	O
key	O
molecules	O
modified	O
by	O
d	B
-pen	I
do	O
not	O
require	O
subsequent	O
processing	O
.	O

Thus	O
,	O
these	O
data	O
strongly	O
suggest	O
that	O
d	B
-pen	I
is	O
acting	O
by	O
directly	O
coupling	O
to	O
a	O
component	O
of	O
the	O
MHC	O
/	O
peptide	B
complex	O
.	O

It	O
was	O
therefore	O
intriguing	O
that	O
two	O
different	O
DR1	O
+	O
EBV	O
-	O
B	O
cell	O
lines	O
(	O
one	O
of	O
them	O
autologous	O
)	O
consistently	O
failed	O
to	O
`	O
present	O
'	O
d	B
-pen	I
to	O
the	O
clones	O
;	O
this	O
deficiency	O
was	O
not	O
corrected	O
by	O
pre	O
-	O
culturing	O
the	O
EBV	O
-	O
B	O
cells	O
in	O
human	O
serum	O
rather	O
than	O
the	O
FCS	O
in	O
which	O
these	O
cells	O
were	O
normally	O
maintained	O
(	O
Fig.	O
7	O
)	O
.	O

The	O
autologous	O
B	O
cell	O
line	O
,	O
which	O
also	O
has	O
HLA	O
-	O
DR52a	O
,	O
presented	O
specific	O
peptides	B
very	O
well	O
to	O
the	O
DR52a	O
-	O
restricted	O
clone	O
TB-2	O
when	O
tested	O
in	O
parallel	O
,	O
confirming	O
its	O
efficient	O
antigen	O
-	O
presenting	O
ability	O
.	O

Thus	O
,	O
these	O
results	O
suggest	O
that	O
these	O
T	O
cells	O
are	O
recognizing	O
a	O
modification	O
of	O
some	O
resident	O
peptide	B
,	O
rather	O
than	O
of	O
the	O
DR1	O
itself	O
,	O
and	O
that	O
this	O
peptide	B
differs	O
in	O
the	O
PBMC	O
and	O
the	O
B	O
cell	O
lines	O
.	O

4	O
Discussion	O
In	O
this	O
study	O
on	O
d	B
-pen	I
-	O
induced	O
MG	O
,	O
we	O
report	O
the	O
isolation	O
and	O
characterization	O
of	O
CD4	O
+	O
Th1	O
cell	O
clones	O
specific	O
for	O
d	B
-pen	I
,	O
which	O
recognized	O
DR1	O
+	O
APC	O
preincubated	O
with	O
the	O
drug	B
.	O

Our	O
evidence	O
suggests	O
that	O
it	O
is	O
acting	O
by	O
directly	O
modifying	O
pre	O
-	O
existing	O
MHC	O
molecules	O
and/or	O
resident	O
peptides	B
on	O
the	O
APC	O
surface	O
,	O
though	O
the	O
nature	O
of	O
this	O
modification	O
still	O
requires	O
elucidation	O
.	O

Responses	O
of	O
these	O
T	O
cells	O
became	O
significant	O
at	O
approximately	O
50	O
μg	O
/	O
ml	O
of	O
d	B
-pen	I
,	O
and	O
optimal	O
at	O
500	O
μg	O
/	O
ml	O
;	O
the	O
latter	O
is	O
very	O
similar	O
to	O
that	O
previously	O
used	O
in	O
vitro	O
for	O
d	B
-pen	I
-	O
specific	O
T	O
cells	O
isolated	O
from	O
experimental	O
animals	O
immunized	O
with	O
the	O
drug	B
(	O
O'Donnell	O
and	O
Coleman	O
,	O
1992	O
)	O
.	O

It	O
apparently	O
contrasts	O
with	O
the	O
peak	O
levels	O
of	O
about	O
5	O
μg	O
/	O
ml	O
measured	O
in	O
the	O
peripheral	O
blood	O
of	O
patients	O
taking	O
750	O
mg	O
/	O
day	O
(	O
Brooks	O
et	O
al.	O
,	O
1984	O
)	O
.	O

However	O
,	O
much	O
higher	O
doses	O
are	O
usually	O
required	O
in	O
culture	O
than	O
in	O
vivo	O
,	O
as	O
has	O
been	O
observed	O
previously	O
with	O
other	O
drugs	B
such	O
as	O
sulfonamides	B
,	O
carbamazepine	B
and	O
phenytoin	B
(	O
Mauri	O
-	O
Hellweg	O
et	O
al.	O
,	O
1995	O
)	O
,	O
as	O
well	O
as	O
with	O
d	B
-pen	I
itself	O
(	O
O'Donnell	O
and	O
Coleman	O
,	O
1992	O
)	O
.	O

It	O
therefore	O
seems	O
likely	O
that	O
,	O
in	O
vivo	O
,	O
the	O
drug	B
becomes	O
concentrated	O
in	O
specialized	O
microenvironments	O
or	O
reactive	O
under	O
conditions	O
that	O
are	O
not	O
reproduced	O
in	O
culture	O
,	O
and/or	O
that	O
prolonged	O
exposure	O
is	O
required	O
.	O

It	O
is	O
well	O
recognized	O
that	O
d	B
-pen	I
can	O
couple	O
directly	O
to	O
proteins	O
,	O
forming	O
disulfide	B
bonds	O
with	O
free	O
cysteine	B
residues	O
(	O
Coleman	O
et	O
al.	O
,	O
1988	O
):	O
it	O
can	O
also	O
break	O
pre	O
-	O
existing	O
disulfide	B
bonds	O
,	O
and	O
so	O
unfold	O
proteins	O
or	O
disaggregate	O
complexes	O
.	O

Several	O
published	O
reports	O
demonstrate	O
that	O
it	O
couples	O
directly	O
to	O
the	O
surface	O
of	O
presenting	O
cells	O
of	O
experimental	O
animals	O
in	O
vivo	O
,	O
though	O
the	O
identity	O
of	O
the	O
target	O
protein	O
(	O
s	O
)	O
has	O
not	O
been	O
determined	O
.	O

At	O
doses	O
of	O
125–1000	O
μg	O
/	O
ml	O
,	O
d	B
-pen	I
rapidly	O
couples	O
directly	O
to	O
the	O
surface	O
of	O
rat	O
macrophages	O
,	O
a	O
process	O
that	O
is	O
not	O
affected	O
by	O
cell	O
fixation	O
or	O
chloroquine	B
,	O
but	O
is	O
enhanced	O
by	O
oxidizing	O
agents	O
(	O
O'Donnell	O
et	O
al.	O
,	O
1991	O
)	O
.	O

These	O
cells	O
take	O
up	O
the	O
labeled	B
drug	I
in	O
a	O
dose-	O
and	O
time	O
-	O
dependent	O
manner	O
and	O
retain	O
it	O
for	O
over	O
24	O
h.	O
In	O
contrast	O
,	O
although	O
lymphocytes	O
rapidly	O
acquire	O
labeled	O
d	B
-pen	I
,	O
they	O
also	O
lose	O
it	O
completely	O
within	O
2	O
h	O
(	O
Binderup	O
and	O
Arrigoni	O
-	O
Martelli	O
,	O
1979	O
)	O
.	O

Our	O
present	O
results	O
also	O
suggest	O
that	O
d	B
-pen	I
is	O
acting	O
by	O
coupling	O
directly	O
to	O
the	O
APC	O
,	O
and	O
it	O
seems	O
logical	O
to	O
suppose	O
that	O
its	O
target	O
is	O
the	O
class	O
II	O
/	O
peptide	B
complex	O
.	O

Since	O
there	O
is	O
a	O
well	O
-	O
known	O
association	O
with	O
HLA	O
-	O
DR1	O
in	O
d	B
-pen	I
-	O
induced	O
MG	O
(	O
Garlepp	O
et	O
al.	O
,	O
1983	O
)	O
,	O
the	O
uniform	O
restriction	O
of	O
our	O
clones	O
to	O
this	O
allele	O
argues	O
strongly	O
for	O
their	O
disease	O
-	O
relevance	O
.	O

This	O
would	O
be	O
further	O
supported	O
if	O
the	O
same	O
modification	O
were	O
already	O
present	O
in	O
vivo	O
on	O
the	O
APC	O
of	O
DR1	O
+	O
MG	O
patients	O
taking	O
d	B
-pen	I
,	O
and	O
recognizable	O
by	O
the	O
D	O
-	O
P1	O
T	O
cells	O
.	O

We	O
were	O
unable	O
to	O
test	O
this	O
possibility	O
because	O
our	O
patient	O
had	O
stopped	O
the	O
treatment	O
before	O
enrolment	O
in	O
the	O
study	O
.	O

Several	O
other	O
drugs	B
/	O
haptens	B
are	O
known	O
to	O
couple	O
either	O
to	O
peptides	B
resident	O
in	O
the	O
MHC	O
groove	O
or	O
directly	O
to	O
MHC	O
molecules	O
.	O

Examples	O
of	O
the	O
former	O
include	O
trinitrophenyl	B
(	O
TNP	B
)	O
and	O
penicillin	B
which	O
both	O
couple	O
to	O
lysine	B
residues	O
(	O
Martin	O
et	O
al.	O
,	O
1992	O
;	O
Padovan	O
et	O
al.	O
,	O
1997	O
)	O
,	O
and	O
nickel	B
which	O
couples	O
to	O
histidines	B
(	O
Romagnoli	O
et	O
al.	O
,	O
1992	O
)	O
,	O
while	O
gold	B
salts	I
are	O
thought	O
to	O
directly	O
modify	O
the	O
class	O
II	O
molecule	O
(	O
Sinigaglia	O
,	O
1994	O
)	O
.	O

Although	O
further	O
work	O
is	O
required	O
to	O
determine	O
which	O
of	O
these	O
two	O
possibilities	O
applies	O
to	O
d	B
-pen	I
,	O
it	O
is	O
worthy	O
of	O
note	O
that	O
HLA	O
-	O
DR1	O
is	O
the	O
only	O
human	O
DR	O
molecule	O
that	O
has	O
an	O
unpaired	O
cysteine	B
residue	O
.	O

It	O
is	O
at	O
position	O
30	O
in	O
the	O
floor	O
of	O
the	O
peptide	B
-	O
binding	O
groove	O
(	O
Stern	O
et	O
al.	O
,	O
1994	O
)	O
,	O
where	O
modification	O
of	O
analogous	B
amino	I
acids	I
in	O
other	O
HLA	O
alleles	O
can	O
dramatically	O
alter	O
T	O
cell	O
recognition	O
of	O
the	O
epitope	O
peptides	B
(	O
Krieger	O
et	O
al.	O
,	O
1991	O
;	O
Boehncke	O
et	O
al.	O
,	O
1993	O
)	O
.	O

Work	O
on	O
the	O
class	O
I	O
allele	O
HLA	O
-	O
B27	O
also	O
suggests	O
that	O
oxidative	O
modification	O
of	O
the	O
unusual	O
free	O
sulfhydryl	B
group	I
(	O
67	O
Cys	B
)	O
on	O
this	O
HLA	O
molecule	O
can	O
directly	O
influence	O
its	O
immunogenicity	O
(	O
Archer	O
et	O
al.	O
,	O
1990	O
)	O
.	O

The	O
failure	O
of	O
the	O
d	B
-pen	I
-	O
treated	O
B	O
cell	O
lines	O
to	O
stimulate	O
our	O
clones	O
is	O
intriguing	O
and	O
argues	O
that	O
the	O
drug	B
was	O
modifying	O
distinctive	O
resident	O
peptides	B
in	O
the	O
autologous	O
PBMC	O
that	O
are	O
not	O
identical	O
in	O
the	O
B	O
cell	O
lines	O
.	O

It	O
would	O
therefore	O
be	O
interesting	O
to	O
identify	O
the	O
key	O
cell	O
type	O
in	O
the	O
PBMC	O
(	O
e.g.	O
,	O
macrophage	O
or	O
dendritic	O
cell	O
)	O
.	O

One	O
might	O
then	O
,	O
in	O
principle	O
,	O
take	O
advantage	O
of	O
this	O
failure	O
by	O
comparing	O
the	O
peptides	B
that	O
react	O
with	O
labeled	O
d	B
-pen	I
in	O
these	O
cells	O
and	O
in	O
the	O
B	O
cell	O
lines	O
,	O
though	O
they	O
may	O
be	O
too	O
heterogeneous	O
to	O
allow	O
precise	O
identification	O
of	O
the	O
key	O
epitope	O
(	O
s	O
)	O
.	O

Remarkably	O
,	O
however	O
,	O
one	O
resident	O
AChR	O
peptide	B
has	O
already	O
been	O
identified	O
in	O
a	O
DR3	O
+	O
B	O
cell	O
line	O
(	O
Chicz	O
et	O
al.	O
,	O
1993	O
)	O
.	O

The	O
d	B
-pen	I
-	O
specific	O
clones	O
characterized	O
here	O
could	O
provide	O
important	O
clues	O
to	O
the	O
pathogenesis	O
of	O
both	O
drug	B
-	O
induced	O
and	O
idiopathic	O
MG	O
.	O

The	O
first	O
obvious	O
mechanism	O
is	O
that	O
d	B
-pen	I
-	B
modified	I
peptides	I
activate	O
T	O
cells	O
that	O
can	O
cross	O
-	O
react	O
with	O
epitopes	O
derived	O
from	O
the	O
AChR	O
,	O
though	O
it	O
is	O
hard	O
to	O
envisage	O
the	O
exact	O
nature	O
of	O
such	O
cross	O
-	O
reactions	O
,	O
and	O
,	O
as	O
yet	O
,	O
there	O
is	O
no	O
direct	O
evidence	O
for	O
them	O
.	O

In	O
fact	O
,	O
the	O
clone	O
we	O
tested	O
showed	O
no	O
detectable	O
recognition	O
of	O
either	O
AChR	O
or	O
its	O
α	O
,	O
γ	O
or	O
ε	O
subunits	O
after	O
these	O
were	O
pre	O
-	O
incubated	O
with	O
d	O
-pen	O
(	O
not	O
shown	O
)	O
,	O
though	O
some	O
of	O
the	O
69	O
other	O
clones	O
may	O
be	O
sufficiently	O
sensitive	O
to	O
do	O
so	O
.	O

We	O
also	O
tested	O
five	O
patients	O
with	O
d	B
-pen	I
-	O
induced	O
MG	O
for	O
recognition	O
of	O
the	O
untreated	O
AChR	O
α	O
-	O
subunit	O
(	O
present	O
in	O
all	O
isoforms	O
)	O
,	O
the	O
fetal	O
-	O
specific	O
γ	O
and	O
the	O
adult	O
-	O
specific	O
ε	O
.	O

Interestingly	O
,	O
in	O
four	O
of	O
these	O
five	O
cases	O
,	O
we	O
saw	O
responses	O
to	O
the	O
ε	O
rather	O
than	O
the	O
other	O
subunits	O
(	O
not	O
shown	O
)	O
.	O

Since	O
the	O
present	O
case	O
(	O
D	O
-	O
P1	O
)	O
again	O
appeared	O
to	O
be	O
representative	O
,	O
we	O
went	O
on	O
to	O
isolate	O
clones	O
that	O
proved	O
to	O
be	O
specific	O
for	O
the	O
ε:201–219	O
sequence	O
(	O
Hill	O
et	O
al.	O
,	O
1999	O
)	O
.	O

This	O
also	O
appears	O
to	O
be	O
a	O
dominant	O
epitope	O
for	O
EOMG	O
patients	O
and	O
is	O
presented	O
by	O
the	O
candidate	O
susceptibility	O
allele	O
,	O
DR52a	O
(	O
Hill	O
et	O
al.	O
,	O
1999	O
)	O
.	O

Thus	O
,	O
one	O
might	O
hypothesize	O
that	O
AChR	O
-	O
cross	O
-	O
reactive	O
T	O
cells	O
initially	O
activated	O
by	O
d	B
-pen	I
lead	O
,	O
by	O
a	O
process	O
of	O
determinant	O
spreading	O
,	O
to	O
responsiveness	O
to	O
the	O
ε	O
subunit	O
that	O
then	O
induces	O
a	O
pathogenic	O
autoantibody	O
response	O
,	O
as	O
in	O
idiopathic	O
MG	O
.	O

These	O
T	O
cells	O
would	O
be	O
well	O
equipped	O
to	O
help	O
in	O
the	O
generation	O
of	O
complement	O
-	O
fixing	O
antibodies	O
by	O
virtue	O
of	O
their	O
Th1	O
cytokine	O
profile	O
.	O

However	O
,	O
whereas	O
this	O
response	O
appears	O
to	O
be	O
self	O
-	O
perpetuating	O
in	O
EOMG	O
,	O
the	O
antibody	O
titers	O
usually	O
fall	O
upon	O
withdrawal	O
of	O
d	B
-pen	I
,	O
with	O
concomitant	O
remission	O
of	O
symptoms	O
.	O

A	O
second	O
possibility	O
is	O
that	O
d	B
-pen	I
directly	O
`	O
haptenates	O
'	O
AChR	O
and/or	O
AChR	O
fragments	O
that	O
then	O
activate	O
pathogenic	O
T	O
cells	O
.	O

Hence	O
,	O
it	O
is	O
interesting	O
that	O
the	O
above	O
ε:201–219	O
sequence	O
includes	O
an	O
unpaired	O
210	O
Cys	B
at	O
p6	O
in	O
the	O
epitope	O
core	O
(	O
Beeson	O
et	O
al.	O
,	O
1993	O
)	O
.	O

This	O
residue	O
appears	O
to	O
be	O
important	O
for	O
T	O
cell	O
recognition	O
,	O
since	O
pre	O
-	O
exposure	O
to	O
d	B
-pen	I
prevented	O
this	O
peptide	B
from	O
stimulating	O
another	O
ε201–219-specific	O
clone	O
from	O
an	O
EOMG	O
patient	O
(	O
unpublished	O
observations	O
)	O
.	O

Hence	O
,	O
this	O
sequence	O
itself	O
may	O
be	O
an	O
alternative	O
target	O
for	O
d	B
-pen	I
modification	O
.	O

In	O
either	O
case	O
,	O
it	O
is	O
a	O
particularly	O
intriguing	O
possibility	O
that	O
d	O
-pen	O
is	O
mimicking	O
the	O
action	O
of	O
an	O
as	O
yet	O
unidentified	O
natural	O
`	O
counterpart	O
'	O
that	O
is	O
responsible	O
for	O
initiating	O
the	O
idiopathic	O
disease	O
.	O

An	O
analogous	O
process	O
has	O
been	O
implicated	O
in	O
other	O
conditions	O
presenting	O
with	O
autoimmune	O
features	O
such	O
as	O
the	O
plant	O
amino	B
acid	I
,	O
canavanine	B
,	O
in	O
SLE	O
,	O
and	O
an	O
analogue	B
of	I
l	I
-tryptophan	I
,	O
1,1′-ethylidenebis	B
[	I
l	I
-tryptophan	I
]	O
that	O
is	O
thought	O
to	O
induce	O
Eosinophilia	O
–	O
Myalgia	O
syndrome	O
(	O
Yoshida	O
and	O
Gershwin	O
,	O
1993	O
)	O
.	O

Although	O
definitive	O
proof	O
that	O
these	O
agents	B
are	O
responsible	O
for	O
causing	O
disease	O
is	O
awaited	O
,	O
the	O
latter	O
compound	O
has	O
been	O
shown	O
to	O
be	O
incorporated	O
into	O
self	O
-	O
proteins	O
,	O
apparently	O
creating	O
novel	O
epitopes	O
(	O
Buss	O
et	O
al.	O
,	O
1996	O
)	O
.	O

Anti	O
-	O
hapten	O
responses	O
have	O
also	O
been	O
implicated	O
in	O
active	O
ankylosing	O
spondylitis	O
by	O
the	O
isolation	O
of	O
HLA	O
-	O
B27-restricted	O
cytotoxic	O
T	O
cells	O
that	O
recognize	O
both	O
APC	O
treated	O
with	O
the	O
compound	O
homocysteine	B
and	O
B	O
cells	O
infected	O
with	O
Salmonella	O
typhimurium	O
(	O
Gao	O
et	O
al.	O
,	O
1996	O
)	O
.	O

In	O
summary	O
,	O
the	O
isolation	O
and	O
characterization	O
of	O
these	O
d	B
-pen	I
-	O
specific	O
T	O
cell	O
clones	O
should	O
provide	O
a	O
useful	O
experimental	O
system	O
with	O
which	O
to	O
elucidate	O
the	O
basis	O
of	O
hapten	B
recognition	O
by	O
human	O
T	O
cells	O
,	O
and	O
perhaps	O
also	O
the	O
mechanisms	O
of	O
drug	B
-	O
induced	O
autoimmune	O
disease	O
.	O

Ultimately	O
it	O
may	O
also	O
provide	O
insights	O
into	O
the	O
factors	O
involved	O
in	O
the	O
initiation	O
of	O
idiopathic	O
MG	O
.	O

Acknowledgements	O

We	O
are	O
very	O
grateful	O
to	O
several	O
colleagues	O
for	O
referring	O
patients	O
or	O
providing	O
mAbs	O
,	O
to	O
donor	O
D	O
-	O
P1	O
and	O
to	O
Drs	O
.	O

E.	O
Sim	O
,	O
J.	O
Coleman	O
and	O
A.	O
Vincent	O
for	O
invaluable	O
suggestions	O
and	O
advice	O
.	O

MEH	O
was	O
supported	O
by	O
the	O
Medical	O
Research	O
Council	O
of	O
Great	O
Britain	O
.	O

Human	O
fascioliasis	O
,	O
caused	O
by	O
Fasciola	O
hepatica	O
,	O
is	O
a	O
great	O
worldwide	O
health	O
problem	O
(	O
CHEN	O
&	O
MOTT	O
,	O
1990	O
;	O
ESTEBAN	O
et	O
al.	O
,	O
1998e	O
)	O
.	O

Several	O
areas	O
have	O
been	O
de-	O
scribed	O
as	O
presenting	O
true	O
human	O
endemics	O
,	O
ranging	O
from	O
low	O
to	O
very	O
high	O
prevalences	O
and	O
intensities	O
(	O
MAS	O
-	O
COMA	O
al.	O
,	O
1999a	O
)	O
.	O

Studies	O
carried	O
out	O
in	O
recent	O
years	O
have	O
demonstrated	O
that	O
the	O
most	O
important	O
human	O
fascioliasis	O
endemic	O
regions	O
are	O
located	O
in	O
South	O
America	O
(	O
MAS	O
-	O
COMAetfl	O
/	O
.	O
,	O
1995	O
,	O
1999a	O
;	O
WHO	O
,	O
1995;HlLLYER	O
&	O
APT	O
,	O
1997	O
;	O
ESTEBAN	O
et	O
al.	O
,	O
1998e	O
)	O
.	O

Coprological	O
(	O
MAS	O
-	O
COMA	O
al.	O
,	O
1995	O
;	O
ESTEBAN	O
al.	O
,	O
1997a	O
,	O
1997b	O
)	O
and	O
immunological	O
surveys	O
(	O
HILLYER	O
et	O
al.	O
,	O
1992	O
;	O
BJORLAND	O
et	O
al.	O
,	O
1995	O
;	O
MAS	O
-	O
COMA	O
et	O
al.	O
,	O
1995	O
;	O
O'NEILL	O
et	O
al.	O
,	O
1998	O
)	O
,	O
concerning	O
either	O
a	O
given	O
locality	O
or	O
only	O
a	O
very	O
few	O
,	O
have	O
shown	O
that	O
the	O
Northern	O
Bolivian	O
Altiplano	O
,	O
between	O
Lake	O
Titicaca	O
and	O
the	O
valley	O
of	O
the	O
city	O
of	O
La	O
Paz	O
,	O
presents	O
high	O
human	O
prevalences	O
and	O
intensities	O
.	O

Concerning	O
the	O
intermediate	O
snail	O
host	O
involved	O
,	O
despite	O
initial	O
reports	O
of	O
2	O
different	O
lymnaeid	O
transmit-	O
ting	O
species	O
(	O
Lymnaea	O
matrix	O
and	O
L.	O
cubensis	O
)	O
in	O
the	O
Bolivian	O
Altiplano	O
(	O
UENO	O
et	O
al.	O
,	O
1975	O
)	O
,	O
it	O
has	O
been	O
recently	O
demonstrated	O
that	O
only	O
1	O
transmitting	O
species	O
is	O
there	O
.	O

Shell	O
morphology	O
and	O
visceral	O
mass	O
anatomy	O
(	O
OVIEDO	O
et	O
al.	O
,	O
1995	O
)	O
,	O
and	O
molecular	O
(	O
BARGUES	O
&	O
MAS-	O
COMA	O
,	O
1997	O
;	O
BARGUES	O
et	O
al.	O
,	O
1997	O
)	O
and	O
isoenzyme	O
(	O
JABBOUR	O
-	O
ZAHAB	O
et	O
al.	O
,	O
1997	O
)	O
studies	O
have	O
proved	O
that	O
this	O
species	O
is	O
the	O
European	O
L.	O
truncatula	O
,	O
most	O
probably	O
introduced	O
by	O
Spanish	O
colonizers	O
long	O
ago	O
.	O

Investigations	O
carried	O
out	O
in	O
the	O
Northern	O
Bolivian	O
Altiplano	O
have	O
shown	O
that	O
there	O
are	O
different	O
animal	O
species	O
which	O
play	O
the	O
role	O
of	O
reservoirs	O
and	O
others	O
that	O
are	O
potential	O
definitive	O
hosts	O
(	O
UENO	O
&	O
MORALES	O
,	O
1973	O
;	O
UENO	O
et	O
al.	O
,	O
1975	O
;	O
MAS	O
-	O
COMA	O
et	O
al.	O
,	O
1995	O
,	O
1997	O
;	O
HILLYER	O
et	O
al.	O
,	O
1996	O
;	O
BUCHON	O
et	O
al.	O
,	O
1997	O
;	O
FUENTES	O
et	O
al.	O
,	O
1997	O
;	O
GROCK	O
et	O
al.	O
,	O
1998	O
)	O
.	O

Sheep	O
may	O
be	O
consid-	O
ered	O
the	O
most	O
important	O
reservoir	O
(	O
GROCK	O
et	O
al.	O
,	O
1998	O
)	O
,	O
followed	O
by	O
cattle	O
(	O
BUCHON	O
et	O
al.	O
,	O
1997	O
)	O
.	O

Pigs	O
and	O
donkeys	O
represent	O
effective	O
secondary	O
reservoir	O
hosts	O
of	O
the	O
parasite	O
in	O
this	O
area	O
and	O
must	O
also	O
be	O
taken	O
into	O
account	O
within	O
preventive	O
and	O
control	O
measures	O
(	O
MAS-	O
Address	O
for	O
correspondence	O
:	O
Professor	O
Dr	O
Jose	O
-	O
Guillermo	O
Esteban	O
,	O
Department	O
of	O
Parasitology	O
,	O
Faculty	O
of	O
Pharmacy	O
,	O
University	O
of	O
Valencia	O
,	O
Av	O
.	O

Vicente	O
Andres	O
Estelies	O
s	O
/	O
n	O
,	O
46100	O
Burjassot	O
-	O
Valencia	O
,	O
Spain	O
;	O
phone	O
+	O
34	O
96	O
3864298	O
,	O
fax	O
+	O
34	O
96	O
3864769	O
,	O
e	O
-	O
mail	O
jguillermo	O
.	O

esteban@uv.es	O
COMA	O
al.	O
,	O
1997	O
)	O
.	O

Horses	O
,	O
goats	O
,	O
llamas	O
and	O
alpacas	O
,	O
as	O
well	O
as	O
rabbits	O
,	O
hares	O
and	O
rodents	O
,	O
do	O
not	O
participate	O
in	O
the	O
transmission	O
(	O
FUENTES	O
et	O
al.	O
,	O
1997	O
;	O
MAS	O
-	O
COMA	O
et	O
al.	O
,	O
1997	O
)	O
.	O

The	O
aim	O
of	O
this	O
paper	O
is	O
to	O
present	O
and	O
analyse	O
the	O
results	O
obtained	O
in	O
31	O
coprological	O
surveys	O
including	O
different	O
Altiplanic	O
localities	O
.	O

The	O
purpose	O
is	O
to	O
obtain	O
a	O
general	O
overview	O
of	O
human	O
infection	O
prevalences	O
and	O
intensities	O
throughout	O
the	O
endemic	O
zone	O
.	O

This	O
is	O
the	O
first	O
time	O
that	O
such	O
a	O
large	O
epidemiological	O
study	O
of	O
a	O
human	O
fascioliasis	O
area	O
has	O
been	O
carried	O
out	O
.	O

Materials	O
and	O
Methods	O
This	O
study	O
was	O
conducted	O
in	O
the	O
Department	O
of	O
La	O
Paz	O
,	O
Bolivia	O
,	O
and	O
more	O
specifically	O
in	O
a	O
region	O
of	O
the	O
Northern	O
Bolivian	O
Altiplano	O
,	O
between	O
Lake	O
Titicaca	O
and	O
the	O
valley	O
of	O
the	O
city	O
of	O
La	O
Paz	O
,	O
at	O
a	O
very	O
high	O
altitude	O
(	O
3800	O
-	O
4200	O
m	O
)	O
(	O
Figure	O
)	O
.	O

The	O
surface	O
area	O
and	O
human	O
population	O
characteristics	O
of	O
this	O
zone	O
have	O
already	O
been	O
summarized	O
m	O
a	O
balantidiasis	O
study	O
concerning	O
the	O
same	O
area	O
(	O
ESTEBAN	O
etal	O
.	O
,	O
1998b	O
)	O
.	O

A	O
total	O
of	O
31	O
coprological	O
surveys	O
were	O
carried	O
out	O
in	O
24	O
localities	O
over	O
the	O
6-year	O
period	O
1992	O
-	O
97	O
(	O
Table	O
1	O
)	O
.	O

These	O
surveys	O
involved	O
2723	O
Aymara	O
subjects	O
(	O
1483	O
males	O
,	O
1240	O
females	O
)	O
aged	O
1	O
-	O
100	O
years	O
(	O
mean	O
SD	O
,	O
10	O
-	O
9	O
7	O
-	O
5	O
years	O
)	O
,	O
among	O
whom	O
were	O
2521	O
students	O
(	O
1350	O
boys	O
,	O
1171	O
girls	O
)	O
aged	O
5	O
to	O
19	O
years	O
(	O
9	O
-	O
6	O
-7	O
years	O
)	O
from	O
the	O
schools	O
of	O
these	O
24	O
localities	O
.	O

These	O
surveys	O
were	O
carried	O
out	O
so	O
that	O
the	O
sample	O
size	O
in	O
each	O
school	O
was	O
representative	O
of	O
both	O
the	O
student	O
enrolment	O
in	O
the	O
school	O
(	O
at	O
least	O
50	O
%	O
)	O
and	O
the	O
number	O
of	O
children	O
present	O
on	O
the	O
day	O
of	O
the	O
survey	O
(	O
at	O
least	O
75	O
%	O
)	O
.	O

In	O
Chijipata	O
Alto	O
and	O
Huacullani	O
,	O
where	O
high	O
prevalences	O
in	O
the	O
schools	O
were	O
detected	O
,	O
surveys	O
were	O
extended	O
to	O
total	O
inhabitants	O
and	O
involved	O
202	O
subjects	O
(	O
133	O
males	O
,	O
69	O
females	O
)	O
aged	O
1	O
to	O
100	O
years	O
(	O
26	O
-	O
7	O
0	O
-	O
1	O
years	O
)	O
.	O

Surveys	O
were	O
performed	O
so	O
that	O
the	O
sample	O
size	O
was	O
always	O
at	O
least	O
20	O
%	O
of	O
the	O
subject	O
number	O
of	O
each	O
locality	O
.	O

None	O
of	O
the	O
children	O
that	O
participated	O
in	O
these	O
community	O
surveys	O
was	O
included	O
in	O
the	O
school	O
surveys	O
of	O
the	O
same	O
localities	O
.	O

All	O
the	O
surveys	O
were	O
made	O
on	O
randomly	O
selected	O
persons	O
on	O
a	O
given	O
day	O
among	O
all	O
participating	O
subjects	O
.	O

One	O
stool	O
sample	O
per	O
subject	O
was	O
collected	O
from	O
all	O
participating	O
individuals	O
and	O
personal	O
data	O
(	O
name	O
,	O
sex	O
,	O
and	O
age	O
)	O
were	O
noted	O
.	O

The	O
relatively	O
low	O
receptivity	O
of	O
Aymara	O
adults	O
,	O
related	O
to	O
their	O
ethnic	O
and	O
religious	O
characteristics	O
(	O
ESTEBAN	O
et	O
al.	O
,	O
1998b	O
)	O
,	O
made	O
it	O
impos-	O
sible	O
to	O
obtain	O
multiple	O
stool	O
specimens	O
collected	O
at	O
2-	O
or	O
132	O
JOSE	O
-	O
GUILLERMO	O
ESTEBAN	O
ETAL	O
.	O

Figure	O
.	O

Map	O
showing	O
the	O
location	O
of	O
the	O
24	O
localities	O
surveyed	O
m	O
the	O
Northern	O
Bolivian	O
Altiplano	O
.	O

Closed	O
circles	O
,	O
localities	O
with	O
fascioliasis	O
;	O
open	O
circles	O
,	O
localities	O
in	O
which	O
fascioliasis	O
was	O
not	O
detected	O
.	O

3-day	O
intervals	O
.	O

Each	O
stool	O
sample	O
was	O
examined	O
using	O
the	O
Kato	O
-	O
Katz	O
technique	O
(	O
KATZ	O
et	O
al.	O
,	O
1972	O
)	O
for	O
hel-	O
minth	O
eggs	O
and	O
,	O
if	O
possible	O
,	O
direct	O
and	O
concentration	O
MIF	O
(	O
SAPERO	O
&	O
LAWLESS	O
,	O
1953	O
;	O
BLAGG	O
et	O
al.	O
,	O
1955	O
)	O
,	O
formol	B
-	O
ether	B
concentration	O
(	O
KNIGHT	O
et	O
al.	O
,	O
1976	O
)	O
,	O
and	O
modified	O
Ziehl	O
-	O
Neelsen	O
(	O
HENRIKSEN	O
&	O
POHLENZ	O
,	O
1981	O
)	O
techniques	O
were	O
applied	O
in	O
order	O
to	O
cover	O
all	O
the	O
protozoan	O
spectrum	O
.	O

Statistical	O
analyses	O
were	O
done	O
using	O
SPSS	O
6.1	O
(	O
SPSS	O
Institute	O
,	O
Chicago	O
,	O
IL	O
,	O
USA	O
)	O
for	O
Windows	O
.	O

Statistical	O
comparison	O
of	O
categorical	O
variables	O
was	O
carried	O
out	O
with	O
X2	O
or	O
Fisher	O
's	O
exact	O
tests	O
.	O

Normally	O
distributed	O
data	O
were	O
analysed	O
using	O
Student	O
's	O
t	O
-	O
test	O
and	O
analysis	O
of	O
variance	O
(	O
ANOVA	O
)	O
.	O

Mann	O
-	O
Whitney	O
utest	O
and	O
Kruskal	O
-	O
Wallis	O
test	O
(	O
Jf	O
)	O
were	O
used	O
for	O
non	O
-	O
normally	O
distributed	O
data	O
.	O

Prevalences	O
and	O
intensities	O
m	O
the	O
same	O
schoolchildren	O
studied	O
in	O
different	O
years	O
were	O
compared	O
with	O
McNemar	O
and	O
Wilcoxon	O
signed	O
-	O
rank	O
tests	O
,	O
respectively	O
.	O

Values	O
of	O
P	O
<	O
0	O
-	O
05	O
were	O
taken	O
as	O
significant	O
.	O

This	O
study	O
was	O
conducted	O
with	O
the	O
agreement	O
of	O
the	O
Secretaria	O
Nacional	O
de	O
Salud	O
del	O
Ministerio	O
de	O
Desar-	O
rollo	O
Humano	O
(	O
La	O
Paz	O
,	O
Bolivia	O
)	O
and	O
was	O
performed	O
in	O
collaboration	O
with	O
the	O
INLASA	O
Institute	O
in	O
La	O
Paz	O
.	O

All	O
investigations	O
were	O
made	O
with	O
the	O
consent	O
of	O
the	O
subjects	O
or	O
,	O
in	O
the	O
case	O
of	O
young	O
children	O
,	O
their	O
guardians	O
.	O

Results	O
Prevalences	O

The	O
total	O
prevalence	O
of	O
fascioliasis	O
in	O
the	O
2723	O
subjects	O
studied	O
was	O
15	O
-	O
4	O
%	O
.	O

The	O
maximum	O
prevalences	O
in	O
the	O
school	O
and	O
community	O
surveys	O
were	O
obtained	O
in	O
Chiji-	O
pata	O
Alto	O
(	O
68	O
-	O
2	O
%	O
and	O
65	O
-	O
4	O
%	O
,	O
respectively	O
in	O
1996	O
)	O
,	O
whereas	O
in	O
some	O
other	O
school	O
surveys	O
F.	O
hepatica	O
infec-	O
tion	O
was	O
not	O
even	O
detected	O
(	O
Table	O
1	O
)	O
.	O

Significant	O
differ-	O
ences	O
between	O
prevalence	O
rates	O
both	O
among	O
combined	O
school	O
surveys	O
and	O
among	O
combined	O
community	O
surveys	O
(	O
P	O
=	O
0	O
-	O
0001	O
by	O
Fisher	O
's	O
exact	O
test	O
,	O
and	O
x2=312	O
,	O
P	O
=	O
0	O
-	O
0001	O
,	O
respectively	O
)	O
were	O
detected	O
.	O

Comparison	O
analysis	O
of	O
prevalence	O
rates	O
detected	O
in	O
the	O
surveys	O
carried	O
out	O
in	O
the	O
same	O
school	O
(	O
i.e.	O
,	O
Acha-	O
cachi	O
,	O
Chijipata	O
Alto	O
and	O
Huacullani	O
)	O
or	O
in	O
the	O
same	O
community	O
(	O
i.e.	O
,	O
Huacullani	O
)	O
in	O
different	O
years	O
showed	O
no	O
statistical	O
differences	O
.	O

Moreover	O
,	O
no	O
statistical	O
differ-	O
ences	O
were	O
detected	O
between	O
prevalences	O
among	O
the	O
same	O
schoolchildren	O
analysed	O
in	O
different	O
years	O
.	O

Discrepancies	O
in	O
the	O
results	O
were	O
,	O
however	O
,	O
observed	O
when	O
comparing	O
the	O
total	O
prevalences	O
(	O
including	O
the	O
different	O
years	O
)	O
obtained	O
in	O
the	O
school	O
and	O
community	O
surveys	O
in	O
the	O
same	O
locality	O
:	O
in	O
Chijipata	O
Alto	O

no	O
signifi-	O
ca	O
nt	O
difference	O
was	O
observed	O
(	O
60	O
-	O
5	O
%	O
in	O
the	O
2	O
combined	O
school	O
surveys	O
vs.	O
65	O
-	O
4	O
%	O
in	O
the	O
community	O
)	O
,	O
whereas	O
in	O
Huacullani	O
(	O
33	O
-	O
8	O
%	O
for	O
the	O
3	O
combined	O
school	O
surveys	O
vs.	O
16	O
-	O
5	O
%	O
for	O
the	O
2	O
combined	O
community	O
surveys	O
)	O
a	O
signifi-	O
ca	O
nt	O
difference	O
was	O
detected	O
(	O
%	O
2	O
=	O
19	O
-	O
06	O
,	O
P	O
=	O
0	O
-	O
0001	O
)	O
.	O

Similar	O
results	O
were	O
obtained	O
when	O
comparing	O
the	O
pre-	O
valences	O
obtained	O
in	O
the	O
school	O
survey	O
and	O
the	O
commu-	O
nity	O
survey	O
in	O
the	O
same	O
locality	O
carried	O
out	O
in	O
the	O
same	O
year	O
1996	O
:	O
in	O
Chijipata	O
Alto	O
there	O
was	O
no	O
significant	O
difference	O
(	O
68	O
-	O
2	O
%	O
in	O
the	O
school	O
vs.	O
65	O
-	O
4	O
%	O
in	O
the	O
com-	O
munity	O
)	O
,	O
whereas	O
in	O
Huacullani	O
(	O
34	O
-	O
8	O
%	O
in	O
the	O
school	O
vs.	O
18	O
-	O
4	O
%	O
in	O
the	O
community	O
)	O
a	O
significant	O
difference	O
was	O
detected	O
(	O
/2	O
=	O
8	O
-	O
89	O
,	O
P	O
=	O
0	O
-	O
0029	O
)	O
.	O

The	O
distribution	O
of	O
prevalences	O
according	O
to	O
sex	O
and	O
age	O
-	O
groups	O
in	O
the	O
school	O
surveys	O
and	O
also	O
in	O
the	O
com-	O
munity	O
surveys	O
is	O
shown	O
in	O
Table	O
2	O
.	O

In	O
relation	O
to	O
sex	O
,	O
a	O
significant	O
difference	O
was	O
detected	O
neither	O
among	O
schools	O
,	O
nor	O
among	O
communities	O
,	O
and	O
a	O
similar	O
result	O
was	O
obtained	O
when	O
considering	O
the	O
total	O
of	O
the	O
subjects	O
studied	O
in	O
all	O
the	O
surveys	O
.	O

In	O
the	O
school	O
surveys	O
,	O
the	O
distribution	O
of	O
prevalences	O
according	O
to	O
age	O
-	O
groups	O
did	O
show	O
significant	O
differences	O
Cy2	O
=	O
19	O
-	O
00	O
,	O
P	O
=	O
0	O
-	O
0001	O
)	O
when	O
comparing	O
age	O
-	O
groups	O
established	O
according	O
to	O
school	O
criteria	O
:	O
age	O
5	O
-	O
8	O
years	O
,	O
basic	O
level	O
,	O
9	O
-	O
12	O
years	O
,	O
intermediate	O
;	O
13	O
-	O
19	O
years	O
,	O
medium	O
level	O
and	O
students	O
still	O
in	O
school	O
but	O
eligible	O
for	O
military	O
service	O
.	O

The	O
highest	O
prevalences	O
were	O
de-	O
Table	O
1	O
.	O

The	O
study	O
populations	O
of	O
the	O
schools	O
and	O
communities	O
surveyed	O
in	O
Bolivia	O
and	O
the	O
prevalences	O
and	O
intensities	O
from	O
faecal	O
egg	O
counts	O
off	O
.	O

hepatica	O
Locality	O
Survey	O
year	O
;	O
Male	O
mple	O
studie	O
<	O
Female	O
i	O
Total	O
Age	O
Range	O
(	O
years	O
)	O
Meai	O
tt	O
(	O
SD	O
)	O
Prevalence%	O
(	O
CI	O
)	O
1	O
'	O
Inl	O
Range	O
:	O
ensity	O
(	O
epg	O
)	O
'	O
AM	O
GM	O
Schools	O
Achacachi	O
(	O
I	O
)	O
3	O
1996	O
48	O
44	O
92	O
5	O
-	O
13	O
8	O
-	O
7	O
(	O
2	O
-	O
1	O
)	O
6	O
-	O
5	O
(	O
5	O
-	O
0	O
)	O
48	O
-	O
336	O
139	O
106	O
Achacachi	O
(	O
1	O
)	O
1997	O
42	O
45	O
87	O
6	O
-	O
13	O
9	O
-	O
1	O
(	O
1	O
-	O
7	O
)	O
1	O
-	O
1	O
(	O
2	O
-	O
2	O
)	O
240	O
-	O
-	O
Acbocalla	O
(	O
ll	O
)	O
1996	O
92	O
96	O
188	O
5	O
-	O
16	O
8	O
-	O
8	O
(	O
2	O
-	O
6	O
)	O
5	O
-	O
3	O
(	O
3	O
-	O
2	O
)	O
48	O
-	O
744	O
304	O
226	O
Ancocagua	O
(	O
9	O
)	O
1997	O
85	O
83	O
168	O
5	O
-	O
19	O
10	O
-	O
6	O
(	O
3	O
-	O
4	O
)	O
5	O
-	O
9	O
(	O
3	O
-	O
6	O
)	O
24	O
-	O
4512	O
1229	O
332	O
Aygachi	O
(	O
16	O
)	O
1994	O
68	O
37	O
105	O
5	O
-	O
17	O
11	O
-	O
1	O
(	O
2	O
-	O
8	O
)	O
17	O
-	O
1	O
(	O
7	O
-	O
2	O
)	O
24	O
-	O
1200	O
320	O
179	O
BelYayes	O
(	O
17	O
)	O
1994	O
26	O
17	O
43	O
5	O
-	O
12	O
8	O
-	O
5	O
(	O
1	O
-	O
9	O
)	O
7	O
-	O
0	O
(	O
7	O
-	O
6	O
)	O
72	O
-	O
144	O
112	O
108	O
Caleria	O
(	O
15	O
)	O
1993	O
29	O
22	O
51	O
6	O
-	O
14	O
9	O
-	O
1	O
(	O
2	O
-	O
3	O
)	O
5	O
-	O
9	O
(	O
6	O
-	O
5	O
)	O
24	O
-	O
48	O
40	O
38	O
Causaya	O
(	O
24	O
)	O
1995	O
22	O
37	O
59	O
5	O
-	O
18	O
10	O
-	O
6	O
(	O
2	O
-	O
8	O
)	O
ND'1	O
-	O
-	O
-	O
Chambi	O
Grande	O
(	O
23	O
)	O
1995	O
9	O
16	O
25	O
5	O
-	O
12	O
7.4	O
(	O
1	O
-	O
6	O
)	O
12	O
-	O
0	O
(	O
12	O
-	O
7	O
)	O
240	O
-	O
840	O
496	O
435	O
Chijipata	O
Alto	O
(	O
4	O
)	O
1996	O
11	O
11	O
22	O
5	O
-	O
10	O
7	O
-	O
5	O
(	O
1	O
-	O
3	O
)	O
68	O
-	O
2	O
(	O
19	O
-	O
5	O
)	O
24	O
-	O
3000	O
613	O
211	O
Chijipata	O
Alto	O
(	O
4	O
)	O
1997	O
29	O
25	O
54	O
5	O
-	O
15	O
8	O
-	O
7	O
(	O
2	O
-	O
4	O
)	O
57	O
-	O
4	O
(	O
13	O
-	O
2	O
)	O
24	O
-	O
2424	O
477	O
240	O
Cohana	O
(	O
18	O
)	O
1994	O
97	O
70	O
167	O
5	O
-	O
16	O
10	O
-	O
4	O
(	O
2	O
-	O
6	O
)	O
3	O
-	O
6	O
(	O
2	O
-	O
8	O
)	O
24	O
-	O
120	O
72	O
60	O
Corapata	O
(	O
10	O
)	O
1993	O
43	O
42	O
85	O
5	O
-	O
16	O
10	O
-	O
2	O
(	O
2	O
-	O
7	O
)	O
17	O
-	O
6	O
(	O
8	O
-	O
1	O
)	O
48	O
-	O
480	O
198	O
157	O
Cuyahuani	O
(	O
3	O
)	O
1996	O
57	O
54	O
111	O
5	O
-	O
16	O
10	O
-	O
7	O
(	O
2	O
-	O
8	O
)	O
6	O
-	O
3	O
(	O
4	O
-	O
5	O
)	O
72	O
-	O
600	O
300	O
206	O
Huacullani	O
(	O
21	O
)	O
1992	O
70	O
53	O
123	O
5	O
-	O
15	O
10	O
-	O
0	O
(	O
1	O
-	O
9	O
)	O
38	O
-	O
2	O
(	O
8	O
-	O
6	O
)	O
24	O
-	O
2160	O
283	O
134	O
Huacullani	O
(	O
21	O
)	O
1993	O
141	O
115	O
256	O
5	O
-	O
19	O
10	O
-	O
8	O
(	O
3	O
-	O
4	O
)	O
31	O
-	O
2	O
(	O
5	O
-	O
7	O
)	O
24	O
-	O
5064	O
705	O
323	O
Huacullani	O
(	O
21	O
)	O
1996	O
65	O
70	O
135	O
8	O
-	O
15	O
11	O
-	O
5	O
(	O
1	O
-	O
5	O
)	O
34	O
-	O
8	O
(	O
8	O
-	O
0	O
)	O
24	O
-	O
4368	O
347	O
168	O
Huatajata	O
(	O
2	O
)	O
1996	O
102	O
91	O
193	O
5	O
-	O
12	O
7	O
-	O
8	O
(	O
1	O
-	O
7	O
)	O
ND'1	O
-	O
-	O
-	O
Iquiaca	O
(	O
8)	O
1995	O
71	O
62	O
133	O
5	O
-	O
14	O
9.4	O
(	O
2	O
-	O
3	O
)	O
9	O
-	O
0	O
(	O
4	O
-	O
9	O
)	O
48	O
-	O
2448	O
415	O
147	O
Kajchiri	O
(	O
13	O
)	O
1994	O
10	O
11	O
21	O
5	O
-	O
10	O
8	O
-	O
0	O
(	O
1	O
-	O
7	O
)	O
9	O
-	O
5	O
(	O
12	O
-	O
6	O
)	O
168	O
168	O
168	O
Kharapata	O
(	O
5	O
)	O
1996	O
48	O
49	O
97	O
5	O
-	O
15	O
9	O
-	O
5	O
(	O
2	O
-	O
2	O
)	O
11	O
-	O
3	O
(	O
6	O
-	O
3	O
)	O
24	O
-	O
216	O
85	O
59	O
Lacaya	O
Baja	O
(	O
20	O
)	O
1997	O
39	O
32	O
71	O
5	O
-	O
12	O
8	O
-	O
1	O
(	O
2	O
-	O
0	O
)	O
28	O
-	O
2	O
(	O
10	O
-	O
5	O
)	O
24	O
-	O
1224	O
302	O
208	O
Oketiti	O
(	O
7	O
)	O
1995	O
9	O
11	O
20	O
5	O
-	O
9	O
6	O
-	O
6	O
(	O
1	O
-	O
1	O
)	O
10	O
-	O
0	O
(	O
13	O
-	O
1	O
)	O
288	O
-	O
-	O
Pantini	O
(	O
6	O
)	O
1995	O
19	O
14	O
33	O
5	O
-	O
13	O
8	O
-	O
9	O
(	O
1	O
-	O
6	O
)	O
30	O
-	O
3	O
(	O
15	O
-	O
7	O
)	O
24	O
-	O
648	O
230	O
139	O
Quiripujo	O
(	O
19	O
)	O
1993	O
25	O
18	O
43	O
5	O
-	O
12	O
7	O
-	O
7	O
(	O
2	O
-	O
0	O
)	O
20	O
-	O
9	O
(	O
12	O
-	O
1	O
)	O
24	O
-	O
240	O
102	O
78	O
Ticuyo	O
(	O
14	O
)	O
1995	O
29	O
3	O
32	O
6	O
-	O
12	O
9	O
-	O
4	O
(	O
1	O
-	O
8	O
)	O
Niy1	O
-	O
-	O
-	O
Tuni	O
(	O
12	O
)	O
1994	O
13	O
12	O
25	O
5	O
-	O
10	O
7	O
-	O
5	O
(	O
1	O
-	O
5	O
)	O
ND'1	O
-	O
-	O
-	O
Yanarico	O
(	O
22	O
)	O
1995	O
51	O
31	O
82	O
5	O
-	O
16	O
9	O
-	O
7	O
(	O
2	O
-	O
5	O
)	O
7	O
-	O
3	O
(	O
5	O
-	O
6	O
)	O
72	O
-	O
120	O
96	O
93	O
Total	O
1992	O
-	O
97	O
1350	O
1171	O
2521	O
5	O
-	O
19	O
9	O
-	O
6	O
(	O
2	O
-	O
7	O
)	O
14	O
-	O
8	O
(	O
1	O
-	O
4	O
)	O
24	O
-	O
5064	O
419	O
185	O
Communities	O
Chijipata	O
Alto	O
(	O
4	O
)	O
1996	O
17	O
9	O
26	O
6	O
-	O
75	O
25	O
-	O
8	O
(	O
20	O
-	O
8	O
)	O
65	O
-	O
4	O
(	O
18	O
-	O
3	O
)	O
48	O
-	O
4440	O
1345	O
678	O
Huacullani	O
(	O
21	O
)	O
1996	O
80	O
45	O
125	O
1	O
-	O
70	O
22	O
-	O
9	O
(	O
17	O
-	O
9	O
)	O
18	O
-	O
4	O
(	O
6	O
-	O
8	O
)	O
24	O
-	O
1608	O
253	O
140	O
Huacullani	O
(	O
21	O
)	O
1997	O
36	O
15	O
51	O
2	O
-	O
100	O
35	O
-	O
4	O
(	O
22	O
-	O
6	O
)	O
11	O
-	O
8	O
(	O
8	O
-	O
8	O
)	O
24	O
-	O
264	O
144	O
113	O
Total	O
1996	O
-	O
97	O
133	O
69	O
202	O
1	O
-	O
100	O
26	O
-	O
7	O
(	O
20	O
-	O
1	O
)	O
22	O
-	O
8	O
(	O
5	O
-	O
8	O
)	O
24	O
-	O
4440	O
660	O
250	O
Total	O
surveys	O
1992	O
-	O
97	O
1483	O
1240	O
2723	O
1	O
-	O
100	O
10	O
-	O
9	O
(	O
7	O
-	O
5	O
)	O
15	O
-	O
4	O
(	O
1	O
-	O
4	O
)	O
24	O
-	O
5064	O

446	O
191	O
'	O
Number	O
m	O
map	O
(	O
see	O
Figure	O
)	O
.	O

'	O
'	O
Confidence	O
interval	O
(	O
95	O
%	O
)	O
.	O

'	O
Eggs	O
per	O
gram	O
of	O
faeces	O
(	O
AM	O
,	O
arithmetic	O
mean	O
;	O
GM	O
,	O
geometric	O
mean	O
)	O
.	O

'	O
'	O
Not	O
detected	O
.	O

154	O
JOSE	O
-	O
GUILLERMO	O
ESTEBAN	O
ETAL	O
.	O

Table	O
2	O
.	O

Prevalences	O
and	O
intensities	O
of	O
fasciolia-	O
sis	O
,	O
by	O
sex	O
and	O
age	O
-	O
group	O
,	O
in	O
the	O
school	O
and	O
com-	O
munity	O
surveys	O
in	O
Bolivia	O
Prevalence	O
Intensity	O
(	O
epg	O
)	O
b	O
)	O
%	O
(	O
CI	O
)	O
3	O
Range	O
AM	O
GM	O
Schools	O
Sex	O
Boys	O
14	O
-	O
5	O
(	O
1	O
-	O
9	O
)	O
24	O
-	O
3408	O
323	O
159	O
Girls	O
15	O
-	O
2	O
(	O
2	O
-	O
1	O
)	O
24	O
-	O
5064	O
528	O
219	O
Age	O
-	O
group	O
(	O
years	O
)	O
5	O
-	O
8	O
10	O
-	O
8	O
(	O
2	O
-	O
0	O
)	O
24	O
-	O
4512	O
377	O
202	O
9	O
-	O
12	O
17	O
-	O
0	O
(	O
2	O
-	O
1	O
)	O
24	O
-	O
5064	O
446	O
191	O
13	O
-	O
19	O
17	O
-	O
9	O
(	O
3	O
-	O
8	O
)	O
24	O
-	O
4488	O
401	O
147	O
Communities	O
Sex	O
Males	O
20	O
-	O
3	O
(	O
6	O
-	O
8	O
)	O
24	O
-	O
4440	O
753	O
280	O
Females	O
27	O
-	O
5	O
(	O
10	O
-	O
5	O
)	O
48	O
-	O
3758	O
525	O
212	O
Age	O
-	O
group	O
(	O
years	O
)	O
1	O
-	O
10	O
29	O
-	O
3	O
(	O
11	O
-	O
7	O
)	O
24	O
-	O
4440	O
796	O
198	O
11	O
-	O
20	O
43	O
-	O
8	O
(	O
17	O
-	O
2	O
)	O
48	O
-	O
3768	O
825	O
410	O
21	O
-	O
40	O
13	O
-	O
8	O
(	O
8	O
-	O
4	O
)	O
72	O
-	O
864	O
373	O
263	O
>	O
40	O
13	O
-	O
3	O
(	O
9	O
-	O
9	O
)	O
24	O
-	O
1608	O
368	O
147	O
""""	O
Confidence	O
interval	O
(	O
95	O
%	O
)	O
.	O

'	O
'	O
Eggs	O
per	O
gram	O
of	O
faeces	O
(	O
AM	O
,	O
arithmetic	O
mean	O
;	O
GM	O
,	O
geometric	O
mean	O
)	O
.	O

tected	O
in	O
the	O
age	O
-	O
groups	O
9	O
-	O
12	O
years	O
(	O
17	O
-	O
0	O
%	O
)	O
and	O
13	O
-	O
19	O
years	O
(	O
17	O
-	O
9	O
%	O
)	O
(	O
Table	O
2	O
)	O
.	O

In	O
the	O
community	O
surveys	O
,	O
significant	O
differences	O
(	O
/2	O
=	O
14	O
-	O
5	O
,	O
P	O
=	O
0	O
-	O
0023	O
)	O
were	O
also	O
detected	O
,	O
with	O
highest	O
prevalences	O
in	O
the	O
age	O
-	O
groups	O
1	O
-	O
10	O
years	O
(	O
29	O
-	O
3	O
%	O
)	O
and	O
11	O
-	O
20	O
years	O
(	O
43	O
-	O
8	O
%	O
)	O
(	O
Table	O
2	O
)	O
.	O

Intensities	O
Intensity	O
of	O
infection	O
,	O
measured	O
as	O
epg	O
by	O
the	O
Kato-	O
Katz	O
technique	O
,	O
in	O
school	O
and	O
community	O
surveys	O
is	O
shown	O
in	O
Table	O
1	O
.	O

Absolute	O
egg	O
counts	O
in	O
the	O
total	O
individuals	O
surveyed	O
with	O
detectable	O
infection	O
ranged	O
from	O
24	O
to	O
5064	O
epg	O
,	O
with	O
arithmetic	O
and	O
geometric	O
means	O
of	O
446	O
and	O
191	O
epg	O
,	O
respectively	O
.	O

Significant	O
differences	O
were	O
detected	O
among	O
the	O
different	O
school	O
surveys	O
(	O
.H	O
=	O
51	O
-	O
82	O
,	O
P	O
=	O
0	O
-	O
0005	O
)	O
as	O
well	O
as	O
among	O
the	O
different	O
community	O
surveys	O
=	O
12	O
-	O
66	O
,	O
P	O
=	O
0	O
-	O
0018	O
)	O
.	O

Comparison	O
analysis	O
of	O
intensities	O
detected	O
in	O
school	O
surveys	O
carried	O
out	O
in	O
different	O
years	O
in	O
the	O
same	O
locality	O
did	O
not	O
show	O
statistical	O
differences	O
in	O
the	O
case	O
of	O
Chiji-	O
pata	O
Alto	O
,	O
but	O
it	O
did	O
in	O
that	O
of	O
Huacullani	O
(	O
F	O
=	O
4	O
-	O
80	O
,	O
P	O
=	O
0	O
-	O
009	O
)	O
.	O

In	O
the	O
latter	O
,	O
however	O
,	O
no	O
significant	O
differ-	O
ence	O
was	O
detected	O
between	O
the	O
results	O
obtained	O
in	O
the	O
2	O
community	O
surveys	O
.	O

No	O
significant	O
differences	O
were	O
detected	O
between	O
intensities	O
among	O
the	O
same	O
school-	O
children	O
analysed	O
in	O
different	O
years	O
.	O

When	O
comparing	O
the	O
intensity	O
values	O
obtained	O
in	O
the	O
school	O
and	O
community	O
surveys	O
in	O
the	O
same	O
locality	O
,	O
the	O
combined	O
results	O
showed	O
significant	O
differences	O
between	O
the	O
school	O
and	O
the	O
community	O
in	O
Chijipata	O
Alto	O
(=	O
229	O
-	O
5	O
,	O
P	O
=	O
0	O
-	O
0123	O
)	O
but	O
not	O
between	O
the	O
school	O
and	O
the	O
community	O
in	O
Huacullani	O
.	O

Similar	O
results	O
were	O
obtained	O
when	O
comparing	O
the	O
intensity	O
values	O
obtained	O
in	O
the	O
school	O
survey	O
and	O
community	O
survey	O
carried	O
out	O
in	O
a	O
given	O
locality	O
in	O
the	O
same	O
year	O
:	O
significant	O
differences	O
in	O
Chijipata	O
Alto	O
(	O
(	O
7=75	O
-	O
0	O
,	O
P	O
=	O
0	O
-	O
0472	O
)	O
,	O
but	O
not	O
in	O
Huacullani	O
.	O

Intensities	O
according	O
to	O
sex	O
and	O
age	O
-	O
groups	O
in	O
the	O
school	O
and	O
community	O
surveys	O
are	O
shown	O
in	O
Table	O
2	O
.	O

No	O
significant	O
differences	O
according	O
to	O
sex	O
were	O
detected	O
in	O
the	O
total	O
study	O
and	O
in	O
the	O
community	O
surveys	O
,	O
but	O
the	O
significantly	O
higher	O
F.	O
hepatica	O
egg	O
counts	O
for	O
the	O
girls	O
in	O
the	O
school	O
surveys	O
(	O
t	O
=	O
2	O
-	O
59	O
,	O
P	O
=	O
0	O
-	O
010	O
)	O
is	O
worth	O
men-	O
tioning	O
.	O

The	O
analyses	O
according	O
to	O
age	O
-	O
groups	O
did	O
not	O
show	O
any	O
significant	O
difference	O
.	O

Discussion	O
The	O
prevalences	O
and	O
intensities	O
obtained	O
by	O
coprolo-	O
gical	O
methods	O
in	O
this	O
study	O
are	O
the	O
highest	O
known	O
up	O
to	O
the	O
present	O
.	O

These	O
results	O
are	O
even	O
more	O
noteworthy	O
when	O
taking	O
into	O
consideration	O
the	O
fact	O
that	O
the	O
localities	O
surveyed	O
in	O
the	O
Northern	O
Bolivian	O
Altiplano	O
were	O
se-	O
lected	O
only	O
because	O
of	O
their	O
geographical	O
situation	O
,	O
in	O
order	O
to	O
cover	O
a	O
wide	O
geographical	O
area	O
.	O

The	O
probability	O
of	O
detecting	O
high	O
infection	O
rates	O
of	O
fascioliasis	O
was	O
not	O
taken	O
into	O
account	O
and	O
thus	O
survey	O
efforts	O
were	O
not	O
concentrated	O
on	O
the	O
subzones	O
presenting	O
the	O
highest	O
human	O
fascioliasis	O
rates	O
.	O

Owing	O
to	O
the	O
important	O
clinical	O
and	O
pathogenic	O
effects	O
of	O
fascioliasis	O
(	O
CHEN	O
&	O
MOTT	O
,	O
1990	O
;	O
MAS	O
-	O
COMA	O
et	O
al.	O
,	O
1999a	O
,	O
m	O
press	O
)	O
,	O
the	O
analyses	O
of	O
prevalences	O
and	O
intensities	O
obtained	O
allow	O
us	O
to	O
conclude	O
that	O
the	O
Northern	O
Bolivian	O
Altiplano	O
must	O
be	O
catalogued	O
as	O
a	O
true	O
human	O
fascioliasis	O
endemic	O
area	O
.	O

The	O
term	O
outbreak	O
sometimes	O
used	O
for	O
this	O
area	O
(	O
BJORLAND	O
et	O
al.	O
,	O
1995	O
)	O
may	O
consequently	O
be	O
used	O
only	O
when	O
a	O
temporary	O
prevalence	O
increase	O
in	O
a	O
given	O
Altiplanic	O
locality	O
is	O
detected	O
.	O

Differences	O
detected	O
between	O
the	O
results	O
of	O
the	O
pre-	O
valences	O
obtained	O
in	O
different	O
localities	O
are	O
not	O
related	O
to	O
different	O
seasons	O
and	O
may	O
be	O
linked	O
to	O
the	O
patchy	O
distribution	O
of	O
the	O
transmission	O
foci	O
,	O
marked	O
by	O
the	O
presence	O
of	O
the	O
necessary	O
freshwater	O
lymnaeids	O
,	O
as	O
well	O
as	O
to	O
the	O
Aymara	O
children	O
's	O
tendency	O
not	O
to	O
travel	O
far	O
.	O

The	O
lack	O
of	O
seasonality	O
in	O
the	O
prevalences	O
detected	O
contrasts	O
with	O
the	O
well	O
-	O
known	O
seasonal	O
transmission	O
characteristics	O
of	O
fascioliasis	O
in	O
other	O
parts	O
of	O
the	O
world	O
.	O

This	O
may	O
be	O
explained	O
by	O
the	O
absence	O
of	O
marked	O
climatic	O
differences	O
between	O
the	O
different	O
seasons	O
in	O
the	O
Northern	O
Altiplano	O
.	O

The	O
non	O
-	O
significant	O
differences	O
in	O
prevalences	O
by	O
sex	O
and	O
the	O
fact	O
that	O
all	O
ages	O
are	O
susceptible	O
to	O
infection	O
(	O
positive	O
cases	O
from	O
2	O
to	O
70	O
years	O
)	O
,	O
despite	O
the	O
fact	O
that	O
the	O
subjects	O
aged	O
<	O
20	O
years	O
are	O
those	O
with	O
a	O
higher	O
infection	O
risk	O
,	O
could	O
be	O
explained	O
by	O
the	O
lack	O
of	O
gender	O
role	O
differences	O
and	O
by	O
the	O
ingestion	O
of	O
several	O
aquatic	O
vegetables	O
(	O
MAS	O
-	O
COMAeta	O
/	O
.	O
,	O
1995	O
)	O
as	O
a	O
risk	O
factor	O
for	O
F.	O
hepatica	O
infection	O
.	O

These	O
results	O
agree	O
with	O
a	O
few	O
studies	O
performed	O
in	O
areas	O
of	O
Egypt	O
(	O
FARAG	O
et	O
al.	O
,	O
1979	O
)	O
,	O
Peru	O
(	O
KNOBLOCH	O
et	O
al.	O
,	O
1985	O
;	O
SCHEZ	O
et	O
al.	O
,	O
1993	O
)	O
and	O
Chile	O
(	O
APT	O
et	O
al.	O
,	O
1993	O
)	O
.	O

The	O
very	O
high	O
egg	O
counts	O
are	O
worth	O
noting	O
when	O
compared	O
with	O
the	O
epg	O
normally	O
found	O
to	O
date	O
in	O
human	O
fascioliasis	O
diagnosis	O
:	O
1	O
-	O
4	O
epg	O
(	O
BENDEZet	O
al.	O
,	O
1982	O
;	O
KNOBLOCH	O
et	O
al.	O
,	O
1985	O
)	O
is	O
the	O
most	O
common	O
;	O
a	O
case	O
with	O
440	O
epg	O
(	O
AKAHANE	O
et	O
al.	O
,	O
1975	O
)	O
may	O
be	O
considered	O
as	O
rare	O
.	O

However	O
,	O
the	O
prospective	O
study	O
by	O
SAMPAIO	O
SILVA	O
(	O
1990	O
)	O
provided	O
a	O
geometric	O
mean	O
(	O
range	O
)	O
of	O
233	O
(	O
25-	O
2100	O
)	O
epg	O
,	O
which	O
was	O
the	O
highest	O
epg	O
count	O
known	O
up	O
to	O
our	O
study	O
.	O

With	O
the	O
exception	O
of	O
a	O
few	O
localities	O
,	O
the	O
distribution	O
of	O
intensities	O
corresponds	O
to	O
the	O
distribution	O
of	O
preva-	O
lences	O
,	O
and	O
the	O
scarce	O
disagreements	O
in	O
some	O
localities	O
may	O
be	O
explained	O
by	O
the	O
few	O
children	O
coming	O
from	O
the	O
very	O
few	O
surrounding	O
zones	O
including	O
transmission	O
foci	O
.	O

Intensity	O
results	O
obtained	O
in	O
schools	O
and	O
communities	O
surveyed	O
more	O
than	O
once	O
,	O
in	O
different	O
seasons	O
and	O
throughout	O
different	O
years	O
,	O
as	O
well	O
as	O
those	O
obtained	O
in	O
the	O
school	O
and	O
community	O
surveys	O
in	O
the	O
same	O
locality	O
are	O
difficult	O
to	O
interpret	O
.	O

Similarly	O
,	O
the	O
significantly	O
higher	O
F.	O
hepatica	O
egg	O
counts	O
for	O
the	O
girls	O
in	O
the	O
school	O
surveys	O
are	O
surprising	O
.	O

Concerning	O
intensity	O
in	O
humans	O
,	O
a	O
relationship	O
between	O
the	O
number	O
of	O
fluke	O
adults	O
and	O
eggs	O
in	O
faeces	O
has	O
never	O
been	O
studied	O
.	O

Data	O
from	O
animals	O
suggest	O
that	O
a	O
direct	O
relation	O
does	O
not	O
necessarily	O
exist	O
(	O
CHEN	O
&	O
MOTT	O
,	O
1990	O
)	O
.	O

It	O
is	O
evident	O
that	O
further	O
studies	O
on	O
this	O
aspect	O
are	O
needed	O
.	O

Intensity	O
data	O
according	O
to	O
age	O
-	O
groups	O
show	O
that	O
egg	O
output	O
counts	O
decrease	O
with	O
an	O
increase	O
of	O
age	O
.	O

In	O
3	O
persons	O
aged	O
>	O
60	O
years	O
,	O
egg	O
counts	O
of	O
24	O
-	O
168	O
epg	O
were	O
found	O
.	O

Consequently	O
,	O
adult	O
subjects	O
either	O
maintain	O
the	O
parasites	O
acquired	O
when	O
young	O
or	O
can	O
be	O
newly	O
infected	O
HUMAN	O
FASCIOLIASIS	O
IN	O
BOLIVIA	O
155	O
as	O
the	O
consequence	O
of	O
inhabiting	O
a	O
zone	O
of	O
high	O
infection	O
risk	O
.	O

A	O
case	O
of	O
a	O
2-year	O
-	O
old	O
child	O
shedding	O
48	O
epg	O
is	O
worth	O
mentioning	O
,	O
as	O
it	O
is	O
the	O
youngest	O
human	O
fascioliasis	O
case	O
reported	O
so	O
far	O
.	O

The	O
human	O
health	O
problem	O
of	O
this	O
distomatosis	O
in	O
the	O
Northern	O
Bolivian	O
Altiplano	O
is	O
related	O
to	O
the	O
hygienic-	O
sanitation	O
status	O
of	O
the	O
human	O
population	O
.	O

The	O
numer-	O
ous	O
different	O
protozoan	O
and	O
helminth	O
species	O
detected	O
in	O
the	O
area	O
surveyed	O
and	O
the	O
multiple	O
parasite	O
infections	O
detected	O
,	O
including	O
F.	O
hepatica	O
infection	O
,	O
in	O
the	O
same	O
subjects	O
(	O
ESTEBAN	O
et	O
al.	O
,	O
1996	O
,	O
1997a	O
;	O
1998a	O
,	O
1998b	O
)	O
are	O
illustrative	O
of	O
this	O
situation	O
.	O

Acknowledgements	O
Collaboration	O
by	O
Dr	O
J.	O
A.	O
Oviedo	O
(	O
Valencia	O
,	O
Spain	O
)	O
and	O
Miss	O
W.	O
Strauss	O
,	O
N.	O
lihoshi	O
,	O
M.	O
Magarinos	O
and	O
Dr	O
C.	O
Aguirre	O
(	O
La	O
Paz	O
,	O
Bolivia	O
)	O
is	O
acknowledged	O
.	O

Thanks	O
are	O
also	O
given	O
to	O
the	O
following	O
Bolivian	O
institutions	O
in	O
La	O
Paz	O
:	O
Direccion	O
Nacional	O
de	O
Epidemiologia	O
of	O
the	O
Ministerio	O
de	O
Prevision	O
Social	O
y	O
Salud	O
Plica	O
;	O
ComitRegional	O
de	O
Zoonosis	O
and	O
Centro	O
Piloto	O
of	O
the	O
Unidad	O
Sanitaria	O
La	O
Paz	O
;	O
and	O
Office	O
of	O
the	O
Pan	O
American	O
Health	O
Organization	O
.	O

This	O
work	O
was	O
supported	O
by	O
funding	O
from	O
the	O
STD	O
Program	O
of	O
the	O
Commission	O
of	O
the	O
European	O
Communities	O
(	O
DG	O
XII	O
:	O
Science	O
,	O
Research	O
and	O
Development	O
)	O
(	O
Contract	O
no.	O
TS3-	O
CT94	O
-	O
0294	O
)	O
,	O
Brussels	O
,	O
EU	O
,	O
by	O
the	O
Program	O
of	O
Scientific	O
Co-	O
operation	O
with	O
Latin	O
America	O
,	O
Institute	O
de	O
Cooperaci	O
Ibero-	O
americana	O
,	O
Agencia	O
Espanola	O
de	O
Cooperaci	O
Intemacional	O
(	O
ICI	O
-	O
AECI	O
)	O
and	O
by	O
Projects	O
no.	O
UE96	O
-	O
0001	O
and	O
no.	O
PM97-	O
0099	O
of	O
the	O
Direccion	O
General	O
de	O
Investigacion	O
Cientifica	O
y	O
Tnica	O
(	O
DGICYT	O
)	O
,	O
Spanish	O
Ministry	O
of	O
Education	O
and	O
Science	O
,	O
Madrid	O
.	O

Modular	O
polyketide	O
synthases	O
(	O
PKSs	O
)	O
are	O
responsible	O
for	O
producing	O
a	O
large	O
number	O
of	O
12	B
,	O
14-	B
and	O
16-membered	B
macrolide	I
antibiotics	I
including	O
methymycin	B
,	O
erythromycin	B
and	O
tylosin	B
.	O

These	O
large	O
,	O
multifunctional	O
enzymes	O
(	O
>	O
300,000	O
kDa	O
)	O
catalyze	O
the	O
biosynthesis	O
of	O
polyketide	B
macrolactones	I
through	O
multistep	O
pathways	O
involving	O
decarboxylative	O
condensations	O
between	O
acyl	B
thioesters	I
fol-	O
lowed	O
by	O
cycles	O
of	O
varying	O
B	O
-	O
carbon	B
processing	O
[	O
l	O
]	O
.	O

The	O
ability	O
to	O
control	O
aspects	O
of	O
polyketide	B
biosynthesis	O
,	O
such	O
as	O
monomer	B
selection	O
,	O
degree	O
of	O
B	O
-	O
carbon	B
processing	O
and	O
stereoselectivity	O
,	O
by	O
genetic	O
manipulation	O
of	O
PKSs	O
has	O
stimulated	O
great	O
interest	O
in	O
the	O
combinatorial	O
engineering	O
of	O
novel	O
antibiotics	B
[	O
2,3	O
]	O
.	O

Picromycin	B
(	O
1	B
;	O
Figure	O
1	O
)	O
is	O
of	O
par-	O
ticular	O
interest	O
for	O
such	O
use	O
because	O
of	O
its	O
close	O
structural	O
relationship	O
to	O
ketolide	B
compounds	O
(	O
e.g.	O
HMR	B
3004	I
)	O
,	O
a	O
new	O
class	O
of	O
semisynthetic	O
macrolides	B
with	O
activity	O
against	O
pathogens	O
resistant	O
to	O
erythromycin	B
[	O
4	O
]	O
.	O

Genetic	O
systems	O
that	O
allow	O
rapid	O
engineering	O
of	O
the	O
picromycin	B
PKS	O
would	O
therefore	O
be	O
valuable	O
for	O
creating	O
novel	O
ketolide	B
analogs	I
for	O
pharmaceutical	O
applications	O
.	O

A	O
pivotal	O
development	O
for	O
modular	O
PKS	O
engineering	O
was	O
the	O
heterologous	O
expression	O
of	O
the	O
erythromycin	B
PKS	O
(	O
6-deoxyerythronolide	O
B	O
synthase	O
,	O
DEBS	O
)	O
in	O
Streptomyces	O
coelicolor	O
[	O
5,6	O
]	O
.	O

The	O
advantages	O
to	O
this	O
plasmid	O
-	O
based	O
genetic	O
system	O
for	O
DEBS	O
were	O
that	O
it	O
overcame	O
the	O
tedious	O
and	O
limited	O
techniques	O
for	O
manipulating	O
the	O
natural	O
DEBS	O
host	O
organism	O
,	O
Saccharopolyspora	O
etythaea	O
,	O
it	O
allowed	O
more	O
facile	O
construction	O
of	O
mutant	O
PKSs	O
,	O
and	O
it	O
reduced	O
the	O
complexity	O
of	O
PKS	O
property	O
analysis	O
by	O
pro-	O
viding	O
a	O
leanhost	O
background	O
.	O

This	O
system	O
also	O
expe-	O
dited	O
the	O
construction	O
of	O
the	O
first	O
combinatorial	O
modular	O
polyketide	B
library	O
in	O
Streptomyces	O
[	O
7	O
]	O
.	O

Despite	O
the	O
success	O
of	O
this	O
system	O
,	O
as	O
well	O
as	O
the	O
increased	O
number	O
of	O
modular	O
PKS	O
gene	O
clusters	O
currently	O
available	O
,	O
DEBS	O
remained	O
the	O
only	O
modular	O
PKS	O
reported	O
to	O
be	O
expressed	O
in	O
a	O
het-	O
erologous	O
organism	O
.	O

The	O
picromycin	B
gene	O
cluster	O
from	O
Streptomyces	O
venezuelae	O
was	O
recently	O
cloned	O
and	O
sequenced	O
by	O
Sherman	O
and	O
coworkers	O
[	O
8	O
]	O
and	O
in	O
our	O
own	O
laboratories	O
(	O
[	O
9	O
]	O
;	O
M.C.B.	O
,	O
unpublished	O
observations	O
)	O
.	O

S.	O
venezuelae	O
is	O
unique	O
among	O
macrolide	B
-	O
producing	O
organisms	O
because	O
it	O
produces	O
primary	O
polyketides	B
with	O
two	O
different	O
ring	O
sizes	O
.	O

In	O
addi-	O
tion	O
to	O
the	O
14-membered	B
macrolide	I
picromycin	B
(	O
l	B
)	O
,	O
the	O
12-membered	B
macrolide	I
methymycin	B
(	O
2	B
;	O
Figure	O
1	O
)	O
is	O
also	O
produced	O
.	O

Based	O
on	O
the	O
structural	O
similarities	O
between	O
CHBIOL	O
80087	O
S1074	O
-	O
5521	O
(	O
99	O
)	O
80087	O
-	O
8	O
10.1016	O
/	O
S1074	O
-	O
5521	O
(	O
99	O
)	O
80087	O
-	O
8	O
Elucidating	O
the	O
mechanism	O
of	O
chain	O
termination	O
switching	O
in	O
the	O
picromycin	B
/	O
methymycin	B
polyketide	O
synthase	O
Li	O
Tang	O
Hong	O
Fu	O

Melanie	O
C	O
Betlach	O

Robert	O
McDaniel	O

*	O
mcdaniel@kosan.com	O

KOSAN	O
Biosciences	O
,	O
Inc.	O
,	O
3832	O
Bay	O
Center	O
Place	O
,	O
Hayward	O
,	O
CA	O
94545	O
,	O
USA	O

*	O
Correspondence	O
:	O
Robert	O
McDaniel	O
.	O

Background	O
A	O
single	O
modular	O
polyketide	O
synthase	O
(	O
PKS	O
)	O
gene	O
cluster	O
is	O
responsible	O
for	O
production	O
of	O
both	O
the	O
14-membered	B
macrolide	I
antibiotic	I
picromycin	B
and	O
the	O
12-membered	B
macrolide	I
antibiotic	I
methymycin	B
in	O
Streptomyces	O
Venezuelas	O
.	O

Building	O
on	O
the	O
success	O
of	O
the	O
heterologous	O
expression	O
system	O
engineered	O
using	O
the	O
erythromycin	B
PKS	O
,	O
we	O
have	O
constructed	O
an	O
analogous	O
system	O
for	O
the	O
picromycin	B
/	O
methymycin	B
PKS	O
.	O

Through	O
heterologous	O
expression	O
and	O
construction	O
of	O
a	O
hybrid	O
PKS	O
,	O
we	O
have	O
examined	O
the	O
contributions	O
that	O
the	O
PKS	O
,	O
its	O
internal	O
thioesterase	O
domain	O
(	O
pikTE	O
)	O
and	O
the	O
Pik	O
TEII	O
thioesterase	O
domain	O
make	O
in	O
termination	O
and	O
cyclization	O
of	O
the	O
two	O
polyketide	B
intermediates	O
.	O

Results	O
The	O
picromycin	B
/	O
methymycin	B
PKS	O
genes	O
were	O
functionally	O
expressed	O
in	O
the	O
heterologous	O
host	O
Streptomyces	O
lividans	O
,	O
resulting	O
in	O
production	O
of	O
both	O
narbonolide	B
and	O
10-deoxymethynolide	B
(	O
the	O
precursors	O
of	O
picromycin	B
and	O
methymycin	B
,	O
respectively	O
)	O
.	O

Co	O
-	O
expression	O
with	O
the	O
Pik	O
TEII	O
thioesterase	O
led	O
to	O
increased	O
production	O
levels	O
,	O
but	O
did	O
not	O
change	O
the	O
ratio	O
of	O
the	O
two	O
compounds	B
produced	O
,	O
leaving	O
the	O
function	O
of	O
this	O
protein	O
largely	O
unknown	O
.	O

Fusion	O
of	O
the	O
PKS	O
thioesterase	O
domain	O
(	O
pikTE	O
)	O
to	O
6-deoxyerythronolide	O
B	O
synthase	O
(	O
DEBS	O
)	O
resulted	O
in	O
formation	O
of	O
only	O
14-membered	B
macrolactones	I
.	O

Conclusions	O
These	O
experiments	O
demonstrate	O
that	O
the	O
PKS	O
alone	O
is	O
capable	O
of	O
catalyzing	O
the	O
synthesis	O
of	O
both	O
14-	B
and	O
12-membered	B
macrolactones	I
and	O
favor	O
a	O
model	O
by	O
which	O
different	O
macrolactone	B
rings	O
result	O
from	O
a	O
combination	O
of	O
the	O
arrangement	O
between	O
the	O
module	O
5	O
and	O
module	O
6	O
subunits	O
in	O
the	O
picromycin	B
PKS	O
complex	O
and	O
the	O
selectivity	O
of	O
the	O
pikTE	O
domain	O
.	O

Key	O
words	O
erythromycin	B
methymycin	B
picromycin	B
polyketide	O
thioesterase	O

Diltiazem	B
(	O
d	B
-cis	I
-diltiazem	I
)	O
,	O
a	O
benzothiazepine	B
Ca2	B
+	I
channel	O
blocker	O
,	O
has	O
been	O
used	O
for	O
the	O
treatment	O
of	O
ischemic	O
heart	O
disease	O
.	O

The	O
primary	O
mechanism	O
of	O
the	O
anti	O
-	O
ischemic	O
action	O
of	O
d	B
-cis	I
-diltiazem	I
is	O
considered	O
to	O
be	O
its	O
Ca2	O
+	O
channel	O
blocking	O
action	O
,	O
which	O
produces	O
improvement	O
of	O
the	O
myocardial	O
oxygen	O
balance	O
between	O
supply	O
and	O
demand	O
by	O
either	O
increasing	O
coronary	O
flow	O
or	O
decreasing	O
cardiac	O
mechanical	O
function	O
,	O
or	O
both	O
.	O

However	O
,	O
l	B
-cis	I
-diltiazem	I
,	O
which	O
is	O
an	O
optical	O
isomer	O
of	O
d	B
-cis	I
-diltiazem	I
with	O
about	O
1	O
/	O
20–1	O
/	O
100	O
the	O
Ca2	O
+	O
channel	O
blocking	O
action	O
of	O
d	B
-cis	I
-diltiazem	I
(	O
Nasa	O
et	O
al.	O
,	O
1992	O
;	O
Itogawa	O
et	O
al.	O
,	O
1996	O
)	O
,	O
and	O
d	B
-cis	I
-diltiazem	I
attenuate	O
the	O
myocardial	O
derangements	O
induced	O
by	O
ischemia	O
–	O
reperfusion	O
to	O
a	O
similar	O
degree	O
(	O
Nasa	O
et	O
al.	O
,	O
1990	O
)	O
.	O

This	O
fact	O
suggests	O
that	O
the	O
anti	O
-	O
ischemic	O
action	O
of	O
d	B
-cis	I
-diltiazem	I
does	O
not	O
entirely	O
depend	O
on	O
its	O
Ca2	O
+	O
channel	O
blocking	O
action	O
,	O
but	O
depends	O
on	O
other	O
unknown	O
actions	O
.	O

Recently	O
,	O
we	O
(	O
Xiao	O
et	O
al.	O
,	O
1997	O
)	O
have	O
demonstrated	O
that	O
both	O
d	B
-cis	I
-	I
and	O
l	B
-cis	I
-diltiazem	I
attenuate	O
the	O
myocardial	O
derangements	O
induced	O
by	O
palmitoyl	B
-	I
l	I
-carnitine	I
,	O
which	O
accumulates	O
in	O
the	O
heart	O
during	O
ischemia	O
and	O
reperfusion	O
,	O
supporting	O
the	O
above	O
suggestion	O
.	O

During	O
ischemia	O
and	O
reperfusion	O
,	O
reactive	B
oxygen	I
species	I
,	O
such	O
as	O
superoxide	B
anion	I
,	O
hydroxyl	B
radical	I
and	O
hydrogen	B
peroxide	I
(	O
H2	B
O2	I
)	O
,	O
are	O
generated	O
intra-	O
and	O
extracellularly	O
in	O
the	O
myocardium	O
and	O
endothelium	O
(	O
Hess	O
and	O
Manson	O
,	O
1984	O
;	O
Lucchesi	O
,	O
1990	O
;	O
Loesser	O
et	O
al.	O
,	O
1991	O
)	O
.	O

These	O
reactive	B
oxygen	I
species	I
are	O
considered	O
important	O
in	O
producing	O
irreversible	O
damage	O
in	O
the	O
ischemia	O
-	O
reperfused	O
heart	O
(	O
Hess	O
and	O
Manson	O
,	O
1984	O
;	O
Lucchesi	O
,	O
1990	O
;	O
Loesser	O
et	O
al.	O
,	O
1991	O
)	O
.	O

In	O
fact	O
,	O
oxygen	B
radical	I
scavengers	I
and	O
anti	B
-	I
oxidants	I
protect	O
the	O
myocardium	O
against	O
ischemia	O
–	O
reperfusion	O
damage	O
(	O
Hess	O
and	O
Manson	O
,	O
1984	O
;	O
Lucchesi	O
,	O
1990	O
;	O
Loesser	O
et	O
al.	O
,	O
1991	O
)	O
.	O

We	O
(	O
Hara	O
et	O
al.	O
,	O
1993	O
;	O
Hara	O
and	O
Abiko	O
,	O
1996	O
;	O
Kokita	O
and	O
Hara	O
,	O
1996	O
)	O
have	O
demonstrated	O
that	O
H2	B
O2	I
decreases	O
cardiac	O
mechanical	O
function	O
and	O
the	O
tissue	O
levels	O
of	O
high	O
-	O
energy	O
phosphates	B
in	O
the	O
isolated	O
perfused	O
rat	O
heart	O
.	O

According	O
to	O
recent	O
physiological	O
studies	O
,	O
H2	B
O2	I
increases	O
the	O
intracellular	O
concentration	O
of	O
Na+	B
(	O
[	B
Na+	I
]	I
i	I
)	O
in	O
the	O
myocardium	O
(	O
Yanagida	O
et	O
al.	O
,	O
1995	O
)	O
,	O
probably	O
because	O
of	O
an	O
increase	O
in	O
Na+	B
current	O
in	O
cardiac	O
cells	O
(	O
Bhatnagar	O
et	O
al.	O
,	O
1990	O
;	O
Ward	O
and	O
Giles	O
,	O
1997	O
)	O
.	O

The	O
increase	O
in	O
[	B
Na+	I
]	I
i	I
activates	O
the	O
Na+	B
/Ca2	O
+	B
exchanger	O
,	O
leading	O
to	O
intracellular	O
Ca2	B
+	I
overload	O
,	O
which	O
is	O
responsible	O
for	O
irreversible	O
myocardial	O
derangements	O
(	O
Goldhaber	O
,	O
1996	O
)	O
.	O

In	O
order	O
to	O
elucidate	O
the	O
mechanisms	O
of	O
action	O
of	O
l	B
-cis	I
-diltiazem	I
responsible	O
for	O
its	O
anti	O
-	O
ischemic	O
effect	O
and	O
to	O
relate	O
its	O
anti	B
-	I
ischemic	I
action	O
to	O
the	O
Ca2	O
+	O
channel	O
blocking	O
action	O
,	O
the	O
following	O
two	O
series	O
of	O
experiments	O
were	O
designed	O
.	O

The	O
first	O
series	O
of	O
experiments	O
was	O
performed	O
to	O
determine	O
the	O
effect	O
of	O
d	B
-cis	I
-	O
and	O
l	B
-cis	I
-diltiazem	I
on	O
the	O
H2	B
O2	I
-induced	O
mechanical	O
dysfunction	O
,	O
decrease	O
in	O
the	O
tissue	O
levels	O
of	O
high	O
-	O
energy	O
phosphates	B
and	O
damage	O
of	O
the	O
cell	O
membrane	O
,	O
and	O
the	O
second	O
series	O
of	O
experiments	O
was	O
carried	O
out	O
to	O
examine	O
the	O
effect	O
of	O
d	B
-cis	I
-	I
and	O
l	B
-cis	I
-diltiazem	I
on	O
the	O
H2	B
O2	I
-induced	O
increase	O
in	O
[	B
Na+	I
]	I
i	I
.	O

2	O
Methods	O
The	O
protocol	O
of	O
animal	O
experiments	O
in	O
the	O
present	O
study	O
was	O
approved	O
by	O
the	O
`	O
Asahikawa	O
Medical	O
College	O
Committee	O
on	O
Animal	O
Research	O
'	O
.	O

2.1	O
Heart	O
perfusion	O
(	O
the	O
first	O
series	O
of	O
experiments	O
)	O

Male	O
Sprague	O
–	O
Dawley	O
rats	O
,	O
weighing	O
310–340	O
g	O
(	O
9–10	O
weeks	O
old	O
)	O
,	O
were	O
used	O
in	O
the	O
first	O
series	O
of	O
experiments	O
.	O

The	O
rats	O
were	O
anesthetized	O
with	O
sodium	B
pentobarbital	I
(	O
50	O
mg	O
kg−1	O
,	O
i.p	O
.	O
)	O
20	O
min	O
after	O
an	O
injection	O
with	O
heparin	B
(	O
1000	O
u	O
kg−1	O
,	O
i.p	O
.	O
)	O
.	O

After	O
thoracotomy	O
,	O
the	O
hearts	O
were	O
rapidly	O
removed	O
,	O
and	O
then	O
retrograde	O
perfusion	O
was	O
started	O
using	O
a	O
cannula	O
inserted	O
into	O
the	O
aorta	O
according	O
to	O
the	O
Langendorff	O
technique	O
.	O

The	O
perfusion	O
buffer	O
was	O
a	O
Krebs	O
–	O
Henseleit	O
bicarbonate	B
(	O
KHB	O
)	O
buffer	O
containing	O
(	O
in	O
mM	O
)	O
:	O
NaCl	B
,	O
118	O
;	O
KCl	O
,	O
4.7	O
;	O
KH2	B
PO4	I
,	O
1.2	O
;	O
MgSO4	B
,	O
1.2	O
;	O
CaCl2	B
,	O
2.5	O
;	O
NaHCO3	B
,	O
25	O
;	O
and	O
glucose	B
,	O
11	O
,	O
equilibrated	O
with	O
a	O
gas	O
mixture	O
of	O
95	O
%	O
O2	B
+	O
5	O
%	O
CO2	B
and	O
maintained	O
at	O
37	O
°	O
C	O
.	O

The	O
oxygen	B
tension	O
of	O
the	O
buffer	O
measured	O
by	O
a	O
blood	O
gas	O
analyzer	O
(	O
Model	O
813	O
,	O
Instrumentation	O
Laboratory	O
,	O
Lexington	O
,	O
USA	O
)	O
was	O
about	O
550	O
mm	O
Hg	O
.	O

The	O
hearts	O
,	O
mounted	O
in	O
a	O
water	B
-	O
jacketed	O
chamber	O
(	O
37	O
°	O
C	O
)	O
,	O
were	O
initially	O
perfused	O
at	O
a	O
constant	O
perfusion	O
pressure	O
of	O
80	O
cm	O
H2	B
O.	I
About	O
10	O
min	O
after	O
constant	O
pressure	O
perfusion	O
,	O
perfusion	O
was	O
switched	O
to	O
constant	O
flow	O
perfusion	O
(	O
10	O
ml	O
min−1	O
)	O
,	O
using	O
a	O
microtube	O
pump	O
(	O
Eyela	O
MP-3	O
,	O
Tokyo	O
-	O
Rikakikai	O
Instruments	O
,	O
Tokyo	O
,	O
Japan	O
)	O
,	O
which	O
was	O
maintained	O
until	O
the	O
end	O
of	O
the	O
experiment	O
.	O

The	O
heart	O
rate	O
was	O
kept	O
constant	O
by	O
pacing	O
the	O
heart	O
at	O
300	O
beats	O
min−1	O
with	O
an	O
electronic	O
stimulator	O
(	O
3F46	O
,	O
San	O
-	O
Ei	O
Instruments	O
,	O
Tokyo	O
,	O
Japan	O
)	O
during	O
the	O
course	O
of	O
the	O
study	O
.	O

Rectangular	O
pulses	O
of	O
2	O
ms	O
in	O
duration	O
with	O
a	O
voltage	O
of	O
6	O
V	O
(	O
about	O
3	O
×	O
the	O
threshold	O
voltage	O
)	O
were	O
applied	O
to	O
the	O
left	O
ventricle	O
for	O
pacing	O
of	O
the	O
heart	O
.	O

As	O
indices	O
of	O
mechanical	O
function	O
,	O
left	O
ventricular	O
systolic	O
pressure	O
,	O
left	O
ventricular	O
end	O
-	O
diastolic	O
pressure	O
and	O
left	O
ventricular	O
developed	O
pressure	O
were	O
used	O
.	O

The	O
values	O
of	O
left	O
ventricular	O
systolic	O
pressure	O
and	O
left	O
ventricular	O
end	O
-	O
diastolic	O
pressure	O
were	O
determined	O
from	O
the	O
left	O
ventricular	O
pressure	O
curves	O
recorded	O
continuously	O
during	O
the	O
course	O
of	O
the	O
study	O
,	O
and	O
the	O
left	O
ventricular	O
developed	O
pressure	O
value	O
was	O
calculated	O
as	O
left	O
ventricular	O
systolic	O
pressure	O
minus	O
left	O
ventricular	O
end	O
-	O
diastolic	O
pressure	O
.	O

For	O
measurement	O
of	O
left	O
ventricular	O
pressure	O
,	O
a	O
saline	B
-	O
filled	O
polyethylene	B
cannula	O
,	O
connected	O
to	O
a	O
pressure	O
transducer	O
,	O
was	O
inserted	O
into	O
the	O
left	O
ventricular	O
cavity	O
via	O
the	O
left	O
atrium	O
.	O

2.2	O
Experimental	O
protocol	O
(	O
the	O
first	O
series	O
of	O
experiments	O
)	O

The	O
hearts	O
were	O
divided	O
into	O
five	O
groups	O
:	O
vehicle	O
,	O
l	B
-cis	I
-diltiazem	I
(	O
5	O
μM	O
)	O
,	O
l	B
-cis	I
-diltiazem	I
(	O
10	O
μM	O
)	O
,	O
l	B
-cis	I
-diltiazem	I
(	O
15	O
μM	O
)	O
and	O
d	B
-cis	I
-diltiazem	I
(	O
15	O
μM	O
)	O
groups	O
.	O

In	O
these	O
groups	O
,	O
the	O
hearts	O
were	O
perfused	O
at	O
a	O
constant	O
flow	O
for	O
75	O
min	O
(	O
stabilization	O
period	O
for	O
20	O
min	O
and	O
observation	O
period	O
for	O
55	O
min	O
)	O
.	O

d	B
-cis	I
-Diltiazem	I
,	O
l	B
-cis	I
-diltiazem	I
or	O
vehicle	O
(	O
KHB	O
buffer	O
for	O
both	O
d	B
-cis	I
-diltiazem	I
and	O
l	B
-cis	I
-diltiazem	I
solutions	O
)	O
was	O
infused	O
into	O
the	O
aortic	O
cannula	O
at	O
a	O
constant	O
flow	O
rate	O
of	O
0.1	O
ml	O
min−1	O
for	O
45	O
min	O
from	O
10	O
min	O
after	O
the	O
start	O
of	O
observation	O
period	O
.	O

The	O
final	O
concentration	O
of	O
d	B
-cis	I
-diltiazem	I
in	O
the	O
perfusate	O
was	O
set	O
to	O
15	O
μM	O
and	O
that	O
of	O
l	B
-cis	I
-diltiazem	I
in	O
the	O
perfusate	O
was	O
set	O
to	O
5	O
,	O
10	O
or	O
15	O
μM.	O
H2	B
O2	I
was	O
infused	O
into	O
the	O
aortic	O
cannula	O
at	O
a	O
constant	O
flow	O
rate	O
of	O
0.1	O
ml	O
min−1	O
for	O
3.5	O
min	O
from	O
10	O
min	O
after	O
the	O
start	O
of	O
infusion	O
of	O
d	B
-cis	I
-diltiazem	I
,	O
l	B
-cis	I
-diltiazem	I
or	O
vehicle	O
.	O

The	O
final	O
concentration	O
of	O
H2	B
O2	I
in	O
the	O
perfusate	O
was	O
set	O
to	O
600	O
μM.	O
During	O
the	O
observation	O
period	O
,	O
left	O
ventricular	O
systolic	O
pressure	O
and	O
left	O
ventricular	O
end	O
-	O
diastolic	O
pressure	O
were	O
continuously	O
recorded	O
and	O
the	O
coronary	O
effluent	O
was	O
collected	O
for	O
determination	O
of	O
lactate	O
dehydrogenase	O
(	O
LDH	O
)	O
released	O
from	O
the	O
myocardium	O
.	O

To	O
measure	O
the	O
tissue	O
levels	O
of	O
high	O
-	O
energy	O
phosphates	B
,	O
the	O
hearts	O
were	O
frozen	O
at	O
the	O
end	O
of	O
experiment	O
(	O
45	O
min	O
after	O
the	O
start	O
of	O
infusion	O
of	O
vehicle	O
,	O
d	B
-cis	I
-diltiazem	I
or	O
l	B
-cis	I
-diltiazem	I
)	O
with	O
freezing	O
clamps	O
previously	O
chilled	O
in	O
liquid	O
nitrogen	B
.	O

In	O
addition	O
,	O
some	O
hearts	O
in	O
the	O
vehicle	O
,	O
d	B
-cis	I
-diltiazem	I
(	O
15	O
μM	O
)	O
and	O
l	B
-cis	I
-diltiazem	I
(	O
15	O
μM	O
)	O
groups	O
were	O
frozen	O
immediately	O
before	O
H2	B
O2	I
infusion	O
(	O
10	O
min	O
after	O
the	O
start	O
of	O
infusion	O
of	O
vehicle	O
,	O
d	B
-cis	I
-diltiazem	I
or	O
l	B
-cis	I
-diltiazem	I
)	O
.	O

The	O
frozen	O
myocardial	O
samples	O
were	O
stored	O
in	O
liquid	O
nitrogen	B
(	O
at	O
−196	O
°	O
C	O
)	O
until	O
the	O
biochemical	O
analysis	O
was	O
performed	O
.	O

2.3	O
Biochemical	O
analysis	O
(	O
the	O
first	O
series	O
of	O
experiments	O
)	O

The	O
frozen	O
myocardial	O
sample	O
was	O
pulverized	O
in	O
a	O
mortar	O
cooled	O
with	O
liquid	O
nitrogen	B
.	O

A	O
part	O
of	O
the	O
pulverized	O
tissue	O
powder	O
(	O
about	O
0.8–1.0	O
g	O
)	O
was	O
weighed	O
and	O
put	O
into	O
an	O
oven	O
overnight	O
,	O
in	O
order	O
to	O
measure	O
the	O
tissue	O
water	B
content	O
and	O
dry	O
weight	O
of	O
the	O
tissue	O
.	O

The	O
remainder	O
of	O
the	O
tissue	O
powder	O
was	O
used	O
for	O
determination	O
of	O
the	O
tissue	O
levels	O
of	O
ATP	B
,	O
ADP	B
,	O
AMP	B
and	O
creatine	B
phosphate	I
.	O

ATP	B
,	O
ADP	B
,	O
AMP	B
and	O
creatine	B
phosphate	I
were	O
measured	O
according	O
to	O
standard	O
enzymatic	O
procedures	O
(	O
Bergmeyer	O
,	O
1974a	O
)	O
,	O
using	O
a	O
spectrophotometer	O
(	O
Gilford	O
system	O
2600	O
,	O
Gilford	O
Instrument	O
Laboratories	O
,	O
Oberlin	O
,	O
USA	O
)	O
.	O

The	O
LDH	O
activity	O
in	O
the	O
coronary	O
effluent	O
was	O
measured	O
spectrophotometrically	O
according	O
to	O
an	O
enzymatic	O
method	O
(	O
Bergmeyer	O
,	O
1974b	O
)	O
,	O
using	O
an	O
LDH	O
assay	O
kit	O
(	O
Sigma	O
,	O
St.	O
Louis	O
,	O
USA	O
)	O
.	O

2.4	O
Heart	O
perfusion	O
(	O
the	O
second	O
series	O
of	O
experiments	O
)	O

Male	O
Sprague	O
–	O
Dawley	O
rats	O
,	O
weighing	O
180–210	O
g	O
(	O
6–7	O
weeks	O
old	O
)	O
,	O
were	O
used	O
in	O
the	O
second	O
series	O
of	O
experiments	O
.	O

According	O
to	O
the	O
procedure	O
described	O
in	O
the	O
first	O
series	O
of	O
experiments	O
,	O
the	O
isolated	O
hearts	O
were	O
initially	O
perfused	O
by	O
the	O
Langendorff	O
technique	O
at	O
a	O
constant	O
perfusion	O
pressure	O
of	O
80	O
cm	O
H2	B
O.	I
About	O
10	O
min	O
after	O
constant	O
pressure	O
perfusion	O
,	O
perfusion	O
was	O
switched	O
to	O
constant	O
flow	O
perfusion	O
(	O
8.5	O
ml	O
min−1	O
)	O
,	O
using	O
a	O
microtube	O
pump	O
(	O
Eyela	O
MP-3	O
,	O
Tokyo	O
-	O
Rikakikai	O
Instruments	O
)	O
,	O
which	O
was	O
maintained	O
until	O
the	O
end	O
of	O
the	O
experiment	O
.	O

During	O
the	O
first	O
10	O
min	O
of	O
constant	O
flow	O
perfusion	O
,	O
the	O
hearts	O
were	O
perfused	O
with	O
normal	O
KHB	O
buffer	O
.	O

To	O
obtain	O
23	O
Na	O
-nuclear	O
magnetic	O
resonance	O
(	O
NMR	O
)	O
spectra	O
,	O
perfusion	O
buffer	O
was	O
then	O
switched	O
to	O
a	O
KHB	O
buffer	O
containing	O
thulium	B
(	I
III	I
)	I
-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrakis-	I
(	I
methylenephosphonate	I
)	I
[	O
Tm	B
(	I
DOTP	I
)	I
5−	I
]	O
(	O
a	O
23	O
Na	O
-NMR	O
shift	B
reagent	I
)	O
,	O
equilibrated	O
with	O
a	O
gas	O
mixture	O
of	O
95	O
%	O
O2	B
+	O
5	O
%	O
CO2	B
and	O
maintained	O
at	O
37	O
°	O
C	O
.	O

The	O
buffer	O
for	O
the	O
study	O
with	O
23	O
Na	O
-NMR	O
spectra	O
was	O
the	O
same	O
as	O
the	O
normal	O
KHB	O
buffer	O
,	O
except	O
that	O
it	O
contained	O
104	O
mM	O
NaCl	B
,	O
3.5	O
mM	O
Na4	B
HTmDOTP	I
and	O
3.9	O
mM	O
CaCl2	B
.	O

The	O
reason	O
for	O
use	O
of	O
3.9	O
mM	O
CaCl2	B
was	O
that	O
addition	O
of	O
3.9	O
mM	O
CaCl2	B
would	O
produce	O
1	O
mM	O
free	O
Ca2	B
+	I
in	O
the	O
presence	O
of	O
the	O
shift	B
reagent	I
(	O
Buster	O
et	O
al.	O
,	O
1990	O
)	O
.	O

Although	O
the	O
concentration	O
of	O
free	O
Ca2	B
+	I
was	O
lower	O
than	O
that	O
used	O
in	O
the	O
first	O
series	O
of	O
experiments	O
(	O
2.5	O
mM	O
)	O
,	O
it	O
(	O
1	O
mM	O
)	O
was	O
chosen	O
to	O
avoid	O
precipitation	O
of	O
the	O
shift	B
reagent	I
(	O
Van	O
Emous	O
et	O
al.	O
,	O
1997	O
)	O
.	O

The	O
heart	O
rate	O
was	O
kept	O
constant	O
by	O
pacing	O
the	O
heart	O
at	O
300	O
beats	O
min−1	O
,	O
using	O
a	O
pair	O
of	O
copper	B
electrodes	O
and	O
an	O
electronic	O
stimulator	O
(	O
SEN-3301	O
,	O
Nihon	O
Kohden	O
,	O
Tokyo	O
,	O
Japan	O
)	O
.	O

For	O
measurement	O
of	O
left	O
ventricular	O
pressure	O
,	O
a	O
latex	O
balloon	O
connected	O
to	O
a	O
pressure	O
transducer	O
was	O
inserted	O
into	O
the	O
left	O
ventricular	O
cavity	O
via	O
the	O
left	O
atrium	O
.	O

Before	O
experiments	O
,	O
the	O
balloon	O
was	O
inflated	O
with	O
distilled	O
water	B
to	O
achieve	O
an	O
initial	O
end	O
-	O
diastolic	O
pressure	O
of	O
10	O
mm	O
Hg	O
;	O
thereafter	O
,	O
the	O
volume	O
was	O
kept	O
constant	O
during	O
the	O
course	O
of	O
the	O
study	O
.	O

The	O
hearts	O
perfused	O
with	O
the	O
buffer	O
were	O
placed	O
inside	O
a	O
glass	O
NMR	O
tube	O
(	O
13.4	O
mm	O
in	O
internal	O
diameter	O
)	O
that	O
was	O
introduced	O
into	O
the	O
NMR	O
probe	O
placed	O
in	O
a	O
superconducting	O
magnet	O
.	O

Because	O
the	O
internal	O
diameter	O
of	O
the	O
glass	O
NMR	O
tube	O
was	O
small	O
,	O
only	O
small	O
hearts	O
were	O
used	O
for	O
the	O
NMR	O
experiments	O
.	O

Therefore	O
,	O
relatively	O
small	O
rats	O
weighing	O
about	O
200	O
g	O
were	O
used	O
in	O
the	O
second	O
series	O
of	O
experiments	O
.	O

The	O
temperature	O
surrounding	O
the	O
glass	O
NMR	O
tube	O
was	O
maintained	O
at	O
about	O
20	O
°	O
C	O
by	O
air	B
conditioner	O
,	O
because	O
the	O
apparatus	O
used	O
in	O
the	O
present	O
study	O
is	O
not	O
equipped	O
to	O
provide	O
a	O
temperature	O
-	O
controlled	O
air	B
stream	O
around	O
the	O
NMR	O
tube	O
.	O

Coronary	O
effluent	O
was	O
removed	O
from	O
the	O
NMR	O
glass	O
tube	O
to	O
a	O
level	O
of	O
about	O
10	O
mm	O
above	O
the	O
heart	O
.	O

Perfusion	O
fluid	O
was	O
not	O
recirculated	O
.	O

2.5	O
23	O
Na	O
-NMR	O
measurements	O
(	O
the	O
second	O
series	O
of	O
experiments	O
)	O
23	O
Na	O
-spectra	O
were	O
obtained	O
using	O
a	O
GX-270	O
spectrometer	O
(	O
JEOL	O
,	O
Tokyo	O
,	O
Japan	O
)	O
at	O
71.32	O
MHz	O
with	O
a	O
pulse	O
width	O
of	O
90	O
°	O
,	O
an	O
interpulse	O
delay	O
of	O
0.5	O
s	O
,	O
a	O
spectral	O
width	O
of	O
3000	O
Hz	O
and	O
data	O
size	O
of	O
2048	O
.	O

The	O
spectrometer	O
was	O
equipped	O
with	O
a	O
6.3-T	O
superconducting	O
magnet	O
and	O
an	O
NMR	O
probe	O
(	O
TU	O
(	O
15	O
)	O
,	O
JEOL	O
)	O
in	O
which	O
the	O
glass	O
NMR	O
tube	O
was	O
placed	O
.	O

Four	O
glass	O
capillaries	O
,	O
each	O
containing	O
1.67	O
μmol	O
NaCl	B
in	O
the	O
presence	O
of	O
50	O
mM	O
Tris	B
form	I
of	I
dysprosium	I
triethylenetetraminehexaacetic	I
acid	I
[	O
Tris3	B
Dy	I
(	I
TTHA	I
)	I
·3Tris	I
–	I
HCl	I
]	O
(	O
another	O
23	O
Na	O
-NMR	O
shift	B
reagent	I
)	O
,	O
were	O
placed	O
inside	O
of	O
the	O
NMR	O
tube	O
as	O
an	O
internal	O
standard	O
.	O

The	O
area	O
of	O
each	O
peak	O
in	O
the	O
23	O
Na	O
-NMR	O
spectra	O
was	O
analyzed	O
by	O
integration	O
after	O
Gaussian	O
and	O
Lorentzian	O
multiplication	O
and	O
baseline	O
correction	O
using	O
JEOL	O
ALICE2	O
software	O
(	O
JEOL	O
DATUM	O
,	O
Tokyo	O
,	O
Japan	O
)	O
.	O

The	O
[	B
Na+	I
]	I
i	I
of	O
the	O
cardiac	O
cells	O
was	O
calculated	O
by	O
a	O
comparison	O
between	O
the	O
peak	O
area	O
of	O
[	B
Na+	I
]	I
i	I
and	O
that	O
of	O
the	O
reference	O
solution	O
in	O
the	O
glass	O
capillaries	O
.	O

2.6	O
Experimental	O
protocol	O
(	O
the	O
second	O
series	O
of	O
experiments	O
)	O

The	O
hearts	O
were	O
divided	O
into	O
four	O
groups	O
:	O
vehicle	O
,	O
d	B
-cis	I
-diltiazem	I
(	O
15	O
μM	O
)	O
,	O
l	B
-cis	I
-diltiazem	I
(	O
15	O
μM	O
)	O
and	O
tetrodotoxin	B
(	O
3	O
μM	O
)	O
groups	O
.	O

In	O
these	O
groups	O
,	O
the	O
hearts	O
were	O
perfused	O
with	O
the	O
Tm	B
(	I
DOTP	I
)	I
5−	I
-containing	O
KHB	O
buffer	O
throughout	O
the	O
experiment	O
(	O
stabilization	O
period	O
for	O
10	O
min	O
and	O
observation	O
period	O
for	O
40	O
min	O
)	O
.	O

After	O
the	O
stabilization	O
period	O
,	O
d	B
-cis	I
-diltiazem	I
,	O
l	B
-cis	I
-diltiazem	I
or	O
vehicle	O
(	O
KHB	O
buffer	O
for	O
both	O
d	B
-cis	I
-diltiazem	I
and	O
l	B
-cis	I
-diltiazem	I
)	O
was	O
infused	O
into	O
the	O
aortic	O
cannula	O
for	O
40	O
min	O
at	O
a	O
constant	O
flow	O
rate	O
of	O
0.1	O
ml	O
min−1	O
.	O

The	O
final	O
concentration	O
of	O
d	B
-cis	I
-diltiazem	I
and	O
l	B
-cis	I
-diltiazem	I
in	O
the	O
perfusate	O
was	O
set	O
to	O
15	O
μM	O
and	O
the	O
final	O
concentration	O
of	O
tetrodotoxin	B
in	O
the	O
perfusate	O
was	O
set	O
to	O
3	O
μM.	O
H2	B
O2	I
was	O
infused	O
into	O
the	O
aortic	O
cannula	O
at	O
a	O
constant	O
flow	O
rate	O
of	O
0.1	O
ml	O
min−1	O
for	O
4	O
min	O
from	O
10	O
min	O
after	O
the	O
start	O
of	O
infusion	O
of	O
l	B
-cis	I
-diltiazem	I
,	O
d	B
-cis	I
-diltiazem	I
or	O
tetrodotoxin	B
.	O

The	O
final	O
concentration	O
of	O
H2	B
O2	I
in	O
the	O
perfusate	O
was	O
set	O
to	O
1	O
mM.	O
Thus	O
,	O
the	O
concentration	O
of	O
H2	B
O2	I
used	O
in	O
the	O
second	O
series	O
of	O
experiments	O
was	O
higher	O
than	O
that	O
used	O
in	O
the	O
first	O
series	O
of	O
experiments	O
,	O
because	O
in	O
a	O
preliminary	O
experiment	O
,	O
a	O
high	O
concentration	O
of	O
H2	B
O2	I
was	O
needed	O
to	O
induce	O
mechanical	O
dysfunction	O
to	O
a	O
degree	O
similar	O
to	O
that	O
in	O
the	O
first	O
series	O
of	O
experiments	O
.	O

After	O
the	O
experiment	O
,	O
the	O
hearts	O
were	O
put	O
into	O
an	O
oven	O
(	O
80	O
°	O
C	O
)	O
for	O
48	O
h	O
,	O
in	O
order	O
to	O
measure	O
the	O
dry	O
weight	O
of	O
the	O
tissue	O
.	O

The	O
volume	O
of	O
intracellular	O
water	B
was	O
assumed	O
to	O
be	O
2.45	O
ml	O
g−1	O
dry	O
weight	O
(	O
Askenasy	O
et	O
al.	O
,	O
1995	O
)	O
.	O

2.7	O
Direct	O
effect	O
of	O
d	B
-cis	I
-diltiazem	I
and	O
l	B
-cis	I
-diltiazem	I
on	O
the	O
H2	B
O2	I
concentration	O
in	O
vitro	O
(	O
another	O
experiment	O
)	O
To	O
determine	O
whether	O
d	B
-cis	I
-	I
and	O
l	B
-cis	I
-diltiazem	I
have	O
a	O
direct	O
scavenging	O
effect	O
on	O
H2	B
O2	I
,	O
the	O
effect	O
of	O
d	B
-cis	I
-diltiazem	I
and	O
l	B
-cis	I
-diltiazem	I
on	O
the	O
H2	B
O2	I
concentration	O
was	O
investigated	O
and	O
compared	O
with	O
that	O
of	O
dimethylthiourea	B
,	O
which	O
has	O
an	O
H2	B
O2	I
-scavenging	O
action	O
(	O
Jackson	O
et	O
al.	O
,	O
1985	O
)	O
.	O

A	O
mixture	O
of	O
H2	B
O2	I
(	O
600	O
μM	O
)	O
and	O
d	B
-cis	I
-	I
or	O
l	B
-cis	I
-diltiazem	I
(	O
15	O
μM	O
)	O
or	O
that	O
of	O
H2	B
O2	I
(	O
600	O
μM	O
)	O
and	O
dimethylthiourea	B
(	O
10	O
mM	O
)	O
in	O
0.1	O
M	O
phosphate	B
buffer	O
(	O
pH	O
7.0	O
)	O
was	O
incubated	O
at	O
37	O
°	O
C	O
for	O
30	O
min	O
.	O

The	O
H2	B
O2	I
concentration	O
in	O
the	O
buffer	O
was	O
measured	O
according	O
to	O
a	O
spectrophotometric	O
method	O
(	O
Hayashi	O
et	O
al.	O
,	O
1989	O
)	O
.	O

2.8	O
Drugs	B
d	B
-cis	I
-Diltiazem	I
(	O
Sigma	O
)	O
,	O
l	B
-cis	I
-diltiazem	I
(	O
Tanabe	O
Seiyaku	O
,	O
Osaka	O
,	O
Japan	O
)	O
and	O
tetrodotoxin	O
(	O
Sankyo	O
,	O
Tokyo	O
,	O
Japan	O
)	O
were	O
dissolved	O
in	O
KHB	O
buffer	O
solution	O
.	O

These	O
agents	B
were	O
infused	O
at	O
a	O
flow	O
rate	O
of	O
0.1	O
ml	O
min−1	O
,	O
using	O
an	O
infusion	O
pump	O
,	O
into	O
the	O
inflow	O
tube	O
connected	O
to	O
the	O
side	O
arm	O
of	O
the	O
aortic	O
cannula	O
.	O

H2	B
O2	I
(	O
Nacalai	O
Tesque	O
,	O
Kyoto	O
,	O
Japan	O
)	O
was	O
diluted	O
with	O
saline	B
solution	O
.	O

H2	B
O2	I
was	O
also	O
infused	O
into	O
the	O
inflow	O
tube	O
at	O
a	O
flow	O
rate	O
of	O
0.1	O
ml	O
min−1	O
using	O
another	O
infusion	O
pump	O
.	O

Dimethylthiourea	B
was	O
purchased	O
from	O
Aldrich	O
Chemical	O
(	O
St.	O
Louis	O
,	O
USA	O
)	O
.	O

The	O
reagents	B
and	O
enzymes	O
used	O
for	O
biochemical	O
analysis	O
were	O
purchased	O
from	O
Sigma	O
.	O

Na4	B
HTmDOTP	I
was	O
purchased	O
from	O
Magnetic	O
Resonance	O
Solutions	O
(	O
Dallas	O
,	O
USA	O
)	O
.	O

Tris3	B
Dy	I
(	I
TTHA	I
)	I
·3Tris	I
–	I
HCl	I
(	O
50	O
mM	O
)	O
was	O
prepared	O
by	O
mixing	O
DyCl3	B
·	I
6H2	I
O	I
(	O
Sigma	O
)	O
(	O
50	O
mM	O
)	O
with	O
H6	B
TTHA	I
(	O
Sigma	O
)	O
(	O
50	O
mM	O
)	O
in	O
the	O
Tris	B
buffer	O
(	O
pH	O
7.4	O
)	O
.	O

2.9	O
Statistical	O
analysis	O
All	O
values	O
are	O
expressed	O
as	O
means±S.E.M.	O
When	O
changes	O
in	O
left	O
ventricular	O
systolic	O
pressure	O
,	O
left	O
ventricular	O
end	O
-	O
diastolic	O
pressure	O
,	O
left	O
ventricular	O
developed	O
pressure	O
,	O
LDH	O
release	O
and	O
[	B
Na+	I
]	I
i	I
were	O
compared	O
between	O
vehicle	O
-	O
treated	O
and	O
drug	B
-	O
treated	O
groups	O
,	O
statistical	O
analysis	O
was	O
performed	O
with	O
a	O
two	O
-	O
way	O
repeated	O
measures	O
analysis	O
of	O
variance	O
(	O
ANOVA	O
)	O
followed	O
by	O
Dunnett	O
's	O
test	O
for	O
multiple	O
comparisons	O
.	O

If	O
a	O
significant	O
difference	O
was	O
obtained	O
between	O
these	O
groups	O
,	O
further	O
comparisons	O
at	O
each	O
time	O
point	O
were	O
performed	O
by	O
means	O
of	O
Dunnett	O
's	O
test	O
(	O
Fig.	O
1	O
Figs.	O
3	O
,	O
4	O
and	O
6	O
and	O
8	O
)	O
.	O

When	O
the	O
tissue	O
levels	O
of	O
energy	O
metabolites	B
in	O
the	O
vehicle	O
group	O
were	O
compared	O
between	O
H2	B
O2	I
-untreated	O
and	O
H2	B
O2	I
-treated	O
hearts	O
,	O
unpaired	O
Student	O
's	O
t	O
-test	O
was	O
used	O
(	O
Fig.	O
2	O
Fig.	O
5	O
)	O
.	O

When	O
the	O
tissue	O
levels	O
of	O
energy	O
metabolites	B
and	O
the	O
H2	B
O2	I
concentration	O
were	O
compared	O
between	O
vehicle	O
-	O
treated	O
and	O
drug	B
-	O
treated	O
groups	O
,	O
statistical	O
analysis	O
was	O
performed	O
with	O
a	O
one	O
-	O
way	O
ANOVA	O
followed	O
by	O
Dunnett	O
's	O
test	O
for	O
multiple	O
comparisons	O
(	O
Figs.	O
2	O
and	O
5	O
,	O
Table	O
1	O
)	O
.	O

A	O
difference	O
was	O
considered	O
statistically	O
significant	O
at	O
P	O
<	O
0.05	O
.	O

3	O
Results	O
3.1	O
Effects	O
of	O
d	B
-cis	I
-	I
and	O
l	B
-cis	I
-diltiazem	I
on	O
H2	B
O2	I
-induced	O
mechanical	O
derangements	O
in	O
the	O
heart	O
Fig.	O
1	O
shows	O
the	O
effect	O
of	O
various	O
concentrations	O
of	O
l	B
-cis	I
-diltiazem	I
(	O
5	O
,	O
10	O
or	O
15	O
μM	O
)	O
on	O
the	O
H2	B
O2	I
-induced	O
mechanical	O
dysfunction	O
.	O

Before	O
the	O
start	O
of	O
the	O
infusion	O
of	O
l	B
-cis	I
-diltiazem	I
(	O
0	O
,	O
5	O
and	O
10	O
min	O
in	O
Fig.	O
1	O
)	O
,	O
there	O
was	O
no	O
significant	O
difference	O
in	O
the	O
values	O
of	O
left	O
ventricular	O
systolic	O
pressure	O
and	O
left	O
ventricular	O
end	O
-	O
diastolic	O
pressure	O
between	O
the	O
vehicle	O
and	O
l	B
-cis	I
-diltiazem	I
groups	O
.	O

No	O
concentration	O
of	O
l	B
-cis	I
-diltiazem	I
(	O
5	O
,	O
10	O
or	O
15	O
μM	O
)	O
had	O
a	O
significant	O
action	O
on	O
left	O
ventricular	O
systolic	O
pressure	O
and	O
left	O
ventricular	O
end	O
-	O
diastolic	O
pressure	O
before	O
H2	B
O2	I
infusion	O
(	O
20	O
min	O
in	O
Fig.	O
1	O
)	O
.	O

In	O
the	O
vehicle	O
group	O
,	O
H2	B
O2	I
produced	O
a	O
temporary	O
,	O
but	O
marked	O
decrease	O
in	O
left	O
ventricular	O
systolic	O
pressure	O
(	O
P	O
<	O
0.001	O
by	O
ANOVA	O
)	O
,	O
which	O
was	O
followed	O
by	O
incomplete	O
recovery	O
to	O
the	O
initial	O
level	O
.	O

H2	B
O2	I
also	O
produced	O
a	O
marked	O
increase	O
in	O
left	O
ventricular	O
end	O
-	O
diastolic	O
pressure	O
(	O
P	O
<	O
0.001	O
by	O
ANOVA	O
)	O
,	O
which	O
was	O
accompanied	O
by	O
an	O
increase	O
in	O
left	O
ventricular	O
systolic	O
pressure	O
.	O

The	O
decrease	O
in	O
left	O
ventricular	O
systolic	O
pressure	O
induced	O
by	O
H2	B
O2	I
was	O
not	O
significantly	O
modified	O
by	O
any	O
concentration	O
of	O
l	B
-cis	I
-diltiazem	I
(	O
P	O
=	O
0.616	O
by	O
ANOVA	O
)	O
.	O

In	O
contrast	O
,	O
a	O
high	O
concentration	O
of	O
l	B
-cis	I
-diltiazem	I
(	O
15	O
μM	O
)	O
significantly	O
attenuated	O
the	O
H2	B
O2	I
-induced	O
increase	O
in	O
left	O
ventricular	O
end	O
-	O
diastolic	O
pressure	O
(	O
P	O
<	O
0.05	O
by	O
ANOVA	O
followed	O
by	O
Dunnett	O
's	O
test	O
)	O
,	O
although	O
lower	O
concentrations	O
of	O
l	B
-cis	I
-diltiazem	I
(	O
5	O
or	O
10	O
μM	O
)	O
did	O
not	O
.	O

Fig.	O
2	O
shows	O
the	O
effects	O
of	O
various	O
concentrations	O
of	O
l	B
-cis	I
-diltiazem	I
(	O
5	O
,	O
10	O
or	O
15	O
μM	O
)	O
on	O
the	O
H2	B
O2	I
-induced	O
decrease	O
in	O
the	O
tissue	O
levels	O
of	O
high	O
-	O
energy	O
phosphates	B
.	O

In	O
the	O
vehicle	O
group	O
,	O
H2	B
O2	I
decreased	O
the	O
tissue	O
levels	O
of	O
ATP	B
,	O
ADP	B
and	O
creatine	B
phosphate	I
and	O
increased	O
the	O
tissue	O
level	O
of	O
AMP	B
(	O
P	O
<	O
0.05	O
)	O
.	O

These	O
changes	O
in	O
the	O
tissue	O
levels	O
of	O
high	O
-	O
energy	O
phosphates	B
were	O
not	O
attenuated	O
by	O
lower	O
concentrations	O
of	O
l	B
-cis	I
-diltiazem	I
(	O
5	O
or	O
10	O
μM	O
)	O
.	O

However	O
,	O
a	O
high	O
concentration	O
of	O
l	B
-cis	I
-diltiazem	I
(	O
15	O
μM	O
)	O
significantly	O
attenuated	O
the	O
H2	B
O2	I
-induced	O
changes	O
in	O
the	O
tissue	O
levels	O
of	O
ATP	B
,	O
AMP	B
and	O
creatine	B
phosphate	I
(	O
P	O
<	O
0.05	O
by	O
ANOVA	O
followed	O
by	O
Dunnett	O
's	O
test	O
)	O
.	O

These	O
results	O
suggest	O
that	O
at	O
the	O
concentration	O
of	O
15	O
μM	O
,	O
l	B
-cis	I
-diltiazem	I
attenuates	O
the	O
H2	B
O2	I
-induced	O
mechanical	O
and	O
metabolic	O
derangements	O
in	O
the	O
heart	O
.	O

Next	O
,	O
the	O
effect	O
of	O
l	B
-cis	I
-diltiazem	I
(	O
15	O
μM	O
)	O
was	O
compared	O
with	O
that	O
of	O
d	B
-cis	I
-diltiazem	I
(	O
15	O
μM	O
)	O
.	O

Fig.	O
3	O
shows	O
the	O
effects	O
of	O
d	B
-cis	I
-diltiazem	I
(	O
15	O
μM	O
)	O
and	O
l	B
-cis	I
-diltiazem	I
(	O
15	O
μM	O
)	O
on	O
the	O
H2	B
O2	I
-induced	O
changes	O
in	O
left	O
ventricular	O
systolic	O
pressure	O
and	O
left	O
ventricular	O
end	O
-	O
diastolic	O
pressure	O
.	O

Before	O
the	O
infusion	O
of	O
d	B
-cis	I
-	I
or	O
l	B
-cis	I
-diltiazem	I
(	O
0	O
,	O
5	O
and	O
10	O
min	O
in	O
Fig.	O
3	O
)	O
,	O
there	O
was	O
no	O
significant	O
difference	O
in	O
the	O
values	O
of	O
left	O
ventricular	O
systolic	O
pressure	O
and	O
left	O
ventricular	O
end	O
-	O
diastolic	O
pressure	O
among	O
vehicle	O
,	O
d	B
-cis	I
-diltiazem	I
and	O
l	B
-cis	I
-diltiazem	I
groups	O
.	O

Before	O
the	O
H2	B
O2	I
infusion	O
(	O
15	O
and	O
20	O
min	O
in	O
Fig.	O
3	O
)	O
,	O
there	O
was	O
a	O
significant	O
decrease	O
in	O
the	O
left	O
ventricular	O
systolic	O
pressure	O
in	O
the	O
d	B
-cis	I
-diltiazem	I
group	O
(	O
P	O
<	O
0.05	O
by	O
ANOVA	O
followed	O
by	O
Dunnett	O
's	O
test	O
)	O
,	O
while	O
there	O
was	O
no	O
decrease	O
in	O
the	O
l	B
-cis	I
-diltiazem	I
group	O
;	O
left	O
ventricular	O
systolic	O
pressure	O
decreased	O
only	O
in	O
the	O
d	B
-cis	I
-diltiazem	I
group	O
(	O
15–55	O
min	O
in	O
Fig.	O
3	O
)	O
.	O

As	O
seen	O
in	O
Fig.	O
1	O
,	O
in	O
the	O
vehicle	O
group	O
H2	B
O2	I
decreased	O
left	O
ventricular	O
systolic	O
pressure	O
(	O
P	O
<	O
0.001	O
by	O
ANOVA	O
)	O
and	O
increased	O
left	O
ventricular	O
end	O
-	O
diastolic	O
pressure	O
(	O
P	O
<	O
0.001	O
by	O
ANOVA	O
)	O
.	O

It	O
is	O
noteworthy	O
,	O
however	O
,	O
that	O
both	O
d	B
-cis	I
-	I
and	O
l	B
-cis	I
-diltiazem	I
attenuated	O
significantly	O
the	O
H2	B
O2	I
-induced	O
increase	O
in	O
left	O
ventricular	O
end	O
-	O
diastolic	O
pressure	O
(	O
P	O
<	O
0.05	O
by	O
ANOVA	O
followed	O
by	O
Dunnett	O
's	O
test	O
)	O
.	O

Fig.	O
4	O
shows	O
the	O
effects	O
of	O
d	B
-cis	I
-diltiazem	I
(	O
15	O
μM	O
)	O
and	O
l	B
-cis	I
-diltiazem	I
(	O
15	O
μM	O
)	O
on	O
the	O
H2	B
O2	I
-induced	O
decrease	O
in	O
left	O
ventricular	O
developed	O
pressure	O
,	O
which	O
is	O
expressed	O
as	O
left	O
ventricular	O
systolic	O
pressure	O
minus	O
left	O
ventricular	O
end	O
-	O
diastolic	O
pressure	O
.	O

Before	O
the	O
infusion	O
of	O
d	B
-cis	I
-	I
or	O
l	B
-cis	I
-diltiazem	I
(	O
0	O
,	O
5	O
and	O
10	O
min	O
in	O
Fig.	O
4	O
)	O
,	O
there	O
was	O
no	O
significant	O
difference	O
in	O
the	O
left	O
ventricular	O
developed	O
pressure	O
value	O
among	O
vehicle	O
,	O
d	B
-cis	I
-	I
and	O
l	B
-cis	I
-diltiazem	I
groups	O
.	O

Before	O
the	O
H2	B
O2	I
infusion	O
(	O
15	O
and	O
20	O
min	O
in	O
Fig.	O
4	O
)	O
,	O
there	O
was	O
a	O
significant	O
decrease	O
in	O
the	O
left	O
ventricular	O
developed	O
pressure	O
in	O
the	O
d	B
-cis	I
-diltiazem	I
group	O
(	O
P	O
<	O
0.05	O
by	O
ANOVA	O
followed	O
by	O
Dunnett	O
's	O
test	O
)	O
,	O
while	O
there	O
was	O
no	O
decrease	O
in	O
the	O
l	B
-cis	I
-diltiazem	I
group	O
;	O
d	B
-cis	I
-diltiazem	I
alone	O
decreased	O
left	O
ventricular	O
developed	O
pressure	O
(	O
15–55	O
min	O
in	O
Fig.	O
4	O
)	O
.	O

In	O
the	O
vehicle	O
group	O
,	O
H2	B
O2	I
decreased	O
left	O
ventricular	O
developed	O
pressure	O
markedly	O
(	O
P	O
<	O
0.001	O
by	O
ANOVA	O
)	O
.	O

l	B
-cis	I
-Diltiazem	I
attenuated	O
significantly	O
the	O
H2	B
O2	I
-induced	O
decrease	O
in	O
left	O
ventricular	O
developed	O
pressure	O
(	O
P	O
<	O
0.001	O
by	O
ANOVA	O
followed	O
by	O
Dunnett	O
's	O
test	O
)	O
,	O
whereas	O
d	B
-cis	I
-diltiazem	I
did	O
not	O
attenuate	O
it	O
,	O
probably	O
because	O
of	O
its	O
cardiodepressive	O
action	O
.	O

Thus	O
,	O
l	B
-cis	I
-diltiazem	I
(	O
15	O
μM	O
)	O
attenuated	O
the	O
H2	B
O2	I
-induced	O
changes	O
in	O
both	O
left	O
ventricular	O
developed	O
pressure	O
and	O
left	O
ventricular	O
end	O
-	O
diastolic	O
pressure	O
.	O

Fig.	O
5	O
shows	O
the	O
tissue	O
levels	O
of	O
ATP	B
,	O
ADP	B
,	O
AMP	B
and	O
creatine	B
phosphate	I
in	O
the	O
vehicle	O
,	O
d	B
-cis	I
-diltiazem	I
(	O
15	O
μM	O
)	O
and	O
l	B
-cis	I
-diltiazem	I
(	O
15	O
μM	O
)	O
groups	O
before	O
H2	B
O2	I
infusion	O
(	O
20	O
min	O
in	O
Fig.	O
4	O
)	O
and	O
after	O
the	O
H2	B
O2	I
infusion	O
(	O
55	O
min	O
in	O
Fig.	O
4	O
)	O
.	O

The	O
tissue	O
levels	O
of	O
ATP	B
,	O
ADP	B
,	O
AMP	B
and	O
creatine	B
phosphate	I
before	O
H2	B
O2	I
infusion	O
were	O
similar	O
among	O
the	O
vehicle	O
,	O
d	B
-cis	I
-diltiazem	I
and	O
l	B
-cis	I
-diltiazem	I
groups	O
(	O
P	O
>	O
0.05	O
by	O
ANOVA	O
)	O
.	O

In	O
the	O
vehicle	O
group	O
,	O
H2	B
O2	I
decreased	O
the	O
tissue	O
levels	O
of	O
ATP	B
,	O
ADP	B
and	O
creatine	B
phosphate	I
,	O
and	O
increased	O
the	O
tissue	O
level	O
of	O
AMP	B
(	O
P	O
<	O
0.05	O
)	O
.	O

These	O
changes	O
in	O
the	O
tissue	O
levels	O
of	O
energy	O
metabolites	B
induced	O
by	O
H2	B
O2	I
were	O
significantly	O
attenuated	O
by	O
d	B
-cis	I
-diltiazem	I
(	O
P	O
<	O
0.01	O
by	O
ANOVA	O
followed	O
by	O
Dunnett	O
's	O
test	O
)	O
.	O

l	B
-cis	I
-Diltiazem	I
also	O
attenuated	O
the	O
H2	B
O2	I
-induced	O
changes	O
in	O
the	O
tissue	O
levels	O
of	O
ATP	B
,	O
AMP	B
and	O
creatine	B
phosphate	I
(	O
P	O
<	O
0.01	O
by	O
ANOVA	O
followed	O
by	O
Dunnett	O
's	O
test	O
)	O
,	O
although	O
it	O
failed	O
to	O
attenuate	O
the	O
H2	B
O2	I
-induced	O
decrease	O
in	O
the	O
tissue	O
level	O
of	O
ADP	B
.	O

These	O
results	O
suggest	O
that	O
both	O
d	B
-cis	I
-	O
and	O
l	B
-cis	I
-diltiazem	I
attenuate	O
the	O
H2	B
O2	I
-induced	O
decrease	O
in	O
high	O
-	O
energy	O
phosphates	B
in	O
the	O
heart	O
.	O

Fig.	O
6	O
shows	O
the	O
effects	O
of	O
d	B
-cis	I
-diltiazem	I
(	O
15	O
μM	O
)	O
and	O
l	B
-cis	I
-diltiazem	I
(	O
15	O
μM	O
)	O
on	O
the	O
H2	B
O2	I
-induced	O
release	O
of	O
LDH	O
.	O

In	O
the	O
vehicle	O
,	O
d	B
-cis	I
-diltiazem	I
and	O
l	B
-cis	I
-diltiazem	I
groups	O
,	O
there	O
was	O
no	O
significant	O
difference	O
in	O
the	O
release	O
of	O
LDH	O
before	O
H2	B
O2	I
infusion	O
.	O

In	O
the	O
vehicle	O
group	O
,	O
H2	B
O2	I
produced	O
a	O
marked	O
release	O
of	O
LDH	O
from	O
the	O
myocardium	O
into	O
the	O
effluent	O
(	O
P	O
<	O
0.001	O
by	O
ANOVA	O
)	O
;	O
the	O
LDH	O
release	O
reached	O
a	O
maximum	O
21.5	O
min	O
after	O
the	O
end	O
of	O
H2	B
O2	I
infusion	O
(	O
35	O
min	O
in	O
Fig.	O
6	O
)	O
.	O

The	O
LDH	O
release	O
induced	O
by	O
H2	B
O2	I
was	O
significantly	O
attenuated	O
by	O
d	B
-cis	I
-	I
or	O
l	B
-cis	I
-diltiazem	I
(	O
P	O
<	O
0.05	O
by	O
ANOVA	O
followed	O
by	O
Dunnett	O
's	O
test	O
)	O
.	O

These	O
results	O
suggest	O
that	O
both	O
d	B
-cis	I
-	I
and	O
l	B
-cis	I
-diltiazem	I
attenuate	O
the	O
H2	B
O2	I
-induced	O
damage	O
of	O
the	O
cardiac	O
cell	O
membrane	O
.	O

3.2	O
Effect	O
of	O
d	B
-cis	I
-	I
and	O
l	B
-cis	I
-diltiazem	I
on	O
H2	B
O2	I
-induced	O
changes	O
in	O
[	B
Na+	I
]	I
i	I
Fig.	O
7	O
shows	O
typical	O
23	O
Na	O
spectra	O
for	O
the	O
rat	O
heart	O
in	O
the	O
presence	O
of	O
the	O
23	B
Na	I
shift	I
reagent	I
Tm	B
(	I
DOTP	I
)	I
5−	I
.	O

H2	B
O2	I
(	O
1	O
mM	O
)	O
was	O
added	O
to	O
the	O
heart	O
for	O
4	O
min	O
(	O
from	O
15	O
to	O
19	O
min	O
in	O
Fig.	O
7	O
)	O
.	O

It	O
is	O
evident	O
that	O
in	O
the	O
vehicle	O
group	O
,	O
H2	B
O2	I
caused	O
an	O
increase	O
in	O
the	O
peak	O
of	O
[	B
Na+	I
]	I
i	I
,	O
which	O
was	O
markedly	O
attenuated	O
by	O
d	B
-cis	I
-diltiazem	I
(	O
15	O
μM	O
)	O
,	O
l	B
-cis	I
-diltiazem	I
(	O
15	O
μM	O
)	O
or	O
tetrodotoxin	B
(	O
3	O
μM	O
)	O
.	O

Fig.	O
8	O
shows	O
the	O
effects	O
of	O
d	B
-cis	I
-diltiazem	I
(	O
15	O
μM	O
)	O
,	O
l	B
-cis	I
-diltiazem	I
(	O
15	O
μM	O
)	O
and	O
tetrodotoxin	B
(	O
3	O
μM	O
)	O
on	O
the	O
H2	B
O2	I
-induced	O
increase	O
in	O
[	B
Na+	I
]	I
i	I
in	O
myocardial	O
cells	O
.	O

In	O
the	O
vehicle	O
group	O
,	O
H2	B
O2	I
(	O
1	O
mM	O
)	O
increased	O
[	B
Na+	I
]	I
i	I
markedly	O
(	O
P	O
<	O
0.001	O
by	O
ANOVA	O
)	O
and	O
the	O
increase	O
reached	O
a	O
maximum	O
20	O
min	O
after	O
the	O
end	O
of	O
H2	B
O2	I
infusion	O
(	O
34	O
min	O
in	O
Fig.	O
8	O
)	O
.	O

The	O
increase	O
in	O
[	B
Na+	I
]	I
i	I
induced	O
by	O
H2	B
O2	I
was	O
almost	O
completely	O
inhibited	O
by	O
d	B
-cis	I
-	I
or	O
l	B
-cis	I
-diltiazem	I
(	O
P	O
<	O
0.05	O
by	O
ANOVA	O
followed	O
by	O
Dunnett	O
's	O
test	O
)	O
.	O

Tetrodotoxin	B
also	O
attenuated	O
the	O
H2	B
O2	I
-induced	O
increase	O
in	O
[	B
Na+	I
]	I
i	I
(	O
P	O
<	O
0.05	O
by	O
ANOVA	O
followed	O
by	O
Dunnett	O
's	O
test	O
)	O
.	O

These	O
results	O
suggest	O
that	O
both	O
d	B
-cis	I
-	O
and	O
l	B
-cis	I
-diltiazem	I
attenuate	O
the	O
intracellular	O
accumulation	O
of	O
intracellular	O
Na+	B
induced	O
by	O
H2	B
O2	I
.	O

In	O
the	O
second	O
series	O
of	O
experiments	O
,	O
we	O
also	O
continuously	O
recorded	O
the	O
mechanical	O
function	O
(	O
left	O
ventricular	O
pressure	O
)	O
of	O
the	O
heart	O
,	O
and	O
similar	O
results	O
as	O
in	O
the	O
first	O
series	O
of	O
experiments	O
(	O
Fig.	O
3	O
)	O
were	O
obtained	O
:	O
H2	B
O2	I
decreased	O
left	O
ventricular	O
systolic	O
pressure	O
and	O
increased	O
left	O
ventricular	O
end	O
-	O
diastolic	O
pressure	O
,	O
and	O
the	O
H2	B
O2	I
-induced	O
increase	O
in	O
left	O
ventricular	O
end	O
-	O
diastolic	O
pressure	O
was	O
attenuated	O
by	O
d	B
-cis	I
-diltiazem	I
(	O
15	O
μM	O
)	O
,	O
l	B
-cis	I
-diltiazem	I
(	O
15	O
μM	O
)	O
or	O
tetrodotoxin	B
(	O
data	O
not	O
shown	O
)	O
.	O

If	O
d	B
-cis	I
-	I
and	O
l	B
-cis	I
-diltiazem	I
have	O
a	O
Na+	O
channel	O
blocking	O
action	O
,	O
[	B
Na+	I
]	I
i	I
in	O
normal	O
cardiac	O
cells	O
(	O
without	O
H2	B
O2	I
)	O
should	O
decrease	O
after	O
treatment	O
of	O
the	O
heart	O
with	O
d	B
-cis	I
-	I
or	O
l	B
-cis	I
-diltiazem	I
.	O

However	O
,	O
neither	O
tetrodotoxin	B
,	O
nor	O
d	B
-cis	I
-	I
and	O
l	B
-cis	I
-diltiazem	I
changed	O
[	B
Na+	I
]	I
i	I
in	O
the	O
normal	O
cardiac	O
cells	O
:	O
[	B
Na+	I
]	I
i	I
remained	O
unchanged	O
within	O
the	O
accuracy	O
of	O
the	O
assay	O
.	O

3.3	O
Effect	O
of	O
d	B
-cis	I
-	I
and	O
l	B
-cis	I
-diltiazem	I
on	O
the	O
concentration	O
of	O
H2	B
O2	I
in	O
the	O
buffer	O
solution	O
in	O
vitro	O
We	O
examined	O
whether	O
d	B
-cis	I
-	I
and	O
l	B
-cis	I
-diltiazem	I
have	O
a	O
direct	O
scavenging	B
effect	O
on	O
H2	B
O2	I
in	O
vitro	O
.	O

d	B
-cis	I
-	I
or	O
l	B
-cis	I
-Diltiazem	I
,	O
however	O
,	O
did	O
not	O
modify	O
the	O
H2	B
O2	I
concentration	O
in	O
the	O
buffer	O
solution	O
(	O
Table	O
1	O
)	O
.	O

In	O
contrast	O
,	O
dimethylthiourea	B
,	O
which	O
has	O
a	O
H2	B
O2	I
-scavenging	O
action	O
,	O
decreased	O
the	O
H2	B
O2	I
concentration	O
markedly	O
.	O

These	O
results	O
suggest	O
that	O
neither	O
d	B
-cis	I
-diltiazem	I
nor	O
l	B
-cis	I
-diltiazem	I
has	O
a	O
direct	O
scavenging	O
action	O
on	O
H2	B
O2	I
in	O
vitro	O
.	O

4	O
Discussion	O
In	O
the	O
present	O
study	O
,	O
we	O
examined	O
the	O
effect	O
of	O
d	B
-cis	I
-	I
and	O
l	B
-cis	I
-diltiazem	I
on	O
the	O
H2	B
O2	I
-induced	O
myocardial	O
derangements	O
in	O
the	O
isolated	O
perfused	O
rat	O
heart	O
.	O

l	B
-cis	I
-Diltiazem	I
is	O
an	O
optical	O
isomer	O
of	O
d	B
-cis	I
-diltiazem	I
and	O
is	O
about	O
20–100	O
times	O
less	O
potent	O
than	O
d	B
-cis	I
-diltiazem	I
in	O
its	O
Ca2	O
+	O
channel	O
blocking	O
action	O
(	O
Nasa	O
et	O
al.	O
,	O
1992	O
;	O
Itogawa	O
et	O
al.	O
,	O
1996	O
)	O
.	O

We	O
used	O
H2	B
O2	I
as	O
a	O
substance	O
that	O
may	O
be	O
responsible	O
for	O
ischemic	O
derangements	O
for	O
the	O
following	O
reasons	O
:	O
(	O
1	O
)	O
H2	B
O2	I
and	O
its	O
metabolite	B
,	O
hydroxyl	B
radical	I
,	O
are	O
considered	O
important	O
in	O
the	O
pathogenesis	O
of	O
myocardial	O
damage	O
induced	O
by	O
ischemia	O
–	O
reperfusion	O
(	O
Brown	O
et	O
al.	O
,	O
1988	O
;	O
Loesser	O
et	O
al.	O
,	O
1991	O
)	O
;	O
(	O
2	O
)	O
H2	B
O2	I
penetrates	O
the	O
cell	O
membrane	O
and	O
reaches	O
the	O
intracellular	O
site	O
(	O
Fisher	O
,	O
1988	O
)	O
,	O
and	O
therefore	O
it	O
may	O
produce	O
severe	O
damage	O
to	O
the	O
cell	O
.	O

In	O
the	O
first	O
series	O
of	O
experiments	O
,	O
H2	B
O2	I
produced	O
an	O
increase	O
in	O
left	O
ventricular	O
end	O
-	O
diastolic	O
pressure	O
and	O
a	O
decrease	O
in	O
left	O
ventricular	O
developed	O
pressure	O
(	O
i.e.	O
,	O
mechanical	O
dysfunction	O
)	O
,	O
a	O
decrease	O
in	O
the	O
tissue	O
levels	O
of	O
ATP	B
and	O
creatine	B
phosphate	I
and	O
an	O
increase	O
in	O
the	O
tissue	O
AMP	B
level	O
(	O
i.e.	O
,	O
energy	O
deficiency	O
)	O
,	O
and	O
an	O
increase	O
in	O
LDH	O
release	O
from	O
the	O
myocardium	O
(	O
i.e.	O
,	O
membrane	O
damage	O
)	O
.	O

These	O
alterations	O
induced	O
by	O
H2	B
O2	I
were	O
attenuated	O
by	O
l	B
-cis	I
-diltiazem	I
(	O
15	O
μM	O
)	O
.	O

In	O
contrast	O
to	O
l	B
-cis	I
-diltiazem	I
,	O
d	B
-cis	I
-diltiazem	I
(	O
15	O
μM	O
)	O
failed	O
to	O
attenuate	O
the	O
decrease	O
in	O
left	O
ventricular	O
developed	O
pressure	O
induced	O
by	O
H2	B
O2	I
,	O
because	O
d	B
-cis	I
-diltiazem	I
has	O
a	O
potent	O
Ca2	O
+	O
channel	O
blocking	O
action	O
,	O
leading	O
to	O
a	O
decrease	O
in	O
mechanical	O
function	O
.	O

In	O
fact	O
,	O
the	O
cardiodepressive	O
action	O
of	O
d	B
-cis	I
-diltiazem	I
was	O
observed	O
before	O
H2	B
O2	I
infusion	O
.	O

These	O
results	O
suggest	O
that	O
both	O
d	B
-cis	I
-	I
and	O
l	B
-cis	I
-diltiazem	I
protect	O
the	O
myocardium	O
against	O
the	O
H2	B
O2	I
-induced	O
derangements	O
,	O
and	O
that	O
their	O
cardioprotective	O
action	O
is	O
not	O
only	O
due	O
to	O
the	O
Ca2	O
+	O
channel	O
blocking	O
action	O
.	O

Some	O
radical	O
scavengers	O
or	O
anti	O
-	O
oxidants	O
have	O
been	O
demonstrated	O
to	O
protect	O
the	O
myocardium	O
against	O
oxidative	O
stress	O
(	O
Nakaya	O
et	O
al.	O
,	O
1987	O
;	O
Weglicki	O
et	O
al.	O
,	O
1990	O
;	O
Nagy	O
et	O
al.	O
,	O
1996	O
)	O
.	O

In	O
fact	O
,	O
we	O
have	O
reported	O
that	O
,	O
in	O
the	O
isolated	O
perfused	O
rat	O
heart	O
,	O
catalase	O
(	O
a	O
H2	B
O2	I
scavenger	O
)	O
(	O
Hara	O
et	O
al.	O
,	O
1993	O
)	O
or	O
propofol	B
(	O
an	O
intravenous	O
anesthetic	O
drug	B
with	O
an	O
anti	O
-	O
oxidant	O
action	O
)	O
(	O
Kokita	O
and	O
Hara	O
,	O
1996	O
)	O
attenuates	O
the	O
H2	B
O2	I
-induced	O
mechanical	O
dysfunction	O
and	O
the	O
decrease	O
in	O
the	O
tissue	O
levels	O
of	O
high	O
-	O
energy	O
phosphates	B
.	O

There	O
is	O
evidence	O
to	O
show	O
that	O
d	B
-cis	I
-diltiazem	I
has	O
an	O
anti	O
-	O
oxidant	O
action	O
(	O
Janero	O
et	O
al.	O
,	O
1988	O
;	O
Mak	O
and	O
Weglicki	O
,	O
1990	O
;	O
Weglicki	O
et	O
al.	O
,	O
1990	O
)	O
,	O
whereas	O
there	O
is	O
no	O
information	O
about	O
the	O
anti	O
-	O
oxidant	O
action	O
of	O
l	B
-cis	I
-diltiazem	I
.	O

The	O
concentration	O
of	O
d	B
-cis	I
-diltiazem	I
required	O
for	O
its	O
anti	O
-	O
oxidant	O
action	O
is	O
much	O
higher	O
than	O
that	O
used	O
in	O
the	O
present	O
study	O
;	O
in	O
the	O
sarcolemmal	O
membrane	O
,	O
the	O
concentration	O
required	O
to	O
inhibit	B
50	O
%	O
of	O
lipid	B
peroxidation	O
(	O
IC50	O
)	O
induced	O
by	O
oxygen	B
radicals	B
is	O
510	O
μM	O
(	O
Janero	O
et	O
al.	O
,	O
1988	O
)	O
or	O
850	O
μM	O
(	O
Mak	O
and	O
Weglicki	O
,	O
1990	O
)	O
.	O

In	O
the	O
present	O
study	O
,	O
neither	O
d	B
-cis	I
-diltiazem	I
(	O
15	O
μM	O
)	O
nor	O
l	B
-cis	I
-diltiazem	I
(	O
15	O
μM	O
)	O
modified	O
the	O
H2	B
O2	I
concentration	O
in	O
the	O
buffer	O
solution	O
in	O
vitro	O
.	O

It	O
is	O
unlikely	O
,	O
therefore	O
,	O
that	O
the	O
protective	O
effect	O
of	O
d	B
-cis	I
-	I
and	O
l	B
-cis	I
-diltiazem	I
on	O
the	O
H2	B
O2	I
-induced	O
derangements	O
is	O
due	O
to	O
the	O
radical	B
scavenging	O
or	O
anti	O
-	O
oxidant	O
effect	O
.	O

According	O
to	O
recent	O
electrophysiological	O
studies	O
,	O
H2	B
O2	I
causes	O
an	O
increase	O
in	O
Na+	B
current	O
in	O
ventricular	O
myocytes	O
,	O
an	O
increase	O
which	O
is	O
blocked	O
by	O
tetrodotoxin	B
(	O
Bhatnagar	O
et	O
al.	O
,	O
1990	O
;	O
Ward	O
and	O
Giles	O
,	O
1997	O
)	O
.	O

Ver	O
Donck	O
and	O
Borgers	O
(	O
1991	O
)	O
have	O
suggested	O
that	O
the	O
reactive	B
oxygen	I
species	I
causes	O
excessive	O
Na+	B
entry	O
through	O
the	O
fast	O
Na+	O
channel	O
,	O
leading	O
to	O
intracellular	O
Ca2	B
+	I
overload	O
through	O
the	O
Na+	B
–Ca2	O
+	B
exchange	O
system	O
,	O
and	O
hence	O
myocardial	O
damage	O
.	O

In	O
fact	O
,	O
H2	B
O2	I
increases	O
intracellular	O
concentrations	O
of	O
both	O
Na+	B
and	O
Ca2	B
+	I
in	O
the	O
myocardium	O
(	O
Yanagida	O
et	O
al.	O
,	O
1995	O
)	O
.	O

Interestingly	O
,	O
both	O
d	B
-cis	I
-	I
and	O
l	B
-cis	I
-diltiazem	I
have	O
been	O
demonstrated	O
to	O
block	O
the	O
Na+	O
channel	O
(	O
Nakajima	O
et	O
al.	O
,	O
1975	O
;	O
Itogawa	O
et	O
al.	O
,	O
1996	O
)	O
.	O

Itogawa	O
et	O
al.	O
(	O
1996	O
)	O
reported	O
that	O
both	O
d	B
-cis	I
-	I
and	O
l	B
-cis	I
-diltiazem	I
inhibited	O
the	O
veratridine	B
(	O
a	O
Na+	O
channel	O
opener	O
)	O
-induced	O
increase	O
in	O
[	B
Na+	I
]	I
i	I
and	O
hypercontracture	O
in	O
rat	O
myocytes	O
at	O
the	O
concentration	O
of	O
10	O
μM	O
or	O
higher	O
.	O

There	O
is	O
a	O
possibility	O
,	O
therefore	O
,	O
that	O
the	O
beneficial	O
effect	O
of	O
d	B
-cis	I
-	O
and	O
l	B
-cis	I
-diltiazem	I
on	O
the	O
H2	B
O2	I
-induced	O
derangements	O
is	O
due	O
to	O
their	O
blocking	O
effect	O
on	O
the	O
Na+	O
channel	O
.	O

To	O
determine	O
this	O
possibility	O
,	O
we	O
examined	O
the	O
effect	O
of	O
d	B
-cis	I
-	I
and	O
l	B
-cis	I
-diltiazem	I
on	O
the	O
H2	B
O2	I
-induced	O
increase	O
in	O
[	B
Na+	I
]	I
i	I
in	O
the	O
myocardium	O
using	O
an	O
NMR	O
technique	O
(	O
the	O
second	O
series	O
of	O
experiments	O
)	O
.	O

We	O
used	O
a	O
higher	O
concentration	O
of	O
H2	B
O2	I
in	O
the	O
second	O
series	O
of	O
experiments	O
than	O
in	O
the	O
first	O
series	O
of	O
experiments	O
:	O
in	O
the	O
second	O
series	O
of	O
experiments	O
,	O
1	O
mM	O
H2	B
O2	I
was	O
applied	O
for	O
4	O
min	O
,	O
whereas	O
in	O
the	O
first	O
series	O
of	O
experiments	O
,	O
600	O
μM	O
H2	B
O2	I
was	O
applied	O
for	O
3.5	O
min	O
.	O

This	O
is	O
because	O
in	O
the	O
second	O
series	O
of	O
experiments	O
,	O
a	O
large	O
amount	O
of	O
H2	B
O2	I
was	O
needed	O
to	O
induce	O
mechanical	O
dysfunction	O
to	O
a	O
degree	O
similar	O
to	O
that	O
seen	O
in	O
the	O
first	O
series	O
of	O
experiments	O
.	O

The	O
decreased	O
response	O
of	O
the	O
heart	O
to	O
H2	B
O2	I
in	O
the	O
second	O
series	O
of	O
experiments	O
may	O
be	O
due	O
to	O
the	O
difference	O
in	O
perfusion	O
conditions	O
,	O
such	O
as	O
lower	O
Ca2	B
+	I
concentration	O
and	O
lower	O
temperature	O
,	O
which	O
are	O
determinants	O
of	O
cardioprotection	O
;	O
the	O
concentration	O
of	O
free	O
Ca2	B
+	I
(	O
1	O
mM	O
)	O
in	O
the	O
Tm	B
(	I
DOTP	I
)	I
5−	I
-containing	O
KHB	O
buffer	O
used	O
in	O
the	O
second	O
series	O
of	O
experiments	O
was	O
lower	O
than	O
that	O
(	O
2.5	O
mM	O
)	O
in	O
the	O
KHB	O
buffer	O
(	O
normal	O
KHB	O
buffer	O
)	O
used	O
in	O
the	O
first	O
series	O
of	O
experiments	O
,	O
and	O
the	O
temperature	O
around	O
the	O
NMR	O
tube	O
(	O
about	O
20	O
°	O
C	O
)	O
used	O
in	O
the	O
second	O
series	O
of	O
experiments	O
was	O
lower	O
that	O
in	O
the	O
water	B
-	O
jacketed	O
chamber	O
(	O
37	O
°	O
C	O
)	O
used	O
in	O
the	O
first	O
series	O
of	O
experiments	O
.	O

When	O
the	O
membrane	O
is	O
severely	O
damaged	O
,	O
intracellular	O
Na+	B
resonance	O
collapses	O
and	O
a	O
broad	O
Na+	B
resonance	O
appears	O
in	O
the	O
23	O
Na	O
-NMR	O
spectra	O
because	O
of	O
entry	O
of	O
the	O
shift	B
reagent	I
into	O
the	O
cell	O
,	O
and	O
therefore	O
measurement	O
of	O
[	B
Na+	I
]	I
i	I
is	O
impossible	O
(	O
Jansen	O
et	O
al.	O
,	O
1998	O
)	O
.	O

As	O
shown	O
in	O
Fig.	O
7	O
,	O
however	O
,	O
no	O
broad	O
Na+	B
resonance	O
was	O
observed	O
,	O
suggesting	O
that	O
the	O
measurement	O
of	O
[	B
Na+	I
]	I
i	I
was	O
appropriate	O
in	O
the	O
present	O
study	O
.	O

The	O
results	O
of	O
the	O
second	O
series	O
of	O
experiments	O
indicate	O
that	O
both	O
d	B
-cis	I
-	I
and	O
l	B
-cis	I
-diltiazem	I
attenuate	O
the	O
H2	B
O2	I
-induced	O
increase	O
in	O
[	B
Na+	I
]	I
i	I
in	O
the	O
heart	O
.	O

Tetrodotoxin	B
(	O
3	O
μM	O
)	O
,	O
a	O
specific	O
inhibitor	O
of	O
Na+	O
channels	O
(	O
Duff	O
et	O
al.	O
,	O
1988	O
)	O
,	O
also	O
attenuated	O
the	O
H2	B
O2	I
-induced	O
increase	O
in	O
[	B
Na+	I
]	I
i	I
in	O
the	O
heart	O
and	O
the	O
H2	B
O2	I
-induced	O
myocardial	O
derangements	O
.	O

Therefore	O
,	O
the	O
protective	O
action	O
of	O
d	B
-cis	I
-	I
and	O
l	B
-cis	I
-diltiazem	I
may	O
be	O
due	O
to	O
their	O
ability	O
to	O
inhibit	O
the	O
Na+	O
channel	O
.	O

The	O
above	O
view	O
can	O
be	O
supported	O
by	O
our	O
previous	O
findings	O
that	O
tetrodotoxin	B
(	O
Hara	O
et	O
al.	O
,	O
1998	O
)	O
,	O
lidocaine	B
(	O
Hara	O
et	O
al.	O
,	O
1993	O
)	O
and	O
dilazep	B
(	O
Hara	O
and	O
Abiko	O
,	O
1996	O
)	O
,	O
all	O
of	O
which	O
have	O
a	O
Na+	O
channel	O
blocking	O
action	O
,	O
are	O
effective	O
in	O
attenuating	O
the	O
H2	B
O2	I
-induced	O
mechanical	O
dysfunction	O
and	O
decrease	O
in	O
the	O
tissue	O
levels	O
of	O
high	O
-	O
energy	O
phosphates	B
.	O

It	O
should	O
be	O
noted	O
,	O
however	O
,	O
that	O
d	B
-cis	I
-	I
and	O
l	B
-cis	I
-diltiazem	I
attenuated	O
the	O
H2	B
O2	I
-induced	O
mechanical	O
and	O
metabolic	O
derangements	O
incompletely	O
,	O
even	O
when	O
they	O
attenuated	O
the	O
H2	B
O2	I
-induced	O
increase	O
in	O
[	B
Na+	I
]	I
i	I
completely	O
.	O

It	O
is	O
possible	O
therefore	O
that	O
the	O
harmful	O
action	O
of	O
H2	B
O2	I
on	O
the	O
heart	O
is	O
not	O
only	O
due	O
to	O
activation	O
of	O
the	O
fast	O
Na+	O
channel	O
,	O
but	O
also	O
due	O
to	O
other	O
mechanisms	O
,	O
such	O
as	O
activation	O
of	O
nonselective	O
cation	O
channels	O
(	O
Jabr	O
and	O
Cole	O
,	O
1995	O
)	O
and	O
inactivation	O
of	O
creatine	O
kinase	O
(	O
Banerjee	O
et	O
al.	O
,	O
1991	O
)	O
.	O

According	O
to	O
Nasa	O
et	O
al.	O
(	O
1990	O
)	O
,	O
d	B
-cis	I
-diltiazem	I
(	O
15	O
μM	O
)	O
and	O
l	B
-cis	I
-diltiazem	I
(	O
15	O
μM	O
)	O
are	O
capable	O
of	O
attenuating	O
the	O
myocardial	O
derangements	O
induced	O
by	O
ischemia	O
–	O
reperfusion	O
in	O
the	O
isolated	O
,	O
working	O
rat	O
heart	O
.	O

Therefore	O
,	O
the	O
beneficial	O
action	O
of	O
d	B
-cis	I
-	I
and	O
l	B
-cis	I
-diltiazem	I
on	O
the	O
H2	B
O2	I
-induced	O
changes	O
may	O
contribute	O
to	O
their	O
protective	O
effect	O
on	O
the	O
myocardium	O
against	O
ischemia	O
–	O
reperfusion	O
damage	O
.	O

5	O
Conclusion	O
Both	O
d	B
-cis	I
-	I
and	O
l	B
-cis	I
-diltiazem	I
protect	O
the	O
myocardium	O
against	O
the	O
H2	B
O2	I
-induced	O
derangements	O
in	O
the	O
isolated	O
perfused	O
rat	O
heart	O
.	O

The	O
protective	O
action	O
of	O
d	B
-cis	I
-	I
and	O
l	B
-cis	I
-diltiazem	I
may	O
be	O
due	O
to	O
inhibition	O
of	O
the	O
H2	B
O2	I
-induced	O
increase	O
in	O
[	B
Na+	I
]	I
i	I
,	O
at	O
least	O
in	O
part	O
.	O

Acknowledgements	O

We	O
thank	O
Mr.	O
Mitsutoshi	O
Kusakabe	O
for	O
his	O
help	O
in	O
experiments	O
with	O
NMR	O
technique	O
.	O

We	O
also	O
thank	O
Ms.	O
Min	O
Chen	O
for	O
her	O
valuable	O
help	O
during	O
experiments	O
,	O
Mr.	O
Tadahiko	O
Yokoyama	O
for	O
his	O
technical	O
assistance	O
,	O
and	O
Ms.	O
Miwa	O
Kashu	O
and	O
Ms.	O
Kaori	O
Inaba	O
for	O
their	O
secretarial	O
assistance	O
.	O

l	B
-cis	I
-Diltiazem	I
hydrochloride	I
was	O
kindly	O
supplied	O
by	O
Tanabe	O
Seiyaku	O
(	O
Osaka	O
,	O
Japan	O
)	O
.	O

Cordyceps	O
sinensis	O
(	O
Berk	O
.	O
)	O

Sacc	O
.	O

(	O
family	O
Clavicipitaceae	O
)	O
has	O
long	O
been	O
used	O
in	O
Chinese	O
medicine	O
to	O
treat	O
numerous	O
illnesses	O
,	O
promote	O
longevity	O
,	O
relieve	O
exhaustion	O
and	O
increase	O
athletic	O
prowess	O
(	O
Pegler	O
,	O
Yao	O
&	O
Li	O
,	O
1994	O
;	O
Steinkraus	O
&	O
Whitfield	O
,	O
1994	O
;	O
Jones	O
,	O
1993	O
;	O
Tsunoo	O
,	O
Taketomo	O
,	O
Tsuboi	O
,	O
Kamijio	O
,	O
Nemoto	O
,	O
Sasaki	O
,	O
Uchida	O
,	O
Yamashita	O
,	O
Kinjo	O
&	O
Haung	O
,	O
1995	O
)	O
.	O

The	O
medicinal	O
preparation	O
from	O
the	O
fruiting	O
bodies	O
of	O
C.	O
sinensis	O
is	O
named	O
dong	O
-	O
chong	O
-	O
xia	O
-	O
cao	O
which	O
translates	O
as	O
winter	O
worm	O
and	O
summer	O
grass	O
.	O

C.	O
sinensis	O
infects	O
the	O
larvae	O
of	O
the	O
sphinx	O
moth	O
,	O
Hepialus	O
armoricanus	O
,	O
found	O
only	O
in	O
the	O
highlands	O
of	O
the	O
Himalayan	O
region	O
,	O
and	O
the	O
larva	O
hibernates	O
underground	O
through	O
the	O
winter	O
.	O

The	O
fungus	O
kills	O
the	O
infected	O
host	O
and	O
grows	O
throughout	O
the	O
cadaver	O
,	O
and	O
in	O
the	O
summer	O
,	O
a	O
rod	O
-	O
like	O
stroma	O
of	O
the	O
fungus	O
grows	O
out	O
from	O
the	O
mummified	O
shell	O
of	O
the	O
dead	O
host	O
.	O

Cordyceps	O
species	O
are	O
generally	O
known	O
as	O
the	O
'	O
caterpillar	O
fungus	O
'	O
due	O
to	O
this	O
characteristic	O
parasitism	O
of	O
the	O
living	O
larvae	O
of	O
insects	O
(	O
Pegler	O
,	O
Yao	O
&	O
Li	O
,	O
1994	O
;	O
Steinkraus	O
&	O
Whitfield	O
,	O
1994	O
;	O
Jones	O
,	O
1993	O
)	O
.	O

A	O
number	O
of	O
bioactive	O
constituents	O
from	O
Cordyceps	O
species	O
have	O
been	O
reported	O
.	O

These	O
include	O
:	O
cordycepin	B
(	O
Cunningham	O
,	O
Herchinson	O
,	O
Manson	O
&	O
Spring	O
,	O
1951	O
;	O
Kredich	O
&	O
Guarino	O
,	O
1960	O
)	O
and	O
other	O
antibacterial	O
and	O
antitumor	O
adenosine	B
derivatives	I
(	O
Furuya	O
,	O
Hirotani	O
&	O
Matsuzawa	O
,	O
1983	O
)	O
,	O
ophicordin	B
,	O
an	O
antifungal	O
agent	O
(	O
Kneifel	O
,	O
Srinivasan	O
&	O
Maiti	O
,	O
1957	O
)	O
,	O
a	O
polysaccharide	B
shown	O
to	O
have	O
antitumor	O
activity	O
(	O
Miyazaki	O
,	O
Oikawa	O
&	O
Yamada	O
,	O
1977	O
;	O
Yamada	O
et	O
al.	O
,	O
1984	O
;	O
Ohmori	O
,	O
Tamura	O
,	O
Tsuru	O
&	O
Nomoto	O
,	O
1986	O
)	O
,	O
an	O
immunopotentiating	O
galactomannan	B
,	O
and	O
l	B
-tryptophan	I
(	O
Zhang	O
,	O
Zhang	O
,	O
Zhu	O
&	O
Chen	O
,	O
1991	O
)	O
.	O

A	O
recent	O
report	O
indicated	O
that	O
the	O
fruiting	O
body	O
of	O
C.	O
sinensis	O
contained	O
growth	O
inhibitors	O
against	O
tumor	O
cells	O
(	O
K562	O
,	O
Vero	O
,	O
Wish	O
,	O
Calu-1	O
and	O
Raji	O
)	O
other	O
than	O
cordycepin	B
and	O
polysaccharides	B
(	O
Kuo	O
,	O
Ching	O
-	O
Yuang	O
Lin	O
,	O
Wei	O
-	O
Jern	O
Tsai	O
,	O
Wu	O
,	O
Chen	O
&	O
Shiao	O
,	O
1994	O
)	O
.	O

We	O
report	O
herein	O
the	O
isolation	O
and	O
identification	O
of	O
two	O
antitumor	O
compounds	B
from	O
the	O
mycelia	O
of	O
C.	O
sinensis	O
.	O

Activity	O
guided	O
chemical	O
fractionations	O
of	O
the	O
methanol	B
extract	O
of	O
C.	O
sinensis	O
,	O
led	O
to	O
the	O
isolation	O
of	O
a	O
steroidal	B
glycoside	I
5α	B
,	I
8α	I
-epidioxy-24	I
(	I
R	I
)	I
-methylcholesta-6,22-dien-3β	I
-d	I
-glucopyranoside	I
(	O
1a	B
)	O
and	O
5α	B
,	I
6α	I
-epoxy-24	I
(	I
R	I
)	I
-methylcholesta-7,22-dien-3β	I
-ol	I
(	O
2	B
)	O
.	O

Two	O
previously	O
identified	O
compounds	O
,	O
ergosteryl-3-O	B
-β	I
-d	I
-glucopyranoside	I
(	O
3	B
)	O
and	O
22,23-dihydroergosteryl-3-O	B
-β	I
-d	I
-glucopyranoside	I
(	O
4	B
)	O
were	O
also	O
isolated	O
during	O
the	O
fractionation	O
of	O
the	O
methanol	B
extract	O
(	O
Shiao	O
,	O
Lin	O
,	O
Lien	O
,	O
Tzean	O
&	O
Lee	O
,	O
1989	O
)	O
.	O

These	O
ergosterol	B
derivatives	I
were	O
not	O
active	O
against	O
the	O
tumor	O
cell	O
lines	O
used	O
in	O
this	O
study	O
.	O

2	O
Results	O
and	O
discussion	O
Compounds	B
3	B
and	O
4	B
were	O
identified	O
by	O
1	O
H	O
NMR	O
spectroscopy	O
as	O
ergosteryl-3-O	B
-β	I
-d	I
-glucopyranoside	I
(	O
3	B
)	O
and	O
22,23-dihydroergosteryl-3-O	B
-β	I
-d	I
-glucopyranoside	I
(	O
4	B
)	O
previously	O
isolated	O
from	O
the	O
fruiting	O
body	O
of	O
C.	O
sinensis	O
(	O
Shiao	O
et	O
al.	O
,	O
1989	O
)	O
.	O

Comparison	O
of	O
the	O
1	O
H	O
NMR	O
spectra	O
of	O
1a	B
with	O
3	B
and	O
4	B
suggests	O
that	O
1a	B
was	O
also	O
a	O
glycoside	B
derivative	I
of	I
a	I
sterol	I
.	O

Compound	O
1a	B
was	O
found	O
to	O
have	O
a	O
[	O
M+NH4	O
]	O
+	O
peak	O
from	O
CI	O
of	O
m	O
/z	O
=	O
608	O
[	O
C34	O
H54	O
O8	O
+	O
NH4	O
]	O
+	O
with	O
a	O
prominent	O
fragment	O
ion	O
peak	O
at	O
m	O
/z	O
412	O
in	O
agreement	O
with	O
the	O
proposed	O
presence	O
of	O
a	O
sugar	B
moiety	O
(	O
C6	O
H12	O
O6	O
)	O
.	O

The	O
observation	O
of	O
six	O
methyl	O
signals	O
in	O
the	O
1	O
H	O
NMR	O
spectrum	O
of	O
1a	B
at	O
δ	O
0.69	O
(	O
3H	O
,	O
d	O
,	O
J	O
=	O
7.0	O
Hz	O
)	O
,	O
0.70	O
(	O
3H	O
,	O
s	O
)	O
,	O
0.71	O
(	O
3H	O
,	O
d	O
,	O
J	O
=	O
6.7	O
Hz	O
)	O
,	O
0.76	O
(	O
3H	O
,	O
s	O
)	O
,	O
0.79	O
(	O
3H	O
,	O
d	O
,	O
J	O
=	O
6.8	O
Hz	O
)	O
,	O
0.88	O
(	O
3H	O
,	O
d	O
,	O
J	O
=	O
6.6	O
Hz	O
)	O
indicates	O
that	O
the	O
sterol	B
fragment	O
of	O
1a	B
is	O
an	O
ergosterol	B
derivative	I
.	O

The	O
doublet	O
at	O
δ	O
4.2	O
(	O
1H	O
,	O
d	O
,	O
J	O
=	O
7.8	O
Hz	O
)	O
indicates	O
that	O
the	O
attachment	O
of	O
the	O
sugar	B
moiety	O
at	O
C3	O
is	O
in	O
the	O
β	O
-configuration	O
(	O
Shiao	O
et	O
al.	O
,	O
1989	O
;	O
Ahmed	O
,	O
Ahmed	O
&	O
Malik	O
,	O
1992	O
;	O
Wasylyk	O
,	O
Martin	O
,	O
Weinheimer	O
&	O
Alam	O
,	O
1989	O
)	O
,	O
similar	O
to	O
that	O
of	O
the	O
ergosteryl-3-O	B
-β	I
-d	I
-glucopyranoside	I
(	O
3	B
)	O
and	O
22,23-dihydroergosteryl-3-O	B
-β	I
-d	I
-glucopyranoside	I
(	O
4	B
)	O
(	O
Shiao	O
et	O
al.	O
,	O
1989	O
)	O
.	O

The	O
observation	O
of	O
the	O
two	O
doublets	O
at	O
δ	O
6.39	O
(	O
1H	O
,	O
d	O
,	O
J	O
=	O
8.5	O
Hz	O
)	O
and	O
6.13	O
(	O
1H	O
,	O
d	O
,	O
J	O
=	O
8.5	O
Hz	O
)	O
,	O
approximately	O
1	O
ppm	O
downfield	O
of	O
the	O
H6	O
and	O
H7	O
olefinic	B
protons	O
in	O
3	B
and	O
4	B
,	O
suggested	O
that	O
the	O
aglycone	O
of	O
1a	B
is	O
5α	B
,	I
8α	I
-epidioxy-24	I
(	I
R	I
)	I
-methylcholesta-6,22-diene-3β	I
-ol	I
(	O
1b	B
)	O
.	O

The	O
close	O
comparison	O
of	O
the	O
13	O
C	O
data	O
of	O
1a	B
with	O
1b	B
listed	O
in	O
Table	O
1	O
agrees	O
with	O
this	O
proposal	O
.	O

The	O
identity	O
of	O
the	O
sugar	B
moiety	O
in	O
1a	B
was	O
not	O
conclusive	O
from	O
the	O
spectroscopic	O
data	O
.	O

However	O
comparison	O
of	O
the	O
1	O
H	O
and	O
13	O
C	O
NMR	O
spectra	O
of	O
1a	B
with	O
the	O
spectra	O
of	O
the	O
glucopyranosides	B
3	B
and	O
4	B
suggests	O
that	O
1a	B
is	O
also	O
a	O
glucopyranoside	B
.	O

The	O
synthesis	O
of	O
5α	B
,	I
8α	I
-epidioxy-24	I
(	I
R	I
)	I
-methylcholesta-6,22-dien-3β	I
-d	I
-glucopyranoside	I
(	O
1a	B
)	O
from	O
ergosterol	B
(	O
6	B
)	O
was	O
carried	O
out	O
as	O
shown	O
in	O
Scheme	O
1	O
.	O

Deacetylation	O
of	O
5	B
(	O
Cerný	O
,	O
Pouzar	O
,	O
Drasar	O
,	O
Budesinsky	O
&	O
Havel	O
,	O
1984	O
)	O
followed	O
by	O
a	O
Diels	O
–	O
Alder	O
addition	O
of	O
singlet	O
O2	B
(	O
1	O
Δg	O
)	O
to	O
the	O
diene	B
in	O
ergosteryl-3-O	B
-β	I
-d	I
-glucopyranoside	I
(	O
3	B
)	O
(	O
Gunatilaka	O
,	O
Gopichand	O
,	O
Schmitz	O
&	O
Djerassi	O
,	O
1981	O
)	O
afforded	O
5α	B
,	I
8α	I
-epidioxy-24	I
(	I
R	I
)	I
-methylcholesta-6,22-dien-3β	I
-d	I
-glucopyranoside	I
(	O
1a	B
)	O
.	O

Comparison	O
of	O
the	O
1	O
H	O
and	O
13	O
C	O
NMR	O
of	O
the	O
synthesized	O
molecule	O
both	O
confirmed	O
the	O
proposed	O
identity	O
of	O
the	O
sugar	B
moiety	O
and	O
the	O
stereochemistry	O
of	O
the	O
5α	B
,	I
8α	I
-epideoxy	I
functionality	O
in	O
the	O
isolated	O
compound	O
1a	B
.	O

5α	B
,	I
8α	I
-Epidioxy-24	I
(	I
R	I
)	I
-methylcholesta-6,22-dien-3β	I
-d	I
-glucopyranoside	I
has	O
previously	O
been	O
isolated	O
from	O
a	O
variety	O
of	O
fungi	O
(	O
including	O
C.	O
sinensis	O
)	O
(	O
Xiao	O
,	O
Liu	O
&	O
Tu	O
,	O
1983	O
;	O
Takaishi	O
,	O
Adachi	O
,	O
Murakami	O
,	O
Ohashi	O
,	O
Nakano	O
&	O
Tomimatsu	O
,	O
1992	O
;	O
Tsantrizos	O
,	O
Folkins	O
,	O
Britten	O
,	O
Harpp	O
,	O
Ogilvie	O
,	O
1992	O
)	O
,	O
lichens	O
(	O
Hirayama	O
,	O
Fujikawa	O
,	O
Yosioka	O
&	O
Kitagawa	O
,	O
1975	O
;	O
Gonzalez	O
,	O
Barrera	O
,	O
Perez	O
&	O
Padron	O
,	O
1992	O
)	O
,	O
and	O
marine	O
organisms	O
(	O
Gunatilaka	O
et	O
al.	O
,	O
1981	O
;	O
Guyot	O
&	O
Durgeat	O
,	O
1981	O
)	O
and	O
has	O
been	O
shown	O
to	O
have	O
both	O
antitumor	O
(	O
Kahlos	O
,	O
Kangas	O
&	O
Hiltunen	O
,	O
1989	O
;	O
Kahlos	O
,	O
Hiltunen	O
&	O
Kangas	O
,	O
1989	O
;	O
Matsueda	O
,	O
Shimoyama	O
,	O
Imaizumi	O
&	O
Tsushima	O
,	O
1982	O
;	O
Cheng	O
,	O
Nagano	O
,	O
Bang	O
,	O
Ourrison	O
,	O
Beck	O
,	O
1977	O
)	O
and	O
anti	O
-	O
inflammatory	O
(	O
Yasukawa	O
et	O
al.	O
,	O
1994	O
,	O
1996	O
)	O
activity	O
.	O

Formation	O
of	O
1b	B
was	O
shown	O
to	O
be	O
endogenous	O
in	O
fungi	O
and	O
not	O
an	O
artifact	O
of	O
the	O
isolation	O
procedure	O
(	O
Nes	O
,	O
Xu	O
&	O
Haddon	O
,	O
1989	O
)	O
.	O

The	O
observation	O
of	O
six	O
methyl	B
signals	O
in	O
the	O
1	O
H	O
NMR	O
spectrum	O
of	O
compound	B
2	I
,	O
δ	O
0.49	O
(	O
3H	O
,	O
s	O
)	O
,	O
0.71	O
(	O
3H	O
,	O
d	O
,	O
J	O
=	O
6.5	O
Hz	O
)	O
,	O
0.73	O
(	O
3H	O
,	O
d	O
,	O
J	O
=	O
6.5	O
Hz	O
)	O
,	O
0.81	O
(	O
3H	O
,	O
d	O
,	O
J	O
=	O
6.8	O
Hz	O
)	O
,	O
0.91	O
(	O
3H	O
,	O
d	O
,	O
J	O
=	O
6.6	O
Hz	O
)	O
,	O
0.95	O
(	O
3H	O
,	O
s	O
)	O
indicates	O
that	O
compound	B
2	I
is	O
also	O
an	O
ergosterol	B
derivative	I
.	O

The	O
molecular	O
formula	O
for	O
compound	B
2	I
was	O
determined	O
to	O
be	O
C28	O
H44	O
O2	O
by	O
HRMS	O
(	O
M+	O
=	O
421.3347	O
)	O
.	O

The	O
additional	O
oxygen	B
in	O
the	O
molecular	O
formula	O
of	O
2	B
in	O
comparison	O
to	O
the	O
molecular	O
formula	O
of	O
ergosterol	B
(	O
6	B
)	O
(	O
C28	O
H44	O
O	O
)	O
and	O
the	O
observation	O
in	O
the	O
1	O
H	O
NMR	O
of	O
a	O
signal	O
at	O
3.50	O
ppm	O
combined	O
with	O
the	O
loss	O
of	O
an	O
olefinic	B
signal	O
indicates	O
that	O
one	O
of	O
the	O
5,7-diene	B
olefins	B
in	O
6	B
has	O
been	O
oxidized	O
to	O
the	O
epoxide	B
.	O

The	O
observation	O
of	O
a	O
correlation	O
in	O
the	O
COSY	O
between	O
the	O
trisubstituted	O
epoxy	B
methine	B
signal	O
at	O
3.50	O
ppm	O
and	O
the	O
olefin	B
methine	B
signal	O
at	O
5.20	O
ppm	O
is	O
in	O
agreement	O
with	O
this	O
proposal	O
.	O

The	O
observation	O
of	O
cross	O
-	O
peaks	O
in	O
the	O
HMBC	O
between	O
the	O
signal	O
at	O
5.20	O
ppm	O
with	O
the	O
13	O
C	O
signals	O
corresponding	O
to	O
C5	O
,	O
C9	O
and	O
C14	O
and	O
the	O
cross	O
peaks	O
for	O
the	O
signal	O
at	O
3.50	O
ppm	O
with	O
the	O
13	O
C	O
signals	O
corresponding	O
to	O
C5	O
,	O
C7	O
,	O
C8	O
and	O
C10	O
indicate	O
the	O
epoxide	B
is	O
in	O
the	O
5,6	O
position	O
.	O

The	O
downfield	O
chemical	O
shift	O
of	O
the	O
3β	O
-hydroxy	O
methine	B
at	O
3.90	O
ppm	O
is	O
consistent	O
with	O
the	O
α	O
stereochemistry	O
for	O
the	O
5	O
,	O
6-epoxy	O
group	B
(	O
Aiello	O
,	O
Fattorusso	O
,	O
Magno	O
,	O
Mayol	O
&	O
Menna	O
,	O
1990	O
;	O
Isaacs	O
,	O
Berman	O
&	O
Kashman	O
,	O
1991	O
;	O
Venkateswarlu	O
,	O
Reddy	O
&	O
Rao	O
,	O
1996	O
)	O
.	O

5α	B
,	I
6α	I
-Epoxy	I
sterols	I
similar	O
to	O
compound	O
2	B
are	O
unknown	O
.	O

A	O
small	O
number	O
of	O
5α	B
,	I
6α	I
-epoxy	I
sterols	I
have	O
been	O
isolated	O
from	O
marine	O
sponges	O
and	O
corals	O
(	O
Aiello	O
et	O
al.	O
,	O
1990	O
;	O
Isaacs	O
,	O
Berman	O
&	O
Kashman	O
,	O
1991	O
;	O
Venkateswarlu	O
,	O
Reddy	O
&	O
Rao	O
,	O
1996	O
;	O
Kobayashi	O
&	O
Kanda	O
,	O
1991	O
)	O
and	O
have	O
been	O
shown	O
to	O
have	O
cytotoxic	O
activities	O
.	O

Growth	O
inhibition	O
due	O
to	O
compounds	B
1a	B
,	O
1b	B
,	O
and	O
3	B
of	O
the	O
malignant	O
cell	O
lines	O
K562	O
(	O
erythroleukemia	O
)	O
,	O
Jurkat	O
(	O
T	O
-	O
lymphoblastic	O
)	O
,	O
HL-60	O
(	O
promyelocytic	O
leukemia	O
)	O
,	O
WM1341	O
(	O
malignant	O
melanoma	O
)	O
and	O
RPMI	O
8226	O
(	O
multiple	O
myeloma	O
)	O
from	O
the	O
American	O
Tissue	O
Type	O
Collection	O
(	O
ATCC	O
)	O
Rockville	O
,	O
MD	O
,	O
were	O
studied	O
to	O
compare	O
their	O
antitumor	O
activity	O
.	O

The	O
percent	O
inhibition	O
of	O
the	O
proliferation	O
of	O
these	O
five	O
malignant	O
cells	O
lines	O
determined	O
from	O
3	B
H	I
-	I
thymidine	I
incorporation	O
assays	O
are	O
shown	O
in	O
Fig.	O
1	O
(	O
a	O
–	O
d	O
)	O
for	O
200	O
,	O
100	O
and	O
10	O
μg	O
/	O
ml	O
concentrations	O
of	O
compounds	B
3	B
,	O
1b	B
,	O
and	O
1a	B
.	O

Compound	B
3	I
which	O
does	O
not	O
contain	O
the	O
5	O
,	O
8-epoxy	O
functionality	O
showed	O
little	O
to	O
no	O
significant	O
inhibition	O
of	O
proliferation	O
of	O
the	O
tumor	O
cells	O
.	O

Some	O
inhibition	O
of	O
Jurkat	O
and	O
RPMI	O
8226	O
was	O
detected	O
at	O
200	O
μg	O
/	O
ml	O
,	O
the	O
highest	O
concentration	O
in	O
this	O
study	O
.	O

As	O
clearly	O
shown	O
on	O
the	O
graphs	O
,	O
at	O
the	O
lower	O
concentration	O
,	O
the	O
glycoside	B
1a	I
was	O
found	O
to	O
inhibit	O
proliferation	O
of	O
all	O
five	O
malignant	O
cell	O
lines	O
to	O
a	O
greater	O
extent	O
(	O
10–40	O
%	O
)	O
than	O
the	O
aglycone	B
1b	I
as	O
a	O
control	O
.	O

3	O
Experimental	O
3.1	O
General	O
IR	O
spectra	O
were	O
acquired	O
with	O
a	O
Bomen	O
FT	O
-	O
IR	O
Michaelson-100	O
spectrophotometer	O
.	O

The	O
spectra	O
were	O
obtained	O
either	O
in	O
CHCl3	B
solution	O
using	O
a	O
0.2	O
mm	O
thick	O
NaCl	B
cell	O
,	O
or	O
as	O
a	O
solid	O
in	O
KBr	B
,	O
and	O
processed	O
using	O
the	O
Bomen	O
Spectra	O
Calc	O
program	O
.	O

LRMS	O
and	O
HRMS	O
were	O
obtained	O
on	O
a	O
Kratos	O
-	O
AEI	O
model	O
MS-50	O
spectrometer	O
.	O

All	O
spectra	O
were	O
obtained	O
at	O
an	O
ionization	O
energy	O
of	O
70	O
eV.	O
1	B
H	I
NMR	I
spectra	O
were	O
obtained	O
on	O
a	O
Bruker	O
WH-400	O
spectrometer	O
.	O

13	O
C	O
and	O
APT	O
were	O
obtained	O
on	O
a	O
Bruker	O
AC-200	O
spectrometer	O
.	O

HMBC	O
,	O
and	O
HMQC	O
spectra	O
were	O
obtained	O
on	O
a	O
Bruker	O
AMX-500	O
spectrometer	O
.	O

Silica	B
gel	O
(	O
Art	O
60	O
,	O
230–400	O
mesh	O
)	O
for	O
column	O
chromatography	O
(	O
CC	O
)	O
and	O
silica	B
gel	O
(	O
Kieselgel	O
60	O
F254	O
)	O
coated	O
on	O
aluminum	B
plates	O
for	O
thin	O
layer	O
chromatography	O
were	O
supplied	O
by	O
Merck	O
.	O

3.2	O
Fungal	O
material	O

The	O
mycelial	O
sample	O
of	O
C.	O
sinensis	O
was	O
obtained	O
from	O
North	O
American	O
Reishi	O
,	O
Box	O
1780	O
,	O
Gibsons	O
,	O
British	O
Columbia	O
,	O
Canada	O
,	O
V0N	O
1V0	O
.	O

3.3	O
Malignant	O
cell	O
inhibition	O
studies	O
3	B
H	I
-	I
Thymidine	I
incorporation	O
assays	O
were	O
carried	O
out	O
to	O
determine	O
inhibitory	O
effects	O
.	O

K562	O
(	O
erythroleukemia	O
)	O
,	O
Jurkat	O
(	O
T	O
-	O
lymphoblastic	O
)	O
,	O
HL-60	O
(	O
promyelocytic	O
leukemia	O
)	O
,	O
WM1341	O
(	O
malignant	O
melanoma	O
)	O
and	O
RPMI	O
8226	O
(	O
multiple	O
myeloma	O
)	O
malignant	O
cell	O
lines	O
were	O
obtained	O
from	O
the	O
American	O
Tissue	O
Type	O
Collection	O
(	O
ATCC	O
)	O
,	O
Rockville	O
,	O
MD	O
.	O

The	O
cell	O
lines	O
were	O
maintained	O
in	O
a	O
medium	O
consisting	O
of	O
RPMI	O
1640	O
/	O
FCS	O
10	O
%	O
at	O
37	O
°	O
C	O
in	O
an	O
atmosphere	O
of	O
5	O
%	O
CO2	B
.	O

Malignant	O
cell	O
lines,106	O
cells	O
/	O
ml	O
in	O
96-well	O
round	O
bottom	O
plates	O
(	O
Costar	O
)	O
,	O
were	O
cultured	O
with	O
various	O
concentrations	O
of	O
C.	O
sinensis	O
extracts	O
in	O
a	O
5	O
%	O
CO2	B
-air	O
humidified	O
atmosphere	O
at	O
37	O
°	O
C	O
.	O

After	O
16	O
h	O
of	O
co	O
-	O
culture	O
,	O
3	B
H	I
-	I
thymidine	I
(	O
1	O
MCi	O
/	O
well	O
,	O
Dupont	O
,	O
Montreal	O
)	O
was	O
added	O
to	O
each	O
well	O
.	O

3	B
H	I
-	I
Thymidine	I
uptake	O
was	O
measured	O
after	O
6	O
hours	O
of	O
incubation	O
using	O
a	O
scintillation	O
counter	O
.	O

The	O
inhibitory	O
effect	O
of	O
each	O
extract	O
on	O
tumor	O
cell	O
proliferation	O
was	O
calculated	O
using	O
Eq.	O
1	O
.	O
(	O
1	O
)	O

Inhibition	O
percent	O
(	O
%	O
)	O
=	O
Control	O
group	O
(	O
cpm	O
)	O
−Experimental	O
group	O
(	O
cpm	O
)	O
Control	O
group	O
(	O
cpm	O
)	O
×100	O
3.4	O
Activity	O
guided	O
fractionation	O
of	O
fungal	O
material	O
The	O
dry	O
mycelium	O
of	O
C.	O
sinensis	O
(	O
150	O
g	O
)	O
was	O
extracted	O
with	O
MeOH	B
three	O
times	O
(	O
500	O
ml	O
×	O
3	O
)	O
.	O

The	O
MeOH	B
extracts	O
were	O
combined	O
and	O
the	O
solvent	O
was	O
removed	O
under	O
reduced	O
pressure	O
.	O

The	O
crude	O
MeOH	B
extract	O
was	O
found	O
to	O
inhibit	O
K562	O
proliferation	O
by	O
36	O
%	O
at	O
500	O
μg	O
/	O
ml	O
,	O
in	O
the	O
3	B
H	I
-	I
thymidine	I
incorporation	O
assay	O
.	O

The	O
residue	O
was	O
then	O
redissolved	O
in	O
MeOH	B
/	O
H2	B
O	I
(	O
1:1	O
)	O
and	O
washed	O
with	O
hexanes	B
.	O

Methanol	B
was	O
distilled	O
from	O
the	O
aqueous	O
layer	O
under	O
reduced	O
pressure	O
.	O

The	O
remaining	O
aqueous	O
layer	O
was	O
extracted	O
with	O
EtOAc	B
.	O

Concentration	O
of	O
the	O
combined	O
EtOAc	B
extracts	O
under	O
reduced	O
pressure	O
provided	O
1.57	O
g	O
of	O
a	O
brown	O
oil	O
(	O
B1	O
)	O
.	O

This	O
residue	O
was	O
chromatographed	O
on	O
a	O
silica	B
gel	O
-	O
flash	O
column	O
(	O
230–400	O
mesh	O
,	O
50	O
×	O
8.0	O
cm	O
)	O
.	O

The	O
elution	O
was	O
started	O
with	O
CHCl3	B
and	O
the	O
polarity	O
of	O
solvents	O
was	O
increased	O
stepwise	O
in	O
the	O
following	O
sequence	O
:	O
CHCl3	B
,	O
CHCl3	B
/MeOH	O
(	O
8:2	O
)	O
,	O
CHCl3	B
/MeOH	O
(	O
5:5	O
)	O
,	O
CHCl3	B
/MeOH	O
(	O
2:8	O
)	O
and	O
MeOH	B
.	O

Fourteen	O
fractions	O
(	O
FA1–FA14	O
)	O
were	O
collected	O
and	O
dried	O
in	O
vacuo	O
.	O

Only	O
one	O
fraction	O
(	O
FA8	O
)	O
was	O
found	O
have	O
antitumor	O
activity	O
.	O

Fraction	O
FA8	O
was	O
further	O
chromatographed	O
on	O
a	O
silicagel	B
flash	O
-	O
column	O
eluted	O
with	O
CHCl3	B
/MeOH	O
(	O
8:2	O
)	O
to	O
afford	O
two	O
fractions	O
FB1	O
and	O
FB2	O
having	O
an	O
Rf	O
=	O
6.3	O
and	O
5.4	O
,	O
respectively	O
.	O

FB1	O
was	O
a	O
white	O
solid	O
(	O
38	O
mg	O
)	O
.	O

Recrystallization	O
of	O
FB1	O
in	O
CHCl3	B
afforded	O
10	O
mg	O
of	O
2	B
as	O
a	O
white	O
powder	O
.	O

Compound	B
2	I
was	O
found	O
to	O
have	O
61	O
%	O
antitumor	O
activity	O
against	O
Jurkat	O
cells	O
and	O
36.3	O
%	O
activity	O
against	O
K562	O
cells	O
at	O
100	O
μg	O
/	O
ml	O
.	O

Fraction	O
FB2	O
was	O
found	O
to	O
have	O
96	O
%	O
activity	O
against	O
Jurkat	O
cells	O
and	O
77	O
%	O
activity	O
against	O
K562	O
cancer	O
cells	O
at	O
100	O
μg	O
/	O
ml	O
.	O

FB2	O
was	O
further	O
separated	O
by	O
silica	B
gel	O
chromatography	O
eluted	O
with	O
Et2	B
O	I
:	O
hexanes	B
:	O
MeOH=5:5:1	B
to	O
afford	O
two	O
fractions	O
FC1	O
(	O
Rf	O
=	O
6.3	O
)	O
and	O
3	O
mg	O
of	O
compound	O
1a	B
(	O
Rf	O
=	O
5.4	O
)	O
as	O
a	O
white	O
solid	O
.	O

FC1	O
was	O
further	O
separated	O
by	O
HPLC	O
to	O
give	O
3	B
and	O
4	B
.	O

3.4.1	O
5α	B
,	I
6α	I
-Epoxy-24	I
(	I
R	I
)	I
-methylcholesta-7,22-dien-3β	I

-ol	B
(	O
2	B
)	O
.	O

IR	O
(	O
cm−1	O
,	O
CHCl3	B
):	O
4685	O
-	O
3110	O
(	O
hydroxyl	O
)	O
,	O
2950	O
,	O
2880	O
,	O
1673	O
,	O
1462	O
;	O
1	O
H	O
NMR	O
(	O
500	O
MHz	O
,	O
CDCl3	B
)	O
δ	O
:	O
0.49	O
(	O
3H	O
,	O
s	O
,	O
Me-18	O
)	O
,	O
0.72	O
(	O
3H	O
,	O
d	O
,	O
J	O
=	O
6.5	O
,	O
Me-26	O
or	O
27	O
)	O
,	O
0.73	O
(	O
3H	O
,	O
d	O
,	O
J	O
=	O
6.5	O
,	O
Me-26	O
or	O
27	O
)	O
,	O
1.2	O
(	O
2H	O
,	O
m	O
,	O
H17	O
,	O
H16	O
)	O
,	O
1.32	O
(	O
1H	O
,	O
m	O
,	O
H2	O
)	O
,	O
1.36	O
(	O
1H	O
,	O
m	O
,	O
H25	O
)	O
,	O
1.44–1.48	O
(	O
4H	O
,	O
m	O
,	O
H11	O
,	O
H11′	O
,	O
H15	O
,	O
H1	O
)	O
,	O
1.58	O
(	O
1H	O
,	O
m	O
,	O
H12	O
)	O
,	O
1.64	O
(	O
1H	O
,	O
m	O
,	O
H16′	O
)	O
,	O
1.72	O
(	O
1H	O
,	O
m	O
,	O
H2′	O
)	O
,	O
1.75	O
(	O
1H	O
,	O
m	O
,	O
H24	O
)	O
,	O
1.81	O
(	O
1H	O
,	O
m	O
,	O
H14	O
)	O
,	O
1.85	O
(	O
1H	O
,	O
m	O
,	O
H9	O
)	O
,	O
1.94	O
(	O
1H	O
,	O
m	O
,	O
H20	O
)	O
,	O
1.95	O
(	O
1H	O
,	O
m	O
,	O
H4	O
)	O
,	O
3.5	O
(	O
1H	O
,	O
d	O
,	O
J	O
=	O
5.1	O
,	O
H-6	O
)	O
,	O
3.9	O
(	O
1H	O
,	O
m	O
,	O
H-3	O
)	O
,	O
5.09	O
(	O
1H	O
,	O
m	O
,	O
H-22	O
)	O
,	O
5.11	O
(	O
1H	O
,	O
m	O
,	O
H-23	O
)	O
,	O
5.2	O
(	O
1H	O
,	O
m	O
,	O
H-7	O
)	O
;	O
13	O
C	O
NMR	O
(	O
50	O
MHz	O
,	O
CDCl3	B
)	O
listed	O
in	O
Table	O
2	O
;	O
LRMS	O
(	O
EI	O
)	O
m	O
/z	O
(	O
rel	O
.	O

int	O
.	O

%	O
):	O
413	O
[	O
M+1	O
]	O
+	O
,	O
396	O
[	O
M−16	O
]	O
+	O
;	O
HRMS	O
(	O
EI	O
)	O
:	O
Calculated	O
for	O
C28	O
H44	O
O2	O
:	O
412.33414	O
;	O
found	O
:	O
412.33477	O
.	O

3.4.2	O
5α	B
,	I
8α	I
-epidioxy-24	I
(	I
R	I
)	I
-methylcholesta-6,22-dien-3β	I
-d	I
-glucopyranoside	I
(	O
1a	B
)	O
IR	O
(	O
cm−1	O
,	O
CHCl3	B
):	O
3580–3055	O
(	O
hydroxyl	O
)	O
,	O
2950	O
,	O
2873	O
,	O
1681	O
,	O
1458	O
,	O
1371	O
;	O
[	O
α	O
]	O
D	O
(	O
25	O
°	O
C	O
)	O
:	O
−15.6	O
°	O
;	O
1	O
H	O
NMR	O
(	O
500	O
MHz	O
,	O
CDCl3	B
)	O
δ	O
:	O
0.70	O
(	O
3H	O
,	O
d	O
,	O
J	O
=	O
6.7	O
,	O
Me-26	O
or	O
Me-27	O
)	O
,	O
0.71	O
(	O
3H	O
,	O
s	O
,	O
Me-18	O
)	O
,	O
0.72	O
(	O
3H	O
,	O
d	O
,	O
J	O
=	O
6.7	O
,	O
Me-26	O
or	O
Me-27	O
)	O
,	O
0.79	O
(	O
3H	O
,	O
d	O
,	O
J	O
=	O
6.8	O
Hz	O
,	O
Me-28	O
)	O
,	O
0.76	O
(	O
3H	O
,	O
s	O
,	O
Me-19	O
)	O
,	O
0.88	O
(	O
3H	O
,	O
d	O
,	O
J	O
=	O
6.6	O
Hz	O
,	O
Me-21	O
)	O
,	O
1.0–2.0	O
(	O
19H	O
,	O
m	O
)	O
,	O
2.1	O
(	O
1H	O
,	O
m	O
)	O
,	O
3.1–3.2	O
(	O
2H	O
,	O
m	O
,	O
H-2′	O
,	O
H-3′	O
)	O
,	O
3.2–3.4	O
(	O
2H	O
,	O
m	O
,	O
H-4′	O
,	O
H-5′	O
)	O
,	O
3.5	O
(	O
1H	O
,	O
m	O
,	O
H-6a′	O
)	O
,	O
3.60	O
(	O
1H	O
,	O
m	O
,	O
H6b′	O
)	O
,	O
3.85	O
(	O
1H	O
,	O
m	O
,	O
H-3	O
)	O
;	O
4.23	O
(	O
1H	O
,	O
d	O
,	O
J	O
=	O
7.8	O
Hz	O
,	O
H-1′	O
)	O
,	O
5.05	O
(	O
1H	O
,	O
m	O
,	O
H-22	O
)	O
,	O
5.09	O
(	O
1H	O
,	O
m	O
,	O
H-23	O
)	O
,	O
6.13	O
(	O
1H	O
,	O
d	O
,	O
J	O
=	O
8.5	O
Hz	O
,	O
H-7	O
)	O
,	O
6.39	O
(	O
1H	O
,	O
d	O
,	O
J	O
=	O
8.5	O
Hz	O
,	O
H-6	O
)	O
;	O
13	O
C	O
NMR	O
(	O
50	O
MHz	O
,	O
CDCl3	B
):	O
Table	O
2	O
;	O
LRMS	O
(	O
CIMS	O
)	O
m	O
/z	O
(	O
rel	O
.	O

int	O
.	O
)	O
:	O
608	O
[	O
M+NH4	O
]	O
+	O
,	O
593	O
[	O
M+2	O
]	O
+	O
,	O
590	O
[	O
M	O
]	O
+	O
,	O
412	O
[	O
M−178	O
]	O
+	O
;	O
HRMS	O
(	O
DCIMS	O
)	O
:	O
Calculated	O
for	O
C34	O
H54	O
O8	O
+	O
NH+	O
4	O
:	O
608.41624	O
;	O
found	O
:	O
608.41572	O
.	O

3.5	O
Synthesis	O
of	O
1a	B
from	O
ergosterol	B
(	O
6	B
)	O
All	O
reactions	O
were	O
carried	O
out	O
under	O
nitrogen	B
atmosphere	O
in	O
flame	O
-	O
dried	O
glassware	O
unless	O
otherwise	O
stated	O
.	O

3.5.1	O
2,3,4,6-Tetra	B
-	I
O	I
-acetyl-3-O	I
-	I
β	I
-d	I
-glucopyranosyl	I
-	I
ergosta-6,22-dien-5α	I
,	I
8α	I
-epidioxy-3β	I
-ol	I
(	O
5	B
)	O
To	O
a	O
stirring	O
solution	O
of	O
2,3,4,6-tetra	B
-	I
O	I
-acetyl	I
-	I
α	I
-d	I
-glucosyl	I
trichloroacetimidate	I
(	O
0.172	O
g	O
,	O
0.4	O
mmol	O
)	O
in	O
10	O
ml	O
dry	O
CH2	B
Cl2	I
was	O
added	O
4	B
Å	I
molecular	I
sieves	I
(	O
1	O
g	O
)	O
followed	O
by	O
ergosterol	B
(	O
6	B
)	O
(	O
0.2	O
g	O
,	O
0.5	O
mmol	O
)	O
as	O
a	O
solid	O
powder	O
.	O

The	O
solution	O
was	O
cooled	O
to	O
0	O
°	O
C	O
prior	O
to	O
the	O
dropwise	O
addition	O
of	O
BF3	B
.Et2	I

O	B
(	O
0.4	O
ml	O
of	O
stock	O
30	O
μl	O
in	O
2.5	O
ml	O
CH2	B
Cl2	I
)	O
.	O

Upon	O
the	O
addition	O
of	O
BF3	B
.Et2	I

O	B
the	O
solution	O
turned	O
pink	O
,	O
then	O
quickly	O
returned	O
to	O
a	O
clear	O
colourless	O
solution	O
.	O

After	O
10	O
min	O
the	O
solution	O
was	O
allowed	O
to	O
warm	O
slowly	O
to	O
room	O
temperature	O
.	O

The	O
reaction	O
was	O
quenched	O
with	O
the	O
addition	O
of	O
Et3	B
N	I
(	O
60	O
μl	O
)	O
after	O
40	O
min	O
.	O

The	O
clear	O
solution	O
was	O
diluted	O
with	O
CH2	B
Cl2	I
,	O
filtered	O
to	O
remove	O
the	O
molecular	B
sieves	I
and	O
washed	O
twice	O
with	O
H2	B
O.	I
The	O
organic	O
layer	O
was	O
concentrated	O
under	O
reduced	O
pressure	O
.	O

Column	O
chromatography	O
eluted	O
with	O
5	O
%	O
MeOH	B
in	O
CHCl3	B
afforded	O
5	B
(	O
0.0466	O
,	O
mmol	O
)	O
in	O
16	O
%	O
yield	O
(	O
Rf	O
=	O
0.78	O
,	O
15	O
%	O
MeOH	B
in	O
CHCl3	B
)	O
followed	O
by	O
unreacted	B
starting	I
material	I
(	O
0.1192	O
g	O
,	O
300	O
mmol	O
)	O
(	O
Rf	O
=	O
0.66	O
,	O
15	O
%	O
MeOH	B
in	O
CHCl3	B
)	O
.	O

1	O
H	O
NMR	O
(	O
400	O
MHz	O
,	O
CDCl3	B
)	O
δ	O
:	O
0.59	O
(	O
3H	O
,	O
s	O
,	O
Me-18	O
)	O
,	O
0.79	O
(	O
3H	O
,	O
d	O
,	O
J	O
=	O
6.7	O
,	O
Me-26	O
or	O
27	O
)	O
,	O
0.80	O
(	O
3H	O
,	O
d	O
,	O
J	O
=	O
6.7	O
,	O
Me-26	O
or	O
27	O
)	O
,	O
0.86	O
(	O
3H	O
,	O
d	O
,	O
J	O
=	O
6.9	O
,	O
Me-28	O
)	O
,	O
0.88	O
(	O
3H	O
,	O
s	O
,	O
Me-19	O
)	O
,	O
1.00	O
(	O
3H	O
,	O
d	O
,	O
J	O
=	O
6.5	O
,	O
Me-21	O
)	O
,	O
1.7–2.0	O
(	O
18H	O
,	O
m	O
)	O
1.98	O
(	O
3H	O
,	O
s	O
)	O
,	O
1.99	O
(	O
3H	O
,	O
s	O
)	O
,	O
2.01	O
(	O
3H	O
,	O
s	O
)	O
,	O
2.03	O
(	O
3H	O
,	O
s	O
)	O
,	O
2.21	O
(	O
1H	O
,	O
m	O
)	O
,	O
2.40	O
(	O
1H	O
,	O
m	O
)	O
,	O
3.56	O
(	O
1H	O
,	O
m	O
,	O
H-3	O
)	O
,	O
3.66	O
(	O
1H	O
,	O
m	O
)	O
,	O
4.10	O
(	O
1H	O
,	O
m	O
)	O
,	O
4.24	O
(	O
1H	O
,	O
m	O
)	O
,	O
4.60	O
(	O
1H	O
,	O
d	O
,	O
J	O
=	O
7.7	O
,	O
H-1′	O
)	O
,	O
4.94	O
(	O
1H	O
,	O
m	O
)	O
,	O
5.04	O
(	O
1H	O
,	O
m	O
)	O
,	O
5.18	O
(	O
3H	O
,	O
m	O
,	O
H-22	O
,	O
H-23	O
)	O
,	O
5.36	O
(	O
1H	O
,	O
m	O
,	O
H-7	O
)	O
,	O
5.55	O
(	O
1H	O
,	O
m	O
,	O
H-6	O
)	O
;	O
13	O
C	O
NMR	O
(	O
50	O
MHz	O
,	O
CDCl3	B
)	O
12.0	O
,	O
16.1	O
,	O
17.6	O
,	O
19.2	O
,	O
19.6	O
,	O
19.6	O
,	O
19.9	O
,	O
20.5	O
,	O
20.6	O
,	O
20.7	O
,	O
21.0	O
,	O
22.9	O
,	O
28.2	O
,	O
29.7	O
,	O
33.0	O
,	O
33.0	O
,	O
37.1	O
,	O
37.4	O
,	O
38.2	O
,	O
39.0	O
,	O
40.3	O
,	O
42.8	O
,	O
46.1	O
,	O
54.5	O
,	O
55.7	O
,	O
62.0	O
,	O
68.5	O
,	O
71.4	O
,	O
71.7	O
,	O
72.8	O
,	O
78.6	O
,	O
99.5	O
,	O
116.1	O
,	O
119.9	O
,	O
131.9	O
,	O
135.4	O
,	O
139.0	O
,	O
141.6	O
,	O
169.2	O
,	O
169.3	O
,	O
170.3	O
,	O
170.6	O
.	O

3.5.2	O
Ergosteryl-3-O	B
-β	I
-d	I
-glucopyranoside	I
(	O
3	B
)	O
To	O
a	O
stirring	O
solution	O
of	O
5	B
(	O
0.0564	O
g	O
,	O
0.078	O
mmol	O
)	O
in	O
20	O
ml	O
MeOH	B
was	O
added	O
3	O
ml	O
Et3	B
N	I
and	O
0.5	O
ml	O
H2	B
O.	I
After	O
stirring	O
for	O
48	O
h	O
the	O
solvent	O
was	O
removed	O
under	O
reduced	O
pressure	O
.	O

The	O
residue	O
was	O
applied	O
to	O
a	O
silica	B
gel	O
column	O
,	O
and	O
eluted	O
with	O
15	O
%	O
MeOH	B
in	O
CHCl3	B
(	O
Rf	O
=	O
20.6	O
)	O
to	O
afford	O
a	O
white	O
solid	O
.	O

Recrystallization	O
from	O
MeOH	B
provided	O
3	B
(	O
0.0351	O
g	O
,	O
0.063	O
mmol	O
)	O
in	O
81	O
%	O
yield	O
as	O
small	O
white	O
needles	O
.	O

IR	O
(	O
cm−1	O
,	O
CHCl3	B
):	O
3400	O
,	O
2950	O
,	O
2875	O
,	O
1681	O
,	O
1458	O
,	O
1371	O
;	O
1	O
H	O
NMR	O
(	O
400	O
MHz	O
,	O
DMSO	B
)	O
δ	O
:	O
0.58	O
(	O
3H	O
,	O
s	O
,	O
Me-18	O
)	O
,	O
0.79	O
(	O
3H	O
,	O
d	O
,	O
J	O
=	O
6.7	O
,	O
Me-26	O
or	O
-27	O
)	O
,	O
0.80	O
(	O
3H	O
,	O
d	O
,	O
J	O
=	O
6.7	O
,	O
Me-26	O
or	O
-27	O
)	O
,	O
0.86	O
(	O
3H	O
,	O
s	O
,	O
Me-19	O
)	O
,	O
0.88	O
(	O
3H	O
,	O
d	O
,	O
J	O
=	O
6.9	O
,	O
Me-28	O
)	O
,	O
1.00	O
(	O
3H	O
,	O
d	O
,	O
J	O
=	O
6.5	O
,	O
Me-21	O
)	O
,	O
1.24	O
(	O
2H	O
,	O
m	O
)	O
1.45	O
(	O
1H	O
,	O
m	O
)	O
,	O
1.6	O
(	O
1H	O
,	O
m	O
)	O
1.68	O
(	O
1H	O
,	O
m	O
)	O
,	O
1.85	O
(	O
2H	O
,	O
m	O
)	O
,	O
2.0	O
(	O
1H	O
,	O
m	O
)	O
,	O
2.18	O
(	O
1H	O
,	O
m	O
)	O
,	O
2.54	O
(	O
1H	O
,	O
m	O
)	O
,	O
2.98	O
(	O
1H	O
,	O
m	O
)	O
,	O
3.13	O
(	O
1H	O
,	O
m	O
)	O
,	O
3.14	O
(	O
1H	O
,	O
m	O
)	O
,	O
3.3	O
(	O
1H	O
,	O
bs	O
)	O
,	O
3.46	O
(	O
2H	O
,	O
m	O
)	O
,	O
3.61	O
(	O
1H	O
,	O
m	O
)	O
,	O
4.24	O
(	O
1H	O
,	O
d	O
,	O
J	O
=	O
7.7	O
Hz	O
,	O
H-1′	O
)	O
,	O
5.20	O
(	O
2H	O
,	O
m	O
,	O
H-22	O
,	O
H-23	O
)	O
,	O
5.34	O
(	O
1H	O
,	O
m	O
,	O
H-7	O
)	O
,	O
5.52	O
(	O
1H	O
,	O
m	O
,	O
H-6	O
)	O
;	O
13	O
C	O
NMR	O
(	O
50	O
MHz	O
,	O
CDCl3	B
,	O
):	O
Table	O
2	O
.	O

3.5.3	O
5α	B
,	I
8α	I
-Epidioxy-24	I
(	I
R	I
)	I
-methylcholesta-6,22-dien-3β	I
-d	I
-glucopyranoside	I
(	O
1a	B
)	O
To	O
a	O
solution	O
of	O
3	B
(	O
0.0211	O
g	O
,	O
0.038	O
mmol	O
)	O
in	O
20	O
ml	O
dry	O
EtOH	B
was	O
added	O
2	O
drops	O
of	O
a	O
10	O
%	O
solution	O
of	O
eosin	B
in	O
EtOH	B
.	O

Oxygen	B
was	O
bubbled	O
through	O
the	O
solution	O
.	O

The	O
reaction	O
vessel	O
was	O
then	O
placed	O
in	O
a	O
silver	B
dewa	O
and	O
irradiated	O
with	O
a	O
500	O
W	O
tungsten	B
lamp	O
.	O

Water	B
was	O
circulated	O
into	O
the	O
dewar	O
to	O
maintain	O
room	O
temperature	O
for	O
the	O
reaction	O
.	O

After	O
3	O
h	O
the	O
solution	O
was	O
concentrated	O
under	O
reduced	O
pressure	O
,	O
with	O
the	O
resulting	O
residue	O
applied	O
to	O
a	O
silica	B
gel	O
column	O
what	O
we	O
eluted	O
with	O
15	O
%	O
MeOH	B
in	O
CHCl3	B
to	O
afford	O
1a	B
(	O
0.0138	O
g	O
,	O
0.023	O
mmol	O
)	O
in	O
62	O
%	O
yield	O
as	O
a	O
white	O
solid	O
.	O

IR,1	O
H,13	O
C	O
and	O
LRMS	O
were	O
identical	O
to	O
spectra	O
of	O
1a	B
isolated	O
from	O
the	O
mycelia	O
of	O
C.	O
sinensis	O
.	O

3.5.4	O
Synthesis	O
of	O
5α	B
,	I
8α	I
-epidioxy-24	I
(	I
R	I
)	I
-methylcholesta-6,22-dien-3β	I
-ol	I
(	O
1b	B
)	O
(	O
ergosterol	B
peroxide	I
)	O
from	O
ergosterol	B
(	O
6	O
)	O
Following	O
the	O
same	O
procedure	O
as	O
used	O
for	O
the	O
preparation	O
of	O
1a	B
from	O
3	B
,	O
ergosterol	B
(	O
6	B
)	O
(	O
0.1040	O
g	O
,	O
0.26	O
mmol	O
)	O
was	O
oxidized	O
,	O
then	O
purified	O
by	O
silica	B
gel	O
column	O
eluted	O
with	O
15	O
%	O
EtOAc	B
in	O
CH2	B
Cl2	I
to	O
afford	O
1b	B
(	O
0.0932	O
g	O
,	O
0.22	O
mmol	O
)	O
in	O
85	O
%	O
yield	O
as	O
a	O
white	O
solid	O
.	O

1	O
H	O
NMR	O
(	O
500	O
MHz	O
,	O
CDCl3	B
)	O
0.61	O
(	O
3H	O
,	O
s	O
,	O
Me-18	O
)	O
,	O
0.67	O
(	O
3H	O
,	O
s	O
,	O
Me-19	O
)	O
,	O
0.907	O
(	O
3H	O
,	O
d	O
,	O
J	O
=	O
6.67	O
Hz	O
,	O
Me-26	O
or	O
27	O
)	O
,	O
0.913	O
(	O
3H	O
,	O
d	O
,	O
J	O
=	O
6.71	O
Hz	O
,	O
Me-26	O
or	O
-27	O
)	O
,	O
0.99	O
(	O
3H	O
,	O
d	O
,	O
J	O
=	O
6.78	O
Hz	O
,	O
Me-28	O
)	O
,	O
1.00	O
(	O
3H	O
,	O
d	O
,	O
J	O
=	O
6.49	O
,	O
Me-21	O
)	O
,	O
1.1–2.0	O
(	O
20H	O
,	O
m	O
)	O
,	O
3.92	O
(	O
m	O
,	O
1H	O
,	O
H-3	O
)	O
,	O
5.14	O
(	O
1H	O
,	O
m	O
,	O
H-23	O
)	O
,	O
5.25	O
(	O
1H	O
,	O
m	O
,	O
H-22	O
)	O
,	O
5.95	O
(	O
1H	O
,	O
d	O
,	O
J	O
=	O
8.37	O
Hz	O
,	O
H-6	O
)	O
,	O
6.29	O
(	O
1H	O
,	O
d	O
,	O
J	O
=	O
8.47	O
Hz	O
,	O
H-7	O
)	O
;	O
13	O
C	O
NMR	O
(	O
50	O
MHz	O
,	O
CDCl3	B
):	O
Table	O
2	O
.	O

Acknowledgements	O
This	O
work	O
was	O
supported	O
by	O
North	O
American	O
Reishi	O
Inc.	O
,	O
British	O
Columbia	O
.	O

We	O
also	O
thank	O
Dr	O
S.	O
G.	O
Withers	O
for	O
providing	O
2,3,4,6-tetra	B
-	I
O	I
-acetyl	I
-	I
α	I
-d	I
-glucosyltrichloroacetimidate	I
.	O

The	O
biosynthesis	O
of	O
the	O
vitamin	B
biotin	B
,	O
a	O
cofactor	O
in	O
biological	O
carboxylation	O
reactions	O
,	O
occurs	O
in	O
micro	O
-	O
organisms	O
and	O
plants	O
and	O
involves	O
at	O
least	O
four	O
different	O
enzymes	O
(	O
Eisenberg	O
,	O
1973	O
;	O
Gloeckler	O
et	O
al	O
.	O
,	O
1990	O
;	O
Baldet	O
et	O
al	O
.	O
,	O
1993	O
)	O
.	O

Because	O
biotin	B
synthesis	O
is	O
unique	O
to	O
plants	O
and	O
microorganisms	O
,	O
enzymes	O
of	O
this	O
pathway	O
are	O
potential	O
targets	O
for	O
the	O
development	O
of	O
antimicrobial	O
drugs	B
and	O
herbicides	B
(	O
Rendina	O
et	O
al	O
.	O
,	O
1999	O
)	O
.	O

One	O
of	O
these	O
enzymes	O
is	O
7,8-diaminopelargonic	O
acid	O
synthase	O
(	O
DAPA	O
synthase	O
)	O
,	O
an	O
aminotransferase	O
that	O
catalyses	O
the	O
antepenultimate	O
step	O
in	O
this	O
pathway	O
:	O
the	O
conversion	O
of	O
7-keto-8-aminopelargonic	B
acid	I
(	O
KAPA	B
)	O
to	O
7,8-diaminopelargonic	B
acid	I
(	O
DAPA	B
)	O
(	O
Figure	O
1	O
)	O
(	O
Stoner	O
&	O
Eisenberg	O
,	O
1975a	O
)	O
.	O

DAPA	O
synthase	O
from	O
Escherichia	O
coli	O
is	O
a	O
homodimer	O
with	O
a	O
molecular	O
mass	O
of	O
94	O
kDa	O
(	O
Stoner	O
&	O
Eisenberg	O
1975a	O
)	O
and	O
contains	O
429	O
residues	O
per	O
monomer	O
(	O
Otsuka	O
et	O
al	O
.	O
,	O
1988	O
)	O
.	O

It	O
is	O
unique	O
among	O
aminotransferases	O
in	O
that	O
it	O
uses	O
S	B
-adenosyl	I
-	I
l	I
-methionine	I
(	O
SAM	B
)	O
as	O
amino	B
group	I
donor	O
(	O
Stoner	O
&	O
Eisenberg	O
,	O
1975a	O
)	O
.	O

DAPA	O
synthase	O
uses	O
pyridoxal-5′-phosphate	B
(	O
PLP	B
)	O
as	O
cofactor	O
and	O
hence	O
belongs	O
to	O
the	O
family	O
of	O
vitamin	B
B6	I
-dependent	O
aminotransferases	O
(	O
Stoner	O
&	O
Eisenberg	O
,	O
1975a	O
)	O
.	O

In	O
general	O
terms	O
,	O
the	O
mechanism	O
of	O
vitamin	B
B6	I
-dependent	O
enzymes	O
is	O
rather	O
well	O
understood	O
(	O
John	O
,	O
1995	O
;	O
Hayashi	O
,	O
1995	O
)	O
and	O
it	O
is	O
expected	O
that	O
DAPA	O
synthase	O
follows	O
the	O
established	O
overall	O
scheme	O
of	O
PLP	B
catalysis	O
(	O
Figure	O
2	O
)	O
.	O

PLP	B
binds	O
covalently	O
to	O
the	O
active	O
site	O
lysine	B
residue	O
through	O
a	O
Schiff	B
base	I
linkage	O
(	O
the	O
internal	O
aldimine	B
)	O
.	O

Upon	O
binding	O
of	O
SAM	B
,	O
the	O
substrate	O
for	O
the	O
first	O
part	O
of	O
the	O
catalytic	O
cycle	O
,	O
an	O
external	O
aldimine	B
is	O
formed	O
between	O
the	O
substrate	O
and	O
the	O
cofactor	O
through	O
a	O
transaldimination	O
process	O
.	O

The	O
reaction	O
proceeds	O
through	O
deprotonation	O
of	O
the	O
former	O
Cα	O
carbon	B
of	O
the	O
substrate	O
,	O
leading	O
to	O
the	O
quinonoid	B
intermediate	O
followed	O
by	O
protonation	O
of	O
the	O
C-4′	O
carbon	B
.	O

It	O
has	O
been	O
shown	O
for	O
aspartate	O
aminotransferase	O
that	O
the	O
lysine	B
residue	O
previously	O
covalently	O
bound	O
to	O
the	O
cofactor	O
acts	O
as	O
proton	O
acceptor	O
and	O
donor	O
in	O
these	O
steps	O
(	O
Gehring	O
,	O
1984	O
;	O
Julin	O
et	O
al	O
.	O
,	O
1989	O
)	O
.	O

Hydrolysis	O
of	O
the	O
resulting	O
ketimine	B
intermediate	O
gives	O
the	O
keto	B
acid	I
of	O
the	O
first	O
substrate	O
SAM	B
and	O
pyridoxamine	B
phosphate	I
bound	O
to	O
the	O
enzyme	O
by	O
non	O
-	O
covalent	O
bonds	O
.	O

The	O
second	O
half	O
of	O
the	O
catalytic	O
cycle	O
is	O
in	O
principle	O
a	O
reversal	O
of	O
the	O
first	O
steps	O
.	O

KAPA	B
,	O
the	O
second	O
substrate	O
,	O
binds	O
and	O
receives	O
the	O
amino	B
group	I
from	O
pyridoxamine	B
phosphate	I
as	O
the	O
PLP	O
-	O
enzyme	O
complex	O
is	O
regenerated	O
.	O

Thus	O
,	O
both	O
substrates	O
have	O
to	O
be	O
accommodated	O
in	O
the	O
same	O
active	O
site	O
,	O
despite	O
differences	O
in	O
size	O
and	O
chemical	O
properties	O
.	O

Although	O
KAPA	B
bears	O
an	O
amino	B
group	I
,	O
DAPA	O
synthase	O
uses	O
KAPA	B
only	O
as	O
an	O
amino	B
group	I
acceptor	O
,	O
not	O
as	O
an	O
amino	B
group	I
donor	O
,	O
i.e.	O
KAPA	B
is	O
not	O
transaminated	O
by	O
DAPA	O
synthase	O
(	O
Stoner	O
&	O
Eisenberg	O
,	O
1975b	O
)	O
.	O

The	O
three	O
-	O
dimensional	O
structures	O
of	O
more	O
than	O
20	O
different	O
PLP	B
-	O
dependent	O
enzymes	O
have	O
been	O
determined	O
(	O
for	O
a	O
recent	O
review	O
,	O
see	O
Jansonius	O
1998	O
)	O
.	O

Christen	O
and	O
co	O
-	O
workers	O
organised	O
PLP	B
-	O
dependent	O
enzymes	O
into	O
three	O
different	O
families	O
,	O
α	O
,	O
β	O
and	O
γ	O
,	O
based	O
on	O
the	O
chemical	O
characteristics	O
of	O
the	O
catalysed	O
reaction	O
and	O
attempted	O
to	O
correlate	O
these	O
with	O
amino	B
acid	I
sequence	O
families	O
(	O
Alexander	O
et	O
al	O
.	O
,	O
1994	O
)	O
.	O

The	O
aminotransferases	O
belong	O
to	O
the	O
α	O
-	O
family	O
,	O
which	O
hosts	O
enzymes	O
acting	O
on	O
the	O
carbon	B
atom	O
adjacent	O
to	O
the	O
amino	B
group	I
of	O
the	O
substrate	O
.	O

Another	O
classification	O
based	O
on	O
fold	O
types	O
and	O
sequence	O
comparisons	O
was	O
introduced	O
by	O
Grishin	O
et	O
al.	O
(	O
1995	O
)	O
.	O

So	O
far	O
,	O
five	O
different	O
folds	O
that	O
can	O
bind	O
PLP	B
have	O
been	O
observed	O
and	O
it	O
has	O
been	O
proposed	O
on	O
the	O
basis	O
of	O
sequence	O
analysis	O
that	O
additional	O
hitherto	O
unknown	O
PLP	B
-	O
binding	O
folds	O
might	O
exist	O
(	O
Grishin	O
et	O
al	O
.	O
,	O
1995	O
)	O
.	O

Most	O
aminotransferases	O
of	O
known	O
structure	O
belong	O
to	O
fold	O
type	O
I	O
,	O
first	O
described	O
for	O
aspartate	O
aminotransferase	O
(	O
Ford	O
et	O
al	O
.	O
,	O
1980	O
)	O
.	O

This	O
structural	O
family	O
is	O
characterised	O
by	O
a	O
large	O
domain	O
folded	O
into	O
a	O
central	O
β	O
-	O
sheet	O
,	O
with	O
surrounding	O
loops	O
and	O
helices	O
forming	O
most	O
of	O
the	O
PLP	B
binding	O
site	O
and	O
a	O
smaller	O
domain	O
partly	O
involved	O
in	O
substrate	O
binding	O
.	O

Exceptions	O
are	O
d	O
-amino	O
acid	O
aminotransferase	O
(	O
Sugio	O
et	O
al	O
.	O
,	O
1995	O
)	O
and	O
branched	O
chain	O
aminotransferase	O
(	O
Okada	O
et	O
al	O
.	O
,	O
1997	O
)	O
,	O
which	O
fold	O
in	O
a	O
completely	O
different	O
manner	O
.	O

Sequence	O
analysis	O
suggested	O
that	O
DAPA	O
synthase	O
may	O
belong	O
to	O
the	O
aminotransferase	O
subclass	O
III	O
of	O
the	O
PLP	B
fold	O
type	O
I	O
family	O
(	O
Metha	O
et	O
al	O
.	O
,	O
1993	O
)	O
,	O
which	O
includes	O
a	O
number	O
of	O
enzymes	O
of	O
known	O
structure	O
:	O
ω	O
-	O
aminotransferase	O
(	O
Watanabe	O
et	O
al	O
.	O
,	O
1989	O
)	O
,	O
ornithine	O
aminotransferase	O
(	O
Shah	O
et	O
al	O
.	O
,	O
1997	O
,	O
Shen	O
et	O
al	O
.	O
,	O
1998	O
)	O
,	O
2,2-dialkylglycine	O
decarboxylase	O
(	O
Toney	O
et	O
al	O
.	O
,	O
1993	O
,	O
1995	O
)	O
and	O
glutamate	O
semialdehyde	O
aminomutase	O
(	O
Hennig	O
et	O
al	O
.	O
,	O
1997	O
)	O
.	O

Here	O
we	O
report	O
the	O
three	O
-	O
dimensional	O
structure	O
of	O
DAPA	O
synthase	O
from	O
E.	O
coli	O
at	O
1.8	O
Å	O
resolution	O
.	O

The	O
structure	O
analysis	O
reveals	O
that	O
this	O
enzyme	O
indeed	O
is	O
a	O
member	O
of	O
the	O
aspartate	O
aminotransferase	O
family	O
of	O
vitamin	B
B6	I
-dependent	O
enzymes	O
.	O

A	O
multiple	O
structure	O
alignment	O
suggests	O
that	O
at	O
least	O
six	O
subclasses	O
,	O
which	O
are	O
structurally	O
and	O
evolutionary	O
closely	O
related	O
,	O
exist	O
in	O
this	O
family	O
.	O

Furthermore	O
,	O
the	O
structure	O
of	O
a	O
ternary	O
complex	O
of	O
DAPA	O
synthase	O
with	O
the	O
substrate	O
KAPA	B
,	O
bound	O
to	O
the	O
PLP	B
form	O
of	O
the	O
enzyme	O
,	O
is	O
presented	O
.	O

This	O
structure	O
forms	O
the	O
basis	O
for	O
mechanistic	O
considerations	O
,	O
in	O
particular	O
with	O
respect	O
to	O
substrate	O
recognition	O
.	O

Results	O
Structure	O
determination	O
The	O
structure	O
of	O
DAPA	O
synthase	O
was	O
determined	O
to	O
1.8	O
Å	O
resolution	O
.	O

Despite	O
non	O
-	O
isomorphism	O
between	O
crystals	O
of	O
DAPA	O
synthase	O
,	O
two	O
heavy	O
-	O
atom	O
derivatives	O
containing	O
mercury	B
and	O
platinum	B
,	O
respectively	O
,	O
were	O
identified	O
after	O
extensive	O
screening	O
.	O

However	O
,	O
the	O
phases	O
derived	O
from	O
these	O
derivatives	O
were	O
not	O
of	O
sufficient	O
quality	O
to	O
allow	O
tracing	O
of	O
the	O
polypeptide	O
chain	O
.	O

Therefore	O
multiple	O
anomalous	O
dispersion	O
techniques	O
,	O
using	O
mercury	B
-	O
derivatised	O
crystals	O
were	O
employed	O
to	O
obtain	O
phase	O
information	O
(	O
for	O
data	O
collection	O
and	O
phasing	O
statistics	O
see	O
Table	O
1	O
)	O
.	O

The	O
initial	O
map	O
at	O
2.0	O
Å	O
resolution	O
,	O
calculated	O
after	O
solvent	O
flattening	O
and	O
2-fold	O
non	O
-	O
crystallographic	O
averaging	O
,	O
was	O
of	O
excellent	O
quality	O
(	O
Figure	O
3	O
(	O
a	O
)	O
)	O
and	O
the	O
polypeptide	O
chain	O
could	O
be	O
readily	O
built	O
into	O
the	O
electron	O
density	O
.	O

After	O
a	O
few	O
refinement	O
cycles	O
,	O
most	O
of	O
the	O
side	O
-	O
chains	O
had	O
been	O
assigned	O
.	O

However	O
,	O
native	O
crystals	O
diffracted	O
to	O
higher	O
resolution	O
(	O
1.8	O
Å	O
)	O
and	O
it	O
was	O
desirable	O
to	O
use	O
these	O
data	O
for	O
the	O
refinement	O
.	O

Because	O
of	O
the	O
non	O
-	O
isomorphism	O
between	O
crystals	O
,	O
molecular	O
replacement	O
was	O
necessary	O
for	O
finding	O
the	O
correct	O
orientation	O
of	O
the	O
molecule	O
in	O
the	O
native	O
crystal	O
.	O

The	O
solution	O
was	O
verified	O
by	O
strong	O
and	O
well	O
defined	O
density	O
for	O
the	O
cofactor	O
,	O
PLP	B
,	O
which	O
had	O
been	O
excluded	O
from	O
the	O
search	O
model	O
.	O

Two	O
-	O
fold	O
non	O
-	O
crystallographic	O
symmetry	O
was	O
applied	O
in	O
the	O
subsequent	O
refinement	O
,	O
but	O
released	O
in	O
the	O
very	O
last	O
stages	O
causing	O
a	O
slight	O
drop	O
in	O
the	O
free	O
R	O
-value	O
.	O

Figure	O
3	O
(	O
b	O
)	O
shows	O
a	O
part	O
of	O
the	O
final	O
2F	O
o	O
−F	O
c	O
electron	O
density	O
map	O
,	O
with	O
the	O
refined	O
model	O
superimposed	O
.	O

The	O
final	O
model	O
contains	O
all	O
but	O
one	O
residue	O
,	O
556	O
water	B
molecules	O
,	O
two	O
PLP	B
molecules	O
covalently	O
linked	O
to	O
Lys274	B
in	O
each	O
chain	O
and	O
two	O
Na+	B
.	O

Only	O
the	O
backbone	O
is	O
modelled	O
for	O
the	O
C	B
-	I
terminal	I
residue	I
in	O
both	O
chains	O
(	O
Glu429	B
)	O
,	O
since	O
the	O
side	O
-	O
chains	O
were	O
disordered	O
.	O

The	O
side	O
-	O
chains	O
in	O
the	O
loop	O
region	O
between	O
residues	O
180	O
and	O
192	O
are	O
badly	O
ordered	O
,	O
and	O
in	O
one	O
of	O
the	O
monomers	O
residue	O
183	O
is	O
not	O
included	O
in	O
the	O
model	O
,	O
since	O
no	O
electron	O
density	O
corresponding	O
to	O
its	O
main	O
-	O
chain	O
atoms	O
was	O
observed	O
.	O

In	O
both	O
chains	O
residue	O
Trp14	B
,	O
which	O
is	O
positioned	O
in	O
the	O
interior	O
of	O
the	O
protein	O
,	O
was	O
built	O
as	O
a	O
leucine	B
residue	O
,	O
judged	O
by	O
the	O
electron	O
density	O
and	O
the	O
local	O
environment	O
of	O
the	O
side	O
-	O
chain	O
.	O

This	O
replacement	O
was	O
later	O
supported	O
by	O
N	B
-	I
terminal	I
amino	I
acid	I
sequencing	O
.	O

The	O
model	O
was	O
refined	O
to	O
a	O
final	O
R	O
-factor	O
of	O
17.5	O
%	O
and	O
a	O
free	O
R	O
-factor	O
of	O
22.6	O
%	O
.	O

A	O
summary	O
of	O
the	O
refinement	O
statistics	O
is	O
shown	O
in	O
Table	O
2	O
.	O

Two	O
residues	O
,	O
Trp53	B
and	O
Ile213	B
,	O
which	O
both	O
are	O
well	O
defined	O
in	O
the	O
electron	O
density	O
map	O
,	O
appear	O
in	O
the	O
disallowed	O
region	O
of	O
the	O
Ramachandran	O
plot	O
for	O
each	O
subunit	O
.	O

Trp53	B
is	O
involved	O
in	O
substrate	O
binding	O
and	O
Ile213	B
is	O
found	O
at	O
a	O
sharp	O
turn	O
in	O
the	O
beginning	O
of	O
a	O
β	O
-	O
strand	O
that	O
takes	O
the	O
chain	O
into	O
the	O
cofactor	O
binding	O
region	O
.	O

The	O
structure	O
of	O
the	O
monomer	O
The	O
monomer	O
of	O
DAPA	O
synthase	O
consists	O
of	O
two	O
domains	O
(	O
Figure	O
4	O
(	O
a	O
)	O
)	O
,	O
a	O
small	O
domain	O
comprising	O
the	O
N	O
-	O
and	O
C	O
-	O
terminal	O
parts	O
of	O
the	O
polypeptide	O
chain	O
(	O
residues	O
1–49	O
and	O
330–429	O
)	O
and	O
a	O
large	O
domain	O
formed	O
by	O
the	O
intervening	O
residues	O
containing	O
the	O
cofactor	O
binding	O
site	O
.	O

A	O
topological	O
description	O
of	O
the	O
structure	O
of	O
DAPA	O
synthase	O
is	O
presented	O
in	O
Figure	O
4	O
(	O
b	O
)	O
.	O

The	O
large	O
domain	O
starts	O
with	O
a	O
helix	O
-	O
loop	O
-	O
helix	O
segment	O
formed	O
by	O
helices	O
α2	O
and	O
α3	O
,	O
which	O
takes	O
the	O
chain	O
over	O
the	O
surface	O
of	O
the	O
molecule	O
to	O
the	O
beginning	O
of	O
a	O
seven	O
-	O
stranded	O
β	O
-	O
sheet	O
,	O
the	O
central	O
feature	O
of	O
this	O
domain	O
,	O
which	O
is	O
typical	O
of	O
aminotransferases	O
(	O
Ford	O
et	O
al	O
.	O
,	O
1980	O
)	O
.	O

The	O
order	O
of	O
the	O
strands	O
is	O
β4	O
,	O
β10	O
,	O
β9	O
,	O
β8	O
,	O
β7	O
,	O
β5	O
and	O
β6	O
,	O
where	O
all	O
except	O
β10	O
are	O
parallel	O
to	O
each	O
other	O
.	O

Towards	O
the	O
exterior	O
of	O
the	O
molecule	O
the	O
sheet	O
is	O
covered	O
by	O
two	O
helices	O
,	O
α5	O
and	O
α6	O
,	O
and	O
the	O
loop	O
between	O
strands	O
β8	O
and	O
β9	O
.	O

The	O
sheet	O
is	O
further	O
shielded	O
from	O
the	O
solvent	O
by	O
helices	O
α3	O
and	O
α8	O
,	O
which	O
pack	O
almost	O
perpendicular	O
to	O
the	O
strands	O
in	O
the	O
β	O
-	O
sheet	O
.	O

Helix	O
α4	O
and	O
the	O
extended	O
loop	O
between	O
β5	O
and	O
β6	O
pack	O
against	O
the	O
sheet	O
on	O
the	O
opposite	O
side	O
and	O
are	O
involved	O
in	O
subunit	O
-	O
subunit	O
interactions	O
.	O

Helices	O
α7-α8	O
form	O
a	O
helix	O
-	O
loop	O
-	O
helix	O
segment	O
,	O
which	O
follows	O
after	O
the	O
seven	O
-	O
stranded	O
β	O
-	O
sheet	O
and	O
completes	O
the	O
large	O
domain	O
.	O

The	O
C	O
-	O
terminal	O
part	O
of	O
the	O
small	O
domain	O
folds	O
into	O
a	O
β	O
-	O
sheet	O
which	O
is	O
packed	O
against	O
three	O
helices	O
α9	O
,	O
α10	O
and	O
α11	O
,	O
on	O
one	O
side	O
.	O

The	O
other	O
side	O
of	O
the	O
sheet	O
is	O
turned	O
against	O
the	O
large	O
domain	O
,	O
so	O
that	O
a	O
crevice	O
is	O
formed	O
between	O
the	O
two	O
domains	O
,	O
which	O
accommodates	O
the	O
active	O
site	O
.	O

The	O
N	O
-	O
terminal	O
part	O
of	O
the	O
small	O
domain	O
starts	O
with	O
an	O
α	O
-	O
helix	O
followed	O
by	O
three	O
short	O
β	O
-	O
strands	O
,	O
β1	O
,	O
β2	O
and	O
β3	O
,	O
folded	O
into	O
an	O
anti	O
-	O
parallel	O
β	O
-	O
sheet	O
,	O
and	O
then	O
proceeds	O
into	O
the	O
large	O
domain	O
via	O
a	O
connecting	O
peptide	B
segment	O
.	O

This	O
β	O
-	O
sheet	O
is	O
positioned	O
between	O
the	O
C	O
-	O
terminal	O
part	O
of	O
the	O
small	O
domain	O
and	O
the	O
large	O
domain	O
and	O
provides	O
one	O
wall	O
of	O
the	O
active	O
site	O
.	O

The	O
N	O
-	O
terminal	O
β	O
-	O
sheet	O
is	O
extended	O
by	O
a	O
very	O
short	O
strand	O
,	O
created	O
by	O
residues	O
located	O
between	O
strand	O
β13	O
and	O
helix	O
α10	O
in	O
the	O
C	O
-	O
terminal	O
part	O
of	O
the	O
domain	O
.	O

Following	O
this	O
interaction	O
the	O
polypeptide	O
chain	O
proceeds	O
back	O
into	O
the	O
C	O
-	O
terminal	O
part	O
of	O
the	O
small	O
domain	O
,	O
extending	O
its	O
β	O
-	O
sheet	O
by	O
a	O
short	O
anti	O
-	O
parallel	O
β	O
-	O
strand	O
interaction	O
to	O
strand	O
β13	O
(	O
Figure	O
4	O
(	O
b	O
)	O
)	O
.	O

Most	O
of	O
the	O
interactions	O
between	O
the	O
C	O
-	O
terminal	O
part	O
of	O
the	O
small	O
domain	O
and	O
the	O
large	O
domain	O
involve	O
strand	O
β11	O
,	O
the	O
loop	O
following	O
that	O
strand	O
and	O
the	O
loop	O
between	O
β13	O
and	O
α11	O
.	O

Arg360	B
in	O
strand	O
β11	O
interacts	O
through	O
its	O
side	O
-	O
chain	O
with	O
the	O
main	O
-	O
chain	O
carbonyl	B
groups	I
of	O
residues	O
Gly219	B
and	O
Met220	B
,	O
situated	O
in	O
the	O
loop	O
region	O
between	O
β7	O
and	O
α6	O
in	O
the	O
large	O
domain	O
.	O

Arg253	B
in	O
the	O
large	O
domain	O
interacts	O
via	O
its	O
side	O
-	O
chain	O
with	O
the	O
main	O
-	O
chain	O
carbonyl	B
oxygen	B
atoms	O
of	O
Pro401	B
found	O
between	O
strand	O
β13	O
and	O
helix	O
α11	O
,	O
and	O
Ala364	B
between	O
strands	O
β11	O
and	O
β12	O
.	O

It	O
is	O
also	O
hydrogen	B
bonded	O
through	O
its	O
main	O
-	O
chain	O
carbonyl	B
oxygen	B
atom	O
to	O
the	O
phenolic	B
hydroxyl	B
group	I
of	O
Tyr403	B
.	O

Ile56	B
,	O
found	O
in	O
the	O
domain	O
interconnection	O
region	O
,	O
provides	O
a	O
main	O
-	O
chain	O
-	O
main	O
-	O
chain	O
interaction	O
with	O
Tyr403	B
in	O
the	O
small	O
domain	O
.	O

Finally	O
,	O
the	O
side	O
-	O
chain	O
hydroxyl	B
group	I
of	O
Tyr403	B
is	O
within	O
hydrogen	B
bonding	O
distance	O
of	O
the	O
main	O
-	O
chain	O
carbonyl	B
oxygen	B
atom	O
of	O
Phe251	B
in	O
the	O
loop	O
between	O
β8	O
and	O
β9	O
.	O

All	O
residues	O
involved	O
in	O
this	O
interface	O
except	O
Tyr403	B
and	O
Ala364	B
are	O
either	O
conserved	O
or	O
invariant	O
within	O
the	O
DAPA	O
synthases	O
(	O
Figure	O
4	O
(	O
c	O
)	O
)	O
.	O

The	O
domain	O
-	O
domain	O
interface	O
between	O
the	O
N	O
-	O
terminal	O
part	O
of	O
the	O
small	O
domain	O
and	O
the	O
large	O
domain	O
involves	O
hydrogen	B
bond	O
interactions	O
between	O
the	O
main	O
-	O
chain	O
atoms	O
of	O
the	O
C	O
-	O
terminal	O
residues	O
of	O
strand	O
β1	O
,	O
Ala32	B
and	O
Gly34	B
,	O
and	O
main	O
-	O
chain	O
atoms	O
of	O
Tyr59	B
and	O
the	O
side	O
-	O
chain	O
of	O
Asn60	B
,	O
which	O
precede	O
helix	O
α2	O
in	O
the	O
large	O
domain	O
.	O

Tyr17	B
,	O
located	O
in	O
the	O
loop	O
between	O
α1	O
and	O
β1	O
,	O
is	O
hydrogen	B
-	O
bonded	O
through	O
its	O
phenolic	B
oxygen	B
to	O
the	O
side	O
-	O
chain	O
of	O
Asp147	B
,	O
which	O
is	O
part	O
of	O
the	O
extended	O
loop	O
between	O
strands	O
β5	O
and	O
β6	O
of	O
the	O
large	O
domain	O
.	O

Furthermore	O
,	O
two	O
of	O
the	O
residues	O
involved	O
in	O
the	O
domain	O
interconnection	O
,	O
Ser50	B
and	O
Trp53	B
,	O
interact	O
through	O
the	O
side	O
-	O
chain	O
hydroxyl	B
and	O
main	O
-	O
chain	O
carbonyl	B
oxygen	B
atom	O
,	O
respectively	O
,	O
with	O
the	O
guanidinium	B
group	I
of	O
Arg253	B
located	O
between	O
strands	O
β8	O
and	O
β9	O
.	O

These	O
three	O
residues	O
and	O
Gly34	B
are	O
invariant	O
throughout	O
the	O
sequenced	O
DAPA	O
synthases	O
(	O
Figure	O
4	O
(	O
c	O
)	O
)	O
.	O

The	O
DAPA	O
synthase	O
dimer	O
In	O
the	O
crystal	O
,	O
a	O
homodimer	O
of	O
DAPA	O
synthase	O
(	O
Figure	O
5	O
)	O
is	O
found	O
with	O
the	O
subunits	O
related	O
by	O
a	O
2-fold	O
non	O
-	O
crystallographic	O
axis	O
.	O

This	O
finding	O
is	O
consistent	O
with	O
solution	O
studies	O
that	O
showed	O
that	O
DAPA	O
synthase	O
is	O
active	O
in	O
dimeric	O
form	O
(	O
Stoner	O
&	O
Eisenberg	O
,	O
1975a	O
)	O
.	O

Upon	O
dimerisation	O
,	O
an	O
area	O
of	O
5240	O
Å2	O
per	O
subunit	O
is	O
buried	O
,	O
which	O
corresponds	O
to	O
27	O
%	O
of	O
the	O
total	O
solvent	O
-	O
accessible	O
area	O
.	O

The	O
overall	O
dimension	O
of	O
the	O
dimer	O
is	O
85	O
Å	O
×	O
60	O
Å	O
×	O
60	O
Å.	O
Both	O
subunits	O
are	O
involved	O
in	O
building	O
up	O
the	O
two	O
identical	O
active	O
sites	O
of	O
the	O
DAPA	O
synthase	O
dimer	O
,	O
which	O
are	O
positioned	O
approximately	O
20	O
Å	O
apart	O
.	O

The	O
pattern	O
of	O
subunit	O
-	O
subunit	O
interactions	O
is	O
extensive	O
and	O
residues	O
from	O
both	O
domains	O
are	O
involved	O
in	O
these	O
interactions	O
.	O

In	O
the	O
large	O
domain	O
helix	O
α2	O
lines	O
up	O
with	O
and	O
packs	O
against	O
α2	O
from	O
the	O
other	O
monomer	O
,	O
and	O
both	O
form	O
the	O
top	O
of	O
the	O
molecule	O
,	O
as	O
shown	O
in	O
Figure	O
5	O
.	O

The	O
extended	O
loop	O
following	O
helix	O
α2	O
protrudes	O
into	O
the	O
neighbouring	O
subunit	O
,	O
forming	O
several	O
strong	O
interactions	O
with	O
loop	O
regions	O
from	O
both	O
domains	O
of	O
that	O
subunit	O
.	O

Helix	O
α3	O
,	O
which	O
covers	O
the	O
central	O
β	O
-	O
sheet	O
of	O
its	O
own	O
subunit	O
,	O
interacts	O
with	O
residues	O
from	O
the	O
N	O
-	O
terminal	O
part	O
of	O
the	O
small	O
domain	O
from	O
the	O
other	O
subunit	O
.	O

Helix	O
α4	O
and	O
the	O
loop	O
between	O
β5	O
and	O
β6	O
,	O
which	O
protrude	O
from	O
the	O
central	O
β	O
-	O
sheet	O
region	O
,	O
pack	O
against	O
the	O
corresponding	O
residues	O
in	O
the	O
second	O
monomer	O
at	O
an	O
angle	O
of	O
approximately	O
90	O
°	O
,	O
mainly	O
through	O
hydrophobic	O
interactions	O
.	O

Furthermore	O
,	O
the	O
top	O
end	O
of	O
this	O
part	O
of	O
the	O
sheet	O
involving	O
strands	O
β4	O
,	O
β10	O
and	O
β11	O
,	O
including	O
PLP	B
binding	O
residue	O
Lys274	B
,	O
and	O
connecting	O
loops	O
form	O
interactions	O
with	O
the	O
other	O
subunit	O
of	O
DAPA	O
synthase	O
,	O
in	O
particular	O
with	O
helices	O
α7	O
and	O
α8	O
.	O

Dimer	O
interactions	O
formed	O
by	O
the	O
small	O
domain	O
are	O
almost	O
exclusively	O
made	O
up	O
of	O
the	O
N	O
-	O
terminal	O
part	O
in	O
which	O
the	O
N	O
-	O
terminal	O
helix	O
and	O
the	O
following	O
loop	O
folds	O
over	O
the	O
surface	O
of	O
the	O
second	O
monomer	O
.	O

The	O
loop	O
between	O
helix	O
α2	O
and	O
α3	O
is	O
of	O
central	O
importance	O
for	O
the	O
subunit	O
-	O
subunit	O
interactions	O
.	O

It	O
interacts	O
with	O
residues	O
located	O
in	O
helix	O
α1	O
,	O
in	O
the	O
loop	O
between	O
helix	O
α1	O
and	O
strand	O
β1	O
,	O
in	O
strand	O
β1	O
,	O
in	O
the	O
domain	O
interconnection	O
region	O
,	O
in	O
the	O
loop	O
between	O
strands	O
β9	O
and	O
β10	O
,	O
and	O
in	O
the	O
loop	O
between	O
helix	O
α10	O
and	O
strand	O
β13	O
of	O
the	O
second	O
subunit	O
.	O

The	O
pyridoxal-5′-phosphate	B
binding	O
site	O
The	O
electron	O
density	O
for	O
the	O
cofactor	O
is	O
very	O
well	O
defined	O
and	O
shows	O
clearly	O
that	O
PLP	B
is	O
covalently	O
bound	O
to	O
the	O
active	O
site	O
Lys274	B
(	O
Figure	O
3	O
(	O
b	O
)	O
)	O
.	O

The	O
PLP	B
binding	O
site	O
is	O
located	O
between	O
the	O
two	O
domains	O
of	O
the	O
monomer	O
at	O
the	O
interface	O
of	O
the	O
two	O
subunits	O
(	O
Figure	O
6	O
)	O
.	O

Residues	O
from	O
both	O
subunits	O
are	O
involved	O
in	O
cofactor	O
binding	O
,	O
although	O
each	O
active	O
site	O
cleft	O
is	O
mainly	O
made	O
up	O
of	O
one	O
monomer	O
.	O

The	O
lysine	B
residue	O
covalently	O
attached	O
to	O
PLP	B
is	O
located	O
on	O
the	O
loop	O
between	O
strands	O
β9	O
and	O
β10	O
,	O
and	O
points	O
towards	O
the	O
interior	O
of	O
the	O
protein	O
so	O
that	O
PLP	B
is	O
found	O
on	O
the	O
side	O
of	O
the	O
β	O
-	O
sheet	O
facing	O
the	O
second	O
subunit	O
in	O
the	O
dimer	O
.	O

The	O
cofactor	O
is	O
bound	O
at	O
the	O
bottom	O
of	O
the	O
active	O
site	O
,	O
with	O
its	O
re	O
side	O
facing	O
the	O
solvent	O
.	O

The	O
oxygen	B
atoms	O
of	O
the	O
phosphate	B
group	O
interact	O
with	O
the	O
main	O
-	O
chain	O
amides	B
of	O
Gly112	B
and	O
Ser113	B
,	O
and	O
the	O
side	O
-	O
chain	O
of	O
Ser113	B
,	O
located	O
at	O
the	O
N	O
terminus	O
of	O
helix	O
α4	O
,	O
thus	O
anchoring	O
PLP	B
firmly	O
to	O
the	O
enzyme	O
.	O

The	O
negative	O
charges	O
on	O
the	O
phosphate	B
oxygen	B
atoms	O
are	O
partly	O
neutralised	O
by	O
the	O
positive	O
dipole	O
charge	O
of	O
helix	O
α4	O
.	O

Further	O
,	O
Thr309	B
from	O
the	O
other	O
subunit	O
forms	O
a	O
hydrogen	B
bond	O
interaction	O
through	O
its	O
main	O
-	O
chain	O
amide	B
to	O
one	O
of	O
the	O
phosphate	B
oxygen	B
atoms	O
.	O

Several	O
well	O
ordered	O
water	B
molecules	O
within	O
hydrogen	B
bond	O
distance	O
of	O
the	O
phosphate	B
oxygen	B
atoms	O
are	O
also	O
found	O
in	O
the	O
active	O
site	O
of	O
the	O
holo	O
-	O
enzyme	O
.	O

The	O
carboxyl	B
group	I
of	O
Asp245	B
is	O
within	O
hydrogen	B
bonding	O
distance	O
of	O
the	O
pyridine	B
nitrogen	B
.	O

This	O
indicates	O
either	O
that	O
the	O
carboxyl	B
side	O
-	O
chain	O
is	O
protonated	O
and	O
can	O
form	O
a	O
hydrogen	B
bond	O
to	O
the	O
nitrogen	B
atom	O
or	O
that	O
this	O
nitrogen	B
is	O
protonated	O
.	O

The	O
aspartic	B
acid	I
side	O
-	O
chain	O
is	O
kept	O
in	O
place	O
by	O
interactions	O
with	O
the	O
main	O
-	O
chain	O
amide	B
of	O
residue	O
Ile247	B
and	O
with	O
the	O
side	O
-	O
chain	O
of	O
His145	B
.	O

No	O
direct	O
interactions	O
with	O
protein	O
atoms	O
are	O
found	O
for	O
the	O
phenolic	B
hydroxyl	B
group	I
,	O
O-3′	O
,	O
of	O
the	O
cofactor	O
.	O

There	O
are	O
,	O
however	O
,	O
water	B
-	O
mediated	O
contacts	O
to	O
the	O
side	O
-	O
chain	O
of	O
Glu211	B
and	O
the	O
main	O
-	O
chain	O
amide	B
of	O
Ala217	B
.	O

The	O
pyridine	B
ring	O
of	O
PLP	B
is	O
sandwiched	O
between	O
the	O
side	O
-	O
chain	O
of	O
Tyr144	B
protruding	O
from	O
the	O
active	O
site	O
,	O
which	O
stacks	O
perpendicular	O
to	O
the	O
ring	O
,	O
and	O
Ile247	B
,	O
which	O
provides	O
support	O
from	O
the	O
si	O
side	O
of	O
the	O
ring	O
facing	O
the	O
protein	O
.	O

Binding	O
of	O
the	O
substrate	O
KAPA	B
The	O
electron	O
density	O
map	O
for	O
the	O
ternary	O
complex	O
was	O
continuous	O
except	O
for	O
a	O
few	O
disordered	O
loop	O
regions	O
at	O
the	O
surface	O
of	O
the	O
molecule	O
.	O

These	O
regions	O
comprise	O
residues	O
160–168	O
and	O
300–301	O
in	O
each	O
subunit	O
with	O
no	O
electron	O
density	O
for	O
the	O
backbone	O
.	O

As	O
in	O
the	O
crystals	O
of	O
the	O
holoenzyme	O
,	O
the	O
loop	O
comprising	O
residues	O
180–192	O
has	O
weak	O
electron	O
density	O
,	O
with	O
disordered	O
side	O
-	O
chains	O
for	O
residues	O
180–192	O
and	O
no	O
electron	O
density	O
for	O
the	O
backbone	O
of	O
residues	O
183–184	O
.	O

The	O
C	B
-	I
terminal	I
residue	I
was	O
not	O
modelled	O
because	O
of	O
very	O
weak	O
electron	O
density	O
.	O

The	O
stereochemistry	O
of	O
the	O
refined	O
model	O
is	O
reasonable	O
(	O
Table	O
2	O
)	O
.	O

The	O
Ramachandran	O
plot	O
showed	O
one	O
outlier	O
,	O
residue	O
Ile213	B
,	O
with	O
well	O
defined	O
electron	O
density	O
.	O

This	O
residue	O
is	O
also	O
found	O
in	O
the	O
disallowed	O
region	O
of	O
the	O
Ramachandran	O
plot	O
for	O
the	O
model	O
of	O
the	O
holoenzyme	O
.	O

The	O
most	O
characteristic	O
feature	O
of	O
the	O
initial	O
electron	O
density	O
map	O
for	O
the	O
ternary	O
complex	O
was	O
the	O
clear	O
and	O
well	O
defined	O
difference	O
electron	O
density	O
in	O
the	O
active	O
site	O
close	O
to	O
the	O
PLP	B
molecule	O
.	O

A	O
KAPA	B
molecule	O
could	O
be	O
modelled	O
straightforwardly	O
into	O
this	O
difference	O
density	O
.	O

Refinement	O
gave	O
similar	O
B	O
-factors	O
for	O
the	O
atoms	O
of	O
the	O
substrate	O
to	O
those	O
for	O
surrounding	O
protein	O
atoms	O
,	O
indicating	O
high	O
occupancy	O
of	O
the	O
substrate	O
in	O
the	O
active	O
site	O
.	O

The	O
initial	O
difference	O
electron	O
density	O
for	O
bound	O
KAPA	B
is	O
shown	O
in	O
Figure	O
3	O
(	O
c	O
)	O
.	O

The	O
substrate	O
is	O
bound	O
in	O
a	O
rather	O
bent	O
fashion	O
in	O
the	O
active	O
site	O
cleft	O
,	O
with	O
the	O
carboxyl	B
tail	O
close	O
to	O
the	O
entrance	O
of	O
the	O
cleft	O
and	O
the	O
polar	O
head	O
group	O
close	O
to	O
the	O
re	O
face	O
of	O
the	O
cofactor	O
at	O
the	O
bottom	O
of	O
the	O
active	O
site	O
(	O
Figure	O
7	O
)	O
.	O

The	O
polar	O
head	O
/	O
tail	O
groups	O
anchor	O
the	O
substrate	O
to	O
the	O
protein	O
through	O
salt	B
bridges	O
and	O
hydrogen	B
bonds	O
,	O
while	O
the	O
hydrophobic	O
carbon	B
chain	O
packs	O
with	O
hydrophobic	O
amino	B
acid	I
side	O
-	O
chains	O
in	O
the	O
active	O
site	O
pocket	O
.	O

The	O
carboxyl	B
group	I
of	O
KAPA	B
forms	O
a	O
salt	B
bridge	O
with	O
the	O
side	O
-	O
chain	O
of	O
the	O
invariant	O
Arg391	B
.	O

One	O
of	O
the	O
oxygen	B
atoms	O
of	O
this	O
carboxyl	B
groups	I
is	O
also	O
within	O
hydrogen	B
bonding	O
distance	O
of	O
the	O
Nϵ	O
atom	O
of	O
the	O
side	O
-	O
chain	O
of	O
Trp52	B
.	O

The	O
aliphatic	O
carbon	B
atoms	O
of	O
the	O
KAPA	B
molecule	O
form	O
van	O
der	O
Waals	O
'	O
interactions	O
with	O
the	O
side	O
-	O
chains	O
of	O
residues	O
Tyr17	B
,	O
Trp53	B
,	O
Tyr144	B
and	O
Phe393	B
.	O

The	O
7-keto	O
oxygen	B
atom	O
of	O
KAPA	B
forms	O
a	O
hydrogen	B
bond	O
to	O
the	O
Nϵ	O
atom	O
of	O
Lys274	B
,	O
which	O
is	O
covalently	O
linked	O
to	O
the	O
PLP	B
in	O
this	O
ternary	O
complex	O
.	O

The	O
N8	O
nitrogen	B
atom	O
of	O
the	O
substrate	O
is	O
held	O
in	O
position	O
through	O
hydrogen	B
bonds	O
formed	O
to	O
the	O
hydroxyl	B
group	I
of	O
Tyr17	B
,	O
and	O
the	O
peptide	B
oxygen	B
of	O
Gly307	B
.	O

The	O
terminal	O
methyl	B
group	I
of	O
KAPA	B
forms	O
a	O
hydrophobic	O
contact	O
with	O
the	O
side	O
-	O
chain	O
of	O
Trp52	B
.	O

Very	O
few	O
significant	O
conformational	O
changes	O
occur	O
upon	O
binding	O
of	O
the	O
substrate	O
.	O

The	O
largest	O
changes	O
involve	O
only	O
side	O
-	O
chain	O
movements	O
.	O

They	O
include	O
the	O
side	O
-	O
chain	O
of	O
Tyr17	B
,	O
which	O
shifts	O
towards	O
the	O
KAPA	B
substrate	O
.	O

The	O
guanidinium	B
group	I
of	O
the	O
side	O
-	O
chain	O
of	O
Arg391	B
moves	O
about	O
3	O
Å	O
in	O
order	O
to	O
form	O
a	O
tight	O
salt	B
bridge	O
to	O
the	O
carboxyl	B
group	I
of	O
KAPA	B
.	O

The	O
most	O
pronounced	O
conformational	O
change	O
involves	O
the	O
side	O
-	O
chain	O
of	O
Trp53	B
,	O
which	O
adopts	O
a	O
position	O
perpendicular	O
to	O
its	O
location	O
in	O
the	O
unliganded	O
protein	O
.	O

This	O
conformational	O
change	O
has	O
as	O
a	O
consequence	O
that	O
this	O
residue	O
,	O
which	O
had	O
been	O
one	O
of	O
the	O
outliers	O
in	O
the	O
Ramachandran	O
plot	O
for	O
the	O
holoenzyme	O
,	O
is	O
now	O
located	O
in	O
a	O
favourable	O
region	O
of	O
the	O
Ramachandran	O
plot	O
.	O

The	O
metal	O
binding	O
site	O
A	O
strong	O
peak	O
in	O
electron	O
density	O
(	O
11	O
times	O
the	O
standard	O
deviation	O
of	O
a	O
F	O
o	O
−F	O
c	O
electron	O
density	O
map	O
)	O
was	O
found	O
located	O
close	O
to	O
a	O
tight	O
turn	O
between	O
helix	O
α3	O
and	O
strand	O
β4	O
,	O
formed	O
by	O
residues	O
96	O
to	O
100	O
.	O

Observed	O
distances	O
to	O
surrounding	O
protein	O
atoms	O
(	O
2.3	O
to	O
2.6	O
Å	O
)	O
were	O
not	O
consistent	O
with	O
a	O
water	B
molecule	O
in	O
this	O
position	O
.	O

On	O
the	O
basis	O
of	O
peak	O
height	O
,	O
ligand	O
distance	O
and	O
geometry	O
,	O
this	O
difference	O
density	O
was	O
modelled	O
as	O
a	O
sodium	B
ion	O
.	O

Binding	O
of	O
a	O
potassium	B
ion	O
at	O
this	O
site	O
was	O
excluded	O
,	O
since	O
it	O
is	O
not	O
present	O
in	O
the	O
crystallisation	O
solution	O
,	O
whereas	O
sodium	B
is	O
present	O
in	O
high	O
concentration	O
as	O
a	O
buffer	O
counterion	O
(	O
>	O
50	O
mM	O
)	O
.	O

The	O
ligands	O
to	O
the	O
Na+	B
form	O
a	O
close	O
to	O
octahedral	O
coordination	O
sphere	O
,	O
with	O
oxygen	B
atoms	O
provided	O
by	O
main	O
-	O
chain	O
carbonyl	B
groups	I
of	O
residues	O
Val96	B
,	O
Thr99	B
,	O
Pro100	B
and	O
Leu103	B
(	O
Figure	O
8)	O
.	O

Additional	O
ligands	O
are	O
the	O
side	O
-	O
chain	O
of	O
Thr99	B
and	O
a	O
water	B
molecule	O
.	O

Binding	O
sites	O
for	O
monovalent	O
metal	B
ions	O
have	O
been	O
observed	O
in	O
other	O
vitamin	B
B6	I
-dependent	O
enzymes	O
,	O
for	O
instance	O
2,2-dialkylglycine	O
decarboxylase	O
(	O
Toney	O
et	O
al	O
.	O
,	O
1993	O
,	O
1995	O
)	O
and	O
tryptophanase	O
(	O
Isupov	O
et	O
al	O
.	O
,	O
1998	O
)	O
.	O

The	O
metal	B
binding	O
site	O
observed	O
in	O
DAPA	O
synthase	O
is	O
identical	O
to	O
site	O
II	O
in	O
the	O
decarboxylase	O
,	O
with	O
the	O
same	O
set	O
of	O
ligands	O
,	O
four	O
carbonyl	B
oxygen	B
atoms	O
,	O
a	O
threonine	B
side	O
-	O
chain	O
and	O
a	O
water	B
molecule	O
.	O

Because	O
this	O
metal	B
binding	O
site	O
is	O
remote	O
from	O
the	O
active	O
site	O
(	O
>	O
20	O
Å	O
)	O
,	O
its	O
role	O
is	O
likely	O
to	O
be	O
structural	O
rather	O
than	O
catalytic	O
.	O

Crystal	O
packing	O
DAPA	O
synthase	O
crystals	O
grown	O
under	O
the	O
same	O
conditions	O
occur	O
in	O
two	O
space	O
groups	O
,	O
C	O
2	O
and	O
P	O
21	O
,	O
with	O
cell	O
dimensions	O
a	O
=	O
130	O
Å	O
,	O
b	O
=	O
57.5	O
Å	O
,	O
c	O
=	O
117	O
Å	O
and	O
β=110	O
°	O
,	O
and	O
a	O
=	O
58.5	O
Å	O
,	O
b	O
=	O
55.6	O
Å	O
,	O
c	O
=	O
117	O
Å	O
and	O
β=96.9	O
°	O
,	O
respectively	O
(	O
Käck	O
et	O
al	O
.	O
,	O
1998	O
)	O
.	O

It	O
was	O
evident	O
that	O
the	O
two	O
space	O
groups	O
were	O
closely	O
related	O
as	O
the	O
crystal	O
lattice	O
could	O
change	O
from	O
C	O
2	O
to	O
P	O
21	O
during	O
data	O
collection	O
.	O

This	O
transition	O
can	O
be	O
triggered	O
by	O
cooling	O
the	O
crystal	O
from	O
room	O
temperature	O
to	O
4	O
°	O
C	O
.	O

Further	O
,	O
the	O
native	O
Patterson	O
map	O
obtained	O
from	O
the	O
P	O
21	O
crystals	O
had	O
two	O
peaks	O
very	O
close	O
to	O
(	O
1	O
/	O
2,1	O
/	O
2,1	O
/	O
2	O
)	O
,	O
indicating	O
a	O
pseudo	O
symmetry	O
in	O
the	O
packing	O
pattern	O
(	O
Käck	O
et	O
al	O
.	O
,	O
1998	O
)	O
.	O

A	O
slight	O
rearrangement	O
of	O
the	O
molecules	O
in	O
the	O
crystal	O
disrupts	O
the	O
perfect	O
alignment	O
between	O
the	O
2-fold	O
molecular	O
axes	O
relating	O
the	O
monomers	O
and	O
the	O
crystallographic	O
dyad	O
and	O
shifts	O
its	O
positions	O
from	O
exactly	O
(	O
1	O
/	O
4	O
,	O
y	O
,	O
0	O
)	O
and	O
(	O
3	O
/	O
4	O
,	O
y	O
,	O
0	O
)	O
,	O
resulting	O
in	O
a	O
change	O
from	O
space	O
group	O
C	O
2	O
to	O
P	O
21	O
(	O
Figure	O
9	O
)	O
.	O

The	O
relationship	O
between	O
the	O
two	O
space	O
groups	O
can	O
be	O
described	O
as	O
X	O
C	O
2=	O
−X	O
P	O
21	O
−Z	O
P	O
21	O
,	O
Y	O
C	O
2	O
=	O
Y	O
P	O
21	O
,	O
Z	O
C	O
2=2X	O
P	O
21	O
.	O

Discussion	O
Structural	O
relationships	O
between	O
vitamin	B
B6	I
enzymes	O
of	O
fold	O
type	O
I	O
In	O
order	O
to	O
analyse	O
structural	O
relationships	O
within	O
the	O
PLP	B
fold	O
type	O
I	O
family	O
,	O
a	O
general	O
search	O
of	O
the	O
Protein	B
Data	O
Bank	O
for	O
PLP	B
-	O
dependent	O
enzymes	O
topologically	O
similar	O
to	O
DAPA	O
synthase	O
was	O
performed	O
,	O
followed	O
by	O
a	O
multiple	O
structural	O
alignment	O
between	O
these	O
(	O
see	O
Materials	O
and	O
Methods	O
for	O
details	O
)	O
.	O

Ten	O
different	O
enzymes	O
aligned	O
with	O
DAPA	O
synthase	O
(	O
Table	O
3	O
)	O
.	O

The	O
pairwise	O
amino	B
acid	I
identities	O
of	O
structurally	O
aligned	O
elements	O
are	O
presented	O
in	O
Table	O
4	O
.	O

Furthermore	O
,	O
the	O
relationships	O
based	O
on	O
the	O
structural	O
similarities	O
between	O
these	O
enzymes	O
are	O
presented	O
in	O
Figure	O
10	O
(	O
a	O
)	O
(	O
see	O
Materials	O
and	O
Methods	O
for	O
details	O
)	O
.	O

Although	O
the	O
enzymes	O
in	O
the	O
fold	O
type	O
I	O
class	O
of	O
the	O
vitamin	B
B6	I
enzyme	O
superfamily	O
share	O
the	O
same	O
overall	O
fold	O
,	O
only	O
five	O
elements	O
of	O
secondary	O
structure	O
could	O
be	O
structurally	O
aligned	O
between	O
all	O
of	O
them	O
.	O

These	O
elements	O
correspond	O
to	O
strands	O
β4	O
,	O
β6	O
,	O
β7	O
,	O
β8	O
and	O
β9	O
,	O
as	O
defined	O
for	O
DAPA	O
synthase	O
Figure	O
10	O
(	O
b	O
)	O
.	O

A	O
slight	O
difference	O
in	O
the	O
twist	O
of	O
the	O
sheet	O
in	O
the	O
different	O
enzymes	O
prevents	O
alignment	O
of	O
the	O
two	O
outmost	O
strands	O
of	O
the	O
sheet	O
,	O
even	O
though	O
they	O
are	O
present	O
in	O
all	O
structures	O
.	O

Genuinely	O
different	O
areas	O
are	O
loops	O
involved	O
in	O
substrate	O
binding	O
and	O
subunit	O
-	O
subunit	O
interactions	O
.	O

According	O
to	O
the	O
multiple	O
structural	O
alignment	O
these	O
11	O
enzymes	O
can	O
be	O
divided	O
into	O
six	O
different	O
subclasses	O
(	O
Figure	O
10	O
(	O
a	O
)	O
and	O
Table	O
3	O
)	O
.	O

The	O
largest	O
subclass	O
includes	O
DAPA	O
synthase	O
,	O
2,2-dialkylglycine	O
decarboxylase	O
,	O
glutamate	O
semialdehyde	O
aminomutase	O
and	O
human	O
ornithine	O
aminotransferase	O
,	O
and	O
corresponds	O
to	O
aminotransferases	O
subclass	O
III	O
in	O
Grishin	O
's	O
classification	O
(	O
Grishin	O
et	O
al	O
.	O
,	O
1995	O
)	O
.	O

Aromatic	O
amino	O
acid	O
aminotransferase	O
and	O
aspartate	O
aminotransferase	O
make	O
up	O
the	O
members	O
of	O
aminotransferases	O
subclass	O
I	O
,	O
and	O
phosphoserine	O
aminotransferase	O
is	O
the	O
only	O
representative	O
of	O
the	O
aminotransferase	O
subclass	O
V.	O
There	O
are	O
no	O
coordinates	O
released	O
in	O
the	O
PDB	O
database	O
for	O
enzymes	O
that	O
might	O
belong	O
to	O
aminotransferase	O
subclass	O
II	O
as	O
defined	O
by	O
Grishin	O
et	O
al	O
.	O

(	O
1995	O
)	O
.	O

A	O
structure	O
-	O
based	O
classification	O
of	O
the	O
fold	O
type	O
I	O
enzymes	O
outside	O
the	O
aminotransferase	O
subclasses	O
had	O
not	O
been	O
addressed	O
earlier	O
.	O

In	O
our	O
comparison	O
,	O
tyrosine	O
phenol	O
-	O
lyase	O
and	O
tryptophan	O
indole	O
-	O
lyase	O
form	O
a	O
distinct	O
class	O
(	O
the	O
tyrosine	O
phenol	O
-	O
lyase	O
subclass	O
)	O
.	O

Cystathionine	O
β	O
-	O
lyase	O
shows	O
sequence	O
identities	O
in	O
the	O
range	O
of	O
26	O
%	O
to	O
32	O
%	O
to	O
metathione	O
γ	O
-	O
lyase	O
,	O
cystathionine	O
γ	O
-	O
lyase	O
,	O
O	O
-acetyl	O
-	O
l	O
-homoserine	O
sulfhydrylase	O
,	O
O	O
-succinylhomoserine	O
sulphfhydrylase	O
,	O
and	O
cystathionine	O
γ	O
-	O
synthase	O
,	O
indicating	O
that	O
they	O
belong	O
to	O
the	O
same	O
structural	O
subclass	O
(	O
the	O
cystathionine	O
β	O
-	O
lyase	O
subclass	O
)	O
.	O

The	O
larger	O
prokaryotic	O
ornithine	O
decarboxylase	O
is	O
the	O
sole	O
representative	O
of	O
its	O
subclass	O
so	O
far	O
.	O

There	O
is	O
a	O
striking	O
correlation	O
between	O
the	O
structure	O
of	O
the	O
N	O
-	O
terminal	O
part	O
of	O
the	O
polypeptide	O
chain	O
and	O
the	O
subclass	O
definition	O
obtained	O
from	O
the	O
multiple	O
structure	O
alignment	O
within	O
this	O
family	O
.	O

The	O
structure	O
of	O
this	O
chain	O
segment	O
is	O
rather	O
different	O
between	O
the	O
subclasses	O
,	O
but	O
similar	O
within	O
a	O
given	O
subclass	O
(	O
Figure	O
11	O
)	O
.	O

For	O
instance	O
,	O
the	O
N	O
-	O
terminal	O
β	O
-	O
meander	O
followed	O
by	O
a	O
helix	O
as	O
described	O
for	O
DAPA	O
synthase	O
holds	O
for	O
all	O
enzymes	O
in	O
subclass	O
III	O
(	O
Figure	O
11	O
(	O
a	O
)	O
)	O
.	O

In	O
the	O
tyrosine	O
phenol	O
-	O
lyase	O
subclass	O
a	O
helix	O
folds	O
over	O
the	O
hinge	O
region	O
and	O
covers	O
one	O
end	O
of	O
the	O
C	O
-	O
terminal	O
β	O
-	O
sheet	O
.	O

This	O
leaves	O
the	O
entrance	O
to	O
the	O
active	O
site	O
more	O
open	O
than	O
in	O
the	O
subclass	O
III	O
enzymes	O
.	O

An	O
N	O
-	O
terminal	O
arm	O
extends	O
outside	O
the	O
catalytic	O
dimer	O
and	O
is	O
involved	O
in	O
a	O
four	O
-	O
stranded	O
(	O
-sheet	O
built	O
up	O
by	O
two	O
strands	O
from	O
each	O
subunit	O
mediating	O
tetramer	O
formation	O
(	O
Antson	O
et	O
al	O
.	O
,	O
1993	O
)	O
(	O
Figure	O
11	O
(	O
b	O
)	O
)	O
.	O

In	O
cystathionine	O
-	O
β	O
-	O
lyase	O
(	O
Figure	O
11	O
(	O
c	O
)	O
)	O
the	O
N	O
-	O
terminus	O
protrudes	O
out	O
from	O
the	O
monomer	O
into	O
the	O
active	O
site	O
of	O
the	O
other	O
monomer	O
in	O
the	O
catalytic	O
dimer	O
and	O
then	O
turns	O
back	O
and	O
folds	O
into	O
an	O
α	O
-	O
helix	O
which	O
packs	O
against	O
the	O
outside	O
of	O
the	O
hinge	O
between	O
the	O
domains	O
in	O
its	O
original	O
subunit	O
.	O

Some	O
of	O
the	O
residues	O
in	O
the	O
N	O
-	O
terminal	O
segment	O
are	O
also	O
involved	O
in	O
tetramer	O
formation	O
.	O

In	O
the	O
aspartate	O
aminotransferase	O
and	O
aromatic	O
amino	O
acid	O
aminotransferase	O
the	O
N	O
terminus	O
starts	O
on	O
the	O
surface	O
of	O
the	O
second	O
subunit	O
and	O
then	O
crosses	O
over	O
the	O
active	O
site	O
cleft	O
before	O
joining	O
the	O
small	O
domain	O
.	O

The	O
N	O
-	O
terminal	O
part	O
of	O
the	O
small	O
domain	O
forms	O
an	O
α	O
-	O
helix	O
which	O
lines	O
the	O
active	O
site	O
entrance	O
and	O
contributes	O
with	O
a	O
β	O
-	O
strand	O
interaction	O
to	O
the	O
C	O
-	O
terminal	O
β	O
-	O
sheet	O
(	O
Figure	O
11	O
(	O
d	O
)	O
)	O
.	O

Ornithine	O
decarboxylase	O
is	O
a	O
larger	O
PLP	B
-	O
dependent	O
enzyme	O
of	O
which	O
only	O
parts	O
,	O
domain	O
three	O
and	O
domain	O
four	O
,	O
correspond	O
to	O
the	O
fold	O
type	O
I	O
enzymes	O
.	O

The	O
small	O
domain	O
is	O
built	O
up	O
solely	O
by	O
domain	O
four	O
,	O
corresponding	O
to	O
the	O
C	O
-	O
terminal	O
part	O
of	O
the	O
small	O
domain	O
in	O
the	O
smaller	O
fold	O
type	O
I	O
enzymes	O
.	O

The	O
N	O
-	O
terminal	O
domains	O
consist	O
of	O
one	O
independently	O
folded	O
domain	O
followed	O
by	O
a	O
long	O
linker	O
connecting	O
it	O
to	O
the	O
PLP	B
binding	O
domain	O
three	O
(	O
Figure	O
11	O
(	O
f	O
)	O
)	O
.	O

Finally	O
,	O
the	O
subclass	O
V	O
enzymes	O
seem	O
to	O
lack	O
the	O
N	O
-	O
terminal	O
domain	O
completely	O
.	O

The	O
polypeptide	O
chain	O
starts	O
at	O
the	O
domain	O
linker	O
region	O
and	O
enters	O
the	O
large	O
domain	O
directly	O
(	O
Figure	O
11	O
(	O
e	O
)	O
)	O
.	O

The	O
active	O
site	O
:	O
similarities	O
and	O
differences	O
in	O
the	O
fold	O
type	O
I	O
enzymes	O
The	O
active	O
site	O
and	O
in	O
particular	O
the	O
pyridine	B
ring	O
of	O
the	O
PLP	B
cofactor	O
of	O
the	O
fold	O
type	O
I	O
enzymes	O
of	O
known	O
3-D	O
structure	O
superpose	O
very	O
well	O
(	O
Figure	O
12	O
)	O
.	O

The	O
maximum	O
distance	O
from	O
the	O
Schiff	B
-	I
base	I
nitrogen	B
atom	O
in	O
DAPA	O
synthase	O
to	O
the	O
corresponding	O
atom	O
of	O
related	O
enzymes	O
is	O
1.4	O
Å	O
(	O
ornithine	O
decarboxylase	O
and	O
phosphoserine	B
amino	I
transferase	I
)	O
,	O
and	O
that	O
for	O
the	O
pyridine	B
nitrogen	B
is	O
1.4	O
Å	O
(	O
phosphoserine	O
amino	O
transferase	O
)	O
.	O

The	O
residues	O
participating	O
in	O
binding	O
of	O
the	O
cofactor	O
are	O
presented	O
in	O
Table	O
5	O
.	O

It	O
is	O
notable	O
that	O
,	O
despite	O
the	O
similar	O
position	O
of	O
the	O
cofactor	O
in	O
the	O
active	O
site	O
(	O
Figure	O
12	O
)	O
,	O
the	O
loop	O
between	O
strands	O
β9	O
and	O
β10	O
carrying	O
the	O
active	O
site	O
lysine	B
residue	O
is	O
not	O
structurally	O
conserved	O
.	O

In	O
all	O
aminotransferase	O
subclass	O
III	O
enzymes	O
this	O
loop	O
is	O
shorter	O
,	O
with	O
the	O
consequence	O
that	O
the	O
lysine	B
residue	O
is	O
positioned	O
out	O
of	O
register	O
with	O
the	O
corresponding	O
lysine	B
in	O
the	O
enzymes	O
belonging	O
to	O
the	O
other	O
subclasses	O
(	O
Figure	O
12	O
)	O
.	O

This	O
suggests	O
a	O
deletion	O
of	O
one	O
amino	B
acid	I
in	O
the	O
ancestral	O
subclass	O
III	O
aminotransferase	O
.	O

The	O
Nϵ	O
atom	O
of	O
the	O
lysine	B
side	O
-	O
chain	O
,	O
however	O
,	O
is	O
found	O
at	O
approximately	O
the	O
same	O
position	O
.	O

The	O
aspartic	B
acid	I
residue	O
which	O
corresponds	O
to	O
Asp245	B
in	O
DAPA	O
synthase	O
is	O
the	O
only	O
structurally	O
conserved	O
residue	O
in	O
this	O
enzyme	O
family	O
.	O

This	O
amino	B
acid	I
forms	O
a	O
salt	B
bridge	O
/	O
hydrogen	B
bond	O
with	O
the	O
pyridine	B
nitrogen	B
and	O
was	O
proposed	O
to	O
provide	O
one	O
of	O
the	O
key	O
interactions	O
for	O
the	O
regulation	O
of	O
the	O
pK	O
a	O
of	O
the	O
aldimine	B
nitrogen	B
(	O
Hayashi	O
,	O
1995	O
;	O
John	O
,	O
1995	O
)	O
.	O

Stabilisation	O
of	O
this	O
interaction	O
is	O
provided	O
by	O
a	O
non	O
-	O
conserved	O
pattern	O
of	O
hydrogen	B
bonds	O
to	O
surrounding	O
residues	O
,	O
except	O
in	O
the	O
case	O
of	O
ornithine	O
decarboxylase	O
and	O
tryptophanase	O
in	O
which	O
the	O
aspartic	B
acid	I
only	O
interacts	O
with	O
the	O
pyridine	B
nitrogen	B
of	O
PLP	B
.	O

In	O
DAPA	O
synthase	O
,	O
glutamate	O
semialdehyde	O
aminomutase	O
and	O
dialkylglycine	O
decarboxylase	O
a	O
histidine	B
residue	O
forms	O
a	O
hydrogen	B
bond	O
to	O
one	O
of	O
the	O
carboxyl	B
oxygen	B
atoms	O
of	O
the	O
aspartic	B
acid	I
.	O

Similar	O
interactions	O
are	O
provided	O
by	O
a	O
histidine	B
from	O
a	O
different	O
loop	O
in	O
the	O
aspartate	O
and	O
aromatic	O
amino	O
acid	O
aminotransferases	O
.	O

In	O
the	O
subclass	O
III	O
and	O
V	O
enzymes	O
,	O
the	O
main	O
-	O
chain	O
amide	B
of	O
the	O
second	O
residue	O
following	O
the	O
aspartic	B
acid	I
is	O
within	O
hydrogen	B
bonding	O
distance	O
(	O
<	O
3.3	O
Å	O
)	O
to	O
the	O
carboxyl	B
group	I
of	O
this	O
aspartic	B
acid	I
whereas	O
in	O
cystathionine	O
β	O
-	O
lyase	O
,	O
phosphoserine	O
aminotransferase	O
and	O
tyrosine	O
phenol	O
-	O
lyase	O
the	O
side	O
-	O
chain	O
of	O
this	O
residue	O
(	O
Thr	B
/	O
Ser	B
)	O
provides	O
an	O
interaction	O
with	O
the	O
same	O
group	O
.	O

In	O
all	O
enzymes	O
except	O
DAPA	O
synthase	O
,	O
the	O
protein	O
provides	O
a	O
hydrogen	B
bond	O
partner	O
to	O
the	O
phenolic	B
oxygen	B
,	O
O-3′	O
,	O
of	O
the	O
pyridine	B
ring	O
.	O

The	O
nature	O
and	O
strength	O
of	O
this	O
interaction	O
might	O
influence	O
the	O
pK	O
a	O
of	O
the	O
resulting	O
Schiff	B
base	I
of	O
the	O
cofactor	O
with	O
the	O
catalytic	O
lysine	B
residue	O
(	O
Goldberg	O
et	O
al	O
.	O
,	O
1991	O
;	O
Inoue	O
et	O
al	O
.	O
,	O
1991	O
)	O
.	O

As	O
described	O
,	O
a	O
water	B
-	O
mediated	O
interaction	O
with	O
a	O
glutamic	B
acid	I
residue	O
replaces	O
this	O
interaction	O
in	O
DAPA	O
synthase	O
.	O

A	O
structural	O
feature	O
distinguishing	O
the	O
subclass	O
III	O
aminotransferases	O
from	O
other	O
fold	O
type	O
I	O
PLP	B
enzymes	O
is	O
the	O
stacking	O
interactions	O
with	O
the	O
re	O
face	O
of	O
the	O
pyridine	B
ring	O
of	O
PLP	B
.	O

All	O
enzymes	O
of	O
known	O
structure	O
have	O
aromatic	B
residues	I
in	O
this	O
position	O
,	O
corresponding	O
to	O
Tyr144	B
in	O
DAPA	O
synthase	O
.	O

However	O
,	O
in	O
the	O
subclass	O
III	O
aminotransferases	O
the	O
aromatic	B
residue	I
packs	O
nearly	O
perpendicular	O
to	O
the	O
pyridine	B
ring	O
of	O
the	O
cofactor	O
,	O
while	O
in	O
the	O
other	O
fold	O
type	O
I	O
enzymes	O
the	O
stacking	O
is	O
close	O
to	O
parallel	O
.	O

It	O
has	O
been	O
proposed	O
for	O
aspartate	O
aminotransferase	O
that	O
the	O
parallel	O
stacking	O
,	O
which	O
is	O
optimised	O
from	O
nearly	O
parallel	O
to	O
parallel	O
in	O
the	O
external	O
aldimine	B
complex	O
,	O
increases	O
the	O
electron	O
withdrawing	O
effect	O
of	O
the	O
cofactor	O
and	O
favours	O
the	O
formation	O
of	O
the	O
quinonoid	B
intermediate	O
(	O
Ford	O
et	O
al	O
.	O
,	O
1980	O
;	O
Hayashi	O
et	O
al	O
.	O
,	O
1990	O
)	O
.	O

In	O
the	O
aminotransferase	O
subclass	O
III	O
enzymes	O
,	O
the	O
stacking	O
residue	O
is	O
part	O
of	O
the	O
loop	O
between	O
strands	O
β5	O
and	O
β6	O
,	O
which	O
narrows	O
the	O
active	O
site	O
entrance	O
.	O

With	O
this	O
conformation	O
of	O
the	O
polypeptide	O
backbone	O
,	O
the	O
aromatic	B
residue	I
would	O
clash	O
with	O
the	O
main	O
chain	O
if	O
it	O
packed	O
parallel	O
to	O
the	O
ring	O
.	O

In	O
the	O
other	O
fold	O
type	O
I	O
enzymes	O
the	O
loop	O
is	O
replaced	O
by	O
a	O
short	O
helix	O
beginning	O
immediately	O
after	O
the	O
aromatic	B
residue	I
.	O

This	O
difference	O
in	O
backbone	O
conformation	O
enables	O
a	O
parallel	O
stacking	O
to	O
the	O
pyridine	B
ring	O
of	O
the	O
cofactor	O
and	O
leaves	O
the	O
active	O
site	O
much	O
more	O
open	O
.	O

In	O
tryptophanase	O
,	O
cystathionine	O
β	O
-	O
lyase	O
and	O
tyrosine	O
phenol	O
-	O
lyase	O
the	O
active	O
site	O
entrance	O
is	O
instead	O
restricted	O
by	O
a	O
loop	O
protruding	O
from	O
the	O
β	O
-	O
sheet	O
in	O
the	O
small	O
domain	O
whereas	O
the	O
other	O
enzymes	O
simply	O
have	O
a	O
wider	O
active	O
site	O
entrance	O
.	O

Human	O
ornithine	O
decarboxylase	O
is	O
an	O
exception	O
,	O
having	O
an	O
extra	O
C	O
-	O
terminal	O
domain	O
packing	O
against	O
the	O
active	O
site	O
cleft	O
.	O

There	O
are	O
two	O
distinct	O
positions	O
of	O
the	O
phosphate	B
group	I
of	O
PLP	B
;	O
one	O
for	O
the	O
subclass	O
I	O
aminotransferases	O
and	O
one	O
for	O
all	O
the	O
others	O
fold	O
type	O
I	O
PLP	B
enzymes	O
(	O
Figure	O
12	O
)	O
.	O

This	O
is	O
caused	O
by	O
interactions	O
of	O
phosphate	B
oxygen	B
atoms	O
with	O
an	O
arginine	B
residue	O
(	O
Arg266	B
in	O
aspartate	O
aminotransferase	O
)	O
which	O
result	O
in	O
a	O
different	O
tilt	O
of	O
the	O
cofactor	O
in	O
aspartate	O
and	O
aromatic	O
amino	O
acid	O
aminotransferases	O
in	O
relation	O
to	O
the	O
other	O
fold	O
type	O
I	O
enzymes	O
.	O

Substrate	O
recognition	O
In	O
order	O
to	O
locate	O
the	O
active	O
site	O
in	O
DAPA	O
synthase	O
,	O
the	O
crystal	O
structure	O
of	O
a	O
ternary	O
complex	O
of	O
the	O
enzyme	O
with	O
PLP	B
and	O
KAPA	B
was	O
determined	O
(	O
Figure	O
7	O
)	O
.	O

This	O
complex	O
is	O
unproductive	O
,	O
since	O
it	O
combines	O
the	O
PLP	B
form	O
of	O
the	O
cofactor	O
with	O
the	O
amino	B
group	I
acceptor	O
KAPA	B
,	O
which	O
in	O
the	O
catalytic	O
reaction	O
reacts	O
with	O
the	O
pyridoxamine	B
form	O
of	O
the	O
enzyme	O
.	O

Since	O
KAPA	B
is	O
an	O
amino	B
acid	I
,	O
the	O
question	O
arises	O
as	O
to	O
why	O
it	O
does	O
not	O
act	O
as	O
amino	B
donor	O
in	O
the	O
reaction	O
,	O
i.e.	O
react	O
with	O
the	O
PLP	B
form	O
of	O
the	O
enzyme	O
.	O

The	O
structure	O
of	O
the	O
ternary	O
complex	O
provides	O
an	O
immediate	O
answer	O
.	O

In	O
order	O
to	O
react	O
with	O
the	O
C-4′	O
carbon	B
atom	O
of	O
the	O
cofactor	O
to	O
form	O
the	O
internal	O
aldimine	B
,	O
the	O
N8	O
amino	B
group	I
of	O
KAPA	B
must	O
bind	O
very	O
closely	O
to	O
this	O
part	O
of	O
the	O
cofactor	O
in	O
an	O
orientation	O
favourable	O
for	O
the	O
reaction	O
to	O
occur	O
.	O

In	O
the	O
complex	O
,	O
the	O
N8	O
amino	B
group	I
is	O
bound	O
tightly	O
to	O
protein	O
main	O
-	O
chain	O
and	O
side	O
-	O
chain	O
atoms	O
in	O
such	O
a	O
manner	O
that	O
it	O
points	O
away	O
from	O
the	O
internal	O
aldimine	B
group	O
,	O
thus	O
preventing	O
transamination	O
(	O
Figure	O
7	O
)	O
.	O

The	O
observed	O
binding	O
of	O
KAPA	B
does	O
however	O
position	O
the	O
seven	O
-	O
carbon	B
atom	O
of	O
KAPA	B
close	O
to	O
the	O
aldimine	B
and	O
thereby	O
facilitates	O
transfer	O
of	O
an	O
amino	B
group	I
to	O
this	O
carbon	B
atom	O
,	O
which	O
would	O
yield	O
the	O
product	O
,	O
7,8-diaminopelargonic	B
acid	I
.	O

An	O
important	O
conclusion	O
to	O
be	O
drawn	O
from	O
the	O
structure	O
of	O
the	O
ternary	O
complex	O
is	O
that	O
in	O
DAPA	B
synthase	I
,	O
as	O
opposed	O
to	O
other	O
enzymes	O
of	O
this	O
class	O
of	O
vitamin	B
B6	I
-dependent	O
enzymes	O
,	O
no	O
domain	O
-	O
domain	O
rotation	O
occurs	O
upon	O
substrate	O
binding	O
.	O

The	O
absence	O
of	O
such	O
large	O
-	O
scale	O
conformational	O
changes	O
is	O
not	O
unique	O
for	O
DAPA	O
synthase	O
but	O
has	O
also	O
been	O
shown	O
for	O
another	O
enzyme	O
in	O
this	O
family	O
,	O
human	O
ornithine	O
aminotransferase	O
(	O
Shah	O
et	O
al	O
.	O
,	O
1997	O
)	O
.	O

The	O
substrate	O
reacting	O
with	O
the	O
PLP	B
form	O
of	O
the	O
enzyme	O
is	O
SAM	B
and	O
the	O
active	O
site	O
,	O
as	O
seen	O
in	O
the	O
holoenzyme	O
should	O
therefore	O
be	O
poised	O
to	O
bind	O
SAM	B
.	O

The	O
outer	O
part	O
of	O
the	O
active	O
site	O
pocket	O
is	O
quite	O
open	O
and	O
there	O
are	O
several	O
areas	O
which	O
could	O
provide	O
hydrophobic	O
interactions	O
with	O
the	O
adenine	B
ring	O
and	O
still	O
leave	O
space	O
for	O
the	O
sugar	B
moiety	O
.	O

Therefore	O
,	O
modelling	O
the	O
binding	O
site	O
of	O
SAM	B
in	O
DAPA	O
synthase	O
is	O
highly	O
speculative	O
and	O
a	O
reliable	O
model	O
for	O
the	O
enzyme	O
-	O
PLP	B
-	O
SAM	B
complex	O
will	O
have	O
to	O
await	O
a	O
crystal	O
structure	O
determination	O
.	O

A	O
more	O
detailed	O
discussion	O
of	O
the	O
reaction	O
mechanism	O
of	O
DAPA	O
synthase	O
will	O
require	O
structural	O
information	O
from	O
this	O
and	O
other	O
complexes	O
along	O
the	O
reaction	O
pathway	O
,	O
in	O
combination	O
with	O
the	O
results	O
from	O
site	O
-	O
directed	O
mutagenesis	O
experiments	O
.	O

Materials	O
and	O
methods	O
Crystallisation	O
DAPA	O
synthase	O
was	O
expressed	O
,	O
purified	O
and	O
crystallised	O
as	O
described	O
(	O
Käck	O
et	O
al	O
.	O
,	O
1998	O
)	O
,	O
with	O
one	O
modification	O
in	O
the	O
crystallisation	O
protocol	O
.	O

After	O
one	O
week	O
of	O
equilibration	O
,	O
micro	O
-	O
seeding	O
was	O
employed	O
to	O
increase	O
the	O
reproducibility	O
of	O
crystal	O
formation	O
.	O

At	O
the	O
same	O
time	O
,	O
20–40	O
μl	O
of	O
4	O
M	O
sodium	B
chloride	I
was	O
added	O
to	O
the	O
well	O
solution	O
.	O

Crystals	O
of	O
the	O
ternary	O
complex	O
DAPA	O
synthase	O
-	O
PLP	B
-	O
KAPA	B
were	O
prepared	O
by	O
soaking	O
crystals	O
of	O
the	O
holoenzyme	O
overnight	O
in	O
5	O
mM	O
KAPA	B
,	O
25	O
%	O
PEG-4000	B
,	O
20	O
%	O
MPD	B
,	O
100	O
mM	O
Hepes	B
(	O
pH	O
7.5	O
)	O
.	O

The	O
substrate	O
KAPA	B
was	O
synthesised	O
as	O
described	O
(	O
Nudelman	O
et	O
al	O
.	O
,	O
1998	O
)	O
.	O

Data	O
collection	O
,	O
phasing	O
and	O
model	O
building	O
The	O
cell	O
dimensions	O
differed	O
slightly	O
between	O
crystals	O
,	O
reflecting	O
non	O
-	O
isomorphism	O
between	O
crystals	O
.	O

A	O
large	O
number	O
of	O
different	O
heavy	O
atoms	O
were	O
screened	O
in	O
order	O
to	O
find	O
a	O
useful	O
derivative	O
.	O

Finally	O
,	O
crystals	O
soaked	O
for	O
24	O
hours	O
at	O
4	O
°	O
C	O
in	O
25	O
%	O
polyethylene	B
glycol	I
4000	I
,	O
22	O
%	O
2-methyl-2,4	B
pentanediol	I
and	O
5	O
mM	O
ethyl	B
mercury	I
thiosalicylate	I
(	O
EMTS	B
)	O
or	O
K2	B
Pt	I
(	I
NO2	I
)	I
4	I
at	O
pH	O
7.5	O
were	O
isomorphous	O
enough	O
to	O
allow	O
identification	O
of	O
the	O
heavy	O
-	O
atom	O
sites	O
.	O

However	O
,	O
neither	O
the	O
multiple	O
isomorphous	O
replacement	O
electron	O
density	O
map	O
nor	O
the	O
2-fold	O
averaged	O
electron	O
density	O
map	O
was	O
interpretable	O
.	O

Multiple	O
anomalous	O
difference	O
data	O
were	O
therefore	O
collected	O
on	O
a	O
EMTS	B
-	O
soaked	O
crystal	O
with	O
cell	O
dimensions	O
a	O
=	O
58.50	O
Å	O
,	O
b	O
=	O
56.63	O
Å	O
,	O
c	O
=	O
121.7	O
Å	O
and	O
β=96.14	O
°	O
,	O
space	O
group	O
P	O
21	O
,	O
at	O
beamline	O
BM	O
14	O
at	O
the	O
ESRF	O
in	O
Grenoble	O
.	O

Data	O
were	O
collected	O
at	O
three	O
different	O
wavelengths	O
,	O
λ1	O
(	O
peak	O
)	O
=0.9918	O
Å	O
,	O
λ2	O
(	O
inflection	O
point	O
)	O
=1.007	O
Å	O
and	O
λ3	O
(	O
high	O
energy	O
remote	O
)	O
=0.8265	O
Å	O
at	O
100	O
K	O
to	O
2.0	O
Å	O
resolution	O
.	O

Data	O
processing	O
and	O
scaling	O
were	O
performed	O
with	O
the	O
programs	O
Denzo	O
and	O
Scalepack	O
(	O
Otwinowski	O
,	O
1993	O
)	O
.	O

Eight	O
mercury	B
sites	O
were	O
identified	O
by	O
visual	O
inspection	O
of	O
the	O
difference	O
Patterson	O
maps	O
and	O
using	O
difference	O
Fourier	O
methods	O
(	O
for	O
phasing	O
statistics	O
see	O
Table	O
1	O
)	O
.	O

The	O
five	O
strongest	O
peaks	O
coincided	O
with	O
the	O
binding	O
sites	O
determined	O
earlier	O
,	O
while	O
three	O
minor	O
sites	O
differed	O
in	O
their	O
positions	O
,	O
compared	O
to	O
those	O
previously	O
derived	O
.	O

A	O
map	O
calculated	O
after	O
refinement	O
of	O
the	O
parameters	O
of	O
the	O
mercury	B
positions	O
using	O
mlphare	O
(	O
Otwinowski	O
,	O
1991	O
)	O
and	O
solvent	O
flattening	O
by	O
DM	O
(	O
Cowtan	O
&	O
Main	O
,	O
1996	O
)	O
was	O
of	O
excellent	O
quality	O
,	O
and	O
backbone	O
tracing	O
and	O
sequence	O
assignment	O
(	O
Otsuka	O
et	O
al	O
.	O
,	O
1988	O
)	O
were	O
straighforward	O
for	O
the	O
whole	O
protein	O
except	O
for	O
two	O
mobile	O
regions	O
containing	O
residues	O
160	O
to	O
183	O
and	O
298	O
to	O
304	O
,	O
respectively	O
;	O
2-fold	O
averaging	O
did	O
not	O
improve	O
the	O
map	O
significantly	O
.	O

The	O
model	O
was	O
refined	O
using	O
XPLOR	O
(	O
Brünger	O
et	O
al	O
.	O
,	O
1987	O
)	O
with	O
NCS	O
constraints	O
to	O
R	O
free	O
=	O
35.9	O
%	O
and	O
R	O
=	O
30.4	O
%	O
without	O
including	O
mercury	B
atoms	O
.	O

A	O
native	O
data	O
set	O
was	O
collected	O
using	O
a	O
300	O
mm	O
MAR	O
image	O
plate	O
detector	O
(	O
MAR	O
research	O
Hamburg	O
)	O
at	O
beam	O
line	O
X11	O
at	O
EMBL	O
in	O
Hamburg	O
to	O
1.8	O
Å	O
resolution	O
(	O
for	O
data	O
collection	O
statistics	O
see	O
Table	O
1	O
)	O
.	O

The	O
cell	O
-	O
dimensions	O
of	O
this	O
crystal	O
were	O
a	O
=	O
58.3	O
Å	O
,	O
b	O
=	O
55.6	O
Å	O
,	O
c	O
=	O
120.9	O
Å	O
and	O
β=97.0	O
°	O
,	O
space	O
group	O
P	O
21	O
.	O

Diffraction	O
data	O
for	O
the	O
ternary	O
complex	O
DAPA	O
synthase	O
-	O
PLP	B
-	O
KAPA	B
were	O
collected	O
at	O
100	O
K	O
to	O
2.7	O
Å	O
on	O
a	O
Mar	O
Research	O
image	O
plate	O
mounted	O
on	O
a	O
Rikagu	O
rotating	O
anode	O
operating	O
at	O
50	O
kV	O
and	O
90	O
mA.	O
Data	O
were	O
processed	O
and	O
scaled	O
using	O
Denzo	O
and	O
Scalepack	O
software	O
package	O
(	O
Otwinowski	O
,	O
1993	O
)	O
.	O

Data	O
collection	O
statistics	O
are	O
given	O
in	O
Table	O
1	O
.	O

The	O
cell	O
-	O
dimensions	O
of	O
this	O
crystal	O
were	O
a	O
=	O
58.0	O
Å	O
,	O
b	O
=	O
55.9	O
Å	O
,	O
c	O
=	O
120.8	O
Å	O
and	O
β=95.7	O
°	O
.	O

Refinement	O
Because	O
of	O
non	O
-	O
isomorphism	O
between	O
the	O
crystals	O
,	O
molecular	O
replacement	O
had	O
to	O
be	O
used	O
in	O
order	O
to	O
find	O
the	O
position	O
of	O
the	O
native	O
enzyme	O
in	O
the	O
unit	O
cell	O
.	O

The	O
program	O
AMORE	O
(	O
Navaza	O
,	O
1994	O
)	O
was	O
used	O
for	O
this	O
task	O
with	O
the	O
dimer	O
as	O
the	O
search	O
molecule	O
.	O

Before	O
refinement	O
,	O
the	O
same	O
set	O
of	O
reflections	O
(	O
in	O
total	O
5	O
%	O
of	O
the	O
reflection	O
data	O
)	O
were	O
set	O
aside	O
to	O
monitor	O
R	O
free	O
.	O

The	O
top	O
solution	O
(	O
correlation	O
coefficient=76.7	O
%	O
)	O
gave	O
an	O
R	O
free	O
of	O
37.5	O
%	O
after	O
an	O
initial	O
rigid	O
body	O
refinement	O
to	O
2.5	O
Å	O
resolution	O
using	O
the	O
program	O
XPLOR	O
(	O
Brünger	O
et	O
al	O
.	O
,	O
1987	O
)	O
.	O

A	O
clear	O
and	O
strong	O
difference	O
density	O
was	O
found	O
at	O
the	O
position	O
of	O
the	O
cofactor	O
,	O
PLP	B
,	O
which	O
had	O
not	O
been	O
included	O
in	O
the	O
model	O
,	O
confirming	O
that	O
this	O
was	O
the	O
correct	O
solution	O
.	O

After	O
rigid	O
body	O
refinement	O
the	O
structure	O
was	O
rebuilt	O
using	O
the	O
program	O
O	O
(	O
Jones	O
et	O
al	O
.	O
,	O
1991	O
)	O
and	O
refined	O
using	O
the	O
maximum	O
likelihood	O
method	O
as	O
implemented	O
in	O
Refmac	O
(	O
Murshudov	O
et	O
al	O
.	O
,	O
1997	O
)	O
with	O
strong	O
NCS	O
restraints	O
giving	O
R	O
=	O
35.4	O
%	O
and	O
R	O
free	O
=	O
36.4	O
%	O
after	O
the	O
first	O
round	O
of	O
refinement	O
.	O

On	O
the	O
basis	O
of	O
a	O
sigma	O
-	O
weighted	O
electron	O
density	O
map	O
calculated	O
subsequently	O
,	O
residues	O
162	O
-	O
180	O
and	O
residues	O
298	O
-	O
303	O
missing	O
from	O
the	O
previous	O
model	O
could	O
be	O
modelled	O
.	O

After	O
the	O
second	O
round	O
of	O
refinement	O
PLP	B
was	O
included	O
in	O
the	O
model	O
.	O

In	O
subsequent	O
refinement	O
runs	O
the	O
loop	O
region	O
between	O
residue	O
181	O
and	O
191	O
was	O
built	O
.	O

In	O
one	O
of	O
the	O
subunits	O
residue	O
183	O
is	O
still	O
not	O
included	O
in	O
the	O
final	O
model	O
.	O

Eighty	O
water	B
molecules	O
were	O
included	O
after	O
each	O
refinement	O
cycle	O
using	O
the	O
program	O
arp	O
(	O
Lamzin	O
&	O
Wilson	O
,	O
1993	O
)	O
,	O
resulting	O
in	O
a	O
final	O
number	O
of	O
556	O
water	B
molecules	O
of	O
which	O
about	O
two	O
thirds	O
follow	O
the	O
NCS	O
.	O

All	O
solvent	O
sites	O
were	O
inspected	O
manually	O
.	O

Non	O
-	O
crystallographic	O
restraints	O
were	O
used	O
until	O
the	O
last	O
stages	O
of	O
the	O
refinement	O
,	O
their	O
release	O
resulted	O
in	O
a	O
slight	O
drop	O
of	O
the	O
free	O
R	O
value	O
.	O

The	O
quality	O
of	O
the	O
final	O
model	O
was	O
assessed	O
with	O
PROCHECK	O
(	O
Laskowski	O
et	O
al	O
.	O
,	O
1993	O
)	O
.	O

The	O
structure	O
of	O
the	O
ternary	O
complex	O
was	O
determined	O
to	O
2.7	O
Å	O
by	O
difference	O
Fourier	O
methods	O
.	O

Initial	O
phases	O
were	O
calculated	O
from	O
the	O
refined	O
model	O
of	O
the	O
holoenzyme	O
,	O
with	O
the	O
water	B
molecules	O
and	O
the	O
sodium	B
ions	O
excluded	O
.	O

A	O
KAPA	B
molecule	O
was	O
fitted	O
into	O
the	O
difference	O
electron	O
density	O
found	O
in	O
the	O
active	O
site	O
close	O
to	O
the	O
PLP	B
cofactor	O
;	O
5	O
%	O
of	O
the	O
reflection	O
data	O
were	O
excluded	O
from	O
the	O
refinement	O
and	O
used	O
to	O
calculate	O
the	O
free	O
R	O
value	O
.	O

The	O
model	O
of	O
the	O
ternary	O
complex	O
was	O
refined	O
using	O
Refmac	O
(	O
Murshudov	O
et	O
al	O
.	O
,	O
1997	O
)	O
,	O
starting	O
in	O
the	O
first	O
cycle	O
as	O
a	O
rigid	O
body	O
refinement	O
.	O

Cycles	O
of	O
refinement	O
were	O
followed	O
by	O
manual	O
intervention	O
using	O
the	O
graphics	O
program	O
O	O
(	O
Jones	O
et	O
al	O
.	O
,	O
1991	O
)	O
.	O

The	O
final	O
model	O
contains	O
94	O
water	B
molecules	O
and	O
two	O
sodium	B
ions	O
,	O
refinement	O
statistics	O
are	O
given	O
in	O
Table	O
2	O
.	O

Structural	O
alignments	O
and	O
database	O
searches	O
The	O
program	O
TOP	O
(	O
Lu	O
,	O
1996	O
)	O
was	O
used	O
for	O
searching	O
the	O
Protein	O
Data	O
Bank	O
with	O
the	O
large	O
domain	O
of	O
the	O
refined	O
model	O
of	O
DAPA	O
synthase	O
as	O
probe	O
and	O
for	O
subsequent	O
superpositions	O
.	O

Exclusion	O
of	O
mutant	O
structures	O
and	O
complexes	O
resulted	O
in	O
15	O
different	O
PLP	B
enzymes	O
with	O
identical	O
topology	O
.	O

Five	O
of	O
these	O
were	O
structures	O
of	O
aspartate	O
aminotransferases	O
from	O
different	O
sources	O
.	O

As	O
these	O
enzymes	O
are	O
very	O
similar	O
,	O
only	O
one	O
of	O
these	O
,	O
the	O
E.	O
coli	O
enzyme	O
,	O
was	O
included	O
in	O
the	O
subsequent	O
multiple	O
structure	O
alignment	O
.	O

For	O
the	O
same	O
reason	O
,	O
only	O
one	O
of	O
the	O
two	O
structures	O
of	O
phosphoserine	O
aminotransferase	O
,	O
deposited	O
in	O
the	O
Protein	O
Data	O
Bank	O
was	O
used	O
in	O
the	O
following	O
multiple	O
structural	O
alignment	O
.	O

Generally	O
,	O
the	O
internal	O
aldimine	B
form	O
of	O
the	O
enzymes	O
was	O
used	O
in	O
this	O
comparison	O
.	O

The	O
domain	O
-	O
domain	O
orientation	O
as	O
compared	O
with	O
DAPA	O
synthase	O
varies	O
substantially	O
between	O
different	O
enzymes	O
,	O
from	O
27	O
°	O
rotation	O
for	O
aspartate	O
aminotransferase	O
to	O
6	O
°	O
rotation	O
for	O
ornithine	O
aminotransferase	O
.	O

In	O
order	O
to	O
extend	O
the	O
structural	O
alignment	O
and	O
comparison	O
to	O
the	O
whole	O
subunit	O
of	O
these	O
enzymes	O
,	O
a	O
second	O
topological	O
alignment	O
was	O
carried	O
out	O
using	O
the	O
small	O
domain	O
of	O
DAPA	O
synthase	O
as	O
search	O
model	O
.	O

The	O
superposed	O
large	O
and	O
small	O
domains	O
were	O
then	O
artificially	O
connected	O
with	O
the	O
same	O
rotation	O
as	O
in	O
DAPA	O
synthase	O
.	O

This	O
set	O
of	O
enzyme	O
models	O
formed	O
the	O
basis	O
for	O
the	O
multiple	O
structural	O
alignment	O
using	O
the	O
program	O
MAPS	O
(	O
G.	O
Lu	O
,	O
unpublished	O
)	O
.	O

In	O
this	O
program	O
,	O
an	O
initial	O
alignment	O
is	O
carried	O
out	O
using	O
the	O
same	O
algorithm	O
as	O
in	O
TOP	O
(	O
Lu	O
,	O
1996	O
)	O
.	O

The	O
program	O
then	O
proceeds	O
by	O
minimising	O
a	O
target	O
function	O
made	O
up	O
by	O
the	O
sum	O
of	O
pairwise	O
distances	O
between	O
equivalent	O
Cα	O
atoms	O
.	O

Segments	O
identified	O
as	O
structurally	O
equivalent	O
must	O
fulfil	O
certain	O
criteria	O
:	O
(	O
i	O
)	O
consist	O
of	O
at	O
least	O
three	O
consecutive	O
residues	O
;	O
(	O
ii	O
)	O
the	O
distance	O
between	O
aligned	O
Cα	O
—Cα	O
atoms	O
should	O
not	O
exceed	O
3.8	O
Å	O
;	O
and	O
(	O
iii	O
)	O
the	O
side	O
-	O
chain	O
should	O
point	O
in	O
a	O
similar	O
direction	O
(	O
the	O
angles	O
formed	O
by	O
the	O
Cα	O
—Cβ	O
bond	O
between	O
equivalent	O
residues	O
should	O
not	O
exceed	O
50	O
°	O
)	O
.	O

The	O
result	O
of	O
the	O
multiple	O
alignment	O
is	O
presented	O
in	O
terms	O
of	O
aligned	O
residues	O
between	O
all	O
proteins	O
and	O
an	O
alignment	O
score	O
of	O
r.m.s.	O
/	O
(	O
N	O
match	O
/N	O
average	O
)	O
a	O
(	O
structure	O
diversity	O
factor	O
)	O
,	O
where	O
a	O
is	O
chosen	O
empirically	O
as	O
1.5	O
.	O

The	O
structure	O
diversity	O
score	O
can	O
be	O
used	O
to	O
illustrate	O
the	O
structural	O
and	O
possibly	O
evolutionary	O
relationships	O
between	O
the	O
aligned	O
enzymes	O
.	O

Protein	O
data	O
bank	O
accession	O
Number	O

The	O
atomic	O
coordinates	O
and	O
observed	O
structure	O
factor	O
amplitudes	O
have	O
been	O
deposited	O
with	O
the	O
Protein	O
Data	O
Bank	O
,	O
Brookhaven	O
,	O
with	O
accession	O
codes	O
1qj5	O
,	O
1qj5sf	O
for	O
the	O
enzyme	O
-	O
PLP	B
and	O
1qj3	O
,	O
r1qj3sf	O
for	O
the	O
enzyme	O
-	O
PLP	B
-	O
KAPA	B
complex	O
,	O
respectively	O
.	O

Acknowledgements	O

We	O
thank	O
Ivan	O
M.	O
Turner	O
Sr	O
for	O
excellent	O
technical	O
assistance	O
and	O
Tom	O
Milller	O
for	O
carrying	O
out	O
the	O
N	O
-	O
terminal	O
sequencing	O
.	O

We	O
acknowledge	O
access	O
to	O
synchrotron	O
radiation	O
at	O
the	O
ESRF	O
,	O
Grenoble	O
,	O
France	O
,	O
and	O
thank	O
Dr	O
Andy	O
Thompson	O
at	O
beamline	O
BM14	O
for	O
assistance	O
and	O
advice	O
with	O
data	O
collection	O
.	O

We	O
also	O
acknowledge	O
access	O
to	O
beamline	O
X11	O
,	O
EMBL	O
outstation	O
,	O
c	O
/	O
o	O
DESY	O
,	O
Hamburg	O
.	O

This	O
work	O
was	O
supported	O
by	O
the	O
Swedish	O
Agricultural	O
Research	O
Council	O
and	O
the	O
Swedish	O
Natural	O
Science	O
Research	O
Council	O
.	O

Stilbenes	B
occur	O
naturally	O
in	O
a	O
number	O
of	O
plant	O
families	O
[	O
1	O
]	O
but	O
grapes	O
and	O
related	O
products	O
are	O
considered	O
the	O
most	O
important	O
dietary	O
sources	O
of	O
these	O
substances	O
[	O
2,3	O
]	O
.	O

Trans	B
-resveratrol	I
and	O
the	O
3-O	B
-	I
β	I
-	I
glucoside	I
of	I
trans	I
-resveratrol	I
,	O
trans	B
-piceid	I
,	O
were	O
recently	O
identified	O
in	O
wine	O
[	O
4–6	O
]	O
.	O

Another	O
compound	O
3′-OH	B
-	I
trans	I
-piceid	I
(	O
trans	B
-astringin	I
)	O
has	O
recently	O
been	O
reported	O
to	O
be	O
a	O
constituent	O
of	O
Vitis	O
vinifera	O
cells	O
[	O
7	O
]	O
(	O
Fig.	O
1	O
)	O
.	O

The	O
beneficial	O
role	O
that	O
moderate	O
wine	O
consumption	O
may	O
have	O
in	O
preventing	O
cardiovascular	O
disease	O
is	O
still	O
under	O
debate	O
[	O
8	O
]	O
,	O
and	O
great	O
interest	O
has	O
been	O
focused	O
on	O
stilbenes	B
.	O

Trans-	B
astringin	I
has	O
been	O
reported	O
to	O
have	O
antioxidant	O
properties	O
,	O
inhibiting	O
in	O
particular	O
the	O
oxidation	O
of	O
human	O
LDL	B
in	O
vitro	O
[	O
9	O
]	O
,	O
but	O
its	O
occurrence	O
in	O
wine	O
has	O
never	O
been	O
reported	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
develop	O
a	O
simple	O
and	O
sensitive	O
method	O
to	O
determine	O
this	O
occurrence	O
.	O

A	O
HPLC	O
method	O
coupled	O
with	O
fluorimetric	O
detection	O
was	O
developed	O
for	O
this	O
.	O

2	O
Experimental	O
Methanol	B
and	O
acetic	B
acid	I
were	O
purchased	O
from	O
Carlo	O
Erba	O
(	O
Val	O
de	O
Reuil	O
,	O
France	O
)	O
and	O
Merck	O
(	O
Nogent	O
sur	O
Marne	O
,	O
France	O
)	O
.	O

Trans	B
-astringin	I
was	O
obtained	O
from	O
cell	O
suspension	O
cultures	O
[	O
10	O
]	O
and	O
identified	O
unambiguously	O
by	O
MS	O
and	O
NMR	O
as	O
previously	O
described	O
[	O
7	O
]	O
.	O

The	O
fluorescence	O
properties	O
of	O
trans	B
-astringin	I
were	O
determined	O
with	O
the	O
1064	O
Hewlett	O
-	O
Packard	O
spectrofluorimeter	O
.	O

Calibration	O
was	O
performed	O
with	O
solutions	O
of	O
different	O
concentrations	O
of	O
trans	B
-astringin	I
obtained	O
by	O
suitable	O
dilution	O
of	O
methanolic	B
solution	O
at	O
10	O
mg	O
/	O
l	O
.	O

Standard	O
solutions	O
were	O
stored	O
at	O
−20	O
°	O
C	O
and	O
protected	O
from	O
light	O
.	O

The	O
linear	O
regression	O
was	O
Y	O
=	O
499.9x	O
−0.8	O
(	O
r	O
=	O
0.999	O
;	O
CV<4.71	O
)	O
.	O

2.1	O
HPLC	O
analysis	O
A	O
Hewlett	O
-	O
Packard	O
Model	O
1100	O
with	O
two	O
low	O
pressure	O
pumps	O
and	O
a	O
1064	O
Hewlett	O
-	O
Packard	O
fluorimetric	O
detector	O
coupled	O
to	O
an	O
HP	O
Chem	O
Station	O
were	O
used	O
for	O
solvent	O
delivery	O
system	O
and	O
detection	O
.	O

A	O
Hewlett	O
-	O
Packard	O
column	O
,	O
packed	O
with	O
Nucleosil	O
100	O
C18	O
,	O
250	O
×	O
4	O
mm	O
,	O
5	O
μm	O
particle	O
size	O
was	O
used	O
for	O
the	O
stationary	O
phase	O
.	O

The	O
eluents	O
were	O
for	O
solvent	O
A	O
,	O
an	O
aqueous	O
solution	O
of	O
20	O
mM	O
acetic	B
acid	I
,	O
and	O
for	O
solvent	O
B	O
,	O
methanol	B
(	O
HPLC	O
grade	O
)	O
;	O
both	O
were	O
filtered	O
through	O
0.45	O
μm	O
Millipore	O
filters	O
.	O

Elution	O
was	O
performed	O
with	O
the	O
following	O
gradient	O
:	O
0–5	O
min	O
98	O
%	O
solvent	O
A	O
;	O
5–12	O
min	O
from	O
98	O
to	O
93	O
%	O
solvent	O
A	O
;	O
12–18	O
min	O
from	O
93	O
to	O
89	O
%	O
A	O
;	O
18–28	O
min	O
from	O
89	O
to	O
85	O
%	O
A	O
;	O
28–38	O
min	O
from	O
85	O
to	O
70	O
%	O
;	O
38–48	O
min	O
from	O
70	O
to	O
60	O
%	O
;	O
48–55	O
min	O
from	O
60	O
to	O
50	O
%	O
A	O
,	O
55–75	O
min	O
50	O
%	O
A.	O

The	O
flow	O
rate	O
was	O
0.5	O
ml	O
/	O
min	O
.	O

Ten	O
French	O
wines	O
(	O
5	O
red	O
,	O
5	O
white	O
)	O
from	O
the	O
South	O
of	O
France	O
were	O
analyzed	O
.	O

Wine	O
samples	O
were	O
directly	O
injected	O
into	O
the	O
HPLC	O
system	O
after	O
dilution	O
in	O
bi	O
-	O
distilled	O
water	B
and	O
filtration	O
(	O
Millex	O
-	O
FH13	O
;	O
Millipore	O
;	O
St.	O
Quentin	O
,	O
Yvelines	O
,	O
France	O
)	O
.	O

Dilution	O
of	O
1	O
/	O
3	O
was	O
used	O
,	O
and	O
20	O
μl	O
were	O
injected	O
.	O

3	O
Results	O
and	O
discussion	O
The	O
maximum	O
excitation	O
and	O
emission	O
wavelength	O
in	O
a	O
methanolic	B
solution	O
as	O
well	O
as	O
in	O
a	O
mixture	O
of	O
20	O
mM	O
methanol	B
–	O
acetic	B
acid	I
(	O
v	O
/	O
v	O
,	O
50:50	O
)	O
(	O
the	O
composition	O
of	O
the	O
trans	B
-astringin	I
gradient	O
was	O
measured	O
when	O
in	O
the	O
spectrofluorimeter	O
cell	O
)	O
were	O
298	O
and	O
400	O
nm	O
respectively	O
.	O

The	O
threshold	O
of	O
detection	O
was	O
defined	O
as	O
the	O
amount	O
of	O
the	O
compound	O
resulting	O
in	O
a	O
peak	O
10-fold	O
higher	O
than	O
the	O
standard	O
deviation	O
of	O
the	O
baseline	O
noise	O
.	O

This	O
was	O
found	O
to	O
be	O
0.03	O
mg	O
/	O
l	O
.	O

Chromatograms	O
of	O
trans	B
-astringin	I
and	O
of	O
a	O
red	O
wine	O
sample	O
monitored	O
by	O
fluorescence	O
detection	O
are	O
reported	O
in	O
Fig.	O
2A	O
and	O
B	O
.	O

The	O
retention	O
time	O
was	O
53.7	O
min	O
.	O

The	O
HPLC	O
separation	O
and	O
the	O
good	O
resolution	O
of	O
the	O
peak	O
without	O
interference	O
allowed	O
the	O
identification	O
of	O
the	O
trans	B
-astringin	I
.	O

A	O
co	O
-	O
chromatographic	O
analysis	O
was	O
also	O
performed	O
;	O
it	O
confirmed	O
the	O
identification	O
of	O
trans	B
-astringin	I
by	O
HPLC	O
with	O
fluorimetric	O
detection	O
.	O

The	O
chromatogram	O
of	O
the	O
wine	O
in	O
which	O
trans	B
-astringin	I
was	O
added	O
is	O
reported	O
in	O
Fig.	O
2C	O
.	O

This	O
progressive	O
gradient	O
run	O
developed	O
here	O
has	O
allowed	O
the	O
analysis	O
of	O
other	O
stilbenes	B
:	O
trans	B
-resveratrol	I
,	O
trans	B
-piceid	I
[	O
11	O
]	O
,	O
and	O
other	O
phenolic	B
compounds	I
such	O
as	O
(	B
+	I
)	I
-catechin	I
,	O
tyrosol	B
,	O
gentisic	B
acid	I
[	O
12	O
]	O
.	O

The	O
standard	O
methanolic	B
solution	O
of	O
trans	B
-astringin	I
was	O
stable	O
for	O
at	O
least	O
30	O
days	O
at	O
−20	O
°	O
C	O
in	O
the	O
dark	O
.	O

When	O
this	O
solution	O
was	O
exposed	O
to	O
wide	O
-	O
spectrum	O
fluorescent	O
lighting	O
at	O
a	O
light	O
intensity	O
of	O
40	O
μmol	O
m−2	O
s−1	O
at	O
25	O
°	O
C	O
,	O
no	O
degradation	O
of	O
trans	B
-astringin	I
was	O
observed	O
during	O
the	O
first	O
two	O
h	O
,	O
corresponding	O
to	O
the	O
time	O
of	O
analysis	O
.	O

Therefore	O
,	O
trans	B
-astringin	I
can	O
be	O
handled	O
in	O
the	O
laboratory	O
without	O
very	O
stringent	O
precautions	O
.	O

We	O
found	O
low	O
levels	O
of	O
trans	B
-astringin	I
in	O
the	O
wine	O
analyzed	O
,	O
and	O
the	O
results	O
were	O
confirmed	O
by	O
mass	O
spectrometry	O
.	O

Trans	B
-astringin	I
was	O
extracted	O
from	O
red	O
wine	O
and	O
FAB	O
-	O
MS	O
spectra	O
showed	O
a	O
[	O
MH	O
]	O
+	O
peak	O
at	O
m	O
/	O
z	O
407	O
(	O
C20	O
H22	O
O9	O
requires	O
406	O
)	O
.	O

In	O
this	O
research	O
,	O
trans	B
-astringin	I
is	O
reported	O
for	O
the	O
first	O
time	O
to	O
be	O
present	O
in	O
both	O
red	O
and	O
white	O
wines	O
.	O

Concentrations	O
ranged	O
from	O
0.09	O
mg	O
/	O
l	O
to	O
0.29	O
mg	O
/	O
l	O
for	O
red	O
wines	O
and	O
from	O
0.10	O
mg	O
/	O
l	O
to	O
0.22	O
mg	O
/	O
l	O
for	O
white	O
wines	O
.	O

To	O
study	O
the	O
reproducibility	O
,	O
the	O
same	O
red	O
and	O
white	O
wine	O
samples	O
were	O
analyzed	O
on	O
five	O
different	O
days	O
.	O

The	O
CV	O
obtained	O
were	O
less	O
than	O
4.72	O
%	O
for	O
red	O
wines	O
and	O
less	O
than	O
4.23	O
%	O
for	O
white	O
wines	O
.	O

Fluorimetric	O
detection	O
evidenced	O
low	O
levels	O
of	O
trans	B
-astringin	I
in	O
wine	O
.	O

As	O
already	O
described	O
by	O
Pezet	O
et	O
al.	O
[	O
13	O
]	O
for	O
trans-	B
resveratrol	I
and	O
pterostilbene	B
,	O
the	O
use	O
of	O
a	O
fluorimetric	O
detector	O
is	O
well	O
adapted	O
to	O
the	O
low	O
concentrations	O
of	O
stilbenes	B
in	O
wines	O
.	O

In	O
particular	O
,	O
no	O
prior	O
treatment	O
of	O
the	O
wine	O
sample	O
is	O
required	O
.	O

For	O
the	O
ten	O
French	O
wines	O
analyzed	O
here	O
,	O
no	O
large	O
differences	O
were	O
observed	O
between	O
red	O
and	O
white	O
wines	O
,	O
but	O
analysis	O
of	O
more	O
samples	O
of	O
commercial	O
wine	O
is	O
needed	O
to	O
estimate	O
the	O
dietary	O
impact	O
and	O
bioavailability	O
of	O
the	O
trans	B
-astringin	I
in	O
the	O
wines	O
of	O
world	O
.	O

4	O
Conclusion	O
The	O
present	O
method	O
for	O
the	O
analysis	O
of	O
trans	B
-astringin	I
in	O
wine	O
combines	O
the	O
simplicity	O
of	O
direct	O
HPLC	O
injection	O
with	O
the	O
sensitivity	O
of	O
fluorescence	O
detection	O
.	O

Acknowledgements	O
The	O
authors	O
thank	O
Ray	O
Cooke	O
for	O
revising	O
the	O
English	O
manuscript	O
and	O
F.	O
Gasc	O
for	O
glassware	O
expertise	O
.	O

DNA	O
topoisomerases	O
are	O
the	O
enzymes	O
which	O
regulate	O
the	O
state	O
of	O
DNA	O
topology	O
.	O

The	O
enzymes	O
are	O
,	O
therefore	O
,	O
important	O
for	O
DNA	O
metabolism	O
,	O
such	O
as	O
replication	O
,	O
recombination	O
and	O
transcription	O
)	O

Nidulalin	B
A	I
(	O
1	B
)	O
2	O
and	O
its	O
derivatives	B
,	O
F390B	B
(	O
2	B
)	O
and	O
C	B
(	O
3	B
)	O
,	O
were	O
isolated	O
from	O
Penicillium	O
sp.	O
as	O
potent	O
cytotoxic	O
agents	O
(	O
Figure	O
1	O
)	O
.3	O
Nidulalin	B
A	I
,	O
a	O
major	O
metabolite	B
of	O
the	O
producing	O
strain	O
,	O
showed	O
potent	O
inhibitory	O
activity	O
against	O
DNA	O
topoisomerase	O
II	O
(	O
Topo	O
II	O
)	O
in	O
vitro.4	O
The	O
antitumor	O
activity	O
of	O
nidulalin	B
A	I
against	O
Colon	O
26	O
routine	O
adenocarcinoma	O
was	O
evaluated	O
in	O
vivo	O
,	O
however	O
,	O
no	O
antitumor	O
effect	O
was	O
observed	O
.	O

Further	O
investigation	O
revealed	O
that	O
rapid	O
hydrolysis	O
and	O
decarboxylation	O
of	O
the	O
methyl	B
ester	I
moiety	O
of	O
1	B
by	O
esterases	O
in	O
murine	O
plasma	O
gave	O
an	O
inactive	O
xanthone	B
derivative	B
4	I
,	O
which	O
was	O
identical	O
to	O
the	O
compound	O
derived	O
from	O
1	B
by	O
alkaline	O
hydrolysis	O
.	O

This	O
result	O
prompted	O
us	O
to	O
synthesize	O
stable	O
analogs	B
against	O
hydrolysis	O
.	O

In	O
this	O
communication	O
,	O
we	O
report	O
synthesis	O
and	O
antitumor	O
activity	O
of	O
derivatives	B
of	I
nidulalin	I
A	I
with	O
amide	B
moieties	O
in	O
place	O
of	O
the	O
methoxycarbonyl	B
group	I
.	O

Figure	O
1	O
MeO2C	O
ORe	O
Nidulalin	B
A	I
(	O
1	B
)	O
RI	O
=	O
R2	O
=	O
H	O
F390B	B
(	O
2	B
)	O
R~=H	O
,	O
R2	O
=	O
Ac	O
F390C	B
(	O
3	B
)	O
RI	O
=	O
OH	O
,	O
R2	O
=	O
H	O
4	O
0960	O
-	O
894X	O
/	O
99	O
/	O
$	O
-	O
see	O
front	O
matter	O
1999	O
Elsevier	O
Science	O
Ltd.	O
All	O
rights	O
reserved	O
.	O

PII	O
:	O
S0960	O
-	O
894X	O
(	O
99	O
)	O
00440	O
-	O
0	O
2654	O
S.	O
Sato	O
et	O
al.	O
/	O
Bioorg	O
.	O

Med	O
.	O

Chem	O
.	O

Lett	O
.	O

9	O
(	O
1999	O
)	O
2653	O
-	O
2656	O
Synthesis	O
The	O
syntheses	O
of	O
amide	B
analogs	O
of	O
nidulalin	B
A	I
are	O
outlined	O
in	O
Scheme	O
1	O
.	O

Direct	O
amidation	O
by	O
methylamine	B
in	O
MeOH	B
afforded	O
approximately	O
4:3	O
mixture	O
of	O
lactams	B
10a	B
and	O
10b	B
via	O
Michael	O
addition	O
followed	O
by	O
intramolecular	O
aminolysis	O
(	O
Scheme	O
2	O
)	O
.	O

To	O
avoid	O
lactam	B
formation	O
,	O
nidulalin	B
A	I
was	O
reduced	O
by	O
NaBH4	B
in	O
MeOH	B
to	O
give	O
a	O
tetrahydroxanthone	B
derivative	I
5	I
in	O
87	O
%	O
yield,5	O
which	O
was	O
treated	O
with	O
1N	O
NaOH	B
followed	O
by	O
acetylation	O
with	O
acetic	B
anhydride	I
in	O
pyridine	B
to	O
give	O
carboxylic	B
acid	I
6	I
.	I

Condensation	O
of	O
6	B
with	O
various	O
amines	B
,	O
including	O
ammonia	B
,	O
methylamine	B
,	O
dimethylamine	B
,	O
2-aminoethanol	B
,	O
and	O
pyrrolidine	B
,	O
via	O
acid	B
chloride	I
followed	O
by	O
acetylation	O
of	O
a	O
hydroxyl	B
group	I
,	O
which	O
was	O
generated	O
during	O
amine	B
treatment	O
,	O
gave	O
corresponding	O
amides	B
7a	I
-	I
e	I
,	O
respectively	O
.	O

Oxidation	O
of	O
7a	B
with	O
SeOz	B
in	O
dioxane	B
at	O
65	O
gave	O
a	O
dihydroxanthone	B
derivative	I
8a	I
in	O
18	O
%	O
yield	O
.	O

In	O
the	O
same	O
manner	O
,	O
7h	B
-	I
e	I
were	O
converted	O
to	O
8h	B
-	I
e	I
,	O
respectively	O
.	O

The	O
acetyl	B
groups	I
of	O
8a	B
-	I
e	I
were	O
removed	O
by	O
alkaline	B
hydrolysis	O
to	O
give	O
amide	B
analogs	I
9a	I
-	I
e	I
,	O
respectively.6	O
Scheme	O
1	O
H	O
~	O
a	O
""""	O
"Me,""~"	O
b'c	O
""""	O
M~-O~.	O
Y	O
M	O
87	O
%	O
~	O
,	O
^,,-	O
,	O
7-	O
i	O
..	O
91	O
%	O
..	O

_	O
.=.	O
,	O
~w	O
~	O
v2'~	O
'	O
OH	O
I'-IU2U	O
OAc	O
Nidulalin	B
A	I
(	O
1	B
)	O

5	O
6	O
65	O
-	O
97	O
Yo	O
ROC	O
(	O
~Ac	O
17	O
-	O
35o	O
Me	O
""""	O
""""	O
~	O
-ROo~	O
OTAc	O
quan	O
.	O

7a	O
R	O
=	O
NH2	O
8a	O
R	O
=	O
NH2	O
9a	O
R	O
=	O
NH2	O
7b	O
R	O
=	O
NHMe	O
8b	O
R	O
=	O
NHMe	O
9b	O
R	O
=	O
NHMe	O
7R	O
=	O
NMe2	O
8c	O
R	O
=	O
NMe2	O
9c	O
R	O
=	O
NMe2	O
7d	O
R	O
=	O
NHCH2CH2OAc	O
8d	O
R	O
=	O
NHCH2CH2OAc	O
9d	O
R	O
=	O
NHCH2CH2OH	O
a	O
)	O
NaBH4	B
,	O
MeOH	B
,	O
5	O
b	O
)	O
1N	O
NaOH	B
,	O
5	O
c	O
)	O
Ac20	B
,	O
pyridine	B
,	O
rt	O
d	O
)	O
SOCI2	B
,	O
cat	O
.	O

DMF	B
,	O
CH2CI2	B
,	O
rt	O
e	O
)	O
aq	O
.	O

amines	B
,	O
5	O
f	O
)	O
Ac20	B
,	O
pyridine	B
,	O
rt	O
g	O
)	O
SeO2	B
,	O
dioxane	B
,	O
65	O
h	O
)	O

1N	O
NaOH	B
,	O
MeOH	B
,	O
5	O
Scheme	O
2	O
a	O
1	O
a	O
)	O
MeNH2	B
,	O
MeOH	B
,	O
rt	O
+	O
M	O
M	O
Me	O
O	O
/	O
j	O
OH	O
10a	O
10b	O
S.	O
Sato	O
et	O
al.	O
/	O
Bioorg	O
.	O

Med	O
.	O

Chem	O
.	O

Lett	O
.	O

9	O
(	O
1999	O
)	O
2653	O
-	O
2656	O
2655	O
Result	O
and	O
Discussion	O
To	O
test	O
the	O
stability	O
,	O
the	O
amide	B
derivatives	I
were	O
treated	O
with	O
murine	O
plasma	O
.	O

The	O
inactive	O
compound	B
4	I
was	O
not	O
detected	O
by	O
HPLC	O
analyses	O
,	O
and	O
it	O
was	O
revealed	O
that	O
the	O
amide	B
analogs	I
were	O
stable	O
against	O
esterases	O
]	O
The	O
biological	O
activities	O
of	O
the	O
semisynthetic	B
compounds	I
of	I
nidulalin	I
A	I
are	O
shown	O
in	O
Table	O
1	O
.	O

The	O
amide	B
derivatives	I
9a	I
-	I
e	I
retained	O
cytotoxic	O
activity	O
against	O
both	O
human	O
and	O
murine	O
cancer	O
cell	O
lines	O
in	O
vitro	O
.	O

9a	B
inhibited	O
Topo	O
II	O
in	O
dose	O
dependent	O
manner	O
with	O
IC~0	O
value	O
of	O
29gM.	O
Furthermore	O
,	O
9a	B
possessed	O
weak	O
inhibitory	O
activity	O
against	O
topoisomerase	O
I	O
(	O
Topo	O
I	O
)	O
with	O
ICs0	O
value	O
of	O
631.tM.	O
In	O
spite	O
of	O
decreased	O
activity	O
against	O
Topo	O
II	O
,	O
cytotoxicity	O
of	O
9a	B
was	O
comparable	O
to	O
that	O
of	O
1	B
.	O

Lactam	B
10a	I
inhibited	O
neither	O
Topo	O
I	O
nor	O
Topo	O
II	O
since	O
a	O
conjugated	B
dienone	I
moiety	O
was	O
required	O
for	O
inhibitory	O
activity	O
against	O
Topo	O
II.4	O
The	O
reason	O
for	O
the	O
discrepancy	O
between	O
cytotoxicity	O
and	O
inhibitory	O
activity	O
against	O
Topo	O
I	O
and	O
Topo	O
II	O
of	O
these	O
compounds	O
is	O
not	O
clear	O
.	O

There	O
might	O
be	O
other	O
mechanisms	O
for	O
cytotoxicity	O
of	O
these	O
analogs	B
or	O
instability	O
of	O
1	B
in	O
cell	O
culture	O
might	O
decrease	O
its	O
cytotoxicity	O
.	O

Table	O
1	O
.	O

Biological	O
Activities	O
of	O
Nidulalin	B
A	I
Derivatives	B
in	O
vitro	O
Cytotoxicitya	O
Inhibitory	O
Activity	O
ICso	O
(	O
gM	O
)	O
IC,0	O
(	O
gM	O
)	O
Compound	O
HCT-116	O
K562	O
P388	O
Topo	O
Ib	O
Topo	O
IIc	O
9a	O
0.33	O
0.59	O
0.052	O
63	O
29	O
9b	O
1.13	O
2.26	O
0.24	O
>	O
300	O
132	O
9	O
e	O
0.79	O
0.98	O
0.15	O
ndd	O
nd	O
9d	O
7.88	O
10.61	O
2.67	O
102	O
23	O
9e	O
1.64	O
1.52	O
0.56	O
nd	O
nd	O
10a	O
19.6	O
6.31	O
nd	O
>	O
300	O
>	O
300	O
l	O
(	O
Nidulalin	B
A	I
)	O
0.14	O
0.32	O
0.024	O
172	O
2.2	O
a	O
)	O
Cells	O
were	O
treated	O
with	O
each	O
compound	O
for	O
72	O
hours	O
.	O

Cell	O
viability	O
was	O
evaluated	O
by	O
MTT	B
assay	O
,	O
b	O
)	O
Relaxation	O
assay	O
of	O
Topo	O
I	O
was	O
performed	O
as	O
shown	O
in	O
ref	O
.	O

8	O
.	O
c	O
)	O
Decatenation	O
assay	O
of	O
Topo	O
II	O
was	O
performed	O
as	O
shown	O
in	O
ref	O
.	O

9	O
.	O
d	O
)	O
not	O
determined	O
Table	O
2	O
.	O

Antitumor	O
Activity	O
of	O
9a	B
in	O
vivo	O
Compound	O
Route	O
IR	O
(	O
%	O
)	O
a	O
(	O
dose	O
)	O
9a	B
iv	O
42b	O
(	O
10mg	O
/	O
Kg	O
)	O
1	O
iv	O
24	O
(	O
20mg	O
/	O
Kg	O
)	O
a	O
)	O
Tumor	O
growth	O
suppression	O
was	O
determined	O
as	O
shown	O
in	O
note	O
10	O
.	O

b	O
)	O
P<0.01	O
by	O
T	O
-	O
test	O
Antitumor	O
activity	O
of	O
9a	O
was	O
evaluated	O
against	O
Colon	O
26	O
murine	O
tumor	O
model	O
in	O
vivo	O
(	O
Table	O
2	O
)	O
.	O

9a	B
,	O
at	O
a	O
dose	O
of	O
10mg	O
/	O
Kg	O
,	O
showed	O
moderate	O
antitumor	O
activity	O
in	O
this	O
model	O
,	O
while	O
1	B
showed	O
only	O
marginal	O
effect	O
even	O
at	O
a	O
higher	O
dose	O
(	O
20mg	O
/	O
Kg	O
)	O
.	O

From	O
above	O
results	O
,	O
it	O
is	O
demonstrated	O
that	O
the	O
methoxycarbonyl	B
group	I
modified	O
nidulalin	B
A	I
analogs	B
are	O
stable	O
against	O
esterases	O
and	O
effective	O
in	O
murine	O
tumor	O
model	O
in	O
vivo	O
.	O

Further	O
evaluation	O
of	O
antitumor	O
activity	O
and	O
synthesis	O
of	O
other	O
stable	O
analogs	B
are	O
underway	O
.	O

Acknowledgement	O

:	O
We	O
thank	O
Dr.	O
Yukio	O
Iino	O
,	O
Toshimi	O
Mizukoshi	O
,	O
Uno	O
Tagami	O
,	O
and	O
Reiko	O
Yuji	O
for	O
measurement	O
of	O
NMR	O
and	O
mass	O
spectra	O
.	O

We	O
are	O
also	O
grateful	O
to	O
Yumiko	O
Fukuda	O
for	O
skillful	O
technical	O
assistance	O
.	O

2656	O
S.	O
Sato	O
et	O
al.	O
/	O
Bioorg	O
.	O

Med	O
.	O

Chem	O
.	O

Lett	O
.	O

9	O
(	O
1999	O
)	O
2653	O
-	O
2656	O

Phytosterol	B
supplements	O
decrease	O
serum	O
cholesterol	B
and	O
may	O
reduce	O
the	O
risk	O
of	O
cardiovascular	O
disease	O
[	O
1	O
]	O
.	O

In	O
a	O
feeding	O
trial	O
involving	O
a	O
stanol	B
-	O
supplemented	O
margarine	O
spread	O
[	O
2	O
]	O
,	O
a	O
method	O
was	O
needed	O
for	O
sensitive	O
and	O
precise	O
determination	O
of	O
sitosterol	B
,	O
campesterol	B
,	O
stigmasterol	B
,	O
sitostanol	B
,	O
campestanol	B
,	O
lathosterol	B
,	O
and	O
desmosterol	B
in	O
human	O
serum	O
.	O

Quantitation	O
of	O
serum	O
sterols	B
and	O
stanols	B
(	O
5,6-dihydrosterols	B
)	O
is	O
complicated	O
by	O
the	O
presence	O
of	O
numerous	O
other	O
lipids	B
and	O
low	O
concentrations	O
(	O
0.2–13	O
μg	O
/	O
ml	O
)	O
of	O
the	O
analytes	O
relative	O
to	O
cholesterol	B
(	O
∼1500–3000	O
μg	O
/	O
ml	O
)	O
.	O

A	O
method	O
[	O
3,4	O
]	O
previously	O
reported	O
for	O
measurement	O
of	O
phytosterols	B
,	O
stanols	B
,	O
and	O
cholesterol	B
metabolites	B
[	O
5	O
]	O
lacked	O
sufficient	O
detail	O
about	O
preparation	O
of	O
serum	O
samples	O
,	O
chromatographic	O
conditions	O
,	O
and	O
analytical	O
sensitivity	O
,	O
and	O
was	O
not	O
readily	O
reproduced	O
.	O

Other	O
reports	O
[	O
6,7	O
]	O
do	O
not	O
include	O
validation	O
of	O
the	O
separation	O
and	O
quantification	O
of	O
phytosterols	B
and	O
stanols	B
as	O
well	O
as	O
cholesterol	B
metabolites	B
(	O
e.g.	O
desmosterol	B
,	O
lathosterol	B
)	O
.	O

Sample	O
clean	O
-	O
up	O
was	O
not	O
reported	O
in	O
some	O
of	O
the	O
published	O
methods	O
,	O
and	O
others	O
used	O
thin	O
-	O
layer	O
chromatography	O
.	O

Carryover	O
and	O
column	O
/	O
injector	O
contamination	O
are	O
problems	O
in	O
the	O
absence	O
of	O
serum	O
sample	O
clean	O
-	O
up	O
prior	O
to	O
chromatography	O
.	O

Very	O
polar	O
compounds	O
(	O
e.g.	O
phospholipids	B
)	O
are	O
an	O
important	O
consideration	O
in	O
sterol	B
analysis	O
when	O
semi	O
-	O
polar	O
or	O
polar	O
stationary	O
phases	O
are	O
employed	O
,	O
especially	O
when	O
analyzing	O
a	O
large	O
number	O
of	O
samples	O
.	O

A	O
60-m	O
capillary	O
column	O
with	O
a	O
moderately	O
polar	O
stationary	O
phase	O
(	O
14	O
%	O
cyanopropylphenyl–86	B
%	O
dimethylpolysiloxane	B
)	O
was	O
used	O
,	O
and	O
a	O
one	O
-	O
step	O
solid	O
-	O
phase	O
extraction	O
was	O
added	O
to	O
remove	O
highly	O
polar	O
compounds	O
from	O
the	O
saponified	O
total	O
lipid	B
extract	O
.	O

Epicholesterol	B
was	O
used	O
as	O
an	O
internal	O
standard	O
.	O

Since	O
the	O
primary	O
concern	O
was	O
to	O
detect	O
changes	O
in	O
low	O
levels	O
of	O
serum	O
sterols	B
and	O
stanols	B
as	O
a	O
result	O
of	O
dietary	O
supplementation	O
,	O
we	O
required	O
a	O
very	O
precise	O
assay	O
.	O

Consequently	O
,	O
numerous	O
quality	O
control	O
measures	O
were	O
implemented	O
.	O

In	O
this	O
paper	O
we	O
give	O
a	O
detailed	O
description	O
of	O
the	O
methodology	O
and	O
quality	O
control	O
employed	O
for	O
the	O
precise	O
quantitative	O
analysis	O
of	O
sitosterol	B
,	O
campesterol	B
,	O
stigmasterol	B
,	O
sitostanol	B
,	O
campestanol	B
,	O
lathosterol	B
,	O
and	O
desmosterol	B
in	O
human	O
serum	O
.	O

2	O
Experimental	O
2.1	O
Materials	O
2.1.1	O
Chemicals	O
Epicholesterol	B
was	O
obtained	O
from	O
Steraloids	O
(	O
Wilton	O
,	O
NH	O
,	O
USA	O
)	O
.	O

Beta	B
-	I
sitosterol	I
,	O
campesterol	B
,	O
stigmasterol	B
,	O
sitostanol	B
,	O
fucosterol	B
,	O
lathosterol	B
,	O
lanosterol	B
,	O
and	O
desmosterol	B
,	O
cholestanol	B
,	O
squalene	B
,	O
pyrogallol	B
,	O
cyclohexane	B
,	O
and	O
pyridine	B
were	O
purchased	O
from	O
Sigma	O
Chemical	O
(	O
St.	O
Louis	O
,	O
MO	O
,	O
USA	O
)	O
.	O

Campestanol	B
was	O
from	O
Research	O
Plus	O
(	O
Bayonne	O
,	O
NJ	O
,	O
USA	O
)	O
,	O
and	O
bis	B
(	I
trimethylsilyl	I
)	I
trifluoroacetamide	I
with	O
1	O
%	O
trimethylchlorosilane	B
(	O
BSTFA	B
w	O
/	O
1	O
%	O
TMCS	B
)	O
was	O
obtained	O
from	O
Alltech	O
Associates	O
(	O
Deerfield	O
,	O
IL	O
,	O
USA	O
)	O
.	O

Hexane	B
,	O
chloroform	B
,	O
methanol	B
,	O
isopropanol	B
,	O
sodium	B
chloride	I
(	O
ACS	O
grade	O
)	O
,	O
and	O
potassium	B
hydroxide	I
(	O
NF	O
/	O
FCC	O
grade	O
)	O
were	O
from	O
Fisher	O
Scientific	O
(	O
Fairlawn	O
,	O
NJ	O
,	O
USA	O
)	O
.	O

Absolute	O
ethanol	B
was	O
obtained	O
from	O
AAPER	O
Alcohol	B
and	O
Chemical	O
(	O
Shelbyville	O
,	O
KY	O
,	O
USA	O
)	O
.	O

All	O
solvents	O
were	O
HPLC	O
grade	O
and	O
used	O
without	O
further	O
purification	O
.	O

2.1.2	O
Serum	O
samples	O
Serum	O
samples	O
(	O
1–2	O
ml	O
)	O
frozen	O
in	O
2-ml	O
cryovials	O
were	O
obtained	O
from	O
a	O
human	O
feeding	O
trial	O
conducted	O
at	O
Pennsylvania	O
State	O
University	O
(	O
University	O
Park	O
,	O
PA	O
,	O
USA	O
)	O
and	O
Pennington	O
Biomedical	O
Research	O
Center	O
(	O
Baton	O
Rouge	O
,	O
LA	O
,	O
USA	O
)	O
.	O

Subjects	O
consumed	O
a	O
stanol	B
-	O
supplemented	O
margarine	O
that	O
provided	O
3	O
g	O
per	O
day	O
stanols	B
and	O
16	O
g	O
per	O
day	O
fat	O
in	O
a	O
controlled	O
feeding	O
trial	O
;	O
details	O
of	O
the	O
study	O
are	O
reported	O
elsewhere	O
[	O
2	O
]	O
.	O

Serum	O
samples	O
were	O
stored	O
at	O
−80	O
°	O
C	O
until	O
analyzed	O
.	O

2.2	O
Instrumentation	O
2.2.1	O
Gas	O
chromatography	O
Gas	O
chromatography	O
was	O
performed	O
with	O
a	O
Perkin	O
Elmer	O
GC	O
Autosystem	O
™	O
(	O
Perkin	O
Elmer	O
,	O
Norwalk	O
,	O
CT	O
,	O
USA	O
)	O
,	O
an	O
Rtx	O
®	O
-1701	O
(	O
14	O
%	O
cyanopropylphenyl–86	B
%	O
dimethylpolysiloxane	B
)	O
capillary	O
column	O
(	O
60-m	O
×	O
0.25-mm	O
I.D.	O
,	O
0.25-μm	O
film	O
thickness	O
;	O
Restek	O
,	O
Bellefonte	O
,	O
PA	O
,	O
USA	O
)	O
,	O
and	O
a	O
flame	O
ionization	O
detector	O
with	O
hydrogen	B
(	O
45	O
ml	O
/	O
min	O
)	O
and	O
air	O
(	O
450	O
ml	O
/	O
min	O
)	O
as	O
fuel	O
source	O
.	O

Hydrogen	B
at	O
1.18	O
ml	O
/	O
min	O
was	O
the	O
carrier	O
gas	O
.	O

Operating	O
conditions	O
were	O
:	O
injection	O
temperature	O
,	O
280	O
°	O
C	O
;	O
detector	O
temperature	O
,	O
280	O
°	O
C	O
;	O
oven	O
temperature	O
,	O
265	O
°	O
C	O
;	O
split	O
ratio	O
,	O
9:1	O
(	O
split	O
vent	O
flow	O
9.44	O
ml	O
/	O
min	O
)	O
;	O
injection	O
volume	O
,	O
1	O
μl	O
;	O
head	O
pressure	O
21	O
p.s.i	O
.	O

Detector	O
signal	O
output	O
was	O
monitored	O
by	O
computer	O
(	O
Dell	O
Dimension	O
XPS	O
D233	O
;	O
Dell	O
Computer	O
,	O
Round	O
Rock	O
,	O
TX	O
,	O
USA	O
)	O
and	O
all	O
chromatograms	O
and	O
data	O
were	O
generated	O
and	O
processed	O
using	O
Turbochrom	O
™	O
Workstation	O
version	O
6.0.2.1	O
software	O
(	O
Perkin	O
Elmer	O
)	O
.	O

2.3	O
Quality	O
control	O
measures	O
2.3.1	O
Preparation	O
of	O
glassware	O
All	O
glassware	O
(	O
and	O
other	O
labware	O
,	O
such	O
as	O
stir	O
bars	O
and	O
spatulas	O
)	O
was	O
scrupulously	O
cleaned	O
and	O
rinsed	O
with	O
distilled	O
deionized	O
water	B
and	O
acetone	B
,	O
then	O
immediately	O
before	O
use	O
,	O
rinsed	O
with	O
chloroform	B
,	O
then	O
ethanol	B
,	O
and	O
allowed	O
to	O
air	O
dry	O
.	O

All	O
glass	O
test	O
tubes	O
were	O
silanized	O
with	O
5	O
%	O
dimethyldicholorosilane	B
in	O
hexane	B
(	O
Sigma	O
)	O
.	O

2.3.2	O
Other	O
measures	O
to	O
prevent	O
contamination	O
Since	O
sterols	B
are	O
ubiquitous	O
in	O
the	O
lab	O
(	O
e.g.	O
in	O
skin	O
secretions	O
,	O
rubber	O
septa	O
,	O
vegetable	O
oils	B
and	O
fats	B
)	O
,	O
and	O
because	O
the	O
levels	O
of	O
these	O
compounds	O
in	O
serum	O
are	O
low	O
(	O
ng	O
to	O
μg	O
/	O
ml	O
)	O
,	O
it	O
is	O
essential	O
to	O
prevent	O
sample	O
contamination	O
to	O
preclude	O
falsely	O
elevated	O
values	O
of	O
the	O
analytes	O
.	O

Precautions	O
against	O
cross	O
-	O
contamination	O
are	O
especially	O
necessary	O
in	O
laboratories	O
where	O
vegetable	O
oils	B
or	O
other	O
materials	O
containing	O
significant	O
levels	O
of	O
phytosterols	B
are	O
analyzed	O
.	O

Tight	O
control	O
of	O
measuring	O
volumes	O
and	O
weights	O
is	O
essential	O
to	O
ensure	O
the	O
precision	O
and	O
accuracy	O
of	O
the	O
assay	O
in	O
the	O
ng	O
to	O
μg	O
range	O
.	O

2.3.3	O
Calibration	O
of	O
pipettes	O
and	O
balances	O
For	O
all	O
critical	O
volume	O
measurements	O
(	O
e.g.	O
standard	O
solutions	O
,	O
serum	O
aliquots	O
taken	O
for	O
analysis	O
)	O
,	O
automatic	O
pipettes	O
were	O
carefully	O
calibrated	O
for	O
accuracy	O
and	O
precision	O
immediately	O
before	O
use	O
,	O
using	O
the	O
solvent	O
of	O
the	O
solution	O
to	O
be	O
dispensed	O
(	O
e.g.	O
chloroform	B
or	O
ethanol	B
for	O
standards	O
,	O
water	B
for	O
serum	O
)	O
,	O
and	O
a	O
five	O
-	O
decimal	O
place	O
analytical	O
balance	O
,	O
calibrated	O
with	O
certified	O
standard	O
weights	O
.	O

The	O
pipetter	O
was	O
held	O
in	O
the	O
hand	O
5	O
min	O
to	O
warm	O
it	O
to	O
a	O
constant	O
temperature	O
before	O
calibration	O
.	O

To	O
determine	O
accuracy	O
,	O
the	O
weighed	O
volumes	O
were	O
compared	O
to	O
the	O
expected	O
mass	O
,	O
determined	O
from	O
the	O
density	O
of	O
the	O
liquid	O
at	O
the	O
measured	O
temperature	O
of	O
the	O
liquid	O
aliquoted	O
[	O
8	O
]	O
.	O

For	O
preparing	O
standard	O
mixtures	O
and	O
for	O
performing	O
standard	O
additions	O
to	O
serum	O
samples	O
,	O
volumetric	O
pipettes	O
were	O
used	O
.	O

2.3.4	O
Preparation	O
of	O
standard	O
solutions	O
2.3.4.1	O
Internal	O
standard	O
Test	O
tubes	O
containing	O
internal	O
standard	O
were	O
prepared	O
in	O
batches	O
.	O

Epicholesterol	B
(	O
3	O
mg	O
)	O
was	O
weighed	O
to	O
the	O
nearest	O
0.01	O
mg	O
into	O
a	O
1-l	O
volumetric	O
flask	O
,	O
brought	O
to	O
volume	O
with	O
absolute	O
ethanol	B
,	O
and	O
thoroughly	O
mixed	O
.	O

The	O
solution	O
was	O
dispensed	O
in	O
1.6-ml	O
aliquots	O
into	O
each	O
of	O
approximately	O
one	O
-	O
hundred	O
25	O
×	O
150	O
mm	O
glass	O
test	O
tubes	O
using	O
a	O
bottle	O
-	O
top	O
dispenser	O
that	O
had	O
been	O
calibrated	O
for	O
accuracy	O
and	O
precision	O
(	O
Section	O
2.3.3	O
)	O
,	O
yielding	O
5	O
μg	O
epicholesterol	B
per	O
tube	O
(	O
the	O
exact	O
amount	O
of	O
internal	O
standard	O
was	O
calculated	O
for	O
the	O
exact	O
weights	O
and	O
volumes	O
measured	O
)	O
.	O

The	O
tubes	O
were	O
capped	O
under	O
nitrogen	O
and	O
stored	O
at	O
<	O
10	O
°	O
C	O
for	O
up	O
to	O
2	O
months	O
.	O

Immediately	O
prior	O
to	O
use	O
,	O
the	O
solvent	O
was	O
evaporated	O
at	O
60	O
°	O
C	O
with	O
a	O
stream	O
of	O
nitrogen	B
.	O

2.3.4.2	O
Reference	O
and	O
calibration	O
standards	O
For	O
each	O
component	O
,	O
a	O
6	O
μg	O
/	O
ml	O
stock	O
standard	O
solution	O
was	O
made	O
.	O

Three	O
mg	O
of	O
component	O
was	O
weighed	O
to	O
the	O
nearest	O
0.01	O
mg	O
and	O
diluted	O
to	O
500	O
ml	O
in	O
a	O
volumetric	O
flask	O
,	O
using	O
absolute	O
ethanol	B
for	O
sterols	B
and	O
chloroform	B
for	O
stanols	B
.	O

Calibration	O
standard	O
solutions	O
containing	O
30	O
μg	O
/	O
ml	O
of	O
the	O
analyte	O
and	O
50	O
μg	O
/	O
ml	O
epicholesterol	B
were	O
prepared	O
in	O
batches	O
.	O

Solvent	O
was	O
evaporated	O
at	O
60	O
°	O
C	O
with	O
a	O
stream	O
of	O
nitrogen	B
,	O
then	O
the	O
mixture	O
was	O
derivatized	O
with	O
1	O
ml	O
pyridine	B
/	O
BSTFA	B
as	O
described	O
for	O
samples	O
(	O
Section	O
2.4.4	O
)	O
.	O

The	O
solution	O
was	O
distributed	O
among	O
ten	O
autosampler	O
vials	O
with	O
volume	O
reduction	O
inserts	O
(	O
∼100	O
μl	O
/	O
vial	O
)	O
and	O
stored	O
at	O
−60	O
°	O
C	O
.	O

These	O
standards	O
were	O
used	O
to	O
determine	O
calibration	O
factors	O
and	O
to	O
check	O
instrument	O
calibration	O
throughout	O
the	O
study	O
.	O

Two	O
reference	O
standard	O
mixtures	O
were	O
prepared	O
and	O
run	O
with	O
each	O
batch	O
of	O
samples	O
to	O
determine	O
run	O
-	O
specific	O
retention	O
times	O
for	O
the	O
analytes	O
.	O
'	O

Reference	O
A	O
'	O
contained	O
5	O
μg	O
/	O
ml	O
each	O
of	O
sitosterol	B
,	O
lathosterol	B
,	O
campestanol	B
,	O
stigmasterol	B
,	O
and	O
sitostanol	B
.	O
'	O

Reference	O
B	O
'	O
contained	O
5	O
μg	O
/	O
ml	O
each	O
of	O
desmosterol	B
,	O
campesterol	B
,	O
lanosterol	B
,	O
and	O
fucosterol	B
.	O

2.3.5	O
Preparation	O
of	O
quality	O
control	O
material	O
Accutrol	O
™	O
Human	O
Serum	O
(	O
normal	O
,	O
lyophilized	O
,	O
#	O
A2034	O
;	O
Sigma	O
)	O
was	O
used	O
as	O
a	O
control	O
material	O
.	O

No	O
standard	O
serum	O
with	O
certified	O
or	O
reference	O
values	O
for	O
phytosterols	B
could	O
be	O
found	O
,	O
and	O
homogeneous	O
fortification	O
of	O
the	O
serum	O
with	O
sitostanol	B
was	O
not	O
feasible	O
.	O

Because	O
of	O
the	O
potential	O
heterogeneity	O
of	O
reconstituted	O
aliquots	O
of	O
lyophilized	O
serum	O
(	O
due	O
to	O
variable	O
loss	O
of	O
dried	O
material	O
during	O
reconstitution	O
)	O
,	O
and	O
because	O
we	O
required	O
a	O
large	O
number	O
of	O
homogeneous	O
aliquots	O
to	O
adequately	O
monitor	O
assay	O
precision	O
,	O
we	O
prepared	O
a	O
composite	O
of	O
reconstituted	O
Accutrol	O
™	O
serum	O
and	O
dispensed	O
a	O
batch	O
of	O
380	O
1.25-ml	O
aliquots	O
.	O

One	O
-	O
hundred	O
vials	O
of	O
the	O
lyophilized	O
Accutrol	O
™	O
serum	O
(	O
from	O
the	O
same	O
lot	O
)	O
were	O
reconstituted	O
and	O
combined	O
.	O

In	O
batches	O
of	O
ten	O
at	O
a	O
time	O
,	O
vials	O
were	O
removed	O
from	O
the	O
refrigerator	O
and	O
each	O
was	O
reconstituted	O
with	O
5	O
ml	O
of	O
distilled	O
deionized	O
water	B
,	O
mixed	O
well	O
,	O
and	O
allowed	O
to	O
stand	O
for	O
10–20	O
min	O
at	O
room	O
temperature	O
(	O
20–23	O
°	O
C	O
)	O
,	O
then	O
placed	O
in	O
the	O
refrigerator	O
(	O
2–4	O
°	O
C	O
)	O
.	O

Within	O
3	O
days	O
,	O
a	O
composite	O
of	O
the	O
reconstituted	O
serum	O
was	O
made	O
in	O
a	O
walk	O
-	O
in	O
cold	O
room	O
(	O
7	O
°	O
C	O
)	O
.	O

As	O
much	O
as	O
possible	O
of	O
it	O
was	O
transferred	O
from	O
each	O
of	O
the	O
100	O
serum	O
vials	O
to	O
a	O
500-ml	O
glass	B
reagent	O
bottle	O
,	O
which	O
was	O
then	O
covered	O
and	O
stirred	O
at	O
medium	O
–	O
high	O
speed	O
for	O
1	O
h.	O
The	O
serum	O
was	O
then	O
dispensed	O
in	O
1.25-ml	O
aliquots	O
into	O
380	O
2-ml	O
microcentrifuge	O
tubes	O
in	O
batches	O
of	O
ten	O
at	O
a	O
time	O
,	O
using	O
a	O
new	O
pipette	O
tip	O
after	O
every	O
ten	O
samples	O
.	O

The	O
tubes	O
were	O
stored	O
at	O
−80	O
°	O
C	O
.	O

2.4	O
Sample	O
preparation	O
2.4.1	O
Total	O
lipid	O
extraction	O
Serum	O
samples	O
were	O
thawed	O
overnight	O
(	O
12–20	O
h	O
)	O
at	O
2–4	O
°	O
C	O
then	O
mixed	O
thoroughly	O
.	O

Using	O
a	O
calibrated	O
pipetter	O
,	O
0.90	O
ml	O
serum	O
was	O
dispensed	O
into	O
a	O
test	O
tube	O
containing	O
the	O
internal	O
standard	O
(	O
5	O
μg	O
epicholesterol	B
)	O
.	O

Total	O
lipid	O
was	O
extracted	O
by	O
a	O
modified	O
Folch	O
procedure	O
[	O
9	O
]	O
,	O
using	O
chloroform	B
–	O
methanol	B
(	O
2:1	O
,	O
v	O
/	O
v	O
)	O
followed	O
by	O
a	O
0.9	O
%	O
saline	B
wash	O
,	O
as	O
follows	O
.	O

After	O
mixing	O
the	O
sample	O
,	O
0.9	O
ml	O
of	O
methanol	O
was	O
added	O
,	O
then	O
tubes	O
were	O
capped	O
and	O
vortexed	O
at	O
high	O
speed	O
for	O
15	O
s.	O
Samples	O
were	O
then	O
shaken	O
for	O
10	O
min	O
on	O
an	O
orbital	O
shaker	O
at	O
300	O
rpm	O
.	O

If	O
phases	O
separated	O
before	O
orbital	O
shaking	O
,	O
the	O
tubes	O
were	O
first	O
shaken	O
briefly	O
by	O
hand	O
.	O

Chloroform	B
(	O
2	O
×	O
9.0	O
ml	O
)	O
and	O
6.75	O
ml	O
0.9	O
%	O
(	O
w	O
/	O
v	O
)	O
aqueous	O
sodium	B
chloride	I
were	O
added	O
,	O
tubes	O
were	O
capped	O
tightly	O
and	O
vortex	O
mixed	O
at	O
high	O
speed	O
for	O
15	O
s	O
,	O
then	O
shaken	O
at	O
300	O
rpm	O
on	O
the	O
orbital	O
shaker	O
for	O
10	O
min	O
(	O
if	O
phases	O
began	O
to	O
separate	O
before	O
orbital	O
shaking	O
,	O
tubes	O
were	O
first	O
shaken	O
by	O
hand	O
for	O
a	O
few	O
seconds	O
to	O
remix	O
)	O
.	O

Samples	O
were	O
then	O
centrifuged	O
at	O
200	O
g	O
at	O
20	O
°	O
C	O
for	O
10	O
min	O
to	O
facilitate	O
phase	O
separation	O
.	O

2.4.2	O
Saponification	O
The	O
chloroform	B
(	O
lower	O
)	O
layer	O
from	O
each	O
total	O
lipid	B
extraction	O
was	O
transferred	O
to	O
a	O
25	O
×	O
150	O
mm	O
test	O
tube	O
.	O

Care	O
was	O
taken	O
not	O
to	O
transfer	O
any	O
of	O
the	O
emulsion	O
or	O
solid	O
material	O
at	O
the	O
interface	O
between	O
the	O
upper	O
and	O
lower	O
phases	O
,	O
by	O
pushing	O
out	O
any	O
material	O
that	O
entered	O
the	O
pipette	O
tip	O
before	O
drawing	O
in	O
the	O
chloroform	B
solution	O
.	O

A	O
new	O
pipette	O
tip	O
was	O
used	O
for	O
each	O
sample	O
.	O

The	O
total	O
lipid	B
extract	O
was	O
saponified	O
by	O
a	O
modification	O
of	O
a	O
method	O
previously	O
described	O
by	O
Thompson	O
and	O
Merola	O
[	O
10	O
]	O
.	O

Solvent	O
was	O
evaporated	O
completely	O
from	O
the	O
total	O
lipid	B
extract	O
at	O
60	O
°	O
C	O
with	O
a	O
stream	O
of	O
nitrogen	B
.	O

Ethanol	B
with	O
3	O
%	O
(	O
w	O
/	O
v	O
)	O
pyrogallol	B
(	O
8	O
ml	O
)	O
was	O
added	O
to	O
each	O
sample	O
.	O

Tubes	O
were	O
capped	O
and	O
vortexed	O
at	O
high	O
speed	O
for	O
10	O
s	O
,	O
then	O
0.5	O
ml	O
of	O
1.28	O
g	O
/	O
ml	O
aqueous	O
potassium	B
hydroxide	I
was	O
added	O
.	O

Tubes	O
were	O
capped	O
tightly	O
,	O
vortexed	O
for	O
10	O
s	O
at	O
high	O
speed	O
,	O
sonicated	O
for	O
30	O
s	O
,	O
then	O
heated	O
in	O
a	O
test	O
tube	O
rack	O
in	O
a	O
85–89	O
°	O
C	O
water	O
bath	O
for	O
30	O
min	O
,	O
ensuring	O
that	O
the	O
bottom	O
half	O
of	O
the	O
tubes	O
were	O
immersed	O
.	O

Tubes	O
(	O
in	O
rack	O
)	O
were	O
shaken	O
and	O
inverted	O
vigorously	O
after	O
1	O
,	O
2	O
,	O
5	O
,	O
10	O
,	O
15	O
,	O
20	O
,	O
25	O
,	O
and	O
30	O
min	O
of	O
heating	O
(	O
a	O
second	O
test	O
tube	O
rack	O
was	O
held	O
firmly	O
over	O
the	O
top	O
during	O
shaking	O
to	O
hold	O
the	O
tubes	O
)	O
.	O

The	O
capped	O
tubes	O
were	O
sonicated	O
again	O
for	O
30	O
s	O
,	O
cooled	O
under	O
running	O
tap	O
water	B
,	O
then	O
slowly	O
opened	O
.	O

Cyclohexane	B
(	O
20	O
ml	O
)	O
,	O
then	O
12	O
ml	O
distilled	O
deionized	O
water	B
were	O
added	O
to	O
each	O
sample	O
.	O

Tubes	O
were	O
recapped	O
,	O
shaken	O
vigorously	O
for	O
a	O
few	O
seconds	O
,	O
then	O
rocked	O
15	O
min	O
on	O
a	O
platform	O
mixer	O
at	O
maximum	O
speed	O
(	O
Thermolyne	O
Vari	O
-	O
Mix	O
platform	O
mixer	O
;	O
Barnstead	O
/	O
Thermolyne	O
No.	O
48725	O
)	O
.	O

No	O
residual	O
material	O
was	O
evident	O
in	O
the	O
bottom	O
or	O
on	O
the	O
sides	O
of	O
tubes	O
after	O
shaking	O
.	O

Samples	O
were	O
centrifuged	O
at	O
200	O
g	O
at	O
20	O
°	O
C	O
for	O
10	O
min	O
to	O
accelerate	O
phase	O
separation	O
.	O

For	O
each	O
sample	O
,	O
17.0	O
ml	O
(	O
2	O
×	O
8.5	O
ml	O
)	O
of	O
the	O
cyclohexane	B
(	O
upper	O
)	O
layer	O
was	O
transferred	O
to	O
a	O
25	O
×	O
150	O
mm	O
test	O
tube	O
,	O
with	O
care	O
taken	O
not	O
to	O
include	O
any	O
of	O
the	O
black	O
,	O
aqueous	O
phase	O
.	O

Cyclohexane	B
was	O
evaporated	O
at	O
60	O
°	O
C	O
with	O
a	O
stream	O
of	O
nitrogen	B
.	O

Chloroform	B
(	O
0.5	O
ml	O
)	O
was	O
added	O
to	O
each	O
sample	O
,	O
then	O
samples	O
were	O
vortexed	O
for	O
10	O
s	O
at	O
high	O
speed	O
.	O

2.4.3	O
Solid	O
-	O
phase	O
extraction	O
A	O
modification	O
of	O
the	O
method	O
of	O
Kaluzny	O
et	O
al.	O
[	O
11	O
]	O
was	O
used	O
to	O
separate	O
the	O
neutral	O
lipid	B
fraction	O
(	O
containing	O
sterols	B
and	O
stanols	B
)	O
from	O
more	O
polar	O
lipids	B
.	O

Bond	O
Elute	O
LRC	O
®	O
aminopropyl	B
solid	O
-	O
phase	O
extraction	O
(	O
SPE	O
)	O
cartridges	O
10	O
ml	O
/	O
500	O
mg	O
(	O
Varian	O
Associates	O
,	O
Harbor	O
City	O
,	O
CA	O
,	O
USA	O
)	O
were	O
used	O
.	O

The	O
SPE	O
cartridges	O
were	O
attached	O
to	O
a	O
vacuum	O
manifold	O
(	O
Visaprep	O
DL	O
™	O
;	O
Supelco	O
,	O
Bellefonte	O
,	O
PA	O
,	O
USA	O
)	O
set	O
at	O
slightly	O
less	O
than	O
1″	O
Hg	B
with	O
valves	O
closed	O
.	O

Cartridges	O
were	O
conditioned	O
with	O
4	O
ml	O
hexane	B
,	O
which	O
was	O
discarded	O
.	O

A	O
16	O
×	O
125	O
mm	O
glass	O
test	O
tube	O
was	O
placed	O
under	O
each	O
outlet	O
.	O

With	O
vacuum	O
valves	O
closed	O
and	O
using	O
a	O
new	O
pipette	O
tip	O
for	O
each	O
sample	O
,	O
sample	O
was	O
transferred	O
into	O
the	O
SPE	O
cartridge	O
,	O
directly	O
onto	O
the	O
adsorbent	O
,	O
repeating	O
until	O
as	O
much	O
as	O
possible	O
had	O
been	O
transferred	O
.	O

With	O
vacuum	O
set	O
at	O
slightly	O
less	O
than	O
1″	O
Hg	O
,	O
valves	O
were	O
opened	O
one	O
by	O
one	O
until	O
the	O
sample	O
solution	O
had	O
just	O
completely	O
entered	O
the	O
adsorbent	O
,	O
then	O
turned	O
off	O
until	O
all	O
cartridges	O
had	O
been	O
set	O
.	O

Elution	O
solvent	O
(	O
chloroform	B
–	O
isopropanol	B
,	O
2:1	O
,	O
v	O
/	O
v	O
,	O
0.5	O
ml	O
)	O
was	O
added	O
to	O
each	O
cartridge	O
.	O

The	O
solvent	O
was	O
then	O
drawn	O
under	O
vacuum	O
through	O
the	O
cartridges	O
one	O
at	O
a	O
time	O
until	O
it	O
reached	O
just	O
above	O
the	O
column	O
bed	O
,	O
then	O
valve	O
was	O
closed	O
until	O
all	O
samples	O
had	O
been	O
taken	O
to	O
this	O
stage	O
.	O

An	O
additional	O
3.5	O
ml	O
of	O
the	O
elution	O
solvent	O
was	O
added	O
to	O
each	O
tube	O
,	O
then	O
all	O
valves	O
were	O
opened	O
and	O
the	O
solvent	O
was	O
allowed	O
to	O
pass	O
completely	O
(	O
dropwise	O
)	O
through	O
the	O
cartridges	O
.	O

The	O
vacuum	O
was	O
then	O
increased	O
to	O
draw	O
the	O
columns	O
dry	O
(	O
∼8″	O
Hg	B
for	O
at	O
least	O
2	O
min	O
)	O
.	O

2.4.4	O
Derivatization	O
Solvent	O
was	O
completely	O
evaporated	O
from	O
samples	O
at	O
60	O
°	O
C	O
with	O
a	O
stream	O
of	O
nitrogen	B
.	O

Freshly	O
prepared	O
derivatization	O
reagent	O
(	O
pyridine	B
–	O
BSTFA	B
with	O
1	O
%	O
TMCS	B
,	O
1:1	O
,	O
v	O
/	O
v	O
)	O
,	O
100	O
μl	O
,	O
was	O
pipetted	O
into	O
each	O
tube	O
and	O
vortex	O
mixed	O
for	O
10	O
s.	O

The	O
reagent	O
was	O
then	O
carefully	O
swirled	O
around	O
and	O
∼2″	O
up	O
the	O
sides	O
of	O
each	O
tube	O
.	O

Tubes	O
were	O
allowed	O
to	O
stand	O
at	O
least	O
1	O
min	O
,	O
vortex	O
mixed	O
for	O
3	O
s	O
,	O
then	O
allowed	O
to	O
stand	O
again	O
for	O
at	O
least	O
1	O
min	O
.	O

Each	O
sample	O
was	O
transferred	O
using	O
a	O
9″	O
glass	B
pasteur	O
pipette	O
into	O
a	O
100-μl	O
limited	O
volume	O
insert	O
in	O
an	O
autosampler	O
vial	O
,	O
sealed	O
with	O
a	O
PTFE	B
/	O
silicone	B
septum	O
cap	O
,	O
and	O
stored	O
at	O
<	O
10	O
°	O
C	O
until	O
assayed	O
by	O
GC	O
(	O
within	O
1	O
week	O
)	O
.	O

2.4.5	O
GC	O
analysis	O
and	O
quantitation	O
Analyte	O
retention	O
times	O
were	O
determined	O
using	O
commercially	O
available	O
standards	O
.	O

Analysis	O
of	O
selected	O
serum	O
samples	O
without	O
added	O
epicholesterol	B
internal	O
standard	O
confirmed	O
lack	O
of	O
sample	O
constituents	O
that	O
co	O
-	O
eluted	O
with	O
the	O
internal	O
standard	O
.	O

In	O
routine	O
assays	O
,	O
component	O
peaks	O
were	O
identified	O
by	O
the	O
adjusted	O
retention	O
time	O
,	O
which	O
compensated	O
for	O
any	O
shifts	O
in	O
expected	O
retention	O
times	O
based	O
on	O
that	O
of	O
the	O
internal	O
standard	O
[	O
12	O
]	O
.	O

A	O
relative	O
search	O
window	O
(	O
based	O
on	O
a	O
percent	O
of	O
the	O
absolute	O
retention	O
time	O
)	O
was	O
then	O
applied	O
to	O
the	O
adjusted	O
retention	O
time	O
as	O
the	O
criteria	O
for	O
identification	O
.	O

The	O
size	O
of	O
the	O
relative	O
search	O
window	O
was	O
determined	O
based	O
on	O
the	O
degree	O
of	O
absolute	O
retention	O
time	O
shift	O
that	O
was	O
expected	O
during	O
a	O
run	O
and	O
the	O
proximity	O
of	O
other	O
peaks	O
expected	O
in	O
the	O
samples	O
.	O

After	O
determining	O
the	O
method	O
was	O
linear	O
over	O
the	O
expected	O
concentration	O
ranges	O
(	O
below	O
)	O
,	O
analytes	O
were	O
quantified	O
based	O
on	O
a	O
single	O
point	O
response	O
factor	O
(	O
RF	O
)	O
:RF	O
=	O
RC	O
/RIS	O
MC	O
/MIS	O
where	O
R	O
C	O
is	O
the	O
peak	O
area	O
for	O
the	O
component	O
,	O
R	O
IS	O
is	O
the	O
peak	O
area	O
for	O
the	O
internal	O
standard	O
,	O
M	O
C	O
is	O
the	O
amount	O
of	O
component	O
and	O
M	O
IS	O
is	O
the	O
amount	O
of	O
internal	O
standard	O
added	O
to	O
the	O
sample	O
.	O

For	O
each	O
analyte	O
,	O
the	O
RF	O
was	O
determined	O
at	O
3	O
μg	O
as	O
the	O
average	O
of	O
triplicate	O
analysis	O
of	O
standards	O
.	O

In	O
samples	O
,	O
each	O
component	O
(	O
M	O
C	O
)	O
was	O
determined	O
using	O
the	O
response	O
factor	O
for	O
that	O
component	O
and	O
R	O
C	O
and	O
R	O
IS	O
determined	O
from	O
the	O
GC	O
analysis	O
.	O

Baseline	O
events	O
(	O
timed	O
events	O
in	O
the	O
instrument	O
method	O
which	O
effect	O
integration	O
of	O
peaks	O
)	O
were	O
set	O
up	O
in	O
the	O
standard	O
(	O
routine	O
)	O
Turbochrom	O
™	O
method	O
file	O
based	O
on	O
optimal	O
consistency	O
of	O
peak	O
integration	O
for	O
the	O
control	O
sample	O
.	O

In	O
sample	O
runs	O
,	O
individual	O
attention	O
was	O
paid	O
to	O
the	O
chromatograms	O
to	O
avoid	O
and	O
correct	O
any	O
obvious	O
integration	O
problems	O
(	O
usually	O
as	O
a	O
result	O
of	O
small	O
peak	O
size	O
and	O
interfering	O
peaks	O
)	O
,	O
by	O
modifying	O
baseline	O
events	O
as	O
necessary	O
.	O

2.5	O
Linearity	O
,	O
limit	O
of	O
detection	O
,	O
and	O
limit	O
of	O
quantitation	O
studies	O
The	O
expected	O
concentration	O
ranges	O
for	O
desmosterol	B
,	O
lathosterol	B
,	O
campesterol	B
,	O
sitosterol	B
,	O
stigmasterol	B
,	O
campestanol	B
,	O
sitostanol	B
,	O
lanosterol	B
,	O
and	O
fucosterol	B
were	O
tested	O
for	O
linearity	O
.	O

For	O
each	O
compound	O
,	O
standard	O
solutions	O
were	O
made	O
at	O
four	O
or	O
five	O
different	O
concentrations	O
between	O
0.05	O
μg	O
/	O
ml	O
and	O
25	O
μg	O
/	O
ml	O
.	O

Each	O
standard	O
solution	O
was	O
derivatized	O
and	O
assayed	O
in	O
duplicate	O
at	O
all	O
concentrations	O
,	O
except	O
in	O
quintuplicate	O
at	O
0.75	O
μg	O
/	O
ml	O
for	O
desmosterol	B
,	O
lanosterol	B
,	O
fucosterol	B
,	O
campestanol	B
,	O
and	O
sitostanol	B
and	O
at	O
5	O
μg	O
/	O
ml	O
for	O
campesterol	B
,	O
sitosterol	B
,	O
and	O
stigmasterol	B
.	O

For	O
each	O
compound	O
,	O
a	O
linear	O
regression	O
was	O
performed	O
on	O
the	O
data	O
(	O
component	O
/	O
internal	O
standard	O
area	O
ratio	O
vs.	O
component	O
/	O
internal	O
standard	O
mass	O
ratio	O
)	O
.	O

All	O
curves	O
were	O
linear	O
,	O
above	O
the	O
limit	O
of	O
detection	O
,	O
in	O
the	O
concentration	O
range	O
tested	O
(	O
r	O
2	O
=	O
0.99	O
or	O
greater	O
in	O
all	O
cases	O
)	O
.	O

The	O
method	O
limit	O
of	O
detection	O
(	O
MLOD	O
)	O
and	O
limit	O
of	O
quantitation	O
(	O
MLOQ	O
)	O
for	O
sitosterol	B
,	O
campesterol	B
,	O
lathosterol	B
,	O
and	O
desmosterol	B
were	O
determined	O
from	O
results	O
of	O
the	O
repeated	O
analyses	O
(	O
n	O
=	O
55	O
)	O
of	O
0.9-ml	O
aliquots	O
of	O
the	O
Accutrol	O
™	O
control	O
serum	O
composite	O
.	O

For	O
each	O
component	O
,	O
the	O
MLOD	O
was	O
calculated	O
as	O
three	O
times	O
the	O
standard	O
deviation	O
of	O
the	O
mean	O
and	O
the	O
MLOQ	O
was	O
estimated	O
as	O
ten	O
times	O
the	O
standard	O
deviation	O
of	O
the	O
mean	O
of	O
the	O
55	O
measurements	O
.	O

Since	O
sitostanol	B
and	O
campestanol	B
were	O
not	O
present	O
in	O
the	O
control	O
serum	O
and	O
lanosterol	B
and	O
stigmasterol	B
were	O
barely	O
detectable	O
,	O
the	O
MLODs	O
and	O
MLOQs	O
for	O
these	O
components	O
were	O
determined	O
by	O
analysis	O
of	O
the	O
Accutrol	O
™	O
serum	O
spiked	O
with	O
known	O
amounts	O
of	O
standards	O
,	O
as	O
follows	O
.	O

A	O
chloroform	B
solution	O
containing	O
0.5	O
μg	O
/	O
ml	O
of	O
stigmasterol	B
,	O
sitostanol	B
,	O
and	O
lanosterol	B
and	O
1	O
μg	O
/	O
ml	O
of	O
campestanol	B
was	O
prepared	O
.	O

One	O
ml	O
of	O
the	O
solution	O
was	O
added	O
to	O
each	O
of	O
seven	O
0.9-ml	O
Accutrol	O
™	O
composite	O
aliquots	O
,	O
which	O
were	O
then	O
assayed	O
as	O
described	O
above	O
,	O
except	O
for	O
the	O
volume	O
of	O
chloroform	B
added	O
during	O
the	O
total	O
lipid	B
extraction	O
which	O
was	O
reduced	O
by	O
the	O
volume	O
of	O
standard	O
added	O
.	O

MLOD	O
was	O
calculated	O
as	O
three	O
times	O
the	O
standard	O
deviation	O
of	O
the	O
mean	O
,	O
and	O
MLOQ	O
was	O
calculated	O
as	O
ten	O
times	O
the	O
standard	O
deviation	O
of	O
the	O
mean	O
of	O
the	O
seven	O
measurements	O
.	O

We	O
also	O
checked	O
the	O
method	O
performance	O
in	O
assaying	O
smaller	O
serum	O
aliquots	O
,	O
which	O
may	O
be	O
of	O
interest	O
when	O
the	O
sample	O
volume	O
is	O
limited	O
.	O

Seven	O
0.5-ml	O
and	O
seven	O
0.25-ml	O
aliquots	O
of	O
the	O
control	O
serum	O
composite	O
unspiked	O
and	O
spiked	O
with	O
sitostanol	B
,	O
campestanol	B
,	O
stigmasterol	B
,	O
and	O
lanosterol	B
in	O
amounts	O
near	O
the	O
MLOQ	O
determined	O
for	O
analysis	O
of	O
0.9	O
ml	O
serum	O
were	O
assayed	O
.	O

A	O
chloroform	B
solution	O
of	O
sitostanol	B
,	O
campestanol	B
,	O
stigmasterol	B
,	O
and	O
lanosterol	B
was	O
added	O
to	O
three	O
0.25	O
ml	O
and	O
three	O
0.5-ml	O
aliquots	O
of	O
the	O
Accutrol	O
™	O
control	O
composite	O
such	O
that	O
final	O
concentrations	O
were	O
1	O
μg	O
/	O
ml	O
campestanol	B
and	O
0.5	O
μg	O
/	O
ml	O
sitostanol	B
,	O
stigmasterol	B
,	O
and	O
lanosterol	B
.	O

Additionally	O
,	O
seven	O
serum	O
samples	O
from	O
a	O
clinical	O
feeding	O
trial	O
[	O
2	O
]	O
,	O
in	O
which	O
sitostanol	B
was	O
detected	O
,	O
were	O
re	O
-	O
assayed	O
in	O
0.25-ml	O
aliquots	O
and	O
compared	O
to	O
the	O
results	O
from	O
analysis	O
of	O
the	O
0.9-ml	O
aliquots	O
.	O

2.6	O
Recovery	O
studies	O
Recovery	O
analysis	O
was	O
based	O
on	O
fortification	O
of	O
samples	O
of	O
the	O
control	O
serum	O
composite	O
.	O

For	O
the	O
analytes	O
not	O
present	O
in	O
the	O
control	O
material	O
,	O
fortification	O
was	O
performed	O
at	O
four	O
different	O
concentrations	O
and	O
reported	O
for	O
all	O
concentrations	O
at	O
or	O
above	O
the	O
MLOQ	O
determined	O
for	O
the	O
individual	O
compounds	O
.	O

For	O
the	O
compounds	O
present	O
in	O
the	O
control	O
serum	O
,	O
samples	O
were	O
fortified	O
at	O
one	O
concentration	O
,	O
which	O
was	O
approximately	O
the	O
same	O
as	O
that	O
determined	O
from	O
analysis	O
of	O
the	O
control	O
serum	O
.	O

For	O
these	O
samples	O
,	O
the	O
values	O
calculated	O
for	O
the	O
unfortified	O
control	O
sample	O
analyzed	O
and	O
chromatographed	O
in	O
the	O
same	O
assay	O
were	O
subtracted	O
from	O
the	O
fortified	O
control	O
sample	O
values	O
to	O
determine	O
recovery:%R	O
=	O
Mfc	O
−Mc	O
Mf	O
×100	O
where	O
%	O
R	O
is	O
percent	O
recovery	O
,	O
M	O
fc	O
is	O
the	O
raw	O
amount	O
in	O
μg	O
of	O
component	O
determined	O
in	O
the	O
fortified	O
sample	O
,	O
M	O
c	O
is	O
the	O
raw	O
amount	O
in	O
μg	O
of	O
component	O
in	O
the	O
unfortified	O
material	O
,	O
and	O
M	O
f	O
is	O
the	O
fortification	O
amount	O
in	O
μg	O
.	O

2.6.1	O
Precision	O
studies	O
For	O
sitosterol	B
,	O
campesterol	B
,	O
lathosterol	B
,	O
desmosterol	B
,	O
and	O
lanosterol	B
,	O
precision	O
was	O
evaluated	O
from	O
the	O
results	O
of	O
repeated	O
analyses	O
of	O
the	O
control	O
sample	O
(	O
Accutrol	O
™	O
)	O
.	O

For	O
sitostanol	B
,	O
campestanol	B
,	O
and	O
stigmasterol	B
,	O
precision	O
was	O
estimated	O
from	O
repeated	O
analyses	O
of	O
the	O
control	O
composite	O
spiked	O
with	O
a	O
standard	O
mixture	O
of	O
these	O
components	O
.	O

2.7	O
Routine	O
quality	O
control	O
Prior	O
to	O
analysis	O
of	O
unknown	O
samples	O
,	O
three	O
assay	O
batches	O
of	O
5–13	O
aliquots	O
of	O
the	O
serum	O
control	O
material	O
(	O
Section	O
2.3.5	O
)	O
were	O
analyzed	O
over	O
a	O
period	O
of	O
2	O
weeks	O
.	O

A	O
control	O
chart	O
showing	O
the	O
mean	O
and	O
tolerance	O
limits	O
(	O
±3	O
times	O
the	O
standard	O
deviation	O
)	O
was	O
established	O
for	O
each	O
analyte	O
and	O
used	O
to	O
monitor	O
subsequent	O
assays	O
(	O
[	O
13	O
]	O
,	O
pp	O
.	O

130–132	O
)	O
.	O

An	O
aliquot	O
of	O
the	O
control	O
serum	O
composite	O
was	O
assayed	O
with	O
each	O
batch	O
of	O
samples	O
.	O

3	O
Results	O
and	O
discussion	O
3.1	O
Chromatograms	O
Representative	O
chromatograms	O
for	O
standards	O
,	O
the	O
control	O
serum	O
,	O
and	O
a	O
serum	O
sample	O
from	O
the	O
diet	O
intervention	O
(	O
which	O
contained	O
sitostanol	B
and	O
campestanol	B
)	O
are	O
shown	O
in	O
Fig.	O
1	O
.	O

3.2	O
Retention	O
times	O
and	O
response	O
factors	O
Table	O
1	O
summarizes	O
the	O
retention	O
times	O
,	O
relative	O
retention	O
times	O
,	O
and	O
response	O
factors	O
for	O
sitosterol	B
,	O
campesterol	B
,	O
stigmasterol	B
,	O
sitostanol	B
,	O
campestanol	B
,	O
desmosterol	B
,	O
lathosterol	B
,	O
and	O
also	O
lanosterol	B
,	O
fucosterol	B
,	O
and	O
squalene	B
using	O
the	O
present	O
method	O
.	O

Whereas	O
absolute	O
retention	O
times	O
sometimes	O
varied	O
up	O
to	O
0.2	O
min	O
.	O

(	O
e.g.	O
from	O
slight	O
changes	O
in	O
column	O
activity	O
and/or	O
head	O
pressure	O
)	O
,	O
relative	O
retention	O
times	O
were	O
consistent	O
within	O
0.02	O
min	O
across	O
runs	O
.	O

3.3	O
Linearity	O
,	O
limits	O
of	O
detection	O
,	O
limits	O
of	O
quantitation	O
,	O
and	O
analytical	O
ranges	O
Table	O
2	O
summarizes	O
the	O
method	O
linear	O
range	O
,	O
limit	O
of	O
detection	O
(	O
MLOD	O
)	O
,	O
and	O
limit	O
of	O
quantitation	O
(	O
MLOQ	O
)	O
for	O
each	O
component	O
(	O
sitosterol	B
,	O
campesterol	B
,	O
stigmasterol	B
,	O
sitostanol	B
,	O
campestanol	B
,	O
desmosterol	B
,	O
lathosterol	B
,	O
lanosterol	B
)	O
in	O
the	O
present	O
study	O
.	O

The	O
method	O
enabled	O
detection	O
of	O
all	O
components	O
at	O
concentrations	O
of	O
<	O
0.4	O
μg	O
/	O
ml	O
(	O
<	O
1	O
μmol	O
/	O
l	O
)	O
.	O

The	O
greatest	O
sensitivity	O
was	O
for	O
sitostanol	B
(	O
0.05	O
μg	O
/	O
ml	O
;	O
0.1	O
μmol	O
/	O
l	O
)	O
and	O
the	O
least	O
for	O
campesterol	B
and	O
campestanol	B
(	O
0.4	O
μg	O
/	O
ml	O
;	O
1	O
μmol	O
/	O
l	O
)	O
.	O

The	O
decreased	O
sensitivity	O
for	O
campesterol	B
and	O
campestanol	B
was	O
largely	O
due	O
to	O
interfering	O
peaks	O
in	O
the	O
region	O
which	O
limited	O
the	O
reliability	O
of	O
peak	O
area	O
estimates	O
at	O
low	O
analyte	O
levels	O
.	O

The	O
MLOQ	O
ranged	O
from	O
0.2	O
μg	O
/	O
ml	O
(	O
0.5	O
μmol	O
/	O
l	O
)	O
for	O
sitostanol	B
to	O
1.2	O
μg	O
/	O
ml	O
(	O
3	O
μmol	O
/	O
l	O
)	O
for	O
campesterol	B
and	O
campestanol	B
.	O

Response	O
was	O
linear	O
in	O
the	O
range	O
analyzed	O
for	O
each	O
component	O
(	O
MLOQ	O
to	O
10	O
or	O
25	O
μg	O
/	O
ml	O
)	O
.	O

The	O
statistically	O
determined	O
MLOD	O
and	O
MLOQ	O
(	O
defined	O
as	O
three	O
and	O
ten	O
times	O
the	O
standard	O
deviation	O
of	O
replicates	O
,	O
respectively	O
;	O
13	O
,	O
p.	O
80	O
)	O
included	O
effects	O
of	O
inconsistent	O
automated	O
peak	O
integration	O
due	O
to	O
background	O
interferences	O
.	O

The	O
statistically	O
determined	O
MLOQ	O
for	O
lanosterol	B
was	O
0.1	O
μg	O
/	O
ml	O
,	O
and	O
lanosterol	B
was	O
present	O
in	O
the	O
unfortified	O
control	O
serum	O
at	O
approximately	O
this	O
level	O
.	O

However	O
,	O
uncertainty	O
in	O
quantitation	O
of	O
lanosterol	B
occurred	O
due	O
to	O
occasional	O
incomplete	O
resolution	O
from	O
a	O
nearby	O
peak	O
,	O
and	O
the	O
results	O
for	O
55	O
analyses	O
of	O
the	O
control	O
material	O
and	O
control	O
material	O
spiked	O
with	O
various	O
levels	O
of	O
lanosterol	B
(	O
Table	O
4	O
)	O
suggested	O
that	O
the	O
practical	O
MLOQ	O
was	O
somewhat	O
higher	O
than	O
0.1	O
μg	O
/	O
ml	O
.	O

Therefore	O
,	O
the	O
MLOQ	O
and	O
MLOD	O
for	O
lanosterol	B
reported	O
in	O
Table	O
2	O
are	O
estimated	O
based	O
on	O
these	O
practical	O
findings	O
.	O

3.4	O
Recovery	O
Recovery	O
of	O
spiked	O
standards	O
is	O
shown	O
in	O
Table	O
3	O
and	O
appeared	O
quantitative	O
for	O
lathosterol	B
,	O
campesterol	B
,	O
sitosterol	B
,	O
sitostanol	B
,	O
campestanol	B
,	O
lanosterol	B
,	O
and	O
stigmasterol	B
.	O

Recovery	O
of	O
fortified	O
desmosterol	B
was	O
74	O
%	O
.	O

The	O
reason	O
for	O
this	O
result	O
is	O
unknown	O
;	O
we	O
did	O
not	O
attempt	O
to	O
repeat	O
the	O
experiment	O
.	O

3.5	O
Precision	O
Table	O
4	O
summarizes	O
the	O
mean	O
,	O
standard	O
deviation	O
,	O
and	O
relative	O
standard	O
deviation	O
for	O
sitosterol	B
,	O
campesterol	B
,	O
desmosterol	B
,	O
lathosterol	B
,	O
and	O
lanosterol	B
concentrations	O
assayed	O
in	O
the	O
control	O
material	O
over	O
the	O
course	O
of	O
23	O
assay	O
batches	O
by	O
two	O
analysts	O
over	O
a	O
2-month	O
period	O
.	O

Because	O
sitostanol	B
,	O
campestanol	B
,	O
and	O
stigmasterol	B
are	O
not	O
components	O
of	O
the	O
Accutrol	O
™	O
serum	O
and	O
could	O
not	O
be	O
readily	O
and	O
homogeneously	O
fortified	O
,	O
no	O
control	O
data	O
were	O
generated	O
for	O
these	O
compounds	O
.	O

For	O
sitosterol	B
,	O
campesterol	B
,	O
lathosterol	B
,	O
and	O
desmosterol	B
,	O
the	O
standard	O
deviation	O
over	O
all	O
analyses	O
ranged	O
from	O
0.02	O
μg	O
/	O
ml	O
(	O
lanosterol	B
)	O
to	O
0.12	O
μg	O
/	O
ml	O
(	O
campesterol	B
)	O
.	O

The	O
within	O
-	O
assay	O
standard	O
deviations	O
were	O
similar	O
to	O
the	O
overall	O
RSD	O
for	O
all	O
components	O
.	O

The	O
relative	O
standard	O
deviation	O
for	O
lanosterol	O
was	O
much	O
higher	O
than	O
for	O
other	O
components	O
(	O
14	O
%	O
)	O
,	O
due	O
to	O
the	O
low	O
concentration	O
in	O
the	O
control	O
sample	O
(	O
0.1	O
μg	O
/	O
ml	O
)	O
.	O

Quality	O
control	O
charts	O
for	O
lathosterol	B
and	O
campesterol	B
in	O
the	O
control	O
serum	O
are	O
shown	O
in	O
Fig.	O
2	O
.	O

3.6	O
Method	O
performance	O
in	O
assay	O
of	O
smaller	O
volumes	O
of	O
serum	O
Table	O
5	O
shows	O
data	O
from	O
the	O
analyses	O
of	O
fortified	O
(	O
sitostanol	B
,	O
campestanol	B
,	O
lanosterol	B
,	O
stigmasterol	B
)	O
and	O
unfortified	O
0.25-	O
,	O
0.5-	O
,	O
and	O
0.9-ml	O
aliquots	O
of	O
the	O
control	O
serum	O
composite	O
.	O

All	O
compounds	O
were	O
fortified	O
at	O
concentrations	O
near	O
the	O
MLOQ	O
determined	O
for	O
analysis	O
of	O
0.9	O
ml	O
(	O
Table	O
2	O
)	O
.	O

Results	O
for	O
sitosterol	B
,	O
campesterol	B
,	O
lathosterol	B
,	O
desmosterol	B
,	O
sitostanol	B
,	O
and	O
campestanol	B
were	O
similar	O
for	O
all	O
volumes	O
analyzed	O
,	O
suggesting	O
that	O
for	O
these	O
components	O
,	O
sensitivity	O
and	O
precision	O
are	O
not	O
compromised	O
by	O
assaying	O
as	O
low	O
as	O
0.25	O
ml	O
.	O

In	O
the	O
fortified	O
serum	O
,	O
however	O
,	O
lanosterol	B
and	O
stigmasterol	B
that	O
were	O
measured	O
in	O
the	O
0.9-ml	O
aliquots	O
were	O
undetectable	O
in	O
the	O
smaller	O
aliquots	O
.	O

Table	O
6	O
summarizes	O
results	O
from	O
analyses	O
of	O
0.25-	O
and	O
0.9-ml	O
aliquots	O
of	O
seven	O
sitostanol	B
-	O
containing	O
serum	O
samples	O
(	O
from	O
the	O
feeding	O
trial	O
)	O
,	O
which	O
were	O
analyzed	O
to	O
compare	O
the	O
sensitivity	O
of	O
the	O
method	O
in	O
measuring	O
naturally	O
occurring	O
(	O
i.e.	O
unfortified	O
)	O
sitostanol	B
in	O
smaller	O
and	O
larger	O
sample	O
volumes	O
.	O

The	O
0.25-ml	O
assay	O
failed	O
to	O
detect	O
sitostanol	B
in	O
four	O
of	O
the	O
seven	O
samples	O
and	O
lanosterol	B
in	O
all	O
seven	O
samples	O
.	O

For	O
sitosterol	B
(	O
mean	O
2.24	O
μg	O
/	O
ml	O
)	O
,	O
stigmasterol	B
(	O
not	O
detected	O
)	O
and	O
campestanol	B
(	O
not	O
detected	O
)	O
results	O
were	O
similar	O
in	O
both	O
analyses	O
.	O

For	O
campesterol	B
,	O
lathosterol	B
,	O
and	O
desmosterol	B
,	O
results	O
were	O
somewhat	O
lower	O
(	O
3–25	O
%	O
on	O
average	O
)	O
for	O
the	O
0.25-ml	O
aliquots	O
.	O

These	O
results	O
suggest	O
that	O
in	O
a	O
range	O
of	O
actual	O
serum	O
samples	O
the	O
sensitivity	O
of	O
the	O
analysis	O
may	O
be	O
reduced	O
when	O
0.25-ml	O
vs.	O
0.9-ml	O
is	O
assayed	O
,	O
especially	O
for	O
lanosterol	B
and	O
sitostanol	B
.	O

4	O
Conclusions	O
A	O
sensitive	O
and	O
precise	O
method	O
was	O
developed	O
for	O
quantitation	O
of	O
phytosterols	B
,	O
stanols	B
,	O
and	O
selected	O
cholesterol	B
metabolites	I
in	O
human	O
serum	O
.	O

Analytes	O
were	O
detected	O
at	O
levels	O
of	O
120	O
ng	O
/	O
ml	O
to	O
6	O
μg	O
/	O
ml	O
with	O
standard	O
deviations	O
of	O
0.02	O
to	O
0.12	O
μg	O
/	O
ml	O
.	O

We	O
have	O
communicated	O
the	O
method	O
in	O
detail	O
to	O
facilitate	O
its	O
reproduction	O
in	O
other	O
laboratories	O
.	O

Acknowledgements	O
This	O
work	O
was	O
supported	O
by	O
Fleischmann	O
's	O
Tablespread	O
Company	O
.	O

We	O
gratefully	O
acknowledge	O
technical	O
advice	O
from	O
Dr.	O
Robert	O
Whiton	O
in	O
evaluating	O
method	O
performance	O
parameters	O
and	O
chromatography	O
issues	O
.	O

The	O
majority	O
of	O
adult	O
cancers	O
are	O
carcinomas	O
of	O
epithelial	O
origin	O
with	O
lung	O
,	O
colon	O
,	O
and	O
uterus	O
as	O
the	O
primary	O
sites	O
,	O
which	O
reflects	O
a	O
selective	O
vulnerability	O
of	O
these	O
tissues	O
to	O
carcinogenic	O
insult	O
as	O
a	O
result	O
of	O
frequent	O
exposure	O
to	O
external	O
environment	O
.	O

Indeed	O
,	O
it	O
is	O
estimated	O
that	O
up	O
to	O
80	O
to	O
90	O
%	O
of	O
all	O
cancers	O
are	O
attributable	O
to	O
environmental	O
risk	O
factors	O
,	O
including	O
chemicals	B
,	O
radiations	O
,	O
and	O
viruses	O
.	O

The	O
notion	O
that	O
a	O
majority	O
of	O
human	O
cancers	O
have	O
an	O
environmental	O
origin	O
implies	O
an	O
optimistic	O
outlook	O
in	O
terms	O
of	O
cancer	O
prevention	O
since	O
most	O
cancer	O
-	O
causing	O
substances	O
are	O
introduced	O
into	O
the	O
environment	O
by	O
human	O
activities	O
and	O
are	O
hence	O
,	O
controllable	O
or	O
removable	O
.	O

The	O
elimination	O
of	O
environmental	O
carcinogens	B
or	O
at	O
least	O
avoiding	O
exposure	O
to	O
them	O
offers	O
the	O
opportunity	O
to	O
prevent	O
most	O
cancers	O
,	O
which	O
is	O
a	O
basis	O
of	O
primary	O
prevention	O
.	O

Recent	O
advances	O
in	O
our	O
understanding	O
at	O
the	O
cellular	O
and	O
molecular	O
levels	O
of	O
carcinogenesis	O
have	O
led	O
to	O
the	O
development	O
of	O
a	O
new	O
promising	O
strategy	O
for	O
cancer	O
prevention	O
,	O
that	O
is	O
,	O
chemoprevention	O
[	O
1–3	O
]	O
.	O

Chemoprevention	O
is	O
defined	O
as	O
the	O
use	O
of	O
specific	O
chemical	B
substances	I
(	O
natural	O
or	O
synthetic	O
)	O
or	O
their	O
mixtures	O
to	O
suppress	O
,	O
retard	O
,	O
or	O
reverse	O
the	O
process	O
of	O
carcinogenesis	O
.	O

It	O
is	O
one	O
of	O
the	O
novel	O
approaches	O
of	O
controlling	O
cancer	O
alternative	O
to	O
therapy	O
that	O
has	O
some	O
limitations	O
and	O
drawbacks	O
in	O
the	O
treatment	O
of	O
patients	O
.	O

The	O
term	O
chemoprevention	O
was	O
initially	O
coined	O
by	O
Michael	O
Sporn	O
who	O
utilized	O
retinoids	B
to	O
halt	O
experimental	O
carcinogenesis	O
[	O
4	O
]	O
.	O

Since	O
we	O
are	O
all	O
exposed	O
in	O
greater	O
or	O
lesser	O
degree	O
to	O
environmental	O
carcinogens	B
from	O
diverse	O
sources	O
,	O
it	O
is	O
important	O
to	O
find	O
a	O
way	O
to	O
neutralize	O
these	O
carcinogens	B
or	O
protect	O
against	O
deleterious	O
effects	O
they	O
exert	O
.	O

In	O
this	O
respect	O
,	O
chemoprevention	O
offers	O
a	O
realistic	O
promise	O
of	O
reducing	O
the	O
incidence	O
of	O
human	O
cancer	O
.	O

The	O
primary	O
goal	O
of	O
chemoprevention	O
research	O
is	O
to	O
identify	O
effective	O
agents	O
and/or	O
develop	O
efficient	O
strategies	O
for	O
clinical	O
trials	O
and	O
ultimately	O
,	O
application	O
to	O
human	O
populations	O
.	O

In	O
order	O
to	O
better	O
practice	O
the	O
chemoprevention	O
,	O
one	O
must	O
precisely	O
understand	O
the	O
nature	O
and	O
mechanisms	O
of	O
carcinogenesis	O
.	O

2	O
Molecular	O
basis	O
of	O
chemoprevention	O
Carcinogenesis	O
is	O
characterized	O
by	O
a	O
complex	O
process	O
that	O
involves	O
a	O
series	O
of	O
individual	O
steps	O
.	O

From	O
the	O
stand	O
point	O
of	O
the	O
experimental	O
carcinogenesis	O
in	O
rodents	O
,	O
tumor	O
development	O
has	O
been	O
generally	O
considered	O
to	O
consist	O
of	O
three	O
distinct	O
steps	O
—	O
initiation	O
,	O
promotion	O
,	O
and	O
progression	O
as	O
depicted	O
in	O
Fig.	O
1	O
.	O

Initiation	O
is	O
an	O
irreversible	O
event	O
that	O
begins	O
when	O
the	O
cells	O
in	O
normal	O
tissues	O
are	O
exposed	O
to	O
a	O
carcinogen	B
and	O
their	O
genomic	O
DNA	O
undergoes	O
damage	O
that	O
remains	O
unrepaired	O
or	O
misrepaired	O
.	O

In	O
case	O
of	O
chemically	O
-	O
induced	O
carcinogenesis	O
,	O
initiation	O
involves	O
uptake	O
of	O
a	O
given	O
carcinogenic	B
agent	I
with	O
subsequent	O
distribution	O
and	O
transport	O
to	O
organs	O
and	O
tissues	O
where	O
metabolism	O
occurs	O
,	O
the	O
interaction	O
of	O
a	O
reactive	O
metabolite	B
with	O
cellular	O
DNA	O
with	O
subsequent	O
structural	O
alterations	O
in	O
the	O
DNA	O
molecule	O
,	O
and	O
final	O
fixation	O
of	O
the	O
genotoxic	O
damage	O
to	O
cause	O
mutation	O
.	O

The	O
resulting	O
somatic	O
mutation	O
in	O
a	O
damaged	O
cell	O
can	O
be	O
reproduced	O
during	O
mitosis	O
,	O
which	O
gives	O
rise	O
to	O
a	O
clone	O
of	O
mutated	O
cells	O
.	O

Promotion	O
is	O
expansion	O
of	O
the	O
damaged	O
cells	O
to	O
form	O
an	O
actively	O
proliferating	O
multi	O
-	O
cellular	O
premalignant	O
tumor	O
cell	O
population	O
.	O

Progression	O
is	O
the	O
irreversible	O
process	O
which	O
produces	O
a	O
new	O
clone	O
of	O
tumor	O
cells	O
with	O
increased	O
proliferative	O
capacity	O
,	O
invasiveness	O
,	O
and	O
metastatic	O
potential	O
.	O

Conventional	O
classification	O
of	O
chemopreventive	B
agents	I
,	O
first	O
proposed	O
by	O
Wattenberg	O
[	O
5	O
]	O
,	O
is	O
based	O
on	O
the	O
underlying	O
mechanisms	O
by	O
which	O
they	O
exert	O
protective	O
effects	O
in	O
a	O
specific	O
stage	O
of	O
multi	O
-	O
step	O
carcinogenesis	O
.	O

According	O
to	O
this	O
system	O
,	O
chemopreventers	B
are	O
subdivided	O
into	O
two	O
major	O
categories	O
,	O
i.e.	O
,	O
blocking	B
agents	I
and	O
suppressing	B
agents	I
(	O
Fig.	O
2	O
)	O
.	O

Blocking	B
agents	I
are	O
typically	O
those	O
compounds	O
that	O
can	O
inhibit	O
initiation	O
either	O
by	O
inhibiting	O
the	O
formation	O
of	O
carcinogens	B
from	O
precursor	B
molecules	I
or	O
reactive	O
metabolites	B
from	O
the	O
parent	O
carcinogens	B
,	O
or	O
by	O
preventing	O
the	O
ultimate	O
electrophilic	O
and	O
carcinogenic	B
species	I
from	O
interacting	O
with	O
critical	O
cellular	O
target	O
molecules	O
,	O
such	O
as	O
DNA	O
,	O
RNA	O
,	O
and	O
proteins	O
.	O

Suppressing	B
agents	I
are	O
considered	O
to	O
inhibit	O
malignant	O
expression	O
of	O
initiated	O
cells	O
,	O
in	O
either	O
the	O
promotion	O
or	O
the	O
progression	O
stage	O
.	O

Certain	O
chemopreventive	B
agents	I
(	O
e.g.	O
,	O
curcumin	B
and	O
resveratrol	B
)	O
have	O
more	O
than	O
one	O
defined	O
mechanism	O
of	O
action	O
,	O
and	O
hence	O
,	O
possess	O
both	O
blocking	O
and	O
suppressive	O
properties	O
[	O
6	O
]	O
.	O

A	O
vast	O
variety	O
of	O
chemical	B
compounds	I
have	O
been	O
identified	O
to	O
elicit	O
pronounced	O
chemopreventive	O
effects	O
and	O
many	O
of	O
them	O
are	O
of	O
plant	O
origin	O
that	O
are	O
present	O
naturally	O
in	O
our	O
daily	O
foods	O
or	O
have	O
been	O
used	O
for	O
traditional	O
herbal	O
medication	O
[	O
7–9	O
]	O
.	O

Some	O
spices	O
or	O
herbs	O
contain	O
bioactive	O
phenolic	B
substances	I
with	O
potent	O
antimutagenic	O
and	O
anticarcinogenic	O
properties	O
.	O

3	O
Some	O
novel	O
strategies	O
applicable	O
for	O
identifying	O
chemopreventive	O
phytochemicals	B
Numerous	O
phenolic	B
substances	I
present	O
in	O
fruits	O
and	O
vegetables	O
or	O
in	O
medicinal	O
plants	O
have	O
been	O
found	O
to	O
retain	O
potential	O
cancer	O
chemopreventive	O
activities	O
.	O

For	O
most	O
of	O
known	O
chemopreventive	O
phytochemicals	B
,	O
however	O
,	O
their	O
protective	O
effects	O
are	O
based	O
solely	O
on	O
the	O
results	O
from	O
animal	O
tests	O
.	O

Unfortunately	O
,	O
however	O
,	O
the	O
predictive	O
capability	O
of	O
the	O
majority	O
of	O
animal	O
model	O
studies	O
in	O
the	O
evaluation	O
of	O
cancer	O
chemopreventive	O
agents	O
for	O
use	O
in	O
humans	O
is	O
uncertain	O
and	O
often	O
limited	O
.	O

The	O
efficacy	O
,	O
as	O
well	O
as	O
the	O
safety	O
of	O
selected	O
phytochemicals	B
with	O
promising	O
chemopreventive	O
potential	O
should	O
be	O
validated	O
through	O
properly	O
-	O
designed	O
and	O
well	O
-	O
controlled	O
clinical	O
intervention	O
trials	O
.	O

The	O
use	O
of	O
a	O
reliable	O
biomarker	O
as	O
an	O
early	O
surrogate	O
endpoint	O
is	O
pivotal	O
in	O
conducting	O
prospective	O
chemopreventive	O
trials	O
.	O

There	O
have	O
been	O
extensive	O
studies	O
conducted	O
during	O
the	O
past	O
two	O
decades	O
to	O
search	O
for	O
potential	O
naturally	O
occurring	O
cancer	O
chemopreventive	B
agents	I
and	O
some	O
of	O
them	O
hold	O
promise	O
for	O
human	O
use	O
.	O

Antioxidant	B
vitamins	I
or	O
their	O
synthetic	O
derivatives	O
have	O
been	O
frequently	O
investigated	O
for	O
their	O
possible	O
chemopreventive	O
efficacy	O
among	O
normal	O
or	O
high	O
risk	O
(	O
e.g.	O
,	O
smokers	O
,	O
asbestos	O
workers	O
,	O
etc	O
.	O
)	O
populations	O
.	O

While	O
there	O
has	O
been	O
substantial	O
body	O
of	O
evidence	O
from	O
both	O
experimental	O
and	O
epidemiologic	O
studies	O
supporting	O
the	O
beneficial	O
effects	O
of	O
fruits	O
and	O
vegetables	O
,	O
which	O
are	O
good	O
sources	O
of	O
antioxidant	B
vitamins	I
,	O
the	O
chemopreventive	O
effects	O
of	O
dietary	O
supplementation	O
of	O
individual	O
vitamins	B
or	O
their	O
mixtures	O
remain	O
controversial	O
at	O
the	O
present	O
time	O
.	O

We	O
have	O
lessons	O
from	O
the	O
large	O
-	O
scale	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
Alpha	B
-	I
Tocopherol	I
,	O
Beta	B
-	I
Carotene	I
(	O
ATBC	O
)	O
Cancer	O
Prevention	O
Study	O
that	O
was	O
conducted	O
with	O
about	O
30,000	O
Finnish	O
male	O
smokers	O
under	O
the	O
joint	O
sponsorship	O
of	O
the	O
US	O
National	O
Cancer	O
Institute	O
and	O
the	O
National	O
Public	O
Health	O
Institute	O
in	O
Finland	O
.	O

In	O
this	O
particular	O
trial	O
,	O
a	O
daily	O
intake	O
of	O
20	O
mg	O
of	O
beta	B
-	I
carotene	I
was	O
not	O
protective	O
against	O
lung	O
cancer	O
.	O

On	O
the	O
contrary	O
,	O
the	O
cumulative	O
incidence	O
and	O
the	O
mortality	O
of	O
lung	O
cancer	O
increased	O
,	O
compared	O
with	O
those	O
observed	O
among	O
people	O
in	O
the	O
placebo	O
control	O
group	O
[	O
10	O
]	O
.	O

The	O
results	O
of	O
this	O
study	O
were	O
contradictory	O
to	O
the	O
beneficial	O
effects	O
of	O
beta	B
-	I
carotene	I
demonstrated	O
in	O
the	O
previous	O
intervention	O
trials	O
,	O
as	O
well	O
as	O
laboratory	O
studies	O
.	O

Nonetheless	O
,	O
the	O
unexpected	O
negative	O
finding	O
in	O
the	O
ATBC	O
study	O
is	O
not	O
surprising	O
and	O
may	O
not	O
be	O
fortuitous	O
.	O

Since	O
the	O
subjects	O
who	O
participated	O
in	O
this	O
study	O
were	O
relatively	O
old	O
(	O
50	O
to	O
69	O
years	O
of	O
age	O
)	O
with	O
a	O
smoking	O
habit	O
,	O
it	O
seems	O
likely	O
that	O
the	O
majority	O
of	O
them	O
already	O
had	O
mutated	O
genes	O
(	O
e.g.	O
,	O
p53	O
tumor	O
-	O
suppressor	O
or	O
ras	O
-oncogenes	O
)	O
or	O
premalignant	O
lesions	O
before	O
starting	O
beta	B
-	I
carotene	I
supplementation	O
,	O
as	O
a	O
result	O
of	O
cigarette	O
smoking	O
.	O

If	O
it	O
is	O
the	O
case	O
,	O
one	O
may	O
not	O
expect	O
the	O
beneficial	O
effects	O
of	O
beta	B
-	I
carotene	I
that	O
is	O
most	O
active	O
in	O
early	O
stages	O
of	O
carcinogenesis	O
.	O

Excess	O
amount	O
of	O
beta	B
-	I
carotene	I
might	O
have	O
met	O
the	O
substantial	O
growth	O
requirement	O
of	O
rapidly	O
proliferating	O
cancerous	O
cells	O
,	O
thereby	O
stimulating	O
their	O
growth	O
rather	O
than	O
suppressing	O
it	O
.	O

In	O
support	O
of	O
this	O
assumption	O
,	O
post	O
-	O
initiation	O
application	O
of	O
this	O
compound	O
stimulated	O
the	O
mammary	O
carcinogenesis	O
in	O
rodents	O
[	O
11	O
]	O
.	O

Similarly	O
,	O
dietary	O
supplementation	O
of	O
beta	B
-	I
carotene	I
enhanced	O
the	O
development	O
of	O
papillomas	O
in	O
mice	O
[	O
12	O
]	O
,	O
probably	O
via	O
stimulation	O
of	O
the	O
promotion	O
of	O
carcinogenesis	O
.	O

Besides	O
antioxidative	B
vitamins	I
,	O
fruits	O
and	O
vegetables	O
contain	O
countless	O
phytochemicals	B
of	O
less	O
nutritional	O
value	O
but	O
with	O
substantial	O
chemopreventive	O
potential	O
.	O

However	O
,	O
few	O
population	O
-	O
based	O
chemoprevention	O
trials	O
with	O
non	O
-	O
vitamin	O
phytochemicals	B
have	O
been	O
conducted	O
.	O

Rational	O
and	O
successful	O
implementation	O
of	O
chemopreventive	O
strategies	O
rely	O
on	O
the	O
precise	O
understanding	O
of	O
underlying	O
molecular	O
mechanisms	O
.	O

Alterations	O
of	O
carcinogen	B
metabolism	O
and	O
subsequent	O
DNA	O
adduction	O
may	O
represent	O
an	O
important	O
mechanism	O
by	O
which	O
a	O
given	O
phytochemical	B
modulates	O
chemically	O
-	O
induced	O
carcinogenesis	O
in	O
the	O
initiation	O
stage	O
.	O

Modulation	O
of	O
carcinogen	B
metabolism	O
is	O
often	O
considered	O
by	O
many	O
investigators	O
as	O
a	O
mechanistic	O
basis	O
for	O
protective	O
effects	O
of	O
many	O
types	O
of	O
chemopreventive	O
phytochemicals	B
.	O

However	O
,	O
carcinogen	B
-	O
metabolizing	O
enzymes	O
in	O
general	O
have	O
dual	O
roles	O
and	O
preventive	O
modulation	O
of	O
metabolism	O
,	O
i.e.	O
,	O
suppression	O
of	O
activation	O
or	O
acceleration	O
of	O
detoxification	O
of	O
one	O
carcinogen	B
,	O
may	O
alter	O
the	O
fate	O
of	O
other	O
xenobiotics	B
and	O
endogenous	B
compounds	I
[	O
13–15	O
]	O
,	O
which	O
may	O
limit	O
its	O
utilization	O
as	O
a	O
criterion	O
in	O
identifying	O
or	O
defining	O
new	O
chemopreventive	O
agents	O
.	O

Furthermore	O
,	O
inhibition	O
of	O
initiation	O
is	O
unlikely	O
to	O
be	O
a	O
practical	O
approach	O
to	O
chemoprevention	O
,	O
since	O
there	O
are	O
diverse	O
types	O
of	O
initiators	O
present	O
in	O
our	O
environment	O
and	O
it	O
is	O
not	O
feasible	O
to	O
find	O
a	O
chemopreventive	O
agent	O
that	O
can	O
nullify	O
the	O
initiating	O
activities	O
of	O
all	O
the	O
carcinogens	B
to	O
which	O
we	O
are	O
exposed	O
.	O

Therefore	O
,	O
recent	O
chemopreventive	O
strategies	O
are	O
more	O
concerned	O
with	O
identifying	O
substances	O
with	O
antiproliferative	O
or	O
antiprogressive	O
activities	O
that	O
can	O
suppress	O
the	O
transformation	O
of	O
initiated	O
or	O
precancerous	O
cells	O
to	O
malignant	O
ones	O
,	O
rather	O
than	O
search	O
for	O
anti	O
-	O
initiators	O
.	O

Chemopreventive	B
agents	I
that	O
fall	O
into	O
this	O
category	O
include	O
modulators	O
of	O
signal	O
transduction	O
,	O
inhibitors	O
of	O
oncogene	O
activation	O
,	O
inhibitors	O
of	O
polyamine	B
metabolism	O
,	O
enhancers	O
of	O
gap	O
junctional	O
intercellular	O
communication	O
,	O
inhibitors	O
of	O
angiogenesis	O
,	O
etc	O
.	O

[	O
16	O
]	O
.	O

Recently	O
,	O
considerable	O
attention	O
has	O
been	O
focused	O
on	O
dietary	O
and/or	O
pharmacological	O
manipulation	O
of	O
apoptosis	O
as	O
a	O
novel	O
and	O
promising	O
strategy	O
for	O
cancer	O
chemoprevention	O
,	O
as	O
well	O
as	O
therapy	O
[	O
17–19	O
]	O
.	O

The	O
maintenance	O
of	O
homeostasis	O
in	O
normal	O
mammalian	O
tissues	O
reflects	O
a	O
critical	O
balance	O
between	O
cell	O
proliferation	O
and	O
cell	O
death	O
via	O
apoptosis	O
.	O

In	O
contrast	O
,	O
apoptosis	O
may	O
be	O
inhibited	O
or	O
perturbed	O
in	O
tumors	O
in	O
which	O
the	O
rate	O
of	O
cell	O
proliferation	O
exceeds	O
that	O
of	O
cell	O
loss	O
.	O

If	O
misregulation	O
of	O
apoptosis	O
results	O
in	O
a	O
failure	O
of	O
tissue	O
size	O
regulation	O
,	O
which	O
eventually	O
leads	O
to	O
the	O
malignant	O
transformation	O
,	O
apoptotic	O
cell	O
death	O
could	O
be	O
induced	O
to	O
augment	O
interventions	O
designed	O
to	O
suppress	O
or	O
reverse	O
the	O
development	O
of	O
cancer	O
.	O

Indeed	O
,	O
various	O
chemopreventive	B
and	O
chemotherapeutic	B
agents	I
are	O
now	O
known	O
to	O
exert	O
their	O
antiproliferative	O
or	O
cytostatic	O
effects	O
by	O
inducing	O
apoptosis	O
in	O
(	O
pre	O
)	O
malignant	O
cells	O
[	O
17–23	O
]	O
.	O

Selected	O
chemopreventive	B
vitamins	I
or	O
phytochemicals	B
have	O
the	O
propensity	O
to	O
suppress	O
or	O
retard	O
the	O
growth	O
of	O
cancer	O
cells	O
in	O
this	O
way	O
[	O
[	O
17	O
,	O
24	O
,	O
25	O
]	O
,	O
and	O
more	O
examples	O
in	O
this	O
review	O
]	O
.	O

Suppression	O
of	O
prostaglandin	B
synthesis	O
through	O
selective	O
inhibition	O
of	O
cyclooxygenase-2	O
(	O
COX-2	O
)	O
is	O
another	O
promising	O
strategy	O
applicable	O
to	O
identification	O
and	O
development	O
of	O
chemopreventive	B
drugs	I
.	O

Prostaglandins	B
are	O
known	O
to	O
play	O
crucial	O
roles	O
in	O
pathogenesis	O
of	O
malignancy	O
,	O
particularly	O
in	O
colon	O
carcinogenesis	O
and	O
certain	O
nonsteroidal	B
anti	I
-	I
inflammatory	I
drugs	I
(	O
NSAIDs	B
)	O
,	O
such	O
as	O
aspirin	B
,	O
piroxicam	B
,	O
and	O
sulindac	B
,	O
have	O
protective	O
effects	O
on	O
experimental	O
carcinogenesis	O
[	O
26	O
,	O
27	O
]	O
.	O

Furthermore	O
,	O
epidemiologic	O
data	O
indicate	O
a	O
reduced	O
risk	O
of	O
colorectal	O
cancer	O
among	O
individuals	O
who	O
intake	O
aspirin	B
or	O
other	O
NSAIDs	B
on	O
a	O
regular	O
basis	O
[	O
28	O
]	O
.	O

Moreover	O
,	O
in	O
patients	O
with	O
familial	O
adenomatous	O
polyposis	O
,	O
the	O
NSAID	B
sulindac	B
caused	O
marked	O
regression	O
of	O
polyps	O
and	O
prevented	O
their	O
recurrence	O
[	O
29	O
]	O
.	O

Selected	O
NSAIDs	B
have	O
been	O
reported	O
to	O
suppress	O
growth	O
and	O
proliferation	O
of	O
cancer	O
cells	O
by	O
inducing	O
apoptosis	O
[	O
30–32	O
]	O
.	O

Some	O
phenolic	B
substances	I
derived	O
from	O
Zingiberaceae	O
(	O
ginger	O
family	O
)	O
plants	O
have	O
potent	O
anti	O
-	O
inflammatory	O
activity	O
and	O
induce	O
apoptosis	O
in	O
human	O
cancer	O
cell	O
lines	O
[	O
[	O
33–36	O
]	O
;	O
vide	O
infra	O
]	O
.	O

4	O
Selected	O
chemopreventive	O
dietary	O
and/or	O
medicinal	O
phenolic	B
substances	I
4.1	O
Capsaicin	B
Capsaicin	B
(	O
trans	B
-8-methyl	I
-	I
N	I
-vanillyl-6-nonenamide	I
;	O
structure	O
shown	O
in	O
Fig.	O
3	O
)	O
is	O
a	O
principal	O
pungent	O
ingredient	O
present	O
in	O
hot	O
red	O
and	O
chili	O
peppers	O
that	O
belong	O
to	O
the	O
plant	O
genus	O
Capsicum	O
(	O
Solanaceae	O
)	O
.	O

The	O
compound	O
has	O
been	O
tested	O
by	O
many	O
investigators	O
for	O
its	O
effects	O
on	O
experimental	O
carcinogenesis	O
and	O
mutagenesis	O
[	O
for	O
review	O
,	O
see	O
Refs	O
.	O

[	O
37	O
,	O
38	O
]	O
and	O
references	O
therein	O
]	O
.	O

Data	O
in	O
the	O
literature	O
indicate	O
that	O
capsaicin	B
has	O
a	O
dual	O
role	O
in	O
carcinogenic	O
and	O
mutagenic	O
processes	O
and	O
its	O
effects	O
in	O
some	O
degree	O
relies	O
on	O
the	O
doses	O
,	O
routes	O
of	O
administration	O
,	O
and	O
types	O
of	O
tissues	O
affected	O
.	O

Although	O
the	O
previous	O
studies	O
were	O
mainly	O
focused	O
on	O
evaluation	O
of	O
carcinogenic	O
or	O
co	O
-	O
carcinogenic	O
potential	O
of	O
capsaicin	B
in	O
hot	O
peppers	O
in	O
consideration	O
of	O
its	O
irritancy	O
,	O
the	O
compound	O
has	O
recently	O
been	O
reported	O
to	O
retain	O
protective	O
properties	O
against	O
experimental	O
carcinogenesis	O
and	O
mutagenesis	O
[	O
37	O
,	O
38	O
]	O
.	O

In	O
several	O
instances	O
,	O
it	O
has	O
been	O
demonstrated	O
that	O
capsaicin	B
modulates	O
microsomal	O
cytochrome	O
P	O
450-dependent	O
monooxygenase	O
activities	O
,	O
thereby	O
affecting	O
metabolism	O
of	O
carcinogens	B
and	O
other	O
xenobiotics	B
[	O
39–45	O
]	O
.	O

Capsaicin	B
was	O
found	O
to	O
interact	O
with	O
rat	O
hepatic	O
mixed	O
-	O
function	O
oxidases	O
as	O
revealed	O
by	O
prolongation	O
of	O
pentobarbital	B
or	O
hexobarbital	B
sleeping	O
time	O
[	O
39–41	O
]	O
and	O
inhibition	O
of	O
ethylmorphine	O
demethylase	O
activity	O
,	O
as	O
well	O
as	O
production	O
of	O
a	O
type	O
I	O
spectral	O
change	O
[	O
39	O
]	O
.	O

The	O
compound	O
also	O
suppresses	O
the	O
activity	O
of	O
rat	O
epidermal	O
aryl	O
hydrocarbon	O
hydroxylase	O
[	O
42	O
]	O
that	O
is	O
responsible	O
for	O
the	O
biotransformation	O
of	O
benzo	B
[	I
a	I
]	I
pyrene	I
and	O
other	O
polyaromatic	B
hydrocarbons	I
.	O

Metabolism	O
and	O
subsequent	O
covalent	O
DNA	O
binding	O
of	O
benzo	B
[	I
a	I
]	I
pyrene	I
in	O
human	O
and	O
murine	O
keratinocytes	O
were	O
attenuated	O
by	O
capsaicin	B
[	O
42	O
]	O
.	O

Taken	O
together	O
,	O
the	O
above	O
findings	O
suggest	O
that	O
capsaicin	B
can	O
influence	O
the	O
initiating	O
activities	O
of	O
certain	O
chemical	O
carcinogens	B
through	O
modulation	O
of	O
their	O
metabolic	O
activation	O
and/or	O
detoxification	O
.	O

Benzo	B
[	I
a	I
]	I
pyrene	I
-	O
induced	O
pulmonary	O
tumor	O
in	O
mice	O
was	O
inhibited	O
by	O
capsaicin	B
treatment	O
[	O
43	O
]	O
.	O

Capsaicin	B
displayed	O
inhibitory	O
effects	O
on	O
metabolism	O
,	O
mutagenicity	O
and/or	O
covalent	O
DNA	O
binding	O
of	O
aflatoxin	B
B1	I
[	O
44	O
]	O
and	O
the	O
tobacco	O
-	O
specific	O
nitrosamine	B
,	O
4-	B
(	I
methylnitrosamino	I
)	I
-1-	I
(	I
3-pyridyl	I
)	I
-1-butanone	I
(	O
NNK	B
)	O
[	O
45–47	O
]	O
.	O

Capsaicin	B
and	O
its	O
saturated	O
analog	O
dihydrocapsaicin	B
(	O
Fig.	O
3	O
for	O
chemical	O
structures	O
)	O
have	O
been	O
shown	O
to	O
inhibit	O
cytochrome	O
P	O
450	O
2E1	O
[	O
48	O
,	O
49	O
]	O
,	O
an	O
isoform	O
that	O
catalyzes	O
metabolic	O
activation	O
,	O
as	O
well	O
as	O
detoxification	O
of	O
many	O
low	O
molecular	O
weight	O
carcinogens	B
.	O

In	O
agreement	O
with	O
these	O
findings	O
,	O
both	O
compounds	O
inhibited	O
the	O
mutagenicity	O
and/or	O
tumorigenicity	O
of	O
vinyl	B
carbamate	I
and	O
dimethylnitrosamine	B
[	O
49	O
]	O
,	O
which	O
are	O
preferentially	O
activated	O
by	O
cytochrome	O
P	O
450	O
2E1	O
.	O

In	O
another	O
study	O
,	O
capsaicin	B
ameliorated	O
the	O
peroxidative	O
changes	O
in	O
rat	O
hepatic	O
and	O
pulmonary	O
tissues	O
induced	O
by	O
chloroform	B
,	O
carbon	B
tetrachloride	I
,	O
or	O
dichloromethane	B
[	O
50	O
]	O
.	O

Cytochrome	O
P	O
450	O
2E1	O
again	O
plays	O
a	O
role	O
in	O
activation	O
of	O
these	O
halogenated	B
hydrocarbons	I
.	O

Capsaicin	B
pretreatment	O
also	O
protects	O
against	O
the	O
free	B
radical	I
-	O
induced	O
pulmonary	O
damage	O
in	O
rats	O
exposed	O
to	O
such	O
gaseous	O
chemical	O
irritants	O
as	O
sulfur	B
dioxide	I
and	O
nitrogen	B
dioxide	I
[	O
51	O
]	O
.	O

It	O
has	O
been	O
reported	O
that	O
intraperitoneal	O
administration	O
of	O
capsaicin	B
attenuates	O
cyclophosphamide	B
-	O
induced	O
chromosomal	O
aberrations	O
and	O
DNA	O
breaks	O
in	O
mice	O
[	O
52	O
]	O
.	O

Although	O
topical	O
application	O
of	O
capsaicin	B
can	O
initially	O
induce	O
ear	O
edema	O
in	O
mice	O
[	O
53	O
]	O
,	O
subsequent	O
reapplications	O
of	O
the	O
compound	O
suppressed	O
the	O
inflammatory	O
response	O
[	O
54	O
]	O
.	O

Carrageenan	B
-	O
induced	O
inflammation	O
in	O
rats	O
was	O
also	O
ameliorated	O
by	O
capsaicin	B
treatment	O
[	O
55	O
]	O
.	O

Furthermore	O
,	O
capsaicin	B
was	O
found	O
to	O
inhibit	O
platelet	O
aggregation	O
[	O
56–58	O
]	O
.	O

Another	O
study	O
,	O
however	O
,	O
has	O
demonstrated	O
the	O
stimulation	O
of	O
prostaglandin	B
biosynthesis	O
by	O
capsaicin	B
[	O
59	O
]	O
.	O

The	O
observed	O
antiplatelet	O
or	O
anti	O
-	O
inflammatory	O
effects	O
of	O
capsaicin	B
appears	O
to	O
be	O
associated	O
with	O
its	O
interference	O
with	O
phospholipase	O
A2	O
[	O
60	O
]	O
,	O
a	O
key	O
enzyme	O
mediating	O
the	O
inflammatory	O
process	O
.	O

Since	O
tumor	O
promotion	O
is	O
related	O
to	O
inflammation	O
which	O
can	O
stimulate	O
the	O
proliferation	O
of	O
initiated	O
cells	O
,	O
it	O
would	O
be	O
of	O
interest	O
to	O
determine	O
if	O
capsaicin	B
could	O
act	O
as	O
an	O
anti	O
-	O
tumor	O
promoting	O
agent	O
.	O

Capsaicin	B
was	O
found	O
to	O
antagonize	O
the	O
mouse	O
ear	O
edema	O
induced	O
by	O
croton	B
oil	I
[	O
61	O
]	O
,	O
lending	O
further	O
support	O
to	O
the	O
above	O
idea	O
.	O

Our	O
preliminary	O
study	O
indicates	O
that	O
topical	O
application	O
of	O
capsaicin	B
along	O
with	O
phorbol	B
ester	I
onto	O
shaven	O
backs	O
of	O
ICR	O
mice	O
,	O
after	O
initiation	O
with	O
7,12-dimethylbenz	B
[	I
a	I
]	I
anthracene	I
,	O
transiently	O
increased	O
the	O
skin	O
tumor	O
formation	O
,	O
but	O
the	O
overall	O
papillomagenesis	O
did	O
not	O
increase	O
[	O
62	O
]	O
.	O

Apparently	O
,	O
some	O
of	O
the	O
tumors	O
became	O
slightly	O
regressed	O
after	O
12	O
weeks	O
of	O
post	O
-	O
initiation	O
.	O

Epithelial	O
thickening	O
and	O
appearance	O
of	O
atypical	O
cells	O
caused	O
by	O
combination	O
of	O
7,12-dimethylbenz	B
[	I
a	I
]	I
anthracene	I
and	O
phorbol	B
ester	I
were	O
also	O
reduced	O
by	O
capsaicin	B
treatment	O
.	O

According	O
to	O
a	O
recent	O
study	O
by	O
Morre	O
et	O
al.	O
[	O
63	O
]	O
,	O
capsaicin	B
preferentially	O
repressed	O
the	O
growth	O
of	O
some	O
transformed	O
cells	O
of	O
human	O
origin	O
,	O
including	O
HeLa	O
,	O
ovarian	O
carcinoma	O
,	O
mammary	O
adenocarcinoma	O
,	O
and	O
promyelocytic	O
leukemia	O
(	O
HL-60	O
)	O
cells	O
in	O
culture	O
.	O

The	O
inhibition	O
of	O
cell	O
survival	O
was	O
associated	O
with	O
induction	O
of	O
apoptosis	O
as	O
revealed	O
by	O
characteristic	O
morphological	O
changes	O
and	O
appearance	O
of	O
fragmented	O
nuclear	O
DNA	O
[	O
63	O
]	O
.	O

The	O
capsaicin	B
-	O
induced	O
growth	O
inhibition	O
and	O
apoptosis	O
in	O
the	O
aforementioned	O
cells	O
were	O
correlated	O
with	O
inhibition	O
of	O
plasma	O
membrane	O
NADH	O
oxidase	O
activity	O
[	O
63	O
]	O
.	O

The	O
same	O
investigators	O
have	O
subsequently	O
observed	O
the	O
similar	O
findings	O
with	O
human	O
and	O
mouse	O
melanoma	O
cell	O
lines	O
in	O
terms	O
of	O
growth	O
inhibition	O
,	O
apoptosis	O
induction	O
,	O
and	O
inhibition	O
of	O
plasma	O
membrane	O
NADH	O
oxidase	O
[	O
64	O
]	O
.	O

Interestingly	O
,	O
direct	O
injection	O
of	O
capsaicin	B
into	O
the	O
B16	O
mouse	O
melanoma	O
transplanted	O
in	O
C57BL	O
/	O
6	O
mice	O
significantly	O
blunted	O
the	O
growth	O
of	O
tumors	O
[	O
64	O
]	O
.	O

Capsaicin	B
-	O
induced	O
apoptosis	O
has	O
been	O
suggested	O
to	O
be	O
regulated	O
by	O
Bcl-2	O
and	O
the	O
protein	O
phosphatase	O
,	O
calcineurin	O
[	O
65	O
]	O
.	O

In	O
another	O
study	O
,	O
capsaicin	B
-	O
induced	O
apoptotic	O
death	O
of	O
cultured	O
human	O
gastric	O
cancer	O
cells	O
,	O
which	O
appeared	O
to	O
be	O
mediated	O
via	O
overexpression	O
of	O
the	O
p53	O
tumor	O
suppressor	O
gene	O
and/or	O
c	O
-	O
myc	O
proto	O
-	O
oncogene	O
[	O
66	O
]	O
.	O

One	O
of	O
the	O
important	O
cellular	O
mediators	O
of	O
cellular	O
processes	O
in	O
response	O
to	O
diversified	O
extracellular	O
stimuli	O
including	O
oxidants	O
,	O
UV	O
,	O
mitogens	O
,	O
cytokines	O
,	O
viruses	O
,	O
tumor	O
necrosis	O
factor	O
-	O
α	O
(	O
TNF	O
-	O
α	O
)	O
,	O
interleukin-1	O
(	O
IL-1	O
)	O
,	O
etc	O
.	O
is	O
a	O
nuclear	O
transcription	O
factor	O
NF	O
-	O
κB	O
[	O
67–71	O
]	O
.	O

Upon	O
activation	O
by	O
external	O
signals	O
,	O
NF	O
-	O
κB	O
is	O
migrated	O
to	O
the	O
nucleus	O
where	O
it	O
binds	O
to	O
a	O
specific	O
segment	O
of	O
DNA	O
,	O
thereby	O
triggering	O
expression	O
of	O
a	O
variety	O
of	O
rapid	O
-	O
response	O
genes	O
involved	O
in	O
some	O
important	O
physiological	O
reactions	O
,	O
such	O
as	O
inflammation	O
,	O
cell	O
adhesion	O
,	O
viral	O
replication	O
,	O
immune	O
response	O
,	O
and	O
proliferation	O
.	O

Reactive	B
oxygen	I
species	I
(	O
ROS	B
)	O
has	O
been	O
suggested	O
as	O
a	O
second	O
messenger	O
in	O
a	O
signal	O
transduction	O
pathway	O
for	O
activation	O
of	O
NF	O
-	O
κB	O
[	O
72	O
,	O
73	O
]	O
.	O

According	O
to	O
the	O
study	O
of	O
Singh	O
et	O
al.	O
[	O
74	O
]	O
,	O
capsaicin	B
abrogates	O
the	O
activation	O
of	O
NF	O
-	O
κB	O
by	O
TPA	B
,	O
as	O
well	O
as	O
by	O
TNF	O
-	O
α	O
,	O
which	O
may	O
provide	O
a	O
mechanistic	O
basis	O
for	O
the	O
possible	O
anti	O
-	O
tumor	O
promoting	O
activity	O
of	O
capsaicin	B
.	O

Another	O
eukaryotic	O
transcription	O
factor	O
that	O
is	O
responsive	O
to	O
ROS	B
and	O
is	O
hence	O
,	O
regulated	O
by	O
cellular	O
redox	O
status	O
is	O
activator	O
protein	O
1	O
(	O
AP-1	O
)	O
[	O
67	O
]	O
.	O

The	O
regulation	O
of	O
AP-1	O
in	O
response	O
to	O
external	O
stimuli	O
is	O
considered	O
to	O
be	O
mediated	O
by	O
members	O
of	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPK	O
)	O
family	O
,	O
among	O
which	O
c	O
-	O
jun	O
-N	O
-	O
terminal	O
kinase	O
(	O
JNK	O
;	O
also	O
known	O
as	O
stress	O
-	O
activated	O
protein	O
kinase	O
abbreviated	O
as	O
SAPK	O
)	O
and	O
extracellular	O
signal	O
-	O
regulated	O
kinase	O
(	O
ERK	O
)	O
isoforms	O
are	O
best	O
characterized	O
.	O

There	O
is	O
some	O
evidence	O
that	O
JNK	O
and	O
ERK	O
exert	O
opposite	O
effects	O
on	O
apoptosis	O
[	O
75	O
]	O
.	O

Capsaicin	B
induced	O
apoptosis	O
in	O
cultured	O
Jurkat	O
cells	O
through	O
generation	O
of	O
ROS	B
[	O
76	O
]	O
.	O

When	O
treated	O
to	O
these	O
cells	O
at	O
a	O
concentration	O
of	O
300	O
μM	O
,	O
capsaicin	B
rapidly	O
activated	O
JNK	O
:	O
the	O
activity	O
was	O
detectable	O
as	O
early	O
as	O
5	O
min	O
after	O
the	O
treatment	O
,	O
while	O
ERK	O
activity	O
was	O
not	O
affected	O
under	O
the	O
same	O
experimental	O
conditions	O
[	O
76	O
]	O
.	O

Despite	O
the	O
activation	O
of	O
JNK	O
by	O
capsaicin	B
,	O
there	O
was	O
no	O
induction	O
of	O
AP-1	O
activity	O
.	O

On	O
the	O
contrary	O
,	O
capsaicin	B
blocked	O
the	O
TPA	B
-	O
induced	O
AP-1	O
activation	O
[	O
76	O
]	O
.	O

The	O
latter	O
finding	O
,	O
together	O
with	O
the	O
previous	O
observation	O
by	O
Singh	O
et	O
al.	O
[	O
74	O
]	O
on	O
suppression	O
of	O
TPA	B
-	O
induced	O
NF	O
-	O
κB	O
activation	O
by	O
capsaicin	B
,	O
may	O
provide	O
important	O
molecular	O
basis	O
for	O
anti	O
-	O
tumor	O
promoting	O
potential	O
of	O
this	O
vanilloid	B
.	O

4.2	O
Gingerol	B
and	O
paradol	B
Ginger	O
(	O
Zingiber	O
officinale	O
Roscoe	O
,	O
Zingiberaceae	O
)	O
is	O
among	O
the	O
most	O
frequently	O
and	O
heavily	O
consumed	O
dietary	O
condiments	O
throughout	O
the	O
world	O
.	O

Besides	O
its	O
extensive	O
use	O
as	O
a	O
spice	O
,	O
the	O
rhizome	O
of	O
ginger	O
has	O
also	O
been	O
used	O
in	O
traditional	O
oriental	O
herbal	O
medicine	O
for	O
the	O
management	O
of	O
such	O
symptoms	O
as	O
common	O
cold	O
,	O
digestive	O
disorders	O
,	O
rheumatism	O
,	O
neurologia	O
,	O
colic	O
and	O
motion	O
-	O
sickness	O
.	O

The	O
oleoresin	B
from	O
rhizomes	O
of	O
ginger	O
contains	O
[	B
6	I
]	I
-gingerol	I
(	O
1-	B
[	I
4′-hydroxy-3′-methoxyphenyl	I
]	I
-5-hydroxy-3-decanone	I
)	O
and	O
its	O
homologs	B
as	O
pungent	O
ingredients	O
that	O
have	O
been	O
found	O
to	O
possess	O
many	O
interesting	O
pharmacological	O
and	O
physiological	O
activities	O
,	O
such	O
as	O
anti	O
-	O
inflammatory	O
,	O
analgesic	O
,	O
antipyretic	O
,	O
antihepatotoxic	O
,	O
and	O
cardiotonic	O
effects	O
[	O
77	O
,	O
78	O
]	O
.	O

The	O
chemical	O
structure	O
of	O
[	B
6	I
]	I
-gingerol	I
that	O
is	O
known	O
as	O
a	O
major	O
pungent	O
and	O
pharmacologically	O
active	O
principle	O
of	O
ginger	O
is	O
shown	O
in	O
Fig.	O
3	O
.	O

Gingerol	B
has	O
been	O
found	O
to	O
possess	O
substantial	O
antioxidant	O
activity	O
as	O
determined	O
by	O
inhibition	O
of	O
phospholipid	B
peroxidation	O
induced	O
by	O
the	O
FeCl3	B
–ascorbate	O
system	O
[	O
79	O
]	O
.	O

The	O
antioxidative	O
properties	O
of	O
gingerol	B
and	O
other	O
constituents	O
of	O
ginger	O
have	O
been	O
confirmed	O
in	O
various	O
in	O
vitro	O
and	O
in	O
vivo	O
test	O
systems	O
[	O
80	O
,	O
81	O
]	O
.	O

Gingerol	B
also	O
exerts	O
an	O
inhibitory	O
effect	O
on	O
xanthine	O
oxidase	O
[	O
82	O
]	O
responsible	O
for	O
generation	O
of	O
superoxide	B
anion	I
.	O

Guh	O
et	O
al.	O
[	O
83	O
]	O
reported	O
concentration	O
-	O
dependent	O
inhibition	O
by	O
gingerol	B
of	O
arachidonic	B
acid	I
-	O
induced	O
platelet	O
aggregation	O
and	O
formation	O
of	O
thromboxane	B
B2	I
and	O
prostaglandin	B
D2	I
.	O

The	O
compound	O
also	O
completely	O
abolished	O
phosphoinositide	B
breakdown	O
induced	O
by	O
arachidonic	B
acid	I
.	O

Gingerol	B
,	O
shogaol	B
and	O
other	O
structurally	O
-	O
related	O
substances	O
in	O
ginger	O
inhibit	O
prostaglandin	O
and	O
leukotriene	O
biosynthesis	O
through	O
suppression	O
of	O
5-lipoxygenase	O
or	O
prostaglandin	O
synthetase	O
[	O
84–87	O
]	O
.	O

Since	O
tumor	O
promotion	O
is	O
closely	O
associated	O
with	O
inflammation	O
and	O
oxidative	O
stress	O
,	O
it	O
is	O
likely	O
that	O
a	O
compound	O
with	O
a	O
strong	O
inhibitory	O
effect	O
on	O
the	O
arachidonic	B
acid	I
metabolism	O
would	O
have	O
anti	O
-	O
tumor	O
promoting	O
potential	O
.	O

In	O
line	O
with	O
this	O
notion	O
,	O
our	O
recent	O
study	O
has	O
demonstrated	O
that	O
gingerol	B
protects	O
TPA	B
-	O
induced	O
ear	O
edema	O
,	O
epidermal	O
ornithine	O
decarboxylase	O
(	O
ODC	O
)	O
activity	O
,	O
and	O
skin	O
tumor	O
promotion	O
in	O
female	O
ICR	O
mice	O
[	O
88	O
]	O
.	O

Furthermore	O
,	O
topical	O
application	O
of	O
the	O
ginger	O
extract	O
30	O
min	O
prior	O
to	O
TPA	B
led	O
to	O
dramatic	O
protection	O
against	O
DMBA	B
-	O
initiated	O
skin	O
carcinogenesis	O
in	O
SENCAR	O
mice	O
[	O
89	O
]	O
and	O
suppressed	O
TPA	B
-	O
caused	O
induction	O
of	O
epidermal	O
ODC	O
and	O
its	O
mRNA	O
expression	O
,	O
as	O
well	O
as	O
cyclooxygenase	O
(	O
COX	O
)	O
and	O
lipoxygenase	O
activities	O
[	O
89	O
]	O
.	O

Azoxymethane	B
-	O
induced	O
intestinal	O
carcinogenesis	O
in	O
rats	O
was	O
significantly	O
suppressed	O
by	O
dietary	O
administration	O
of	O
gingerol	B
[	O
90	O
]	O
.	O

Gingerol	B
was	O
reported	O
as	O
one	O
of	O
the	O
most	O
active	O
constituents	O
contained	O
in	O
traditional	O
oriental	O
herbal	O
medication	O
,	O
`	O
Keishi	O
-	O
ka	O
-	O
kei	O
-	O
to	O
'	O
that	O
exhibited	O
substantial	O
inhibitory	O
effects	O
on	O
pulmonary	O
metastasis	O
in	O
mice	O
transplanted	O
with	O
B16F10	O
melanoma	O
cells	O
[	O
91	O
]	O
.	O

[	B
6	I
]	I
-Paradol	I
(	O
1-	B
[	I
4′-hydroxy-3′-methoxyphenyl	I
]	I
-3-decanone	I
;	O
Fig.	O
3	O
)	O
,	O
a	O
pungent	O
compound	O
isolated	O
from	O
the	O
seeds	O
of	O
Grains	O
of	O
Paradise	O
(	O
Aframomum	O
melegueta	O
Roscoe	O
,	O
Zingiberaceae	O
)	O
,	O
as	O
well	O
as	O
from	O
the	O
rhizome	O
of	O
ginger	O
,	O
also	O
attenuated	O
promotion	O
of	O
skin	O
carcinogenesis	O
and	O
TPA	B
-	O
induced	O
ear	O
edema	O
in	O
female	O
ICR	O
mice	O
[	O
92	O
]	O
.	O

Both	O
[	B
6	I
]	I
-gingerol	I
and	O
[	B
6	I
]	I
-paradol	I
induce	O
apoptosis	O
in	O
HL-60	O
cells	O
[	O
36	O
]	O
.	O

4.3	O
Curcumin	B
Curcumin	B
(	O
diferuloylmethane	B
;	O
Fig.	O
4	O
)	O
is	O
a	O
yellow	O
odorless	O
pigment	O
isolated	O
from	O
the	O
rhizome	O
of	O
turmeric	O
(	O
Curcuma	O
longa	O
L.	O
,	O
Zingiberaceae	O
)	O
.	O

Curcumin	B
possesses	O
anti	O
-	O
inflammatory	O
and	O
antioxidant	O
properties	O
[	O
93–102	O
]	O
.	O

This	O
yellow	O
-	O
coloured	O
compound	O
inhibits	O
mutagenicity	O
of	O
certain	O
chemical	O
carcinogens	B
[	O
103–105	O
]	O
and	O
also	O
hampers	O
their	O
covalent	O
DNA	O
binding	O
in	O
vivo	O
[	O
106	O
]	O
,	O
as	O
well	O
as	O
,	O
in	O
vitro	O
[	O
107	O
,	O
108	O
]	O
.	O

Curcumin	B
also	O
protected	O
against	O
chemically	O
-	O
induced	O
liver	O
damage	O
in	O
experimental	O
animals	O
[	O
109	O
,	O
110	O
]	O
.	O

Its	O
anticarcinogenic	O
activity	O
was	O
evaluated	O
in	O
many	O
animal	O
tumor	O
models	O
[	O
reviewed	O
in	O
Refs	O
.	O

[	O
111–113	O
]	O
]	O
.	O

One	O
of	O
the	O
most	O
prominent	O
effects	O
curcumin	B
exerts	O
on	O
experimental	O
carcinogenesis	O
is	O
its	O
capability	O
to	O
inhibit	O
tumor	O
promotion	O
[	O
113–116	O
]	O
.	O

Thus	O
,	O
curcumin	B
was	O
reported	O
to	O
alleviate	O
TPA	B
-	O
induced	O
skin	O
tumor	O
promotion	O
and	O
epidermal	O
ODC	O
mRNA	O
expression	O
[	O
115	O
]	O
,	O
as	O
well	O
as	O
,	O
ODC	O
activity	O
[	O
114	O
]	O
.	O

Topical	O
application	O
of	O
curcumin	B
onto	O
dorsal	O
skins	O
of	O
mice	O
significantly	O
inhibited	O
epidermal	O
COX	O
and	O
lipoxygenase	O
[	O
117	O
]	O
.	O

Colonic	O
mucosal	O
COX	O
and	O
lipoxygenase	O
activities	O
were	O
suppressed	O
by	O
dietary	O
curcumin	B
,	O
which	O
appears	O
to	O
account	O
for	O
its	O
chemopreventive	O
effects	O
on	O
colon	O
carcinogenesis	O
.	O

Likewise	O
,	O
F344	O
rats	O
fed	O
curcumin	B
in	O
the	O
diet	O
exhibited	O
reduced	O
catalytic	O
activities	O
of	O
phospholipase	O
A2	O
and	O
phospholipase	O
Cγ1	O
that	O
are	O
involved	O
in	O
arachidonic	B
acid	I
release	O
from	O
cellular	O
phospholipid	B
[	O
118	O
]	O
.	O

It	O
also	O
attenuates	O
oxidative	O
DNA	O
damage	O
in	O
mouse	O
epidermis	O
[	O
116	O
]	O
and	O
in	O
cultured	O
mouse	O
fibroblast	O
cells	O
[	O
119	O
]	O
.	O

The	O
compound	O
was	O
found	O
to	O
suppress	O
the	O
generation	O
of	O
ROS	B
including	O
superoxide	B
and	O
hydrogen	B
peroxide	I
in	O
peritoneal	O
macrophages	O
[	O
120	O
,	O
121	O
]	O
.	O

Its	O
antioxidant	O
effects	O
were	O
confirmed	O
in	O
various	O
systems	O
.	O

It	O
is	O
of	O
interest	O
to	O
note	O
that	O
tetrahydrocurcumin	B
,	O
that	O
is	O
one	O
of	O
the	O
plausible	O
metabolites	B
of	O
curcumin	B
,	O
exhibits	O
stronger	O
antioxidative	O
[	O
102	O
]	O
and	O
anti	O
-	O
inflammatory	O
[	O
97	O
]	O
activities	O
than	O
does	O
curcumin	B
.	O

Curcumin	B
inhibits	O
lipopolysaccharide-	B
and	O
interferon	O
-	O
γ	O
-	O
induced	O
production	O
of	O
nitric	B
oxide	I
in	O
macrophages	O
[	O
122	O
]	O
or	O
nitrite	B
in	O
mouse	O
peritoneal	O
cells	O
[	O
123	O
]	O
,	O
possibly	O
by	O
suppression	O
of	O
nitric	O
oxide	O
synthase	O
.	O

More	O
recently	O
,	O
Chan	O
et	O
al.	O
[	O
124	O
]	O
have	O
reported	O
the	O
inhibition	O
by	O
curcumin	B
of	O
inducible	O
nitric	O
oxide	O
synthase	O
gene	O
expression	O
in	O
isolated	O
BALB	O
/	O
c	O
mouse	O
peritoneal	O
macrophages	O
and	O
also	O
in	O
the	O
livers	O
of	O
lipopolysaccharide	B
-	O
injected	O
mice	O
.	O

TPA	B
-	O
induced	O
protein	O
kinase	O
C	O
activation	O
and	O
c	O
-	O
jun	O
expression	O
were	O
markedly	O
suppressed	O
by	O
curcumin	B
in	O
mouse	O
fibroblast	O
cells	O
[	O
125	O
]	O
.	O

When	O
applied	O
topically	O
on	O
the	O
dorsal	O
side	O
of	O
mouse	O
skin	O
,	O
curcumin	B
significantly	O
inhibited	O
expression	O
of	O
such	O
proto	O
-	O
oncogenes	O
as	O
c	O
-	O
fos	O
,	O
c	O
-	O
jun	O
,	O
and	O
c	O
-	O
myc	O
[	O
126	O
]	O
.	O

Curcumin	B
also	O
exhibited	O
inhibitory	O
effects	O
on	O
epidermal	O
growth	O
factor	O
(	O
EGF	O
)	O
receptor	O
kinase	O
activity	O
in	O
cultured	O
human	O
epidermoid	O
carcinoma	O
A431	O
[	O
127	O
]	O
or	O
NIH3T3	O
cells	O
[	O
128	O
]	O
.	O

Other	O
types	O
of	O
protein	O
kinases	O
were	O
also	O
found	O
to	O
be	O
inhibited	O
by	O
this	O
compound	O
in	O
a	O
non	O
-	O
competitive	O
manner	O
[	O
129	O
]	O
.	O

The	O
pleiotropic	O
effects	O
of	O
curcumin	B
appear	O
to	O
be	O
mediated	O
at	O
least	O
in	O
part	O
through	O
inhibition	O
of	O
transcription	O
factors	O
[	O
130	O
]	O
.	O

According	O
to	O
a	O
recent	O
study	O
by	O
Huang	O
et	O
al.	O
[	O
131	O
]	O
,	O
curcumin	B
suppresses	O
TPA	B
-	O
responsive	O
element	O
-	O
binding	O
activity	O
of	O
c	O
-	O
Jun	O
/	O
AP-1	O
,	O
which	O
may	O
account	O
for	O
the	O
anti	O
-	O
tumor	O
promoting	O
effect	O
of	O
this	O
chemopreventive	B
agent	I
.	I

More	O
recently	O
,	O
curcumin	B
has	O
been	O
reported	O
to	O
inhibit	O
TNF	O
-	O
α	O
-	O
induced	O
binding	O
of	O
AP-1	O
to	O
DNA	O
in	O
bovine	O
aortic	O
endothelial	O
cells	O
[	O
132	O
]	O
.	O

Besides	O
interfering	O
with	O
AP-1	O
activation	O
,	O
curcumin	B
has	O
been	O
shown	O
to	O
suppress	O
the	O
activation	O
of	O
NF	O
-	O
κB	O
[	O
133	O
]	O
that	O
is	O
another	O
important	O
eukaryotic	O
transcription	O
factor	O
.	O

The	O
suppression	O
of	O
protein	O
kinases	O
,	O
ODC	O
,	O
and	O
nuclear	O
transcription	O
factors	O
by	O
curcumin	B
suggests	O
that	O
this	O
phenolic	B
compound	I
can	O
act	O
as	O
a	O
cytostatic	O
agent	O
by	O
interfering	O
with	O
certain	O
signal	O
transduction	O
pathways	O
that	O
are	O
critical	O
for	O
cell	O
growth	O
and	O
proliferation	O
.	O

Indeed	O
,	O
curcumin	B
possesses	O
antiproliferative	O
activity	O
[	O
134	O
,	O
135	O
]	O
and	O
the	O
capability	O
of	O
inducing	O
programmed	O
death	O
or	O
apoptosis	O
in	O
cancer	O
cells	O
[	O
34	O
,	O
35	O
]	O
.	O

Furthermore	O
,	O
curcumin	B
exhibited	O
synergistic	O
effects	O
on	O
induction	O
of	O
differentiation	O
in	O
HL-60	O
cells	O
when	O
combined	O
with	O
all	B
-	I
trans	I
retinoic	I
acid	I
or	O
1α,25-dihydroxyvitamin	B
D3	I
[	O
113	O
]	O
.	O

It	O
also	O
has	O
a	O
strong	O
inhibitory	O
effect	O
on	O
farnesyl	O
protein	O
transferase	O
[	O
136	O
]	O
that	O
plays	O
a	O
crucial	O
role	O
in	O
functional	O
activation	O
of	O
Ras	O
protein	O
.	O

A	O
recent	O
study	O
by	O
Ciolino	O
et	O
al.	O
[	O
137	O
]	O
has	O
revealed	O
inhibition	O
of	O
cytochrome	O
P	O
450	O
1A1	O
activity	O
and	O
formation	O
of	O
carcinogen	B
-	O
DNA	O
adducts	O
in	O
7,12-dimethylbenz	B
[	I
a	I
]	I
anthracene	I
-	O
treated	O
human	O
mammary	O
epithelial	O
carcinoma	O
(	O
MCF-7	O
)	O
cells	O
by	O
competitively	O
binding	O
to	O
the	O
aryl	O
hydrocarbon	O
receptor	O
.	O

Besides	O
preventing	O
malignant	O
transformation	O
,	O
the	O
compound	O
has	O
antimetastatic	O
potential	O
as	O
demonstrated	O
by	O
suppression	O
of	O
matrix	O
metalloproteinase-9	O
in	O
the	O
human	O
hepatocellular	O
carcinoma	O
cell	O
line	O
[	O
138	O
]	O
.	O

4.4	O
Diarylheptanoids	B
structurally	O
-	O
related	O
to	O
curcuminoids	B
Diarylheptanoids	B
structurally	O
-	O
related	O
to	O
curcumin	B
are	O
present	O
in	O
certain	O
plants	O
of	O
ginger	O
family	O
(	O
Zingiberaceae	O
)	O
and	O
have	O
been	O
reported	O
to	O
possess	O
a	O
strong	O
anti	O
-	O
inflammatory	O
activity	O
.	O

For	O
instance	O
,	O
yakuchinone	B
A	I
(	O
1-	B
[	I
4′-hydroxy-3′-methoxyphenyl	I
]	I
-7-phenyl-3-heptanone	I
)	O
and	O
yakuchinone	B
B	I
(	O
1-	B
[	I
4′-hydroxy-3′-methoxyphenyl	I
]	I
-7-phenylhept-1-en-3-one	I
)	O
which	O
are	O
present	O
in	O
Alpinia	O
oxyphylla	O
Miquel	O
have	O
been	O
reported	O
to	O
be	O
strong	O
inhibitors	O
of	O
prostaglandin	B
biosynthesis	O
in	O
vitro	O
[	O
85	O
,	O
87	O
]	O
.	O

Like	O
curcumin	B
,	O
these	O
substances	O
have	O
a	O
diarylheptanoid	B
moiety	O
with	O
a	O
carbonyl	B
functional	O
group	B
(	O
refer	O
to	O
the	O
structures	O
in	O
Fig.	O
4	O
)	O
and	O
are	O
hence	O
,	O
anticipated	O
to	O
exhibit	O
potential	O
cancer	O
chemopreventive	O
activities	O
.	O

Results	O
of	O
our	O
recent	O
study	O
showed	O
that	O
topical	O
application	O
of	O
the	O
methanol	B
extract	O
of	O
A.	O
oxyphylla	O
to	O
the	O
dorsal	O
epidermis	O
of	O
mice	O
during	O
the	O
process	O
of	O
tumor	O
promotion	O
markedly	O
suppressed	O
the	O
papilloma	O
formation	O
[	O
33	O
]	O
.	O

The	O
extract	O
also	O
attenuated	O
the	O
mouse	O
ear	O
edema	O
induced	O
by	O
the	O
tumor	O
promoter	O
,	O
TPA	B
[	O
33	O
]	O
.	O

Subsequent	O
studies	O
have	O
revealed	O
that	O
yakuchinone	B
A	I
and	O
yakuchinone	B
B	I
,	O
major	O
pungent	O
ingredients	O
derived	O
from	O
A.	O
oxyphylla	O
,	O
can	O
act	O
as	O
anti	O
-	O
tumor	O
promoters	O
as	O
determined	O
by	O
their	O
ability	O
to	O
suppress	O
phorbol	B
ester	I
-	O
induced	O
ODC	O
activation	O
and	O
papilloma	O
formation	O
in	O
mouse	O
skin	O
[	O
139	O
,	O
140	O
]	O
.	O

TPA	B
-	O
stimulated	O
superoxide	B
generation	O
and	O
TNF	O
-	O
α	O
production	O
in	O
HL-60	O
cells	O
and	O
on	O
DNA	O
binding	O
of	O
AP-1	O
in	O
NIH3T3	O
cells	O
were	O
also	O
suppressed	O
by	O
the	O
above	O
compounds	O
[	O
139	O
,	O
140	O
]	O
.	O

Furthermore	O
,	O
both	O
yakuchinone	B
A	I
and	O
yakuchinone	B
B	I
induce	O
apoptotic	O
death	O
in	O
HL-60	O
cells	O
,	O
which	O
accounts	O
for	O
their	O
antiproliferative	O
activity	O
[	O
139	O
]	O
.	O

Phenolic	B
diarylheptanoids	I
from	O
Alpinia	O
officinarum	O
Hance	O
(	O
Zingiberaceae	O
)	O
,	O
structurally	O
analogous	O
to	O
yakuchinone	B
A	I
and	O
yakuchinone	B
B	I
,	O
and	O
non	B
-	I
phenolic	I
diarylheptanoids	I
present	O
in	O
a	O
Thai	O
medicinal	O
plant	O
,	O
Curcuma	O
xanthorrhiza	O
(	O
Zingiberaceae	O
)	O
,	O
also	O
exhibit	O
strong	O
anti	O
-	O
inflammatory	O
effects	O
[	O
86	O
,	O
141	O
]	O
.	O

Certain	O
diarylheptanoids	B
isolated	O
from	O
the	O
seeds	O
of	O
Alpinia	O
blepharocalyx	O
K.	O
Schum	O
mitigated	O
collagen-	B
,	O
arachidonic	B
acid-	I
and	O
adenosine	B
diphosphate	I
-	O
induced	O
platelet	O
aggregation	O
of	O
human	O
blood	O
[	O
142	O
]	O
and	O
suppressed	O
nitric	B
oxide	I
production	O
in	O
lipopolysaccharide	B
-	O
activated	O
murine	O
macrophages	O
in	O
vitro	O
[	O
143	O
]	O
.	O

Bioassay	O
-	O
directed	O
fractionation	O
of	O
the	O
ethanol	B
extract	O
of	O
Curcuma	O
zedoaria	O
(	O
Zingiberaceae	O
)	O
afforded	O
demethoxy-	B
and	O
bisdemethoxycurcumin	B
,	O
as	O
well	O
as	O
curcumin	B
,	O
which	O
were	O
cytotoxic	O
against	O
human	O
ovarian	O
cancer	O
cells	O
[	O
144	O
]	O
.	O

The	O
same	O
diarylheptanoids	B
were	O
also	O
found	O
in	O
C.	O
longa	O
L.	O
and	O
displayed	O
topoisomerase	O
I	O
and	O
II	O
inhibitory	O
activity	O
[	O
145	O
]	O
.	O

It	O
will	O
be	O
worthwhile	O
investigating	O
chemopreventive	O
effects	O
of	O
these	O
novel	O
diarylheptanoids	B
,	O
particularly	O
with	O
regard	O
to	O
their	O
anti	O
-	O
tumor	O
promotional	O
potential	O
.	O

4.5	O
Resveratrol	B
Resveratrol	B
(	O
3,5,4′-trihydroxy	B
-	I
trans	I
-stilbene	I
;	O
Fig.	O
5	O
)	O
,	O
a	O
phytoalexin	B
present	O
in	O
grapes	O
and	O
other	O
plants	O
,	O
has	O
potent	O
antioxidant	O
and	O
anti	O
-	O
inflammatory	O
activities	O
which	O
have	O
been	O
considered	O
to	O
be	O
responsible	O
for	O
beneficial	O
effects	O
of	O
red	O
wine	O
consumption	O
on	O
coronary	O
heart	O
disease	O
[	O
146–148	O
]	O
.	O

This	O
triphenolic	B
stilbene	I
has	O
been	O
suggested	O
as	O
a	O
potential	O
cancer	O
chemopreventive	O
agent	O
based	O
on	O
its	O
striking	O
inhibitory	O
effects	O
on	O
diverse	O
cellular	O
events	O
associated	O
with	O
tumor	O
initiation	O
,	O
promotion	O
,	O
and	O
progression	O
[	O
149	O
]	O
.	O

Resveratrol	B
has	O
been	O
reported	O
to	O
be	O
a	O
potent	O
inhibitor	O
of	O
hepatic	O
cytochrome	O
P	O
450-linked	O
alkoxyresorufin	O
O	O
-dealkylase	O
activities	O
[	O
150	O
]	O
responsible	O
for	O
oxidative	O
metabolism	O
of	O
many	O
carcinogenic	O
polynuclear	O
aromatic	O
carcinogens	B
.	O

It	O
also	O
induces	O
phase-2	O
detoxification	O
enzymes	O
,	O
such	O
as	O
NAD	O
(	O
P	O
)	O
H	O
:	O
quinone	O
oxidoreductase	O
[	O
149	O
]	O
.	O

Recent	O
work	O
by	O
Uenobe	O
et	O
al.	O
[	O
151	O
]	O
demonstrated	O
an	O
antimutagenic	O
activity	O
of	O
resveratrol	B
against	O
the	O
foodborne	O
heterocyclic	B
amine	I
,	O
3-amino-1,4-dimethyl-5H	B
-	I
pyrido	I
[	I
4,3-b	I
]	I
indole	I
(	O
Trp	B
-	I
P-1	I
)	O
in	O
bacteria	O
.	O

Resveratrol	B
attenuated	O
PC12	O
cell	O
death	O
induced	O
by	O
ter	B
-butyl	I
hydroperoxide	I
in	O
the	O
presence	O
of	O
ferric	B
ion	I
[	O
152	O
]	O
or	O
by	O
ethanol	B
[	O
153	O
]	O
,	O
and	O
was	O
found	O
to	O
be	O
protective	O
against	O
cytotoxicity	O
and	O
NF	O
-	O
κB	O
activation	O
induced	O
by	O
oxidized	O
lipoproteins	O
in	O
PC12	O
cells	O
[	O
154	O
,	O
155	O
]	O
.	O

In	O
addition	O
,	O
the	O
compound	O
inhibited	O
growth	O
of	O
human	O
breast	O
epithelial	O
cells	O
in	O
culture	O
[	O
156	O
]	O
.	O

Proliferation	O
of	O
K-562	O
human	O
erythroleukemia	O
cells	O
and	O
P-815	O
murine	O
mastocytoma	O
cells	O
was	O
also	O
suppressed	O
by	O
resveratrol	B
treatment	O
,	O
which	O
might	O
be	O
associated	O
with	O
inhibition	O
of	O
ribonucleotide	O
reductase	O
[	O
157	O
]	O
.	O

One	O
of	O
the	O
plausible	O
mechanisms	O
that	O
could	O
account	O
for	O
the	O
chemopreventive	O
activity	O
of	O
resveratrol	B
is	O
suppression	O
of	O
prostaglandin	B
biosynthesis	O
catalyzed	O
COX	O
.	O

Prostaglandins	B
are	O
known	O
to	O
play	O
pivotal	O
roles	O
in	O
pathogenesis	O
of	O
malignancy	O
,	O
particularly	O
in	O
colon	O
and	O
mammary	O
carcinogenesis	O
and	O
suppression	O
of	O
prostaglandin	B
biosynthesis	O
through	O
selective	O
inhibition	O
of	O
COX	O
is	O
hence	O
,	O
now	O
regarded	O
as	O
an	O
important	O
cancer	O
chemopreventive	O
strategy	O
.	O

Resveratrol	B
was	O
shown	O
to	O
inhibit	O
COX-1	O
activity	O
in	O
microsomes	O
derived	O
from	O
sheep	O
seminal	O
vesicles	O
[	O
149	O
]	O
.	O

More	O
recently	O
,	O
Subbaramaiah	O
et	O
al.	O
[	O
158	O
]	O
have	O
reported	O
that	O
resveratrol	B
inhibits	O
the	O
catalytic	O
activity	O
of	O
the	O
inducible	O
isozyme	O
COX-2	O
in	O
cultured	O
human	O
mammary	O
epithelial	O
cells	O
with	O
and	O
without	O
TPA	B
treatment	O
.	O

Likewise	O
,	O
human	O
recombinant	O
COX-2	O
expressed	O
in	O
baculovirus	O
was	O
inhibited	O
by	O
resveratrol	B
[	O
158	O
]	O
.	O

Besides	O
inhibiting	O
the	O
catalytic	O
activity	O
of	O
COX-2	O
,	O
the	O
compound	O
also	O
blocked	O
TPA	B
-	O
mediated	O
induction	O
of	O
cox	O
-2	O
mRNA	O
in	O
cultured	O
human	O
mammary	O
epithelial	O
cells	O
through	O
repression	O
of	O
AP-1-dependent	O
transactivation	O
[	O
158	O
]	O
.	O

More	O
recently	O
,	O
topical	O
application	O
of	O
resveratrol	B
onto	O
dorsal	O
skin	O
of	O
CD-1	O
mice	O
led	O
to	O
profound	O
attenuation	O
of	O
oxidative	O
stress	O
and	O
expression	O
of	O
epidermal	O
TGF	O
-	O
β1	O
and	O
c	O
-	O
fos	O
induced	O
by	O
TPA	B
,	O
but	O
the	O
induction	O
of	O
cox	O
-1	O
,	O
cox	O
-2	O
,	O
c	O
-	O
myc	O
,	O
c	O
-	O
jun	O
and	O
TNF	O
-	O
α	O
mRNAs	O
was	O
not	O
affected	O
[	O
159	O
]	O
.	O

As	O
mentioned	O
earlier	O
,	O
some	O
anti	B
-	I
inflammatory	I
chemopreventive	B
agents	I
have	O
been	O
found	O
to	O
suppress	O
growth	O
and	O
proliferation	O
of	O
transformed	O
cells	O
through	O
induction	O
of	O
programmed	O
death	O
or	O
apoptosis	O
[	O
30–32	O
]	O
.	O

Although	O
resveratrol	B
exerts	O
anti	O
-	O
inflammatory	O
effects	O
through	O
selective	O
suppression	O
of	O
COX-2	O
,	O
little	O
information	O
is	O
available	O
in	O
the	O
literature	O
in	O
regards	O
to	O
its	O
apoptosis	O
-	O
inducing	O
capability	O
in	O
tumor	O
cells	O
.	O

Mgbonyebi	O
et	O
al.	O
[	O
156	O
]	O
reported	O
the	O
growth	O
inhibition	O
by	O
resveratrol	B
of	O
several	O
types	O
of	O
human	O
breast	O
epithelial	O
cells	O
,	O
which	O
was	O
independent	O
of	O
estrogen	O
receptor	O
status	O
of	O
the	O
cells	O
.	O

Although	O
the	O
antiproliferative	O
activity	O
of	O
resveratrol	B
was	O
demonstrated	O
[	O
156	O
]	O
,	O
the	O
mode	O
of	O
cell	O
death	O
induced	O
by	O
this	O
phytochemical	B
was	O
not	O
clarified	O
in	O
the	O
above	O
investigation	O
.	O

Suppression	O
of	O
HL-60	O
cells	O
by	O
resveratrol	B
was	O
shown	O
to	O
be	O
mediated	O
via	O
induction	O
of	O
apoptosis	O
as	O
determined	O
by	O
nuclear	O
fragmentation	O
,	O
chromatin	O
condensation	O
,	O
a	O
time	O
-	O
related	O
increase	O
in	O
the	O
frequency	O
of	O
subdiploid	O
(	O
apoptotic	O
)	O
cells	O
,	O
and	O
internucleosomal	O
DNA	O
fragmentation	O
[	O
160	O
]	O
.	O

Besides	O
suppression	O
of	O
proliferation	O
,	O
the	O
compound	O
induced	O
differentiation	O
of	O
HL-60	O
cells	O
at	O
concentrations	O
as	O
low	O
as	O
30	O
μM	O
,	O
which	O
appears	O
to	O
be	O
associated	O
with	O
reversible	O
cell	O
cycle	O
arrest	O
at	O
the	O
S	O
-	O
phase	O
check	O
point	O
[	O
161	O
]	O
.	O

Moreover	O
,	O
resveratrol	B
was	O
found	O
to	O
induce	O
apoptosis	O
in	O
HL-60	O
cells	O
by	O
triggering	O
the	O
CD95	O
signaling	O
system	O
[	O
162	O
]	O
.	O

The	O
growth	O
of	O
estrogen	B
-	O
dependent	O
T47D	O
breast	O
carcinoma	O
cells	O
was	O
also	O
suppressed	O
by	O
resveratrol	B
treatment	O
[	O
162	O
]	O
.	O

The	O
latter	O
finding	O
is	O
contradictory	O
to	O
the	O
result	O
of	O
a	O
previous	O
work	O
by	O
Gehm	O
et	O
al.	O
[	O
163	O
]	O
,	O
who	O
demonstrated	O
stimulation	O
of	O
T47D	O
cell	O
proliferation	O
by	O
resveratrol	B
through	O
interaction	O
with	O
the	O
estrogen	O
receptor	O
.	O

The	O
exact	O
reason	O
for	O
this	O
discrepancy	O
remains	O
unknown	O
.	O

In	O
another	O
study	O
,	O
resveratrol	B
caused	O
estrogen	B
mimic	O
induction	O
of	O
prolactin	O
secretion	O
in	O
the	O
immortalized	O
pituitary	O
cell	O
line	O
PR1	O
,	O
but	O
it	O
exhibited	O
neither	O
estrogen	O
receptor	O
binding	O
nor	O
growth	O
stimulatory	O
activity	O
in	O
these	O
cells	O
[	O
164	O
]	O
.	O

4.6	O
Epigallocatechin	B
gallate	I
Epidemiologic	O
,	O
as	O
well	O
as	O
laboratory	O
studies	O
,	O
have	O
revealed	O
that	O
increased	O
consumption	O
of	O
green	O
tea	O
has	O
been	O
associated	O
with	O
reduced	O
frequencies	O
of	O
several	O
types	O
of	O
malignant	O
tumors	O
[	O
165–169	O
]	O
.	O

Among	O
many	O
polyphenolic	B
compounds	I
isolated	O
from	O
green	O
tea	O
,	O
(	B
−	I
)	I
-epigallocatechin	I
gallate	I
(	O
EGCG	B
;	O
Fig.	O
5	O
)	O
is	O
believed	O
to	O
be	O
a	O
key	O
active	O
constituent	O
in	O
terms	O
of	O
cancer	O
chemopreventive	O
potential	O
[	O
113	O
,	O
165	O
,	O
170–172	O
]	O
.	O

The	O
strong	O
antioxidative	O
activity	O
retained	O
in	O
this	O
polyphenol	B
has	O
been	O
confirmed	O
in	O
numerous	O
in	O
vivo	O
and	O
in	O
vitro	O
studies	O
[	O
173–186	O
]	O
,	O
which	O
appears	O
to	O
contribute	O
in	O
part	O
to	O
the	O
antimutagenic	O
and	O
anticarcinogenic	O
effects	O
of	O
green	O
tea	O
.	O

Thus	O
,	O
pretreatment	O
of	O
SENCAR	O
mice	O
with	O
EGCG	B
significantly	O
ameliorated	O
TPA	B
-	O
induced	O
infiltration	O
and	O
diminished	O
the	O
formation	O
of	O
hydrogen	B
peroxide	I
and	O
oxidized	O
DNA	B
bases	I
including	O
8-hydroxy-2′-deoxyguanosine	B
(	O
8-OH	B
-	I
dG	I
)	O
and	O
5-hydroxymethyl-2′-deoxyuridine	B
in	O
the	O
skin	O
[	O
174	O
]	O
.	O

Likewise	O
,	O
TPA	B
-	O
induced	O
oxidative	O
DNA	O
base	O
modification	O
was	O
inhibited	O
dose	O
-	O
dependently	O
by	O
EGCG	B
in	O
cultured	O
HeLa	O
cells	O
[	O
175	O
]	O
.	O

EGCG	B
and	O
structurally	O
-	O
related	O
green	O
tea	O
catechins	B
were	O
found	O
to	O
be	O
stronger	O
inhibitors	O
of	O
lipid	B
peroxidation	O
in	O
rat	O
liver	O
homogenates	O
than	O
such	O
antioxidants	O
as	O
glutathione	B
,	O
ascorbic	B
acid	I
,	O
tocopherol	B
,	O
butylated	B
hydroxytoluene	I
,	O
and	O
butylated	B
hydroxyanisole	I
[	O
176	O
]	O
.	O

The	O
antioxidant	O
activities	O
of	O
theaflavins	B
and	O
thearubigin	B
purified	O
from	O
the	O
infusion	O
of	O
black	O
tea	O
leaves	O
were	O
lower	O
than	O
those	O
of	O
green	O
tea	O
polyphenols	B
[	O
176	O
]	O
,	O
although	O
the	O
total	O
lyophilized	O
infusion	O
products	O
of	O
green	O
tea	O
and	O
black	O
tea	O
leaves	O
were	O
equally	O
active	O
.	O

EGCG	B
exhibited	O
a	O
strong	O
inhibitory	O
effect	O
on	O
Cu2	B
+	I
-mediated	O
oxidation	O
of	O
low	O
density	O
lipoprotein	O
(	O
LDL	B
)	O
in	O
vitro	O
and	O
was	O
again	O
more	O
potent	O
than	O
theaflavin	B
,	O
α	B
-	I
tocopherol	I
,	O
and	O
butylated	B
hydroxytoluene	I
in	O
this	O
regard	O
[	O
177	O
]	O
.	O

Kidney	O
slices	O
from	O
rats	O
subjected	O
to	O
oral	O
administration	O
of	O
EGCG	B
(	O
50	O
mg	O
/	O
kg	O
body	O
weight	O
)	O
for	O
7	O
days	O
or	O
fed	O
3	O
%	O
green	O
tea	O
leaf	O
powder	O
for	O
50	O
days	O
exhibited	O
lesser	O
extent	O
of	O
ter	B
-butyl	I
hydroperoxide	I
-	O
induced	O
lipid	B
peroxidation	O
,	O
compared	O
with	O
the	O
control	O
animals	O
[	O
178	O
]	O
.	O

EGCG	B
,	O
as	O
well	O
as	O
green	O
tea	O
given	O
to	O
rats	O
in	O
drinking	O
water	B
was	O
protective	O
against	O
hepatotoxicity	O
and	O
liver	O
nuclear	O
8-OH	B
-	I
dG	I
formation	O
induced	O
by	O
the	O
carcinogen	B
2-nitropropane	B
[	O
179	O
]	O
.	O

Pentachlorophenol	B
-	O
induced	O
hepatic	O
8-OH	B
-	I
dG	I
formation	O
in	O
male	O
B6C3F1	O
mice	O
was	O
reduced	O
by	O
oral	O
administration	O
of	O
EGCG	B
[	O
180	O
]	O
.	O

Peroxynitrite	B
-	O
mediated	O
formation	O
of	O
8-OH	B
-	I
dG	I
in	O
calf	O
thymus	O
DNA	O
and	O
nitration	O
of	O
tyrosine	B
to	O
3-nitrotyrosine	B
were	O
suppressed	O
by	O
EGCG	B
[	O
181	O
]	O
.	O

Strand	O
scission	O
in	O
Escherichia	O
coli	O
pUC18	O
plasmid	O
DNA	O
by	O
gamma	O
-	O
ray	O
or	O
beta	O
-	O
ray	O
was	O
inhibited	O
in	O
the	O
presence	O
of	O
EGCG	B
,	O
which	O
might	O
be	O
attributable	O
to	O
its	O
hydroxyl	B
radical	I
scavenging	O
effect	O
[	O
182	O
,	O
183	O
]	O
.	O

Among	O
the	O
tea	O
flavonoids	B
tested	O
,	O
EGCG	B
exerted	O
the	O
most	O
pronounced	O
protection	O
against	O
oxidation	O
of	O
LDL	O
as	O
revealed	O
by	O
prolongation	O
of	O
the	O
oxidation	O
time	O
[	O
184	O
]	O
.	O

The	O
EGCG	B
was	O
found	O
to	O
block	O
the	O
production	O
of	O
ROS	B
derived	O
from	O
NADPH	O
-	O
cytochrome	O
P	O
450-mediated	O
oxidation	O
of	O
the	O
cooked	O
meat	O
carcinogen	B
,	O
2-amino-3-methylimidazo	B
[	I
4,5-f	I
]	I
quinoline	I
(	O
IQ	B
)	O
[	O
185	O
]	O
.	O

The	O
EGCG	B
and	O
epigallocatechin	B
were	O
found	O
to	O
inhibit	O
xanthine	O
oxidase	O
[	O
186	O
]	O
.	O

The	O
EGCG	B
has	O
also	O
been	O
reported	O
to	O
attenuate	O
the	O
nitric	B
oxide	I
production	O
[	O
187	O
,	O
188	O
]	O
,	O
which	O
appears	O
to	O
be	O
mediated	O
through	O
suppression	O
of	O
inducible	O
nitric	O
oxide	O
synthase	O
(	O
iNOS	O
)	O
or	O
its	O
mRNA	O
expression	O
[	O
187	O
,	O
189	O
]	O
.	O

The	O
electrophorectic	O
mobility	O
shift	O
assay	O
revealed	O
that	O
EGCG	B
blunted	O
activation	O
of	O
NF	O
-	O
κB	O
responsible	O
for	O
iNOS	O
induction	O
[	O
187	O
]	O
.	O

These	O
results	O
indicate	O
that	O
EGCG	B
inhibits	O
the	O
binding	O
of	O
NF	O
-	O
κB	O
to	O
iNOS	B
promoter	I
,	O
thereby	O
hampering	O
the	O
transcription	O
of	O
iNOS	O
gene	O
.	O

Interferon	O
-	O
gamma	O
and	O
lipopolysaccharide	B
-	O
induced	O
nitrite	B
production	O
in	O
mouse	O
peritoneal	O
cells	O
was	O
also	O
inhibited	O
by	O
EGCG	B
[	O
190	O
]	O
.	O

The	O
chemopreventive	O
effects	O
of	O
EGCG	B
and	O
other	O
structurally	O
-	O
related	O
green	O
tea	O
polyphenols	B
have	O
been	O
investigated	O
using	O
diverse	O
rodent	O
tumor	O
models	O
(	O
recently	O
reviewed	O
in	O
Ref	O
.	O

[	O
191	O
]	O
)	O
.	O

Thus	O
,	O
EGCG	B
exhibited	O
protective	O
effects	O
against	O
N	B
-ethyl	I
-	I
N	I
′-nitrosoguanidine	I
-	O
induced	O
murine	O
duodenum	O
carcinogenesis	O
[	O
165	O
,	O
192	O
,	O
193	O
]	O
,	O
N	B
-methyl	I
-	I
N	I
′-nitrosoguanidine	I
-	O
induced	O
rat	O
gastric	O
carcinogenesis	O
[	O
193	O
,	O
194	O
]	O
,	O
diethylnitrosamine	B
-	O
initiated	O
and	O
phenobarbital	B
-	O
promoted	O
formation	O
of	O
hepatic	O
preneoplastic	O
foci	O
in	O
male	O
F344	O
rats	O
[	O
195	O
]	O
,	O
mouse	O
skin	O
carcinogenesis	O
[	O
170	O
,	O
196–200	O
]	O
,	O
tobacco	O
-	O
specific	O
nitrosamine	B
-	O
induced	O
mouse	O
pulmonary	O
tumorigenesis	O
[	O
[	O
201	O
]	O
,	O
reviewed	O
in	O
Ref	O
.	O

[	O
202	O
]	O
]	O
,	O
rat	O
sarcoma	O
induction	O
following	O
subcutaneous	O
injection	O
of	O
benzo	B
[	I
a	I
]	I
pyrene	I
[	O
203	O
]	O
,	O
and	O
spontaneous	O
hepatoma	O
formation	O
in	O
C3H	O
/	O
HeNCrj	O
mice	O
[	O
204	O
]	O
.	O

One	O
of	O
the	O
most	O
plausible	O
mechanisms	O
underlying	O
the	O
chemopreventive	O
activity	O
of	O
EGCG	B
is	O
suppression	O
of	O
promotion	O
of	O
carcinogenesis	O
[	O
170	O
,	O
193	O
,	O
196	O
,	O
197	O
]	O
examined	O
in	O
animals	O
and	O
also	O
in	O
cultured	O
cells	O
[	O
205	O
]	O
.	O

Thus	O
,	O
EGCG	B
has	O
been	O
reported	O
to	O
influence	O
some	O
biochemical	O
events	O
related	O
to	O
tumor	O
promotion	O
,	O
such	O
as	O
suppression	O
of	O
mouse	O
epidermal	O
ODC	O
activity	O
induced	O
by	O
TPA	B
[	O
197	O
]	O
or	O
okadaic	B
acid	I
[	O
170	O
]	O
,	O
inhibition	O
of	O
protein	O
kinase	O
C	O
activation	O
induced	O
by	O
teleocidin	B
[	O
171	O
]	O
or	O
TPA	B
[	O
206	O
]	O
,	O
attenuation	O
of	O
okadaic	B
acid	I
-	O
stimulated	O
production	O
of	O
TNF	O
-	O
α	O
and	O
its	O
mRNA	O
expression	O
in	O
cultured	O
BALB	O
/	O
3T3	O
cells	O
[	O
172	O
,	O
207	O
]	O
,	O
inhibition	O
of	O
binding	O
of	O
tumor	O
promoters	O
to	O
the	O
particulate	O
fraction	O
of	O
mouse	O
skin	O
[	O
170	O
]	O
or	O
to	O
its	O
receptor	O
protein	O
kinase	O
C	O
[	O
206	O
]	O
,	O
mitigation	O
of	O
TPA	B
-	O
induced	O
oxidative	O
damage	O
in	O
mouse	O
skin	O
[	O
174	O
]	O
and	O
cultured	O
cells	O
[	O
175	O
]	O
,	O
enhancement	O
of	O
gap	O
junctional	O
intercellular	O
communication	O
[	O
208	O
]	O
.	O

The	O
ODC	O
activity	O
in	O
gastric	O
mucosal	O
cells	O
of	O
N	B
-methyl	I
-	I
N	I
′-nitrosoguanidine	I
-	O
treated	O
rats	O
was	O
also	O
reduced	O
by	O
oral	O
administration	O
of	O
EGCG	B
[	O
194	O
]	O
.	O

TPA	B
-	O
induced	O
expression	O
of	O
ODC	O
gene	O
,	O
protein	O
kinase	O
C	O
gene	O
,	O
and	O
c	O
-	O
myc	O
proto	O
-	O
oncogene	O
in	O
mouse	O
skin	O
was	O
all	O
repressed	O
by	O
topical	O
application	O
of	O
EGCG	B
[	O
209	O
]	O
.	O

Likewise	O
,	O
increases	O
in	O
the	O
transcript	O
level	O
of	O
epidermal	O
IL-1α	O
gene	O
in	O
SENCAR	O
mice	O
treated	O
with	O
different	O
types	O
of	O
tumor	O
promoters	O
were	O
suppressed	O
by	O
topical	O
pretreatment	O
with	O
EGCG	B
[	O
210	O
]	O
.	O

In	O
contrast	O
,	O
EGCG	B
alone	O
stimulated	O
the	O
production	O
of	O
IL-1α	O
and	O
its	O
mRNA	O
expression	O
in	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
in	O
culture	O
[	O
211	O
]	O
.	O

EGCG	B
abrogated	O
TPA	B
-	O
induced	O
activation	O
of	O
protein	O
kinase	O
C	O
,	O
c	O
-	O
jun	O
expression	O
,	O
and	O
transformation	O
in	O
cultured	O
mouse	O
fibroblasts	O
in	O
culture	O
[	O
212	O
]	O
.	O

Very	O
recently	O
,	O
Dong	O
et	O
al.	O
[	O
213	O
]	O
reported	O
that	O
EGCG	B
and	O
theaflavins	B
inhibited	O
EGF-	O
or	O
TPA	B
-	O
induced	O
transformation	O
of	O
JB6	O
mouse	O
epidermal	O
cell	O
line	O
which	O
was	O
associated	O
with	O
their	O
repression	O
of	O
AP-1-dependent	O
transcriptional	O
activity	O
and	O
its	O
DNA	O
binding	O
activity	O
.	O

The	O
inhibition	O
of	O
AP-1	O
activation	O
by	O
these	O
substances	O
appears	O
to	O
be	O
mediated	O
via	O
down	O
-	O
regulation	O
of	O
JNK	O
,	O
but	O
not	O
the	O
ERK	O
pathway	O
[	O
213	O
]	O
.	O

The	O
anticarcinogenic	O
,	O
as	O
well	O
as	O
antigenotoxic	O
activities	O
of	O
EGCG	B
have	O
been	O
confirmed	O
in	O
many	O
other	O
in	O
vivo	O
and	O
in	O
vitro	O
bioassays	O
(	O
extensively	O
reviewed	O
in	O
Ref	O
.	O

[	O
192	O
]	O
and	O
see	O
references	O
therein	O
)	O
although	O
some	O
studies	O
revealed	O
no	O
protective	O
effects	O
[	O
214	O
]	O
.	O

Besides	O
inhibiting	O
the	O
tumor	O
promotion	O
,	O
EGCG	B
administered	O
intraperitoneally	O
and	O
the	O
green	O
tea	O
polyphenol	B
fraction	O
given	O
orally	O
or	O
intraperitoneally	O
caused	O
growth	O
inhibition	O
and/or	O
regression	O
of	O
experimentally	O
induced	O
skin	O
papillomas	O
in	O
mice	O
[	O
198	O
]	O
.	O

Topically	O
applied	O
green	O
tea	O
polyphenol	B
fraction	O
also	O
inhibited	O
the	O
progression	O
of	O
papillomas	O
to	O
squamous	O
cell	O
carcinoma	O
[	O
199	O
]	O
.	O

Similarly	O
,	O
i.p	O
.	O

injection	O
of	O
this	O
polyphenol	B
caused	O
growth	O
inhibition	O
and	O
regression	O
of	O
tumors	O
arising	O
from	O
human	O
prostate	O
cancer	O
cells	O
,	O
PC-3	O
and	O
LNCaP	O
104-R	O
,	O
subcutaneously	O
inoculated	O
into	O
nude	O
mice	O
[	O
215	O
]	O
.	O

Other	O
structurally	O
-	O
related	O
catechins	B
,	O
such	O
as	O
(	B
−	I
)	I
-epicatechin	I
gallate	I
,	O
were	O
not	O
active	O
in	O
this	O
respect	O
.	O

EGCG	B
also	O
effectively	O
suppressed	O
the	O
growth	O
of	O
human	O
mammary	O
cancer	O
cells	O
(	O
MCF-7	O
)	O
in	O
athymic	O
mice	O
[	O
215	O
]	O
.	O

In	O
line	O
with	O
these	O
in	O
vivo	O
findings	O
,	O
EGCG	B
downregulated	O
the	O
aberrant	O
hyperproliferation	O
of	O
c	O
-	O
myc	O
oncogene	O
-	O
transfected	O
mouse	O
mammary	O
epithelial	O
cells	O
as	O
demonstrated	O
by	O
its	O
ability	O
to	O
suppress	O
the	O
anchorage	O
-	O
independent	O
growth	O
of	O
these	O
cells	O
in	O
soft	O
agar	B
[	O
216	O
]	O
.	O

Aberrant	O
hyperproliferation	O
of	O
spontaneously	O
immortalized	O
murine	O
mammary	O
epithelial	O
cells	O
subjected	O
to	O
initiation	O
with	O
a	O
chemical	O
carcinogen	B
or	O
by	O
oncogene	O
transfection	O
and	O
their	O
subsequent	O
growth	O
in	O
syngenic	O
mice	O
were	O
also	O
blocked	O
by	O
EGCG	B
treatment	O
[	O
217	O
]	O
.	O

In	O
contrast	O
to	O
the	O
above	O
positive	O
findings	O
,	O
EGCG	B
given	O
as	O
a	O
diet	O
to	O
female	O
Sprague	O
–	O
Dawley	O
rats	O
during	O
the	O
late	O
promotion	O
or	O
progression	O
stages	O
of	O
7,12-dimethylbenz	B
[	I
a	I
]	I
anthracene	I
-	O
initiated	O
mammary	O
carcinogenesis	O
exhibited	O
no	O
significant	O
protective	O
effects	O
[	O
218	O
]	O
.	O

There	O
have	O
been	O
a	O
series	O
of	O
papers	O
published	O
,	O
which	O
deal	O
with	O
the	O
growth	O
inhibitory	O
or	O
antiproliferative	O
activities	O
of	O
green	O
tea	O
polyphenols	B
in	O
numerous	O
types	O
of	O
tumor	O
cells	O
[	O
[	O
219	O
,	O
220	O
]	O
,	O
and	O
vide	O
infra	O
]	O
.	O

Like	O
other	O
chemopreventive	O
phytochemicals	B
listed	O
above	O
,	O
the	O
growth	O
inhibitory	O
effects	O
of	O
EGCG	B
in	O
cancer	O
cells	O
appears	O
in	O
part	O
to	O
be	O
mediated	O
via	O
apoptosis	O
.	O

Hibasami	O
et	O
al.	O
[	O
221	O
]	O
reported	O
that	O
human	O
lymphoid	O
leukemia	O
Molt	O
4B	O
cells	O
exposed	O
to	O
EGCG	B
underwent	O
programmed	O
death	O
as	O
determined	O
by	O
appearance	O
of	O
DNA	O
ladder	O
on	O
agarose	B
gel	O
electrophoresis	O
.	O

Other	O
green	O
tea	O
polyphenols	B
,	O
such	O
as	O
epigallocatechin	B
and	O
epicatechin	B
gallate	I
,	O
also	O
inhibited	O
growth	O
of	O
Molt	O
4B	O
cells	O
via	O
induction	O
of	O
apoptotic	O
death	O
[	O
221	O
,	O
222	O
]	O
.	O

Each	O
of	O
these	O
polyphenols	B
exhibited	O
an	O
inhibitory	O
effect	O
on	O
the	O
growth	O
of	O
human	O
lung	O
cancer	O
cell	O
line	O
PC-9	O
,	O
possibly	O
through	O
arrest	O
of	O
the	O
cell	O
cycle	O
in	O
the	O
G2	O
/M	O
phase	O
[	O
166	O
,	O
223	O
]	O
.	O

In	O
a	O
subsequent	O
study	O
,	O
the	O
apoptosis	O
-	O
inducing	O
activity	O
of	O
EGCG	B
in	O
PC-9	O
cells	O
has	O
been	O
found	O
to	O
be	O
synergistically	O
enhanced	O
by	O
combined	O
treatment	O
with	O
other	O
chemopreventive	O
agents	O
,	O
including	O
sulindac	B
and	O
tamoxifen	B
[	O
224	O
]	O
.	O

In	O
another	O
study	O
,	O
EGCG	B
induced	O
apoptosis	O
of	O
human	O
epidermoid	O
carcinoma	O
cell	O
line	O
(	O
A431	O
)	O
,	O
human	O
carcinoma	O
keratinocyte	O
cell	O
line	O
(	O
HaCaT	O
)	O
,	O
human	O
prostate	O
carcinoma	O
cell	O
line	O
(	O
DU145	O
)	O
,	O
and	O
mouse	O
lymphoma	O
cell	O
line	O
(	O
L5178Y	O
)	O
and	O
its	O
apoptosis	O
inducing	O
activity	O
was	O
related	O
to	O
the	O
cell	O
cycle	O
arrest	O
in	O
the	O
G0	O
–G1	O
phase	O
[	O
225	O
]	O
.	O

Antiproliferative	O
activity	O
of	O
EGCG	B
against	O
A431	O
cells	O
has	O
been	O
attributed	O
to	O
its	O
suppression	O
of	O
EGF	O
binding	O
to	O
its	O
receptor	O
and	O
subsequent	O
autophosphorylation	O
of	O
the	O
EGF	O
receptor	O
required	O
for	O
EGF	O
signaling	O
[	O
226	O
]	O
.	O

The	O
EGCG	B
and	O
epigallocatechin	B
treated	O
to	O
Ehrlich	O
ascites	O
tumor	O
cells	O
caused	O
significant	O
reduction	O
in	O
cell	O
viability	O
[	O
227	O
]	O
.	O

While	O
epigallocatechin	B
suppressed	O
the	O
tyrosine	B
phosphorylation	O
of	O
42	O
kDa	O
and	O
45	O
kDa	O
proteins	O
in	O
treated	O
cells	O
,	O
EGCG	B
was	O
not	O
inhibitory	O
on	O
the	O
protein	O
tyrosine	O
kinase	O
activity	O
[	O
227	O
]	O
.	O

The	O
growth	O
of	O
premalignant	O
and	O
malignant	O
cells	O
derived	O
respectively	O
from	O
dysplastic	O
leukoplakia	O
and	O
squamous	O
carcinoma	O
of	O
oral	O
epithelial	O
origin	O
was	O
also	O
inhibited	O
by	O
EGCG	B
,	O
which	O
was	O
considered	O
to	O
be	O
associated	O
with	O
cell	O
cycle	O
arrest	O
in	O
the	O
G1	O
phase	O
[	O
228	O
,	O
229	O
]	O
.	O

The	O
malignant	O
oral	O
epithelium	O
was	O
less	O
responsive	O
to	O
EGCG	B
than	O
normal	O
and	O
dysplastic	O
cells	O
[	O
229	O
]	O
.	O

Treatment	O
of	O
benzo	B
[	I
a	I
]	I
pyrene	I
-	O
initiated	O
human	O
mammary	O
epithelial	O
184-B5	O
cells	O
with	O
EGCG	B
led	O
to	O
increases	O
in	O
sub	O
G0	O
population	O
and	O
apoptotic	O
cell	O
death	O
,	O
which	O
might	O
account	O
for	O
suppression	O
of	O
aberrant	O
proliferation	O
in	O
these	O
cells	O
[	O
230	O
]	O
.	O

Human	O
stomach	O
KATO	O
III	O
cells	O
also	O
underwent	O
apoptotic	O
death	O
when	O
exposed	O
to	O
EGCG	B
[	O
231	O
]	O
.	O

When	O
different	O
types	O
of	O
polyphenols	B
derived	O
from	O
green	O
tea	O
extracts	O
were	O
treated	O
to	O
human	O
lung	O
and	O
colon	O
cancer	O
cell	O
lines	O
,	O
EGCG	B
and	O
epigallocatechin	B
exhibited	O
strong	O
growth	O
inhibitory	O
effects	O
followed	O
by	O
epicatechin	B
gallate	I
and	O
epicatechin	B
[	O
232	O
]	O
.	O

The	O
incubation	O
of	O
the	O
human	O
lung	O
tumor	O
cell	O
line	O
H661	O
with	O
EGCG	B
resulted	O
in	O
apoptosis	O
,	O
which	O
was	O
considered	O
to	O
be	O
mediated	O
by	O
hydrogen	B
peroxide	I
produced	O
by	O
this	O
polyphenol	B
[	O
232	O
]	O
.	O

EGCG	B
was	O
proven	O
to	O
be	O
the	O
most	O
potent	O
green	O
tea	O
catechin	B
in	O
terms	O
of	O
suppressing	O
the	O
growth	O
of	O
several	O
human	O
prostate	O
cancer	O
cell	O
lines	O
,	O
including	O
LNCaP	O
,	O
PC-3	O
,	O
and	O
DU145	O
[	O
233	O
]	O
.	O

The	O
selective	O
inhibition	O
of	O
5α	O
-	O
reductase	O
by	O
EGCG	B
suggests	O
that	O
its	O
antiproliferative	O
activity	O
against	O
prostate	O
cancer	O
cells	O
is	O
mediated	O
via	O
modulation	O
of	O
androgen	O
action	O
[	O
234	O
]	O
.	O

The	O
antiproliferative	O
and	O
apoptosis	O
-	O
inducing	O
effects	O
of	O
EGCG	B
were	O
shown	O
to	O
be	O
specific	O
for	O
tumor	O
cells	O
[	O
225	O
,	O
235	O
]	O
,	O
which	O
was	O
partly	O
associated	O
with	O
its	O
differential	O
modulation	O
of	O
c	O
-	O
myc	O
and	O
c	O
-	O
fos	O
expression	O
[	O
235	O
]	O
.	O

EGCG	B
also	O
possesses	O
a	O
potential	O
antimetastatic	O
activity	O
as	O
revealed	O
by	O
inhibition	O
of	O
matrix	O
metalloproteinase	O
activity	O
in	O
mouse	O
Lewis	O
lung	O
carcinoma	O
cells	O
[	O
236	O
]	O
.	O

Furthermore	O
,	O
administration	O
of	O
EGCG	B
inhibited	O
metastasis	O
of	O
mouse	O
B16	O
melanoma	O
cells	O
[	O
237	O
]	O
.	O

Adhesion	O
of	O
mouse	O
lung	O
carcinoma	O
cells	O
to	O
endothelial	O
cells	O
was	O
also	O
inhibited	O
by	O
EGCG	B
[	O
238	O
]	O
.	O

It	O
also	O
reduced	O
the	O
lifespan	O
of	O
cultured	O
monoblastoid	O
leukemia	O
and	O
HT29	O
colon	O
adenocarcinoma	O
cells	O
through	O
direct	O
inactivation	O
of	O
telomerase	O
[	O
239	O
]	O
,	O
an	O
enzyme	O
essential	O
for	O
unlocking	O
the	O
proliferation	O
of	O
cancer	O
cells	O
.	O

5	O
Concluding	O
remarks	O
A	O
wide	O
variety	O
of	O
phenolic	B
substances	I
present	O
in	O
dietary	O
and	O
medicinal	O
plants	O
possess	O
striking	O
antioxidative	O
and	O
anti	O
-	O
inflammatory	O
properties	O
,	O
which	O
to	O
some	O
extent	O
,	O
contribute	O
to	O
their	O
cancer	O
chemopreventive	O
potential	O
.	O

Examples	O
are	O
pungent	O
vanilloids	B
in	O
red	O
pepper	O
and	O
ginger	O
,	O
and	O
diarylheptanoids	B
isolated	O
from	O
certain	O
medicinal	O
plants	O
of	O
ginger	O
family	O
.	O

These	O
phenolic	B
substances	I
have	O
the	O
ability	O
to	O
inhibit	O
mouse	O
skin	O
tumor	O
promotion	O
and	O
to	O
abrogate	O
various	O
biochemical	O
processes	O
induced	O
or	O
mediated	O
by	O
the	O
tumor	O
promoters	O
including	O
TPA	B
and	O
okadaic	B
acid	I
.	O

They	O
also	O
induce	O
apoptosis	O
in	O
premalignant	O
or	O
cancerous	O
cells	O
.	O

Resveratrol	B
,	O
a	O
phytoalexin	B
present	O
in	O
grapes	O
and	O
red	O
wine	O
and	O
EGCG	B
,	O
one	O
of	O
the	O
major	O
antioxidative	O
polyphenols	B
contained	O
in	O
green	O
tea	O
,	O
have	O
been	O
shown	O
to	O
possess	O
a	O
broad	O
spectrum	O
of	O
anticarcinogenic	O
effects	O
.	O

Recent	O
studies	O
have	O
revealed	O
that	O
resveratrol	B
and	O
EGCG	B
suppress	O
growth	O
and	O
proliferation	O
of	O
various	O
types	O
of	O
tumor	O
cells	O
via	O
induction	O
of	O
apoptosis	O
or	O
arrest	O
of	O
a	O
specific	O
phase	O
of	O
the	O
cell	O
cycle	O
.	O

Most	O
of	O
the	O
naturally	O
occurring	O
chemopreventive	O
phenolics	B
exert	O
multifacet	O
action	O
,	O
and	O
any	O
clinical	O
applications	O
using	O
these	O
substances	O
should	O
be	O
based	O
on	O
the	O
precise	O
understanding	O
of	O
the	O
physiologically	O
relevant	O
action	O
mechanism	O
(	O
s	O
)	O
.	O

Acknowledgements	O
This	O
work	O
was	O
supported	O
by	O
a	O
grant	O
from	O
Korea	O
Science	O
Engineering	O
Foundation	O
through	O
the	O
Research	O
Center	O
for	O
New	O
Drug	B
Development	O
of	O
Seoul	O
National	O
University	O
and	O
also	O
by	O
a	O
grant	O
for	O
'	O
98	O
Good	O
Health	O
R&D	O
project	O
(	O
HMP-96-D-2	O
-	O
1034	O
)	O
sponsored	O
by	O
the	O
Ministry	O
of	O
Health	O
and	O
Welfare	O
,	O
Republic	O
of	O
Korea	O
.	O

Guillain	O
-	O
Barré	O
syndrome	O
(	O
GBS	O
)	O
is	O
an	O
acute	O
immune	O
-	O
mediated	O
polyradiculoneuropathy	O
.	O

An	O
infection	O
often	O
precedes	O
the	O
onset	O
of	O
GBS	O
.	O

Although	O
a	O
subtype	O
with	O
primary	O
axonal	O
degeneration	O
has	O
recently	O
been	O
reported	O
[	O
1	O
]	O
,	O
the	O
predominant	O
pathogenetic	O
process	O
is	O
considered	O
to	O
be	O
demyelination	O
.	O

Gangliosides	B
are	O
surface	O
membrane	O
antigens	B
distributed	O
predominantly	O
in	O
the	O
nervous	O
system	O
.	O

Antiganglioside	O
antibodies	O
are	O
frequently	O
elevated	O
in	O
the	O
acute	O
phase	O
sera	O
of	O
GBS	O
[	O
2–4	O
]	O
.	O

Among	O
the	O
gangliosides	B
,	O
LM1	B
(	O
sialosylneolactotetraosylceramide	B
)	O
is	O
the	O
predominant	O
one	O
in	O
the	O
peripheral	O
nerve	O
myelin	O
[	O
5	O
]	O
.	O

Anti	O
-	O
LM1	O
antibody	O
may	O
therefore	O
be	O
related	O
to	O
the	O
pathogenesis	O
of	O
GBS	O
.	O

In	O
this	O
paper	O
,	O
we	O
investigate	O
the	O
presence	O
of	O
the	O
anti	O
-	O
LM1	O
antibody	O
in	O
the	O
serum	O
of	O
patients	O
with	O
GBS	O
and	O
the	O
clinical	O
and	O
electrophysiological	O
features	O
of	O
GBS	O
patients	O
with	O
the	O
anti	O
-	O
LM1	O
IgG	O
antibody	O
.	O

2	O
Materials	O
and	O
methods	O
2.1	O
Patients	O
'	O
sera	O
Serum	O
samples	O
were	O
obtained	O
from	O
140	O
consecutive	O
patients	O
with	O
acute	O
GBS	O
within	O
two	O
weeks	O
of	O
the	O
onset	O
of	O
neurologic	O
symptoms	O
,	O
24	O
normal	O
controls	O
and	O
147	O
disease	O
controls	O
,	O
which	O
included	O
patients	O
with	O
chronic	O
inflammatory	O
demyelinating	O
polyneuropathy	O
(	O
CIDP	O
)	O
,	O
33	O
;	O
Miller	O
Fisher	O
syndrome	O
(	O
MFS	O
)	O
,	O
47	O
;	O
other	O
neuropathies	O
,	O
7	O
;	O
multiple	O
sclerosis	O
,	O
13	O
;	O
collagen	O
disease	O
,	O
13	O
;	O
myasthenia	O
gravis	O
,	O
6	O
and	O
other	O
neurodegenerative	O
disease	O
,	O
28	O
.	O

All	O
the	O
patients	O
with	O
GBS	O
met	O
the	O
clinical	O
criteria	O
defined	O
by	O
Asbury	O
and	O
Cornblath	O
[	O
6	O
]	O
.	O

Except	O
for	O
the	O
subjects	O
with	O
degenerative	O
disorders	O
and	O
normal	O
controls	O
,	O
the	O
serum	O
samples	O
were	O
collected	O
during	O
the	O
acute	O
phase	O
or	O
relapse	O
.	O

2.2	O
Enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
An	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
was	O
performed	O
as	O
described	O
elsewhere	O
[	O
2	O
]	O
to	O
investigate	O
the	O
serum	O
anti	O
-	O
LM1	O
antibodies	O
.	O

Ninety	O
-	O
six	O
-	O
well	O
Linbro	O
microtiter	O
plates	O
(	O
Flow	O
Laboratories	O
,	O
McLean	O
,	O
VA	O
,	O
USA	O
)	O
were	O
used	O
.	O

Each	O
well	O
was	O
coated	O
with	O
0.2	O
μg	O
of	O
antigen	B
,	O
with	O
an	O
uncoated	O
well	O
being	O
used	O
as	O
the	O
control	O
.	O

After	O
incubation	O
with	O
1	O
%	O
bovine	O
serum	O
albumin	O
(	O
BSA	O
)	O
in	O
phosphate	B
-	I
buffered	I
saline	I
(	O
PBS	B
)	O
,	O
serum	O
diluted	O
1:40	O
with	O
1	O
%	O
BSA	O
in	O
PBS	B
was	O
added	O
to	O
each	O
well	O
and	O
the	O
plate	O
was	O
incubated	O
at	O
room	O
temperature	O
for	O
1.5	O
h.	O
After	O
each	O
well	O
had	O
been	O
washed	O
with	O
0.1	O
%	O
BSA	O
in	O
PBS	B
,	O
peroxidase	O
-	O
conjugated	O
anti	O
-	O
human	O
IgM	O
or	O
IgG	O
antibody	O
(	O
Cappel	O
,	O
West	O
Chester	O
,	O
PA	O
,	O
USA	O
)	O
,	O
diluted	O
1:200	O
and	O
1:500	O
,	O
respectively	O
,	O
with	O
1	O
%	O
BSA	O
in	O
PBS	B
,	O
was	O
added	O
to	O
each	O
well	O
and	O
the	O
plate	O
was	O
incubated	O
at	O
room	O
temperature	O
for	O
1.5	O
h.	O

The	O
wells	O
then	O
were	O
washed	O
with	O
0.1	O
%	O
BSA	O
in	O
PBS	B
and	O
a	O
color	O
reaction	O
was	O
obtained	O
by	O
incubation	O
with	O
200	O
μl	O
of	O
orthophenylenediamine	B
dihydrochloride	I
(	O
40	O
mg	O
/	O
dl	O
of	O
phosphate	B
–	O
citrate	B
buffer	O
,	O
pH	O
5.0	O
)	O
at	O
room	O
temperature	O
for	O
2	O
min	O
.	O

The	O
reaction	O
was	O
stopped	O
by	O
the	O
addition	O
of	O
8	O
N	O
H2	B
SO4	I
,	O
after	O
which	O
the	O
optical	O
density	O
(	O
OD	O
,	O
492	O
nm	O
)	O
was	O
read	O
with	O
an	O
ELISA	O
reader	O
(	O
Bio	O
-	O
Rad	O
,	O
Hercules	O
,	O
CA	O
,	O
USA	O
)	O
.	O

Each	O
OD	O
value	O
was	O
corrected	O
by	O
subtracting	O
the	O
OD	O
of	O
a	O
control	O
well	O
that	O
had	O
been	O
processed	O
the	O
same	O
way	O
.	O

Serum	O
with	O
an	O
OD	O
of	O
more	O
than	O
the	O
mean+3	O
SD	O
of	O
the	O
ODs	O
of	O
the	O
24	O
normal	O
controls	O
was	O
considered	O
positive	O
.	O

Each	O
serum	O
sample	O
positive	O
for	O
the	O
anti	O
-	O
LM1	O
antibody	O
was	O
diluted	O
serially	O
from	O
1:40	O
to	O
1:5120	O
and	O
ELISA	O
was	O
preformed	O
as	O
described	O
.	O

Anti	O
-	O
LM1	O
antibody	O
titer	O
was	O
expressed	O
as	O
the	O
maximal	O
dilution	O
factor	O
that	O
gave	O
a	O
corrected	O
OD	O
of	O
more	O
than	O
0.1	O
.	O

Serum	O
samples	O
with	O
anti	O
-	O
LM1	O
IgG	O
antibody	O
were	O
assayed	O
for	O
antibodies	O
to	O
several	O
other	O
gangliosides	B
such	O
as	O
GM1	B
,	O
GM2	B
,	O
GM3	B
,	O
GM1b	B
,	O
GD1a	B
,	O
GD1b	B
,	O
GD3	B
,	O
GalNAc	B
-	I
GD1a	I
,	O
GT1b	B
and	O
GQ1b	B
,	O
and	O
serum	O
samples	O
of	O
all	O
patients	O
with	O
GBS	O
were	O
assayed	O
for	O
anti	O
-	O
GQ1b	O
IgG	O
antibodies	O
.	O

Antibodies	O
against	O
those	O
gangliosides	B
were	O
investigated	O
by	O
the	O
use	O
of	O
ELISA	O
as	O
described	O
previously	O
[	O
2	O
]	O
.	O

2.3	O
Thin	O
-	O
layer	O
chromatogram	O
immunostaining	O
Thin	O
-	O
layer	O
chromatogram	O
(	O
TLC	O
)	O
immunostaining	O
was	O
performed	O
as	O
described	O
elsewhere	O
[	O
2	O
]	O
to	O
confirm	O
the	O
serum	O
antibody	O
reactivities	O
with	O
gangliosides	B
.	O

2.4	O
Clinical	O
features	O
The	O
clinical	O
and	O
electrophysiological	O
features	O
of	O
GBS	O
patients	O
with	O
the	O
anti	O
-	O
LM1	O
IgG	O
antibody	O
were	O
investigated	O
.	O

The	O
clinical	O
grade	O
was	O
determined	O
as	O
described	O
by	O
Hughes	O
et	O
al.	O
[	O
7	O
]	O
.	O

Patients	O
were	O
classified	O
electrophysiologically	O
as	O
having	O
either	O
acute	O
inflammatory	O
demyelinating	O
polyradiculoneuropathy	O
(	O
AIDP	O
)	O
,	O
with	O
or	O
without	O
axonal	O
degeneration	O
(	O
AD	O
)	O
,	O
acute	O
motor	O
axonal	O
neuropathy	O
,	O
or	O
acute	O
motor	O
and	O
sensory	O
axonal	O
neuropathy	O
according	O
to	O
the	O
criteria	O
described	O
by	O
Rees	O
et	O
al.	O
[	O
8	O
]	O
.	O

Patients	O
who	O
had	O
insufficient	O
evidence	O
of	O
demyelination	O
or	O
axonal	O
degeneration	O
were	O
labeled	O
as	O
unclassifiable	O
.	O

2.5	O
Statistical	O
analysis	O
The	O
difference	O
in	O
the	O
percentages	O
of	O
anti	O
-	O
GQ1b	O
IgG	O
antibody	O
-	O
positive	O
cases	O
among	O
GBS	O
patients	O
with	O
or	O
without	O
the	O
anti	O
-	O
LM1	O
IgG	O
antibody	O
was	O
analyzed	O
using	O
the	O
Fisher	O
's	O
exact	O
test	O
.	O

3	O
Results	O
3.1	O
Investigation	O
of	O
serum	O
antiganglioside	O
antibodies	O
Seven	O
patients	O
with	O
GBS	O
,	O
one	O
with	O
CIDP	O
and	O
two	O
with	O
MFS	O
had	O
the	O
IgG	O
anti	O
-	O
LM1	O
antibody	O
in	O
the	O
serum	O
(	O
Fig.	O
1	O
)	O
.	O

All	O
the	O
patients	O
with	O
anti	O
-	O
LM1	O
IgG	O
antibody	O
titers	O
of	O
1:160	O
or	O
more	O
were	O
GBS	O
patients	O
.	O

The	O
IgM	O
anti	O
-	O
LM1	O
antibody	O
was	O
detected	O
in	O
only	O
two	O
patients	O
,	O
one	O
with	O
GBS	O
and	O
the	O
other	O
with	O
MFS	O
.	O

The	O
binding	O
of	O
the	O
patients	O
'	O
antibody	O
to	O
LM1	B
was	O
confirmed	O
by	O
TLC	O
-	O
immunostaining	O
(	O
Fig.	O
2	O
)	O
.	O

Follow	O
-	O
up	O
serum	O
samples	O
were	O
available	O
from	O
three	O
patients	O
(	O
patients	O
3	O
,	O
4	O
and	O
5	O
)	O
.	O

Anti	O
-	O
LM1	O
IgG	O
antibody	O
titer	O
decreased	O
over	O
the	O
course	O
of	O
the	O
disease	O
in	O
each	O
patient	O
;	O
1:80	O
on	O
day	O
2	O
of	O
neurological	O
onset	O
and	O
1:40	O
on	O
day	O
7	O
in	O
patient	O
3	O
;	O
1:160	O
on	O
day	O
3	O
,	O
1:80	O
on	O
day	O
12	O
and	O
<	O
1:40	O
on	O
day	O
25	O
in	O
patient	O
4	O
;	O
1:640	O
on	O
day	O
2	O
and	O
<	O
1:40	O
on	O
day	O
22	O
in	O
patient	O
5	O
.	O

No	O
anti	O
-	O
LM1	O
antibody	O
was	O
detected	O
either	O
in	O
the	O
normal	O
or	O
in	O
the	O
disease	O
controls	O
other	O
than	O
CIDP	O
and	O
MFS	O
.	O

Six	O
of	O
seven	O
GBS	O
patients	O
with	O
the	O
anti	O
-	O
LM1	O
IgG	O
antibody	O
also	O
had	O
antibodies	O
against	O
other	O
gangliosides	B
.	O

In	O
particular	O
,	O
five	O
patients	O
had	O
the	O
anti	O
-	O
GQ1b	O
IgG	O
antibody	O
(	O
Table	O
1	O
)	O
.	O

The	O
anti	O
-	O
GQ1b	O
IgG	O
antibody	O
was	O
detected	O
in	O
14	O
of	O
the	O
140	O
serum	O
samples	O
of	O
patients	O
with	O
GBS	O
.	O

The	O
percentage	O
of	O
anti	O
-	O
GQ1b	O
IgG	O
antibody	O
-	O
positive	O
cases	O
was	O
significantly	O
higher	O
in	O
GBS	O
cases	O
with	O
the	O
anti	O
-	O
LM1	O
IgG	O
antibody	O
than	O
in	O
those	O
without	O
it	O
(	O
P	O
<	O
0.001	O
)	O
.	O

3.2	O
Clinical	O
features	O
of	O
GBS	O
patients	O
with	O
anti	O
-	O
LM1	O
IgG	O
antibody	O
Of	O
the	O
seven	O
cases	O
with	O
the	O
anti	O
-	O
LM1	O
IgG	O
antibody	O
,	O
respiratory	O
tract	O
infection	O
preceded	O
the	O
onset	O
of	O
GBS	O
in	O
five	O
patients	O
and	O
gastrointestinal	O
tract	O
infection	O
in	O
two	O
patients	O
.	O

All	O
the	O
five	O
patients	O
in	O
whom	O
the	O
onset	O
of	O
GBS	O
was	O
preceded	O
by	O
respiratory	O
tract	O
infection	O
had	O
anti	O
-	O
GQ1b	O
IgG	O
antibodies	O
.	O

Four	O
of	O
those	O
five	O
patients	O
had	O
ophthalmoplegia	O
.	O

One	O
of	O
the	O
two	O
patients	O
(	O
patient	O
7	O
)	O
with	O
preceding	O
gastrointestinal	O
infection	O
had	O
an	O
antibody	O
to	O
Campylobacter	O
jejuni	O
(	O
C.	O
jejuni	O
)	O
.	O

Electrophysiological	O
examinations	O
showed	O
that	O
four	O
of	O
the	O
seven	O
patients	O
with	O
the	O
anti	O
-	O
LM1	O
IgG	O
antibody	O
were	O
of	O
the	O
AIDP	O
type	O
and	O
one	O
patient	O
(	O
patient	O
7	O
)	O
was	O
of	O
the	O
AIDP	O
type	O
with	O
axonal	O
damage	O
.	O

In	O
the	O
remaining	O
two	O
patients	O
,	O
no	O
abnormal	O
findings	O
were	O
seen	O
electrophysiologically	O
.	O

Plasmapheresis	O
was	O
performed	O
for	O
all	O
those	O
patients	O
with	O
the	O
anti	O
-	O
LM1	O
IgG	O
antibody	O
.	O

One	O
month	O
after	O
the	O
onset	O
of	O
neuropathy	O
,	O
six	O
patients	O
had	O
recovered	O
to	O
clinical	O
Grade	O
1	O
,	O
whereas	O
only	O
patient	O
7	O
still	O
had	O
Grade	O
4	O
.	O

4	O
Discussion	O
We	O
detected	O
the	O
IgG	O
antibody	O
to	O
LM1	B
in	O
the	O
sera	O
of	O
7	O
out	O
of	O
140	O
(	O
5	O
%	O
)	O
GBS	O
patients	O
,	O
1	O
out	O
of	O
33	O
(	O
3.0	O
%	O
)	O
CIDP	O
patients	O
,	O
and	O
2	O
out	O
of	O
47	O
(	O
4.3	O
%	O
)	O
MFS	O
patients	O
.	O

The	O
IgM	O
antibody	O
to	O
LM1	B
was	O
found	O
only	O
in	O
two	O
patients	O
,	O
each	O
with	O
GBS	O
and	O
MFS	O
.	O

The	O
sera	O
of	O
patients	O
with	O
other	O
diseases	O
and	O
of	O
the	O
normal	O
controls	O
did	O
not	O
contain	O
anti	O
-	O
LM1	O
antibodies	O
.	O

Several	O
research	O
groups	O
have	O
found	O
serum	O
anti	O
-	O
LM1	O
antibodies	O
in	O
patients	O
with	O
demyelinating	O
neuropathies	O
[	O
9–11	O
]	O
,	O
however	O
,	O
the	O
results	O
are	O
conflicting	O
.	O

Fredman	O
et	O
al.	O
[	O
9	O
]	O
reported	O
that	O
43	O
%	O
of	O
GBS	O
patients	O
,	O
67	O
%	O
of	O
CIDP	O
patients	O
and	O
20	O
%	O
of	O
the	O
normal	O
controls	O
had	O
anti	O
-	O
LM1	O
antibodies	O
,	O
mostly	O
of	O
the	O
IgG	O
type	O
.	O

Ilyas	O
et	O
al.	O
[	O
10	O
]	O
reported	O
that	O
23	O
%	O
of	O
GBS	O
patients	O
and	O
2.3	O
%	O
of	O
the	O
disease	O
and	O
normal	O
controls	O
had	O
the	O
anti	O
-	O
LM1	O
IgG	O
antibody	O
,	O
but	O
no	O
significant	O
elevation	O
of	O
anti	O
-	O
LM1	O
IgM	O
antibody	O
titers	O
was	O
detected	O
.	O

Yuki	O
et	O
al.	O
[	O
11	O
]	O
found	O
the	O
IgG	O
antibody	O
to	O
LM1	B
in	O
8	O
%	O
of	O
GBS	O
patients	O
,	O
3	O
%	O
of	O
CIDP	O
patients	O
and	O
5	O
%	O
of	O
MFS	O
patients	O
,	O
and	O
the	O
IgM	O
antibody	O
to	O
LM1	B
in	O
13	O
%	O
of	O
GBS	O
patients	O
,	O
7	O
%	O
of	O
CIDP	O
patients	O
and	O
7	O
%	O
of	O
MFS	O
patients	O
.	O

These	O
differences	O
in	O
results	O
could	O
have	O
been	O
caused	O
by	O
differences	O
in	O
the	O
cut	O
-	O
off	O
levels	O
of	O
the	O
methods	O
used	O
and	O
in	O
the	O
immunogenetic	O
background	O
.	O

We	O
then	O
investigated	O
the	O
clinical	O
and	O
electrophysiological	O
features	O
of	O
GBS	O
patients	O
with	O
the	O
anti	O
-	O
LM1	O
IgG	O
antibody	O
,	O
which	O
have	O
never	O
been	O
reported	O
so	O
far	O
.	O

Considering	O
that	O
LM1	B
is	O
the	O
predominant	O
ganglioside	B
in	O
the	O
peripheral	O
nerve	O
myelin	O
,	O
the	O
anti	O
-	O
LM1	O
antibody	O
can	O
possibly	O
play	O
a	O
role	O
as	O
a	O
demyelinating	O
factor	O
in	O
the	O
pathogenesis	O
of	O
GBS	O
.	O

Of	O
the	O
seven	O
patients	O
with	O
the	O
anti	O
-	O
LM1	O
IgG	O
antibody	O
in	O
this	O
study	O
,	O
demyelination	O
was	O
confirmed	O
in	O
five	O
,	O
and	O
two	O
patients	O
were	O
labeled	O
as	O
unclassifiable	O
.	O

Only	O
patient	O
7	O
,	O
subsequent	O
to	O
C.	O
jejuni	O
infection	O
,	O
had	O
electrophysiological	O
findings	O
suggestive	O
of	O
axonal	O
damage	O
in	O
addition	O
to	O
demyelination	O
.	O

GBS	O
patients	O
subsequent	O
to	O
C.	O
jejuni	O
infection	O
have	O
been	O
reported	O
to	O
frequently	O
have	O
axonal	O
degeneration	O
[	O
8	O
]	O
.	O

In	O
patient	O
7	O
,	O
some	O
other	O
factor	O
induced	O
by	O
the	O
preceding	O
C.	O
jejuni	O
infection	O
might	O
also	O
be	O
elevated	O
to	O
cause	O
axonal	O
damage	O
.	O

Except	O
for	O
patient	O
7	O
,	O
all	O
patients	O
with	O
the	O
anti	O
-	O
LM1	O
IgG	O
antibody	O
exhibited	O
good	O
recovery	O
,	O
being	O
classified	O
Grade	O
1	O
within	O
one	O
month	O
of	O
the	O
onset	O
of	O
neuropathy	O
.	O

The	O
anti	O
-	O
LM1	O
IgG	O
antibody	O
might	O
be	O
a	O
demyelinating	O
factor	O
,	O
not	O
being	O
associated	O
with	O
axonal	O
degeneration	O
.	O

Five	O
of	O
the	O
seven	O
GBS	O
patients	O
with	O
an	O
elevated	O
anti	O
-	O
LM1	O
IgG	O
antibody	O
titer	O
also	O
had	O
anti	O
-	O
GQ1b	O
IgG	O
antibody	O
elevation	O
.	O

This	O
percentage	O
is	O
significantly	O
higher	O
than	O
that	O
in	O
the	O
GBS	O
patient	O
group	O
without	O
the	O
anti	O
-	O
LM1	O
IgG	O
antibody	O
.	O

The	O
anti	O
-	O
GQ1b	O
IgG	O
antibody	O
is	O
specifically	O
and	O
very	O
frequently	O
found	O
in	O
patients	O
with	O
MFS	O
and	O
GBS	O
with	O
ophthalmoplegia	O
[	O
12,13	O
]	O
.	O

As	O
ganglioside	B
GQ1b	I
is	O
localized	O
in	O
the	O
paranodal	O
regions	O
of	O
the	O
human	O
cranial	O
nerves	O
innervating	O
the	O
extraocular	O
muscles	O
,	O
it	O
could	O
be	O
a	O
causative	O
factor	O
of	O
ophthalmoplegia	O
in	O
MFS	O
and	O
GBS	O
[	O
13	O
]	O
.	O

Because	O
the	O
carbohydrate	B
structure	O
of	O
LM1	B
is	O
quite	O
different	O
from	O
that	O
of	O
GQ1b	B
(	O
Table	O
2	O
)	O
,	O
coexistence	O
of	O
antibody	O
activities	O
against	O
LM1	B
and	O
GQ1b	B
can	O
not	O
be	O
explained	O
by	O
cross	O
-	O
reactivity	O
.	O

Most	O
of	O
the	O
patients	O
with	O
elevated	O
titers	O
of	O
anti	O
-	O
GQ1b	O
IgG	O
antibody	O
have	O
the	O
antecedent	O
respiratory	O
tract	O
infections	O
(	O
Kusunoki	O
et	O
al.	O
,	O
unpublished	O
observation	O
)	O
.	O

The	O
data	O
in	O
this	O
study	O
show	O
that	O
all	O
five	O
patients	O
with	O
both	O
the	O
anti	O
-	O
LM1	O
and	O
anti	O
-	O
GQ1b	O
IgG	O
antibodies	O
in	O
the	O
serum	O
had	O
a	O
respiratory	O
tract	O
infection	O
before	O
the	O
onset	O
of	O
neuropathy	O
.	O

This	O
is	O
in	O
striking	O
contrast	O
to	O
antibodies	O
to	O
GM1	B
and	O
GalNAc	B
-	I
GD1a	I
,	O
which	O
are	O
elevated	O
mainly	O
subsequent	O
to	O
gastrointestinal	O
tract	O
infections	O
[	O
2,14	O
]	O
.	O

Elevated	O
titers	O
of	O
both	O
anti	O
-	O
GQ1b	O
and	O
anti	O
-	O
LM1	O
antibodies	O
may	O
be	O
associated	O
with	O
some	O
unknown	O
infectious	O
agent	O
(	O
s	O
)	O
affecting	O
the	O
respiratory	O
tract	O
.	O

Direct	O
evidence	O
that	O
anti	O
-	O
LM1	O
antibodies	O
cause	O
demyelination	O
has	O
not	O
yet	O
been	O
shown	O
.	O

Although	O
the	O
anti	O
-	O
LM1	O
antibody	O
is	O
present	O
in	O
only	O
about	O
5	O
%	O
of	O
GBS	O
patients	O
,	O
it	O
is	O
still	O
an	O
important	O
clue	O
to	O
understanding	O
the	O
pathogenetic	O
mechanisms	O
of	O
demyelination	O
in	O
a	O
subset	O
of	O
GBS	O
cases	O
.	O

Further	O
studies	O
are	O
needed	O
to	O
see	O
whether	O
it	O
is	O
actually	O
a	O
demyelinating	O
factor	O
or	O
not	O
.	O

Acknowledgments	O
This	O
work	O
was	O
supported	O
in	O
part	O
by	O
a	O
Grant	O
-	O
in	O
-	O
Aid	O
for	O
Scientific	O
Research	O
from	O
the	O
Ministry	O
of	O
Education	O
,	O
Science	O
and	O
Culture	O
of	O
Japan	O
(	O
10670576	O
)	O
,	O
and	O
by	O
a	O
Research	O
Grant	O
for	O
Neuroimmunological	O
Diseases	O
from	O
the	O
Ministry	O
of	O
Health	O
and	O
Welfare	O
of	O
Japan	O
.	O

We	O
thank	O
Ms	O
R.	O
Mashiko	O
and	O
Ms	O
H.	O
Mashiko	O
for	O
their	O
technical	O
assistance	O
.	O

We	O
also	O
thank	O
Drs	O
K.	O
Ikeguchi	O
,	O
K.	O
Fujiwara	O
,	O
Y.	O
Yasukawa	O
,	O
K.	O
Ohta	O
,	O
N.	O
Shima	O
and	O
K.	O
Arimura	O
for	O
providing	O
us	O
with	O
the	O
clinical	O
information	O
of	O
the	O
patients	O
.	O

Chalcone	O
synthase	O
(	O
CHS	O
,	O
E.C.	O
2.3.1.74	O
)	O
catalyzes	O
the	O
first	O
reaction	O
of	O
flavonoid	B
biosynthesis	O
and	O
stilbene	O
synthase	O
(	O
STS	O
,	O
E.C.	O
2.3.1.95	O
)	O
catalyzes	O
biosynthesis	O
of	O
stilbene	B
backbone	O
of	O
stilbene	B
-	O
type	O
phytoalexins	B
.	O

CHS	O
and	O
STS	O
are	O
similar	O
both	O
in	O
mechanistic	O
and	O
structural	O
aspects	O
and	O
are	O
representative	O
members	O
of	O
the	O
CHS	O
superfamily	O
[	O
1	O
]	O
.	O

CHS	O
and	O
STS	O
are	O
homodimers	O
of	O
identical	O
subunits	O
of	O
43	O
kDa	O
and	O
catalyze	O
repetitive	O
decarboxylative	O
condensation	O
of	O
a	O
p	B
-coumaroyl	I
residue	I
with	O
three	O
C2	O
-units	O
from	O
malonyl	B
-	I
CoA.	I
Although	O
both	O
enzymes	O
share	O
common	O
starting	O
materials	O
with	O
identical	O
stoichiometry	O
and	O
apparently	O
use	O
the	O
same	O
condensation	O
mechanism	O
up	O
to	O
the	O
common	O
tetraketide	B
intermediate	O
,	O
CHS	O
and	O
STS	O
catalyze	O
different	O
ring	O
closure	O
reactions	O
involving	O
different	O
atoms	O
to	O
give	O
rise	O
to	O
different	O
products	O
,	O
naringenin	B
chalcone	B
and	O
resveratrol	B
,	O
respectively	O
(	O
Fig.	O
1	O
)	O
.	O

The	O
amino	B
acid	I
homology	O
between	O
these	O
two	O
enzymes	O
is	O
more	O
than	O
65	O
%	O
,	O
and	O
a	O
phylogenetic	O
analysis	O
showed	O
a	O
higher	O
homology	O
between	O
CHS	O
and	O
STS	O
from	O
related	O
plants	O
than	O
among	O
CHSs	O
and	O
STSs	O
,	O
suggesting	O
that	O
STSs	O
have	O
evolved	O
from	O
CHSs	O
several	O
times	O
independently	O
[	O
2	O
]	O
.	O

It	O
has	O
been	O
demonstrated	O
that	O
,	O
under	O
certain	O
in	O
vitro	O
conditions	O
,	O
CHS	O
produces	O
not	O
only	O
naringenin	B
chalcone	B
but	O
also	O
triacetic	B
acid	I
lactone	I
(	O
TAL	B
)	O
and	O
styrylpyrone	B
as	O
early	O
release	O
(	O
derailment	O
)	O
byproducts	O
[	O
3,4	O
]	O
.	O

TAL	B
was	O
also	O
detected	O
from	O
the	O
reaction	O
products	O
by	O
fatty	O
acid	O
synthase	O
[	O
5	O
]	O
and	O
certain	O
polyketide	O
synthases	O
[	O
6,7	O
]	O
.	O

On	O
the	O
other	O
hand	O
,	O
such	O
derailment	O
products	O
have	O
not	O
been	O
observed	O
in	O
the	O
reaction	O
catalyzed	O
by	O
STS	O
[	O
8	O
]	O
.	O

Using	O
purified	O
Pueraria	O
lobata	O
(	O
kudzu	O
)	O
CHS	O
and	O
Arachis	O
hypogaea	O
(	O
peanut	O
)	O
STS	O
that	O
was	O
overexpressed	O
in	O
Escherichia	O
coli	O
,	O
we	O
have	O
detected	O
bisnoryangonin	B
(	O
BNY	B
,	O
the	O
derailed	O
lactone	B
after	O
two	O
condensations	O
)	O
and	O
p	B
-coumaroyltriacetic	I
acid	I
lactone	I
(	I
CTAL	B
,	O
the	O
derailed	O
lactone	B
after	O
three	O
condensations	O
)	O
from	O
the	O
reaction	O
products	O
produced	O
by	O
either	O
CHS	O
or	O
STS	O
.	O

Furthermore	O
,	O
we	O
found	O
a	O
cross	O
-	O
reaction	O
between	O
CHS	O
and	O
STS	O
,	O
i.e.	O
resveratrol	B
production	O
by	O
CHS	O
and	O
naringenin	B
production	O
by	O
STS	O
in	O
small	O
but	O
detectable	O
amounts	O
.	O

2	O
Materials	O
and	O
methods	O
2.1	O
Cloning	O
Transcription	O
of	O
STS	O
was	O
induced	O
by	O
cutting	O
peanut	O
seedlings	O
(	O
Sakata	O
,	O
Japan	O
)	O
into	O
slices	O
(	O
1	O
mm	O
thick	O
)	O
that	O
had	O
been	O
immersed	O
in	O
water	B
for	O
3	O
days	O
[	O
9	O
]	O
.	O

The	O
slices	O
were	O
then	O
left	O
overnight	O
in	O
water	B
at	O
25	O
°	O
C	O
in	O
darkness	O
.	O

Total	O
RNA	O
was	O
prepared	O
by	O
the	O
phenol	B
method	O
.	O

cDNA	O
was	O
synthesized	O
using	O
an	O
oligo	O
dT	O
-	O
Xba	O
I	O
primer	O
(	O
5′-GTC	B
GAC	I
TCT	I
AGA	I
(	I
T	I
)	I
15	I
-3′	I
)	O
and	O
PCR	O
-	O
amplified	O
with	O
primers	O
designed	O
from	O
the	O
published	O
A.	O
hypogaea	O
STS	O
sequence	O
[	O
10	O
]	O
;	O
the	O
forward	O
primer	O
(	O
5′-CAT	B
CCA	I
TG	I
G	I
TGT	I
CTG	I
TGA	I
GTG	I
AAT	I
TC-3′	I
)	O
and	O
the	O
reverse	O
primer	O
(	O
5′-GTA	B
TTA	I
TAT	I
GGC	I
CAT	I
GCT	I
GCG	I
GAG-3′	I
)	O
.	O

The	O
forward	O
primer	O
carries	O
an	O
Nco	O
I	O
site	O
suitable	O
for	O
cloning	O
into	O
the	O
expression	O
vector	O
,	O
pET-3d	O
.	O

The	O
resulting	O
PCR	O
product	O
was	O
first	O
blunt	O
-	O
ligated	O
into	O
the	O
Sma	O
I	O
site	O
of	O
pBluescriptIISK	O
(	O
+	O
)	O
(	O
MBI	O
Fermentas	O
)	O
,	O
rescued	O
by	O
Nco	O
I	O
/	O
Bam	O
HI	O
digestion	O
,	O
and	O
ligated	O
into	O
the	O
Nco	O
I	O
/	O
Bam	O
HI	O
restricted	O
vector	O
pET-3d	O
to	O
give	O
pET-3d	O
/	O
STS	O
.	O

The	O
Nco	O
I	O
digestion	O
was	O
carried	O
out	O
in	O
the	O
presence	O
of	O
EtBr	B
(	O
40	O
μg	O
/	O
ml	O
)	O
to	O
obtain	O
the	O
1.2-kb	O
full	O
-	O
length	O
cDNA	O
because	O
of	O
the	O
presence	O
of	O
another	O
Nco	O
I	O
site	O
in	O
the	O
coding	O
region	O
.	O

DNA	O
sequencing	O
was	O
carried	O
out	O
on	O
both	O
strands	O
with	O
several	O
forward	O
and	O
reverse	O
primers	O
using	O
the	O
Dye	O
Terminator	O
Cycle	O
Sequencing	O
kit	O
from	O
Applied	O
Biosystems	O
(	O
CA	O
,	O
USA	O
)	O
.	O

Construction	O
of	O
pET-3d	O
/	O
CHS	O
using	O
similar	O
methods	O
has	O
been	O
described	O
[	O
11	O
]	O
.	O

2.2	O
Protein	O
expression	O
and	O
purification	O
E.	O
coli	O
BL21	O
(	O
DE3	O
)	O
pLysE	O
cells	O
transformed	O
with	O
either	O
pET-3d	O
/	O
CHS	O
or	O
pET-3d	O
/	O
STS	O
were	O
grown	O
at	O
37	O
°	O
C	O
in	O
LB	O
medium	O
containing	O
50	O
μg	O
/	O
ml	O
ampicillin	B
and	O
25	O
μg	O
/	O
ml	O
chloramphenicol	B
and	O
induced	O
with	O
0.4	O
mM	O
IPTG	B
.	O

After	O
an	O
induction	O
period	O
of	O
4	O
h	O
at	O
37	O
°	O
C	O
,	O
the	O
cells	O
were	O
harvested	O
,	O
washed	O
and	O
suspended	O
in	O
buffer	O
A	O
(	O
10	O
mM	O
potassium	B
phosphate	I
(	O
KPi	B
)	O
buffer	O
(	O
pH	O
7.5	O
)	O
,	O
2	O
mM	O
DTT	B
)	O
.	O

Following	O
sonication	O
(	O
10	O
s	O
×10	O
)	O
on	O
ice	B
and	O
centrifugation	O
(	O
12	O
000	O
×	O
g	O
,	O
4	O
°	O
C	O
,	O
15	O
min	O
)	O
,	O
soluble	O
fractions	O
were	O
obtained	O
.	O

After	O
(	B
NH4	I
)	I
2	I
SO4	I
precipitation	O
(	O
30–80	O
%	O
saturation	O
)	O
,	O
CHS	O
was	O
purified	O
to	O
apparent	O
homogeneity	O
by	O
successive	O
chromatography	O
procedures	O
:	O
(	O
1	O
)	O
DEAE	B
-	O
Toyopearl	O
(	O
TOSOH	O
,	O
Tokyo	O
,	O
Japan	O
)	O
anion	O
exchange	O
chromatography	O
using	O
a	O
linear	O
gradient	O
of	O
NaCl	B
(	O
0–500	O
mM	O
)	O
in	O
buffer	O
A	O
,	O
(	O
2	O
)	O
Bio	O
-	O
Gel	O
hydroxyapatite	B
(	O
Bio	O
-	O
Rad	O
)	O
using	O
a	O
linear	O
gradient	O
of	O
10–300	O
mM	O
KPi	B
(	O
pH	O
7.5	O
)	O
containing	O
2	O
mM	O
DTT	B
and	O
(	O
3	O
)	O
chromatofocusing	O
on	O
polybuffer	B
exchanger	I
(	O
PBE94	O
,	O
Pharmacia	O
)	O
pre	O
-	O
equilibrated	O
with	O
25	O
mM	O
imidazole	B
-	I
HCl	I
(	O
pH	O
7.4	O
)	O
,	O
2	O
mM	O
DTT	B
and	O
eluted	O
with	O
Polybuffer74-HCl	B
(	O
pH	O
5.0	O
)	O
,	O
2	O
mM	O
DTT	B
.	O

STS	O
was	O
similarly	O
purified	O
after	O
successive	O
DEAE	B
ion	O
exchange	O
and	O
hydroapatite	B
chromatography	O
steps	O
.	O

Protein	O
contents	O
were	O
determined	O
with	O
Bradford	O
's	O
dye	O
method	O
(	O
Bio	O
-	O
Rad	O
)	O
[	O
12	O
]	O
,	O
using	O
bovine	O
serum	O
albumin	O
as	O
standard	O
.	O

Expression	O
and	O
purification	O
of	O
P.	O
lobata	O
CHS	O
and	O
A.	O
hypogaea	O
STS	O
as	O
thioredoxin	O
-	O
HisTag	O
fusion	O
proteins	O
(	O
Trx	O
-	O
CHS	O
and	O
Trx	O
-	O
STS	O
)	O
used	O
in	O
the	O
LC	O
-	O
MS	O
analysis	O
of	O
cross	O
-	O
reaction	O
will	O
be	O
described	O
elsewhere	O
.	O

2.3	O
Enzyme	O
assay	O
For	O
both	O
CHS	O
and	O
STS	O
,	O
the	O
reaction	O
mixture	O
(	O
0.1	O
ml	O
)	O
contained	O
appropriate	O
amounts	O
of	O
protein	O
(	O
2–5	O
μg	O
of	O
purified	O
enzyme	O
)	O
,	O
0.1	O
mM	O
p	B
-coumaroyl	I
-	I
CoA	I
and	O
16.8	O
μM	O
[	B
2	I
-	I
14	I
C	I
]	I
malonyl	I
-	I
CoA	I
(	O
2.2	O
GBq	O
/	O
mmol	O
,	O
NEN	O
)	O
in	O
0.1	O
M	O
KPi	B
buffer	O
(	O
pH	O
7.5	O
)	O
(	O
K2	B
HPO4	I
/KH2	O
PO4	B
)	O
containing	O
2	O
mM	O
DTT	B
.	O

After	O
incubation	O
at	O
37	O
°	O
C	O
for	O
30	O
min	O
,	O
50	O
μl	O
of	O
50	O
%	O
acetic	B
acid	I
was	O
added	O
and	O
the	O
reaction	O
products	O
were	O
extracted	O
with	O
200	O
μl	O
of	O
ethyl	B
acetate	I
.	O

A	O
portion	O
(	O
50	O
μl	O
)	O
of	O
the	O
extract	O
was	O
analyzed	O
by	O
TLC	O
on	O
RP18	O
plate	O
(	O
Merck	O
)	O
with	O
methanol	B
:	O
H2	B
O	I
:	O
acetic	B
acid	I
(	O
60:40:1	O
)	O
as	O
solvent	B
and	O
the	O
radioactive	O
products	O
were	O
quantified	O
with	O
an	O
Imaging	O
Plate	O
analyzer	O
(	O
BAS2000	O
,	O
Fuji	O
)	O
.	O

Authentic	O
compounds	O
,	O
TAL	B
(	O
R	O
f	O
=	O
0.65	O
,	O
Tokyo	O
Kasei	O
)	O
,	O
resveratrol	O
(	O
R	O
f	O
=	O
0.50	O
,	O
Sigma	O
)	O
and	O
naringenin	B
(	O
R	O
f	O
=	O
0.32	O
,	O
Nacalai	O
tesque	O
)	O
were	O
used	O
as	O
internal	O
standards	O
to	O
identify	O
the	O
products	O
.	O

The	O
specific	O
enzyme	O
activity	O
was	O
expressed	O
in	O
pmol	O
of	O
the	O
product	O
produced	O
/	O
s	O
/	O
mg	O
(	O
pkat	O
/	O
mg	O
)	O
.	O

2.4	O
Identification	O
of	O
bisnoryangonin	B
and	O
p	B
-coumaroyltriacetic	I
acid	I
lactone	I
For	O
identification	O
of	O
BNY	B
,	O
the	O
ethyl	B
acetate	I
-	O
extracted	O
products	O
produced	O
by	O
STS	O
and	O
CHS	O
were	O
first	O
separated	O
by	O
HPLC	O
.	O

The	O
column	O
(	O
5	O
μm	O
,	O
4.6	O
mm	O
I.D.	O
×150	O
mm	O
,	O
ODS80Ts	O
,	O
TOSOH	O
)	O
was	O
washed	O
at	O
a	O
flow	O
rate	O
of	O
0.6	O
ml	O
/	O
min	O
at	O
40	O
°	O
C	O
with	O
45	O
%	O
methanol	B
in	O
H2	B
O	I
containing	O
1	O
%	O
acetic	B
acid	I
for	O
10	O
min	O
and	O
then	O
the	O
concentration	O
of	O
methanol	B
was	O
increased	O
to	O
55	O
%	O
during	O
the	O
next	O
30	O
min	O
.	O

Detection	O
was	O
with	O
an	O
UV	O
monitor	O
at	O
254	O
nm	O
.	O

The	O
peak	O
at	O
R	O
t	O
=	O
16.3	O
min	O
was	O
collected	O
and	O
,	O
after	O
evaporation	O
of	O
the	O
solvent	B
,	O
the	O
residues	O
were	O
dissolved	O
in	O
methanol	B
and	O
reacted	O
with	O
trimethylsilyldiazomethane	B
in	O
the	O
dark	O
for	O
30	O
min	O
at	O
22	O
°	O
C	O
.	O

The	O
resulting	O
sample	O
was	O
subjected	O
to	O
GC	O
-	O
MS	O
(	O
Hewlett	O
Packard	O
5890	O
coupled	O
with	O
JEOL	O
JMS	O
-	O
SX102A	O
)	O
analysis	O
using	O
a	O
DB5	O
column	O
(	O
0.25	O
mm	O
I.D.	O
×30	O
m	O
,	O
film	O
thickness	O
0.25	O
μm	O
,	O
J	O
and	O
W	O
)	O
at	O
200	O
°	O
C	O
to	O
250	O
°	O
C	O
(	O
10	O
°	O
C	O
/	O
min	O
)	O
.	O

The	O
retention	O
time	O
and	O
mass	O
spectrum	O
were	O
found	O
to	O
be	O
identical	O
to	O
those	O
of	O
authentic	O
yangonin	B
:	O
GC	O
,	O
R	O
t	O
=	O
22	O
min	O
;	O
EIMS	O
(	O
70	O
eV	O
,	O
m	O
/z	O
)	O
,	O
258	O
(	O
M+	O
)	O
,	O
230	O
,	O
187	O
.	O

Production	O
of	O
CTAL	B
by	O
CHS	O
and	O
STS	O
was	O
confirmed	O
by	O
LC	O
-	O
MS	O
(	O
see	O
below	O
)	O
.	O

CTAL	B
:	O
Multi	O
-	O
stage	O
LC	O
-	O
APCIMS	O
,	O
MS	O
m	O
/z	O
273.1	O
[	O
M+H	O
]	O
+	O
,	O
271.1	O
[	O
M−H	O
]	O
−	O
,	O
MS	O
/	O
MS	O
(	O
precursor	O
ion	O
of	O
m	O
/z	O
271.1	O
)	O
227.2	O
[	O
M−H−CO2	O
]	O
−	O
,	O
MS	O
/	O
MS	O
/	O
MS	O
(	O
transitions	O
m	O
/z	O
271.1>227.2	O
)	O
185.2	O
[	O
M−H−CO2	O
−CH2	O
CO	O
]	O
−	O
.	O

2.5	O
Cross	O
-	O
reaction	O
The	O
enzyme	O
reaction	O
was	O
carried	O
out	O
under	O
the	O
same	O
conditions	O
as	O
described	O
above	O
except	O
that	O
the	O
reaction	O
volume	O
was	O
1	O
ml	O
and	O
about	O
50	O
μg	O
of	O
enzyme	O
(	O
10–40	O
pkat	O
/	O
mg	O
)	O
was	O
used	O
.	O

Radioactive	O
products	O
thus	O
obtained	O
were	O
redissolved	O
in	O
500	O
μl	O
of	O
50	O
%	O
aqueous	O
methanol	B
containing	O
1	O
%	O
acetic	B
acid	I
in	O
which	O
authentic	O
resveratrol	B
(	O
1.5	O
μg	O
)	O
and	O
naringenin	B
(	O
2	O
μg	O
)	O
were	O
added	O
.	O

Using	O
a	O
Hitachi	O
655	O
HPLC	O
system	O
and	O
ODS-80Ts	O
column	O
(	O
TOSOH	O
)	O
,	O
the	O
radioactive	O
products	O
were	O
separated	O
with	O
isocratic	O
elution	O
with	O
50	O
%	O
aqueous	O
methanol	B
containing	O
1	O
%	O
acetic	B
acid	I
for	O
30	O
min	O
.	O

Radioactivity	O
of	O
each	O
0.5	O
ml	O
fraction	O
was	O
measured	O
with	O
a	O
β	O
-	O
scintillation	O
counter	O
and	O
the	O
fractions	O
corresponding	O
to	O
main	O
product	O
(	O
naringenin	B
for	O
CHS	O
and	O
resveratrol	B
for	O
STS	O
)	O
and	O
cross	O
-	O
reaction	O
product	O
(	O
resveratrol	B
for	O
CHS	O
and	O
naringenin	B
for	O
STS	O
)	O
were	O
collected	O
.	O

For	O
carrier	O
dilution	O
analysis	O
,	O
recrystallization	O
of	O
the	O
radioactive	O
products	O
with	O
carrier	O
compounds	O
was	O
performed	O
at	O
least	O
four	O
times	O
in	O
two	O
different	O
solvent	B
systems	O
(	O
methanol	B
and	O
ethyl	B
acetate	I
/	O
hexane	B
)	O
and	O
specific	O
radioactivity	O
was	O
measured	O
after	O
each	O
recrystallization	O
step	O
.	O

The	O
identity	O
of	O
the	O
cross	O
-	O
reaction	O
products	O
was	O
further	O
confirmed	O
by	O
GC	O
-	O
MS	O
and	O
LC	O
-	O
MS	O
.	O

First	O
,	O
the	O
CHS	O
and	O
STS	O
reaction	O
products	O
were	O
methylated	O
with	O
trimethylsilyldiazomethane	B
and	O
analyzed	O
by	O
GC	O
-	O
MS	O
as	O
described	O
above	O
.	O

From	O
the	O
methylated	O
CHS	O
reaction	O
products	O
,	O
a	O
peak	O
of	O
m	O
/z	O
=	O
256	O
(	O
R	O
t	O
=	O
12.99	O
min	O
)	O
corresponding	O
to	O
dimethylresveratrol	B
was	O
detected	O
with	O
mono-	B
(	O
m	O
/z	O
286	O
)	O
,	O
di-	O
(	O
m	O
/z	O
300	O
)	O
and	O
trimethylnaringenin	B
(	O
m	O
/z	O
314	O
)	O
.	O

Likewise	O
,	O
a	O
peak	O
of	O
m	O
/z	O
=	O
300	O
(	O
R	O
t	O
=	O
15.35	O
min	O
)	O
corresponding	O
to	O
dimethylnaringenin	B
was	O
detected	O
from	O
the	O
methylated	O
STS	O
reaction	O
mixture	O
together	O
with	O
di-	B
(	O
m	O
/z	O
256	O
)	O
and	O
trimethylresveratrol	B
(	O
m	O
/z	O
270	O
)	O
.	O

For	O
LC	O
-	O
MS	O
analysis	O
,	O
Trx	O
-	O
CHS	O
(	O
11	O
mg	O
,	O
250	O
pkat	O
)	O
or	O
Trx	O
-	O
STS	O
(	O
9.5	O
mg	O
,	O
160	O
pkat	O
)	O
was	O
incubated	O
with	O
0.1	O
mM	O
p	B
-coumaroyl	I
-	I
CoA	I
and	O
0.3	O
mM	O
malonyl	B
-	I
CoA	I
in	O
50	O
ml	O
of	O
0.1	O
M	O
KPi	B
buffer	O
(	O
pH	O
7.4	O
)	O
containing	O
1	O
mM	O
DTT	B
for	O
40	O
min	O
at	O
37	O
°	O
C	O
.	O

At	O
the	O
end	O
of	O
incubation	O
,	O
the	O
pH	O
was	O
raised	O
to	O
9	O
with	O
1	O
N	O
NaOH	B
,	O
and	O
the	O
reaction	O
mixture	O
was	O
further	O
incubated	O
at	O
37	O
°	O
C	O
for	O
another	O
10	O
min	O
to	O
complete	O
chemical	B
transformation	O
of	O
naringenin	B
chalcone	I
to	O
naringenin	B
[	O
13	O
]	O
.	O

The	O
ethyl	B
acetate	I
extract	O
was	O
dried	O
over	O
Na2	B
SO4	I
and	O
the	O
solvent	B
was	O
removed	O
under	O
vacuum	O
at	O
30	O
°	O
C	O
.	O

The	O
remaining	O
products	O
were	O
analyzed	O
by	O
LC	O
-	O
MS	O
(	O
Thermoquest	O
LCQ	O
)	O
as	O
previously	O
described	O
[	O
14	O
]	O
.	O

Resveratrol	B
:	O
LC	O
-	O
APCIMS	O
(	O
positive	O
)	O
,	O
229.1	O
[	O
M+H	O
]	O
+	O
,	O
MS	O
/	O
MS	O
(	O
precursor	O
ion	O
at	O
229	O
)	O
m	O
/z	O
(	O
rel	O
.	O

%	O
)	O
211	O
(	O
65	O
)	O
,	O
135	O
(	O
100	O
)	O
,	O
119	O
(	O
12	O
)	O
,	O
107	O
(	O
11	O
)	O
.	O

Naringenin	B
:	O
LC	O
-	O
APCIMS	O
(	O
positive	O
)	O
,	O
273.2	O
[	O
M+H	O
]	O
+	O
,	O
MS	O
/	O
MS	O
(	O
precursor	O
ion	O
at	O
273	O
)	O
m	O
/z	O
(	O
rel	O
.	O

%	O
)	O
171	O
(	O
18	O
)	O
,	O
153	O
(	O
80	O
)	O
,	O
147	O
(	O
100	O
)	O
.	O

3	O
Results	O
3.1	O
Sequence	O
of	O
A.	O
hypogaea	O
STS	O
When	O
the	O
deduced	O
amino	B
acid	I
sequence	O
of	O
Japanese	O
peanut	O
STS	O
cloned	O
in	O
this	O
study	O
(	O
Accession	O
number	O
:	O
AB027606	O
)	O
was	O
compared	O
to	O
the	O
published	O
peanut	O
STS	O
sequence	O
(	O
Swiss	O
-	O
Prot	O
P20178	O
)	O
[	O
10	O
]	O
,	O
8	O
out	O
of	O
389	O
amino	B
acids	I
were	O
found	O
to	O
be	O
different	O
.	O

Those	O
are	O
Ser-46	B
corresponding	O
to	O
Gly-46	B
in	O
Ref	O
.	O

[	O
10	O
]	O
,	O
Ser-195	B
to	O
Ala-195	B
,	O
Ser-202	B
to	O
Asn-202	B
,	O
Leu-236	B
to	O
Ile-236	B
,	O
Asp-281	B
to	O
Gly-281	B
,	O
Pro-304	B
to	O
Leu-304	B
,	O
Glu-315	B
to	O
Gln-315	B
and	O
Ala-356	B
to	O
Thr-356	B
.	O

This	O
difference	O
in	O
amino	B
acid	I
sequence	O
probably	O
reflects	O
different	O
origins	O
of	O
the	O
plant	O
materials	O
used	O
.	O

3.2	O
Purification	O
of	O
CHS	O
and	O
STS	O
Purification	O
of	O
CHS	O
and	O
STS	O
overexpressed	O
in	O
E.	O
coli	O
is	O
summarized	O
in	O
Table	O
1	O
.	O

Typical	O
experiments	O
yielded	O
0.3–0.4	O
mg	O
of	O
apparently	O
homogeneous	O
enzymes	O
from	O
300	O
ml	O
bacteria	O
culture	O
(	O
Fig.	O
2A	O
)	O
.	O

Recovery	O
was	O
10–30	O
%	O
with	O
about	O
10-fold	O
enrichment	O
.	O

3.3	O
Identification	O
of	O
BNY	B
and	O
p	B
-coumaroyltriacetic	I
acid	I
lactone	I
Production	O
of	O
BNY	B
and	O
CTAL	B
by	O
STS	O
as	O
well	O
as	O
by	O
CHS	O
was	O
clearly	O
visualized	O
by	O
TLC	O
(	O
Fig.	O
2B	O
)	O
.	O

The	O
TLC	O
spots	O
were	O
identified	O
with	O
non	O
-	O
labeled	O
carrier	O
compounds	O
(	O
resveratrol	B
and	O
naringenin	B
)	O
and	O
with	O
parallel	O
experiment	O
using	O
p	O
-coumaroyltriacetic	O
acid	O
synthase	O
which	O
has	O
been	O
recently	O
cloned	O
from	O
Hydrangea	O
macrophylla	O
and	O
shown	O
to	O
produce	O
CTAL	B
and	O
BNY	B
as	O
the	O
main	O
product	O
and	O
a	O
major	O
byproduct	O
,	O
respectively	O
[	O
14	O
]	O
.	O

Further	O
,	O
the	O
identity	O
of	O
BNY	B
and	O
CTAL	B
was	O
unambiguously	O
determined	O
by	O
GC	O
-	O
MS	O
and	O
LC	O
-	O
MS	O
.	O

The	O
production	O
of	O
these	O
derailment	O
products	O
by	O
CHS	O
and	O
STS	O
were	O
dependent	O
on	O
the	O
presence	O
of	O
sulfhydryl	B
reagents	I
such	O
as	O
DTT	B
in	O
the	O
reaction	O
mixture	O
,	O
consistent	O
with	O
the	O
earlier	O
report	O
with	O
CHS	O
[	O
3	O
]	O
.	O

It	O
was	O
thought	O
that	O
sulfhydryl	B
reagent	I
would	O
act	O
as	O
an	O
acceptor	O
to	O
the	O
enzyme	O
-	O
bound	O
triketide	B
(	O
or	O
tetraketide	B
)	O
intermediate	O
in	O
a	O
non	O
-	O
enzymatic	O
trans	O
-esterification	O
to	O
form	O
unstable	O
thiol	B
adduct	O
,	O
which	O
should	O
be	O
immediately	O
converted	O
to	O
the	O
corresponding	O
pyrone	B
[	O
3	O
]	O
.	O

In	O
agreement	O
with	O
this	O
notion	O
,	O
DTT	B
showed	O
apparently	O
parallel	O
effects	O
on	O
formation	O
of	O
BNY	B
and	O
CTAL	B
.	O

However	O
,	O
the	O
requirement	O
of	O
the	O
sulfhydryl	B
reagent	I
was	O
not	O
absolute	O
,	O
as	O
these	O
byproducts	O
were	O
still	O
detectable	O
when	O
the	O
enzyme	O
reaction	O
was	O
carried	O
out	O
in	O
the	O
absence	O
of	O
DTT	B
(	O
data	O
not	O
shown	O
)	O
.	O

Acidification	O
of	O
the	O
reaction	O
mixture	O
to	O
pH<5	O
greatly	O
enhanced	O
the	O
amounts	O
of	O
BNY	B
and	O
CTAL	B
detected	O
on	O
TLC	O
.	O

These	O
results	O
suggest	O
that	O
the	O
majority	O
of	O
these	O
compounds	O
,	O
both	O
being	O
pyrone	B
derivatives	I
,	O
are	O
present	O
in	O
the	O
reaction	O
mixture	O
as	O
free	O
acids	B
at	O
neutral	O
pH	O
,	O
thus	O
poorly	O
extractable	O
by	O
ethyl	B
acetate	I
,	O
and	O
that	O
lactonization	O
to	O
form	O
pyrone	B
ring	O
is	O
non	O
-	O
enzymatic	O
.	O

Similar	O
pH	O
-	O
dependence	O
of	O
extraction	O
of	O
pyrone	B
derivatives	I
was	O
also	O
reported	O
recently	O
by	O
others	O
[	O
15	O
]	O
.	O

Whereas	O
CTAL	B
was	O
a	O
major	O
byproduct	O
of	O
the	O
CHS	O
reaction	O
,	O
BNY	B
was	O
a	O
major	O
byproduct	O
of	O
the	O
STS	O
reaction	O
(	O
Fig.	O
2B	O
)	O
.	O

3.4	O
Cross	O
-	O
reaction	O
When	O
the	O
reaction	O
products	O
produced	O
by	O
purified	O
recombinant	O
enzyme	O
were	O
analyzed	O
by	O
HPLC	O
,	O
a	O
small	O
radioactive	O
peak	O
corresponding	O
to	O
resveratrol	B
(	O
R	O
t	O
=	O
10	O
min	O
)	O
was	O
detected	O
in	O
the	O
CHS	O
products	O
and	O
a	O
peak	O
corresponding	O
to	O
naringenin	B
(	O
R	O
t	O
=	O
20	O
min	O
)	O
was	O
detected	O
in	O
the	O
STS	O
products	O
(	O
Fig.	O
3	O
)	O
.	O

Cross	O
-	O
reaction	O
was	O
verified	O
by	O
carrier	O
dilution	O
analysis	O
.	O

Successive	O
rounds	O
of	O
recrystallization	O
of	O
radioactive	O
products	O
in	O
the	O
presence	O
of	O
non	O
-	O
labeled	O
compounds	O
gave	O
crystals	O
of	O
constant	O
specific	O
radioactivity	O
.	O

For	O
resveratrol	B
produced	O
by	O
CHS	O
,	O
the	O
specific	O
radioactivity	O
was	O
8200	O
dpm	O
/	O
mmol	O
(	O
methanol	O
)	O
,	O
7300	O
(	O
methanol	B
)	O
,	O
7000	O
(	O
ethyl	B
acetate	I
/	O
hexane	B
)	O
and	O
6700	O
(	O
ethyl	B
acetate	I
/	O
hexane	B
)	O
,	O
and	O
for	O
naringenin	B
produced	O
by	O
STS	O
,	O
it	O
was	O
8900	O
dpm	O
/	O
mmol	O
(	O
methanol	B
)	O
,	O
7900	O
(	O
methanol	B
)	O
,	O
7500	O
(	O
ethyl	B
acetate	I
/	O
hexane	B
)	O
and	O
8300	O
(	O
ethyl	B
acetate	I
/	O
hexane	B
)	O
.	O

The	O
cross	O
-	O
reaction	O
was	O
determined	O
to	O
be	O
2.7–4.2	O
%	O
(	O
resveratrol	B
/	O
naringenin	B
)	O
for	O
CHS	O
and	O
1.4–2.3	O
%	O
(	O
naringenin	B
/	O
resveratrol	B
)	O
for	O
STS	O
.	O

The	O
cross	O
-	O
reaction	O
was	O
further	O
confirmed	O
by	O
GC	O
-	O
MS	O
and	O
LC	O
-	O
MS	O
analyses	O
.	O

The	O
retention	O
time	O
,	O
molecular	O
mass	O
and	O
major	O
daughter	O
ions	O
in	O
MS	O
/	O
MS	O
were	O
indistinguishable	O
to	O
those	O
of	O
authentic	O
compounds	O
and	O
those	O
found	O
in	O
the	O
literature	O
[	O
16	O
]	O
.	O

Trx	O
fusion	O
enzymes	O
were	O
indistinguishable	O
from	O
the	O
native	O
enzymes	O
with	O
regard	O
to	O
the	O
pattern	O
of	O
byproduct	O
production	O
and	O
kinetic	O
parameters	O
(	O
data	O
not	O
shown	O
)	O
.	O

4	O
Discussion	O
CHS	O
purified	O
from	O
plants	O
was	O
shown	O
to	O
produce	O
styrylpyrones	B
and	O
other	O
minor	O
byproducts	O
in	O
certain	O
in	O
vitro	O
conditions	O
[	O
3,4	O
]	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
showed	O
that	O
,	O
like	O
CHS	O
,	O
purified	O
recombinant	O
peanut	O
STS	O
produced	O
not	O
only	O
BNY	O
,	O
a	O
styrylpyrone	B
,	O
but	O
also	O
CTAL	B
,	O
the	O
recently	O
found	O
derailment	O
product	O
at	O
the	O
stage	O
of	O
tetraketide	B
intermediate	O
[	O
14	O
]	O
.	O

This	O
was	O
not	O
unexpected	O
since	O
it	O
has	O
been	O
thought	O
that	O
CHS	O
and	O
STS	O
catalyze	O
identical	O
condensation	O
steps	O
leading	O
to	O
the	O
linear	O
tetraketide	B
intermediate	O
prior	O
to	O
different	O
cyclization	O
steps	O
[	O
1	O
]	O
.	O

Detection	O
of	O
BNY	B
and	O
CTAL	B
from	O
the	O
STS	O
reaction	O
products	O
provides	O
an	O
unequivocal	O
evidence	O
for	O
this	O
notion	O
.	O

Under	O
the	O
conditions	O
employed	O
,	O
CHS	O
produces	O
more	O
byproducts	O
than	O
STS	O
(	O
Figs.	O
2B	O
and	O
3	O
)	O
.	O

This	O
may	O
reflect	O
the	O
more	O
loosely	O
structured	O
active	O
site	O
of	O
CHS	O
compared	O
with	O
that	O
of	O
STS	O
,	O
in	O
vitro	O
,	O
which	O
allows	O
to	O
a	O
greater	O
extent	O
premature	O
thioester	B
exchange	O
with	O
sulfhydryl	B
reagent	I
present	O
in	O
the	O
reaction	O
mixture	O
or	O
thioester	B
hydrolysis	O
by	O
water	B
to	O
give	O
derailment	O
products	O
.	O

CHS	O
is	O
believed	O
to	O
be	O
present	O
in	O
the	O
cell	O
as	O
a	O
part	O
of	O
multi	O
-	O
enzyme	O
complex	O
of	O
flavonoid	B
biosynthesis	O
including	O
polyketide	O
reductase	O
,	O
chalcone	O
isomerase	O
and	O
other	O
modifying	O
enzymes	O
to	O
achieve	O
'	O
metabolite	B
channeling	O
'	O
[	O
1,17	O
]	O
.	O

Cyclization	O
steps	O
in	O
CHS	O
and	O
STS	O
are	O
different	O
;	O
Dieckmann	O
condensation	O
leading	O
to	O
naringenin	B
chalcone	I
in	O
CHS	O
and	O
aldol	B
condensation	O
to	O
stilbene	B
in	O
STS	O
.	O

Nonetheless	O
,	O
CHS	O
and	O
STS	O
produce	O
counterpart	O
products	O
in	O
low	O
amounts	O
(	O
2–4	O
%	O
of	O
main	O
products	O
)	O
which	O
could	O
not	O
be	O
detected	O
by	O
routine	O
assays	O
.	O

The	O
possibility	O
that	O
the	O
cross	O
-	O
reaction	O
products	O
were	O
formed	O
during	O
work	O
-	O
up	O
by	O
chemical	B
transformation	O
was	O
thought	O
to	O
be	O
unlikely	O
based	O
on	O
the	O
following	O
.	O

First	O
,	O
although	O
the	O
corresponding	O
chemical	B
transformations	O
are	O
known	O
,	O
they	O
are	O
normally	O
carried	O
out	O
under	O
harsh	O
conditions	O
unlike	O
the	O
work	O
-	O
up	O
procedures	O
used	O
in	O
this	O
study	O
.	O

For	O
example	O
,	O
the	O
Dieckmann	O
condensation	O
of	O
methyl	B
ester	I
of	I
7-phenyl-3,5,7-trioxoheptanoic	I
acid	I
to	O
corresponding	O
acylphloroglucinol	B
required	O
a	O
prolonged	O
incubation	O
under	O
strongly	O
basic	O
conditions	O
,	O
such	O
as	O
2	O
M	O
KOH	B
[	O
18	O
]	O
.	O

Even	O
though	O
aldol	B
condensation	O
of	O
triketo	B
acids	I
can	O
proceed	O
in	O
weakly	O
acidic	B
(	O
pH	O
5	O
)	O
aqueous	O
buffer	O
,	O
the	O
products	O
are	O
fairly	O
stable	O
β	B
-	I
resorcylic	I
acids	I
[	O
18	O
]	O
.	O

Decarboxylation	O
of	O
aromatic	B
carboxylic	I
acids	I
such	O
as	O
conversion	O
of	O
6-styryl	B
-	I
β	I
-	I
resorcylic	I
acid	I
to	O
pinosylvin	B
and	O
of	O
orsellinic	B
acid	I
to	O
orcinol	B
have	O
been	O
achieved	O
either	O
by	O
heat	O
(	O
180	O
°	O
C	O
)	O
[	O
18,19	O
]	O
,	O
by	O
alcoholic	O
KOH	B
[	O
20	O
]	O
or	O
by	O
a	O
decarboxylase	O
[	O
21	O
]	O
.	O

It	O
should	O
be	O
noted	O
that	O
stilbene	B
carboxylic	I
acids	I
,	O
though	O
found	O
in	O
nature	O
[	O
22	O
]	O
,	O
have	O
not	O
been	O
detected	O
from	O
the	O
STS	O
reaction	O
mixture	O
.	O

Secondly	O
,	O
neither	O
naringenin	B
nor	O
resveratrol	B
was	O
detected	O
after	O
using	O
an	O
identical	O
work	O
-	O
up	O
procedure	O
in	O
the	O
reaction	O
mixture	O
produced	O
by	O
p	O
-coumaroyltriacetic	O
acid	O
synthase	O
(	O
CTAS	O
)	O
,	O
which	O
catalyzes	O
,	O
like	O
CHS	O
and	O
STS	O
,	O
three	O
condensation	O
reactions	O
between	O
p	B
-coumaroyl	I
-	I
CoA	I
and	O
malonyl	B
-	I
CoA	I
to	O
triketo	B
acid	I
but	O
does	O
not	O
catalyze	O
any	O
cyclization	O
reaction	O
[	O
14	O
]	O
.	O

This	O
suggested	O
that	O
lactonization	O
of	O
the	O
free	O
triketo	B
acid	I
predominates	O
during	O
work	O
-	O
up	O
to	O
give	O
CTAL	B
as	O
a	O
major	O
byproduct	O
(	O
Fig.	O
1	O
)	O
and	O
,	O
therefore	O
,	O
we	O
concluded	O
that	O
the	O
cross	O
-	O
reaction	O
of	O
CHS	O
and	O
STS	O
was	O
most	O
likely	O
enzymatic	O
of	O
nature	O
.	O

One	O
reasonable	O
interpretation	O
for	O
this	O
seemingly	O
unnatural	O
cross	O
-	O
reaction	O
is	O
that	O
parts	O
of	O
heterologously	O
overexpressed	O
enzymes	O
are	O
in	O
unnatural	O
conformational	O
states	O
and	O
these	O
misfolded	O
,	O
yet	O
soluble	O
enzymes	O
are	O
responsible	O
for	O
the	O
observed	O
cross	O
-	O
reaction	O
.	O

Overexpression	O
in	O
E.	O
coli	O
often	O
leads	O
to	O
misfolding	O
especially	O
for	O
membrane	O
-	O
associated	O
eukaryotic	O
proteins	O
,	O
as	O
bacteria	O
lack	O
an	O
intracellular	O
membrane	O
environment	O
that	O
may	O
be	O
necessary	O
for	O
efficient	O
and	O
accurate	O
folding	O
[	O
23	O
]	O
.	O

Both	O
CHS	O
and	O
STS	O
are	O
shown	O
to	O
be	O
weakly	O
membrane	O
-	O
associated	O
in	O
the	O
plant	O
cells	O
[	O
24,25	O
]	O
and	O
CHS	O
is	O
associated	O
with	O
other	O
enzymes	O
involved	O
in	O
the	O
flavonoid	B
biosynthesis	O
pathway	O
[	O
17	O
]	O
.	O

However	O
,	O
an	O
attempt	O
to	O
resolve	O
conformational	O
heterogeneity	O
using	O
hydroxyapatite	B
chromatography	O
was	O
unsuccessful	O
,	O
as	O
cross	O
-	O
reaction	O
activities	O
were	O
co	O
-	O
purified	O
with	O
the	O
natural	O
activities	O
(	O
data	O
not	O
shown	O
)	O
.	O

Another	O
intriguing	O
and	O
probably	O
more	O
conceivable	O
possibility	O
is	O
that	O
CHS	O
and	O
STS	O
possess	O
intrinsic	O
potential	O
to	O
catalyze	O
cross	O
-	O
reaction	O
possibly	O
due	O
to	O
conformational	O
flexibility	O
of	O
their	O
active	O
sites	O
,	O
and	O
that	O
this	O
intrinsic	O
,	O
yet	O
'	O
cryptic	O
'	O
capability	O
of	O
these	O
enzymes	O
to	O
perform	O
the	O
cross	O
-	O
reaction	O
was	O
manifested	O
under	O
non	O
-	O
optimal	O
folding	O
conditions	O
during	O
bacterial	O
overexpression	O
.	O

Our	O
recent	O
finding	O
that	O
cross	O
-	O
reaction	O
of	O
CHS	O
and	O
STS	O
expressed	O
in	O
eukaryotic	O
systems	O
(	O
yeasts	O
and	O
insect	O
cells	O
)	O
apparently	O
decreased	O
as	O
compared	O
to	O
the	O
cross	O
-	O
reaction	O
found	O
in	O
this	O
study	O
with	O
bacterial	O
expression	O
system	O
seems	O
to	O
support	O
this	O
idea	O
(	O
Sankawa	O
,	O
unpublished	O
data	O
)	O
.	O

In	O
line	O
with	O
this	O
idea	O
,	O
it	O
should	O
be	O
noted	O
that	O
cyclization	O
steps	O
in	O
CHS	O
and	O
STS	O
are	O
proposed	O
to	O
be	O
under	O
pure	O
topological	O
control	O
[	O
8	O
]	O
.	O

Indeed	O
,	O
the	O
recently	O
solved	O
crystal	O
structure	O
of	O
alfalfa	O
(	O
Medicago	O
sativa	O
)	O
CHS	O
by	O
Ferrer	O
et	O
al.	O
did	O
not	O
reveal	O
apparent	O
functional	O
amino	B
acids	I
in	O
the	O
cyclization	O
pocket	O
that	O
might	O
participate	O
in	O
a	O
specific	O
CHS	O
-	O
type	O
cyclization	O
reaction	O
[	O
26	O
]	O
.	O

The	O
authors	O
,	O
therefore	O
,	O
proposed	O
that	O
alterations	O
in	O
the	O
surface	O
topology	O
of	O
the	O
cyclization	O
pockets	O
of	O
CHS	O
and	O
STS	O
may	O
affect	O
the	O
stereochemistry	O
of	O
the	O
cyclization	O
reactions	O
.	O

Based	O
on	O
phylogenetic	O
analysis	O
,	O
Schröder	O
et	O
al.	O
[	O
2	O
]	O
proposed	O
different	O
STSs	O
evolved	O
from	O
CHSs	O
independently	O
several	O
times	O
by	O
a	O
limited	O
number	O
of	O
amino	B
acid	I
exchanges	O
.	O

However	O
,	O
consensus	O
(	O
signature	O
)	O
amino	B
acid	I
sequences	O
characteristic	O
to	O
CHS	O
or	O
to	O
STS	O
have	O
yet	O
to	O
be	O
recognized	O
.	O

It	O
may	O
result	O
from	O
the	O
insufficient	O
number	O
of	O
STS	O
sequences	O
available	O
(	O
6	O
entries	O
in	O
Swiss	O
-	O
Prot	O
)	O
.	O

On	O
the	O
other	O
hand	O
,	O
STS	O
conceivably	O
gained	O
its	O
new	O
activity	O
by	O
changing	O
active	O
site	O
geometry	O
rather	O
than	O
by	O
introducing	O
a	O
few	O
new	O
functional	O
amino	B
acids	I
in	O
the	O
active	O
site	O
of	O
STS	O
.	O

A	O
closely	O
related	O
case	O
can	O
be	O
found	O
in	O
chemical	O
diversity	O
of	O
higher	O
plant	O
fatty	B
acids	I
,	O
where	O
independent	O
,	O
multiple	O
evolution	O
of	O
oleate	O
12-hydroxylase	O
from	O
oleate	O
12-desaturase	O
was	O
proposed	O
.	O

Site	O
-	O
directed	O
mutagenesis	O
studies	O
involving	O
as	O
few	O
as	O
seven	O
amino	B
acids	I
suggested	O
that	O
catalytic	O
plasticity	O
in	O
these	O
two	O
enzymes	O
is	O
achieved	O
by	O
changing	O
active	O
site	O
geometry	O
leading	O
to	O
different	O
partitioning	O
of	O
a	O
common	O
intermediate	O
into	O
different	O
reaction	O
products	O
[	O
27	O
]	O
.	O

Clearly	O
,	O
further	O
studies	O
with	O
regard	O
to	O
the	O
origin	O
of	O
the	O
cross	O
-	O
reaction	O
of	O
CHS	O
and	O
STS	O
overexpressed	O
in	O
E.	O
coli	O
are	O
warranted	O
.	O

Acknowledgements	O
The	O
authors	O
are	O
grateful	O
to	O
the	O
Ministry	O
of	O
Education	O
,	O
Science	O
,	O
Sports	O
and	O
Culture	O
of	O
Japan	O
for	O
Grants	O
-	O
in	O
Aid	O
for	O
Scientific	O
Research	O
(	O
B	O
)	O
(	O
No.	O
09044212	O
)	O
and	O
(	O
C	O
)	O
(	O
No.	O
10680564	O
)	O
.	O

D	O
.-	O
Y.	O
Suh	O
thanks	O
the	O
Tokyo	O
Biochemistry	O
Research	O
Foundation	O
for	O
a	O
fellowship	O
(	O
TBRF-98	O
-	O
10	O
)	O
.	O

There	O
are	O
currently	O
several	O
potent	O
fungal	O
inhibitors	O
of	O
serine	O
palmitoyl-	O
transferase	O
(	O
3-ketosphinganine	O
synthase	O
)	O
[	O
palmitoyl	O
-	O
CoA	O
:	O
L	O
-	O
serine	O
C	O
-	O
pal-	O
mitoyltransferase	O
(	O
decarboxylating	O
)	O
;	O
EC	O
2.31.50	O
]	O
,	O
the	O
first	O
enzyme	O
in	O
the	O
de	O
novo	O
biosynthesis	O
of	O
ceramides	B
and	O
more	O
complex	O
sphingolipids	B
.	O

1'2	O
In	O
t	O
A.	O
H.	O
Merrill	O
,	O
Jr.	O
and	O
E.	O
Wang	O
,	O
Methods	O
Enzymol	O
.	O
51	O
,	O
427	O
(	O
1992	O
)	O
.	O

2	O
R.	O
C.	O
Dickson	O
,	O
R.	O
L.	O
Lester	O
,	O
and	O
M.	O
Marek	O
,	O
Methods	O
Enzymol	O
.	O

311	O
[	O
1	O
]	O
1999	O
(	O
this	O
volume	O
)	O
.	O

Copyright	O
©	O
1999	O
by	O
Academic	O
Press	O
All	O
rights	O
of	O
reproduction	O
in	O
any	O
form	O
reserved	O
.	O

0076	O
-	O
6879	O
/	O
99	O
$	O
30.00	O
METHODS	O
IN	O
ENZYMOLOGY	O
,	O
VOL	O
.	O

311	O
is	O
measured	O
when	O
casamino	B
acids	I
are	O
omitted	O
from	O
the	O
sphingolipid	B
inhibition	O
assay	O
and	O
the	O
comparatively	O
poor	O
activity	O
that	O
australifungin	B
demonstrates	O
in	O
medium	O
that	O
contains	O
serum	O
or	O
peptone	O
.	O

In	O
addition	O
to	O
the	O
loss	O
in	O
potency	O
,	O
caution	O
is	O
also	O
advised	O
when	O
using	O
australifungin	B
in	O
assays	O
that	O
employ	O
trace	O
amounts	O
of	O
sphingoid	B
bases	I
;	O
high	O
concentrations	O
of	O
australifungin	B
can	O
result	O
in	O
nonspecific	O
inhibition	O
due	O
to	O
sequestration	O
of	O
the	O
sphingoid	B
base	I
.	O

Serine	O
Palmitolytransferase	O
Inhibitors	O
Viridiofungins	B
are	O
at	O
least	O
five	O
-	O
fold	O
less	O
potent	O
and	O
are	O
not	O
as	O
specific	O
for	O
serine	O
palmitoyltransferase	O
inhibition	O
as	O
the	O
sphingofungin	B
/	O
myriocin	B
class	O
of	O
compounds	O
.	O

Viridiofungins	B
are	O
known	O
to	O
inhibit	O
squalene	O
synthase	O
,	O
geranyl	O
geranyltransferase	O
,	O
and	O
other	O
enzymes	O
that	O
are	O
sensitive	O
to	O
di-	B
and	O
tricarboxylic	B
acids	I
,	O
albeit	O
at	O
higher	O
concentrations	O
than	O
required	O
for	O
serine	O
palmitoyltransferase	O
inhibition	O
.	O

Because	O
of	O
this	O
difference	O
in	O
enzyme	O
sensi-	O
tivity	O
,	O
viridiofungin	B
A	I
showed	O
selective	O
inhibition	O
of	O
sphingolipid	B
synthesis	O
in	O
labeling	O
studies	O
in	O
C.	O
albicans	O
,	O
with	O
no	O
evidence	O
for	O
inhibition	O
of	O
sterol	B
synthesis	O
at	O
growth	O
inhibitory	O
concentrations	O
of	O
drug	B
.	O

7'22	O
For	O
unknown	O
reasons	O
,	O
viridiofungins	B
lack	O
in	O
vitro	O
activity	O
against	O
Saccharomyces	O
serine	O
palmitoyltransferase	O
and	O
do	O
not	O
inhibit	O
sphingolipid	B
synthesis	O
in	O
this	O
yeast	O
,	O
although	O
they	O
do	O
inhibit	O
the	O
mammalian	O
enzyme	O
and	O
appear	O
to	O
be	O
selective	O
for	O
sphingolipid	B
inhibition	O
in	O
HepG2	O
cells	O
.	O

2t~	O
A.	O
H.	O
Merrill	O
,	O
Jr.	O
,	O
D.	O
C.	O
Liotta	O
,	O
and	O
R.	O
T.	O
Riley	O
,	O
Trends	O
Cell	O
Biol	O
.	O

6	O
,	O
218	O
(	O
1996	O
)	O
.	O

3o	O
R.	O
T.	O
Riley	O
et	O
al.	O
,	O
J.	O
Food	O
Protect	O
.	O

57	O
,	O
638	O
(	O
1994	O
)	O
.	O

INHIBITORS	O
OF	O
SPHINGOLIPID	B
BIOSYNTHESIS	O
348	O
[	O
36	O
]	O
Inositol	O
Phosphoceramide	O
Synthase	O
Inhibitors	O
Unlike	O
inhibitors	O
to	O
earlier	O
steps	O
in	O
sphingolipid	B
synthesis	O
,	O
khafrefungin	B
and	O
rustmicin	B
do	O
not	O
have	O
any	O
detectable	O
effect	O
on	O
lipid	B
synthesis	O
in	O
mam-	O
malian	O
cells	O
(	O
unpublished	O
data	O
and	O
Ref	O
.	O
13	O
)	O
,	O
and	O
rustmicin	B
and	O
aureobasidin	B
A	O
have	O
been	O
nontoxic	O
in	O
animal	O
studies	O
,	O
a4'31	O
supporting	O
the	O
idea	O
that	O
inositol	O
phosphoceramide	O
synthase	O
is	O
a	O
fungal	O
selective	O
target	O
.	O

Khafrefungin	B
was	O
lytic	O
to	O
washed	O
red	O
blood	O
cells	O
at	O
12.5	O
to	O
25	O
/	O
xg	O
/	O
ml	O
.	O

However	O
,	O
this	O
toxicity	O
may	O
be	O
due	O
to	O
the	O
detergent	O
-	O
like	O
properties	O
of	O
the	O
compound	O
.	O

Although	O
all	O
three	O
inositol	O
phosphoceramide	O
synthase	O
inhibitors	O
are	O
very	O
potent	O
in	O
vitro	O
(	O
picomolar	O
to	O
low	O
nanomolar	O
)	O
,	O
substantially	O
higher	O
concentrations	O
are	O
required	O
to	O
kill	O
fungi	O
.	O

In	O
the	O
case	O
of	O
rustmicin	B
,	O
two	O
factors	O
that	O
limit	O
whole	O
cell	O
activity	O
were	O
identified	O
:	O
efflux	O
via	O
multidrug	O
transporters	O
and	O
chemical	B
instability	O
.	O

TM	O
Even	O
at	O
its	O
optimal	O
pH	O
of	O
5.5	O
,	O
rustmicin	B
degrades	O
relatively	O
rapidly	O
in	O
aqueous	O
media	O
.	O

Despite	O
these	O
limitations	O
,	O
concentrations	O
of	O
rust-	B
micin	I
that	O
are	O
required	O
to	O
completely	O
inhibit	O
phosphosphingolipid	B
synthesis	O
and	O
accumulate	O
ceramide	B
in	O
fungi	O
are	O
achieved	O
easily	O
.	O

Acknowledgments	O

We	O
thank	O
M.	O
Zweerink	O
and	O
BS	O
:	O
MIE	O
00110948	O
S0076	O
-	O
6879	O
(	O
00	O
)	O
11094	O
-	O
8	O
10.1016	O
/	O
S0076	O
-	O
6879	O
(	O
00	O
)	O
11094	O
-	O
8	O
Section	O
II	O
.	O

inhibitors	O
of	O
sphingolipid	B
biosynthesis	O
[	O
35	O
]	O
Isolation	O
and	O
characterization	O
of	O
novel	O
inhibitors	O
of	O
sphingolipid	B
synthesis	O
:	O
Australifungin	B
,	O
viridiofungins	B
,	O
rustmicin	B
,	O
and	O
khafrefungin	B
Suzanne	O
M.	O
Mandala	O
Guy	O
H.	O
Harris	O
Publisher	O
Summary	O
Sphingolipid	B
synthesis	O
is	O
an	O
essential	O
process	O
in	O
yeast	O
and	O
the	O
pathogenic	O
fungi	O
that	O
cause	O
life	O
-	O
threatening	O
human	O
infections	O
such	O
as	O
candidiasis	O
,	O
aspergillosis	O
,	O
and	O
cryptococcosis	O
.	O

Although	O
many	O
steps	O
in	O
the	O
human	O
and	O
fungal	O
sphingolipid	B
biosynthetic	O
pathway	O
are	O
similar	O
,	O
there	O
are	O
several	O
enzymes	O
found	O
uniquely	O
in	O
fungi	O
that	O
are	O
potential	O
targets	O
for	O
the	O
development	O
of	O
nontoxic	O
therapeutic	O
antifungals	O
.	O

In	O
the	O
screening	O
program	O
,	O
it	O
has	O
been	O
found	O
that	O
natural	B
products	I
are	O
a	O
rich	O
source	O
of	O
structurally	O
diverse	O
inhibitors	O
of	O
sphingolipid	B
synthesis	O
.	O

Natural	B
product	I
inhibitors	O
to	O
four	O
different	O
enzymes	O
that	O
affect	O
sphingolipid	B
synthesis	O
have	O
been	O
discovered	O
:	O
sphingofungins	B
,	O
lipoxamycin	B
,	O
myriocin	B
/	O
ISP1	B
,	O
and	O
viridiofungins	B
inhibit	O
serine	O
palmitoyltransferase	O
;	O
fumonisin	B
B1	I
and	O
australifungin	B
,	O
inhibit	O
ceramide	O
synthase	O
;	O
aureobasidins	B
,	O
khafrefungin	B
,	O
and	O
rustmicin	B
inhibit	O
inositol	O
phosphoceramide	O
synthase	O
;	O
and	O
minimoidin	B
inhibits	O
the	O
fatty	B
acid	I
elongation	O
pathway	O
.	O

Most	O
of	O
these	O
compounds	O
have	O
fungicidal	O
activity	O
against	O
a	O
broad	O
spectrum	O
of	O
pathogenic	O
fungi	O
,	O
but	O
only	O
the	O
inhibitors	O
of	O
inositol	O
phosphoceramide	B
are	O
fungal	O
selective	O
;	O
compounds	O
that	O
inhibit	O
early	O
biosynthetic	O
steps	O
show	O
comparable	O
activity	O
against	O
orthologous	O
mammalian	O
enzymes	O
.	O

This	O
chapter	O
describes	O
a	O
method	O
to	O
identify	O
sphingolipid	B
inhibitors	O
and	O
detailed	O
protocol	O
for	O
the	O
isolation	O
of	O
australifungin	B
.	O

More	O
abbreviated	O
descriptions	O
of	O
the	O
isolation	O
of	O
viridiofungins	B
,	O
khafrefungin	B
,	O
and	O
rustmicin	B
are	O
also	O
included	O
.	O

The	O
protein	O
mediator	O
known	O
as	O
macrophage	O
migration	O
inhibitory	O
factor	O
(	O
MIF	O
)	O
has	O
emerged	O
to	O
play	O
a	O
central	O
role	O
in	O
the	O
control	O
of	O
the	O
host	O
inflammatory	O
and	O
immune	O
response	O
.	O

Described	O
originally	O
as	O
a	O
lymphocyte	O
""""	O
activity	O
""""	O
responsible	O
for	O
inhibiting	O
the	O
random	O
migration	O
of	O
macrophages	O
in	O
vitro	O
,	O
l'z	O
MIF	O
has	O
been	O
shown	O
to	O
be	O
released	O
from	O
the	O
anterior	O
pituitary	O
gland	O
during	O
stress	O
and	O
to	O
be	O
critically	O
involved	O
in	O
the	O
toxic	O
response	O
to	O
septic	O
shock.3	O
Macrophages	O
,	O
T	O
cells	O
,	O
and	O
eosinophils	O
release	O
MIF	O
in	O
response	O
to	O
pro	O
-	O
inflammatory	O
stimuli	O
,	O
and	O
the	O
expression	O
of	O
MIF	O
is	O
required	O
for	O
T	O
-	O
cell	O
activation	O
and	O
antibody	O
production	O
by	O
B	O
cells.4'5	O
More	O
recent	O
studies	O
have	O
shown	O
that	O
macrophages	O
and	O
T	O
cells	O
can	O
secrete	O
MIF	O
in	O
response	O
to	O
glucocorticoid	B
stimulation	O
,	O
and	O
that	O
once	O
released	O
,	O
MIF	O
can	O
""""	O
override	O
""""	O
the	O
immuno	O
-	O
suppressive	O
effects	O
of	O
steroids	B
on	O
cytokine	O
production	O
and	O
cellular	O
activation.4'5	O
Studies	O
performed	O
in	O
models	O
of	O
the	O
inflammatory	O
and	O
immune	O
response	O
indicate	O
that	O
MIF	O
acts	O
extracellularly	O
by	O
stimulating	O
the	O
specific	O
response	O
of	O
target	O
cells	O
.	O

In	O
1996	O
however	O
,	O
Rorsman	O
et	O
al.	O
reported	O
that	O
recombinant	O
MIF	O
(	O
rMIF	O
)	O
catalyzes	O
a	O
tautomerization	O
reaction	O
,	O
converting	O
the	O
non	O
-	O
naturally	O
occurring	O
D	B
-	I
isomer	I
of	I
dopachrome	I
(	O
2-carboxy-2,3-dihydroindole-5,6-quinone	B
)	O
to	O
dihydroxyindole	B
carboxylic	I
acid	I
(	O
DHICA	B
)	O
.6	O
Intriguingly	O
,	O
subsequent	O
elucidation	O
of	O
the	O
three	O
-	O
dimensional	O
crystal	O
structure	O
of	O
MIF	O
revealed	O
it	O
to	O
exhibit	O
significant	O
three	O
-	O
dimensional	O
(	O
but	O
not	O
primary	O
sequence	O
)	O
homology	O
with	O
two	O
bacterial	O
isomerases	O
,	O
4-	O
oxalocrotonate	O
tautomerase	O
and	O
5-carboxymethyl-2-hydroxymuconate	O
isomerase.7	O
-	O
9	O
These	O
proteins	O
share	O
with	O
MIF	O
an	O
apparently	O
conserved	O
active	O
site	O
structure	O
that	O
consists	O
of	O
a	O
hydrophobic	O
cleft	O
bearing	O
an	O
active	O
site	O
proline	B
.	O

More	O
recently	O
,	O
Rorsman	O
and	O
colleagues	O
have	O
proposed	O
that	O
MIF	O
acts	O
physiologically	O
to	O
catalyze	O
the	O
keto	B
-	O
enol	B
tautomerization	O
of	O
p	B
-	I
hydroxyphenylpyruvate	I
and	O
phenylpyruvate.lFinally	B
,	O
the	O
presence	O
of	O
the	O
CXXC	O
*	O
Present	O
Address	O
:	O
Chemical	O
Development	O
,	O
New	O
Product	O
Research	O
,	O
R.	O
W.	O
Johnson	O
pharmaceutical	O
Research	O
Institute	O
,	O
Route	O
202	O
,	O
Raritan	O
,	O
NJ	O
08869	O
0960	O
-	O
894X	O
/	O
99	O
/	O
$	O
-	O
see	O
front	O
matter	O
1999	O
Elsevier	O
Science	O
Ltd.	O
All	O
rights	O
reserved	O
.	O

PII	O
:	O
S0960	O
-	O
894X	O
(	O
99	O
)	O
00561	O
-	O
2	O
3194	O
X.	O
Zhang	O
,	O
R.	O
Bucala	O
/	O
Bioorg	O
.	O

Med	O
.	O

Chem	O
.	O

Lett	O
.	O

9	O
(	O
1999	O
)	O
3193	O
-	O
3198	O
motif	O
in	O
MIF	O
has	O
prompted	O
yet	O
additional	O
studies	O
which	O
suggest	O
that	O
MIF	O
may	O
function	O
as	O
a	O
physiologically-	O
relevant	O
protein	O
-	O
thiol	O
oxidoreductase.~	O
These	O
observations	O
notwithstanding	O
,	O
the	O
precise	O
relationship	O
between	O
MIF	O
's	O
enzymatic	O
and	O
immunological	O
activities	O
remain	O
unclear	O
.	O

In	O
two	O
separate	O
studies	O
,	O
the	O
creation	O
of	O
an	O
enzymatically	O
-	O
inactive	O
form	O
of	O
MIF	O
by	O
site	O
-	O
directed	O
mutagenesis	O
shows	O
the	O
protein	O
retains	O
full	O
glucocorticoid	B
-	O
regulatory	O
activity,12	O
but	O
loses	O
neutrophil	O
priming	O
activity	O
)	O
3	O
In	O
an	O
effort	O
to	O
further	O
explore	O
the	O
mechanism	O
of	O
action	O
of	O
MIF	O
in	O
biological	O
systems	O
,	O
we	O
have	O
endeavored	O
to	O
identify	O
potential	O
small	B
molecule	I
inhibitors	O
of	O
MIF	O
's	O
isomerization	O
activity	O
.	O

We	O
report	O
herein	O
a	O
study	O
of	O
MIF	O
substrate	O
analogs	O
which	O
inhibit	O
dopachrome	B
tautomerization	O
at	O
concentrations	O
tenfold	O
less	O
than	O
substrate	O
.	O

Such	O
inhibitors	O
may	O
prove	O
useful	O
in	O
the	O
study	O
of	O
MIF	O
structure	O
function	O
relationships	O
and	O
also	O
assist	O
in	O
the	O
development	O
of	O
small	B
molecules	I
that	O
can	O
be	O
specifically	O
targeted	O
to	O
MIF	O
for	O
pharmacological	O
purposes	O
.	O

Materials	O
and	O
Methods	O
Reagents	O
.	O

All	O
chemicals	B
were	O
from	O
Sigma	O
(	O
St.	O
Louis	O
,	O
MA	O
)	O
or	O
Aldrich	O
(	O
Milwaukee	O
,	O
WI	O
)	O
.	O

Pure	O
,	O
bioactive	O
recombinant	O
human	O
MIF	O
was	O
prepared	O
by	O
expression	O
in	O
E.	O
coli	O
following	O
methods	O
described	O
previously	O
)	O
4	O
Preparation	O
of	O
MIF	O
Substrates	O
and	O
Analogs	O
.	O

The	O
MIF	O
-	O
substrates	O
lb-4b	O
(	O
Table	O
1	O
)	O
and	O
the	O
test	O
inhibitors	O
5b	O
-	O
llb	O
were	O
prepared	O
by	O
oxidizing	O
their	O
precursors	O
la-4a	O
and	O
5a-10a	O
with	O
soCum	O
periodate,7'8	B
as	O
shown	O
in	O
Scheme	O
1	O
.	O

Compounds	B
7a	B
and	O
8a	B
were	O
prepared	O
from	O
5a	B
and	O
6a	B
by	O
an	O
esterification	O
procedure.8	O

The	O
oxidation	O
was	O
performed	O
10	O
min	O
prior	O
to	O
the	O
tautomerization	O
assay	O
and	O
the	O
dopachrome	B
compounds	O
were	O
tested	O
without	O
further	O
purification	O
.	O

The	O
test	O
compounds	B
11	I
-	I
13	I
(	O
Table	O
1	O
)	O
were	O
obtained	O
from	O
Aldrich	O
.	O

Compd	O
D	O
/	O
L	O
RI	O
R2	O
R3	O
R1	O
,	O
.	O

O	O
~	O
R2	O
HO	O
~	O
R2	O
NalO4	O
HO	O
I.,~	O
/	O
Iql~23	O
HO	O
/	O
~-~.	O
/	O
-N	O
R3	O
a	O
b	O
1	O
2	O
3	O
4	O
5	O
6	O
7	O
8	O
9	O
l0	O
D	O
L	O
L	O
DL	O
L	O
DL	O
L	O
DL	O
DL	O
DL	O
H	O
H	O
H	O
H	O
H	O
H	O
H	O
H	O
OH	O
OH	O
H	O
H	O
H	O
H	O
Me	O
Me	O
Me	O
Me	O
H	O
H	O
CO2H	O
CO2H	O
CO2Me	O
CO2Me	O
CO2H	O
CO2H	O
CO2Me	O
CO2Me	O
CO2H	O
CH3	O
Scheme	O
1	O
Dopachrome	B
Tautomerization	O
Assay	O
.	O

The	O
DOPA	B
-	O
related	O
precursors	O
(	O
la-10a	B
)	O
were	O
prepared	O
as	O
10	O
mM	O
stock	O
solutions	O
in	O
MIF	O
assay	O
buffer	O
(	O
10	O
mM	O
sodium	B
phosphate	I
,	O
pH	O
6.0	O
)	O
.	O

Thirty	O
minutes	O
before	O
the	O
tautomerization	O
assay	O
,	O
1.0	O
mL	O
of	O
each	O
stock	O
solution	O
was	O
diluted	O
with	O
7	O
mL	O
of	O
assay	O
buffer	O
,	O
and	O
1.0	O
mL	O
of	O
sodium	B
periodate	I
stock	O
solution	O
(	O
20	O
mM	O
in	O
water	O
)	O
was	O
added	O
to	O
initiate	O
the	O
oxidation	O
of	O
the	O
precursors	O
,	O
thus	O
generating	O
each	O
respective	O
dopachrome	B
derivative	I
(	O
lb-10b	B
)	O
)	O
5	O
After	O
10	O
min	O
,	O
1	O
mL	O
of	O
methionine	B
(	O
20	O
mM	O
in	O
X	O
,	O
Zhang	O
,	O
R.	O
Bucala	O
/	O
Bioorg	O
.	O

Med	O
.	O

Chem	O
.	O

Lett	O
.	O

9	O
(	O
1999	O
)	O
3193	O
-	O
3198	O
3195	O
water	B
)	O
was	O
added	O
to	O
react	O
with	O
the	O
excess	O
periodate	B
.	O

The	O
dopachrome	B
compounds	O
were	O
generated	O
as	O
orange	O
solutions	O
at	O
a	O
final	O
concentration	O
of	O
1	O
mM.	O
Test	O
inhibitors	O
11	O
-	O
13	O
were	O
prepared	O
as	O
10	O
~M	O
stock	O
solution	O
and	O
diluted	O
to	O
1	O
mM	O
solution	O
with	O
assay	O
buffer	O
before	O
the	O
assay	O
.	O

To	O
perform	O
the	O
tautomerization	O
assay	O
,	O
0.5	O
mL	O
of	O
the	O
1	O
mM	O
solution	O
of	O
the	O
MIF	B
-	I
substrate	I
(	O
lb	B
,	O
2b	B
,	O
3b	B
,	O
or	O
4b	B
)	O
was	O
mixed	O
with	O
0.5	O
mL	O
of	O
assay	O
buffer	O
.	O

After	O
the	O
Table	O
1	O
.	O

Inhibition	O
of	O
MIF	O
tautomerase	O
activity	O
by	O
test	O
compounds	O
No.	O
Structure	O
5b	O
L-	O
HO	O
~	O
/	O
~N	O
""""	O
""""	O
CO2H	O
6b	O
7b	O
8b	O
9b	O
10b	O
11	O
12	O
13	O
DL-	O
DL-	O
HOAL'~'	O
/	O
L	O
~	O
N	O
""""	O
""""	O
CO2H	O
O	O

~e	O
L-	O
HO	O
"~'~""~"""	O
/	O
~N~	O
""""	O
CO2Me	O
DL-	O
HO	O
~	O
/	O
"t""~"	O
/	O
X~'N	O
""""	O
""""	O
CO2Me	O
OH	O
OH	O
OH	O
OH3	O
O	O
Conc	O
.	O

of	O
test	O
compounds	O
(	O
mM	O
)	O
0.5	O
0.5	O
0.5	O
0.5	O
0.5	O
0.25	O
0.125	O
0.06	O
0.5	O
0.25	O
0.125	O
0.06	O
0.5	O
0.25	O
0.125	O
0.02	O
0.5	O
0.5	O
%	O
inhibition	O
'	O
29	O
35	O
45	O
34	O
100	O
98	O
41	O
9	O
92	O
88	O
54	O
22	O
98	O
79	O
54	O
21	O
a0.5	O
mM	O
of	O
3b	O
was	O
used	O
as	O
MIF	B
-	I
substrate	I
in	O
this	O
assay	O
.	O

3196	O
X.	O
Zhang	O
,	O
R.	O
Bucala	O
/	O
Bioorg	O
.	O

Med	O
.	O

Chem	O
.	O

Lett	O
.	O

9	O
(	O
1999	O
)	O
3193	O
-	O
3198	O
background	O
rate	O
was	O
monitored	O
,	O
10	O
I.tL	O
of	O
recombinant	O
MIF	O
solution	O
from	O
a	O
20	O
mg	O
/	O
mL	O
stock	O
was	O
added	O
.	O

The	O
decrease	O
in	O
absorbance	O
(	O
~	O
,	O
=	O
475	O
nm	O
)	O
at	O
1	O
min	O
following	O
addition	O
of	O
MIF	O
was	O
measured	O
as	O
an	O
index	O
of	O
tautomerase	O
activity	O
,	O
For	O
the	O
inhibitory	O
assay	O
,	O
0.5	O
mL	O
of	O
the	O
1	O
mM	O
solution	O
of	O
the	O
MIF	B
-	I
substrate	I
(	O
3b	B
)	O
was	O
mixed	O
with	O
0.5	O
mL	O
of	O
the	O
1	O
mM	O
solution	O
of	O
one	O
of	O
the	O
test	O
inhibitors	O
(	O
5b-10b	O
and	O
11	O
-	O
13	O
)	O
,	O
followed	O
by	O
addition	O
of	O
10	O
mL	O
of	O
recombinant	O
MIF	O
stock	O
solution	O
(	O
20	O
mg	O
/	O
mL	O
)	O
.	O

Compounds	B
9b	B
,	O
10b	B
,	O
and	O
12	B
were	O
tested	O
at	O
final	O
concentrations	O
of	O
0.25	O
mM	O
,	O
0.125	O
mM	O
,	O
and	O
0.06	O
mM	O
in	O
addition	O
to	O
the	O
standard	O
0.5	O
mM	O
assay	O
.	O

The	O
percent	O
inhibition	O
of	O
the	O
decrease	O
in	O
absorbance	O
(	O
~	O
,	O
=	O
475	O
nm	O
)	O
at	O
1	O
min	O
in	O
the	O
presence	O
of	O
inhibitors	O
was	O
calculated	O
from	O
the	O
spectrophotometric	O
data	O
by	O
standard	O
methods.6	O
Results	O
and	O
Discussion	O
Tautomerization	O
of	O
an	O
orange	O
colored	O
solution	O
of	O
D	B
-	I
dopachrome	I
(	O
lb	B
)	O
by	O
MIF	O
produces	O
the	O
non	O
-	O
colored	O
DHICA.6	B
This	O
conversion	O
can	O
be	O
quantitated	O
spectrophotometrically	O
by	O
measuring	O
the	O
rate	O
of	O
decrease	O
of	O
the	O
iminochrome	B
absorbance	O
at	O
a	O
wavelength	O
of	O
475	O
nm	O
.	O

The	O
methyl	B
ester	I
derivatives	O
of	B
D-	B
(	O
or	O
L-	B
)	O
dopachrome	B
were	O
found	O
to	O
be	O
better	O
substrates	O
for	O
this	O
reaction	O
than	O
dopachromes	B
(	O
lb	B
and	O
2b	B
)	O
.	O

In	O
our	O
study	O
L	B
-	I
dopachrome	I
methyl	I
ester	I
3b	B
was	O
used	O
as	O
a	O
test	O
substrate	O
for	O
the	O
identification	O
of	O
compounds	O
with	O
the	O
ability	O
to	O
inhibit	O
the	O
tautomerization	O
reaction	O
.	O

The	O
dopachrome	B
tautomerization	O
by	O
MIF	O
may	O
occur	O
by	O
two	O
different	O
pathways	O
as	O
shown	O
in	O
Scheme	O
2	O
.	O

The	O
first	O
proceeds	O
via	O
the	O
initial	O
conversion	O
of	O
dopachrome	B
to	O
indolidine	B
14	B
and	O
subsequent	O
rearrangement	O
to	O
an	O
indole	B
.	O

A	O
possible	O
alternative	O
pathway	O
involves	O
the	O
formation	O
of	O
quinone	B
methide	I
intermediate	O
15	B
which	O
is	O
then	O
transformed	O
further	O
into	O
an	O
indole	B
.	O

H	O
H	O
O	O
H	O
H	O
H	O
O	O
H	O
H	O
H	O
.	O

HO~	O
""""	O
11	O
...	O
L	O

/	O
/	O
'--CO2R	O
HO	O
/	O
~	O
~N	O
14	O
HO	O
~	O
H	O
f	O
O	O
/	O
'~-.,J--~	O
N~	O
""""	O
CO2R	O
H	O
15	O
Scheme	O
2	O
HO	O
~	O
co2R	O
HO	O
/	O
~	O
~N	O
iH	O
Understanding	O
the	O
mechanism	O
of	O
MIF	O
catalyzed	O
substrate	O
tautomerization	O
is	O
helpful	O
in	O
the	O
design	O
and	O
search	O
of	O
MIF	O
inhibitors	O
.	O

Initial	O
molecular	O
modeling	O
studies	O
have	O
suggested	O
that	O
the	O
pathway	O
through	O
indolidine	B
14	B
might	O
be	O
favored	O
,	O
while	O
comparison	O
to	O
structurally	O
related	O
tautomerases	O
and	O
more	O
recent	O
mechanistic	O
data	O
have	O
favored	O
the	O
quinone	B
methide	I
pathway	O
.	O

16,17	O
It	O
is	O
known	O
that	O
s	B
-	I
methyl	I
quinone	I
methide	I
have	O
UV	O
and	O
visible	O
X.	O
Zhang	O
,	O
R.	O
Bucala	O
/	O
Bioorg	O
.	O

Med	O
.	O

Chem	O
.	O

Lett	O
.	O

9	O
(	O
1999	O
)	O
3193	O
-	O
3198	O
3197	O
spectra	O
which	O
are	O
easily	O
distinguished	O
from	O
the	O
corresponding	O
dopachrome	B
spectra.~	O

When	O
5b-41b	O
were	O
exposed	O
to	O
MIF	O
,	O
no	O
change	O
of	O
their	O
spectra	O
was	O
observed	O
.	O

This	O
observation	O
supports	O
the	O
indolidine	B
pathway	O
described	O
above	O
and	O
suggests	O
that	O
R	O
-	O
proton	O
extraction	O
is	O
the	O
initial	O
step	O
in	O
dopachrome	B
tautomerization	O
by	O
MIF	O
.	O

L-	B
and	O
DL-~-methyl	B
dopachrome	I
(	O
Sb	B
and	O
6b	B
)	O
and	O
their	O
methyl	B
esters	I
(	O
7b	B
and	O
8b	B
)	O
,	O
when	O
present	O
at	O
the	O
same	O
concentration	O
(	O
0.5	O
mM	O
)	O
as	O
the	O
MIF	B
-	I
substrate	I
3b	B
,	O
each	O
displayed	O
a	O
moderate	O
inhibitory	O
effect	O
on	O
MIF	O
tautomerase	O
activity	O
,	O
with	O
the	O
esters	B
showing	O
slightly	O
higher	O
activity	O
than	O
the	O
free	O
acids	B
as	O
shown	O
in	O
Table	O
1	O
.	O

The	O
moderate	O
inhibitory	O
activity	O
of	O
or	O
-	O
substituted	O
dopachromes	B
may	O
result	O
from	O
the	O
competition	O
with	O
MIF	B
-	I
substrate	I
3b	B
for	O
the	O
active	O
site	O
of	O
MIF	O
protein	O
.	O

To	O
identify	O
inhibitors	O
with	O
higher	O
activity	O
,	O
we	O
needed	O
to	O
design	O
compounds	O
with	O
stronger	O
binding	O
affinity	O
or	O
even	O
ones	O
capable	O
of	O
binding	O
covalently	O
to	O
the	O
MIF	O
protein	O
thereby	O
blocking	O
the	O
active	O
site	O
and	O
possibly	O
changing	O
the	O
secondary	O
structure	O
of	O
MIF	O
.	O

As	O
proposed	O
in	O
Scheme	O
3	O
,	O
dopachromes	B
with	O
a	O
leaving	B
group	I
at	O
~l	O
-	O
position	O
may	O
form	O
a	O
very	O
reactive	O
intermediate	B
16	I
following	O
et	O
-	O
deprotonation	O
by	O
MIF	O
.	O

Compound	B
16	I
may	O
react	O
with	O
nucleophilic	O
residues	O
of	O
the	O
MIF	O
protein	O
to	O
form	O
a	O
covalent	O
bond	O
with	O
the	O
protein	O
.	O

Our	O
data	O
have	O
indeed	O
shown	O
that	O
9b	B
,	O
10b	B
,	O
and	O
11	B
all	O
displayed	O
strong	O
inhibition	O
on	O
MIF	O
tautomerase	O
activity	O
(	O
Table	O
1	O
)	O
.	O

Particularly	O
,	O
compounds	O
9b	B
,	O
lOb	B
,	O
and	O
11	B
all	O
showed	O
about	O
50	O
%	O
inhibition	O
even	O
at	O
a	O
concentration	O
four	O
times	O
less	O
than	O
that	O
of	O
MIF	B
-	I
substrate	I
.	O

Further	O
,	O
10b	B
and	O
11	B
showed	O
activity	O
at	O
a	O
concentration	O
ten	O
times	O
less	O
than	O
that	O
of	O
MIF	B
-	I
substrate	I
.	O

Studies	O
of	O
the	O
proposed	O
MIF	O
-	O
covalent	O
complexes	O
(	O
MIF-10b	O
or	O
11	O
)	O
by	O
mass	O
spectrometry	O
were	O
,	O
however	O
,	O
inconclusive	O
.	O

Detailed	O
elucidation	O
of	O
the	O
nature	O
of	O
enhanced	O
binding	O
of	O
these	O
inhibitors	O
to	O
MIF	O
requires	O
further	O
study	O
.	O

H	O
H	O
MIF	O
O~~X-	O
HO~~N	O
H	O
R	O
HOI~	O
-N	O
R	O
HOI~	O
-N	O
HO	O
16	O
Scheme	O
3	O
Finally	O
,	O
we	O
examined	O
acyclic	O
compounds	O
containing	O
some	O
structural	O
features	O
similar	O
to	O
the	O
active	O
MIF	B
substrates	I
/	O
inhibitors	O
.	O

Thus	O
,	O
compounds	B
12	B
and	O
13	B
were	O
tested	O
and	O
found	O
to	O
be	O
inactive	O
in	O
the	O
MIF	O
tautomerization	O
assay	O
.	O

We	O
have	O
identified	O
several	O
inhibitors	O
of	O
MIF	O
tautomerase	O
activity	O
.	O

This	O
discovery	O
should	O
lead	O
to	O
the	O
development	O
of	O
inhibitors	O
of	O
MIF	O
biological	O
activities	O
and	O
the	O
development	O
of	O
agents	B
for	O
the	O
treatment	O
of	O
MIF	O
related	O
diseases	O
.	O

Acknowledgments	O
:	O
These	O
studies	O
were	O
supported	O
by	O
NIH	O
grant	O
AI35931	O
.	O

3198	O
X.	O
Zhang	O
,	O
R.	O
Bucala	O
/	O
Bioorg	O
.	O

Med	O
.	O

Chem	O
.	O

Lett	O
.	O

9	O
(	O
1999	O
)	O
3193	O
-	O
3198	O

Parasitic	O
diseases	O
caused	O
by	O
helminths	O
afflict	O
billions	O
of	O
people	O
worldwide	O
and	O
are	O
among	O
the	O
main	O
causes	O
of	O
morbidity	O
and	O
mortality	O
resulting	O
from	O
infectious	O
disease	O
.	O

Such	O
diseases	O
in	O
animals	O
also	O
have	O
major	O
economic	O
consequences	O
.	O

Recent	O
information	O
about	O
the	O
basic	O
biochemistry	O
and	O
the	O
immunological	O
responses	O
of	O
infected	O
hosts	O
to	O
parasitic	O
helminths	O
and	O
their	O
eggs	O
has	O
led	O
to	O
increased	O
interest	O
in	O
parasite	O
glycoconjugates	B
,	O
since	O
they	O
are	O
the	O
major	O
focus	O
of	O
the	O
immune	O
response	O
(	O
for	O
reviews	O
,	O
see	O
[	O
1–4	O
]	O
)	O
.	O

However	O
,	O
only	O
a	O
few	O
helminth	O
carbohydrate	B
structures	O
have	O
sofar	O
been	O
structurally	O
characterized	O
.	O

A	O
typical	O
feature	O
of	O
helminth	O
infections	O
is	O
the	O
induction	O
of	O
specific	O
IgE	O
[	O
5,6	O
]	O
and	O
this	O
is	O
the	O
result	O
of	O
a	O
T	O
-	O
helper-2	O
(	O
Th2	O
)	O
response	O
.	O

In	O
the	O
presence	O
of	O
antigen	B
this	O
IgE	O
triggers	O
the	O
activation	O
and	O
proliferation	O
of	O
mast	O
cells	O
and	O
eosinophils	O
(	O
i.e.	O
type	O
I	O
hypersensitivity	O
reactions	O
)	O
.	O

The	O
exact	O
implications	O
of	O
these	O
IgE	O
responses	O
,	O
however	O
,	O
are	O
still	O
unclear	O
.	O

Several	O
studies	O
have	O
shown	O
that	O
high	O
parasite	O
specific	O
IgE	O
levels	O
are	O
associated	O
with	O
resistance	O
to	O
reinfection	O
,	O
suggesting	O
a	O
protective	O
role	O
for	O
IgE	O
[	O
6–9	O
]	O
.	O

However	O
,	O
very	O
little	O
is	O
known	O
about	O
the	O
structures	O
of	O
the	O
parasite	O
antigens	B
that	O
induce	O
these	O
IgE	O
responses	O
.	O

N	B
-	I
glycans	I
carrying	O
a	O
'	O
core	O
α1→3-Fuc	B
'	I
(	I
R	I
-	I
GlcNAcβ1→4	I
(	I
Fucα1→3	I
)	I
GlcNAcβ1-Asn	I
)	I
or	O
a	O
'	O
core	O
β1→2-Xyl	B
'	I
(	I
Xylβ1→2Manβ1→4GlcNAcβ1-R	I
)	I
are	O
found	O
on	O
many	O
plant	O
,	O
insect	O
and	O
mollusc	O
,	O
but	O
not	O
mammalian	O
,	O
glycoproteins	O
[	O
10–14	O
]	O
,	O
and	O
can	O
contribute	O
to	O
the	O
allergenicity	O
and	O
IgE	O
cross	O
-	O
reactivity	O
between	O
extracts	O
of	O
these	O
organisms	O
[	O
15–17	O
]	O
.	O

Recently	O
it	O
has	O
been	O
reported	O
that	O
the	O
ruminant	O
nematode	O
Haemonchus	O
contortus	O
expresses	O
glycoproteins	O
carrying	O
core	O
α1→3-Fuc	B
residues	I
[	O
18	O
]	O
,	O
and	O
that	O
both	O
core	O
α1→3-Fuc	B
and	O
β1→2-Xyl	B
epitopes	I
have	O
been	O
observed	O
on	O
egg	O
glycoproteins	O
of	O
the	O
human	O
schistosomes	O
,	O
Schistosoma	O
mansoni	O
and	O
Schistosoma	O
japonicum	O
[	O
19	O
]	O
.	O

Thus	O
,	O
core	O
α1→3-Fuc	B
and	O
β1→2-Xyl	B
epitopes	I
might	O
contribute	O
to	O
the	O
IgE	O
response	O
observed	O
in	O
helminth	O
infections	O
.	O

To	O
identify	O
the	O
possible	O
presence	O
of	O
such	O
epitopes	O
in	O
other	O
helminths	O
,	O
we	O
have	O
analyzed	O
the	O
glycoproteins	O
of	O
different	O
parasitic	O
helminths	O
,	O
and	O
also	O
of	O
the	O
free	O
living	O
nematode	O
Caenorhabditis	O
elegans	O
in	O
Western	O
blots	O
using	O
immunopurified	O
core	O
α1→3-Fuc	O
specific	O
and	O
β1→2-Xyl	O
specific	O
antibodies	O
[	O
20	O
]	O
.	O

The	O
results	O
show	O
that	O
core	O
α1→3-fucosylation	O
and	O
β1→2-xylosylation	O
are	O
common	O
glycan	B
modifications	O
occurring	O
in	O
many	O
different	O
helminths	O
.	O

In	O
addition	O
,	O
we	O
report	O
that	O
glycans	B
carrying	O
core	O
α1→3-Fuc	B
are	O
recognized	O
by	O
IgE	O
antibodies	O
from	O
sheep	O
infected	O
with	O
H.	O
contortus	O
and	O
mice	O
infected	O
with	O
S.	O
mansoni	O
.	O

2	O
Materials	O
and	O
methods	O
2.1	O
Antigen	B
preparations	O
and	O
sera	O
Honeybee	O
venom	O
phospholipase	O
A2	O
(	O
PLA2	O
)	O
and	O
cucurbita	O
ascorbate	O
oxidase	O
were	O
purchased	O
from	O
Sigma	O
.	O

Adult	O
H.	O
contortus	O
were	O
obtained	O
post	O
mortem	O
from	O
the	O
abomasum	O
of	O
sheep	O
experimentally	O
infected	O
with	O
20	O
000	O
L3	O
larvae	O
.	O

H.	O
contortus	O
excretory	O
secretory	O
(	O
ES	O
)	O
products	O
were	O
obtained	O
as	O
described	O
before	O
[	O
21	O
]	O
.	O

Sheep	O
antisera	O
were	O
collected	O
28	O
days	O
after	O
infection	O
from	O
two	O
sheep	O
,	O
experimentally	O
infected	O
with	O
the	O
H.	O
contortus	O
larvae	O
.	O

The	O
preparation	O
of	O
extracts	O
of	O
adult	O
Dirofilaria	O
immitis	O
,	O
Hymenolepis	O
diminuta	O
,	O
Fasciola	O
hepatica	O
,	O
S.	O
mansoni	O
,	O
S.	O
japonicum	O
and	O
Schistosoma	O
haematobium	O
was	O
described	O
previously	O
[	O
22	O
]	O
.	O

Extracts	O
of	O
C.	O
elegans	O
were	O
generated	O
by	O
resuspending	O
the	O
worm	O
pellets	O
in	O
SDS	B
-	I
PAGE	I
buffer	O
,	O
followed	O
by	O
incubation	O
for	O
10	O
min	O
at	O
100	O
°	O
C	O
.	O

Insoluble	O
material	O
was	O
removed	O
by	O
centrifugation	O
.	O

Trichinella	O
spiralis	O
,	O
Toxocara	O
canis	O
and	O
cercariae	O
of	O
Trichobilharzia	O
ocellata	O
were	O
resuspended	O
in	O
100	O
μl	O
PBS	B
including	O
the	O
protease	O
inhibitors	O
Pefabloc	B
(	O
1	O
mg	O
/	O
ml	O
)	O
,	O
EDTA	B
(	O
0,5	O
mg	O
/	O
ml	O
)	O
,	O
leupeptin	B
(	O
10	O
μg	O
/	O
ml	O
)	O
,	O
pepstatin	B
(	O
10	O
μg	O
/	O
ml	O
)	O
,	O
aprotinin	O
(	O
1	O
μg	O
/	O
ml	O
)	O
(	O
Boehringer	O
Mannheim	O
)	O
,	O
and	O
homogenized	O
with	O
a	O
polytron	O
.	O

Triton	B
X-100	I
(	O
1	O
%	O
)	O
was	O
added	O
,	O
and	O
the	O
mixture	O
incubated	O
on	O
ice	B
for	O
20	O
min	O
.	O

After	O
addition	O
of	O
SDS	B
-	I
PAGE	I
buffer	O
and	O
incubation	O
for	O
10	O
min	O
at	O
100	O
°	O
C	O
,	O
insoluble	O
material	O
was	O
removed	O
by	O
centrifugation	O
.	O

2.2	O
Preparation	O
of	O
antisera	O
The	O
core	O
α1→3-Fuc	O
and	O
β1→2-Xyl	O
specific	O
antisera	O
were	O
prepared	O
as	O
described	O
previously	O
[	O
20	O
]	O
.	O

Briefly	O
,	O
antiserum	O
raised	O
against	O
horseradish	O
peroxidase	O
was	O
fractionated	O
on	O
an	O
affinity	O
column	O
of	O
honeybee	O
PLA2	O
,	O
resulting	O
in	O
serum	O
fractions	O
specific	O
for	O
core	O
α1→3-Fuc	B
and	O
β1→2-Xyl	B
,	O
respectively	O
.	O

Antisera	O
were	O
tested	O
for	O
their	O
specificity	O
as	O
described	O
.	O

2.3	O
SDS	O
-	O
PAGE	O
and	O
Western	O
blotting	O
Helminth	O
extracts	O
(	O
approximately	O
20–40	O
μg	O
of	O
protein	O
)	O
and	O
controls	O
were	O
separated	O
by	O
SDS	O
/	O
PAGE	O
on	O
15	O
%	O
gels	O
using	O
the	O
Mini	O
-	O
Protean	O
II	O
system	O
(	O
BioRad	O
)	O
.	O

Western	O
blotting	O
and	O
antibody	O
reactions	O
were	O
performed	O
essentially	O
as	O
described	O
previously	O
[	O
23	O
]	O
.	O

For	O
detection	O
of	O
core	O
α1→3-Fuc	O
and	O
β1→2-Xyl	O
containing	O
glycoproteins	O
,	O
rabbit	O
polyclonal	O
anti	O
-	O
core	O
α1→3-Fuc	O
or	O
anti	O
-	O
β1→2-Xyl	O
specific	O
antibodies	O
were	O
used	O
as	O
the	O
first	O
antibody	O
and	O
goat	O
anti	O
-	O
rabbit	O
(	O
IgG	O
/	O
IgM	O
)	O
peroxidase	O
conjugate	O
(	O
TAGO	O
,	O
Inc.	O
Immunodiagnostic	O
reagents	O
)	O
as	O
the	O
second	O
antibody	O
.	O

For	O
detection	O
of	O
mouse	O
IgE	O
(	O
Fig.	O
4	O
)	O
the	O
blots	O
were	O
incubated	O
overnight	O
with	O
1:2	O
diluted	O
mouse	O
serum	O
followed	O
by	O
incubation	O
with	O
rabbit	O
anti	O
-	O
mouse	O
IgE	O
peroxidase	O
conjugate	O
(	O
Nordic	O
,	O
the	O
Netherlands	O
)	O
for	O
1	O
h	O
at	O
room	O
temperature	O
.	O

Bound	O
antibodies	O
were	O
visualized	O
using	O
0.6	O
mg	O
/	O
ml	O
chloronaphtol	B
in	O
TBS	B
containing	O
0.03	O
%	O
H2	B
O2	I
.	O

2.4	O
ELISA	O
ELISA	O
was	O
performed	O
as	O
the	O
ES	O
specific	O
ELISA	O
described	O
previously	O
[	O
24	O
]	O
.	O

Plates	O
were	O
coated	O
with	O
H.	O
contortus	O
ES	O
,	O
PLA2	O
,	O
Arabidopsis	O
thaliana	O
,	O
A.	O
thaliana	O
cgl	O
,	O
and	O
human	O
transferrin	O
.	O

Competitive	O
glycoproteins	O
were	O
added	O
to	O
the	O
sheep	O
serum	O
in	O
a	O
final	O
concentration	O
range	O
of	O
80	O
to	O
0.026	O
μg	O
/	O
ml	O
.	O

Zero	O
%	O
inhibition	O
was	O
defined	O
as	O
the	O
OD	O
value	O
of	O
serum	O
without	O
competitive	O
glycoproteins	O
,	O
and	O
100	O
%	O
inhibition	O
as	O
the	O
OD	O
value	O
measured	O
with	O
80	O
μg	O
/	O
ml	O
autologous	O
glycoproteins	O
.	O

The	O
monosaccharides	B
D	B
-	I
Glc	I
,	O
L	B
-	I
Fuc	I
,	O
D	B
-	I
Xyl	I
or	O
L	B
-	I
Xyl	I
were	O
added	O
to	O
the	O
sheep	O
serum	O
in	O
a	O
final	O
concentration	O
range	O
of	O
0.01	O
to	O
1.4	O
M.	O
3	O
Results	O
3.1	O
Specificity	O
of	O
the	O
core	O
α1→3-Fuc	O
and	O
β1→2-Xyl	O
specific	O
antisera	O
The	O
antisera	O
used	O
in	O
this	O
study	O
were	O
raised	O
against	O
the	O
plant	O
glycoprotein	O
horseradish	O
peroxidase	O
,	O
which	O
carries	O
glycans	B
shown	O
in	O
Fig.	O
1	O
.	O

Fractionation	O
of	O
this	O
antiserum	O
on	O
an	O
affinity	O
column	O
of	O
honeybee	O
venom	O
phospholipase	O
A2	O
(	O
PLA2	O
)	O
resulted	O
in	O
serum	O
fractions	O
highly	O
specific	O
for	O
either	O
the	O
core	O
α1→3-Fuc	B
,	O
or	O
β1→2-Xyl	B
,	O
respectively	O
.	O

To	O
confirm	O
their	O
specificity	O
purified	O
antibodies	O
were	O
tested	O
with	O
many	O
different	O
plant	O
and	O
mammalian	O
glycoproteins	O
,	O
containing	O
either	O
a	O
core	O
α1→3-Fuc	B
or	O
a	O
β1→2-Xyl	B
,	O
or	O
no	O
core	O
modification	O
[	O
20	O
]	O
.	O

Furthermore	O
,	O
both	O
antisera	O
reacted	O
strongly	O
with	O
glycoproteins	O
isolated	O
from	O
the	O
leaves	O
of	O
A.	O
thaliana	O
(	O
Figs.	O
2	O
,	O
4C	O
and	O
D	O
)	O
,	O
the	O
N	B
-	I
glycans	I
of	O
which	O
have	O
been	O
fully	O
identified	O
recently	O
and	O
shown	O
to	O
consist	O
of	O
high	O
mannose	B
-	O
type	O
N	B
-	I
glycans	I
and	O
complex	O
-	O
type	O
core	O
α1→3-fucosylated	B
and	O
β1→2-xylosylated	B
N	I
-	I
glycans	I
[	O
25	O
]	O
.	O

No	O
other	O
complex	O
-	O
type	O
modifications	O
have	O
been	O
demonstrated	O
in	O
A.	O
thaliana	O
[	O
25	O
]	O
.	O

The	O
antisera	O
did	O
not	O
bind	O
to	O
glycoproteins	O
of	O
the	O
cgl	O
mutant	O
of	O
A.	O
thaliana	O
,	O
lacking	O
N	O
-acetylglucosaminyltransferase	O
I	O
,	O
and	O
thus	O
lacking	O
the	O
expression	O
of	O
the	O
core	O
α3-fucosylated	O
and	O
β2-xylosylated	B
N	I
-	I
glycans	I
[	O
26	O
]	O
(	O
Figs.	O
2	O
,	O
4C	O
and	O
D	O
)	O
.	O

Importantly	O
,	O
the	O
results	O
in	O
Fig.	O
2	O
show	O
that	O
no	O
cross	O
-	O
reactivity	O
was	O
observed	O
of	O
the	O
core	O
α1→3-Fuc	O
antiserum	O
with	O
LPS	B
from	O
Helicobacter	O
pylori	O
strain	O
O3	O
,	O
containing	O
Galβ1→4	B
(	I
Fucα1→3	I
)	I
GlcNAc	I
(	O
Lex	O
,	O
[	O
27	O
]	O
)	O
,	O
sialyl	B
-	I
Lex	I
containing	O
α1	O
-acid	O
glycoprotein	O
(	O
AGP	O
)	O
derived	O
from	O
patients	O
suffering	O
from	O
rheumatoid	O
arthritis	O
[	O
28	O
]	O
,	O
core	O
α1→6-fucosylated	O
human	O
IgG	O
,	O
or	O
neoglycoprotein	O
containing	O
GalNAcβ1→4	O
(	O
Fucα1→3	O
)	O
GlcNAc	O
(	O
LDNF	O
)	O
units	O
,	O
indicating	O
that	O
the	O
core	O
α1→3-Fuc	O
specific	O
antiserum	O
does	O
not	O
recognize	O
other	O
Fucα1→3GlcNAc	B
moieties	O
found	O
in	O
the	O
core	O
or	O
outer	O
antennae	O
of	O
N-	B
or	O
O	B
-	I
linked	I
glycans	I
.	O

3.2	O
Core	O
α1→3-Fuc	B
and	O
β1→2-Xyl	B
residues	I
on	O
protein	O
-	O
linked	O
glycans	B
of	O
different	O
helminths	O
The	O
presence	O
of	O
core	O
α1→3-Fuc	B
and	O
β1→2-Xyl	B
residues	I
on	O
protein	O
-	O
linked	O
glycans	B
of	O
different	O
helminths	O
was	O
determined	O
by	O
Western	O
blotting	O
,	O
using	O
the	O
affinity	O
purified	O
core	O
α1→3-Fuc	O
and	O
β1→2-Xyl	O
specific	O
antisera	O
[	O
20	O
]	O
.	O

The	O
extracts	O
were	O
derived	O
from	O
adult	O
helminths	O
,	O
except	O
the	O
extract	O
of	O
T.	O
ocellata	O
,	O
which	O
was	O
derived	O
from	O
cercariae	O
.	O

In	O
addition	O
to	O
the	O
adult	O
stages	O
,	O
soluble	O
antigens	B
were	O
tested	O
from	O
H.	O
contortus	O
(	O
i.e.	O
excretory	B
/	I
secretory	I
(	O
ES	O
)	O
antigens	B
)	O
and	O
S.	O
mansoni	O
(	O
soluble	B
egg	I
antigens	I
(	O
SE	O
)	O
)	O
.	O

The	O
extracts	O
from	O
most	O
helminths	O
tested	O
contained	O
many	O
glycoproteins	O
that	O
reacted	O
moderate	O
to	O
strongly	O
with	O
the	O
core	O
α1→3-Fuc	O
specific	O
antibodies	O
,	O
whereas	O
reaction	O
of	O
H.	O
diminuta	O
,	O
F.	O
hepatica	O
and	O
T.	O
canis	O
glycoproteins	O
was	O
less	O
abundant	O
(	O
Fig.	O
3	O
,	O
upper	O
panel	O
)	O
.	O

The	O
β1→2-Xyl	O
specific	O
antiserum	O
showed	O
binding	O
to	O
glycoproteins	O
of	O
some	O
of	O
the	O
extracts	O
,	O
i.e.	O
of	O
C.	O
elegans	O
,	O
S.	O
mansoni	O
,	O
S.	O
haematobium	O
,	O
S.	O
mansoni	O
SE	B
antigens	I
,	O
D.	O
immitis	O
,	O
T.	O
canis	O
,	O
and	O
of	O
cercariae	O
of	O
T.	O
ocellata	O
,	O
whereas	O
no	O
binding	O
was	O
observed	O
with	O
the	O
other	O
parasite	O
derived	O
samples	O
(	O
Fig.	O
3	O
,	O
lower	O
panel	O
)	O
.	O

3.3	O
IgE	O
in	O
sera	O
of	O
S.	O
mansoni	O
infected	O
mice	O
cross	O
-	O
reacts	O
with	O
A.	O
thaliana	O
glycoproteins	O
We	O
next	O
sought	O
to	O
determine	O
whether	O
infection	O
of	O
mice	O
with	O
S.	O
mansoni	O
results	O
in	O
IgE	O
to	O
core	O
α1→3-fucosylated	B
and/or	O
β1→2-xylosylated	B
N	I
-	I
glycans	I
.	O

Western	O
blots	O
containing	O
proteins	O
of	O
S.	O
mansoni	O
,	O
A.	O
thaliana	O
[	O
25	O
]	O
and	O
the	O
cgl	O
mutant	O
of	O
A.	O
thaliana	O
lacking	O
the	O
core	O
antigens	B
[	O
26	O
]	O
,	O
were	O
analyzed	O
using	O
different	O
antibodies	O
.	O

IgE	O
from	O
pooled	O
sera	O
of	O
mice	O
experimentally	O
infected	O
with	O
S.	O
mansoni	O
binds	O
to	O
several	O
S.	O
mansoni	O
proteins	O
,	O
in	O
contrast	O
to	O
IgE	O
from	O
normal	O
mouse	O
serum	O
that	O
showed	O
no	O
reactivity	O
.	O

IgE	O
from	O
the	O
infected	O
mice	O
serum	O
cross	O
-	O
reacted	O
with	O
many	O
proteins	O
of	O
A.	O
thaliana	O
,	O
but	O
not	O
with	O
the	O
cgl	O
mutant	O
,	O
indicating	O
that	O
the	O
antibodies	O
specifically	O
recognize	O
complex	O
-	O
type	O
glycans	B
carrying	O
a	O
core	O
α1→3-Fuc	B
or	O
β1→2-Xyl	B
residue	I
(	O
Fig.	O
4	O
)	O
.	O

We	O
also	O
could	O
detect	O
a	O
weak	O
binding	O
of	O
the	O
IgE	O
antibodies	O
from	O
infected	O
mice	O
with	O
honeybee	O
PLA2	O
(	O
data	O
not	O
shown	O
)	O
,	O
suggesting	O
that	O
the	O
core	O
-	O
linked	O
α1→3-Fuc	B
is	O
an	O
epitope	O
for	O
IgE	O
of	O
S.	O
mansoni	O
infected	O
mice	O
.	O

3.4	O
IgE	O
in	O
sera	O
from	O
H.	O
contortus	O
infected	O
sheep	O
recognizes	O
core	O
α1→3-fucosylated	B
N	I
-	I
glycans	I
Sera	O
from	O
sheep	O
infected	O
with	O
H.	O
contortus	O
were	O
analyzed	O
by	O
ELISA	O
.	O

The	O
results	O
in	O
Fig.	O
5A	O
show	O
that	O
IgE	O
in	O
serum	O
of	O
infected	O
sheep	O
recognizes	O
H.	O
contortus	O
ES	O
glycoproteins	O
,	O
honeybee	O
PLA2	O
and	O
A.	O
thaliana	O
glycoproteins	O
,	O
and	O
did	O
not	O
recognize	O
human	O
transferrin	O
or	O
glycoproteins	O
from	O
the	O
cgl	O
mutant	O
of	O
A.	O
thaliana	O
lacking	O
the	O
core	O
antigens	B
.	O

In	O
contrast	O
,	O
binding	O
of	O
IgG	O
antibodies	O
from	O
the	O
infected	O
sheep	O
sera	O
to	O
A.	O
thaliana	O
and	O
PLA2	O
proteins	O
was	O
hardly	O
detectable	O
,	O
whereas	O
IgG	O
binding	O
was	O
observed	O
to	O
many	O
H.	O
contortus	O
ES	O
proteins	O
(	O
Fig.	O
5A	O
,	O
[	O
29	O
]	O
)	O
.	O

These	O
results	O
suggest	O
that	O
IgE	O
from	O
the	O
sera	O
of	O
H.	O
contortus	O
infected	O
sheep	O
recognizes	O
the	O
core	O
α1→3-Fuc	B
epitope	I
that	O
occurs	O
on	O
both	O
plant	O
glycoproteins	O
and	O
honeybee	O
PLA2	O
.	O

To	O
further	O
validate	O
this	O
possibility	O
,	O
inhibition	O
experiments	O
were	O
performed	O
(	O
Fig.	O
5B	O
,	O
C	O
)	O
.	O

It	O
was	O
shown	O
that	O
PLA2	O
could	O
block	O
the	O
binding	O
of	O
IgE	O
from	O
infected	O
sheep	O
to	O
ES	O
.	O

Similarly	O
,	O
ES	O
could	O
block	O
the	O
binding	O
of	O
this	O
IgE	O
to	O
PLA2	O
,	O
whereas	O
human	O
transferrin	O
lacking	O
the	O
core	O
fucose	B
did	O
not	O
block	O
the	O
IgE	O
binding	O
.	O

Binding	O
of	O
sheep	O
IgE	O
to	O
H.	O
contortus	O
ES	O
was	O
inhibited	O
to	O
80	O
%	O
by	O
L	B
-	I
Fuc	I
at	O
a	O
concentration	O
of	O
1	O
M	O
,	O
whereas	O
the	O
same	O
concentrations	O
of	O
D	B
-	I
Xyl	I
,	O
L	B
-	I
Xyl	I
or	O
D	B
-	I
Glc	I
showed	O
only	O
25	O
%	O
inhibition	O
in	O
the	O
same	O
experiment	O
(	O
data	O
not	O
shown	O
)	O
.	O

These	O
results	O
demonstrate	O
that	O
an	O
important	O
part	O
of	O
the	O
ES	O
specific	O
IgE	O
in	O
the	O
sera	O
of	O
H.	O
contortus	O
infected	O
sheep	O
recognizes	O
core	O
α1→3-fucosylated	B
N	I
-	I
glycans	I
.	O

4	O
Discussion	O
We	O
report	O
in	O
this	O
study	O
that	O
IgE	O
from	O
serum	O
of	O
S.	O
mansoni	O
infected	O
mice	O
and	O
H.	O
contortus	O
infected	O
sheep	O
cross	O
-	O
reacts	O
with	O
A.	O
thaliana	O
glycoproteins	O
that	O
carry	O
core	O
α1→3-fucosylated	B
and	O
β1→2-xylosylated	B
N	I
-	I
glycans	I
.	O

In	O
contrast	O
,	O
IgE	O
from	O
these	O
sera	O
did	O
not	O
bind	O
to	O
glycoproteins	O
of	O
the	O
cgl	O
mutant	O
of	O
A.	O
thaliana	O
,	O
that	O
lack	O
the	O
core	O
antigens	B
and	O
other	O
complex	O
-	O
type	O
glycan	B
modifications	O
[	O
14,25,26	O
]	O
.	O

These	O
results	O
indicate	O
that	O
the	O
core	O
α1→3-Fuc	B
and/or	O
the	O
β1→2-Xyl	B
residues	I
are	O
epitopes	O
for	O
both	O
IgE	O
from	O
S.	O
mansoni	O
infected	O
mice	O
and	O
H.	O
contortus	O
infected	O
sheep	O
.	O

It	O
has	O
been	O
reported	O
that	O
the	O
human	O
schistosome	O
S.	O
mansoni	O
synthesizes	O
glycoproteins	O
carrying	O
both	O
core	O
α1→3-Fuc	B
and	O
β1→2-Xyl	B
residues	I
[	O
19	O
]	O
,	O
which	O
was	O
confirmed	O
by	O
our	O
studies	O
using	O
the	O
affinity	O
purified	O
α1→3-Fuc	O
and	O
β1→2-Xyl	O
specific	O
antibodies	O
.	O

Since	O
these	O
core	O
antigens	B
do	O
not	O
occur	O
in	O
mammals	O
they	O
may	O
induce	O
the	O
generation	O
of	O
anti	O
-	O
glycan	O
antibodies	O
during	O
schistosome	O
infection	O
.	O

We	O
can	O
not	O
deduce	O
from	O
our	O
data	O
whether	O
one	O
or	O
both	O
of	O
the	O
core	O
antigens	B
in	O
A.	O
thaliana	O
are	O
involved	O
in	O
binding	O
of	O
IgE	O
from	O
S.	O
mansoni	O
infected	O
mice	O
.	O

In	O
contrast	O
,	O
the	O
ruminant	O
nematode	O
H.	O
contortus	O
contains	O
glycoproteins	O
carrying	O
core	O
α1→3-fucosylated	B
N	I
-	I
glycans	I
but	O
no	O
evidence	O
was	O
presented	O
for	O
the	O
presence	O
of	O
a	O
β1→2-Xyl	B
(	O
[	O
18	O
]	O
,	O
this	O
study	O
)	O
.	O

This	O
suggests	O
that	O
the	O
core	O
α1→3-Fuc	B
is	O
likely	O
to	O
be	O
the	O
A.	O
thaliana	O
epitope	O
that	O
reacted	O
with	O
IgE	O
from	O
H.	O
contortus	O
infected	O
sheep	O
.	O

Evidence	O
is	O
presented	O
using	O
both	O
ELISA	O
and	O
competitive	O
ELISA	O
that	O
the	O
core	O
α1→3-Fuc	B
residue	I
indeed	O
is	O
a	O
major	O
epitope	O
recognized	O
by	O
parasite	O
specific	O
IgE	O
from	O
serum	O
of	O
H.	O
contortus	O
infected	O
sheep	O
.	O

Importantly	O
,	O
hardly	O
any	O
IgG	O
reactivity	O
to	O
this	O
core	O
antigen	B
was	O
demonstrable	O
in	O
these	O
sera	O
.	O

In	O
contrast	O
,	O
IgM	O
or	O
IgG	O
antibodies	O
have	O
been	O
demonstrated	O
in	O
sera	O
of	O
parasite	O
infected	O
hosts	O
to	O
other	O
parasite	O
derived	O
carbohydrate	B
components	O
(	O
[	O
30	O
]	O
;	O
Van	O
Remoortere	O
et	O
al.	O
,	O
manuscript	O
in	O
preparation	O
)	O
.	O

This	O
suggests	O
that	O
the	O
core	O
α1→3-Fuc	B
epitope	I
preferentially	O
triggers	O
a	O
Th2	O
response	O
leading	O
to	O
the	O
production	O
of	O
IgE	O
,	O
although	O
we	O
can	O
not	O
rule	O
out	O
the	O
possibility	O
that	O
the	O
core	O
fucose	B
specific	O
IgE	O
is	O
a	O
product	O
rather	O
than	O
an	O
inducer	O
of	O
a	O
Th2	O
response	O
.	O

Interestingly	O
,	O
several	O
T	O
cell	O
clones	O
have	O
been	O
identified	O
from	O
bee	O
venom	O
sensitized	O
subjects	O
which	O
proliferate	O
in	O
response	O
to	O
honeybee	O
PLA2	O
but	O
not	O
to	O
its	O
non	O
-	O
glycosylated	O
variants	O
,	O
providing	O
evidence	O
for	O
the	O
involvement	O
of	O
an	O
N	B
-	I
glycan	I
in	O
T	O
cell	O
recognition	O
[	O
31	O
]	O
.	O

It	O
will	O
be	O
important	O
to	O
establish	O
whether	O
the	O
core	O
α-1→3-Fuc	B
antigen	I
is	O
involved	O
in	O
these	O
immunological	O
processes	O
.	O

Recently	O
it	O
has	O
been	O
demonstrated	O
that	O
vaccination	O
of	O
sheep	O
with	O
ES	O
antigens	B
of	O
H.	O
contortus	O
induces	O
protection	O
against	O
challenge	O
infection	O
and	O
that	O
this	O
protection	O
is	O
correlated	O
with	O
IgE	O
rather	O
than	O
with	O
IgG	O
[	O
32	O
]	O
.	O

It	O
thus	O
appears	O
that	O
the	O
core	O
α1→3-Fuc	B
antigen	I
may	O
be	O
an	O
important	O
protective	O
antigen	B
in	O
H.	O
contortus	O
infections	O
,	O
and	O
perhaps	O
other	O
helminth	O
infections	O
.	O

To	O
identify	O
the	O
possible	O
presence	O
of	O
core	O
-	O
fucosylated	B
and	O
core	O
-	O
xylosylated	B
epitopes	I
in	O
other	O
helminths	O
we	O
analyzed	O
different	O
species	O
.	O

Our	O
results	O
show	O
that	O
many	O
helminths	O
from	O
different	O
orders	O
of	O
the	O
phyla	O
Platyhelminthes	O
and	O
Nematodes	O
synthesize	O
glycoproteins	O
containing	O
core	O
α1→3-fucosylated	B
N	I
-	I
glycans	I
.	O

In	O
addition	O
several	O
of	O
these	O
organisms	O
also	O
synthesize	O
N	B
-	I
glycans	I
containing	O
β1→2-Xyl	O
.	O

Remarkably	O
,	O
only	O
small	O
amounts	O
of	O
β1→2-Xyl	B
were	O
found	O
on	O
glycoproteins	O
of	O
adult	O
S.	O
japonicum	O
,	O
whereas	O
the	O
related	O
S.	O
mansoni	O
and	O
S.	O
haematobium	O
showed	O
many	O
β1→2-xylosylated	O
glycoproteins	O
.	O

Recent	O
data	O
from	O
Khoo	O
et	O
al.	O
[	O
19	O
]	O
described	O
the	O
presence	O
of	O
β1→2-xylosylated	B
N	I
-	I
glycans	I
in	O
egg	O
glycoproteins	O
of	O
S.	O
japonicum	O
.	O

It	O
may	O
be	O
possible	O
that	O
in	O
S.	O
japonicum	O
β1→2-xylosylation	O
is	O
stage	O
specific	O
.	O

Alternatively	O
,	O
the	O
plant	O
specific	O
antiserum	O
may	O
be	O
unable	O
to	O
bind	O
some	O
core	O
β1→2-Xyl	B
residues	I
,	O
due	O
to	O
masking	O
of	O
the	O
epitope	O
,	O
e.g.	O
by	O
the	O
presence	O
of	O
multiple	O
core	O
fucose	B
residues	O
[	O
19	O
]	O
or	O
other	O
modifications	O
.	O

Cross	O
-	O
reactivity	O
has	O
been	O
observed	O
for	O
many	O
years	O
in	O
immunoassays	O
of	O
plant	O
,	O
arthropod	O
and	O
mollusc	O
extracts	O
[	O
33–35	O
]	O
.	O

Part	O
of	O
this	O
cross	O
-	O
reactivity	O
is	O
caused	O
by	O
conserved	O
proteins	O
,	O
as	O
profilins	O
in	O
plants	O
[	O
36	O
]	O
,	O
and	O
tropomyosins	O
in	O
crustacea	O
and	O
mollusca	O
[	O
37	O
]	O
.	O

In	O
addition	O
,	O
cross	O
-	O
reactivity	O
between	O
several	O
parasitic	O
helminths	O
,	O
and	O
between	O
helminths	O
and	O
molluscs	O
has	O
been	O
reported	O
[	O
38–40	O
]	O
.	O

The	O
highly	O
antigenic	O
core	O
α1→3-Fuc	B
and/or	O
β1→2-Xyl	B
in	O
N	B
-	I
glycans	I
,	O
that	O
are	O
conserved	O
among	O
many	O
invertebrates	O
and	O
plants	O
,	O
have	O
been	O
shown	O
to	O
contribute	O
to	O
such	O
cross	O
-	O
reactions	O
[	O
35,41	O
]	O
.	O

In	O
some	O
cases	O
it	O
has	O
been	O
established	O
that	O
IgE	O
antibodies	O
from	O
patients	O
allergic	O
for	O
honeybee	O
venom	O
or	O
plant	O
substances	O
such	O
as	O
cereal	O
flour	O
proteins	O
bind	O
to	O
core	O
α1→3-Fuc	B
and/or	O
β1→2-Xyl	B
containing	I
N	I
-	I
glycans	I
[	O
15–17	O
]	O
.	O

Our	O
results	O
indicate	O
that	O
the	O
core	O
α1→3-Fuc	B
structure	O
is	O
commonly	O
found	O
on	O
helminth	O
glycoproteins	O
and	O
that	O
IgE	O
antibodies	O
from	O
helminth	O
infected	O
hosts	O
bind	O
to	O
this	O
glycan	B
epitope	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
description	O
of	O
an	O
antigen	B
that	O
may	O
be	O
important	O
in	O
the	O
induction	O
of	O
both	O
helminth	O
-	O
mediated	O
Th2-type	O
immunity	O
and	O
in	O
allergic	O
reactions	O
.	O

Recognition	O
of	O
putative	O
features	O
common	O
to	O
helminths	O
presumably	O
informs	O
the	O
host	O
immune	O
system	O
that	O
a	O
stereotypic	O
type	O
2	O
cytokine	O
response	O
will	O
be	O
more	O
protective	O
than	O
a	O
type	O
1	O
or	O
type	O
0	O
.	O

It	O
has	O
been	O
hypothesized	O
previously	O
that	O
some	O
of	O
these	O
helminth	O
features	O
are	O
shared	O
with	O
allergens	B
and	O
may	O
be	O
responsible	O
for	O
the	O
obviously	O
maladaptive	O
responses	O
made	O
to	O
non	O
-	O
threatening	O
molecules	O
as	O
pollen	O
antigens	B
and	O
bee	O
venom	O
phospholipase	O
[	O
42	O
]	O
.	O

This	O
stresses	O
the	O
importance	O
of	O
the	O
conserved	O
core	O
α1→3-Fuc	B
epitope	I
as	O
a	O
potential	O
'	O
pan	O
allergen	B
'	O
[	O
41	O
]	O
.	O

Interestingly	O
,	O
several	O
studies	O
have	O
shown	O
an	O
inverse	O
relationship	O
between	O
exposure	O
to	O
helminth	O
infections	O
and	O
the	O
incidence	O
of	O
allergies	O
[	O
43–45	O
]	O
.	O

It	O
is	O
exciting	O
to	O
consider	O
the	O
possibility	O
that	O
detailed	O
knowledge	O
of	O
the	O
parasite	O
structures	O
involved	O
in	O
Th2	O
activation	O
and	O
IgE	O
induction	O
and	O
a	O
better	O
understanding	O
of	O
the	O
mechanism	O
by	O
which	O
they	O
evoke	O
these	O
immune	O
responses	O
may	O
lead	O
to	O
novel	O
therapies	O
against	O
both	O
parasitic	O
diseases	O
and	O
atopic	O
disorders	O
.	O

Acknowledgments	O
We	O
gratefully	O
acknowledge	O
Ms.	O
A.	O
van	O
Tetering	O
for	O
technical	O
assistance	O
in	O
part	O
of	O
the	O
work	O
.	O

We	O
thank	O
Dr.	O
A.M.	O
Deelder	O
(	O
Dept	O
.	O

of	O
Parasitology	O
,	O
Leiden	O
,	O
The	O
Netherlands	O
)	O
for	O
serum	O
from	O
schistosome	O
infected	O
mice	O
,	O
Dr.	O
H.	O
Bakker	O
(	O
CPRO	O
-	O
DLO	O
,	O
Wageningen	O
,	O
The	O
Netherlands	O
)	O
for	O
extracts	O
of	O
A.	O
thaliana	O
,	O
Dr.	O
H.	O
van	O
Luenen	O
(	O
NKI	O
,	O
Amsterdam	O
,	O
The	O
Netherlands	O
)	O
for	O
C.	O
elegans	O
,	O
Drs	O
.	O

A.K.	O
Nyame	O
(	O
University	O
of	O
Oklahoma	O
,	O
USA	O
)	O
,	O
Y.	O
Rombouts	O
(	O
RIVM	O
,	O
Bilthoven	O
,	O
The	O
Netherlands	O
)	O
,	O
and	O
M.	O
de	O
Jong	O
-	O
Brink	O
(	O
Dept	O
.	O

of	O
Neurobiology	O
,	O
VU	O
,	O
Amsterdam	O
,	O
The	O
Netherlands	O
)	O
for	O
parasites	O
and	O
parasite	O
extracts	O
,	O
Drs	O
A.	O
van	O
Remoortere	O
(	O
Dept	O
.	O
of	O
Medical	O
Chemistry	O
,	O
VU	O
,	O
Amsterdam	O
,	O
The	O
Netherlands	O
)	O
for	O
gift	O
of	O
neoglycoprotein	O
,	O
Dr.	O
B.	O
Appelmelk	O
(	O
Dept	O
.	O
of	O
Medical	O
Microbiology	O
,	O
VU	O
,	O
Amsterdam	O
,	O
The	O
Netherlands	O
)	O
for	O
H.	O
pylori	O
LPS	O
,	O
and	O
Dr.	O
W.	O
van	O
Dijk	O
(	O
Dept	O
.	O
of	O
Medical	O
Chemistry	O
,	O
VU	O
,	O
Amsterdam	O
,	O
The	O
Netherlands	O
)	O
for	O
AGP	O
.	O

We	O
thank	O
Dr.	O
P.	O
Lerouge	O
(	O
CNRS	O
,	O
Rouen	O
,	O
France	O
)	O
for	O
stimulating	O
discussions	O
and	O
Dr.	O
A.W.	O
Cornelissen	O
(	O
Dept	O
.	O

of	O
Parasitology	O
,	O
Utrecht	O
,	O
The	O
Netherlands	O
)	O
for	O
critical	O
reading	O
of	O
the	O
manuscript	O
.	O

L.V.	O
was	O
supported	O
by	O
a	O
grant	O
from	O
The	O
Technology	O
Foundation	O
(	O
STW	O
,	O
The	O
Netherlands	O
;	O
project	O
:	O
UDG55.3762	O
)	O
.	O

Collaboration	O
between	O
Drs	O
.	O

I.	O
van	O
Die	O
and	O
R.	O
Cummings	O
was	O
facilitated	O
by	O
a	O
NATO	O
Collaborative	O
Research	O
Grant	O
(	O
CRG972098	O
)	O
.	O

It	O
is	O
now	O
well	O
established	O
that	O
there	O
are	O
two	O
isozymes	O
of	O
prostaglandin	O
(	O
PG	O
)	O
-forming	O
cyclooxygenase	O
;	O
constitutive	O
cyclooxygenase-1	O
and	O
inducible	O
cyclooxygenase-2	O
[	O
1,2	O
]	O
.	O

MC3T3-E1	O
cell	O
cloned	O
from	O
newborn	O
mouse	O
calvaria	O
is	O
an	O
osteogenic	O
cell	O
line	O
which	O
differentiates	O
into	O
an	O
osteoblast	O
[	O
3,4	O
]	O
.	O

Much	O
earlier	O
our	O
extensive	O
studies	O
demonstrated	O
the	O
production	O
of	O
E2	B
as	O
a	O
major	O
arachidonate	B
metabolite	O
in	O
this	O
cell	O
line	O
[	O
5	O
]	O
and	O
the	O
induction	O
of	O
cyclooxygenase	O
by	O
various	O
bioregulators	O
[	O
5–9	O
]	O
.	O

Later	O
the	O
induced	O
enzyme	O
in	O
MC3T3-E1	O
cells	O
was	O
identified	O
as	O
cyclooxygenase-2	O
[	O
8–10	O
]	O
.	O

Previously	O
humulon	B
(	O
(	B
R	I
)	I
-3,5,6-trihydroxy-4,6-bis	I
(	I
3-methyl-2-butenyl	I
)	I
-2-	I
(	I
3-methyl-1-oxobutyl	I
)	I
-2,4-cyclohexadien-1-one	I
)	O
(	O
Fig.	O
1	O
)	O
isolated	O
from	O
hop	O
(	O
Humulus	O
lupulus	O
L.	O
)	O
extract	O
was	O
found	O
as	O
an	O
inhibitor	O
of	O
bone	O
resorption	O
(	O
IC50	O
:	O
5.9	O
nM	O
)	O
[	O
11	O
]	O
.	O

We	O
noted	O
this	O
activity	O
of	O
humulon	B
,	O
and	O
were	O
interested	O
in	O
a	O
possible	O
inhibitory	O
or	O
suppressive	O
effect	O
of	O
humulon	B
on	O
cyclooxygenase-2	O
leading	O
to	O
a	O
decreased	O
production	O
of	O
PGE2	B
as	O
a	O
bone	O
resorption	O
factor	O
[	O
12	O
]	O
.	O

2	O
Materials	O
and	O
methods	O
2.1	O
Materials	O
Humulon	B
was	O
purified	O
from	O
hop	O
paste	O
as	O
described	O
previously	O
[	O
11	O
]	O
,	O
and	O
the	O
purified	O
material	O
was	O
dissolved	O
in	O
dimethyl	B
sulfoxide	I
at	O
a	O
concentration	O
of	O
10	O
mM.	O
MC3T3-E1	O
cells	O
were	O
cultured	O
as	O
described	O
previously	O
[	O
5	O
]	O
.	O

Confluent	O
cultures	O
were	O
usually	O
obtained	O
on	O
the	O
4th	O
day	O
.	O

Then	O
,	O
the	O
medium	O
was	O
changed	O
to	O
α	B
-	I
MEM	I
(	O
Life	O
Technologies	O
,	O
Gaithersburg	O
,	O
MD	O
,	O
USA	O
)	O
supplemented	O
with	O
2	O
%	O
newborn	O
bovine	O
serum	O
(	O
Irvine	O
Scientific	O
,	O
Santa	O
Ana	O
,	O
CA	O
,	O
USA	O
)	O
and	O
a	O
compound	O
to	O
be	O
tested	O
.	O

At	O
indicated	O
time	O
intervals	O
,	O
the	O
cells	O
were	O
scraped	O
from	O
dishes	O
and	O
subjected	O
to	O
various	O
assays	O
described	O
below	O
.	O

2.2	O
Assays	O
of	O
cyclooxygenase-1	O
and	O
-2	O
activities	O
For	O
cyclooxygenase-1	O
preparation	O
,	O
lyophilized	O
powder	O
of	O
sheep	O
seminal	O
vesicle	O
microsomes	O
(	O
Eldan	O
Technologies	O
,	O
Jerusalem	O
,	O
Israel	O
)	O
was	O
suspended	O
in	O
20	O
mM	O
phosphate	B
buffer	I
(	O
pH	O
7.4	O
)	O
containing	O
5	O
mM	O
tryptophan	B
.	O

For	O
cyclooxygenase-2	O
preparation	O
,	O
5	O
×	O
107	O
MC3T3-E1	O
cells	O
were	O
incubated	O
with	O
100	O
nM	O
phorbol	B
12-myristate	I
13-acetate	I
and	O
100	O
nM	O
A23187	B
for	O
9	O
h.	O
The	O
cells	O
were	O
subjected	O
to	O
sonic	O
disruption	O
,	O
and	O
centrifuged	O
at	O
180	O
000	O
×	O
g	O
for	O
50	O
min	O
.	O

The	O
resultant	O
pellet	O
was	O
collected	O
as	O
the	O
microsomal	O
fraction	O
,	O
and	O
suspended	O
in	O
1	O
ml	O
of	O
20	O
mM	O
Tris	B
–	I
HCl	I
(	O
pH	O
7.4	O
)	O
containing	O
5	O
mM	O
tryptophan	B
.	O

The	O
enzyme	O
assay	O
was	O
performed	O
as	O
described	O
previously	O
[	O
9	O
]	O
.	O

2.3	O
Cyclooxygenase-2	O
induction	O
MC3T3-E1	O
cells	O
(	O
2.2	O
×	O
106	O
cells	O
)	O
were	O
incubated	O
with	O
tumor	O
necrosis	O
factor	O
α	O
(	O
TNFα	O
)	O
(	O
10–20	O
ng	O
/	O
ml	O
)	O
.	O

For	O
determination	O
of	O
PGE2	B
synthesis	O
,	O
aliquots	O
were	O
removed	O
from	O
the	O
culture	O
medium	O
(	O
1	O
ml	O
)	O
of	O
3	O
×	O
105	O
MC3T3-E1	O
cells	O
,	O
and	O
subjected	O
to	O
radioimmunoassay	O
for	O
PGE2	B
as	O
described	O
previously	O
[	O
5	O
]	O
.	O

For	O
catalytic	O
activity	O
assay	O
,	O
the	O
cells	O
were	O
scraped	O
from	O
the	O
dishes	O
,	O
suspended	O
in	O
200	O
μl	O
of	O
20	O
mM	O
Tris	B
–	I
HCl	I
(	O
pH	O
7.4	O
)	O
containing	O
5	O
mM	O
tryptophan	B
,	O
and	O
subjected	O
to	O
sonication	O
.	O

Aliquots	O
(	O
1–30	O
μl	O
)	O
of	O
the	O
sonicate	O
were	O
incubated	O
with	O
10	O
μM	O
[	B
1	I
-	I
14	I
C	I
]	I
arachidonic	I
acid	I
(	O
2.1	O
GBq	O
/	O
mmol	O
,	O
Amersham	O
Pharmacia	O
Biotech	O
,	O
Bucks	O
,	O
UK	O
)	O
for	O
2	O
min	O
at	O
24	O
°	O
C	O
in	O
a	O
100-μl	O
mixture	O
containing	O
100	O
mM	O
Tris	B
–	I
HCl	I
(	O
pH	O
8.0	O
)	O
,	O
2	O
μM	O
hematin	B
,	O
and	O
5	O
mM	O
tryptophan	B
.	O

The	O
reaction	O
products	O
were	O
separated	O
by	O
thin	O
-	O
layer	O
chromatography	O
as	O
described	O
previously	O
[	O
9	O
]	O
.	O

Total	O
RNA	O
was	O
extracted	O
from	O
MC3T3-E1	O
cells	O
using	O
ISOGEN	O
(	O
Nippon	O
Gene	O
,	O
Tokyo	O
,	O
Japan	O
)	O
and	O
subjected	O
to	O
Northern	O
blot	O
analysis	O
for	O
cyclooxygenase-2	O
and	O
β	O
-	O
actin	O
mRNA	O
as	O
described	O
previously	O
[	O
8	O
]	O
.	O

2.4	O
Reporter	O
gene	O
assay	O
A	O
DNA	O
fragment	O
(	O
nucleotides	O
−815	O
to	O
+	O
123	O
)	O
was	O
prepared	O
from	O
the	O
5′-flanking	O
region	O
of	O
the	O
mouse	O
cyclooxygenase-2	O
gene	O
as	O
described	O
previously	O
[	O
9	O
]	O
,	O
and	O
was	O
inserted	O
into	O
the	O
luciferase	O
plasmid	O
pGL3	O
Basic	O
(	O
Promega	O
,	O
Madison	O
,	O
WI	O
,	O
USA	O
)	O
.	O

The	O
complementary	O
oligonucleotide	B
with	O
a	O
specific	O
sequence	O
of	O
glucocorticoid	B
response	O
element	O
(	O
5′-AGAGGATCTGTACA	B
GGATGTTCT	I
AGAT-3′	I
;	O
consensus	O
sequence	O
of	O
the	O
glucocorticoid	B
response	O
element	O
is	O
underlined	O
)	O
was	O
synthesized	O
essentially	O
by	O
the	O
same	O
method	O
as	O
described	O
previously	O
[	O
9	O
]	O
.	O

The	O
oligonucleotide	B
of	O
the	O
glucocorticoid	B
response	O
element	O
,	O
NFκB	O
response	O
element	O
[	O
9	O
]	O
or	O
NF	O
-	O
IL6	O
response	O
element	O
[	O
9	O
]	O
was	O
inserted	O
in	O
front	O
of	O
the	O
herpes	O
simplex	O
virus	O
thymidine	O
kinase	O
gene	O
[	O
13	O
]	O
of	O
the	O
tk	O
-	O
pGL3	O
vector	O
[	O
14	O
]	O
.	O

For	O
the	O
transfection	O
of	O
luciferase	O
plasmid	O
,	O
7.8	O
×	O
105	O
confluent	O
cells	O
were	O
treated	O
with	O
pGL3	O
plasmid	O
DNA	O
(	O
3	O
μg	O
)	O
,	O
standard	O
β	O
-	O
galactosidase	O
DNA	O
(	O
1.5	O
μg	O
)	O
,	O
and	O
13.5	O
μl	O
of	O
Trans	O
IT	O
™	O
-LT1	O
(	O
Takara	O
,	O
Tokyo	O
,	O
Japan	O
)	O
in	O
2.3	O
ml	O
of	O
serum	O
-	O
free	O
α	B
-	I
MEM	I
for	O
4	O
h	O
at	O
37	O
°	O
C	O
.	O

After	O
transfection	O
the	O
medium	O
was	O
changed	O
to	O
5	O
ml	O
of	O
α	B
-	I
MEM	I
with	O
10	O
%	O
fetal	O
bovine	O
serum	O
(	O
Life	O
Technologies	O
,	O
Gaithersburg	O
,	O
MD	O
,	O
USA	O
)	O
,	O
and	O
the	O
transfected	O
cells	O
were	O
further	O
incubated	O
for	O
3	O
days	O
.	O

The	O
medium	O
was	O
changed	O
to	O
α	B
-	I
MEM	I
described	O
above	O
.	O

After	O
12	O
h	O
the	O
cells	O
were	O
scraped	O
from	O
the	O
dishes	O
,	O
and	O
the	O
luciferase	O
assay	O
was	O
performed	O
as	O
described	O
previously	O
[	O
9	O
]	O
.	O

The	O
results	O
were	O
normalized	O
with	O
β	O
-	O
galactosidase	O
activity	O
.	O

3	O
Results	O
We	O
investigated	O
the	O
possibility	O
that	O
humulon	B
suppressed	O
the	O
TNFα	O
-	O
mediated	O
induction	O
of	O
cyclooxygenase-2	O
.	O

When	O
MC3T3-E1	O
cells	O
were	O
incubated	O
with	O
10	O
ng	O
/	O
ml	O
TNFα	O
in	O
the	O
presence	O
of	O
humulon	B
for	O
12	O
h	O
,	O
the	O
amount	O
of	O
released	O
PGE2	B
decreased	O
depending	O
on	O
the	O
concentration	O
of	O
humulon	B
with	O
an	O
IC50	O
of	O
about	O
30	O
nM	O
(	O
Fig.	O
2A	O
)	O
.	O

As	O
shown	O
in	O
Fig.	O
2C	O
,	O
the	O
cyclooxygenase	O
activity	O
of	O
the	O
TNFα	O
-	O
treated	O
cells	O
was	O
reduced	O
by	O
humulon	B
dose	O
-	O
dependently	O
.	O

Furthermore	O
,	O
Northern	O
blot	O
analysis	O
showed	O
that	O
the	O
addition	O
of	O
humulon	B
suppressed	O
the	O
TNFα	O
-	O
induced	O
increase	O
of	O
cyclooxygenase-2	O
mRNA	O
(	O
Fig.	O
2E	O
)	O
.	O

For	O
analysis	O
of	O
the	O
promoter	O
activity	O
,	O
a	O
luciferase	O
vector	O
of	O
cyclooxygenase-2	O
gene	O
was	O
constructed	O
,	O
and	O
transfected	O
to	O
MC3T3-E1	O
cells	O
by	O
the	O
lipofection	O
method	O
.	O

The	O
luciferase	O
activity	O
of	O
the	O
cell	O
lysate	O
was	O
measured	O
12	O
h	O
after	O
the	O
addition	O
of	O
10	O
ng	O
/	O
ml	O
TNFα	O
in	O
the	O
presence	O
of	O
various	O
concentrations	O
of	O
humulon	B
(	O
Fig.	O
2	O
G	O
)	O
.	O

Since	O
the	O
same	O
range	O
of	O
humulon	B
concentration	O
was	O
required	O
for	O
the	O
decrease	O
in	O
the	O
PGE2	B
release	O
,	O
enzyme	O
activity	O
,	O
mRNA	O
level	O
and	O
promoter	O
activity	O
,	O
we	O
presumed	O
that	O
the	O
induction	O
of	O
cyclooxygenase-2	O
by	O
TNFα	O
was	O
inhibited	O
at	O
the	O
step	O
of	O
transcription	O
.	O

Then	O
,	O
we	O
examined	O
whether	O
or	O
not	O
humulon	B
inhibited	O
the	O
catalytic	O
activities	O
of	O
cyclooxygenases-1	O
and	O
-2	O
.	O

As	O
shown	O
in	O
Fig.	O
3	O
,	O
the	O
cyclooxygenase-1	O
activity	O
was	O
hardly	O
affected	O
by	O
humulon	B
below	O
10	O
μM	O
,	O
whereas	O
the	O
cyclooxygenase-2	O
activity	O
was	O
inhibited	O
with	O
an	O
IC50	O
value	O
of	O
about	O
1.6	O
μM.	O
Thus	O
,	O
the	O
catalytic	O
activity	O
of	O
cyclooxygenase-2	O
was	O
inhibited	O
by	O
humulon	B
,	O
but	O
its	O
IC50	O
was	O
higher	O
by	O
about	O
two	O
orders	O
of	O
magnitude	O
than	O
the	O
IC50	O
of	O
the	O
cyclooxygenase-2	O
suppression	O
.	O

As	O
reported	O
preliminarily	O
earlier	O
[	O
15	O
]	O
,	O
the	O
TNFα	O
-	O
dependent	O
cyclooxygenase-2	O
induction	O
in	O
MC3T3-E1	O
cells	O
was	O
suppressed	O
by	O
dexamethasone	B
which	O
is	O
well	O
known	O
as	O
a	O
potent	O
anti	O
-	O
inflammatory	O
drug	O
and	O
a	O
suppressor	O
of	O
cyclooxygenase-2	O
induction	O
in	O
most	O
cells	O
[	O
1,2	O
]	O
.	O

We	O
investigated	O
the	O
effect	O
of	O
dexamethasone	B
in	O
MC3T3-E1	O
cells	O
.	O

When	O
the	O
cells	O
were	O
incubated	O
with	O
20	O
ng	O
/	O
ml	O
TNFα	O
for	O
12	O
h	O
,	O
the	O
amount	O
of	O
released	O
PGE2	B
(	O
Fig.	O
2B	O
)	O
and	O
the	O
cyclooxygenase-2	O
activity	O
(	O
Fig.	O
2D	O
)	O
decreased	O
depending	O
on	O
the	O
concentration	O
of	O
added	O
dexamethasone	B
(	O
IC50	O
:	O
1	O
nM	O
)	O
.	O

As	O
shown	O
in	O
Fig.	O
2F	O
,	O
the	O
cyclooxygenase-2	O
mRNA	O
level	O
was	O
also	O
decreased	O
in	O
the	O
presence	O
of	O
dexamethasone	B
.	O

The	O
TNFα	O
-	O
dependent	O
luciferase	O
activity	O
was	O
also	O
decreased	O
by	O
dexamethasone	B
with	O
an	O
IC50	O
of	O
about	O
1	O
nM	O
(	O
Fig.	O
2H	O
)	O
.	O

These	O
data	O
indicated	O
that	O
dexamethasone	B
suppressed	O
the	O
cyclooxygenase-2	O
induction	O
by	O
reducing	O
its	O
mRNA	O
level	O
in	O
MC3T3-E1	O
cells	O
.	O

Our	O
previous	O
work	O
with	O
MC3T3-E1	O
cells	O
demonstrated	O
the	O
involvement	O
of	O
NFκB	O
and	O
NF	O
-	O
IL6	O
as	O
transcription	O
factors	O
in	O
the	O
cyclooxygenase-2	O
induction	O
by	O
TNFα	O
[	O
9	O
]	O
.	O

We	O
investigated	O
whether	O
or	O
not	O
humulon	B
and	O
dexamethasone	B
functioned	O
with	O
the	O
aid	O
of	O
NFκB	O
(	O
nucleotides	O
−401	O
to	O
−393	O
)	O
and	O
NF	O
-	O
IL6	O
(	O
nucleotides	O
−138	O
to	O
−130	O
)	O
response	O
elements	O
.	O

As	O
shown	O
in	O
Fig.	O
4	O
,	O
we	O
constructed	O
a	O
luciferase	O
vector	O
containing	O
thymidine	O
kinase	O
gene	O
and	O
NFκB	O
or	O
NF	O
-	O
IL6	O
response	O
element	O
.	O

Each	O
vector	O
was	O
transfected	O
to	O
MC3T3-E1	O
cells	O
,	O
and	O
the	O
luciferase	O
activity	O
was	O
measured	O
.	O

Both	O
humulon	B
and	O
dexamethasone	B
decreased	O
the	O
luciferase	O
activity	O
induced	O
by	O
TNFα	O
.	O

Thus	O
,	O
the	O
suppressive	O
effect	O
of	O
humulon	B
and	O
dexamethasone	B
on	O
the	O
cyclooxygenase-2	O
induction	O
was	O
attributable	O
presumably	O
to	O
NFκB	O
or	O
NF	O
-	O
IL6	O
or	O
both	O
.	O

To	O
investigate	O
whether	O
or	O
not	O
humulon	B
bound	O
to	O
glucocorticoid	O
receptor	O
,	O
we	O
used	O
RU486	B
as	O
a	O
glucocorticoid	O
receptor	O
antagonist	O
[	O
16	O
]	O
.	O

The	O
TNFα	O
-	O
dependent	O
PGE2	B
production	O
decreased	O
by	O
dexamethasone	B
was	O
reversed	O
by	O
RU486	B
dose	O
-	O
dependently	O
(	O
Fig.	O
5A	O
)	O
.	O

However	O
,	O
the	O
decreased	O
PGE2	B
production	O
by	O
humulon	B
was	O
not	O
affected	O
by	O
RU486	O
(	O
Fig.	O
5A	O
)	O
.	O

Then	O
,	O
we	O
constructed	O
a	O
luciferase	O
vector	O
containing	O
thymidine	O
kinase	O
gene	O
and	O
glucocorticoid	B
response	O
element	O
(	O
Fig.	O
5B	O
)	O
.	O

The	O
vector	O
was	O
transfected	O
to	O
MC3T3-E1	O
cells	O
,	O
and	O
the	O
luciferase	O
activity	O
of	O
the	O
cell	O
lysate	O
was	O
measured	O
12	O
h	O
after	O
the	O
addition	O
of	O
TNFα	O
plus	O
dexamethasone	B
or	O
humulon	B
.	O

As	O
shown	O
in	O
Fig.	O
5B	O
,	O
the	O
addition	O
of	O
dexamethasone	B
increased	O
luciferase	O
activity	O
of	O
MC3T3-E1	O
cells	O
by	O
16–18	O
fold	O
.	O

Therefore	O
,	O
dexamethasone	B
bound	O
to	O
the	O
glucocorticoid	O
receptor	O
and	O
then	O
to	O
the	O
glucocorticoid	B
response	O
element	O
.	O

In	O
contrast	O
,	O
when	O
the	O
transfected	O
cells	O
were	O
incubated	O
with	O
humulon	B
,	O
the	O
luciferase	O
activity	O
was	O
not	O
increased	O
.	O

These	O
data	O
suggested	O
that	O
the	O
humulon	B
-	O
dependent	O
suppression	O
of	O
cyclooxygenase-2	O
induction	O
was	O
not	O
mediated	O
by	O
glucocorticoid	O
receptor	O
.	O

4	O
Discussion	O
As	O
for	O
the	O
inhibitors	O
of	O
cyclooxygenase	O
induction	O
other	O
than	O
glucocorticoid	B
,	O
a	O
recent	O
paper	O
reported	O
a	O
cyclooxygenase-2	O
transcription	O
in	O
phorbol	B
ester	I
-	O
treated	O
human	O
epithelial	O
cells	O
inhibited	O
by	O
resveratrol	B
,	O
which	O
is	O
a	O
phytoalexin	B
found	O
in	O
grapes	O
and	O
other	O
foods	O
[	O
17	O
]	O
.	O

The	O
compound	O
reduced	O
both	O
the	O
enzyme	O
activity	O
and	O
the	O
gene	O
transcription	O
at	O
a	O
concentration	O
in	O
the	O
order	O
of	O
10	O
μM.	O
Resveratrol	B
also	O
blocked	O
cyclooxygenase-2	O
activation	O
by	O
protein	O
kinase	O
C	O
-	O
α	O
,	O
ERK1	O
,	O
and	O
c	O
-	O
Jun	O
[	O
17	O
]	O
.	O

In	O
addition	O
,	O
sodium	B
salicylate	I
and	O
aspirin	B
at	O
pharmacological	O
concentrations	O
(	O
0.1–100	O
μM	O
)	O
inhibited	O
cyclooxygenase-2	O
transcription	O
induced	O
by	O
phorbol	B
ester	I
,	O
interleukin-1β	O
,	O
and	O
lipopolysaccharide	B
(	O
LPS	B
)	O
[	O
18	O
]	O
.	O

It	O
is	O
established	O
that	O
glucocorticoid	B
binds	O
to	O
its	O
intracellular	O
receptor	O
migrating	O
into	O
nucleus	O
and	O
the	O
steroid	B
-	O
receptor	O
complex	O
binds	O
to	O
a	O
glucocorticoid	B
response	O
element	O
of	O
the	O
promoter	O
region	O
of	O
target	O
gene	O
[	O
19	O
]	O
.	O

Inoue	O
and	O
others	O
reported	O
that	O
the	O
activation	O
of	O
the	O
cyclooxygenase-2	O
gene	O
promoter	O
by	O
LPS	B
was	O
suppressed	O
by	O
glucocorticoid	B
,	O
and	O
the	O
suppression	O
was	O
enhanced	O
by	O
transfection	O
of	O
the	O
glucocorticoid	O
receptor	O
cDNA	O
to	O
vascular	O
endothelial	O
cells	O
[	O
20	O
]	O
.	O

However	O
,	O
there	O
is	O
no	O
typical	O
sequence	O
for	O
glucocorticoid	B
response	O
element	O
within	O
1.2	O
kb	O
upstream	O
in	O
cyclooxygenase-2	O
gene	O
promoter	O
[	O
1,2	O
]	O
.	O

One	O
of	O
the	O
two	O
NFκB	O
sites	O
(	O
nucleotides	O
–223	O
to	O
–214	O
)	O
was	O
involved	O
in	O
both	O
the	O
LPS	B
-	O
induced	O
human	O
cyclooxygenase-2	O
gene	O
expression	O
in	O
U937	O
cells	O
and	O
its	O
suppression	O
by	O
dexamethasone	B
and	O
herbimycin	B
A	I
[	O
21	O
]	O
.	O

In	O
conclusion	O
,	O
our	O
results	O
demonstrated	O
that	O
humulon	B
has	O
a	O
glucocorticoid	B
-	O
like	O
suppression	O
activity	O
in	O
TNFα	O
-	O
induced	O
cyclooxygenase-2	O
transcription	O
and	O
its	O
signal	O
transduction	O
may	O
be	O
independent	O
from	O
glucocorticoid	O
receptor	O
.	O

However	O
,	O
these	O
results	O
required	O
further	O
investigations	O
of	O
a	O
detailed	O
molecular	O
mechanism	O
and	O
of	O
in	O
vivo	O
anti	O
-	O
inflammatory	O
action	O
of	O
humulon	B
.	O

Acknowledgements	O

We	O
thank	O
Dr.	O
H.	O
Kondoh	O
of	O
Osaka	O
University	O
for	O
providing	O
the	O
herpes	O
simplex	O
virus	O
thymidine	O
kinase	O
gene	O
;	O
Dr.	O
Y.	O
Taketani	O
of	O
the	O
University	O
of	O
Tokushima	O
for	O
providing	O
tk	O
-	O
pGL3	O
vector	O
;	O
and	O
Mr.	O
H.	O
Kurobe	O
for	O
technical	O
assistance	O
.	O

This	O
work	O
was	O
supported	O
by	O
grants	O
-	O
in	O
-	O
aid	O
for	O
scientific	O
research	O
from	O
the	O
Ministry	O
of	O
Education	O
,	O
Science	O
,	O
Sports	O
and	O
Culture	O
of	O
Japan	O
,	O
the	O
Japanese	O
Foundation	O
of	O
Metabolism	O
and	O
Disease	O
,	O
and	O
the	O
Japan	O
Foundation	O
for	O
Applied	O
Enzymology	O
.	O

Butea	O
monosperma	O
(	O
Fabaceae	O
)	O
is	O
a	O
medium	O
sized	O
tree	O
native	O
of	O
the	O
mountainous	O
regions	O
of	O
India	O
and	O
Burma	O
and	O
now	O
grows	O
wild	O
throughout	O
India	O
(	O
Anonymous	O
,	O
1988	O
)	O
.	O

The	O
bark	O
is	O
reported	O
to	O
possess	O
antitumour	O
and	O
antiulcer	O
properties	O
(	O
Anonymous	O
,	O
1988	O
)	O
,	O
while	O
stem	O
bark	O
possess	O
antifungal	O
activity	O
(	O
Bandara	O
et	O
al.	O
,	O
1989	O
;	O
1990	O
)	O
.	O

The	O
root	O
bark	O
is	O
used	O
as	O
an	O
aphrodisiac	O
,	O
analgesic	O
and	O
anthelmintic	O
(	O
Anonymous	O
,	O
1988	O
)	O
,	O
whereas	O
the	O
leaves	O
possess	O
antimicrobial	O
property	O
(	O
Zaffar	O
et	O
al.	O
,	O
1989	O
)	O
.	O

The	O
flowers	O
are	O
used	O
for	O
the	O
treatment	O
of	O
liver	O
disorders	O
(	O
Wagner	O
et	O
al.	O
,	O
1986	O
)	O
and	O
the	O
seeds	O
as	O
anthelmintic	O
(	O
Lal	O
et	O
al.	O
,	O
1978	O
)	O
.	O

Flavonoids	B
from	O
flowers	O
(	O
Gupta	O
et	O
al.	O
,	O
1970	O
)	O
,	O
stem	O
bark	O
(	O
Bandara	O
et	O
al.	O
,	O
1990	O
)	O
and	O
nitrogenous	B
compounds	I
from	O
the	O
seeds	O
(	O
Guha	O
et	O
al.	O
,	O
1990	O
;	O
Mehta	O
and	O
Bokadia	O
,	O
1981	O
)	O
have	O
been	O
reported	O
earlier	O
.	O

During	O
the	O
course	O
of	O
investigation	O
on	O
the	O
yellow	O
dye	O
from	O
the	O
flowers	O
,	O
it	O
was	O
of	O
interest	O
to	O
work	O
on	O
the	O
stems	O
as	O
relatively	O
few	O
compounds	O
have	O
been	O
reported	O
from	O
it	O
.	O

This	O
report	O
describes	O
the	O
characterisation	O
of	O
a	O
new	O
euphane	B
and	O
a	O
new	O
lipid	B
derivative	I
.	O

2	O
Results	O
and	O
discussion	O
Compounds	O
1–5	O
were	O
isolated	O
from	O
the	O
stems	O
of	O
B.	O
monosperma	O
.	O

Compound	O
1	O
was	O
obtained	O
as	O
colourless	O
needles	O
.	O

Its	O
IR	O
spectrum	O
bands	O
corresponded	O
to	O
OH	O
(	O
3480	O
cm−1	O
)	O
,	O
terminal	O
unsaturated	O
CH2	O
(	O
1610	O
,	O
880	O
cm−1	O
)	O
and	O
gem	O
dimethyl	O
(	O
1380	O
,	O
1360	O
cm−1	O
)	O
functions	O
.	O

An	O
[	O
M	O
]	O
+	O
at	O
m	O
/	O
z	O
428	O
suggested	O
the	O
molecular	O
formula	O
as	O
C30	O
H52	O
O.	O
Its	O
1	O
H	O
NMR	O
spectrum	O
exhibited	O
signals	O
due	O
to	O
five	O
quaternary	O
methyls	O
(	O
δ	O
0.79	O
,	O
0.83	O
,	O
0.94	O
,	O
0.96	O
,	O
1.04	O
)	O
,	O
a	O
vinylic	O
methyl	O
(	O
δ	O
1.62	O
)	O
,	O
and	O
a	O
secondary	O
methyl	O
(	O
δ	O
1.08	O
)	O
indicative	O
of	O
a	O
tetracyclic	O
triterpene	O
skeleton	O
(	O
Hemmert	O
et	O
al.	O
,	O
1966	O
)	O
.	O

Two	O
broad	O
singlets	O
at	O
δ	O
4.56	O
and	O
4.68	O
,	O
each	O
integrating	O
for	O
one	O
proton	O
,	O
corresponded	O
to	O
the	O
methine	O
protons	O
of	O
an	O
olefinic	O
methylene	O
group	O
(	O
Jagodzinska	O
et	O
al.	O
,	O
1985	O
)	O
which	O
in	O
conjunction	O
with	O
a	O
broad	O
singlet	O
at	O
δ	O
1.62	O
suggested	O
the	O
existence	O
of	O
a	O
isopropylidene	O
group	O
.	O

This	O
was	O
also	O
substantiated	O
by	O
the	O
appearance	O
of	O
signals	O
at	O
δ	O
151.0	O
and	O
109.30	O
in	O
the	O
13	O
C	O
NMR	O
spectrum	O
for	O
>	O
CCH2	O
grouping	O
(	O
Schneider	O
and	O
Agrawal	O
,	O
1984	O
)	O
.	O

A	O
multiplet	O
at	O
δ	O
3.34	O
(	O
W	O
1	O
/	O
2	O
=	O
7	O
Hz	O
)	O
was	O
assigned	O
to	O
a	O
methine	O
proton	O
with	O
an	O
axially	O
oriented	O
C-3	O
OH	O
group	O
(	O
Jolad	O
et	O
al.	O
,	O
1981	O
;	O
Nakanishi	O
et	O
al.	O
,	O
1986	O
)	O
.	O

There	O
is	O
a	O
remarkable	O
similarity	O
in	O
the	O
13	O
C	O
NMR	O
chemical	O
shifts	O
of	O
euphenol	B
and	O
lanosterol	B
except	O
for	O
those	O
of	O
C-12	O
,	O
C-15	O
,	O
C-16	O
and	O
C-19	O
(	O
Knight	O
,	O
1974	O
)	O
.	O

This	O
excludes	O
1	O
to	O
be	O
included	O
under	O
lanosterol	B
series	O
.	O

Such	O
difference	O
is	O
also	O
seen	O
in	O
euphane	B
and	O
tirucallane	B
triterpenoids	I
(	O
Jolad	O
et	O
al.	O
,	O
1981	O
;	O
Bhakuni	O
et	O
al.	O
,	O
1987	O
;	O
Singh	O
et	O
al.	O
,	O
1989	O
)	O
.	O

The	O
chemical	O
shift	O
range	O
of	O
the	O
methyl	O
protons	O
except	O
for	O
vinylic	O
CH3	O
suggested	O
a	O
euphane	B
or	O
tirucallane	B
skeleton	I
(	O
differing	O
C-20	O
stereochemistry	O
)	O
in	O
1	O
,	O
and	O
a	O
(	O
+	O
)	O
optical	O
rotation	O
37.8	O
°	O
of	O
1	O
indicated	O
that	O
it	O
belonged	O
to	O
euphane	B
rather	O
than	O
tirucallane	B
series	O
(	O
Itoh	O
et	O
al.	O
,	O
1976	O
)	O
.	O

In	O
the	O
MS	O
of	O
1	O
,	O
the	O
loss	O
of	O
CH3	O
and	O
H2	O
O	O
from	O
[	O
M	O
]	O
+	O
was	O
seen	O
at	O
m	O
/	O
z	O
413	O
and	O
410	O
.	O

The	O
formation	O
of	O
a	O
fragment	O
ion	O
at	O
m	O
/	O
z	O
316	O
[	O
M	O
-	O
side	O
chain	O
(	O
C8	O
H15	O
)	O
–H	O
]	O
+	O
suggested	O
the	O
presence	O
of	O
a	O
monounsaturated	O
side	O
chain	O
(	O
Wyllie	O
and	O
Djerassi	O
,	O
1968	O
)	O
and	O
the	O
existence	O
of	O
OH	O
group	O
in	O
the	O
tetracyclic	O
system	O
.	O

Compound	O
1	O
on	O
treatment	O
with	O
Ac2	B
O	I
/	O
pyridine	B
afforded	O
an	O
acetate	B
(	B
1a	I
)	I
,	O
C32	O
H54	O
O2	O
,	O
whose	O
1	O
H	O
NMR	O
spectrum	O
was	O
similar	O
to	O
1	O
except	O
for	O
the	O
appearance	O
of	O
a	O
new	O
signal	O
at	O
δ	O
2.04	O
and	O
downfield	O
shifted	O
C-3	O
methine	O
by	O
1.11	O
ppm	O
.	O

In	O
the	O
13	O
C	O
NMR	O
spectrum	O
of	O
1	O
,	O
the	O
appearance	O
of	O
C-18	O
,	O
C-20	O
and	O
C-21	O
at	O
15.4	O
,	O
35.6	O
and	O
19.3	O
also	O
established	O
the	O
euphane	B
skeleton	I
(	O
Wehrli	O
and	O
Nishida	O
,	O
1979	O
;	O
Knight	O
,	O
1974	O
)	O
.	O

The	O
13	O
C	O
NMR	O
spectral	O
data	O
of	O
1	O
(	O
Table	O
1	O
)	O
were	O
analysed	O
by	O
analogy	O
with	O
the	O
reported	O
values	O
for	O
euphane	O
and	O
other	O
related	O
triterpenoids	O
(	O
Wehrli	O
et	O
al.	O
,	O
1979	O
;	O
Knight	O
,	O
1974	O
;	O
Singh	O
et	O
al.	O
,	O
1989	O
)	O
.	O

These	O
data	O
led	O
to	O
characterise	O
1	O
as	O
3α	B
-	I
hydroxyeuph-25-ene	I
.	O

Compound	O
4	O
showed	O
IR	O
bands	O
at	O
3438	O
(	O
OH	O
)	O
,	O
1730	O
(	O
CO	O
)	O
,	O
1670	O
(	O
tetrasubstituted	O
)	O
(	O
Nakanishi	O
and	O
Solomon	O
,	O
1977	O
)	O
,	O
1386	O
(	O
Me	O
)	O
and	O
720	O
cm−1	O
(	O
straight	O
chain	O
)	O
.	O

It	O
was	O
assigned	O
the	O
molecular	O
formula	O
C26	O
H48	O
O3	O
(	O
[	O
M	O
]	O
+	O
=	O
408	O
and	O
elemental	O
analysis	O
)	O
.	O

Successive	O
loss	O
of	O
two	O
H2	O
O	O
molecules	O
was	O
seen	O
at	O
m	O
/	O
z	O
390	O
and	O
372	O
,	O
whereas	O
the	O
location	O
of	O
these	O
OH	O
groups	O
was	O
assigned	O
at	O
C-2	O
and	O
C-14	O
since	O
significant	O
α	O
-	O
fission	O
ions	O
were	O
appeared	O
at	O
m	O
/	O
z	O
311	O
,	O
281	O
,	O
127	O
,	O
97	O
and	O
351	O
,	O
321	O
,	O
87	O
,	O
57	O
,	O
respectively	O
.	O

The	O
other	O
diagnostic	O
α	O
-	O
fission	O
ions	O
at	O
m	O
/	O
z	O
225	O
,	O
211	O
,	O
197	O
,	O
183	O
together	O
with	O
ß	O
-	O
fission	O
ions	O
involving	O
McLafferty	O
rearrangement	O
(	O
Budzikiewicz	O
et	O
al.	O
,	O
1964	O
)	O
at	O
m	O
/	O
z	O
226	O
and	O
182	O
located	O
the	O
keto	O
group	O
at	O
C-8	O
.	O

The	O
abundant	O
ions	O
at	O
m	O
/	O
z	O
83	O
and	O
325	O
indicated	O
the	O
presence	O
of	O
a	O
cyclohexyl	O
moiety	O
at	O
the	O
end	O
carbon	O
atom	O
(	O
Bhakuni	O
and	O
Shukla	O
,	O
1992	O
)	O
.	O

The	O
tetrasubstituted	O
double	O
bond	O
along	O
with	O
the	O
two	O
methyl	O
groups	O
were	O
assigned	O
at	O
C-11,12	O
since	O
significant	O
ions	O
were	O
seen	O
at	O
m	O
/	O
z	O
307	O
,	O
253	O
,	O
155	O
and	O
101	O
.	O

These	O
data	O
suggested	O
the	O
structure	O
of	O
4	O
as	O
2,14-dihydroxy-11,12-dimethyl-8-oxooctadec-11-enylcyclohexane	B
which	O
was	O
also	O
in	O
full	O
accord	O
with	O
its	O
1	O
H	O
NMR	O
(	O
see	O
Section	O
3	O
)	O
.	O

Compounds	O
2	O
,	O
3	O
and	O
5	O
were	O
identified	O
as	O
nonacosanoic	B
acid	I
,	O
stigmasterol	B
and	O
stigmasterol	B
-	I
ßD	I
-glucopyranoside	I
,	O
respectively	O
,	O
by	O
comparison	O
with	O
authentic	O
samples	O
.	O

The	O
straight	B
chain	I
alcohols	I
having	O
a	O
cyclohexane	B
moiety	I
are	O
not	O
commonly	O
found	O
in	O
nature	O
.	O

3	O
Experimental	O
3.1	O
General	O
Mps	O
:	O
uncorrected	O
;	O
IR	O
:	O
KBr	O
;	O
1	O
H	O
NMR	O
:	O
Bruker	O
(	O
200	O
MHz	O
)	O
in	O
CDCl3	B
,	O
chemical	O
shifts	O
in	O
δ	O
(	O
ppm	O
)	O
with	O
TMS	B
as	O
internal	O
standard	O
;	O
13	O
C	O
NMR	O
:	O
75	O
MHz	O
,	O
CDCl3	B
;	O
EIMS	O
:	O
70	O
ev	O
;	O
TLC	O
:	O
silica	B
gel	I
G	I
;	O
CC	O
:	O
silica	B
gel	I
(	O
Merk	O
,	O
60–120	O
mesh	O
)	O
.	O

Spots	O
were	O
detected	O
by	O
exposure	O
to	O
I2	B
vapour	O
.	O

The	O
homogeneity	O
of	O
the	O
isolates	O
was	O
checked	O
on	O
TLC	O
in	O
at	O
least	O
two	O
solvent	O
systems	O
.	O

3.2	O
Plant	O
material	O
The	O
stems	O
of	O
B.	O
monosperma	O
were	O
collected	O
from	O
the	O
local	O
area	O
and	O
identified	O
in	O
our	O
Botany	O
Department	O
where	O
a	O
voucher	O
specimen	O
has	O
been	O
maintained	O
.	O

3.3	O
Extraction	O
and	O
isolation	O
Dried	O
and	O
powdered	O
stems	O
(	O
2.8	O
kg	O
)	O
were	O
extracted	O
with	O
MeOH	B
(	O
5	O
×	O
11	O
l	O
)	O
and	O
the	O
combined	O
extract	O
concentrated	O
to	O
500	O
ml	O
.	O

After	O
the	O
addition	O
of	O
water	B
(	O
500	O
ml	O
)	O
,	O
the	O
extract	O
was	O
fractionated	O
with	O
n	B
-hexane	I
(	O
5	O
×	O
200	O
ml	O
,	O
7.33	O
g	O
)	O
,	O
EtOAc	B
(	O
5	O
×	O
200	O
ml	O
,	O
13.34	O
g	O
)	O
and	O
n	B
-BuOH	I
(	O
5	O
×	O
200	O
ml	O
,	O
33.2	O
g	O
)	O
.	O

A	O
portion	O
(	O
6.1	O
g	O
)	O
of	O
the	O
hexane	B
fraction	O
was	O
chromatographed	O
over	O
silica	B
gel	I
(	O
300	O
g	O
)	O
,	O
eluting	O
with	O
varying	O
proportions	O
of	O
hexane	B
,	O
EtOAc	B
and	O
MeOH	B
to	O
provide	O
compounds	O
1	O
(	O
50	O
mg	O
)	O
,	O
2	O
(	O
61	O
mg	O
)	O
,	O
3	O
(	O
68	O
mg	O
)	O
,	O
4	O
(	O
25	O
mg	O
)	O
and	O
5	O
(	O
46	O
mg	O
)	O
.	O

The	O
fractions	O
collected	O
were	O
100	O
ml	O
each	O
and	O
monitored	O
by	O
TLC	O
.	O

3.4	B
3α	I
-	I
Hydroxyeuph-25-ene	I
(	O
1	O
)	O
Removal	O
of	O
solvent	O
from	O
the	O
fractions	O
65–68	O
of	O
hexane	B
–	O
EtOAc	B
(	O
95:5	O
)	O
gave	O
a	O
residue	O
,	O
mp	O
180–82	O
°	O
C	O
,	O
α	O
D	O
+	O
37.8	O
°	O
(	O
CHCl3	B
)	O
.	O

IR	O
:	O
γ	O
max	O
cm−1	O
:	O
3480	O
,	O
2930	O
,	O
1610	O
,	O
1450	O
,	O
1360	O
,	O
1244	O
,	O
1110	O
,	O
1014	O
,	O
880	O
;	O
1	O
H	O
NMR	O
:	O
δ	O
0.79	O
(	O
3H	O
,	O
s	O
,	O
19-H3	O
)	O
,	O
0.83	O
(	O
3H	O
,	O
s	O
,	O
18-H3	O
)	O
,	O
0.94	O
(	O
3H	O
,	O
s	O
,	O
29-H3	O
)	O
,	O
0.96	O
(	O
3H	O
,	O
s	O
,	O
28-H3	O
)	O
,	O
1.04	O
(	O
3H	O
,	O
s	O
,	O
30-H3	O
)	O
,	O
1.08	O
(	O
3H	O
,	O
d	O
,	O
J	O
=	O
6	O
Hz	O
,	O
21-H3	O
)	O
,	O
1.62	O
(	O
3H	O
,	O
s	O
,	O
27-H3	O
)	O
,	O
1.90	O
(	O
1H	O
,	O
m	O
,	O
20-H	O
)	O
,	O
2.36	O
(	O
2H	O
,	O
m	O
,	O
24-H2	O
)	O
,	O
3.34	O
(	O
1H	O
,	O
m	O
,	O
W	O
1	O
/	O
2	O
=	O
7	O
Hz	O
,	O
3ß	O
-	O
H	O
)	O
,	O
4.56	O
,	O
4.68	O
,	O
(	O
2H	O
,	O
each	O
br	O
s	O
,	O
26-H2	O
)	O
;	O
MS	O
m	O
/	O
z	O
(	O
rel	O
.	O

int	O
.	O
)	O
:	O
428	O
[	O
M	O
]	O
+	O
(	O
C30	O
H52	O
O	O
,	O
67	O
)	O
,	O
413	O
[	O
M	O
−	O
Me	O
]	O
+	O
(	O
19	O
)	O
,	O
410	O
[	O
M	O
−	O
H2	O
O	O
]	O
+	O
(	O
5	O
)	O
,	O
395	O
[	O
M	O
−	O
Me	O
–	O
H2	O
O	O
]	O
+	O
(	O
5	O
)	O
,	O
387	O
[	O
M	O
−	O
41	O
]	O
+	O
(	O
6	O
)	O
,	O
317	O
[	O
M	O
−	O
sc	O
]	O
+	O
(	O
15	O
)	O
,	O
316	O
[	O
M	O
−	O
sc	O
–	O
H	O
]	O
+	O
(	O
18	O
)	O
,	O
301	O
[	O
316	O
−	O
Me	O
]	O
+	O
(	O
5	O
)	O
,	O
298	O
[	O
316	O
−	O
H2	O
O	O
]	O
+	O
(	O
5	O
)	O
,	O
286	O
[	O
301	O
−	O
Me	O
]	O
+	O
(	O
5	O
)	O
,	O
196	O
(	O
5	O
)	O
,	O
194	O
(	O
8)	O
,	O
178	O
[	O
196	O
−	O
H2	O
O	O
]	O
+	O
(	O
18	O
)	O
,	O
179	O
[	O
194	O
−	O
Me	O
]	O
+	O
(	O
10	O
)	O
,	O
161	O
(	O
12	O
)	O
,	O
128	O
(	O
5	O
)	O
,	O
111	O
(	O
20	O
)	O
,	O
110	O
(	O
15	O
)	O
,	O
95	O
(	O
100	O
)	O
,	O
81	O
(	O
80	O
)	O
,	O
69	O
(	O
75	O
)	O
.	O

3.5	O
Monoacetate	B
(	O
1a	O
)	O
of	B
1	I
Compound	O
1	O
(	O
25	O
mg	O
)	O
was	O
acetylated	O
with	O
C5	B
H5	I
N	I
–	O
Ac2	B
O	I
(	O
1	O
ml	O
each	O
)	O
,	O
overnight	O
at	O
room	O
temperature	O
.	O

The	O
usual	O
work	O
-	O
up	O
yielded	O
1a	O
,	O
mp	O
205	O
°	O
C	O
,	O
20	O
mg	O
.	O

IR	O
γ	O
max	O
cm−1	O
:	O
2940	O
,	O
2856	O
,	O
1738	O
,	O
1640	O
,	O
1460	O
,	O
1374	O
,	O
1245	O
,	O
1020	O
,	O
978	O
,	O
880	O
;	O
1	O
H	O
NMR	O
:	O
δ	O
0.79	O
(	O
3H	O
,	O
s	O
,	O
19-H3	O
)	O
,	O
0.84	O
(	O
3H	O
,	O
s	O
,	O
18-H3	O
)	O
,	O
0.94	O
(	O
3H	O
,	O
s	O
,	O
29-H3	O
)	O
,	O
0.97	O
(	O
3H	O
,	O
s	O
,	O
28-H3	O
)	O
,	O
1.03	O
(	O
3H	O
,	O
s	O
,	O
30-H3	O
)	O
,	O
1.08	O
(	O
3H	O
,	O
d	O
,	O
J	O
=	O
6	O
Hz	O
,	O
21-H3	O
)	O
,	O
1.68	O
(	O
3H	O
,	O
s	O
,	O
27-H3	O
)	O
,	O
1.90	O
(	O
1H	O
,	O
m	O
,	O
20-H	O
)	O
,	O
2.04	O
(	O
3H	O
,	O
s	O
,	O
OAc	O
)	O
,	O
2.36	O
(	O
2H	O
,	O
m	O
,	O
24-H2	O
)	O
,	O
4.45	O
(	O
1H	O
,	O
m	O
,	O
W	O
1	O
/	O
2	O
=	O
7	O
Hz	O
,	O
3ßH	O
)	O
,	O
4.56	O
,	O
4.68	O
(	O
2H	O
,	O
each	O
br	O
s	O
,	O
26-H2	O
)	O
;	O
MS	O
m	O
/	O
z	O
(	O
rel	O
.	O

int	O
.	O
)	O
:	O
470	O
[	O
M	O
]	O
+	O
(	O
C32	O
H54	O
O2	O
,	O
11	O
)	O
,	O
455	O
(	O
4	O
)	O
,	O
429	O
(	O
5	O
)	O
,	O
410	O
(	O
2	O
)	O
,	O
359	O
(	O
5	O
)	O
,	O
257	O
(	O
5	O
)	O
,	O
238	O
(	O
5	O
)	O
,	O
236	O
(	O
4	O
)	O
,	O
188	O
(	O
100	O
)	O
,	O
176	O
(	O
15	O
)	O
,	O
161	O
(	O
17	O
)	O
,	O
160	O
(	O
21	O
)	O
,	O
111	O
(	O
20	O
)	O
,	O
110	O
(	O
15	O
)	O
,	O
95	O
(	O
60	O
)	O
,	O
81	O
(	O
80	O
)	O
,	O
69	O
(	O
40	O
)	O
,	O
55	O
(	O
50	O
)	O
,	O
43	O
(	O
98	O
)	O
.	O

3.6	O
Nonacosanoic	B
acid	I
(	O
2	O
)	O
Fractions	O
71–75	O
of	O
hexane	B
–	O
EtOAc	B
(	O
95:5	O
)	O
eluates	O
yielded	O
a	O
residue	O
,	O
mp	O
68–70	O
°	O
C	O
,	O
identified	O
by	O
co	O
-	O
TLC	O
,	O
MS	O
,	O
1	O
H	O
NMR	O
.	O

3.7	O
Stigmasterol	B
(	O
3	O
)	O
Fractions	O
90–95	O
of	O
hexane	B
–	O
EtOAc	B
(	O
95:5	O
)	O
eluates	O
when	O
freed	O
of	O
the	O
solvent	O
provided	O
3	O
,	O
mp	O
160	O
°	O
C	O
,	O
identified	O
by	O
co	O
-	O
TLC	O
,	O
MS	O
,	O
IR	O
,	O
1	O
H	O
NMR	O
.	O

3.8	O
2,14-Dihydroxy-11,12-dimethyl-8-oxooctadec-11-enylcyclohexane	B
(	O
4	O
)	O
Elimination	O
of	O
solvent	O
from	O
the	O
fractions	O
221–226	O
of	O
hexane	B
–	O
EtOAc	B
(	O
1:1	O
)	O
eluates	O
furnished	O
4	O
,	O
mp	O
83–84	O
°	O
C	O
.	O

IR	O
γ	O
max	O
cm−1	O
:	O
3438	O
,	O
2920	O
,	O
2850	O
,	O
1730	O
,	O
1670	O
,	O
1450	O
,	O
1386	O
,	O
1180	O
,	O
1110	O
,	O
1052	O
,	O
720	O
;	O
1	O
H	O
NMR	O
:	O
δ	O
0.88	O
(	O
3H	O
,	O
t	O
,	O
J	O
=	O
6	O
Hz	O
,	O
18-H3	O
)	O
,	O
1.25	O
(	O
10H	O
,	O
br	O
s	O
,	O
5	O
×	O
CH2	O
)	O
,	O
1.50	O
(	O
10H	O
,	O
br	O
s	O
,	O
cyclohexyl	O
(	O
CH2	O
)	O
5	O
)	O
,	O
1.64	O
(	O
1H	O
,	O
m	O
,	O
1′	O
-H	O
)	O
,	O
1.60	O
(	O
6H	O
,	O
s	O
,	O
11-H3	O
,	O
12-H3	O
)	O
,	O
1.90	O
(	O
4H	O
,	O
m	O
,	O
3-H2	O
,	O
15-H2	O
)	O
,	O
2.02	O
(	O
2H	O
,	O
m	O
,	O
1-H2	O
)	O
,	O
2.35	O
(	O
4H	O
,	O
t	O
,	O
J	O
=	O
6	O
Hz	O
,	O
7-H2	O
,	O
9-H2	O
)	O
,	O
2.45	O
(	O
2H	O
,	O
t	O
,	O
J	O
=	O
6	O
Hz	O
,	O
10-H2	O
)	O
,	O
2.48	O
(	O
2H	O
,	O
d	O
,	O
J	O
=	O
5	O
Hz	O
,	O
13-H2	O
)	O
,	O
3.64	O
(	O
1H	O
,	O
m	O
,	O
2-H	O
)	O
,	O
3.94	O
(	O
1H	O
,	O
m	O
,	O
14-H	O
)	O
;	O
MS	O
m	O
/	O
z	O
(	O
rel	O
.	O

int	O
.	O
)	O
:	O
408	O
[	O
M	O
]	O
+	O
(	O
C26	O
H48	O
O3	O
,	O
2	O
)	O
,	O
390	O
[	O
M	O
−	O
H2	O
O	O
]	O
+	O
(	O
7	O
)	O
,	O
372	O
[	O
M	O
−	O
2H2	O
O	O
]	O
+	O
(	O
7	O
)	O
,	O
393	O
[	O
M	O
−	O
Me	O
]	O
+	O
(	O
3	O
)	O
,	O
378	O
[	O
M	O
−2	O
×	O
Me	O
]	O
+	O
(	O
3	O
)	O
,	O
351	O
(	O
4	O
)	O
,	O
325	O
(	O
5	O
)	O
,	O
321	O
(	O
3	O
)	O
,	O
311	O
(	O
4	O
)	O
,	O
307	O
(	O
5	O
)	O
,	O
281	O
(	O
4	O
)	O
,	O
253	O
(	O
5	O
)	O
,	O
226	O
(	O
6	O
)	O
,	O
225	O
(	O
5	O
)	O
,	O
211	O
(	O
7	O
)	O
,	O
197	O
(	O
6	O
)	O
,	O
183	O
(	O
10	O
)	O
,	O
182	O
(	O
7	O
)	O
,	O
155	O
(	O
4	O
)	O
,	O
127	O
(	O
19	O
)	O
,	O
101	O
(	O
6	O
)	O
,	O
97	O
(	O
90	O
)	O
,	O
87	O
(	O
12	O
)	O
,	O
83	O
(	O
65	O
)	O
,	O
57	O
(	O
100	O
)	O
(	O
Found	O
:	O
C	O
,	O
76.40	O
;	O
H	O
,	O
11.82	O
.	O

C26	O
H48	O
O3	O
requires	O
:	O
C	O
,	O
76.47	O
;	O
H	O
,	O
11.76	O
%	O
)	O
.	O

3.9	O
Stigmasterol	B
-	I
ßD	I
-glucopyranoside	I
(	O
5	O
)	O
Removal	O
of	O
solvent	O
from	O
290–301	O
fractions	O
of	O
MeOH	B
–	O
EtOAc	B
(	O
2:98	O
)	O
eluates	O
gave	O
5	O
,	O
mp	O
263–65	O
°	O
C	O
,	O
identified	O
by	O
MS	O
,	O
1	O
H	O
NMR	O
and	O
hydrolysis	O
products	O
.	O

Acknowledgements	O
One	O
of	O
the	O
authors	O
(	O
M.	O
Mishra	O
)	O
is	O
grateful	O
to	O
the	O
Director	O
,	O
CIMAP	O
for	O
the	O
award	O
of	O
a	O
Junior	O
Research	O
Fellowship	O
.	O

Arachidonic	B
acid	I
(	O
AA	B
)	O
is	O
metabolized	O
to	O
form	O
four	O
different	O
epoxides	B
(	O
namely	O
5,6-	B
,	O
8,9-	B
,	O
11,12-	B
,	O
14,15-EET	B
)	O
via	O
the	O
cytochrome	O
P-450	O
monooxygenase	O
(	O
epoxygenase	O
)	O
pathway	O
[	O
1	O
]	O
.	O

14,15-EET	B
is	O
found	O
in	O
the	O
urine	O
[	O
2	O
]	O
and	O
produced	O
by	O
platelets	O
and	O
endothelial	O
cells	O
[	O
3,4	O
]	O
.	O

The	O
occurrence	O
of	O
14,15-EET	B
and	O
other	O
EETs	B
in	O
tissues	O
and	O
various	O
cell	O
types	O
leads	O
to	O
the	O
hypothesis	O
that	O
these	O
substances	O
may	O
be	O
stored	O
in	O
cells	O
by	O
conjugative	O
protein	O
binding	O
or	O
by	O
incorporation	O
into	O
membrane	O
phospholipids	B
(	O
PL	B
)	O
[	O
5	O
]	O
.	O

The	O
stored	O
form	O
of	O
EETs	B
can	O
be	O
released	O
upon	O
activation	O
of	O
specific	O
phospholipase	O
,	O
for	O
example	O
,	O
phospholipase	O
A2	O
(	O
PLA2	O
)	O
or	O
phospholipase	O
C	O
(	O
PLC	O
)	O
,	O
by	O
neuronal	O
,	O
hormonal	O
or	O
chemical	O
stimulation	O
[	O
6,7	O
]	O
.	O

Of	O
the	O
various	O
systems	O
in	O
which	O
,	O
epoxygenase	O
and	O
its	O
epoxides	B
(	O
EETs	B
)	O
have	O
studied	O
,	O
the	O
kidney	O
seems	O
to	O
be	O
a	O
major	O
organ	O
for	O
production	O
and	O
action	O
of	O
the	O
EETs	B
.	O

The	O
main	O
forms	O
of	O
EETs	B
found	O
in	O
the	O
kidney	O
and	O
in	O
urine	O
are	O
8,9-	B
and	O
14,15-EET	B
[	O
2	O
]	O
.	O

The	O
levels	O
of	O
EETs	B
in	O
the	O
kidney	O
seemed	O
to	O
vary	O
as	O
a	O
function	O
of	O
renal	O
pathology	O
[	O
8–10	O
]	O
.	O

In	O
the	O
kidney	O
,	O
certain	O
EETs	B
and	O
their	O
dihydroxyeicosatrienoic	B
acid	I
metabolites	O
(	O
diols	B
or	O
DHETs	B
)	O
have	O
prominent	O
biological	O
functions	O
,	O
such	O
as	O
:	O
inhibition	O
of	O
Na+	O
/K+	O
ATPase	O
[	O
11	O
]	O
and	O
suppression	O
of	O
vasopressin	B
(	O
AVP	B
)	O
action	O
on	O
rabbit	O
kidney	O
cortical	O
collecting	O
duct	O
(	O
CCD	O
)	O
[	O
9	O
]	O
.	O

With	O
our	O
previous	O
reports	O
[	O
12,13	O
]	O
,	O
it	O
is	O
conceivable	O
that	O
14,15-EET	B
and	O
its	O
metabolite	O
(	O
14,15-DHET	B
)	O
may	O
play	O
an	O
important	O
role	O
in	O
maintaining	O
blood	O
pressure	O
,	O
modulating	O
renal	O
function	O
,	O
and	O
regulating	O
monocyte	O
adhesion	O
.	O

In	O
other	O
systems	O
,	O
Malcolm	O
and	O
Fitzpatrick	O
reported	O
that	O
14,15-EET	B
inhibited	O
Ca+2	B
entry	O
into	O
cells	O
[	O
14	O
]	O
.	O

We	O
had	O
shown	O
that	O
14,15-EET	B
can	O
enhance	O
monocyte	O
attachment	O
to	O
endothelium	O
and	O
decrease	O
the	O
mean	O
arterial	O
blood	O
pressure	O
in	O
normal	O
and	O
spontaneously	O
hypertensive	O
rats	O
[	O
12,13	O
]	O
.	O

Catella	O
et	O
al.	O
[	O
15	O
]	O
reported	O
high	O
amounts	O
of	O
14,15-EET	B
in	O
the	O
urine	O
of	O
patients	O
with	O
pregnancy	O
-	O
induced	O
hypertension	O
,	O
suggesting	O
a	O
possible	O
role	O
of	O
14,15-EET	B
in	O
blood	O
pressure	O
regulation	O
.	O

These	O
wide	O
varieties	O
of	O
biological	O
function	O
suggest	O
that	O
14,15-EET	B
may	O
act	O
through	O
specific	O
receptors	O
and	O
signal	O
transduction	O
pathways	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
identified	O
a	O
population	O
of	O
specific	O
high	O
affinity	O
binding	O
sites	O
for	O
14,15-EET	B
in	O
GPM	O
cells	O
that	O
may	O
be	O
associated	O
with	O
receptors	O
.	O

This	O
population	O
of	O
14,15-EET	B
binding	O
sites	O
in	O
GPM	O
cells	O
was	O
down	O
regulated	O
by	O
cholera	O
toxin	O
or	O
dibutyryl	B
-	I
cAMP	I
that	O
suggested	O
a	O
postreceptor	O
mechanism	O
coupled	O
to	O
PKA	O
-	O
dependent	O
signal	O
transduction	O
pathway	O
.	O

2	O
Materials	O
and	O
methods	O
2.1	O
Materials	O
White	O
Hartley	O
guinea	O
pigs	O
weighing	O
250	O
to	O
350	O
g	O
were	O
obtained	O
from	O
Taconic	O
Farms	O
(	O
Germantown	O
,	O
NY	O
,	O
USA	O
)	O
.	O

Percoll	O
,	O
HEPES	B
,	O
deoxyribonuclease	O
,	O
cholera	O
toxin	O
,	O
pertussis	O
toxin	O
,	O
sodium	B
bicarbonate	I
(	O
a	O
cell	O
culture	O
grade	O
)	O
,	O
Tris	B
-	I
base	I
,	O
chymotrypsin	O
(	O
type	O
IS	O
and	O
type	O
II	O
)	O
,	O
papain	O
,	O
pronase	O
E	O
,	O
proteinase	O
K	O
,	O
and	O
dibutyryl	B
cAMP	I
were	O
purchased	O
from	O
Sigma	O
(	O
St.	O
Louis	O
,	O
MO	O
,	O
USA	O
)	O
.	O

The	O
gelatin	O
was	O
obtained	O
from	O
Fisher	O
Scientific	O
(	O
Fairlawn	O
,	O
NJ	O
,	O
USA	O
)	O
.	O

H-89	B
and	O
K252a	B
were	O
from	O
LC	O
Laboratories	O
(	O
Woburn	O
,	O
MA	O
,	O
USA	O
)	O
.	O

Hank	B
's	I
Balanced	I
Salt	I
Solution	I
(	O
HBSS	B
)	O
and	O
horse	O
serums	O
were	O
obtained	O
from	O
GIBCO	O
(	O
Grand	O
Island	O
,	O
NY	O
,	O
USA	O
)	O
,	O
[	B
3	I
H	I
]	I
-14,15-EET	I
(	O
100	O
Ci	O
/	O
mmole	O
)	O
and	O
14,15-EET	B
was	O
synthesized	O
and	O
purified	O
by	O
RP	O
,	O
reversed	O
phase	O
-	O
HPLC	O
,	O
as	O
previously	O
described	O
[	O
16	O
]	O
.	O

2.2	O
Harvest	O
and	O
purification	O
of	O
guinea	O
pig	O
monocytes	O
Female	O
white	O
Hartley	O
guinea	O
pigs	O
(	O
250–350	O
g	O
)	O
were	O
injected	O
intraperitoneally	O
(	O
i.p	O
.	O
)	O
with	O
0.5	O
ml	O
horse	O
serum	O
twice	O
a	O
week	O
for	O
2	O
weeks	O
,	O
and	O
afterwards	O
,	O
once	O
weekly	O
.	O

After	O
a	O
minimum	O
of	O
48	O
h	O
from	O
the	O
last	O
injection	O
,	O
the	O
cells	O
were	O
harvested	O
by	O
peritoneal	O
lavage	O
.	O

The	O
animals	O
were	O
anesthetized	O
with	O
metofane	B
and	O
a	O
20	O
g	O
×	O
2″	O
(	O
Surflo	O
)	O
Teflon	O
intercath	O
was	O
inserted	O
into	O
the	O
peritoneal	O
cavity	O
.	O

The	O
cavity	O
was	O
washed	O
with	O
20	O
ml	O
of	O
Hank	B
's	I
buffered	I
saline	I
solution	O
without	O
calcium	B
or	O
magnesium	B
(	O
HBSS	B
)	O
,	O
containing	O
5	O
mM	O
HEPES	B
,	O
pH	O
7.3	O
and	O
10	O
Units	O
/	O
ml	O
of	O
heparin	O
.	O

The	O
collected	O
cells	O
were	O
centrifuged	O
at	O
275	O
×	O
g	O
for	O
5	O
min	O
,	O
washed	O
and	O
resuspended	O
in	O
4	O
ml	O
of	O
HBSS	B
containing	O
10	O
%	O
gelatin	O
and	O
5	O
mg	O
deoxyribonuclease	O
(	O
HBSS	B
-	O
GD	O
)	O
.	O

Hypotonic	O
lysis	O
removed	O
contaminating	O
red	O
blood	O
cells	O
.	O

Four	O
milliliters	O
of	O
aliquots	O
of	O
the	O
cell	O
suspension	O
were	O
layered	O
on	O
top	O
of	O
a	O
Percoll	O
density	O
gradient	O
and	O
centrifuged	O
at	O
1600	O
×	O
g	O
for	O
30	O
min	O
.	O

The	O
discontinuous	O
density	O
gradient	O
was	O
prepared	O
by	O
overlaying	O
successive	O
layers	O
of	O
86	O
%	O
,	O
76	O
%	O
,	O
64	O
%	O
,	O
and	O
45	O
%	O
isotonic	O
Percoll	O
containing	O
0.03	O
mg	O
/	O
ml	O
deoxyribonuclease	O
to	O
give	O
the	O
following	O
densities	O
:	O
A	O
:	O
1.06	O
,	O
B	O
:	O
1.08	O
,	O
C	O
:	O
1.09	O
,	O
D	O
:	O
1.10	O
g	O
/	O
ml	O
[	O
17,18	O
]	O
.	O

The	O
four	O
bands	O
of	O
cells	O
were	O
collected	O
at	O
the	O
interface	O
of	O
the	O
different	O
density	O
layers	O
,	O
and	O
to	O
remove	O
any	O
remaining	O
Percoll	O
,	O
each	O
was	O
diluted	O
1:4	O
with	O
HBSS	B
-	O
GD	O
,	O
centrifuged	O
,	O
washed	O
once	O
,	O
and	O
resuspended	O
in	O
HBSS	B
-	O
GD	O
.	O

Differential	O
counts	O
were	O
obtained	O
using	O
slide	O
preparation	O
stained	O
with	O
Diff	O
Quick	O
(	O
American	O
Scientific	O
)	O
.	O

From	O
this	O
procedure	O
we	O
could	O
collect	O
the	O
lymphocytes	O
and	O
monocytes	O
,	O
A	O
and	O
B	O
bands	O
,	O
respectively	O
.	O

Eosinophils	O
were	O
collected	O
mainly	O
from	O
the	O
C	O
and	O
D	O
bands	O
[	O
17,18	O
]	O
.	O

Cell	O
viability	O
was	O
determined	O
by	O
trypan	O
blue	O
exclusion	O
and	O
found	O
to	O
be	O
>	O
99	O
%	O
.	O

2.3	O
Radioligand	O
binding	O
assays	O
All	O
assays	O
were	O
performed	O
in	O
duplicate	O
with	O
intact	O
GPM	O
cells	O
suspended	O
in	O
HBSS	B
buffer	O
,	O
pH	O
7.4	O
containing	O
10	O
mM	O
CaCl2	B
and	O
10	O
mM	O
MgCl2	B
at	O
a	O
final	O
volume	O
of	O
250	O
μl	O
.	O

In	O
the	O
saturation	O
binding	O
experiment	O
,	O
GPM	O
cells	O
(	O
106	O
cells	O
)	O
were	O
added	O
to	O
polypropylene	B
tubes	O
(	O
12	O
×	O
75	O
mm	O
)	O
and	O
incubated	O
at	O
4	O
°	O
C	O
for	O
4	O
min	O
with	O
increasing	O
concentrations	O
of	O
[	B
3	I
H	I
]	I
-14,15-EET	I
(	O
0.4	O
nM–30	O
nM	O
)	O
in	O
the	O
presence	O
or	O
absence	O
of	O
20	O
μM	O
unlabeled	O
14,15-EET	B
.	O

For	O
nonsaturation	O
experiments	O
,	O
1000-fold	O
excess	O
of	O
unlabeled	O
14,15-EET	B
was	O
used	O
.	O

Bound	O
and	O
free	O
[	B
3	I
H	I
]	I
-14,15-EET	I
were	O
separated	O
by	O
centrifugation	O
at	O
2000	O
rev.	O
/	O
min	O
,	O
4	O
°	O
C	O
for	O
2	O
min	O
.	O

Pellets	O
were	O
washed	O
with	O
250	O
μl	O
of	O
HBSS	B
twice	O
and	O
centrifuged	O
at	O
2000	O
rev.	O
/	O
min	O
,	O
4	O
°	O
C	O
for	O
2	O
min	O
.	O

Pellets	O
were	O
taken	O
up	O
in	O
200	O
μl	O
20	O
%	O
NaOH	B
,	O
heated	O
on	O
40	O
°	O
C	O
water	O
bath	O
with	O
constant	O
shaking	O
,	O
and	O
then	O
taken	O
up	O
in	O
4.8	O
ml	O
of	O
scintillation	O
liquid	O
.	O

The	O
radioactivity	O
was	O
measured	O
by	O
a	O
Beckman	O
7500	O
Scintillation	O
Counter	O
after	O
equilibration	O
for	O
13	O
to	O
18	O
h	O
in	O
5	O
ml	O
of	O
scintillation	O
fluid	O
.	O

The	O
competition	O
studies	O
of	O
[	O
3	O
H	O
]	O
14,15-EET	O
specific	O
binding	O
to	O
guinea	O
pig	O
mononuclear	O
cells	O
was	O
conducted	O
by	O
incubating	O
GPM	O
cells	O
(	O
106	O
cells	O
)	O
with	O
2	O
nM	O
of	O
[	O
3	O
H	O
]	O
14,15-EET	O
in	O
the	O
presence	O
of	O
various	O
concentrations	O
(	O
10−11	O
to	O
10−4	O
M	O
)	O
of	O
stereo	O
isomers	O
and	O
analogs	O
of	O
14,15-EET	O
.	O

For	O
the	O
experiments	O
on	O
the	O
effects	O
of	O
proteases	O
(	O
chymotrypsin	O
,	O
papain	O
,	O
pronase	O
E	O
,	O
and	O
Proteinase	O
K	O
)	O
,	O
cholera	O
toxin	O
,	O
pertussis	O
toxin	O
,	O
dibutyryl	B
cAMP	I
,	O
and	O
H-89	B
on	O
[	B
3	I
H	I
]	I
-14,15-EET	I
binding	O
to	O
GPM	O
cells	O
,	O
the	O
cells	O
were	O
pretreated	O
with	O
one	O
of	O
the	O
following	O
group	O
of	O
agents	O
:	O
1	O
)	O
proteases	O
(	O
chymotrypsin	O
-	O
type	O
IS	O
and	O
type	O
II	O
,	O
papain	O
,	O
pronase	O
E	O
and	O
proteinase	O
K	O
,	O
100	O
μg	O
/	O
ml	O
)	O
at	O
37	O
°	O
C	O
for	O
20	O
min	O
;	O
2	O
)	O
cholera	O
toxin	O
(	O
25–200	O
μg	O
/	O
ml	O
)	O
and	O
pertussis	O
toxin	O
(	O
20–200	O
ng	O
/	O
ml	O
)	O
at	O
37	O
°	O
C	O
for	O
2	O
h	O
;	O
3	O
)	O
dibutyryl	B
cAMP	I
(	O
DBcAMP	B
)	O
(	O
10–100	O
nM	O
)	O
at	O
37	O
°	O
C	O
for	O
30	O
min	O
;	O
4	O
)	O
H-89	B
(	O
0.01–1	O
μm	O
)	O
at	O
37	O
°	O
C	O
for	O
10	O
min	O
,	O
then	O
in	O
the	O
presence	O
of	O
DBcAMP	B
(	O
100	O
nM	O
)	O
at	O
37	O
°	O
C	O
for	O
another	O
30	O
min	O
,	O
separately	O
before	O
the	O
binding	O
assay	O
.	O

The	O
pretreated	O
GPM	O
cells	O
were	O
centrifuged	O
at	O
1000	O
rev.	O
/	O
min	O
,	O
at	O
4	O
°	O
C	O
for	O
5	O
min	O
,	O
washed	O
with	O
HBSS	B
buffer	I
,	O
centrifuged	O
,	O
and	O
resuspended	O
in	O
HBSS	B
before	O
the	O
binding	O
assay	O
.	O

2.4	O
cAMP	O
and	O
cGMP	O
determination	O
GPM	O
cells	O
(	O
4	O
×	O
106	O
)	O
were	O
preincubated	O
with	O
or	O
without	O
400	O
μM	O
of	O
IBMX	O
for	O
5	O
min	O
before	O
the	O
addition	O
of	O
14,15-EET	O
(	O
0.1–100	O
μM	O
)	O
.	O

The	O
assays	O
were	O
incubated	O
for	O
another	O
10	O
min	O
at	O
37	O
°	O
C	O
and	O
terminated	O
by	O
addition	O
of	O
ethanol	B
(	O
its	O
final	O
concentration	O
was	O
65	O
%	O
)	O
.	O

The	O
cell	O
debris	O
was	O
removed	O
by	O
centrifugation	O
and	O
the	O
supernatant	O
was	O
dried	O
under	O
vacuum	O
and	O
redissolved	O
in	O
0.05	O
M	O
acetate	B
buffer	I
for	O
further	O
determination	O
of	O
cAMP	B
and	O
cGMP	B
by	O
RIA	O
kit	O
(	O
Amersham	O
Corp.	O
,	O
Arlington	O
Heights	O
,	O
IL	O
,	O
USA	O
)	O
.	O

2.5	O
Statistical	O
analysis	O
Experimental	O
results	O
were	O
summarized	O
as	O
mean	O
values	O
±	O
SEM	O
.	O

Data	O
were	O
analyzed	O
using	O
one	O
-	O
way	O
ANOVA	O
through	O
the	O
Sigma	O
stat	O
program	O
(	O
Jandel	O
Scientific	O
)	O
.	O

Difference	O
between	O
groups	O
was	O
then	O
determined	O
using	O
the	O
Bonferroni	O
's	O
t	O
-test	O
.	O

When	O
the	O
test	O
of	O
the	O
normality	O
failed	O
,	O
Dunn	O
's	O
test	O
of	O
ANOVA	O
by	O
ranks	O
was	O
used	O
.	O

Groups	O
were	O
deemed	O
to	O
be	O
significantly	O
different	O
from	O
one	O
another	O
when	O
P	O
<	O
0.05	O
.	O

3	O
Results	O
3.1	O
Binding	O
of	O
[	B
3	I
H	I
]	I
-	I
14,15-EET	I
to	O
GPM	O
cells	O
The	O
binding	O
of	O
[	B
3	I
H	I
]	I
-	I
14,15-EET	I
to	O
GPM	O
cells	O
was	O
time	O
dependent	O
and	O
cell	O
concentration	O
dependent	O
(	O
Fig.	O
1A	O
and	O
B	O
)	O
.	O

Maximum	O
binding	O
at	O
4	O
°	O
C	O
was	O
reached	O
at	O
4	O
min	O
with	O
the	O
cell	O
density	O
of	O
2	O
×	O
106	O
cells	O
/	O
ml	O
.	O

Cell	O
bound	O
[	B
3	I
H	I
]	I
-	I
14,15-EET	I
was	O
readily	O
dissociated	O
in	O
a	O
time	O
-	O
dependent	O
fashion	O
when	O
1000-fold	O
higher	O
concentration	O
of	O
unlabeled	O
of	O
14	B
(	I
R	I
)	I
,	I
15	I
(	I
S	I
)	I
-EET	I
,	O
or	O
14	B
(	I
S	I
)	I
,	I
15	I
(	I
R	I
)	I
-EET	I
was	O
added	O
to	O
the	O
reaction	O
mixture	O
with	O
14	B
(	I
R	I
)	I
,	I
15	I
(	I
S	I
)	I
-EET	I
more	O
effective	O
than	O
the	O
14	B
(	I
S	I
)	I
,	I
15	I
(	I
R	I
)	I
-EET	I
(	O
Fig.	O
2	O
)	O
.	O

The	O
displacement	O
of	O
bound	O
radioligand	O
reached	O
maximum	O
(	O
66	O
%	O
)	O
in	O
5	O
min	O
after	O
the	O
addition	O
of	O
unlabeled	O
14	B
(	I
R	I
)	I
,	I
15	I
(	I
S	I
)	I
-EET	I
.	O

The	O
saturability	O
of	O
the	O
specific	O
[	B
3	I
H	I
]	I
-	I
14,15-EET	I
was	O
shown	O
by	O
incubating	O
the	O
GPM	O
cells	O
with	O
increasing	O
concentrations	O
of	O
radioligand	O
in	O
the	O
presence	O
or	O
absence	O
of	O
20	O
μM	O
unlabeled	O
14,15-EET	B
.	O

As	O
shown	O
in	O
Fig.	O
3A	O
,	O
[	B
3	I
H	I
]	I
-14,15-EET	I
binding	O
to	O
GPM	O
cells	O
was	O
saturable	O
and	O
of	O
high	O
affinity	O
.	O

Nonspecific	O
binding	O
increased	O
linearly	O
with	O
increasing	O
concentration	O
of	O
ligand	O
.	O

Total	O
binding	B
also	O
increased	O
with	O
increasing	O
concentration	O
of	O
[	O
3	O
H	O
]	O
-	O
14,15-EET	O
.	O

This	O
showed	O
that	O
nonspecific	O
binding	O
was	O
of	O
high	O
capacity	O
,	O
nonsaturable	O
and	O
low	O
affinity	O
whereas	O
specific	O
binding	O
was	O
of	O
low	O
capacity	O
,	O
saturable	O
,	O
and	O
high	O
affinity	O
.	O

Scatchard	O
analysis	O
of	O
specific	O
[	B
3	I
H	I
]	I
-14,15-EET	I
binding	O
to	O
GPM	O
cells	O
(	O
Fig.	O
3B	O
)	O
shows	O
that	O
the	O
[	B
3	I
H	I
]	I
-	I
14,15-EET	I
binding	O
sites	O
in	O
GPM	O
cells	O
belong	O
to	O
a	O
high	O
affinity	O
population	O
.	O

The	O
dissociation	O
constant	O
(	O
K	O
d	O
)	O
is	O
35.06	O
±	O
1.73	O
nM	O
(	O
n	O
=	O
4	O
)	O
,	O
and	O
the	O
maximum	O
number	O
of	O
binding	O
sites	O
(	O
B	O
max	O
)	O
was	O
estimated	O
to	O
be	O
2.36	O
±	O
0.31	O
pmol	O
/	O
106	O
cells	O
and	O
the	O
number	O
of	O
binding	O
sites	O
per	O
cell	O
calculated	O
to	O
be	O
1.42	O
±	O
0.19	O
×	O
106	O
sites	O
/	O
cell	O
(	O
n	O
=	O
4	O
)	O
.	O

3.2	O
Competition	O
studies	O
of	O
[	B
3	I
H	I
]	I
14,15-EET	I
specific	O
binding	O
to	O
guinea	O
pig	O
mononuclear	O
cells	O
by	O
14,15-EET	B
stereoisomers	I
and	O
other	O
EETs	B
To	O
examine	O
the	O
specificity	O
of	O
the	O
binding	O
sites	O
for	O
[	B
3	I
H	I
]	I
14,15-EET	I
,	O
we	O
conducted	O
competition	O
binding	O
studies	O
with	O
stereoisomers	B
and	I
analogs	I
of	I
14,15-EET	I
and	O
other	O
EETs	B
.	O

As	O
shown	O
in	O
Fig.	O
4	O
,	O
14	B
(	I
R	I
)	I
,	I
15	I
(	I
S	I
)	I
-EET	I
was	O
an	O
effective	O
competing	O
ligand	O
with	O
a	O
K	O
i	O
of	O
226.3	O
nM	O
followed	O
by	O
11	B
(	I
R	I
)	I
,	I
12	I
(	I
S	I
)	I
-EET	I
,	O
14	B
(	I
S	I
)	I
,	I
15	I
(	I
R	I
)	I
-EET	I
,	O
14,15	B
thia	I
(	I
S	I
)	I
-ET	I
,	O
and	O
14,15-aza	B
(	I
N	I
)	I
-ET	I
with	O
K	O
i	O
of	O
595.1	O
nM	O
,	O
612.5	O
nM	O
,	O
3.54	O
μM	O
,	O
and	O
5	O
μM	O
,	O
respectively	O
.	O

3.3	O
Effects	O
of	O
protease	O
enzymes	O
on	O
[	B
3	I
H	I
]	I
-14,15-EET	I
binding	O
on	O
GPM	O
cells	O
Preincubation	O
of	O
the	O
intact	O
GPM	O
cells	O
with	O
100	O
μg	O
/	O
ml	O
of	O
various	O
protease	O
enzymes	O
such	O
as	O
:	O
chymotrypsin	O
-	O
type	O
IS	O
and	O
type	O
II	O
,	O
papain	O
,	O
pronase	O
E	O
,	O
and	O
proteinase	O
K	O
at	O
37	O
°	O
C	O
for	O
20	O
min	O
led	O
to	O
significant	O
reduction	O
of	O
binding	O
(	O
n	O
=	O
3	O
)	O
(	O
Fig.	O
5	O
)	O
.	O

Papain	O
produced	O
the	O
most	O
reduction	O
(	O
51.60	O
%	O
)	O
on	O
the	O
binding	O
of	O
[	B
3	I
H	I
]	I
-14,15-EET	I
to	O
its	O
receptor	O
followed	O
by	O
proteinase	O
K	O
(	O
47.14	O
%	O
)	O
,	O
chymotrypsin	O
-	O
type	O
II	O
(	O
42.04	O
%	O
)	O
,	O
chymotrypsin	O
-	O
type	O
IS	O
(	O
27.33	O
%	O
)	O
,	O
and	O
pronase	O
E	O
(	O
15.98	O
%	O
)	O
,	O
respectively	O
.	O

These	O
data	O
suggest	O
that	O
14,15-EET	B
binding	O
sites	O
of	O
the	O
intact	O
GPM	O
cells	O
are	O
protein	O
in	O
nature	O
.	O

3.4	O
Effects	O
of	O
cholera	O
toxin	O
and	O
pertussis	O
toxin	O
on	O
[	B
3	I
H	I
]	I
-14,15-EET	I
binding	O
on	O
GPM	O
cells	O
The	O
effects	O
of	O
cholera	O
toxin	O
and	O
pertussis	O
toxin	O
,	O
agents	O
known	O
to	O
enhance	O
cAMP	B
levels	O
,	O
were	O
tested	O
on	O
[	B
3	I
H	I
]	I
-14,15-EET	I
in	O
GPM	O
cells	O
.	O

GPM	O
cells	O
were	O
pretreated	O
with	O
cholera	O
toxin	O
(	O
25–200	O
μg	O
/	O
ml	O
)	O
and	O
pertussis	O
toxin	O
(	O
20–200	O
ng	O
/	O
ml	O
)	O
separately	O
at	O
37	O
°	O
C	O
for	O
2	O
h	O
,	O
followed	O
by	O
radioligand	O
binding	O
assay	O
.	O

14,15-EET	B
receptor	O
binding	O
was	O
decreased	O
58.99	O
±	O
6.37	O
%	O
by	O
cholera	O
toxin	O
(	O
200	O
μg	O
/	O
ml	O
)	O
(	O
Fig.	O
6A	O
)	O
and	O
40.50	O
±	O
3.78	O
%	O
by	O
pertussis	O
toxin	O
(	O
200	O
ng	O
/	O
ml	O
)	O
(	O
data	O
not	O
shown	O
)	O
.	O

Thus	O
,	O
agents	O
that	O
increase	O
intracellular	O
cAMP	B
level	O
can	O
effectively	O
down	O
regulate	O
14,15-EET	B
receptor	O
binding	O
.	O

The	O
down	O
regulation	O
of	O
[	B
3	I
H	I
]	I
-	I
14,15-EET	I
binding	O
in	O
GPM	O
cells	O
by	O
cholera	O
toxin	O
(	O
200	O
μg	O
/	O
ml	O
)	O
is	O
shown	O
by	O
the	O
decrease	O
of	O
number	O
of	O
binding	O
sites	O
(	O
B	O
max	O
,	O
32.0	O
%	O
decrease	O
)	O
on	O
the	O
cell	O
surface	O
without	O
changing	O
the	O
dissociation	O
constant	O
(	O
K	O
d	O
)	O
(	O
Fig.	O
6B	O
)	O
.	O

3.5	O
Effects	O
of	O
dibutyryl	B
cAMP	I
on	O
[	B
3	I
H	I
]	I
-14,15-EET	I
binding	O
on	O
GPM	O
cells	O
We	O
pretreated	O
GPM	O
cells	O
with	O
various	O
concentrations	O
of	O
dibutyryl	B
cAMP	I
(	O
DBcAMP	B
)	O
at	O
37	O
°	O
C	O
for	O
30	O
min	O
followed	O
by	O
the	O
radioligand	O
binding	O
assays	O
as	O
described	O
.	O

Similar	O
to	O
the	O
effect	O
of	O
cholera	O
toxin	O
,	O
a	O
significant	O
reduction	O
of	O
specific	O
binding	O
(	O
>	O
35	O
%	O
reduction	O
)	O
for	O
[	B
3	I
H	I
]	I
14,15-EET	I
was	O
observed	O
after	O
the	O
cells	O
were	O
treated	O
with	O
DBcAMP	B
.	O

The	O
reduction	O
of	O
[	B
3	I
H	I
]	I
-14,15-EET	I
binding	O
to	O
GPM	O
cells	O
was	O
dose	O
-	O
dependent	O
with	O
respect	O
to	O
DBcAMP	B
(	O
Fig.	O
7A	O
)	O
and	O
maximum	O
response	O
was	O
reached	O
at	O
100	O
nM.	O
Scatchard	O
analysis	O
revealed	O
that	O
the	O
number	O
of	O
the	O
[	B
3	I
H	I
]	I
-14,15-EET	I
binding	O
sites	O
(	O
B	O
max	O
)	O
in	O
GPM	O
cell	O
surface	O
was	O
decreased	O
by	O
19.1	O
%	O
after	O
incubation	O
with	O
100	O
nM	O
of	O
DBcAMP	B
without	O
changing	O
the	O
K	O
d	O
(	O
Fig.	O
7B	O
)	O
in	O
the	O
same	O
fashion	O
as	O
the	O
treatment	O
with	O
cholera	O
toxin	O
.	O

3.6	O
Effect	O
of	O
protein	O
kinase	O
inhibitors	O
on	O
the	O
reduction	O
of	O
[	B
3	I
H	I
]	I
-14,15-EET	I
binding	O
in	O
GPM	O
cells	O
by	O
DBcAMP	B
Because	O
pretreatment	O
of	O
GPM	O
cells	O
with	O
DBcAMP	B
or	O
cholera	O
toxin	O
resulted	O
in	O
the	O
down	O
regulation	O
of	O
14,15-EET	B
binding	O
site	O
density	O
,	O
we	O
further	O
examined	O
whether	O
this	O
effect	O
was	O
due	O
to	O
activation	O
of	O
PKA	O
.	O

GPM	O
cells	O
were	O
incubated	O
with	O
various	O
concentrations	O
of	O
PKA	O
inhibitor	O
,	O
H-89	B
[	O
19	O
]	O
,	O
at	O
37	O
°	O
C	O
for	O
10	O
min	O
before	O
the	O
pretreatment	O
of	O
DBcAMP	B
(	O
100	O
nM	O
)	O
at	O
37	O
°	O
C	O
for	O
an	O
30	O
min	O
.	O

The	O
cells	O
were	O
washed	O
with	O
HBSS	B
once	O
and	O
resuspended	O
in	O
HBSS	B
.	O

Low	O
doses	O
of	O
H-89	B
(	O
0.01	O
μM	O
)	O
alone	O
showed	O
a	O
slightly	O
decrease	O
in	O
[	B
3	I
H	I
]	I
-14,15-EET	I
binding	O
but	O
a	O
higher	O
dose	O
(	O
0.1–1.0	O
μM	O
)	O
showed	O
significant	O
increases	O
as	O
compared	O
with	O
controls	O
(	O
untreated	O
GPM	O
cells	O
)	O
.	O

However	O
,	O
when	O
GPM	O
cells	O
were	O
pretreated	O
with	O
H-89	B
from	O
0.1	O
to	O
1.0	O
μM	O
before	O
treatment	O
with	O
DBcAMP	B
,	O
H-89	B
readily	O
reversed	O
the	O
down	O
regulatory	O
response	O
of	O
DBcAMP	B
on	O
[	B
3	I
H	I
]	I
-14,15-EET	I
binding	O
in	O
GPM	O
cells	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
(	O
Fig.	O
8)	O
.	O

Under	O
similar	O
conditions	O
,	O
K252a	B
(	O
a	O
protein	O
kinase	O
C	O
inhibitor	O
)	O
could	O
not	O
reverse	O
the	O
downward	O
regulatory	O
effect	O
of	O
DBcAMP	B
on	O
[	B
3	I
H	I
]	I
-14,15-EET	I
binding	O
in	O
GPM	O
cells	O
.	O

3.7	O
Effects	O
of	O
14,15-EET	B
on	O
the	O
level	O
of	O
cAMP	B
and	O
cGMP	B
in	O
intact	O
GPM	O
cells	O
Because	O
cholera	O
toxin	O
and	O
cAMP	B
both	O
are	O
able	O
to	O
down	O
regulate	O
the	O
14,15-EET	B
receptor	O
binding	O
,	O
the	O
effects	O
of	O
14,15-EET	B
on	O
the	O
intracellular	O
levels	O
of	O
cAMP	B
or	O
cGMP	B
were	O
examined	O
.	O

GPM	O
cells	O
were	O
preincubated	O
with	O
or	O
without	O
400	O
μM	O
of	O
IBMX	B
for	O
5	O
min	O
at	O
37	O
°	O
C	O
and	O
incubated	O
with	O
various	O
concentrations	O
of	O
14,15-EET	B
(	O
0.01–100	O
μM	O
)	O
for	O
additional	O
10	O
min	O
.	O

We	O
found	O
that	O
14,15-EET	B
can	O
indeed	O
induce	O
an	O
increase	O
of	O
intracellular	O
level	O
of	O
cAMP	B
in	O
GPM	O
cells	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
(	O
0.1	O
to	O
100	O
μM	O
)	O
(	O
Fig.	O
9	O
)	O
.	O

Maximal	O
effect	O
on	O
the	O
increase	O
of	O
cAMP	B
in	O
GPM	O
cells	O
required	O
the	O
presence	O
of	O
IBMX	B
,	O
a	O
phospodiesterase	O
inhibitor	O
.	O

When	O
the	O
cells	O
were	O
pretreated	O
with	O
100	O
μM	O
of	O
14,15-EET	B
,	O
there	O
was	O
a	O
nearly	O
12-fold	O
increase	O
in	O
intracellular	O
level	O
of	O
cAMP	B
,	O
from	O
2.67	O
pmol	O
/	O
106	O
cells	O
(	O
without	O
14,15-EET	O
)	O
to	O
32.42	O
pmol	O
/	O
106	O
cells	O
(	O
pretreated	O
with	O
100	O
μM	O
of	O
14,15-EET	B
)	O
.	O

However	O
,	O
under	O
similar	O
conditions	O
,	O
14,15-EET	B
had	O
no	O
effect	O
on	O
the	O
levels	O
of	O
cGMP	B
in	O
GPM	O
cells	O
in	O
the	O
presence	O
of	O
IBMX	B
.	O

4	O
Discussion	O
14,15-epoxyeicosatrienoic	B
acid	I
(	O
14,15-EET	B
)	O
was	O
originally	O
found	O
to	O
produce	O
by	O
platelets	O
and	O
subsequently	O
by	O
endothelial	O
cells	O
[	O
3,4	O
]	O
.	O

Our	O
earlier	O
data	O
showed	O
that	O
a	O
profound	O
increase	O
in	O
EET	B
(	O
especially	O
14,15-EET	B
)	O
generation	O
in	O
endothelial	O
cells	O
(	O
EC	O
)	O
after	O
exposure	O
to	O
240	O
mg	O
/	O
dl	O
low	O
-	O
density	O
lipoprotein	O
(	O
LDL	O
)	O
-cholesterol	O
.	O

Subsequent	O
data	O
showed	O
that	O
14,15-EET	B
induced	O
an	O
8-fold	O
increase	O
of	O
U-937	O
cell	O
adhesion	O
to	O
cultured	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
(	O
HUVEC	O
)	O
as	O
compared	O
with	O
non	O
-	O
treated	O
control	O
[	O
13	O
]	O
.	O

These	O
results	O
support	O
the	O
notion	O
that	O
14,15-EET	B
may	O
mediate	O
the	O
atherogenic	O
LDL	O
induced	O
enhancement	O
of	O
U-937	O
cells	O
'	O
adhesion	O
on	O
HUVEC	O
[	O
20	O
]	O
.	O

Because	O
endothelial	O
cells	O
derived	O
from	O
human	O
umbilical	O
veins	O
(	O
HUVE	O
)	O
do	O
not	O
possess	O
any	O
specific	O
binding	O
for	O
[	B
3	I
H	I
]	I
-14,15-EET	I
that	O
suggested	O
a	O
lack	O
of	O
14,15-EET	B
receptors	O
in	O
endothelium	O
[	O
21,22	O
]	O
,	O
the	O
enhancement	O
of	O
monocyte	O
adhesion	O
by	O
14,15-EET	B
may	O
act	O
through	O
a	O
receptor	O
and	O
the	O
activation	O
of	O
a	O
signal	O
transduction	O
mechanism	O
in	O
monocytes	O
.	O

In	O
this	O
report	O
,	O
we	O
have	O
identified	O
and	O
characterized	O
a	O
population	O
of	O
specific	O
high	O
affinity	O
binding	O
sites	O
for	O
[	B
3	I
H	I
]	I
-14,15-EET	I
in	O
GPM	O
cells	O
and	O
found	O
the	O
ligand	O
binding	O
is	O
high	O
affinity	O
with	O
a	O
K	O
d	O
of	O
35.06	O
±	O
1.73	O
nM	O
and	O
B	O
max	O
of	O
2.36	O
±	O
0.32	O
pmol	O
/	O
106	O
cells	O
.	O

The	O
calculated	O
number	O
of	O
binding	O
sites	O
per	O
cell	O
was	O
1.42	O
±	O
0.19	O
×	O
106	O
sites	O
/	O
cell	O
.	O

This	O
binding	O
site	O
is	O
stereospecific	O
for	O
14	B
(	I
R	I
)	I
,	I
15	I
(	I
S	I
)	I
-EET	I
and	O
has	O
less	O
affinity	O
toward	O
other	O
EETs	B
and	O
11	B
(	I
R	I
)	I
,	I
12	I
(	I
S	I
)	I
-EET	I
(	O
Fig.	O
4	O
)	O
.	O

The	O
binding	O
of	O
[	B
3	I
H	I
]	I
-14,15-EET	I
to	O
GPM	O
cells	O
is	O
reversible	O
(	O
Fig.	O
2	O
)	O
and	O
protease	O
sensitive	O
which	O
showed	O
that	O
this	O
binding	O
site	O
is	O
associated	O
with	O
a	O
protein	O
species	O
(	O
Fig.	O
5	O
)	O
.	O

The	O
rapid	O
time	O
course	O
of	O
radioligand	O
binding	O
in	O
the	O
cold	O
temperature	O
and	O
the	O
reversibility	O
suggested	O
that	O
the	O
binding	O
be	O
not	O
likely	O
due	O
to	O
the	O
esterification	O
of	O
14,15-EET	B
into	O
the	O
membrane	O
phospholipids	B
.	O

14,15-EET	B
binding	O
in	O
GPM	O
cells	O
is	O
attenuated	O
by	O
cholera	O
toxin	O
or	O
pertussis	O
toxin	O
without	O
changing	O
the	O
dissociation	O
constant	O
(	O
K	O
d	O
)	O
.	O

Because	O
both	O
cholera	O
toxin	O
and	O
pertussis	O
toxin	O
activate	O
adenyl	O
cyclase	O
and	O
report	O
to	O
increase	O
intracellular	O
cAMP	B
[	O
23	O
]	O
,	O
we	O
found	O
that	O
addition	O
of	O
dibutyryl	B
cAMP	I
(	O
DBcAMP	B
)	O
can	O
reduce	O
the	O
binding	O
of	O
[	B
3	I
H	I
]	I
-	I
14,15-EET	I
on	O
GPM	O
cells	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
by	O
reducing	O
the	O
cell	O
surface	O
receptor	O
density	O
(	O
B	O
max	O
)	O
without	O
changing	O
the	O
dissociation	O
constant	O
(	O
K	O
d	O
)	O
(	O
Fig.	O
7A	O
and	O
B	O
)	O
.	O

However	O
pertussis	O
toxin	O
was	O
less	O
effective	O
as	O
compared	O
with	O
cholera	O
toxin	O
probably	O
due	O
to	O
the	O
fact	O
it	O
is	O
less	O
effective	O
in	O
increasing	O
intracellular	O
cAMP	B
level	O
in	O
GPM	O
cells	O
.	O

These	O
results	O
suggest	O
that	O
the	O
reagents	O
that	O
elevated	O
intracellular	O
cAMP	B
levels	O
in	O
GPM	O
cells	O
down	O
regulate	O
14,15-EET	B
binding	O
and	O
the	O
binding	O
sites	O
are	O
likely	O
associated	O
with	O
a	O
functional	O
receptor	O
.	O

The	O
fact	O
that	O
the	O
down	O
regulation	O
of	O
14,15-EET	B
receptor	O
binding	O
induced	O
by	O
cAMP	B
can	O
be	O
reversed	O
by	O
a	O
PKA	O
inhibitor	O
,	O
H-89	B
,	O
further	O
suggest	O
these	O
processes	O
may	O
be	O
mediated	O
through	O
the	O
activation	O
of	O
PKA	O
linked	O
signal	O
transduction	O
pathway	O
.	O

The	O
high	O
concentration	O
(	O
μM	O
range	O
)	O
of	O
14,15-EET	B
required	O
to	O
increase	O
the	O
level	O
of	O
cAMP	B
possibly	O
due	O
to	O
phosphodiesterase	O
in	O
GPM	O
cells	O
being	O
active	O
that	O
cAMP	B
could	O
not	O
accumulate	O
even	O
in	O
the	O
presence	O
of	O
IBMX	B
.	O

Another	O
possibility	O
is	O
due	O
to	O
GPM	O
cells	O
that	O
might	O
have	O
different	O
types	O
of	O
phosphodiesterase	O
that	O
IBMX	B
can	O
not	O
effectively	O
inhibit	O
.	O

Although	O
it	O
seems	O
clear	O
that	O
14,15-EET	B
transduction	O
system	O
involves	O
cAMP	B
mediation	O
and	O
a	O
PKA	O
-	O
dependent	O
mechanism	O
,	O
the	O
precise	O
details	O
of	O
the	O
process	O
,	O
i.e.	O
whether	O
down	O
regulation	O
is	O
secondary	O
to	O
phosphorylation	O
of	O
receptor	O
protein	O
or	O
by	O
internalization	O
require	O
further	O
investigation	O
.	O

Salvia	O
is	O
an	O
important	O
genus	O
consisting	O
of	O
ca	O
900	O
species	O
in	O
the	O
family	O
Lamiaceae	O
(	O
formerly	O
Labiatae	O
)	O
and	O
some	O
species	O
of	O
Salvia	O
have	O
been	O
cultivated	O
worldwide	O
for	O
use	O
in	O
folk	O
medicines	O
and	O
for	O
culinary	O
purposes	O
.	O

The	O
dried	O
root	O
of	O
Salvia	O
miltiorrhiza	O
(	O
Chinese	O
Danshen	O
)	O
,	O
for	O
example	O
,	O
has	O
been	O
used	O
extensively	O
for	O
the	O
treatment	O
of	O
coronary	O
heart	O
disease	O
,	O
cerebrovascular	O
disease	O
,	O
hepatitis	O
,	O
hepatocirrhosis	O
,	O
chronic	O
renal	O
failure	O
,	O
dysmenorrhea	O
and	O
neuroasthenic	O
insomnia	O
(	O
Li	O
,	O
1998	O
)	O
.	O

Studies	O
on	O
the	O
chemical	O
constituents	O
of	O
Salvia	O
have	O
been	O
mainly	O
confined	O
to	O
the	O
diterpenoids	B
and	O
the	O
tanshinones	B
(	O
Chang	O
et	O
al.	O
,	O
1990	O
;	O
Zhang	O
et	O
al.	O
,	O
1990	O
)	O
and	O
several	O
reviews	O
on	O
these	O
components	O
have	O
now	O
been	O
published	O
(	O
Prokopenko	O
and	O
Litvinenko	O
,	O
1980	O
;	O
Kong	O
,	O
1989	O
;	O
Tang	O
and	O
Eisenbrand	O
,	O
1992	O
;	O
Al	O
-	O
Hazimi	O
and	O
Miana	O
,	O
1994	O
;	O
Rodriguez	O
-	O
Hahn	O
et	O
al.	O
,	O
1995	O
;	O
Ulubelen	O
and	O
Topcu	O
,	O
1998	O
)	O
.	O

However	O
,	O
in	O
recent	O
years	O
much	O
attention	O
has	O
been	O
directed	O
to	O
the	O
biologically	O
active	O
,	O
water	B
-	O
soluble	O
components	O
in	O
the	O
dried	O
root	O
decoction	O
used	O
in	O
traditional	O
medicine	O
(	O
Zhang	O
and	O
Liu	O
,	O
1996	O
)	O
.	O

These	O
studies	O
,	O
particularly	O
in	O
China	O
,	O
have	O
led	O
to	O
the	O
isolation	O
and	O
identification	O
of	O
a	O
host	O
of	O
caffeic	B
acid	I
derived	O
metabolites	B
(	O
Li	O
,	O
1998	O
)	O
,	O
many	O
of	O
which	O
possess	O
a	O
variety	O
of	O
biological	O
activities	O
including	O
antioxidant	O
,	O
antiplatelet	O
,	O
antitumor	O
and	O
antiviral	O
activity	O
(	O
see	O
Table	O
1	O
)	O
.	O

This	O
review	O
is	O
written	O
to	O
take	O
into	O
account	O
of	O
the	O
rapid	O
development	O
in	O
the	O
phytochemistry	O
and	O
therapeutical	O
applications	O
of	O
species	O
of	O
Salvia	O
.	O

2	O
Phenolic	B
acids	I
The	O
polar	O
phenolic	B
acids	I
constitute	O
the	O
major	O
part	O
of	O
the	O
water	B
-	O
soluble	O
components	O
of	O
the	O
Salvia	O
decoction	O
.	O

Most	O
of	O
the	O
phenolic	B
acids	I
identified	O
so	O
far	O
are	O
those	O
from	O
the	O
Chinese	O
Danshen	O
,	O
S.	O
miltiorrhiza	O
,	O
S.	O
chinensis	O
and	O
S.	O
yunnanensis	O
and	O
the	O
compounds	O
unique	O
to	O
Salvia	O
are	O
consequently	O
designated	O
salvianolic	B
acids	I
A	I
–	I
K	I
or	O
yunnaneic	B
acids	I
A	I
–	I
H	I
to	O
reflect	O
their	O
origin	O
(	O
see	O
Table	O
2	O
)	O
.	O

Apart	O
from	O
a	O
few	O
simple	O
benzoic	B
acids	I
such	O
as	O
4-hydroxybenzoic	B
acid	I
(	O
Wang	O
et	O
al.	O
,	O
2000	O
)	O
,	O
3,4-dihydroxybenzoic	B
acid	I
or	O
protocatechuic	B
acid	I
(	O
Wu	O
et	O
al.	O
,	O
1999a	O
)	O
,	O
3-methoxy-4-hydroxybenzoic	B
acid	I
or	O
vanillic	B
acid	I
(	O
Cuvelier	O
et	O
al.	O
,	O
1996	O
)	O
and	O
2,4-dimethoxybenzoic	B
acid	I
(	O
Topcu	O
et	O
al.	O
,	O
1995	O
)	O
,	O
an	O
ether	B
linked	I
dimer	I
of	I
hexyl	I
4-hydroxybenzoate	I
or	O
di	B
(	I
4-hexyloxycarbonylphenyl	I
)	I
ether	I
(	O
Ulubelen	O
et	O
al.	O
,	O
1995	O
)	O
and	O
two	O
coumarins	B
6,7-dihydroxycoumarin	B
(	O
esculetin	B
)	O
(	O
Ulubelen	O
and	O
Tuzlaci	O
,	O
1990	O
)	O
and	O
7-methoxycoumarin	B
(	O
herniarin	B
)	O
(	O
El	O
-	O
Missiry	O
et	O
al.	O
,	O
1994	O
)	O
,	O
the	O
majority	O
of	O
the	O
phenolic	B
acids	I
in	O
Salvia	O
species	O
are	O
exclusively	O
those	O
of	O
caffeic	B
acid	I
(	O
1	O
)	O
derivatives	B
,	O
which	O
are	O
unique	O
to	O
Salvia	O
except	O
for	O
rosmarinic	B
acid	I
(	O
2	O
)	O
and	O
lithospermic	B
acid	I
(	O
9	O
)	O
(	O
see	O
Fig.	O
1	O
for	O
chemical	O
structures	O
)	O
.	O

2.1	O
Caffeic	B
acid	I
metabolites	B
Caffeic	B
acid	I
plays	O
a	O
central	O
role	O
in	O
the	O
biochemistry	O
of	O
Lamiaceae	O
and	O
occurs	O
predominantly	O
in	O
the	O
dimer	O
form	O
as	O
rosmarinic	B
acid	I
(	O
Gerhardt	O
and	O
Schroeter	O
,	O
1983	O
)	O
.	O

In	O
the	O
Salvia	O
species	O
the	O
caffeic	B
acid	I
is	O
the	O
building	O
block	O
of	O
a	O
variety	O
of	O
the	O
plant	O
metabolites	O
from	O
the	O
more	O
simple	O
monomers	B
to	O
multiple	O
condensation	O
products	O
to	O
give	O
rise	O
to	O
a	O
variety	O
of	O
oligomers	B
.	O

The	O
trimers	B
and	O
tetramers	B
are	O
more	O
interesting	O
from	O
the	O
therapeutic	O
point	O
of	O
view	O
as	O
they	O
have	O
been	O
shown	O
to	O
possess	O
significant	O
biological	O
activities	O
.	O

2.1.1	O
Caffeic	B
acid	I
monomers	I
The	O
monomers	O
that	O
are	O
frequently	O
present	O
in	O
Salvia	O
are	O
represented	O
by	O
caffeic	B
acid	I
itself	O
and	O
3-	B
(	I
3,4-dihydroxyphenyl	I
)	I
lactic	I
acid	I
(	O
3	O
)	O
(	O
Qian	O
and	O
Li	O
,	O
1992	O
)	O
.	O

The	O
latter	O
compound	O
,	O
also	O
known	O
as	O
danshensu	B
(	O
Chinese	O
word	O
to	O
mean	O
literally	O
the	O
element	O
of	O
Danshen	O
)	O
was	O
first	O
isolated	O
from	O
S.	O
miltiorrhiza	O
(	O
Yang	O
and	O
Zhang	O
,	O
1981	O
)	O
and	O
found	O
to	O
be	O
a	O
coronary	O
vasodilator	O
and	O
to	O
scavenge	O
the	O
free	O
oxygen	O
radicals	O
generated	O
during	O
ischemia	O
-	O
reperfusion	O
injury	O
in	O
the	O
myocardium	O
as	O
effectively	O
as	O
superoxide	O
dismutase	O
(	O
SOD	O
)	O
(	O
Zhao	O
et	O
al.	O
,	O
1996	O
)	O
.	O

The	O
amide	B
of	O
3	O
,	O
3-	B
(	I
3,4-dihydroxyphenyl	I
)	I
lactamide	I
(	O
4	O
)	O
,	O
also	O
found	O
in	O
S.	O
miltiorrhiza	O
,	O
had	O
been	O
reported	O
to	O
possess	O
radical	O
scavenging	O
activity	O
greater	O
than	O
ascorbic	B
acid	I
(	O
Kang	O
et	O
al.	O
,	O
1997	O
)	O
.	O

Other	O
monomeric	O
derivatives	O
including	O
ferulic	B
acid	I
(	O
Cuvelier	O
et	O
al.	O
,	O
1996	O
)	O
,	O
isoferulic	B
acid	I
(	O
Ai	O
and	O
Li	O
,	O
1992	O
)	O
and	O
two	O
caffeic	B
acid	I
esters	I
mono	B
-	I
feruloyl	I
-	I
R	I
,	I
R	I
-	I
(	I
+	I
)	I
-tartaric	I
acid	I
(	O
6	O
)	O
(	O
Qian	O
et	O
al.	O
,	O
1993	O
)	O
and	O
chlorogenic	B
acid	I
(	O
5-caffeoylquinic	B
acid	I
)	O
(	O
7	O
)	O
(	O
Kokkalou	O
and	O
Kapetanidis	O
,	O
1988	O
)	O
have	O
also	O
been	O
described	O
as	O
Salvia	O
constituents	O
.	O

The	O
identification	O
of	O
mono	B
-	I
feruloyl	I
-	I
R	I
,	I
R	I
-	I
(	I
+	I
)	I
-tartaric	I
acid	I
has	O
been	O
corroborated	O
by	O
chemical	O
synthesis	O
,	O
along	O
with	O
its	O
two	O
S	B
,	I
S	I
-	I
(	I
-	I
)	I
-	I
and	O
R	B
,	I
S	I
-	I
(	I
meso	I
)	I
-isomers	I
.	O

Chlorogenic	B
acid	I
,	O
despite	O
being	O
common	O
and	O
widespread	O
in	O
fruits	O
,	O
is	O
surprisingly	O
uncommon	O
in	O
Lamiaceae	O
,	O
which	O
is	O
generally	O
dominated	O
by	O
rosmarinic	B
acid	I
(	O
Gerhardt	O
and	O
Schroeter	O
,	O
1983	O
)	O
.	O

Caffeic	B
acids	I
esterified	I
with	I
sugars	I
are	O
quite	O
common	O
in	O
nature	O
and	O
those	O
identified	O
in	O
Salvia	O
are	O
discussed	O
under	O
Phenolic	B
Glycosides	I
(	O
see	O
below	O
)	O
.	O

2.1.2	O
Caffeic	B
acid	I
dimers	I
Rosmarinic	B
acid	I
(	O
2	O
)	O
is	O
the	O
most	O
abundant	O
caffeic	B
acid	I
dimer	I
in	O
Salvia	O
species	O
(	O
Ai	O
and	O
Li	O
,	O
1988	O
;	O
Cuvelier	O
et	O
al.	O
,	O
1994	O
;	O
Lu	O
and	O
Foo	O
,	O
1999	O
)	O
and	O
has	O
been	O
reported	O
to	O
be	O
the	O
major	O
phenolic	B
compound	I
responsible	O
for	O
the	O
high	O
antioxidant	O
activity	O
of	O
Salvia	O
samples	O
(	O
Cuvelier	O
et	O
al.	O
,	O
1996	O
)	O
.	O

There	O
have	O
been	O
many	O
publications	O
on	O
rosmarinic	B
acid	I
dealing	O
with	O
its	O
detection	O
and	O
quantitative	O
estimation	O
in	O
various	O
Salvia	O
preparations	O
(	O
Janicsak	O
and	O
Mathe	O
,	O
1997	O
;	O
Yuan	O
et	O
al.	O
,	O
1998	O
;	O
Areias	O
et	O
al.	O
,	O
2000	O
)	O
,	O
its	O
biochemical	O
production	O
in	O
cell	O
cultures	O
(	O
Morimoto	O
et	O
al.	O
,	O
1994	O
)	O
or	O
chemical	O
synthesis	O
(	O
Eicher	O
et	O
al.	O
,	O
1996	O
)	O
and	O
its	O
metabolism	O
in	O
rats	O
(	O
Nakazawa	O
and	O
Ohsawa	O
,	O
1998	O
)	O
.	O

Other	O
types	O
of	O
dimers	O
identified	O
in	O
Salvia	O
include	O
przewalskinic	B
acid	I
A	I
(	O
8	O
)	O
from	O
the	O
Tibetan	O
sage	O
S.	O
przewalskii	O
(	O
Lu	O
et	O
al.	O
,	O
1991	O
)	O
,	O
salvianolic	B
acid	I
G	I
(	O
11	O
)	O
(	O
Ai	O
and	O
Li	O
,	O
1991	O
)	O
and	O
the	O
stilbenoid	B
salvianolic	B
acid	I
F	I
or	O
2-	B
(	I
3,4-dihydroxystyryl	I
)	I
caffeic	I
acid	I
(	O
12	O
)	O
(	O
Ai	O
and	O
Li	O
,	O
1996	O
)	O
both	O
from	O
S.	O
miltiorrhiza	O
.	O

The	O
dihydrobenzofuran	B
compound	O
przewalskinic	B
acid	I
A	I
is	O
apparently	O
related	O
to	O
lithospermic	B
acid	I
(	O
9	O
)	O
and	O
salvianolic	B
acid	I
B	I
or	O
lithospermic	B
acid	I
B	I
(	O
10	O
)	O
,	O
whereas	O
salvianolic	B
acid	I
G	I
,	O
with	O
a	O
dibenzooxepin	B
skeleton	O
,	O
is	O
the	O
first	O
of	O
its	O
kind	O
found	O
in	O
Salvia	O
.	O

Salvianolic	B
acid	I
F	I
,	O
which	O
has	O
been	O
synthesised	O
by	O
Dalla	O
and	O
Cotelle	O
(	O
1999	O
)	O
,	O
is	O
a	O
decarboxylated	O
caffeic	B
acid	I
dimer	I
.	O

In	O
addition	O
,	O
Ulubelen	O
and	O
co	O
-	O
workers	O
(	O
1996	O
)	O
have	O
reported	O
the	O
existence	O
of	O
two	O
isomeric	O
caffeic	B
acid	I
ester	I
dimers	I
linked	O
by	O
ether	B
bond	I
,	O
namely	O
the	O
dioctyl	B
3-O	I
-3′-di	I
-	B
cis	I
-	O
and	O
di	B
-	I
trans	I
-isoferulate	I
(	O
14	O
,	O
15	O
)	O
in	O
S.	O
forskahlei	O
.	O

2.1.3	O
Caffeic	B
acid	I
trimers	I
Trimers	O
derived	O
from	O
caffeic	B
acid	I
constitute	O
the	O
largest	O
group	O
of	O
metabolites	O
in	O
Salvia	O
.	O

They	O
include	O
compounds	O
such	O
as	O
lithospermic	B
acid	I
(	O
9	O
)	O
(	O
Qian	O
and	O
Li	O
,	O
1992	O
)	O
,	O
salvianolic	B
acids	I
H	B
(	O
16	O
)	O
(	O
Zhang	O
and	O
Li	O
,	O
1993	O
)	O
,	O
I	B
(	O
17	O
)	O
(	O
Zhang	O
and	O
Li	O
,	O
1994	O
)	O
,	O
J	B
(	O
18	O
)	O
(	O
Ai	O
et	O
al.	O
,	O
1994	O
)	O
and	O
K	B
(	O
19	O
)	O
(	O
Tezuka	O
et	O
al.	O
,	O
1998	O
;	O
Lu	O
and	O
Foo	O
,	O
1999	O
)	O
,	O
sagecoumarin	B
(	O
20	O
)	O
(	O
Lu	O
et	O
al.	O
,	O
1999	O
)	O
,	O
three	O
decarboxylated	O
forms	O
of	O
salvianolic	B
acids	I
A	B
(	O
13	O
)	O
(	O
Li	O
et	O
al.	O
,	O
1984	O
)	O
,	O
C	B
(	O
21	O
)	O
(	O
Ai	O
and	O
Li	O
,	O
1988	O
)	O
and	O
isosalvianolic	B
acid	I
C	I
(	O
22	O
)	O
(	O
Qian	O
and	O
Li	O
,	O
1992	O
)	O
as	O
well	O
as	O
yunnaneic	B
acids	I
C	B
(	O
24	O
)	O
,	O
D	B
(	O
25	O
)	O
,	O
E	B
(	O
26	O
)	O
and	O
F	B
(	O
27	O
)	O
(	O
Tanaka	O
et	O
al.	O
,	O
1996	O
;	O
1997	O
)	O
.	O

These	O
last	O
mentioned	O
are	O
apparent	O
Diels	O
–	O
Alder	O
adducts	O
of	O
caffeic	B
acids	I
.	O

Lithospermic	B
acid	I
and	O
both	O
its	O
mono	B
-	I
and	O
dimethyl	B
esters	I
were	O
the	O
active	O
components	O
that	O
inhibited	O
adenylate	O
cyclase	O
(	O
Kohda	O
et	O
al.	O
,	O
1989	O
)	O
.	O

In	O
addition	O
,	O
dimethyl	B
lithospermate	I
was	O
also	O
shown	O
to	O
be	O
a	O
stronger	O
radical	O
scavenger	O
than	O
ascorbic	B
acid	I
(	O
Kang	O
et	O
al.	O
,	O
1997	O
)	O
.	O

The	O
new	O
member	O
of	O
the	O
salvianolic	B
acid	I
series	I
is	O
salvianolic	B
acid	I
K	I
and	O
its	O
presence	O
has	O
been	O
detected	O
by	O
LC	O
–	O
MS	O
in	O
10	O
Salvia	O
species	O
(	O
Kasimu	O
et	O
al.	O
,	O
1998	O
)	O
.	O

Salvianolic	B
acid	I
A	I
,	O
the	O
stilbenoid	B
caffeic	B
acid	I
trimer	I
has	O
been	O
shown	O
to	O
possess	O
a	O
strong	O
oxygen	B
free	I
radical	I
scavenging	O
activity	O
(	O
Huang	O
and	O
Zhang	O
,	O
1992	O
;	O
Li	O
et	O
al.	O
,	O
1995	O
)	O
which	O
may	O
be	O
the	O
basis	O
for	O
some	O
of	O
its	O
biological	O
activities	O
(	O
see	O
Table	O
1	O
)	O
.	O

Salvianolic	B
acid	I
A	I
is	O
apparently	O
not	O
very	O
stable	O
and	O
its	O
reactivity	O
has	O
been	O
demonstrated	O
by	O
its	O
conversion	O
to	O
salvianolic	B
acid	I
C	I
on	O
a	O
TLC	O
plate	O
that	O
was	O
impregnated	O
with	O
2	O
%	O
of	O
formic	B
acid	I
solution	O
.	O

This	O
suggested	O
that	O
salvianolic	B
acid	I
C	I
,	O
a	O
benzofuran	B
compound	I
,	O
was	O
likely	O
a	O
cyclization	O
product	O
of	O
salvianolic	B
acid	I
A	I
(	O
Ai	O
and	O
Li	O
,	O
1988	O
)	O
.	O

Isosalvianolic	B
acid	I
C	I
,	O
a	O
second	O
depside	B
to	O
salvianolic	B
acid	I
G	I
with	O
a	O
dibenzooxepin	B
skeleton	O
,	O
has	O
been	O
identified	O
only	O
in	O
S.	O
chinensis	O
along	O
with	O
salvianolic	B
acid	I
D	I
(	O
23	O
)	O
(	O
Qian	O
and	O
Li	O
,	O
1992	O
)	O
,	O
the	O
latter	O
could	O
be	O
considered	O
as	O
an	O
abridged	O
caffeic	B
acid	I
trimer	I
that	O
was	O
first	O
found	O
in	O
S.	O
miltiorrhiza	O
(	O
Ai	O
and	O
Li	O
,	O
1992	O
)	O
.	O

Yunnaneic	B
acids	I
C	B
and	O
D	B
both	O
of	O
which	O
contain	O
the	O
bicyclo	B
[	I
2.2.2	I
]	I
octane	I
core	O
structure	O
appear	O
to	O
be	O
the	O
Diels	O
–	O
Alder	O
adducts	O
involving	O
the	O
double	O
bond	O
of	O
the	O
caffeic	B
acid	I
and	O
the	O
phenol	B
ring	O
or	O
its	O
quinone	B
form	O
in	O
a	O
rosmarinic	B
acid	I
moiety	O
.	O

Further	O
oxidation	O
of	O
yunnaneic	B
acid	I
C	I
resulted	O
in	O
the	O
formation	O
of	O
yunnaneic	B
acid	I
E	I
while	O
the	O
addition	O
of	O
an	O
acetyl	B
group	I
to	O
the	O
bicyclo	B
[	I
2.2.2	I
]	I
octa-1,2-dione	I
skeleton	I
in	O
yunnaneic	B
acid	I
C	I
led	O
to	O
yunnaneic	B
acid	I
F.	I
2.1.4	O
Caffeic	B
acid	I
tetramers	I
Caffeic	B
acid	I
tetramers	I
are	O
in	O
effect	O
dimerised	B
rosmarinic	I
acids	I
as	O
in	O
salvianolic	B
acids	I
B	B
(	O
10	O
)	O
(	O
Ai	O
and	O
Li	O
,	O
1988	O
)	O
,	O
E	B
(	O
28	O
)	O
(	O
Ai	O
and	O
Li	O
,	O
1992	O
)	O
and	O
L	B
(	O
32	O
)	O
(	O
Lu	O
and	O
Foo	O
,	O
2001b	O
)	O
,	O
rabdosiin	B
(	O
29	O
)	O
,	O
yunnaneic	B
acids	I
G	B
(	O
30	O
)	O
and	O
H	B
(	O
31	O
)	O
(	O
Tanaka	O
et	O
al.	O
,	O
1997	O
)	O
,	O
and	O
sagerinic	B
acid	I
(	O
33	O
)	O
(	O
Lu	O
and	O
Foo	O
,	O
1999	O
)	O
.	O

Distribution	O
of	O
salvianolic	B
acid	I
E	I
is	O
more	O
restricted	O
and	O
has	O
been	O
reported	O
only	O
in	O
S.	O
miltiorrhiza	O
while	O
salvianolic	B
acid	I
B	I
,	O
which	O
is	O
also	O
known	O
as	O
lithospermic	B
acid	I
B	I
,	O
is	O
more	O
common	O
in	O
Salvia	O
species	O
and	O
occurs	O
mainly	O
as	O
potassium	B
,	O
ammonium	B
or	O
magnesium	B
salts	I
.	O

These	O
salts	O
constitute	O
largely	O
the	O
most	O
important	O
bioactive	O
Salvia	O
components	O
in	O
sage	O
(	O
see	O
Table	O
1	O
)	O
.	O

Three	O
methyl	B
esters	I
of	I
lithospermic	I
acid	I
B	I
,	O
namely	O
the	O
9′-	B
and	O
9‴-monomethyl	B
lithospermate	I
B	I
and	O
dimethyl	B
lithospermate	I
B	I
,	O
have	O
been	O
found	O
recently	O
in	O
Tibetan	O
sage	O
together	O
with	O
other	O
known	O
polyphenolic	B
compounds	I
(	O
Wu	O
et	O
al.	O
,	O
1999b	O
)	O
.	O

In	O
addition	O
to	O
the	O
yunnaneic	B
acids	I
C	I
to	I
F	I
mentioned	O
above	O
,	O
Tanaka	O
et	O
al.	O
(	O
1997	O
)	O
have	O
also	O
identified	O
three	O
oxidatively	O
cyclized	O
rosmarinic	B
acid	I
dimers	I
with	O
a	O
1,2-dihydronaphthalene	B
core	O
comprising	O
of	O
rabdosiin	B
,	O
yunnaneic	B
acids	I
G	B
and	O
H	B
in	O
S.	O
yunnanesis	O
.	O

Most	O
recently	O
,	O
salvianolic	B
acid	I
L	I
,	O
an	O
isomer	O
of	O
rabdosiin	B
or	O
yunnaneic	B
acid	I
G	I
,	O
has	O
been	O
found	O
in	O
S.	O
officinalis	O
.	O

In	O
addition	O
,	O
a	O
more	O
structurally	O
interesting	O
new	O
type	O
of	O
[	O
2	O
+	O
2	O
]	O
-rosmarinic	O
acid	B
dimer	I
is	O
sagerinic	B
acid	I
reported	O
in	O
S.	O
officinalis	O
,	O
which	O
contained	O
a	O
cyclobutane	B
ring	I
in	O
the	O
μ	B
-	I
truxinate	I
form	O
.	O

Sagerinic	B
acid	I
is	O
the	O
first	O
example	O
of	O
a	O
natural	O
[	B
2	I
+	I
2	I
]	I
-dimers	I
of	I
caffeic	I
acid	I
esters	I
.	O

2.1.5	O
Higher	O
caffeic	B
acid	I
oligomers	I
Yunnaneic	B
acids	I
A	B
(	O
34	O
)	O
and	O
B	B
(	O
35	O
)	O
found	O
in	O
S.	O
yunnanesis	O
(	O
Tanaka	O
et	O
al.	O
,	O
1996	O
)	O
are	O
the	O
only	O
known	O
hexamers	B
of	O
caffeic	B
acid	I
.	O

These	O
two	O
compounds	O
could	O
be	O
formed	O
by	O
spiroacetal	B
bonding	O
between	O
yunnaneic	B
acid	I
C	I
(	O
24	O
)	O
and	O
yunnaneic	B
acid	I
D	I
(	O
25	O
)	O
or	O
between	O
two	O
molecules	O
of	O
24	O
.	O

The	O
presence	O
of	O
these	O
Diels	O
–	O
Alder	O
type	O
adducts	O
in	O
S.	O
yunnanesis	O
indicates	O
the	O
complexity	O
in	O
the	O
biochemistry	O
of	O
plant	O
metabolism	O
.	O

2.2	O
Phenolic	B
glycosides	I
The	O
phenolic	B
glycosides	I
are	O
apparently	O
not	O
very	O
common	O
in	O
Salvia	O
and	O
rosmarinic	B
acid	I
3′-glucoside1	I
1	O
Unless	O
otherwise	O
mentioned	O
,	O
common	O
sugars	O
glucose	B
,	O
galactose	B
,	O
xylose	B
,	O
arabinose	B
,	O
rhamnose	B
,	O
fructose	B
and	O
apiose	B
denote	O
β	B
-	I
d	I
-glucopyranose	I
,	O
β	B
-	I
d	I
-galactopyranose	I
,	O
β	B
-	I
d	I
-xylopyranose	I
,	O
α	B
-	I
l	I
-arabiopyranose	I
,	O
α	B
-	I
l	I
-rhamnopyranose	I
,	O
β	B
-	I
d	I
-fructofuranose	I
and	O
β	B
-	I
d	I
-apiofuranose	I
,	O
respectively	O
.	O

(	O
salviaflaside	B
)	O
(	O
36	O
)	O
and	O
its	O
methyl	B
ester	I
(	O
Zhao	O
et	O
al.	O
,	O
1996a	O
)	O
as	O
well	O
as	O
the	O
cis	B
and	O
trans	B
-p	I
-coumaric	I
acid	I
4-O	I
-	I
(	I
2-O	I
-apiosyl	I
)	I
glucosides	I
(	O
37	O
,	O
38	O
)	O
(	O
Lu	O
and	O
Foo	O
,	O
2000	O
)	O
are	O
the	O
only	O
examples	O
of	O
the	O
glycosylated	B
phenolic	I
acids	I
.	O

In	O
contrast	O
the	O
phenolic	B
acids	I
esterified	B
with	I
sugars	I
,	O
in	O
which	O
the	O
phenolic	B
acids	I
serve	O
as	O
acylating	O
agents	O
to	O
give	O
rise	O
to	O
acylated	B
sugars	I
,	O
are	O
more	O
common	O
.	O

These	O
acylated	B
sugars	I
include	O
6-O	B
-feruloyl	I
-	I
α-	B
and	O
β	B
-	I
glucose	I
(	O
39	O
,	O
40	O
)	O
(	O
Wang	O
et	O
al.	O
,	O
1998	O
)	O
,	O
1-O	B
-	I
(	I
2,3,4-trihydroxy-3-methyl	I
)	I
butyl-6-O	I
-feruloylglucoside	I
(	O
41	O
)	O
(	O
Wang	O
et	O
al.	O
,	O
2000	O
)	O
,	O
6-O	B
-caffeoyl-1-O	I
-fructosyl	I
-	I
α	I
-	I
glucoside	I
(	O
42	O
)	O
,	O
1-O	B
-caffeoyl-6-O	I
-apiosylglucoside	I
(	O
43	O
)	O
,	O
1-O	B
-p	I
-hydroxybenzoyl-6-O	I
-apiosylglucoside	I
(	O
44	O
)	O
,	O
all	O
from	O
S.	O
officinalis	O
(	O
Wang	O
et	O
al.	O
,	O
1999	O
)	O
,	O
and	O
prionitisides	B
A	B
(	O
45	O
)	O
and	O
B	B
(	O
46	O
)	O
from	O
S.	O
prionitis	O
.	O

The	O
structures	O
of	O
prionitisides	B
A	B
and	O
B	B
were	O
elucidated	O
as	O
2-	B
(	I
3,4-dihydroxyphenyl	I
)	I
-3-glucosyloxycarbonyl-4,6-dihydroxybenzofuran	I
and	O
2-	B
(	I
3,4-dihydroxyphenyl	I
)	I
-3-rutinosyloxy	I
carbonyl-4,6-dihydroxybenzofuran	I
,	O
respectively	O
(	O
Zhao	O
et	O
al.	O
,	O
1996b	O
)	O
.	O

Several	O
phenolic	B
acetophenone	I
glycosides	I
have	O
been	O
also	O
identified	O
in	O
S.	O
officinalis	O
and	O
these	O
include	O
4-hydroxyacetophenone	B
4-O	I
-glucoside	I
(	O
picein	B
)	O
(	O
47	O
)	O
,	O
4-hydroxyacetophenone	B
4-O	I
-	I
(	I
6-O	I
-apiosyl	I
)	I
glucoside	I
(	O
48	O
)	O
,	O
4-hydroxyacetophenone	B
4-O	I
-	I
(	I
2-O	I
-	I
(	I
5-O	I
-syringoylapiosyl	I
)	I
glucoside	I
)	I
(	O
49	O
)	O
(	O
Wang	O
et	O
al.	O
,	O
2000	O
)	O
.	O

Also	O
present	O
in	O
S.	O
officinalis	O
are	O
glycosides	B
of	O
neolignans	B
namely	O
1-hydroxypinoresinol	B
1-O	I
-glucoside	I
(	O
50	O
)	O
,	O
isolariciresinol	B
3α	I
-	I
O	I
-glucoside	I
(	O
51	O
)	O
and	O
2-	B
(	I
3-methoxy-4-glucosyloxyphenyl	I
)	I
-3-hydroxymethyl-5-	I
(	I
3-hydroxypropyl	I
)	I
-7-methoxy-2,3-dihydrobenzofuran	I
(	O
52	O
)	O
(	O
Wang	O
et	O
al.	O
,	O
1998	O
)	O
.	O

In	O
addition	O
,	O
two	O
related	O
isolariciresinol	B
compounds	I
feruloyl	B
-	I
secoisolariciresinol	I
12-methylmyristate	I
(	O
53	O
)	O
(	O
Powell	O
and	O
Plattner	O
,	O
1976	O
)	O
and	O
secoisolariciresinol	B
di	I
(	I
12-methylmyristate	I
)	I
(	O
54	O
)	O
(	O
Plattner	O
and	O
Powell	O
,	O
1978	O
)	O
and	O
a	O
structurally	O
related	O
compound	O
to	O
52	O
2-	B
(	I
3-methoxy-4-hydroxyphenyl	I
)	I
-5-	I
(	I
3-hydroxypropyl	I
)	I
-7-methoxybenzofuran-3-carbaldehyde	I
(	O
55	O
)	O
(	O
Yang	O
et	O
al.	O
,	O
1991	O
)	O
have	O
been	O
reported	O
in	O
the	O
seed	O
of	O
S.	O
plebeia	O
and	O
in	O
the	O
root	O
of	O
S.	O
miltiorrhiza	O
,	O
respectively	O
.	O

Compound	O
55	O
has	O
also	O
been	O
produced	O
synthetically	O
(	O
Kuo	O
and	O
Wu	O
,	O
1996	O
)	O
and	O
shown	O
to	O
be	O
a	O
novel	O
adenosine	O
A1	O
receptor	O
ligand	O
.	O

3	O
Flavonoids	B
Flavonoids	B
are	O
widely	O
distributed	O
in	O
species	O
of	O
Salvia	O
(	O
Sagdullaeva	O
and	O
Khazanovich	O
,	O
1972	O
;	O
Smirnova	O
et	O
al.	O
,	O
1974b	O
;	O
Adzet	O
et	O
al.	O
,	O
1987	O
;	O
Ulubelen	O
and	O
Tuzlaci	O
,	O
1990	O
)	O
,	O
being	O
mostly	O
present	O
as	O
flavones	B
,	O
flavonols	B
and	O
their	O
glycosides	B
(	O
see	O
Tables	O
3	O
and	O
4	O
)	O
.	O

The	O
6-hydroxylated	B
flavones	I
have	O
been	O
reported	O
to	O
be	O
of	O
particularly	O
taxonomic	O
significance	O
to	O
this	O
genus	O
(	O
Tomas	O
-	O
Barberan	O
and	O
Wollenweber	O
,	O
1990	O
)	O
.	O

3.1	O
Flavone	B
and	O
flavonol	B
aglycones	I
The	O
majority	O
of	O
flavonoids	B
are	O
flavones	B
of	O
apigenin	B
(	O
5,7,4′-trihydroxyflavone	B
)	O
(	O
56	O
)	O
and	O
luteolin	B
(	O
5,7,3′,4′-tetrahydroxyflavone	B
)	O
(	O
60	O
)	O
and	O
their	O
corresponding	O
6-hydroxylated	B
derivatives	I
.	O

The	O
methyl	B
ethers	I
of	I
flavones	I
are	O
widely	O
distributed	O
in	O
the	O
leaves	O
of	O
Salvia	O
or	O
in	O
the	O
exudate	O
from	O
aerial	O
parts	O
(	O
Wollenweber	O
,	O
1974	O
;	O
Wollenweber	O
et	O
al.	O
,	O
1992	O
)	O
.	O

The	O
etherification	O
of	O
apigenin	B
seemed	O
to	O
occur	O
preferably	O
on	O
the	O
phenolic	B
7-OH	I
while	O
the	O
catechol	B
B	O
-	O
ring	O
of	O
luteolin	B
is	O
etherified	O
before	O
the	O
A	O
-	O
ring	O
.	O

Thus	O
apigenin	B
7-methyl	B
ether	I
(	O
genkwanin	B
)	O
(	O
57	O
)	O
and	O
7,4′-dimethyl	B
ether	I
(	O
59	O
)	O
are	O
common	O
(	O
Wollenweber	O
et	O
al.	O
,	O
1992	O
)	O
while	O
the	O
4′-methyl	B
ether	I
(	O
acacetin	B
)	O
(	O
58	O
)	O
has	O
been	O
found	O
only	O
in	O
S.	O
nicolsoniana	O
(	O
Pereda	O
-	O
Miranda	O
and	O
Delgado	O
,	O
1986	O
)	O
and	O
S.	O
yosgadensis	O
(	O
Topcu	O
et	O
al.	O
,	O
1996	O
)	O
.	O

Likewise	O
,	O
luteolin	B
3′-methyl	B
ether	I
(	O
chrysoeriol	B
)	O
(	O
62	O
)	O
and	O
4′-methyl	B
ether	I
(	O
diosmetin	B
)	O
(	O
63	O
)	O
are	O
more	O
frequently	O
encountered	O
(	O
Wollenweber	O
et	O
al.	O
,	O
1992	O
;	O
Topcu	O
et	O
al.	O
,	O
1995	O
)	O
,	O
followed	O
by	O
7-methyl	B
ether	I
(	O
61	O
)	O
and	O
7,3′,4′-trimethyl	B
ether	I
(	O
66	O
)	O
(	O
Ulubelen	O
and	O
Tuzlaci	O
,	O
1990	O
)	O
.	O

Luteolin	B
7,4′-dimethyl	B
ether	I
(	O
64	O
)	O
(	O
Miski	O
et	O
al.	O
,	O
1983	O
)	O
and	O
3′,4′-dimethyl	B
ether	I
(	O
65	O
)	O
(	O
Pereda	O
-	O
Miranda	O
and	O
Delgado	O
,	O
1986	O
)	O
have	O
only	O
been	O
reported	O
once	O
before	O
in	O
S.	O
palaestina	O
and	O
S.	O
nicolsoniana	O
,	O
respectively	O
.	O

The	O
6-hydroxyflavones	B
are	O
the	O
flavonoids	B
that	O
characterise	O
species	O
of	O
Salvia	O
.	O

They	O
include	O
a	O
variety	O
of	O
6-hydroxylated	B
apigenin	B
and	O
luteolin	B
derivatives	I
,	O
with	O
6-hydroxyapigenin-6,7-dimethyl	B
ether	B
(	O
cirsimaritin	B
)	O
(	O
69	O
)	O
,	O
6,7,4′-trimethyl	B
ether	I
(	O
salvigenin	B
)	O
(	O
72	O
)	O
,	O
and	O
6-hydroxyluteolin	B
6-methyl	B
ether	I
(	O
nepetin	B
or	O
eupafolin	B
)	O
(	O
75	O
)	O
,	O
6,7-dimethyl	B
ether	I
(	O
cirsiliol	B
)	O
(	O
77	O
)	O
,	O
6,7,4′-trimethyl	B
ether	I
(	O
eupatorin	B
)	O
(	O
81	O
)	O
and	O
6,7,3′,4′-tetramethyl	B
ether	I
(	O
83	O
)	O
being	O
the	O
most	O
common	O
(	O
Tomas	O
-	O
Lorente	O
et	O
al.	O
,	O
1988	O
;	O
Wollenweber	O
et	O
al.	O
,	O
1992	O
)	O
.	O

6-Hydroxyapigenin	B
(	O
scutellarein	B
)	O
itself	O
(	O
67	O
)	O
was	O
only	O
detected	O
in	O
sage	O
extracts	O
by	O
HPLC	O
(	O
Cuvelier	O
et	O
al.	O
,	O
1996	O
)	O
and	O
other	O
6-hydroxyapigenin	B
methyl	B
ethers	I
including	O
6-methyl	B
ether	I
(	O
hispidulin	B
)	O
(	O
68	O
)	O
,	O
6,4′-dimethyl	B
ether	I
(	O
pectolinarigenin	B
)	O
(	O
70	O
)	O
,	O
7,4′-dimethyl	B
ether	I
(	O
71	O
)	O
and	O
5,6,7,4′-tetramethyl	B
ether	I
(	O
5-methoxysalvigenin	B
)	O
(	O
73	O
)	O
were	O
reported	O
only	O
occasionally	O
,	O
as	O
were	O
the	O
6-hydroxyluteolin	B
7-methyl	B
ether	I
(	O
pedalitin	B
)	O
(	O
76	O
)	O
,	O
6,3′-dimethyl	B
ether	I
(	O
jaceosidin	B
)	O
(	O
78	O
)	O
,	O
7,4′-dimethyl	B
ether	I
(	O
nuchensin	B
)	O
(	O
79	O
)	O
,	O
6,7,3′-trimethyl	B
ether	I
(	O
cirsilineol	B
)	O
(	O
80	O
)	O
and	O
6,3′,4′-trimethyl	B
ether	I
(	O
eupatilin	B
)	O
(	O
82	O
)	O
.	O

Cirsimaritin	B
was	O
reported	O
to	O
have	O
a	O
high	O
anti	O
-	O
microbial	O
activity	O
against	O
several	O
bacteria	O
strains	O
(	O
Miski	O
et	O
al.	O
,	O
1983	O
)	O
while	O
hispidulin	B
possessed	O
antihepatotoxic	O
activity	O
(	O
Oshima	O
et	O
al.	O
,	O
1984	O
)	O
.	O

In	O
a	O
more	O
recent	O
report	O
(	O
Viola	O
et	O
al.	O
,	O
1998	O
)	O
,	O
the	O
sedative	O
-	O
depressant	O
property	O
for	O
cirsiliol	B
was	O
described	O
.	O

An	O
unusual	O
flavone	B
which	O
lacks	O
the	O
5-OH	O
group	O
,	O
namely	O
6,7,3′,4′-tetramethoxyflavone	B
(	O
74	O
)	O
,	O
was	O
described	O
by	O
Miski	O
et	O
al.	O
(	O
1983	O
)	O
.	O

The	O
8-hydroxylated	B
flavones	I
are	O
rare	O
in	O
Salvia	O
,	O
with	O
8-hydroxyapigenin	B
7-methyl	I
ether	I
(	O
salvitin	B
)	O
(	O
85	O
)	O
being	O
the	O
only	O
representative	O
found	O
in	O
S.	O
plebeia	O
(	O
Gupta	O
et	O
al.	O
,	O
1975	O
)	O
while	O
8-hydroxyapigenin	B
(	O
isoscutellarein	B
)	O
(	O
84	O
)	O
itself	O
was	O
detected	O
by	O
HPLC	O
in	O
sage	O
samples	O
(	O
Cuvelier	O
et	O
al.	O
,	O
1996	O
)	O
.	O

The	O
four	O
dihydroflavones	B
that	O
have	O
been	O
described	O
to	O
date	O
in	O
Salvia	O
include	O
5-hydroxy-7-methoxyflavanone	B
(	O
86	O
)	O
(	O
Gonzalez	O
et	O
al.	O
,	O
1989	O
)	O
,	O
5,7-dihydroxy-4′-methoxyflavanone	B
(	O
isosakuranetin	B
or	O
narigenin-4′-methyl	B
ether	I
)	O
(	O
87	O
)	O
(	O
Pereda	O
-	O
Miranda	O
and	O
Delgado	O
,	O
1986	O
)	O
,	O
5,7,3′-trihydroxy-4′-methoxyflavanone	B
(	O
hesperetin	B
)	O
(	O
88	O
)	O
(	O
Cuvelier	O
et	O
al.	O
,	O
1996	O
)	O
and	O
5,3′-dihydroxy-7,4′-dimethoxyflavanone	O
(	O
89	O
)	O
.	O

The	O
last	O
mentioned	O
compound	O
was	O
also	O
found	O
to	O
possess	O
coronary	O
dilator	O
activity	O
(	O
Chen	O
et	O
al.	O
,	O
1986	O
)	O
.	O

Flavonols	B
are	O
mostly	O
those	O
of	O
kaempferol	B
(	O
5,7,4′-trihydroxyflavonol	B
)	O
and	O
quercetin	B
(	O
5,7,3′,4′-tetrahydroxyflavonol	B
)	O
methyl	B
ethers	I
.	O

Kaempferol	B
(	O
90	O
)	O
itself	O
was	O
present	O
in	O
S.	O
farinacea	O
(	O
Kamel	O
et	O
al.	O
,	O
1992	O
)	O
and	O
S.	O
folium	O
(	O
Tamas	O
et	O
al.	O
,	O
1986	O
)	O
while	O
quercetin	B
was	O
only	O
reported	O
in	O
S.	O
dorrii	O
(	O
Wollenweber	O
et	O
al.	O
,	O
1992	O
)	O
.	O

Kaempferol	B
3-methyl	B
ether	I
(	O
isokaempferide	B
)	O
(	O
91	O
)	O
,	O
3,7-dimethyl	B
ether	I
(	O
kumatakenin	B
)	O
(	O
92	O
)	O
and	O
quercetin	B
3-methyl	B
ether	I
(	O
94	O
)	O
,	O
3′-methyl	B
ether	I
(	O
isorhamnetin	B
)	O
(	O
95	O
)	O
,	O
3,3′-dimethyl	B
ether	I
(	O
96	O
)	O
and	O
3,7,4′-trimethyl	B
ether	I
(	O
ayanin	B
)	O
(	O
97	O
)	O
are	O
also	O
known	O
Salvia	O
constituents	O
(	O
Topcu	O
et	O
al.	O
,	O
1996	O
;	O
Gökdil	O
et	O
al.	O
,	O
1997	O
)	O
.	O

Kaempferol-3-methyl	B
ether	I
,	O
together	O
with	O
seven	O
other	O
flavones	B
were	O
identified	O
in	O
S.	O
yosgadensis	O
(	O
Topcu	O
et	O
al.	O
,	O
1996	O
)	O
.	O

Quercetin	B
3,7,3′,4′-tetramethyl	I
ether	I
,	O
or	O
retusin	B
(	O
98	O
)	O
was	O
identified	O
by	O
TLC	O
in	O
S.	O
glutinosa	O
(	O
Wollenweber	O
,	O
1974	O
)	O
.	O

6-Hydroxylated	B
flavonols	I
are	O
mostly	O
confined	O
to	O
6-hydroxykaempferol	B
derivatives	I
and	O
include	O
6-hydroxykaempferol	B
3,6-dimethyl	B
ether	I
(	O
99	O
)	O
(	O
Gökdil	O
et	O
al.	O
,	O
1997	O
)	O
,	O
3,6,4′-trimethyl	B
ether	I
(	O
santin	B
)	O
(	O
100	O
)	O
(	O
Ulubelen	O
and	O
Tuzlaci	O
,	O
1990	O
)	O
and	O
interestingly	O
the	O
5,6-dimethyl	B
ether	I
(	O
101	O
)	O
(	O
Wollenweber	O
et	O
al.	O
,	O
1992	O
)	O
.	O

Compound	O
101	O
is	O
one	O
of	O
the	O
only	O
two	O
flavone	O
5-methyl	O
ethers	O
known	O
to	O
Salvia	O
species	O
,	O
the	O
other	O
being	O
6-hydroxygalangin	B
5,6-dimethyl	I
ether	I
(	O
102	O
)	O
found	O
in	O
S.	O
columbariae	O
(	O
Wollenweber	O
et	O
al.	O
,	O
1992	O
)	O
which	O
is	O
also	O
the	O
only	O
one	O
galangin	B
(	O
5,7-dihydroxyflavonol	B
)	O
compound	O
reported	O
in	O
Salvia	O
.	O

No	O
corresponding	O
6-hydroxyquercetin	B
derivatives	I
have	O
been	O
described	O
so	O
far	O
in	O
Salvia	O
.	O

3.2	O
Flavone	B
and	O
flavonol	B
glycosides	I
Flavone	B
O	I
-glycosides	I
are	O
apparently	O
common	O
in	O
Salvia	O
and	O
most	O
of	O
them	O
are	O
flavone	B
7-glycosides	I
represented	O
by	O
apigenin	B
7-glucoside	B
(	O
cosmosiin	B
)	O
(	O
103	O
)	O
,	O
luteolin	B
7-glucoside	B
(	O
cinaroside	B
)	O
(	O
110	O
)	O
and	O
their	O
corresponding	O
7-glucuronides	B
(	O
104	O
,	O
111	O
)	O
.	O

There	O
are	O
several	O
apigenins	B
glycosylated	O
with	O
two	O
or	O
more	O
sugars	B
and	O
among	O
these	O
are	O
apigenin	B
7,4′-diglucoside	I
(	O
105	O
)	O
(	O
Takeda	O
et	O
al.	O
,	O
1994	O
)	O
,	O
apigenin	B
7-cellobioside	I
(	O
107	O
)	O
(	O
Veitch	O
et	O
al.	O
,	O
1998	O
)	O
,	O
apigenin	B
7-rutinoside	I
(	O
108	O
)	O
(	O
Kokkalou	O
and	O
Kapetanidis	O
,	O
1988	O
)	O
and	O
apigenin	B
7-cellobioside-4′-glucoside	I
(	O
109	O
)	O
(	O
Veitch	O
et	O
al.	O
,	O
1998	O
)	O
.	O

The	O
latter	O
compound	O
is	O
the	O
only	O
trisaccharide	B
of	O
flavones	B
and	O
together	O
with	O
apigenin	B
7,4′-diglucoside	I
are	O
the	O
only	O
two	O
apigenin	B
derivatives	I
in	O
which	O
two	O
phenolic	B
hydroxyl	I
groups	I
are	O
glycosylated	B
.	O

Apigenin	B
7,4′-diglucoside	I
occurred	O
as	O
a	O
co	O
-	O
pigment	O
in	O
the	O
blue	O
flower	O
of	O
S.	O
patens	O
(	O
Takeda	O
et	O
al.	O
,	O
1994	O
)	O
.	O

Other	O
flavone	B
disaccharides	I
like	O
apigenin	B
7-cellobioside	I
and	O
apigenin	B
7-cellobioside-4′-glucoside	I
present	O
in	O
Salvia	O
flowers	O
could	O
very	O
well	O
serve	O
as	O
co	O
-	O
pigments	O
(	O
Veitch	O
et	O
al.	O
,	O
1998	O
)	O
.	O

Compared	O
to	O
apigenin	B
,	O
luteolin	B
glycosides	I
appeared	O
to	O
be	O
more	O
common	O
.	O

Luteolin	B
3′-glucuronide	I
(	O
112	O
)	O
was	O
present	O
in	O
S.	O
officinalis	O
(	O
Lu	O
and	O
Foo	O
,	O
2000	O
)	O
while	O
luteolin	B
4′-glucuronide	I
(	O
113	O
)	O
was	O
found	O
in	O
S.	O
lavandulifolia	O
along	O
with	O
other	O
flavonoids	B
(	O
Canigueral	O
et	O
al.	O
,	O
1989	O
)	O
.	O

The	O
3′-OH	B
of	I
luteolin	I
is	O
often	O
methylated	O
and	O
thus	O
chrysoeriol	B
glycosides	B
such	O
as	O
7-glucoside	B
(	O
114	O
)	O
,	O
7-glucuronide	B
(	O
115	O
)	O
and	O
7-xyloside	B
(	O
116	O
)	O
have	O
been	O
frequently	O
reported	O
in	O
Salvia	O
(	O
Smirnova	O
et	O
al.	O
,	O
1974b	O
;	O
Abdalla	O
et	O
al.	O
,	O
1983	O
)	O
.	O

Several	O
luteolin	B
disaccharides	I
have	O
been	O
identified	O
in	O
Salvia	O
and	O
these	O
include	O
luteolin	B
3′-glucoside-7-glucuronide	B
(	O
117	O
)	O
(	O
Abdalla	O
et	O
al.	O
,	O
1983	O
)	O
,	O
7-rutinoside	B
(	O
118	O
)	O
(	O
Kokkalou	O
and	O
Kapetanidis	O
,	O
1988	O
;	O
Tomas	O
-	O
Lorente	O
et	O
al.	O
,	O
1988	O
)	O
,	O
7-cellobioside	B
(	O
119	O
)	O
(	O
Abdalla	O
,	O
1984	O
)	O
and	O
5-rutinoside	B
(	O
127	O
)	O
(	O
Zarzuelo	O
et	O
al.	O
,	O
1995	O
)	O
.	O

The	O
6-hydroxyflavone	B
glycosides	I
,	O
like	O
their	O
aglycones	B
,	O
are	O
also	O
important	O
constituents	O
of	O
Salvia	O
.	O

While	O
6-hydroxyapigenin	B
glycosides	I
are	O
exclusively	O
those	O
of	O
6-methylated	B
derivatives	I
such	O
as	O
6-methoxyapigenin	B
7-glucoside	B
(	O
homoplantagenin	B
)	O
(	O
120	O
)	O
and	O
7-glucuronide	B
(	O
121	O
)	O
,	O
salvigenin	B
5-glucoside	I
(	O
122	O
)	O
(	O
Abdalla	O
et	O
al.	O
,	O
1983	O
;	O
Ulubelen	O
and	O
Topcu	O
,	O
1984	O
)	O
,	O
the	O
corresponding	O
6-hydroxyluteolin	B
glycosides	I
are	O
evenly	O
distributed	O
between	O
those	O
that	O
are	O
methylated	O
and	O
unmethylated	O
,	O
thus	O
6-hydroxyluteolin	B
7-glucoside	B
(	O
123	O
)	O
and	O
7-glucuronide	B
(	O
124	O
)	O
(	O
Lu	O
and	O
Foo	O
,	O
2000	O
)	O
,	O
6-methoxyluteolin	B
7-glucoside	B
(	O
nepitrin	B
)	O
(	O
125	O
)	O
,	O
7-glucuronide	B
(	O
126	O
)	O
(	O
Abdalla	O
et	O
al.	O
,	O
1983	O
)	O
,	O
6-hydroxyluteolin	B
5-glucoside	I
(	O
128	O
)	O
(	O
Ulubelen	O
et	O
al.	O
,	O
1981	O
)	O
and	O
6-methoxyluteolin	B
7-methyl	I
ether-5-glucoside	I
(	O
129	O
)	O
(	O
Saleh	O
and	O
Sabri	O
,	O
1980	O
)	O
have	O
all	O
been	O
found	O
in	O
Salvia	O
.	O

Another	O
compound	O
,	O
identified	O
as	O
acetylpectolinarin	B
by	O
Smirnova	O
et	O
al.	O
(	O
1974a	O
)	O
,	O
could	O
likely	O
be	O
6-methoxyapigenin	B
4′-methyl	I
ether-7-rutinoside	I
,	O
as	O
its	O
acidic	O
hydrolysis	O
gave	O
pectolinarigenin	B
(	O
6-hydroxyapigenin	B
6,4′-dimethyl	I
ether	I
)	O
together	O
with	O
glucose	B
and	O
rhamnose	B
.	O

Flavone	B
C	I
-glycosides	I
are	O
widespread	O
in	O
nature	O
and	O
those	O
present	O
in	O
Salvia	O
are	O
mostly	O
those	O
of	O
apigenin	B
including	O
apigenin	B
8-C	I
-glucoside	I
(	O
vitexin	B
)	O
(	O
130	O
)	O
and	O
apigenin	B
8-C	I
-arabinoside	I
(	O
schaftoside	B
)	O
(	O
131	O
)	O
from	O
S.	O
blepharophylla	O
(	O
Bisio	O
et	O
al.	O
,	O
1997	O
)	O
and	O
the	O
more	O
common	O
apigenin	B
6,8-di	I
-	I
C	I
-glucoside	I
(	O
vicenin-2	O
)	O
(	O
132	O
)	O
(	O
Abdalla	O
,	O
1984	O
;	O
Lu	O
and	O
Foo	O
,	O
2000	O
)	O
.	O

Luteolin	B
6,8-di	I
-	I
C	I
-glucoside	I
(	O
133	O
)	O
from	O
S.	O
aegypteacae	O
(	O
Abdalla	O
,	O
1984	O
)	O
is	O
the	O
only	O
example	O
of	O
luteolin	B
C	I
-glycosides	I
reported	O
.	O

The	O
flavonol	B
glycosides	B
found	O
in	O
Salvia	O
are	O
exclusively	O
those	O
of	O
the	O
3-glycosides	B
.	O

There	O
are	O
three	O
kaempferol	B
glycosides	I
known	O
but	O
they	O
cover	O
a	O
range	O
of	O
compounds	O
from	O
mono-	B
to	O
triglycoside	B
which	O
are	O
exemplified	O
by	O
kaempferol	B
3-glucoside	B
(	O
astragalin	B
)	O
(	O
134	O
)	O
in	O
S.	O
cavaleriei	O
(	O
Zhao	O
et	O
al.	O
,	O
1997	O
)	O
,	O
3-robinoside	B
(	O
141	O
)	O
and	O
3-	B
(	I
2,6-dirhamnosylglucoside	I
)	I
or	O
3-	B
(	I
2	I
G	I
-rhamnosylrutinoside	I
)	I
(	O
135	O
)	O
in	O
S.	O
farnacea	O
(	O
Kamel	O
et	O
al.	O
,	O
1992	O
)	O
.	O

The	O
quercetin	B
glycosides	B
also	O
include	O
their	O
methyl	B
ethers	I
,	O
thus	O
in	O
addition	O
to	O
the	O
more	O
common	O
3-glucoside	B
(	O
isoquercitrin	B
)	O
(	O
137	O
)	O
,	O
3-glucuronide	B
(	O
miquelianin	B
)	O
(	O
138	O
)	O
and	O
3-robinoside	B
(	O
142	O
)	O
,	O
all	O
of	O
which	O
occur	O
in	O
S.	O
blepharophylla	O
(	O
Bisio	O
et	O
al.	O
,	O
1997	O
)	O
,	O
rhamnetin	B
(	O
quercetin	B
7-methyl	I
ether	I
)	O
3-glucoside	B
(	O
139	O
)	O
from	O
S.	O
blepharophylla	O
(	O
Bisio	O
et	O
al.	O
,	O
1997	O
)	O
,	O
isorhamnetin	B
(	O
quercetin	B
3′-methyl	I
ether	I
)	O
3-galactoside	B
(	O
140	O
)	O
and	O
3-	B
(	I
2	I
G	I
-rhamnosylrutinoside	I
)	I
(	O
136	O
)	O
both	O
from	O
S.	O
farinacea	O
(	O
Kamel	O
et	O
al.	O
,	O
1992	O
)	O
have	O
also	O
been	O
reported	O
.	O

3.3	O
Anthocyanins	B
The	O
anthocyanins	B
are	O
particularly	O
abundant	O
in	O
the	O
red	O
or	O
purple	O
flowers	O
of	O
Salvia	O
(	O
Asen	O
,	O
1961	O
;	O
Shibata	O
et	O
al.	O
,	O
1966	O
;	O
Cornu	O
and	O
Paynot	O
,	O
1969	O
;	O
Albulescu	O
and	O
Gavrila	O
-	O
Dinu	O
,	O
1981	O
;	O
Zhang	O
et	O
al.	O
,	O
1997	O
)	O
.	O

Salvia	O
anthocyanins	B
(	O
see	O
Table	O
5	O
)	O
were	O
first	O
studied	O
by	O
Willstätter	O
and	O
Bolton	O
(	O
1916	O
)	O
and	O
the	O
pigment	O
known	O
as	O
salvianin	B
was	O
identified	O
as	O
pelargonidin	B
diglucoside	I
with	O
caffeic	B
acid	I
and	O
malonic	B
acid	I
substituents	O
.	O

Subsequent	O
investigations	O
led	O
to	O
the	O
first	O
structural	O
assignment	O
of	O
salvianin	B
as	O
pelargonidin	B
3-	I
(	I
6-caffeoylglucoside	I
)	I
-5-glucoside	I
(	O
145	O
)	O
(	O
Birkofer	O
et	O
al.	O
,	O
1965	O
)	O
,	O
but	O
this	O
structure	O
was	O
later	O
revised	O
to	O
pelargonidin	O
3-	O
(	O
6-caffeoylglucoside	O
)	O
-5-	O
(	O
4,6-dimalonylglucoside	O
)	O
(	O
143	O
)	O
(	O
Kondo	O
et	O
al.	O
,	O
1989	O
)	O
.	O

The	O
earlier	O
structure	O
was	O
revised	O
because	O
plant	O
pigments	O
were	O
extracted	O
with	O
alcohols	B
which	O
were	O
acidified	O
with	O
mineral	B
acids	I
causing	O
hydrolysis	O
of	O
the	O
labile	O
malonyl	B
moiety	O
(	O
Tomas	O
-	O
Barberan	O
et	O
al.	O
,	O
1987	O
)	O
.	O

The	O
mono-	B
and	O
bis	B
-	I
demalonyl	I
derivatives	I
of	B
salvianin	I
(	O
144	O
,	O
145	O
)	O
have	O
also	O
been	O
identified	O
(	O
Tomas	O
-	O
Barberan	O
et	O
al.	O
,	O
1987	O
;	O
Kondo	O
et	O
al.	O
,	O
1989	O
)	O
.	O

Furthermore	O
,	O
the	O
caffeoyl	B
group	I
in	O
salvianin	B
can	O
be	O
replaced	O
by	O
a	O
p	B
-coumaroyl	I
group	I
,	O
leading	O
to	O
the	O
corresponding	O
pelargonidin	B
3-	I
(	I
6-p	I
-coumaroylglucoside	I
)	I
-5-	I
(	I
4,6-dimalonylglucoside	I
)	I
or	O
monardaein	B
(	O
146	O
)	O
and	O
its	O
demalonated	B
derivatives	I
(	O
147	O
,	O
148	O
)	O
(	O
Tomas	O
-	O
Barberan	O
et	O
al.	O
,	O
1987	O
)	O
.	O

Likewise	O
,	O
the	O
pelargonidin	B
aglycone	I
can	O
be	O
replaced	O
by	O
cyanidin	B
,	O
delphinidin	B
and	O
even	O
malvidin	B
,	O
so	O
the	O
respective	O
cyanidin	B
and	O
delphinidin	B
3-	B
(	I
caffeoylglucoside	I
)	I
-5-	I
(	I
dimalonylglucosides	I
)	B
(	O
149	O
,	O
155	O
)	O
or	O
3-	B
(	I
p	I
-coumaroylglucoside	I
)	I
-5-	I
(	I
dimalonylglucosides	I
)	B
(	O
152	O
,	O
158	O
)	O
and	O
their	O
demalonated	B
derivatives	I
(	O
150	O
,	O
151	O
,	O
153	O
,	O
154	O
,	O
156	O
,	O
157	O
,	O
159	O
,	O
160	O
)	O
have	O
all	O
been	O
identified	O
in	O
scarlet	O
,	O
purple	O
and	O
blue	O
flowers	O
of	O
Salvia	O
(	O
Takeda	O
et	O
al.	O
,	O
1986	O
;	O
Tomas	O
-	O
Barberan	O
et	O
al.	O
,	O
1987	O
;	O
Kondo	O
et	O
al.	O
,	O
1989	O
)	O
.	O

Malvidin	B
3-	I
(	I
6-p	I
-coumaroylglucoside	I
)	I
-5-	I
(	I
6-malonylglucoside	I
)	I
(	O
salviamalvin	B
)	O
(	O
162	O
)	O
,	O
along	O
with	O
malonylawobanin	B
(	O
159	O
)	O
,	O
have	O
been	O
isolated	O
from	O
the	O
blue	O
flowers	O
of	O
S.	O
farinacea	O
(	O
Kondo	O
et	O
al.	O
,	O
1989	O
)	O
.	O

Studies	O
on	O
the	O
distribution	O
pattern	O
of	O
anthocyanins	B
in	O
10	O
species	O
of	O
Salvia	O
showed	O
that	O
the	O
red	O
,	O
scarlet	O
and	O
pink	O
-	O
coloured	O
flower	O
varieties	O
contained	O
pelargonidin	B
,	O
the	O
blue	O
ones	O
the	O
delphinidin	B
and	O
the	O
amethyst-	O
and	O
grape	O
-	O
violet	O
-	O
colored	O
ones	O
were	O
the	O
cyanidin	B
derivatives	I
(	O
Haque	O
et	O
al.	O
,	O
1981	O
)	O
.	O

An	O
acetylated	B
anthocyanin	I
,	O
delphinidin	B
3-	I
(	I
6-p	I
-coumaroylglucoside	I
)	I
-5-	I
(	I
4-acetyl-6-malonylglucoside	I
)	I
(	O
161	O
)	O
together	O
with	O
its	O
parent	O
compound	O
have	O
been	O
reported	O
in	O
the	O
blue	O
petals	O
of	O
S.	O
uliginosa	O
(	O
Ishikawa	O
et	O
al.	O
,	O
1999	O
)	O
.	O

An	O
example	O
of	O
a	O
stable	O
complex	O
of	O
anthocyanins	B
with	O
flavonoids	B
as	O
co	O
-	O
pigments	O
is	O
a	O
blue	O
pigment	O
found	O
in	O
the	O
blue	O
flowers	O
of	O
S.	O
patens	O
.	O

The	O
pigment	O
is	O
composed	O
of	O
delphinidin	B
3-	I
(	I
6-p	I
-coumaroylglucoside	I
)	I
-5-	I
(	I
6-malonylglucoside	I
)	I
(	I
malonylawobanin	I
)	I
(	O
159	O
)	O
,	O
apigenin	B
7,4′-diglucoside	I
(	O
105	O
)	O
and	O
magnesium	B
cation	I
(	O
Takeda	O
et	O
al.	O
,	O
1994	O
)	O
.	O

3.4	O
Proanthocyanidins	B
Proanthocyanidins	B
,	O
or	O
condensed	O
tannins	B
,	O
have	O
been	O
reported	O
in	O
Salvia	O
species	O
(	O
Brieskorn	O
,	O
1949	O
;	O
Savin	O
and	O
Ivanic	O
,	O
1973	O
;	O
Murko	O
and	O
Baldasar	O
,	O
1977	O
)	O
.	O

The	O
so	O
-	O
called	O
salviatannin	B
(	O
164	O
)	O
has	O
only	O
been	O
investigated	O
with	O
UV	O
and	O
IR	O
and	O
deduced	O
to	O
be	O
based	O
on	O
catechin	B
(	O
163	O
)	O
which	O
gave	O
catechol	B
and	O
catechuic	B
acid	I
after	O
alkali	O
pyrolysis	O
(	O
Murko	O
et	O
al.	O
,	O
1974	O
)	O
.	O

Later	O
,	O
salviatannin	B
was	O
also	O
detected	O
by	O
paper	O
chromatography	O
followed	O
by	O
spraying	O
color	O
reagent	O
(	O
Hu	O
,	O
1982	O
)	O
or	O
analysed	O
by	O
absorption	O
onto	O
hide	O
powder	O
followed	O
by	O
gravimetry	O
(	O
Karuza	O
-	O
Stojakovic	O
et	O
al.	O
,	O
1989	O
)	O
.	O

The	O
tannins	B
present	O
in	O
Salvia	O
intravenous	O
preparations	O
could	O
be	O
removed	O
by	O
passing	O
through	O
a	O
polyamide	B
column	O
(	O
Hu	O
,	O
1982	O
)	O
or	O
by	O
precipitation	O
with	O
5	O
%	O
gelatin	O
solutions	O
followed	O
by	O
filtration	O
(	O
Ren	O
et	O
al.	O
,	O
1986	O
)	O
.	O

4	O
Conclusion	O
Salvia	O
species	O
commonly	O
called	O
sages	O
are	O
widely	O
used	O
in	O
traditional	O
medicine	O
and	O
are	O
a	O
rich	O
source	O
of	O
polyphenolic	B
flavonoids	I
and	O
phenolic	B
acids	I
.	O

Flavones	B
,	O
flavonols	B
and	O
their	O
glycosides	B
constitute	O
the	O
majority	O
of	O
flavonoids	B
present	O
.	O

Malonylated	B
anthocyanins	I
are	O
abundant	O
in	O
red	O
to	O
blue	O
Salvia	O
flowers	O
while	O
the	O
presence	O
of	O
proanthocyanidins	B
(	O
condensed	O
tannins	B
)	O
in	O
Salvia	O
have	O
not	O
been	O
demonstrated	O
conclusively	O
.	O

The	O
phenolic	B
acids	I
are	O
exclusively	O
those	O
based	O
on	O
caffeic	B
acid	I
building	O
block	O
with	O
compounds	O
formed	O
from	O
two	O
to	O
four	O
or	O
more	O
caffeic	B
acid	I
units	O
.	O

The	O
depsides	B
formed	O
from	O
these	O
are	O
believed	O
to	O
be	O
responsible	O
for	O
the	O
many	O
biological	O
activities	O
in	O
the	O
sage	O
decoction	O
used	O
in	O
traditional	O
medicine	O
.	O

In	O
addition	O
to	O
the	O
dried	O
root	O
,	O
the	O
aerial	O
part	O
of	O
sage	O
has	O
been	O
shown	O
to	O
also	O
contain	O
a	O
rich	O
source	O
of	O
polar	O
polyphenols	B
including	O
flavonoids	B
and	O
phenolic	B
acids	I
which	O
could	O
potentially	O
be	O
used	O
also	O
as	O
herbal	O
materials	O
.	O

Daphnia	O
are	O
an	O
important	O
and	O
widely	O
studied	O
model	O
species	O
in	O
ecological	O
and	O
toxicological	O
studies	O
throughout	O
the	O
world	O
and	O
an	O
official	O
(	O
OECD	O
)	O
recommended	O
test	O
organism	O
.	O

Their	O
small	O
size	O
,	O
wide	O
distribution	O
and	O
easy	O
growth	O
conditions	O
make	O
this	O
organism	O
ideal	O
for	O
functional	O
genomics	O
based	O
studies	O
,	O
including	O
metabolic	O
profiling	O
and	O
transcriptomics	O
.	O

In	O
this	O
study	O
we	O
used	O
an	O
integrated	O
systems	O
approach	O
in	O
which	O
transcriptomic	O
,	O
metabolomic	O
and	O
energetic	O
responses	O
of	O
juvenile	O
(	O
4days	O
old	O
)	O
daphnids	O
were	O
evaluated	O
in	O
response	O
to	O
exposure	O
to	O
two	O
poly	B
aromatic	I
hydrocarbons	I
(	O
pyrene	B
and	O
fluoranthene	B
)	O
and	O
binary	O
mixtures	O
thereof	O
.	O

In	O
addition	O
,	O
these	O
responses	O
were	O
linked	O
to	O
responses	O
measured	O
during	O
chronic	O
experiments	O
(	O
21days	O
)	O
assessing	O
survival	O
,	O
growth	O
and	O
reproductive	O
traits	O
.	O

Custom	O
Daphnia	O
magna	O
microarrays	O
were	O
used	O
to	O
assess	O
transcriptomic	O
changes	O
.	O

Hierarchical	O
cluster	O
analysis	O
did	O
not	O
result	O
in	O
a	O
clear	O
distinction	O
between	O
the	O
single	O
compounds	O
suggesting	O
similar	O
molecular	O
modes	O
of	O
action	O
.	O

Cluster	O
analysis	O
with	O
both	O
the	O
single	O
compounds	O
and	O
the	O
binary	O
mixture	O
treatments	O
resulted	O
in	O
a	O
separation	O
of	O
treatments	O
based	O
on	O
differences	O
in	O
toxic	O
ratios	O
rather	O
than	O
component	O
differences	O
.	O

Changes	O
in	O
the	O
metabolic	O
profiles	O
of	O
the	O
organisms	O
were	O
investigated	O
using	O
Nuclear	O
Magnetic	O
Resonance	O
Spectroscopy	O
and	O
Gas	O
and	O
Liquid	O
Chromatography	O
Mass	O
Spectrometry	O
.	O

These	O
multivariate	O
metabolomic	O
datasets	O
were	O
analyzed	O
with	O
Principal	O
Components	O
Analysis	O
and	O
Partial	O
Least	O
Squares	O
Discriminant	O
Analysis	O
.	O

The	O
major	O
metabolite	O
changes	O
responsible	O
for	O
the	O
differences	O
observed	O
indicated	O
a	O
disturbance	O
in	O
aminosugar	B
metabolism	O
in	O
all	O
cases	O
.	O

The	O
study	O
demonstrates	O
the	O
potential	O
of	O
'	O
omics	O
'	O
to	O
provide	O
screening	O
tools	O
for	O
monitoring	O
of	O
the	O
freshwater	O
environment	O
--	O
in	O
invertebrate	O
species	O
--	O
which	O
is	O
reasonably	O
rapid	O
,	O
cost	O
-	O
effective	O
and	O
has	O
the	O
potential	O
to	O
greatly	O
increase	O
the	O
amount	O
of	O
information	O
obtained	O
from	O
aquatic	O
toxicology	O
testing	O
.	O

